Rank,NCT Number,Title,Status,Study Results,Conditions,Interventions,Sponsor/Collaborators,Age,Phases,Funded Bys,Study Type,Study Designs,Locations,Study Documents,URL
1,NCT03763474,Euglyca Application in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,No Results Available,"Diabetes Mellitus, Type 1",Combination Product: Euglyca application,Aristotle University Of Thessaloniki,"6 Years to 18 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,"Endocrine Unit of 3rd Department of Pediatrics of Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03763474/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03763474
2,NCT05013294,Using mHealth (Mobile Health) to Optimize Glycemic Control in Adults With Type 2 Diabetes: Proof of Concept Study,Completed,No Results Available,Diabetes,Other: Intervention,KU Leuven|Jomo Kenyatta University of Agriculture and Technology,"Child, Adult, Older Adult",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT05013294/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT05013294
3,NCT03108521,SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients),Completed,Has Results,Diabetes Mellitus,Drug: Sitagliptin,Sichuan Provincial People's Hospital,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sichuan provincial people's hospital, Chengdu, Sichuan, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03108521/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03108521
4,NCT02928952,Mindful Stress Reduction in Diabetes Self-management Education for Veterans,Completed,Has Results,Diabetes Mellitus,Behavioral: Mind-STRIDE,VA Office of Research and Development,"18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02928952/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02928952
5,NCT05106231,Effectiveness of PICC Improving HBA1C and Knowledge in Diabetes Mellitus Education,Recruiting,No Results Available,Diabetes Mellitus|Type2 Diabetes,Behavioral: PICC Program|Behavioral: Control,"Clinical Research Centre, Malaysia|Ministry of Health, Malaysia","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,"Klinik Kesihatan Daro, Daro, Sarawak, Malaysia|Klinik Kesihatan Kapit, Kapit, Sarawak, Malaysia|Klinik Kesihatan Jalan Masjid Kuching, Kuching, Sarawak, Malaysia|Klinik Kesihatan Bandar Miri, Miri, Sarawak, Malaysia|Klinik Kesihatan Pusa, Pusa, Sarawak, Malaysia|Klinik Kesihatan Sarikei, Sarikei, Sarawak, Malaysia|Klinik Kesihatan Siburan, Serian, Sarawak, Malaysia|Klinik Kesihatan Jalan Oya, Sibu, Sarawak, Malaysia|Klinik Kesihatan Sri Aman, Simanggang, Sarawak, Malaysia","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT05106231/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05106231
6,NCT02002130,The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes,Completed,No Results Available,Type I Diabetes,Drug: Placebo GABA and Placebo GAD-alum|Drug: GABA and Placebo GAD-alum|Drug: Active Oral GABA and Active GAD-alum injection,University of Alabama at Birmingham|Diamyd Inc|NOW Foods|Janssen Pharmaceuticals|Juvenile Diabetes Research Foundation,"4 Years to 18 Years   (Child, Adult)",Phase 1,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's of Alabama, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02002130/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02002130
7,NCT02641522,Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: Siltuximab,"Carla Greenbaum, MD|Janssen Research & Development, LLC|Benaroya Research Institute",18 Years to 45 Years   (Adult),Early Phase 1,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02641522/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02641522
8,NCT03224234,A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes,Completed,Has Results,Diabetes,Device: Insulclock with feedback|Device: Insulclock without feedback,Emory University|Insulcoud S.L.,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory Clinic, Emory University Hospital (non-CRN), Emory University Hospital Clinical Research Network, Emory University Hospital Midtown, Grady Health System (non-CRN), Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03224234/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03224234
9,NCT03626909,Diabetes Treatment in Rural Guatemala,Completed,No Results Available,Diabetes,Other: Primary visit and assessment|Other: Follow up visits|Other: 3 month visits|Other: Unscheduled visits,"University of Wisconsin, Madison|Stanford University","18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Hospital Obras Sociales, San Lucas Tolimán, Solala, Guatemala","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03626909/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03626909
10,NCT02953262,Improving Diabetes Care Through Effective Personalized Patient Portal Interactions,Completed,Has Results,Diabetes Mellitus,Behavioral: My HealtheVet Brochure|Behavioral: My HealtheVet Training Guide for Veterans Living with Diabetes|Behavioral: My HealtheVet Group Training|Behavioral: My HealtheVet Individual Training,VA Office of Research and Development,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,"Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, Bedford, Massachusetts, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02953262/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02953262
11,NCT05187806,Motivational Interviewing With Diabetes Patients,Completed,No Results Available,Type 2 Diabetes,Behavioral: motivational interview,Istanbul University-Cerrahpasa,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Ministry of Health, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT05187806/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05187806
12,NCT03176056,The Effectiveness of Low Carbohydrate Diet in Reducing Polypharmacy for Patients With Type 2 Diabetes Mellitus,Completed,No Results Available,Type 2 Diabetes Mellitus,Dietary Supplement: Low carbohydrate diet|Dietary Supplement: Calori restricted diet,National Taiwan University Hospital,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,Taiwan,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03176056/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03176056
13,NCT03737799,StartRight: Getting the Right Classification and Treatment From Diagnosis in Adults With Diabetes,"Active, not recruiting",No Results Available,Diabetes Mellitus,,"Royal Devon and Exeter NHS Foundation Trust|National Institute for Health Research, United Kingdom|Diabetes UK|University of Exeter","18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Anita Hill, Exeter, Devon, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03737799/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03737799
14,NCT01908530,Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes,Completed,Has Results,Diabetes Mellitus,Device: Microprobe glucose sensor,Imperial College London,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Imperial College London, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT01908530/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01908530
15,NCT01613807,Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes,Completed,Has Results,Gestational Diabetes Mellitus,"Drug: Insulin LISPRO|Drug: Insulin, Long-Acting and Insulin",Sansum Diabetes Research Institute|Eli Lilly and Company,18 Years to 44 Years   (Adult),Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,California,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT01613807/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01613807
16,NCT04529317,Beneficial Effects of Quinoa (Chenopodium Quinoa Willd) in the Prevention of Type 2 Diabetes Mellitus,Completed,No Results Available,Type 2 Diabetes,Dietary Supplement: Quinoa and quinoa-based food,Institut d'Investigacions Biomèdiques August Pi i Sunyer,65 Years and older   (Older Adult),Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Diana A. Díaz Rizzolo, Barcelona, Spain","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04529317/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04529317
17,NCT02889510,Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: liraglutide|Drug: placebo,"Lecube, Albert, M.D.|Dynamic Solutions|Novo Nordisk A/S","40 Years to 65 Years   (Adult, Older Adult)",Phase 3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d´Hebrón, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02889510/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02889510
18,NCT05099198,Replication of the GRADE Diabetes Trial in Healthcare Claims Data,Completed,No Results Available,Diabetes,Drug: Sitagliptin|Drug: Glimepiride,Brigham and Women's Hospital,"30 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT05099198/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05099198
19,NCT05162183,Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data,Completed,No Results Available,Diabetes,Drug: Glimepiride|Drug: Liraglutide,Brigham and Women's Hospital,"18 Years to 80 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT05162183/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05162183
20,NCT04077216,Effect of Extra Virgin Olive Oil on Postprandial Blood Glucose in Type 2 Diabetes Mellitus Patients,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Extra Virgin Olive Oil (EVOO),Makati Medical Center,"30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Makati Medical Center, Makati City, NCR, Philippines","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04077216/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04077216
21,NCT01973972,Jump Start Shared Medical Appointments for Diabetes With Weight Management,Completed,Has Results,Diabetes,Behavioral: Weight management|Behavioral: Shared medical appointments (SMA),VA Office of Research and Development,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT01973972/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01973972
22,NCT03020069,Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Device: CGMS Device|Other: No Device,NYU Langone Health,"13 Years to 19 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"New York University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03020069/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03020069
23,NCT04970810,"My Diabetes, My Community",Recruiting,No Results Available,Type 2 Diabetes,Behavioral: My Diabetes Goal|Behavioral: My Diabetes Goal + CommunityRx,University of Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"60 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"University of Chicago Medicine, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04970810/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04970810
24,NCT03695913,Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes,Completed,Has Results,Pre-diabetes,Other: Normal Diet|Other: Low carb diet|Device: CGM with no real time feedback|Device: CGM with real time feedback)|Behavioral: Education material,University of Michigan,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Michigan, Livonia, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03695913/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03695913
25,NCT03053518,Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes,Terminated,Has Results,Type2 Diabetes,Device: Abbott Freestyle Libre Pro|Behavioral: LifeStyle,NYU Langone Health,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03053518/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03053518
26,NCT03562767,Cognitive Behavioral Therapy for African Americans With Uncontrolled Type-2 Diabetes,Terminated,Has Results,"Diabetes Mellitus, Type 2",Behavioral: Group-based Cognitive Behavioral Intervention|Behavioral: Web-based Cognitive Behavioral Intervention|Behavioral: Usual Care,Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,"Emory Dunwoody Clinic, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03562767/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03562767
27,NCT04215536,Replication of the EMPAREG Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Empagliflozin|Drug: DPP-4 inhibitor,Brigham and Women's Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04215536/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04215536
28,NCT03936062,Replication of the TECOS Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Sitagliptin|Drug: Sulfonylurea,Brigham and Women's Hospital,"50 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03936062/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03936062
29,NCT03936049,Replication of the LEADER Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Liraglutide|Drug: DPP-4 inhibitor,Brigham and Women's Hospital,"50 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham And Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03936049/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT03936049
30,NCT03936036,Replication of the CARMELINA Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Linagliptin|Drug: Sulfonylurea,Brigham and Women's Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03936036/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03936036
31,NCT01876485,Point-of-care Health Literacy and Activation Information to Improve Diabetes Care,Completed,Has Results,Diabetes Mellitus,Behavioral: Empowering Patients in Chronic Care (EPIC)|Behavioral: Enhanced Usual Care (EUC),VA Office of Research and Development,"18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,"Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT01876485/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01876485
32,NCT03936023,Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Saxagliptin|Drug: Sulfonylurea,Brigham and Women's Hospital,"40 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03936023/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03936023
33,NCT04157738,A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus|Type 1 Diabetes,Drug: Rapid-Acting Insulin|Drug: Long acting insulin,Emory University,7 Years to 15 Years   (Child),Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04157738/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04157738
34,NCT04215523,Replication of the DECLARE Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Dapagliflozin|Drug: DPP-4 inhibitor,Brigham and Women's Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04215523/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04215523
35,NCT03936010,Replication of the CANVAS Diabetes Trial in Healthcare Claims,Unknown status,No Results Available,Diabetes,Drug: Canagliflozin|Drug: DPP-4 inhibitor,Brigham and Women's Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03936010/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03936010
36,NCT05104944,Defining Outcome Measures for Acute Charcot Neuroarthropathy in Diabetes and Their Use in Assessing Clinical Management,Completed,No Results Available,Diabetes,Radiation: Serial MRIs,Norfolk and Norwich University Hospitals NHS Foundation Trust|University of East Anglia,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Norfolk & Norwich University Hospital, Norwich, Norfolk, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT05104944/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT05104944
37,NCT03870997,Influenza Vaccination Digital Interventions for People Living With Diabetes,Completed,Has Results,Diabetes,Behavioral: Diabetes Digital Intervention|Behavioral: Generic Digital Intervention,"Evidation Health|Sanofi Pasteur, a Sanofi Company","18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,"Evidation Health, San Mateo, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03870997/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03870997
38,NCT01928199,Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant,Completed,Has Results,Posttransplant Diabetes Mellitus,Drug: Sitagliptin|Drug: Placebo,Washington University School of Medicine|Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Washington University, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01928199/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01928199
39,NCT02569060,Feeding America Intervention Trial for Health--Diabetes Mellitus,Completed,No Results Available,Diabetes Mellitus,Other: Testing and Monitoring of Blood Glucose Levels|Other: Primary care coordination|Other: Diabetes-appropriate food packages|Behavioral: Diabetes self-management education,"University of California, San Francisco|Feeding America|Laura and John Arnold Foundation|Urban Institute","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alameda County Community Food Bank, Oakland, California, United States|University of California San Francisco, San Francisco, California, United States|Gleaners Community Food Bank of Southeastern Michigan, Detroit, Michigan, United States|Houston Food Bank, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02569060/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02569060
40,NCT02426138,Community Servings: Food as Medicine for Diabetes,Completed,Has Results,Diabetes,Other: Medically Tailored Meal Delivery (MTM)|Other: Usual Care + Choose MyPlate,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02426138/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02426138
41,NCT02786953,Sleep Promotion to Improve Diabetes Management in Adolescents With T1D,Completed,Has Results,"Diabetes Mellitus, Type 1",Behavioral: Sleep Promotion,Vanderbilt University Medical Center,13 Years to 17 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02786953/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02786953
42,NCT01269034,New Onset Type 1 Diabetes: Role of Exenatide,Completed,Has Results,Type 1 Diabetes,Drug: Exenatide|Drug: Rapid and long acting insulin|Drug: long acting insulin + rapid acting + 1.25 mcg Exenatide,Albert Einstein College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"12 Years to 18 Years   (Child, Adult)",Phase 4,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albert Einstein CRC- West Campus, Bronx, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01269034/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01269034
43,NCT02407132,Family Model of Diabetes Self-Management Education in the Marshallese Community,Completed,Has Results,Diabetes,Behavioral: Adapted DSME|Behavioral: Standard DSME,University of Arkansas|Patient-Centered Outcomes Research Institute,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02407132/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02407132
44,NCT03159299,Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City,Completed,Has Results,Type 2 Diabetes Mellitus,Behavioral: Yo Puedo + mHealth,Yale University|Universidad Iberoamericana,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Yale School of Nursing, Orange, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03159299/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03159299
45,NCT03884920,Glucose Tolerance and Prevention of Diabetes Mellitus Type 2 by Polyherbal Formulation,Completed,No Results Available,Diabetes Mellitus|Pre Diabetes,Dietary Supplement: Polyherbal formulation,Islamia University of Bahawalpur|Hashmi Herbal Pharma (HHP) Registered Bahawalpur,18 Years to 59 Years   (Adult),,Other,Observational,Observational Model: Case-Crossover|Time Perspective: Cross-Sectional,"Hashmi Dawakhana, Khairpur Tamewali, Punjab, Pakistan|University College of Conventional Medicine, Bahawalpur, Pakistan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03884920/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03884920
46,NCT03039569,Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Behavioral: Text messaging,University of Nebraska Lincoln|The Methodist Hospital Research Institute,"30 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Nebraska-Lincoln (with Methodist Hospital System), Lincoln, Nebraska, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03039569/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03039569
47,NCT02846779,Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes,Completed,Has Results,Diabetes,Other: Low intensity|Other: Moderate intensity|Other: High intensity,Brigham and Women's Hospital|Horizon Blue Cross Blue Shield of New Jersey,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Horizon Blue Cross Blue Shield of New Jersey, Newark, New Jersey, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02846779/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02846779
48,NCT01966978,"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study",Completed,Has Results,"Diabetes Mellitus, Type 2|Diabetes",Drug: Metformin|Drug: Detemir|Drug: Liraglutide|Drug: Insulin Aspart,University of Texas Southwestern Medical Center,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT01966978/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01966978
49,NCT03865381,Onduo Virtual Diabetes Clinic Study,Completed,Has Results,"Diabetes Mellitus, Type 2",Device: Onduo App,Verily Life Sciences LLC,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palo Alto Medical Foundation, Palo Alto, California, United States|Premier Medical Associates, Monroeville, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03865381/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03865381
50,NCT04302168,Choline Supplementation on Fetal Growth in Gestational Diabetes Mellitus,Recruiting,No Results Available,Gestational Diabetes,Dietary Supplement: Choline supplement|Dietary Supplement: Placebo,Maimonides Medical Center,18 Years to 50 Years   (Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Maimonides Medical Center, Brooklyn, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04302168/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04302168
51,NCT02647320,12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin 100 mg|Drug: DS-8500a 25mg|Drug: Placebo Tablet|Drug: Placebo Capsule,"Daiichi Sankyo, Inc.","18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Litchfield Park, Arizona, United States|Tempe, Arizona, United States|Anaheim, California, United States|Chino, California, United States|Chula Vista, California, United States|Fresno, California, United States|Gold River, California, United States|Greenbrae, California, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Hallandale Beach, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Pembroke Pines, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Avon, Indiana, United States|Evansville, Indiana, United States|Franklin, Indiana, United States|Greenfield, Indiana, United States|Council Bluffs, Iowa, United States|Troy, Michigan, United States|Edina, Minnesota, United States|Washington, Missouri, United States|Omaha, Nebraska, United States|Mooresville, North Carolina, United States|Morgantown, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Medford, Oregon, United States|Charleston, South Carolina, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Austin, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|South Jordan, Utah, United States|Burke, Virginia, United States|Victoria, British Columbia, Canada|Brampton, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02647320/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02647320
52,NCT01793909,Type 2 Diabetes and Exercise Function in Single Leg Exercises,Completed,Has Results,Type 2 Diabetes,Other: Single Leg Exercise Training,"University of Colorado, Denver","30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT01793909/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01793909
53,NCT02379078,Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes,Completed,Has Results,Diabetes Mellitus,Other: Shared decision-making aid|Other: Generic hard copy diabetes resources|Other: Generic online diabetes resources,Unity Health Toronto|Canadian Institutes of Health Research (CIHR),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,Canadian,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02379078/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02379078
54,NCT05431686,Group Visits for High Risk Type 1 Diabetes (T1D),Recruiting,No Results Available,Type 1 Diabetes,Behavioral: SMA visits|Behavioral: standard visits,"Children's National Research Institute|American Diabetes Association|DexCom, Inc.","8 Years and older   (Child, Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Children's National Hospital, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT05431686/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05431686
55,NCT04407650,Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus,Unknown status,No Results Available,Gestational Diabetes,Drug: Metformin|Drug: Ursodeoxycholic Acid,King's College London|Guy's and St Thomas' NHS Foundation Trust,"16 Years to 45 Years   (Child, Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,London,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04407650/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04407650
56,NCT05182359,Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus,Recruiting,No Results Available,Type 2 Diabetes,Other: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test,"University Hospitals Cleveland Medical Center|SomaLogic, Inc.","40 Years to 89 Years   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Hospitals, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT05182359/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05182359
57,NCT03727854,Effect of Premeal Protein-bar on Glycemic Control in Patients With Type 2 Diabetes,Completed,Has Results,Patients With Type 2 Diabetes,Dietary Supplement: Premeal protein enriched bar|Behavioral: Dietary modification,Seoul National University Hospital,"19 Years to 79 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Seoul National University Hospital, Seoul, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03727854/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03727854
58,NCT04949867,Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes,Recruiting,No Results Available,Type 1 Diabetes,Drug: Glucagon|Device: Closed-loop System,Steno Diabetes Center Copenhagen|Technical University of Denmark|Herlev Hospital,13 Years to 17 Years   (Child),Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark|Herlev Hospital, Herlev, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04949867/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04949867
59,NCT02372253,Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Verapamil|Drug: Placebo,University of Alabama at Birmingham|Juvenile Diabetes Research Foundation,18 Years to 45 Years   (Adult),Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02372253/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02372253
60,NCT03165110,Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System,Completed,Has Results,Diabetes Mellitus,Device: Onyx BG Meter / App System,Ascensia Diabetes Care,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"AMCR Institute, Escondido, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03165110/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03165110
61,NCT03006666,Integrating Community Health Workers to Improve Diabetes Prevention,Completed,No Results Available,Diabetes Mellitus,Behavioral: CHW Training|Behavioral: Data Only,NYU Langone Health,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"New York University Medical Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03006666/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03006666
62,NCT02607306,"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin degludec|Drug: liraglutide,Novo Nordisk A/S,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Adachi-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Akita-shi, Akita, Japan|Novo Nordisk Investigational Site, Annaka-shi, Gunma, Japan|Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Chiba-shi, Chiba, Japan|Novo Nordisk Investigational Site, Chitose, Hokkaido, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku,Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku,, Japan|Novo Nordisk Investigational Site, Edogawa-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Fujisawa-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Gunma, Japan|Novo Nordisk Investigational Site, Hachioji-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Ichihara-shi, Chiba, Japan|Novo Nordisk Investigational Site, Iruma-shi, Saitama, Japan|Novo Nordisk Investigational Site, Itabashi-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Itabashi-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Izumisano-shi,Osaka, Japan|Novo Nordisk Investigational Site, Izumisano-shi, Japan|Novo Nordisk Investigational Site, Kagoshima-shi, Kagoshima, Japan|Novo Nordisk Investigational Site, Kamakura-shi, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kanra-gun, Gunma, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kawaguchi-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kawasaki-shi,Kanagawa, Japan|Novo Nordisk Investigational Site, Kisarazu-shi, Chiba, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kuki-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kushiro-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Minato-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miura-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo, Japan|Novo Nordisk Investigational Site, Obihiro-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Obihiro-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Onga-gun, Fukuoka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Saijo-shi, Ehime, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Toshima-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Toyonaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Ube-shi, Yamaguchi, Japan|Novo Nordisk Investigational Site, Urasoe-shi,, Japan|Novo Nordisk Investigational Site, Yamaguchi-shi, Yamaguchi, Japan|Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02607306/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02607306
63,NCT03086330,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Andalusia, Alabama, United States|Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tempe, Arizona, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Lincoln, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Edgewater, Florida, United States|Novo Nordisk Investigational Site, Maitland, Florida, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Hutchinson, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Smithtown, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Gastonia, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Kinston, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Victoria, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Smiths Falls, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Nagakute-shi, Aichi, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Hoenefoss, Norway|Novo Nordisk Investigational Site, Namsos, Norway|Novo Nordisk Investigational Site, Olso, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Skedsmokorset, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03086330/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03086330
64,NCT04428645,Assessment of a Decision Support Tool in Participants With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Device: DailyDose Decision Support,Oregon Health and Science University,18 Years to 60 Years   (Adult),Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04428645/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04428645
65,NCT01813929,Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: Metformin|Drug: Placebo,"University of Colorado, Denver|US Department of Veterans Affairs",25 Years to 59 Years   (Adult),Phase 4,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Colorado Denver, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01813929/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01813929
66,NCT03829514,Fenofibrate in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type II",Drug: Fenofibrate,Medical University of South Carolina,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03829514/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03829514
67,NCT04131049,Comparison of Two Different Insulin Dose Calculation Algorithms in Type 1 Diabetes,Completed,No Results Available,Insulin-Dependent Diabetes Mellitus 1,Other: High GI calculated by CC (CHGI)|Other: Low GI calculated by CC (CLGI)|Other: High GI calculated by FII (FHGI)|Other: Low GI calculated by FII (FLGI),TC Erciyes University,"14 Years to 18 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Screening,"Erciyes University Faculty of Health Sciences, Kayseri, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04131049/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04131049
68,NCT03887416,Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes,Unknown status,No Results Available,Type2 Diabetes,Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]|Drug: Placebo Oral Tablet,LM Diagnósticos S.L.|AstraZeneca,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03887416/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03887416
69,NCT02800044,Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study,Terminated,No Results Available,Diabetes Mellitus,Device: Wearing a non-invasive glucose sensor,"University of California, San Diego","18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"UCSD, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02800044/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02800044
70,NCT03692208,Managing Diabetes to Gain Opportunities for a More Active Life,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: My Diabetes Goal Survey and Optional Care Management,University of Chicago,65 Years and older   (Older Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03692208/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03692208
71,NCT03421262,Pregnancy Outcomes and Medical Costs According to Gestational Diabetes Mellitus Diagnostic Criteria,Unknown status,No Results Available,Gestational Diabetes,Diagnostic Test: IADPSG Criteria|Diagnostic Test: NDDG Criteria,Hospital Mutua de Terrassa,18 Years to 50 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03421262/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03421262
72,NCT02582242,Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin,Completed,Has Results,Diabetes|Type 2 Diabetes Mellitus,Drug: biphasic insulin aspart 30,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Shenzhen, Guangdong, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Wuxi, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Dalian, Liaoning, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Chengdu, Sichuan, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Visakhapatnam, Andhra Pradesh, India|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mysore, Karnataka, India|Novo Nordisk Investigational Site, Madurai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Kaohsiung, Taiwan|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Bursa, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Kahramanmaras, Turkey|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Kiev, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02582242/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02582242
73,NCT03270436,Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population,Completed,Has Results,"Diabetes Mellitus, Type 2","Behavioral: Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|Behavioral: Partnership for Improving Lifestyle Intervention Diabetes Prevention Program",University of Arkansas|Patient-Centered Outcomes Research Institute,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03270436/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03270436
74,NCT02464033,EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: GAD-Alum|Drug: Vitamin D|Drug: Etanercept,"Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University","8 Years to 18 Years   (Child, Adult)",Phase 2,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Helsingborg Hospital, Helsingborg, Sweden|Linköping University Hospital, Linköping, Sweden|Lund University Hospital, Lund, Sweden|Skåne University Hospital, UMAS, Malmö, Sweden|Sachsska, Södersjukhuset, Stockholm, Sweden|Uddevalla Hospital, Uddevalla, Sweden|Västerås Hospital, Västerås, Sweden|Örebro University Hospital, Örebro, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02464033/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02464033
75,NCT02972996,Blueberry Consumption and Type 2 Diabetes,Completed,Has Results,Type2 Diabetes,Other: Blueberry|Other: Placebo,"Albany Research Institute, Inc.","45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stratton V.A. Medical Center, Albany, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02972996/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02972996
76,NCT02352974,GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: GAD-Alum|Drug: Vitamin D,"Johnny Ludvigsson|Swedish Child Diabetes Foundation|Ostergotland County Council, Sweden|Diamyd Medical AB|Linkoeping University","12 Years to 30 Years   (Child, Adult)",Phase 1,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Linköping University, Linköping, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02352974/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02352974
77,NCT03977662,Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes,Recruiting,No Results Available,Type 1 Diabetes,Combination Product: Co-transplantation of PTG with pancreatic islets,"Peter Stock|California Institute for Regenerative Medicine (CIRM)|University of California, San Francisco","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03977662/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03977662
78,NCT05067452,Pilot Trial of the Nutrition-Supported Diabetes Education Program,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Food support|Other: Case-management,"University of California, San Francisco|Project Open Hand|Contra Costa Health Services|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Contra Costa Health Services, Martinez, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT05067452/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05067452
79,NCT00780559,Improving Neuropathy and Mobility in People With Early Diabetes,Completed,Has Results,Diabetes|Physical Activity,Behavioral: Tailored Diet and Physical Activity|Behavioral: Standard of Care,"VA Office of Research and Development|University of Maryland, College Park|University of Michigan","30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Maryland, Baltimore, Maryland, United States|Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT00780559/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00780559
80,NCT02561130,Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: insulin glargine|Drug: metformin|Drug: Forxiga|Behavioral: Lifestyle therapy,Population Health Research Institute|AstraZeneca,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Calgary, Calgary, Alberta, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|St. Joseph's Hospital, London, Ontario, Canada|Western University, London, Ontario, Canada|LMC, Toronto, Ontario, Canada|St. Michaels's Hospital, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02561130/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02561130
81,NCT03150199,A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes,Completed,Has Results,Type2 Diabetes,Behavioral: Positive Psychology + Motivational Interviewing|Behavioral: MI-based Health Education Intervention,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03150199/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03150199
82,NCT05434754,Keeping in Touch (KiT) With Youth as They Transition to Adult Type 1 Diabetes Care,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 1",Other: eHealth Tool,"The Hospital for Sick Children|Trillium Health Partners|University Health Network, Toronto","17 Years to 19 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Oak Valley Health, Markham, Ontario, Canada|Trillium Health Partners, Mississauga, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|Saint Justine Hospital, Montréal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT05434754/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT05434754
83,NCT04959487,Changing Health Through Food Support for Diabetes,Recruiting,No Results Available,Type 2 Diabetes|Food Insecurity,Other: Food support|Other: Nutritional Counseling and education,"University of California, San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Project Open Hand","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Project Open Hand, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04959487/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04959487
84,NCT04311164,Steno Tech Explore: A Study of Insulin Pump Users With Type 1 Diabetes,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: Questionnaire-based survey|Other: No intervention given.,Steno Diabetes Center Copenhagen|Nordsjaellands Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,"Steno Diabetes Center Copenhagen, Gentofte, Denmark|Nordsjællands Hospital Hillerød, Hillerød, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04311164/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04311164
85,NCT02888691,Low Carbohydrate Diet vs. High Carbohydrate Diet in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Other: Low carbohydrate diet|Other: High carbohydrate diet,Hvidovre University Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hvidovre University Hospital, Hvidovre, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02888691/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02888691
86,NCT02510664,Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention,Completed,Has Results,Type 1 Diabetes,Behavioral: Diabetes Strengths Study,Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"12 Years to 18 Years   (Child, Adult)",Not Applicable,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Baylor College of Medicine, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02510664/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02510664
87,NCT01808690,EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: Metformin|Drug: Placebo,"University of Colorado, Denver|American Diabetes Association|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","12 Years to 21 Years   (Child, Adult)",Phase 3,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital Colorado and University of Colorado Denver Health Sciences Center, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT01808690/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01808690
88,NCT02544321,Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: Bromocriptine|Other: Placebo,"University of Colorado, Denver|Juvenile Diabetes Research Foundation","12 Years to 60 Years   (Child, Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Colorado-Denver, Anshutz Medical Campus, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02544321/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02544321
89,NCT02752880,YH1 in Poorly Controlled Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: YH1 group|Drug: placebo group,Chang Gung Memorial Hospital,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Taoyuan, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02752880/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02752880
90,NCT01651117,Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control,Completed,Has Results,Type 2 Diabetes Mellitus,Behavioral: Peer Mentoring,VA Office of Research and Development,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT01651117/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01651117
91,NCT02980978,diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED),Completed,Has Results,"Diabetes Mellitus, Type 2",Behavioral: Coaching,Minneapolis Heart Institute Foundation|Academy of Nutrition and Dietetics,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,USA,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02980978/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02980978
92,NCT03336528,Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Degludec|Drug: Glargine|Drug: Aspart,Emory University|Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Hospital, Atlanta, Georgia, United States|Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States|Mount Sinai, New York, New York, United States|Providence Medical Research Centre, Spokane, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03336528/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03336528
93,NCT03557151,Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence,Completed,Has Results,Type 1 Diabetes Mellitus,Other: Usual Care|Behavioral: Transdisciplinary Care-In Person & Telehealth,Nemours Children's Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),11 Years to 17 Years   (Child),Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03557151/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03557151
94,NCT02680054,Additional Insulin for Fat and Protein in Children With Diabetes Study,Terminated,Has Results,Type 1 Diabetes,"Drug: Insulin, Asp(B28)-",Oxford University Hospitals NHS Trust,"6 Years to 18 Years   (Child, Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Berkshire Hospital, Reading, Berkshire, United Kingdom|Oxford Children's Hospital, John Radcliffe Hospital, Oxford, Oxon, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02680054/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02680054
95,NCT04057248,Digital Self-Management and Health Coaching for Type 2 Diabetes - Impact on Diabetes Clinical and Wellness Indicators,Completed,Has Results,"Diabetes Mellitus, Type 2",Device: Dario Blood Glucose Monitoring System|Behavioral: CDE,LabStyle Innovations Ltd.,"35 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrinology Consultants of Pennsylvania, LLC (Decpa LLC), Feasterville, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04057248/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04057248
96,NCT03698708,Cognitive Adaptations to Reduce Emotional Stress Associated With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Behavioral: CARES Intervention,University of Kansas Medical Center,5 Years to 12 Years   (Child),Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Children's Mercy Hospital, Kansas City, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03698708/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03698708
97,NCT03350984,Insulin Schemes for Type 2 Diabetes Control,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: NPH insulin|Drug: Glargine and Lispro insulin,Universidad de Guanajuato,"18 Years to 100 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General de León, León, Guanajuato, Mexico","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03350984/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03350984
98,NCT04090242,Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes,Terminated,Has Results,"Diabetes Mellitus, Type 2",Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle,"Becton, Dickinson and Company","22 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mills Pennisula Medical Center-Diabetes Research Institute, San Mateo, California, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|East West Medical Research Institute, Honolulu, Hawaii, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04090242/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04090242
99,NCT02661165,How Does the Spirituality of Patients With Type 2 Diabetes Influence Their Self-management?,Completed,No Results Available,Type 2 Diabetes,,Natasha Duke|University of Southampton,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"University of Southampton, Southampton, Hampshire, United Kingdom","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02661165/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02661165
100,NCT03354286,Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System,Completed,No Results Available,Type 1 Diabetes Mellitus,"Behavioral: Developmental & Technological Demands|Behavioral: Distress Reduction|Behavioral: Nutrition, Set Point, & C:I Ratio|Behavioral: Hypoglycemia management|Behavioral: Minimal Intervention","Stanford University|University of Colorado, Denver|Indiana University|Yale University|University of South Florida",2 Years to 6 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Stanford University School of Medicine, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03354286/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03354286
101,NCT02682563,Renoprotective Effects of Dapagliflozin in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2|Diabetic Nephropathies",Drug: Dapagliflozin 10mg QD|Drug: Gliclazide 30mg QD,"M.H.H. Kramer|AstraZeneca|Amsterdam UMC, location VUmc","35 Years to 75 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VU University Medical Center, Amsterdam, Noord-Holland, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02682563/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02682563
102,NCT01683331,A Clinical Trial to Prevent New Onset Diabetes After Transplantation,Completed,Has Results,Prevention of New Onset Diabetes Among Kidney Transplant Patients,Drug: Insulin treatment for hyperglycemia,University of Michigan|Medical University of Vienna,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Michigan, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT01683331/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01683331
103,NCT03816761,Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Fast-acting insulin aspart|Device: iLet™,Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03816761/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03816761
104,NCT03222180,A Crowdsourced Social Media Portal for Parents of Very Young Children With Type 1 Diabetes,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Website,Nemours Children's Clinic,up to 6 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,"Nemours Children's Clinic, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03222180/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03222180
105,NCT03164538,A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Behavioral: Positive Psychology + Motivational Interviewing|Behavioral: Diabetes Education,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03164538/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03164538
106,NCT01258075,Colesevelam for Children With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: High-dose colesevelam|Drug: Low-dose colesevelam,"Daiichi Sankyo, Inc.",10 Years to 17 Years   (Child),Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Tucson, Arizona, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Oakland, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|New York, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Greenville, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01258075/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01258075
107,NCT03881956,Health-promoting Lifestyle Education on Women With Gestational Diabetes Mellitus,Completed,No Results Available,Gestational Diabetes Mellitus in Pregnancy,Behavioral: Health-promoting lifestyle education program,Istanbul University,19 Years to 43 Years   (Adult),Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,Istanbul,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03881956/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03881956
108,NCT02772783,"Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus",Completed,Has Results,"Diabetes Mellitus, Type 1",Other: high GI meal|Other: low GI meal|Drug: euglycemic insulin clamp|Drug: primed-variable insulin infusion,Boston Children's Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital,18 Years to 45 Years   (Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02772783/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02772783
109,NCT03466866,Reducing Emergency Diabetes Care for Older African Americans,Completed,No Results Available,Diabetes Mellitus,Behavioral: COPDE|Behavioral: Intensive Diabetes Education,Thomas Jefferson University,"40 Years and older   (Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03466866/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT03466866
110,NCT02948777,Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Evolocumab,Marja-Riitta Taskinen|Göteborg University|Clinical Research Institute HUCH Ltd,"18 Years to 77 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Helsinki University Hospital, Biomedicum 2U, Helsinki, Finland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02948777/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02948777
111,NCT03552523,The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Device: Bionic Pancreas|Other: Usual Care,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03552523/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03552523
112,NCT02877680,Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study,Completed,Has Results,"Diabetes Mellitus, Type 1",Behavioral: T1Doing Well,"Baylor College of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Feinberg School of Medicine, Northwestern University|United States Department of Agriculture (USDA)",12 Years to 17 Years   (Child),Not Applicable,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Children's Hospital, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02877680/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02877680
113,NCT02848833,JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: JARDIANCE 10mg|Drug: JARDIANCE 25mg,Boehringer Ingelheim,"19 Years to 110 Years   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Multiple Locations, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02848833/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02848833
114,NCT03668808,Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Degludec|Drug: Insulin Glargine|Device: TRESIBA® FLEXTOUCH®|Device: LANTUS® SOLOSTAR® INSULIN PEN,Sansum Diabetes Research Institute|Novo Nordisk A/S,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|inControl Diabetes Center, Honolulu, Hawaii, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03668808/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03668808
115,NCT03430856,Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients,Completed,Has Results,Type2 Diabetes Mellitus,Drug: Insulin Tregopil|Drug: Insulin Aspart,Biocon Limited,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diacon Hospital, Bangalore, Karnataka, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03430856/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03430856
116,NCT01928329,A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes,Completed,Has Results,Type I Diabetes,Drug: Exenatide (Bydureon®)|Drug: Placebo,Yale University,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|SUNY Upstate Medical University, Syracuse, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01928329/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01928329
117,NCT02455076,Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Exenatide|Drug: Glargine|Drug: Rapid-acting insulin analogs,Emory University,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02455076/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02455076
118,NCT01485614,Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083),Completed,Has Results,Diabetes Mellitus|Type 2 Diabetes,Drug: Sitagliptin|Drug: Metformin|Drug: Placebo to sitagliptin|Drug: Placebo to metformin|Drug: Glycemic Rescue 1|Biological: Glycemic Rescue 2,Merck Sharp & Dohme LLC,10 Years to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01485614/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01485614
119,NCT02846233,Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: GLP1 receptor agonist|Drug: basal insulin|Drug: SGLT2 inhibitor|Drug: Metformin,"University of California, San Francisco","21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Fresno, Fresno, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02846233/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02846233
120,NCT04230694,Continuous Glucose Monitoring of Hospitalized Patients With Diabetes,Enrolling by invitation,No Results Available,"Diabetes|Diabetes Mellitus|Glucose, High Blood|Glucose, Low Blood",Device: Dexcom Generation 6 CGM (Dexcom Gen6) device,Baylor Research Institute,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Baylor Scott & White Medical Center - Temple, Temple, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04230694/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04230694
121,NCT03092752,Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: oral antidiabetic drugs,Boehringer Ingelheim,"40 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Medical Data Vision Co. Ltd, Shinagawa-ku, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03092752/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03092752
122,NCT02492763,A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004),Terminated,Has Results,Type II Diabetes Mellitus,Drug: MK-8521|Drug: Placebo|Drug: Liraglutide|Drug: Metformin,Merck Sharp & Dohme LLC,"21 Years to 65 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02492763/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02492763
123,NCT02906709,"Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Omarigliptin|Drug: Placebo|Biological: Insulin,Merck Sharp & Dohme LLC,"20 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02906709/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02906709
124,NCT02542631,Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients,Completed,Has Results,"Diabetes Mellitus, Type 2",Device: Bolus Insulin Patch (Calibra Finesse)|Device: Insulin Pen (Novo-Nordisk FlexPen®),"Calibra Medical, Inc.|Medpace, Inc.","22 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Advanced Metabolic Care & Research Institute, Inc. (AMCR), Escondido, California, United States|Marin Endocrine Care and Research, Greenbrae, California, United States|National Research Institute - Wilshire, Los Angeles, California, United States|Diabetes Research Institute Mills-Peninsula Health Service, San Mateo, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Denver VA Medical Center, Denver, Colorado, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Physicians Research Associates, Lawrenceville, Georgia, United States|Endocrine Research Solutions, Inc, Roswell, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center PA, Idaho Falls, Idaho, United States|Northwestern University The Feinberg School of Medicine, Chicago, Illinois, United States|John H. Stroger, Jr. Hospital of Cook County Diabetes Center, Chicago, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, Des Moines, Iowa, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|Great Plains Diabetes, Wichita, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Medstar Health Research Institute, Hyattsville, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Park Nicollet Institute International Diabetes Center, Minneapolis, Minnesota, United States|SUNY Upstate Medical University, Syracuse, New York, United States|VA Medical Center Cleveland, Cleveland, Ohio, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Texas Diabetes & Endocrinology, P.A.- Austin, Austin, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|Diabetes & Glandular Disease Clinic, P.A., San Antonio, Texas, United States|South Texas Veterans Health Care System, San Antonio, Texas, United States|Consano Clinical Research, San Antonio, Texas, United States|Progressive Clinical Research, Bountiful, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Danville Internal Medicine, Danville, Virginia, United States|Private Practice-Larry Stonesifer, Federal Way, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Hopital Avicenne, Bobigny, France|Hopital Saint-Andre, Bordeaux, France|Hopital Hotel-Dieu Site Harfleur, Le Creusot, France|Lapeyronie Hospital, University Hospital Montpellier, Montpellier cedex 5, France|Hopital Lariboisiere, Centre Universitaire du Diabete et de ses Complications, Paris, France|CHU de Nantes-Hospital Nord Laennec, Saint-Herblain, France|GHMP les Portes du Sud, Venissieux, France|Diabeteszentrum DO-Diabetologisch, Dortmund, Germany|BAG Unterm Heilig Kreuz Unterm Heilig Kreuz, Fulda, Germany|Diabetes Zentrum und Praxis Prof. Pfutzner Parcusstr., Mainz, Germany|Royal United Hospital, Diabetes & Lipid Research Wolfson Centre, Bath, United Kingdom|Royal Blackburn Hospital, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom|Chorley and South Ribble Hospital, Chorley, United Kingdom|Ninewells Hospital & Medical School Diabetes Support Unit, Dundee, United Kingdom|Forth Valley Royal Hospital Dept. of Diabetes, Larbert, United Kingdom|Leicester General Hospital Leicester Diabetes Centre, Leicester, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02542631/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02542631
125,NCT02726490,Glyburide vs Glucovance in the Treatment of GDM,Terminated,No Results Available,Gestational Diabetes,Drug: Glyburide|Drug: Glucovance,"Texas Tech University Health Sciences Center, El Paso","18 Years and older   (Adult, Older Adult)",Early Phase 1,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TTUHSC El Paso, El Paso, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02726490/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02726490
126,NCT02248714,The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Dietary Supplement: Glucerna SR,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, Shanghai, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02248714/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02248714
127,NCT04028960,IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase,Terminated,Has Results,Type1diabetes,"Drug: Regular insulin (Humulin-R), intranasal route|Device: SipNose intranasal device",HealthPartners Institute|International Diabetes Center at Park Nicollet|Juvenile Diabetes Research Foundation,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Health Partners Institute dba International Diabetes Center, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT04028960/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04028960
128,NCT02564211,Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ipragliflozin|Drug: Sitagliptin,Merck Sharp & Dohme LLC,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02564211/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02564211
129,NCT01474018,QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: QR-bromocriptine,University of Texas Southwestern Medical Center,"30 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01474018/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01474018
130,NCT02630706,A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ertugliflozin 5 mg|Drug: Ertugliflozin 15 mg|Drug: Placebo matching ertugliflozin|Drug: Metformin|Drug: Glimepiride,Merck Sharp & Dohme LLC|Pfizer,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02630706/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02630706
131,NCT02239354,"A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus",Terminated,Has Results,Type 1 Diabetes Mellitus,Combination Product: VC-01™ Combination Product,ViaCyte|California Institute for Regenerative Medicine (CIRM),18 Years to 55 Years   (Adult),Phase 1|Phase 2,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of California at San Diego, San Diego, California, United States|University of Alberta Hospital, Edmonton, Alberta, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02239354/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02239354
132,NCT01903356,A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Trajenta duo,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,"Multiple Locations, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01903356/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01903356
133,NCT01999218,Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ertugliflozin 5 mg|Drug: Ertugliflozin 10 mg|Drug: Glimerpiride|Drug: Placebo to Ertugliflozin|Drug: Placebo to Glimepiride|Drug: Metformin|Drug: Sitagliptin,Merck Sharp & Dohme LLC|Pfizer,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01999218/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01999218
134,NCT02320253,REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus|Obesity,Behavioral: In Person Group (IP)|Behavioral: Telephone Conference Call Group (TCC)|Behavioral: Medical Nutrition Therapy (MNT),Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Charlestown HealthCare Center, Charlestown, Massachusetts, United States|Chelsea HealthCare Center, Chelsea, Massachusetts, United States|Revere HealthCare Center, Revere, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02320253/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02320253
135,NCT02033889,A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ertugliflozin 5 mg|Drug: Ertugliflozin 15 mg|Drug: Placebo to Ertugliflozin|Other: Glimepiride|Drug: Placebo to Glimepiride|Biological: Basal Insulin|Drug: Metformin,Merck Sharp & Dohme LLC|Pfizer,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02033889/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02033889
136,NCT02290925,The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose in Patients With Diabetes. A Randomized Control Study,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Kothala Himbutu Biscuit|Dietary Supplement: Placebo Biscuit,"Rajarata University, Sri Lanka","30 Years to 65 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teaching Hospital Anuradhapura, Anuradhapura, North Central Province, Sri Lanka","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02290925/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02290925
137,NCT03778580,Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Pyridoxamine Dihydrochloride|Drug: placebo,Columbia University,65 Years and older   (Older Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Columbia University Medical Center - Harkness Pavillion, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03778580/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03778580
138,NCT02532855,A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin|Drug: Dapagliflozin|Drug: Metformin|Drug: Matching placebo to sitagliptin|Drug: Matching placebo to dapagliflozin|Drug: Sulfonylurea,Merck Sharp & Dohme LLC,"25 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02532855/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02532855
139,NCT03095651,Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002),Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Biological: MK-5160 16 nmol/kg|Biological: MK-5160 32 nmol/kg|Biological: MK-5160 64 nmol/kg|Biological: Glargine 0.4 U/kg|Biological: Placebo to Glargine|Biological: Placebo to MK-5160|Drug: Dextrose|Biological: Glargine 0.6 U/kg,Merck Sharp & Dohme LLC,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ProSciento Inc. ( Site 0001), Chula Vista, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03095651/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03095651
140,NCT01760447,A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin plus metformin|Drug: Placebo to metformin|Drug: Metformin|Drug: Placebo to sitagliptin plus metformin|Drug: Sitagliptin plus metformin XR|Drug: Placebo to metformin XR|Drug: Insulin|Drug: Placebo to sitagliptin plus metformin XR|Drug: Metformin XR,Merck Sharp & Dohme LLC,10 Years to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01760447/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01760447
141,NCT03325114,Safety and Efficacy of Chlorthalidone in Type 1 Diabetes,Terminated,Has Results,Type 1 Diabetes Mellitus|Hypercalciuria,Drug: Chlorthalidone,University of Rochester|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"12 Years to 21 Years   (Child, Adult)",Phase 2,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Rochester, Rochester, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03325114/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03325114
142,NCT02174562,Improving Medication Adherence in Older African Americans With Diabetes,Completed,Has Results,Type 2 Diabetes|Mild Cognitive Impairment,Behavioral: Primary Care-Occupational Therapy|Behavioral: Enhanced Usual Care,Thomas Jefferson University|Johns Hopkins University,"60 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02174562/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02174562
143,NCT03170544,Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001),Completed,Has Results,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,"Drug: MK-1092, 4.0 nmol/kg|Drug: MK-1092, 8.0 nmol/kg|Drug: MK-1092, 16 nmol/kg|Drug: MK-1092, 32 nmol/kg|Drug: MK-1092, 64 nmol/kg|Drug: Glargine 3.0 nmol/kg|Drug: Lispro 1.2 nmol/kg|Drug: Placebo to glargine|Drug: Placebo to MK-1092|Other: Dextrose|Biological: Insulin",Merck Sharp & Dohme LLC,18 Years to 60 Years   (Adult),Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ProSciento Inc. ( Site 0001), Chula Vista, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03170544/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03170544
144,NCT03620890,Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Neutral Protamine Hagedorn (NPH)|Drug: Detemir insulin,"The University of Texas Health Science Center, Houston","18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Science Center of Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03620890/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03620890
145,NCT01753362,Liraglutide In Overweight Patients With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: liraglutide|Drug: placebo,University at Buffalo|Juvenile Diabetes Research Foundation,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","diabetes endocrinology center of WNY, Buffalo, New York, United States|Diabetes Endocrinology Research Center of WNY, Buffalo, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01753362/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01753362
146,NCT04801485,Myo-inositol in Prevention of Gestational Diabetes Mellitus in China,Recruiting,No Results Available,Gestational Diabetes Mellitus in Pregnancy,Dietary Supplement: Myo-inositol|Dietary Supplement: Placebo,Women's Hospital School Of Medicine Zhejiang University|Quzhou Maternal and Child Health Care Hospital,18 Years to 50 Years   (Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Xinning Chen, Hangzhou, Zhejiang, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04801485/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04801485
147,NCT04927858,A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Empagliflozin,Boehringer Ingelheim,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Boehringer Ingelheim AB, Stockholm, Sweden","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04927858/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04927858
148,NCT04079881,Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes,Terminated,Has Results,"Type 1 Diabetes|Hyperglycemia, Postprandial",Drug: Insulin,Washington University School of Medicine,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Washington University in St Louis, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04079881/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04079881
149,NCT03483129,15-minute Individual Consultation to Improve Blood Glucose Control in Pre-diabetes,Completed,No Results Available,Pre-Diabetes,Behavioral: Consultation,Aberystwyth University|Hywel Dda Health Board,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Carwyn James Building, Aberystwyth, Ceredigion, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03483129/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03483129
150,NCT03617770,A Sleep Intervention in Type 1 Diabetes,Completed,Has Results,Short Sleep Phenotype|Type1diabetes,Behavioral: Sleep Opt-In|Behavioral: Healthy Living,University of Illinois at Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Chicago,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03617770/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03617770
151,NCT03457818,Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab,Terminated,Has Results,"Diabetes Mellitus, Type 2|Osteoporosis",Drug: Denosumab 60 mg/ml [Prolia]|Other: Placebo,Mishaela Rubin|Columbia University,"50 Years to 90 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Columbia University Irving Medical Center - Harkness Pavillion, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03457818/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03457818
152,NCT02408120,Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin glargine|Drug: Insulin aspart|Drug: Supplemental insulin aspart,Emory University,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02408120/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02408120
153,NCT02235298,Dapagliflozin Effects on Epicardial Fat,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Metformin|Drug: Placebo,University of Miami|AstraZeneca,18 Years to 64 Years   (Adult),Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Miami, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02235298/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02235298
154,NCT03415139,Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant,Recruiting,No Results Available,Diabetes Mellitus|Cancer,Drug: Oral Glucose Tolerance Test (OGTT)|Drug: 2 OGTTs with and without GLP-1 analogue|Drug: Hyperglycemic clamp procedure,Vanderbilt-Ingram Cancer Center,"18 Years to 90 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03415139/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03415139
155,NCT05333718,Characterization of Type 2 Diabetes Subgroups at Diagnosis: a Necessary Step Towards Precision Medicine in Diabetes.,Recruiting,No Results Available,Characteristics Disease|Type 2 Diabetes,,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Institut Català de la Salut,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Hospital of Santa Creu i Sant Pau, Barcelona, Catalunya, Spain|Institut Català de la Salut, Barcelona, Catalunya, Spain","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT05333718/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT05333718
156,NCT00756613,The VA Diabetes Trial Follow-up Study (VADT-FS),Completed,Has Results,Diabetes|Glycemic Control,,VA Office of Research and Development,"40 Years and older   (Adult, Older Adult)",,U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|Hines VAMC, Hines IL, Hines, Illinois, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT00756613/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT00756613
157,NCT02004366,Linagliptin Inpatient Trial,Completed,Has Results,Type 2 Diabetes,Drug: Linagliptin|Drug: Basal Bolus|Drug: Linagliptin + 50% Glargine dose on discharge|Drug: Linagliptin + 80% Glargine,Emory University|Boston Medical Center|Rush University|University of Denver,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Denver, Colorado, United States|Emory University Hospital, Atlanta, Georgia, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02004366/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02004366
158,NCT01901055,Diabetes-Obstructive Sleep Apnea Treatment Trial,Terminated,Has Results,Type 2 Diabetes|Obstructive Sleep Apnea,Device: CPAP|Device: Sham-CPAP|Behavioral: Diabetes Education,Eileen R. Chasens|University of Pittsburgh,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VAMC, Detroit, Michigan, United States|Pittsburgh Veterans Administration Medical Center, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|West Virginia University, Morgantown, West Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT01901055/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01901055
159,NCT02328326,Caring Others Increasing EngageMent in PACT,Completed,Has Results,Diabetes,Other: CO-IMPACT|Other: PACT,VA Office of Research and Development,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02328326/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02328326
160,NCT05174975,Effectiveness of App-based Positive Psychological Intervention on Patients Newly Diagnosed With Type 2 Diabetes,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: App-based Positive Psychological Intervention,Tri-Service General Hospital|Kaohsiung Medical University,20 Years to 64 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Tri-Service General Hospital, Taipei, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT05174975/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05174975
161,NCT02762708,"The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes Mellitus|Obesity,"Procedure: Roux-en-Y Gastric Bypass (RYGB)|Behavioral: Caloric Restriction|Drug: Exendin-9,39|Drug: Normal Saline",Mayo Clinic,"20 Years to 65 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02762708/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02762708
162,NCT02912455,CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes,Terminated,Has Results,"Diabetes Mellitus, Type 2|Obesity",Drug: canagliflozin|Drug: Placebo (for canagliflozin),"The Cleveland Clinic|Janssen Scientific Affairs, LLC","20 Years to 75 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02912455/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02912455
163,NCT01951339,Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes|Cardiovascular Disease,Drug: Sitagliptin|Drug: Glimepiride|Drug: Placebo,"University of Colorado, Denver|Merck Sharp & Dohme LLC","22 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01951339/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01951339
164,NCT02671136,Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes,Terminated,Has Results,Diabetes|Periodontitis,Device: Hyperbaric Oxygen therapy|Other: Conventional Wound Therapies,Loma Linda University,"35 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Loma Linda University, Loma Linda, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02671136/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02671136
165,NCT02325466,Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes,Completed,Has Results,Peripheral Artery Disease|Type 2 Diabetes,Drug: Aspirin|Drug: Ticagrelor|Drug: Aspirin Placebo|Drug: Ticagrelor Placebo,Icahn School of Medicine at Mount Sinai,"18 Years and older   (Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Icahn School of Medicine at Mount Sinai, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02325466/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02325466
166,NCT04098575,A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Empagliflozin,Boehringer Ingelheim,"18 Years to 80 Years   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Diabetes Agenda 2010 GmbH, Mahlow, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04098575/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04098575
167,NCT03333525,Does Protein and Fat Content of Meal Increase Glucose Concentrations,Completed,No Results Available,Type 1 Diabetes Mellitus,Other: Calculation of insulin dosages for different meals,TC Erciyes University|Hacettepe University,"16 Years to 18 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kayseri, ‎Turkiye","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT03333525/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03333525
168,NCT01053078,Naltrexone and Hypoglycemia in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes|Hypoglycemia Unawareness,Drug: Naltrexone|Other: Placebo,University of Minnesota|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|American Diabetes Association,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT01053078/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01053078
169,NCT03495908,Regular Insulin vs Rapid Insulin Delivered by V-Go,Completed,Has Results,Type 2 Diabetes|Type 2 Diabetes Mellitus,Device: VGo,"East Coast Institute for Research|Valeritas, Inc.|Dallas Diabetes Research Center","21 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"East Coast Institute for Research, LLC, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Macon, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03495908/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03495908
170,NCT04214600,Cognitive Behavioral Therapy for Adherence in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes|Depression,Behavioral: Cognitive Behavioral Therapy (CBT),Cairo University,"35 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Al-Agouza Family Medicine Center (AFMC)., Agouza, Giza, Egypt","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT04214600/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04214600
171,NCT04026750,Insulin Tolerance Test Study in Patients With Type 1 Diabetes,Terminated,Has Results,Type 1 Diabetes|Hypoglycemia,Drug: Pitolisant,High Point Clinical Trials Center|Ferox Therapeutics,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","High Point Clinical Trials Center, High Point, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04026750/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04026750
172,NCT01919489,Liraglutide Hospital Discharge Trial,Completed,Has Results,Type 2 Diabetes,Drug: Liraglutide + OADs|Drug: Glargine + OADs,Emory University|Novo Nordisk A/S,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Emory Universtiy Hospital at MIdtown, Atlanta, Georgia, United States|State University of NY at Buffalo, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01919489/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01919489
173,NCT03553862,Collaborative Care Model on Type 2 Diabetic Patients,Completed,No Results Available,Type2 Diabetes,Behavioral: collaborative care,"National University, Singapore","21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Chua Chu Kang Polyclinic, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03553862/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03553862
174,NCT04655131,Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hyperglycemia, Postprandial",Dietary Supplement: Whey protein isolate,University Hospitals Cleveland Medical Center,5 Years to 17 Years   (Child),Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University Hospitals Cleveland medical Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04655131/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04655131
175,NCT02525263,Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD),Terminated,Has Results,Chronic Kidney Disease|Type 2 Diabetes,Biological: Neo-Kidney Augment,Prokidney|CTI Clinical Trial and Consulting Services,"30 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of North Carolina- Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02525263/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02525263
176,NCT03290768,Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3),Completed,Has Results,Type2 Diabetes,Device: Continuous Glucose Monitor (CGM)|Device: Activity Tracker|Behavioral: Coaching,"Savvysherpa, Inc.",65 Years and older   (Older Adult),Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Southwest Medical Associates, Las Vegas, Nevada, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03290768/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03290768
177,NCT03326232,Real-time Continuous Glucose Monitoring,Unknown status,No Results Available,Gestational Diabetes,Device: Continuous glucose monitoring,Eastern Virginia Medical School|Medtronic,18 Years to 45 Years   (Adult),Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eastern Virginia Medical School, Norfolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03326232/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03326232
178,NCT01786564,Home Sleep and Circadian Phase: Mediators of Diabetes Risk,Completed,Has Results,Sleep Deprivation|Diabetes|Circadian Dysregulation,,Northwestern University,21 Years to 50 Years   (Adult),,Other,Observational,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,"Northwestern University, Chicago, Illinois, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01786564/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01786564
179,NCT02973477,Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D),Completed,Has Results,Type2 Diabetes|Cardiovascular Diseases,Drug: Dapagliflozin|Drug: Glimepiride,University of Michigan|AstraZeneca,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Michigan, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02973477/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02973477
180,NCT05173675,Empathy in Action: Sunshine Calls for Life With Diabetes,Enrolling by invitation,No Results Available,"Diabetes Mellitus, Type 2|Diabetes|Mental Health|Health Behavior",Behavioral: Empathy in Action for life with diabetes.|Behavioral: Control Phase 2 Materials Only,University of Texas at Austin|Lone Star Circle of Care,"21 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lone Star Circle of Care at Ben White Health Clinic, Austin, Texas, United States|Lone Star Circle of Care at El Buen Samaritano, Austin, Texas, United States|Lone Star Circle of Care at Collinfield, Austin, Texas, United States|Lone Star Circle of Care at Northwest Austin, Austin, Texas, United States|Lone Star Circle of Care at Bastrop, Bastrop, Texas, United States|Lone Star Circle of Care at Cedar Park, Cedar Park, Texas, United States|Lone Star Circle of Care at Lake Aire Medical Center, Georgetown, Texas, United States|Lone Star Circle of Care at Pflugerville, Pflugerville, Texas, United States|Lone Star Circle of Care at Texas A&M Health Science Center, Round Rock, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT05173675/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT05173675
181,NCT02061969,ADA Linagliptin in Long Term Care,Completed,Has Results,Diabetes,Drug: linagliptin|Drug: insulin glargine,Emory University|American Diabetes Association,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Crestvew Nursing Home, Atlanta, Georgia, United States|Budd Terrace Nursing Home, Atlanta, Georgia, United States|Wesley Woods Nursing Home, Atlanta, Georgia, United States|VA Nursing Home, Decatur, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02061969/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02061969
182,NCT02170870,Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus,Completed,Has Results,Dyspepsia|Diabetes Mellitus With Gastrointestinal Symptoms,Drug: Exendin 9-39|Drug: Microlipid|Drug: Placebo,Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02170870/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02170870
183,NCT02024477,Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients,Completed,Has Results,Type 2 Diabetes,Drug: Saxagliptin|Drug: Placebo,George Washington University|AstraZeneca,"40 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical Faculty Associates Inc, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02024477/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02024477
184,NCT02580877,Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20),Completed,Has Results,Type 1 Diabetes,Drug: 67.5 mg oral insulin crystals daily|Drug: 500mg oral insulin crystals every other week,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Type 1 Diabetes TrialNet,"3 Years to 45 Years   (Child, Adult)",Phase 2,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Emory Children's Center, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|San Raffaele Hospital, Milan, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02580877/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02580877
185,NCT02904512,"Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.",Completed,Has Results,Diabetes Mellitus,Device: Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Other: Point of Care (POC) blood glucose,"University of Maryland, Baltimore|DexCom, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baltimore VA Medical Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02904512/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02904512
186,NCT03324451,The Effectiveness of Intervention on Insulin Injection,Completed,Has Results,Type 2 Diabetes Mellitus,Behavioral: TTM Intervention for Insulin Initiation|Behavioral: Usual care,Kaohsiung Medical University Chung-Ho Memorial Hospital,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Lee's clinic, Kaohsiung, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03324451/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03324451
187,NCT03258281,Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus,Terminated,No Results Available,"Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Percutaneous Coronary Intervention",Drug: Evolocumab|Drug: Placebo,Inova Health Care Services,"Child, Adult, Older Adult",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Inova Fairfax Hospital, Falls Church, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03258281/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03258281
188,NCT03460899,Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation,Completed,Has Results,"Diabetes Mellitus With Hypoglycemia|Diabetes Mellitus, Type 2|Hypoglycemia|Hypoglycemic Episode",Other: Euglycaemic Clamp|Other: Hyperinsulinaemic/Hypoglycaemic Clamp,Medical University of Graz|Merck Sharp & Dohme LLC,18 Years to 64 Years   (Adult),Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Medical University of Graz, Department for Internal Medicine, Graz, Austria","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03460899/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03460899
189,NCT02558296,Bexagliflozin Efficacy and Safety Trial,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo,Theracos,"40 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site 1090, Gilbert, Arizona, United States|Research Site 1041, Little Rock, Arkansas, United States|Research Site 1073, Azusa, California, United States|Research Site 1076, Concord, California, United States|Research Site 1078, Fresno, California, United States|Research Site 1089, Harbor City, California, United States|Research Site 1058, Lincoln, California, United States|Research Site 1051, Los Angeles, California, United States|Research Site 1004, Los Angeles, California, United States|Research Site 1068, Montclair, California, United States|Research Site 1077, Orange, California, United States|Research Site 1218, Denver, Colorado, United States|Research Site 1092, Golden, Colorado, United States|Research Site 1216, Norwalk, Connecticut, United States|Research Site 1083, Newark, Delaware, United States|Research Site 1057, Boca Raton, Florida, United States|Research Site 1059, Brooksville, Florida, United States|Research Site 1050, Panama City, Florida, United States|Research Site 1099, Port Charlotte, Florida, United States|Research Site 1066, Tampa, Florida, United States|Research Site 1072, Augusta, Georgia, United States|Research Site 1082, Pocatello, Idaho, United States|Research Site 1258, Champaign, Illinois, United States|Research Site 1043, Anderson, Indiana, United States|Research Site 1071, Avon, Indiana, United States|Research Site 1086, Des Moines, Iowa, United States|Research Site 1224, Covington, Kentucky, United States|Research Site 1228, Annapolis, Maryland, United States|Research Site 1221, Baltimore, Maryland, United States|Research Site 1079, Hyattsville, Maryland, United States|Research Site 1223, Midland, Michigan, United States|Research Site 1217, Petoskey, Michigan, United States|Research Site 1254, Ypsilanti, Michigan, United States|Research Site 1054, Saint Louis, Missouri, United States|Research Site 1060, Saint Louis, Missouri, United States|Research Site 1252, Kalispell, Montana, United States|Research Site 1052, Omaha, Nebraska, United States|Research Site 1263, Omaha, Nebraska, United States|Research Site 1080, Las Vegas, Nevada, United States|Research Site 1219, Somerset, New Jersey, United States|Research Site 1044, Albuquerque, New Mexico, United States|Research Site 1264, Bronx, New York, United States|Research Site 1220, Saratoga Springs, New York, United States|Research Site 1049, West Seneca, New York, United States|Research Site 1085, Chapel Hill, North Carolina, United States|Research Site 1074, Charlotte, North Carolina, United States|Research Site 1056, Morehead City, North Carolina, United States|Research Site 1229, Wilmington, North Carolina, United States|Research Site 1064, Winston-Salem, North Carolina, United States|Research Site 1075, Fargo, North Dakota, United States|Research Site 1266, Lindsay, Oklahoma, United States|Research Site 1055, Oklahoma City, Oklahoma, United States|Research Site 1265, Oklahoma City, Oklahoma, United States|Research Site 1046, Oklahoma City, Oklahoma, United States|Research Site 1260, Lancaster, Pennsylvania, United States|Research Site 1042, Cumberland, Rhode Island, United States|Research Site 1225, Austin, Texas, United States|Research Site 1259, Dallas, Texas, United States|Research Site 1048, Kingwood, Texas, United States|Research Site 1070, Lampasas, Texas, United States|Research Site 1222, Lewisville, Texas, United States|Research Site 1081, North Richland Hills, Texas, United States|Research Site 1226, San Antonio, Texas, United States|Research Site 1053, San Antonio, Texas, United States|Research Site 1063, Salt Lake City, Utah, United States|Research Site 1230, Salem, Virginia, United States|Research Site 5013, Vancouver, British Columbia, Canada|Research Site 5015, Cambridge, Ontario, Canada|Research Site 5012, Hamilton, Ontario, Canada|Research Site 5023, London, Ontario, Canada|Research Site 5016, Peterborough, Ontario, Canada|Research Site 5005, Sudbury, Ontario, Canada|Research Site 5022, Toronto, Ontario, Canada|Research Site 5014, Toronto, Ontario, Canada|Research Site 5008, Gatineau, Quebec, Canada|Research Site 5007, St-Charles-Borromee, Quebec, Canada|Research Site 5009, St. Georges, Quebec, Canada|Research Site 5006, Quebec, Canada|Research Site 3116, Benesov, Czechia|Research Site 3106, Brandys nad Labem, Czechia|Research Site 3107, Brno, Czechia|Research Site 3118, Brno, Czechia|Research Site 3109, Cesky Krumlov, Czechia|Research Site 3114, Havirov, Czechia|Research Site 3103, Hradec Kralove, Czechia|Research Site 3110, Krnov, Czechia|Research Site 3102, Kromeriz, Czechia|Research Site 3105, Marianske Lazne, Czechia|Research Site 3113, Plzen, Czechia|Research Site 3104, Praha, Czechia|Research Site 3111, Praha, Czechia|Research Site 3112, Praha, Czechia|Research Site 3115, Uherske Hradiste, Czechia|Research Site 6104, Copenhagen, Denmark|Research Site 6103, Copenhagen, Denmark|Research Site 6105, Copenhagen, Denmark|Research Site 7007, Chuncheon, Gangwon-Do, Korea, Republic of|Research Site 7001, Wonju, Gangwon-Do, Korea, Republic of|Research Site 7004, Anyang, Gyeonggi-do, Korea, Republic of|Research Site 7005, Guri, Gyeonggi-do, Korea, Republic of|Research Site 7006, Busan, Korea, Republic of|Research Site 7002, Gwangju, Korea, Republic of|Research Site 7008, Incheon, Korea, Republic of|Research Site 2015, Guadalajara, Jalisco, Mexico|Research Site 2013, Culiacan, Sinaloa, Mexico|Research Site 2008, Tampico, Tamaulipas, Mexico|Research Site 2012, Merida, Yucatan, Mexico|Research Site 2011, Aguascalientes, Mexico|Research Site 2009, Chihuahua, Mexico|Research Site 2014, Mexico, Mexico|Research Site 2016, Queretaro, Mexico|Research Site 2010, Veracruz, Mexico|Research Site 5110, Amsterdam, Netherlands|Research Site 5113, Harderwijk, Netherlands|Research Site 5101, Hertogenbosch, Netherlands|Research Site 5112, Hoofddorp, Netherlands|Research Site 5102, Hoogeveen, Netherlands|Research Site 5106, Rotterdam, Netherlands|Research Site 5103, Zwijndrecht, Netherlands|Research Site 7122, Aleksandrow Lodzki, Poland|Research Site 7113, Gdansk, Poland|Research Site 7119, Gdynia, Poland|Research Site 7109, Grodzisk Mazowiecki, Poland|Research Site 7115, Katowice, Poland|Research Site 7106, Katowice, Poland|Research Site 7121, Katowice, Poland|Research Site 7111, Kutno, Poland|Research Site 7104, Lodz, Poland|Research Site 7135, Lodz, Poland|Research Site 7120, Lublin, Poland|Research Site 7108, Olawa, Poland|Research Site 7118, Otwock, Poland|Research Site 7107, Pulawy, Poland|Research Site 7105, Sobotka, Poland|Research Site 7112, Sochaczew, Poland|Research Site 7123, Warsaw, Poland|Research Site 7117, Warszawa, Poland|Research Site 7116, Warszawa, Poland|Research Site 9309, Lomonosov, Russian Federation|Research Site 9303, Moscow, Russian Federation|Research Site 9315, Moscow, Russian Federation|Research Site 9314, Novosibirsk, Russian Federation|Research Site 9318, Novosibirsk, Russian Federation|Research Site 9301, Novosibirsk, Russian Federation|Research Site 9310, Saint Petersburg, Russian Federation|Research Site 9304, Saint Petersburg, Russian Federation|Research Site 9307, Saint Petersburg, Russian Federation|Research Site 9311, Saint Petersburg, Russian Federation|Research Site 9312, Saint Petersburg, Russian Federation|Research Site 9302, Tomsk, Russian Federation|Research Site 8001, Kaohsiung, Taiwan|Research Site 8002, New Taipei, Taiwan|Research Site 8006, Taichung, Taiwan|Research Site 8005, Tainan, Taiwan|Research Site 8007, Taipei, Taiwan|Research Site 8004, Taipei, Taiwan|Research Site 8003, Taipei, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02558296/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02558296
190,NCT02788903,A Patient-Centered PaTH to Addressing Diabetes,Completed,Has Results,Obesity|Diabetes|Covid19,Other: Weight Counseling,Milton S. Hershey Medical Center|Patient-Centered Outcomes Research Institute,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Other,Pennsylvania,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02788903/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02788903
191,NCT05220917,Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study,"Active, not recruiting",No Results Available,Cardiovascular Events|Type2 Diabetes|Renal Disease,Drug: SGLT2 inhibitor|Drug: DPP-4 inhibitor|Drug: GLP-1RA|Drug: 2nd generation SU,Brigham and Women's Hospital|Patient-Centered Outcomes Research Institute|VA Boston Healthcare System|McGill University,"18 Years and older   (Adult, Older Adult)",,Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT05220917/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT05220917
192,NCT02132676,Shared Health Appointments and Reciprocal Enhanced Support,Completed,Has Results,Diabetes Insipidus,,VA Office of Research and Development,"18 Years and older   (Adult, Older Adult)",,U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Northern California Health Care System, Mather, CA, Sacramento, California, United States|VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02132676/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02132676
193,NCT04267770,Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion,Completed,Has Results,Type 1 Diabetes,Drug: Insulin (circadian)|Drug: Insulin (flat rate),Imperial College London,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Imperial College Clinical Research Facility, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04267770/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04267770
194,NCT03987191,Insulin Pump to Multiple Daily Injection Transition Clinical Trial,Completed,Has Results,Type 1 Diabetes,Drug: Multiple daily ijnection using Insulin Degludec and Insulin Aspart,"University of Colorado, Denver","18 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03987191/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03987191
195,NCT00179777,TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk,Completed,Has Results,"Diabetes Mellitus, Type 1",Dietary Supplement: Hydrolysed infant formula|Dietary Supplement: Nonhydrolysed infant formula,"University of Helsinki|US Congress|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Canadian Institutes of Health Research (CIHR)|Juvenile Diabetes Research Foundation|European Community (EC)|European Foundation for the Study of Diabetes|Mead Johnson Nutrition|Academy of Finland|Diabetes Research Foundation, Finland|Dutch Diabetes Research Foundation",up to 7 Days   (Child),Not Applicable,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","The University of South Florida, Tampa, Florida, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Robarts Research Institute, London, Ontario, Canada|3rd Faculty of Medicine, Charles University, University Hospital Vinohrady, Prague, Czechia|Tartu University Children's Hospital, Tartu, Estonia|University of Helsinki, Helsinki, Finland|Kinderkrankenhaus auf der Bult, Hannover, Germany|Semmelweis Medical University, Budapest, Hungary|St. Michele Hospital, Cagliari, Sardinia, Italy|University Campus Bio-Medico of Rome, Rome, Italy|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Sophia Children's Hospital, Rotterdam, Netherlands|Medical University of Wroclaw, Wroclaw, Poland|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Clinico San Carlos, Madrid, Spain|University of Linkoping, Linkoping, Sweden|University Children's Hospital, Zurich, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT00179777/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00179777
196,NCT04536480,Impact of Meal Timing on Glycemic Profiles in Adolescents With Type 2 Diabetes,Recruiting,No Results Available,Pediatric Obesity|Type 2 Diabetes|Time Restricted Eating,Behavioral: Time Limited Eating|Behavioral: Components Common to All Study Arms.|Behavioral: Control|Device: Continuous Glucose Monitor,Children's Hospital Los Angeles,"14 Years to 21 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Children's Hospital of Los Angeles, Los Angeles, California, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04536480/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04536480
197,NCT02014740,Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes|Overweight|Obesity,Drug: Liraglutide|Drug: Metformin,University of Miami,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02014740/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02014740
198,NCT03899402,Triple Therapy in T1DM,Unknown status,No Results Available,Type 1 Diabetes Mellitus,Drug: Insulin|Drug: Semaglutide|Drug: Dapagliflozin|Drug: Placebo to Dapagliflozin,State University of New York at Buffalo|University of Glasgow,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Diabetes and Endocrinology Research Center of WNY, Williamsville, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03899402/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03899402
199,NCT02088658,Technology Intensified Diabetes Education Study in African Americans,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset|Diabetes Mellitus, Non-Insulin-Dependent|Diabetes Mellitus, Noninsulin Dependent|Diabetes Mellitus, Type II",Behavioral: Technology Intensified,Medical College of Wisconsin|Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02088658/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02088658
200,NCT02722499,Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST),Completed,Has Results,"Diabetes Mellitus|Type 2 Diabetes Mellitus|Adult-Onset Diabetes Mellitus|Non-Insulin-Dependent Diabetes Mellitus|Noninsulin Dependent Diabetes Mellitus, Type II",Behavioral: High Frequency Financial Incentive|Behavioral: Moderate Frequency Financial Incentive|Behavioral: Low Frequency Financial Incentive,Medical College of Wisconsin|Medical University of South Carolina,"21 Years to 100 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02722499/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02722499
201,NCT02920918,Treatment of Diabetes in Patients With Systolic Heart Failure,Completed,Has Results,"Heart Failure, Systolic|Diabetes Mellitus, Type 2",Drug: Canagliflozin|Drug: Sitagliptin,"Virginia Commonwealth University|Janssen Scientific Affairs, LLC","18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02920918/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02920918
202,NCT04847778,Assess the Impact of Insulclock on Glycemic Variability and Treatment Compliance in Uncontrolled DM1 Patients,Completed,No Results Available,"Diabetes Mellitus, Type 1","Device: Use of Insulclock system, both Insulclock device and Insulclock 360 app.|Device: Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.",Hospital General de Segovia|Insulcloud S.L.,"14 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Endocrinology and Nutrition Unit, Arquitecto Marcide Hospital, Ferrol, A Coruña, Spain|Endocrinology and Nutrition Service, Hospital de Cruces., Bilbao, Spain|Endocrinology and Nutrition Service, Hospital Central de Asturias, Oviedo, Spain|Endocrinology and Nutrition Unit /Diabetes Unit, Hospital General de Segovia, Segovia, Spain","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04847778/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04847778
203,NCT04409587,Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump,Completed,No Results Available,Type1 Diabetes Mellitus,Drug: Aspart,Mountain Diabetes and Endocrine Center|Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04409587/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04409587
204,NCT03528174,Single Hormone Closed Loop Study With PDT Sensor,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Artificial Pancreas Control system (APC)|Device: Pacific Diabetes Technologies CGM Insulin Infusion system,Oregon Health and Science University,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03528174/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03528174
205,NCT04414579,The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus,Recruiting,No Results Available,Type 1 Diabetes Mellitus,Drug: Faster Insulin Aspart (Fiasp®),Mountain Diabetes and Endocrine Center,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04414579/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04414579
206,NCT01833988,The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas,Completed,Has Results,Type 1 Diabetes,Device: Bi-hormonal Bionic Pancreas|Other: Usual Care,Massachusetts General Hospital|Boston University,"12 Years to 20 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT01833988/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01833988
207,NCT03977727,FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Fiasp®|Drug: Novolog®|Device: 670G hybrid closed loop continuous subcutaneous insulin infusion system,"Texas Diabetes & Endocrinology, P.A.","18 Years and older   (Adult, Older Adult)",Phase 3,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Diabetes & Endocrinology, Austin, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03977727/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03977727
208,NCT02556554,Pilot Prospective CGM Quality Improvement (QI) Project in Pregnancy,Completed,Has Results,"Diabetes Mellitus, Type I",Device: Dexcom G4 or G5 Platinum CGM system|Device: Dexcom G4 or G5 Platinum CGM system with Share,"University of Colorado, Denver|DexCom, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02556554/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02556554
209,NCT03549104,A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Behavioral: Fear Reduction Intervention|Behavioral: Attention Control,University of Illinois at Chicago|Loyola University Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),18 Years to 35 Years   (Adult),Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Illinois at Chicago, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03549104/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03549104
210,NCT03798717,To Bathe or Not to Bathe,Completed,Has Results,"Diabetes Mellitus, Type 2",Diagnostic Test: Heating,University of Portsmouth|Portsmouth Hospitals NHS Trust,"35 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Sport and Exercise Science, Portsmouth, Hampshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03798717/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03798717
211,NCT01831921,Latinos Combating Diabetes,Completed,Has Results,Pre Diabetes|Obesity|Metabolic Syndrome,Behavioral: Lifestyle Weight Loss|Behavioral: Counseling,Wake Forest University Health Sciences|National Institute on Minority Health and Health Disparities (NIMHD),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT01831921/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01831921
212,NCT03338803,Real World Glycemic Effectiveness of Linagliptin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,"40 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Optum, Eden Prairie, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03338803/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03338803
213,NCT05216172,AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce,Recruiting,No Results Available,"Type 2 Diabetes|Diabetes Mellitus, Type 2|Renal Transplant|Kidney Transplant; Complications|End Stage Renal Disease",Drug: AZD1656|Drug: Placebo,Queen Mary University of London|AstraZeneca,"18 Years and older   (Adult, Older Adult)",Phase 2,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal London Hospital Barts Health NHS Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT05216172/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05216172
214,NCT02779556,Health Literacy Intervention to Improve Diabetes Outcomes Among Rural Primary Care Patients,Completed,Has Results,Diabetes,Other: ACP Living with Diabetes Guide|Other: ADA Living Well with Diabetes Workbook,University of Arkansas|Northwestern University|Louisiana State University Health Sciences Center Shreveport|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"21 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAMS Family Medical Center Northwest, Fayetteville, Arkansas, United States|UAMS Family Medical Center Fort Smith, Fort Smith, Arkansas, United States|UAMS Family Medical Center Jonesboro, Jonesboro, Arkansas, United States|UAMS Family Medical Center Magnolia, Magnolia, Arkansas, United States|UAMS Family Medical Center Pine Bluff, Pine Bluff, Arkansas, United States|UAMS Family Medical Center Texarkana, Texarkana, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02779556/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02779556/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02779556
215,NCT03014011,Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type II|Hypoglycemia|Cognitive Change",Other: Hypoglycaemic clamp|Other: Euglycaemic clamp,"Bispebjerg Hospital|University Hospital, Gentofte, Copenhagen|Psychiatric Centre Rigshospitalet","35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Department of Research in Endocrinology, Bispebjerg University Hospital, Copenhagen, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03014011/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03014011
216,NCT03161964,Propranolol in Treating Hypoglycemia Unawareness,Terminated,Has Results,Type 1 Diabetes Mellitus,"Drug: Propranolol 80 Mg Oral Capsule, Extended Release|Drug: Placebo oral capsule",Anu Sharma|University of Utah,21 Years to 59 Years   (Adult),Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03161964/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03161964
217,NCT03840850,Type 2 Diabetes: Risk Perceptions and Self-management Behaviour,Completed,No Results Available,Type 2 Diabetes Mellitus,Other: Personalized Risk Communication for People with Type 2 Diabetes,University of Oxford|NIHR Collaboration for Leadership in Applied Health Research and Care (Oxford),"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,"27 Beaumont Street Surgery Practice, Oxford, Oxfordshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03840850/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03840850/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03840850
218,NCT02791490,A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin|Drug: Placebo|Drug: Metformin IR,Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02791490/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02791490
219,NCT02738879,Randomized Sitagliptin Withdrawal Study (MK-0431-845),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin|Drug: Placebo to sitagliptin|Drug: Metformin|Drug: Metformin XR|Drug: Insulin glargine,Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","New Jersey, United States.","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02738879/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02738879
220,NCT03113916,De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women,Completed,Has Results,Diabetes|Weight Loss|PreDiabetes|Obesity,Behavioral: Behavioural Lifestyle Intervention,Kaiser Permanente|Arizona State University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",Arizona,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03113916/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03113916
221,NCT03010683,"Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus",Completed,Has Results,Type 2 Diabetes Mellitus|Coronary Artery Disease,Drug: Liraglutide|Drug: Metformin,University of Athens,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"'Attikon'' University General Hospital, Athens, Attiki, Greece","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03010683/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03010683
222,NCT03255902,Family Routines - Healthy Families,Completed,Has Results,"Diabetes Mellitus, Type 1",Behavioral: Parenting classes,William Beaumont Hospitals|University of Michigan,2 Years to 5 Years   (Child),Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Michigan United States,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03255902/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03255902
223,NCT01781975,Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type I|Diabetes Mellitus, Insulin-Dependent, 1|Type 1 Diabetes Mellitus|Insulin-Dependent Diabetes Mellitus 1|IDDM",Drug: Imatinib Mesylate|Drug: Placebo (For imatinib mesylate),"University of California, San Francisco|Juvenile Diabetes Research Foundation",18 Years to 45 Years   (Adult),Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of California-San Francisco, San Francisco, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas Southwestern, Dallas, Texas, United States|Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01781975/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01781975
224,NCT01377844,Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: EGT0001442|Drug: Placebo,Theracos,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Site 5, Buena Park, California, United States|Site 4, Los Angeles, California, United States|Site 3, Santa Ana, California, United States|Site 1, Hialeah, Florida, United States|Site 9, Berlin, New Jersey, United States|Site 7, Cary, North Carolina, United States|Site 6, Marion, Ohio, United States|Site 8, Munroe Falls, Ohio, United States|Site 2, Portland, Oregon, United States|Site 11, North Richland Hills, Texas, United States|Site 7, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT01377844/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT01377844/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01377844
225,NCT02910089,ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus Type 2,Behavioral: Shared Decision Making,AstraZeneca|Brigham Women's Health,"18 Years to 130 Years   (Adult, Older Adult)",Phase 4,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Research Site, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02910089/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02910089/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02910089
226,NCT03538743,"4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-06882961,Pfizer,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Anaheim Clinical Trials, LLC, Anaheim, California, United States|Qps-Mra, Llc, South Miami, Florida, United States|Qps-Mra,Llc, South Miami, Florida, United States|Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03538743/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03538743/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03538743
227,NCT02879383,Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D),Completed,Has Results,"Diabetes Mellitus, Type 2|Noninsulin-Dependent Diabetes Mellitus",Procedure: DMR Procedure|Procedure: Sham Procedure,"Fractyl Laboratories, Inc.","28 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hopital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Hospital das Clinicas da Faculdade de medicina da Universidade de São Paulo, Sao Paulo, Brazil|ABC Hospital, São Paulo, Brazil|Policlinico Gemelli (Sacro Cuore), Rome, Lazio, Italy|Humanitas Research Hospital & Humanitas University Via Manzoni 56, Rozzano, Milano, Italy|Amsterdam University Medical Center, Amsterdam, Netherlands|Glasgow Royal Infirmary, Glasgow, United Kingdom|University College London Hospitals, London, United Kingdom|King's College, Denmark Hill, London, United Kingdom|Queens Medical Centre campus, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02879383/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02879383/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02879383
228,NCT03303196,Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes,Completed,Has Results,Hyperinsulinism|Diabetes|Pancreatic Diseases|Pancreatectomy; Hyperglycemia,Device: Bihormonal Bionic Pancreas,Children's Hospital of Philadelphia|Boston University|Massachusetts General Hospital,"6 Years to 30 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03303196/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03303196
229,NCT03623607,Diabetes to Go: Inpatient Education Implementation,Completed,No Results Available,Diabetes Mellitus,Other: Diabetes Survival Skills Education,Medstar Health Research Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,"MedStar Washington Hospital Center, Washington, District of Columbia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03623607/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03623607/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03623607
230,NCT04862858,Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes,"Active, not recruiting",No Results Available,"Diabetes Mellitus, Type 2|Cardiovascular Diseases",Other: Educational Intervention,"Humana Inc.|Boehringer Ingelheim|Humana Healthcare Research, Inc.","18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Humana, Louisville, Kentucky, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04862858/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04862858
231,NCT02771093,An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Trelagliptin|Drug: Alogliptin,Takeda,"20 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Naka-city, Ibaragi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02771093/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02771093/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02771093
232,NCT04440449,Effect of Behavioral Lifestyle Intervention on Frailty in Older Adults With Diabetes,Completed,Has Results,"Frailty|Weight, Body|Type 2 Diabetes",Behavioral: Lifestyle App|Behavioral: Look AHEAD behavior lifestyle intervention|Behavioral: Abbreviated Look AHEAD behavior lifestyle intervention,The University of Texas Health Science Center at San Antonio|The Claude D. Pepper Older Americans Independence Centers|National Institute on Aging (NIA),65 Years and older   (Older Adult),Not Applicable,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04440449/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04440449
233,NCT04369833,Development of Continuous Glucose Monitoring System Cohort for Personalized Diabetes Prevention and Management Platform,Completed,Has Results,PreDiabetes|Glucose Metabolism Disorders|Diabetes Mellitus,Device: continuous glucose monitoring system,Pusan National University Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Pusan national university hospital, Busan, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04369833/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04369833
234,NCT01729156,Effects of Metformin on Hepatic FFA Metabolism,Completed,Has Results,Type 2 Diabetes|Dyslipidemia,Drug: Metformin|Drug: Placebo,Lars Christian Gormsen|University of Aarhus,"50 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",Denmark,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01729156/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01729156
235,NCT02672176,Improving Health in Diabetes Project,Completed,Has Results,Diabetes Mellitus,Behavioral: Usual Care|Behavioral: P2E2T2 Program,"University of California, Davis|Patient-Centered Outcomes Research Institute","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","School of Nursing, University of California, Davis and UC Davis Health System, Sacramento, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02672176/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02672176/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02672176
236,NCT02886884,Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells,"Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","21 Years to 90 Years   (Adult, Older Adult)",Phase 1|Phase 2,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02886884/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02886884
237,NCT03324737,Smartphone App to Restore Optimal Weight in Women With Recent Gestational Diabetes,Completed,No Results Available,Gestational Diabetes|Weight Loss|Diet Habit,Device: Interactive Smartphone App,"National University Hospital, Singapore","21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"National University Hospital, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03324737/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03324737
238,NCT02548650,Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus,Completed,Has Results,Myocardial Infarction|Diabetes Mellitus|Peripheral Arterial Disease,Drug: Vorapaxar|Drug: Clopidogrel|Drug: Aspirin,University of Florida|Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02548650/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02548650
239,NCT01980914,Hypoglycemia (Low Blood Sugar) and the Heart,Completed,Has Results,Hypoglycemia|Type 2 Diabetes,Device: iPro2 glucose sensor attachment,University of British Columbia|icentia,70 Years and older   (Older Adult),Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Vancouver Coastal Health Research Institute (VCHRI/VCHA) site -Vancouver General Hospital, Vancouver, British Columbia, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01980914/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01980914
240,NCT04877730,Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation,Completed,No Results Available,Type 1 Diabetes,Device: Fully Closed Loop (FCL)|Device: Fully Closed Loop with meal anticipation module (FCL+)|Device: Hybrid Closed Loop (HCL),University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04877730/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04877730/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04877730
241,NCT04114682,Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes,"Active, not recruiting",No Results Available,Type 2 Diabetes,Other: Multi parametric MRI scan,Perspectum|University of Liverpool|Liverpool University Hospitals NHS Foundation Trust|Oxford University Hospitals NHS Trust|Royal Free Hospital NHS Foundation Trust,"18 Years and older   (Adult, Older Adult)",,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Aintree University Hospital NHS Foundation Trust, Liverpool, Merseyside, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom|Perspectum Ltd., Oxford, Oxfordshire, United Kingdom|Royal Free Hospital NHS Foundation Trust, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04114682/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04114682/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04114682
242,NCT03334643,Fiber Mix and Glycemic Response,Completed,No Results Available,Type2 Diabetes Mellitus,Dietary Supplement: Fiber mix,"Rutgers, The State University of New Jersey","18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute for Food, Nutrition & Health, New Brunswick, New Jersey, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03334643/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03334643
243,NCT02814838,"A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes",Completed,Has Results,"Diabetes Mellitus, Insulin-Dependent",Drug: Ladarixin|Drug: Placebo,Dompé Farmaceutici S.p.A,18 Years to 45 Years   (Adult),Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Universitair Ziekenhuis Brussel Diabetes Clinic, Brussels, Belgium|Universitair Ziekenhuis Leuven Campus Gasthuisberg Endocrinology, Leuven, Belgium|Med. Klinik und Poliklinik 3, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany|Zentrum für Diabetes und Gefäßerkrankungen, Münster, Germany|Università Aldo Moro-Ospedale Policlinico, Bari, Italy|Presidio Policlinico di Monserrato, Cagliari, Italy|Internal Medicine - Diabetes & Endocrinology Unit, San Raffaele Hospital Milan, Milan, Italy|Unità Operativa Complessa di Endocrinologia e Dialettologia. Università Campus Bio-Medico di Roma, Rome, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02814838/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02814838/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02814838
244,NCT02620917,Continuos Subcutaneous Insulin Infusion in Italy,Completed,Has Results,Type 1 Diabetes,,University of Padova,"Child, Adult, Older Adult",,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,"University of Padova, Padova, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02620917/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02620917
245,NCT02284009,Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: Albiglutide weekly injection|Biological: Placebo weekly injection|Biological: Insulin,GlaxoSmithKline,18 Years to 30 Years   (Adult),Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Bois-Guillaume, France|GSK Investigational Site, Caen Cedex 9, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Latina, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Roma, Italy|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Hospitalet de Llobregat, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Pama de Mallorca, Spain|GSK Investigational Site, San Juan (Alicante), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Darlington, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Durham, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02284009/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02284009
246,NCT03786718,Usability of Diabetes Dashboard Embedded Within a Patient Web Portal,Completed,Has Results,"Diabetes Mellitus, Type 2",Other: Patient-facing Diabetes Dashboard,Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"21 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"William Martinez, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03786718/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03786718/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03786718
247,NCT02954601,A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: ORMD-0801 (qd)|Drug: ORMD-0801 (bid)|Drug: ORMD-0801 (tid)|Other: Placebo,"Oramed, Ltd.|Integrium","20 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Orange County Research Center, Tustin, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02954601/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02954601/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02954601
248,NCT03550066,Patients Engaged in Prevention: Enhancing Outreach to Increase Patient Engagement in Diabetes Prevention,Completed,Has Results,Preventive Health Services|Health Communication,Behavioral: Values affirmation|Behavioral: No affirmation,Kaiser Permanente|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Kaiser Permanente Northern California, Oakland, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03550066/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03550066
249,NCT03938233,Diabetes Self Management Education Programme in Thailand,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system,London School of Hygiene and Tropical Medicine|Medical Research Council|Chiang Mai University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,London,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03938233/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03938233/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03938233
250,NCT04113694,Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes,Completed,Has Results,Diabetes,Device: Extended Infusion Set,Medtronic Diabetes,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical Investigations, Little Rock, Arkansas, United States|AMCR Institute, Escondido, California, United States|Stanford University, Palo Alto, California, United States|SoCal Diabetes, West Covina, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Endocrine Research Solutions, Roswell, Georgia, United States|Iowa Diabetes and Endocrinology Center, West Des Moines, Iowa, United States|Grunberger Diabetes Institute, Bloomfield Hills, Michigan, United States|Mayo Clinic (Rochester MN), Rochester, Minnesota, United States|Diabetes and Endocrinology Consultants of Pennsylvania, Feasterville-Trevose, Pennsylvania, United States|AM Diabetes and Endocrinology Center, Memphis, Tennessee, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Rainier Clinical Research Center, Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04113694/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04113694/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04113694
251,NCT03947333,Evaluation of a Patient Portal Intervention for Diabetes: A Pilot Randomized Controlled Trial,Completed,Has Results,"Diabetes Mellitus, Type 2",Other: My Diabetes Care,Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"21 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03947333/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03947333/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03947333
252,NCT03645421,Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: MEDI0382 100 μg|Drug: MEDI0382 200 μg|Drug: MEDI0382 300 μg|Drug: PlaceboA|Drug: MEDI0382 50 ug|Drug: PlaceboB,AstraZeneca,"20 Years to 120 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03645421/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03645421/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03645421
253,NCT02806700,Twitter and Diabetes,Completed,No Results Available,Diabetes|Cardiovascular Disease,Behavioral: Twitter Diabetes Intervention,University of Pennsylvania,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02806700/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02806700/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02806700
254,NCT02465515,"Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Diabetes Mellitus,Biological: Albiglutide 30 mg|Biological: Albiglutide 50 mg|Biological: Albiglutide matching placebo,GlaxoSmithKline|Duke Clinical Research Institute,"40 Years and older   (Adult, Older Adult)",Phase 4,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Goodyear, Arizona, United States|GSK Investigational Site, Tempe, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Searcy, Arkansas, United States|GSK Investigational Site, Chula Vista, California, United States|GSK Investigational Site, Lancaster, California, United States|GSK Investigational Site, Lomita, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Moreno Valley, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Oakland, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Marino, California, United States|GSK Investigational Site, San Ramon, California, United States|GSK Investigational Site, Simi Valley, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Littleton, Colorado, United States|GSK Investigational Site, Littleton, Colorado, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Belle Glade, Florida, United States|GSK Investigational Site, Bradenton, Florida, United States|GSK Investigational Site, Bradenton, Florida, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Coral Springs, Florida, United States|GSK Investigational Site, Fleming Island, Florida, United States|GSK Investigational Site, Inverness, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Lake Worth, Florida, United States|GSK Investigational Site, Lakeland, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Ponte Vedra, Florida, United States|GSK Investigational Site, Port Charlotte, Florida, United States|GSK Investigational Site, Port Orange, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Vero Beach, Florida, United States|GSK Investigational Site, Wellington, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Cumming, Georgia, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Dunwoody, Georgia, United States|GSK Investigational Site, Snellville, Georgia, United States|GSK Investigational Site, Tucker, Georgia, United States|GSK Investigational Site, Aurora, Illinois, United States|GSK Investigational Site, Champaign, Illinois, United States|GSK Investigational Site, Gurnee, Illinois, United States|GSK Investigational Site, Moline, Illinois, United States|GSK Investigational Site, Avon, Indiana, United States|GSK Investigational Site, Franklin, Indiana, United States|GSK Investigational Site, Greenfield, Indiana, United States|GSK Investigational Site, Muncie, Indiana, United States|GSK Investigational Site, Munster, Indiana, United States|GSK Investigational Site, West Des Moines, Iowa, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Lewiston, Maine, United States|GSK Investigational Site, Annapolis, Maryland, United States|GSK Investigational Site, Saint Cloud, Minnesota, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Camden, New Jersey, United States|GSK Investigational Site, Haddon Heights, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, North Massapequa, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Rocky Mount, North Carolina, United States|GSK Investigational Site, Salisbury, North Carolina, United States|GSK Investigational Site, Statesville, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Fargo, North Dakota, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Sandusky, Ohio, United States|GSK Investigational Site, Springfield, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Camp Hill, Pennsylvania, United States|GSK Investigational Site, Feasterville, Pennsylvania, United States|GSK Investigational Site, Harleysville, Pennsylvania, United States|GSK Investigational Site, Jersey Shore, Pennsylvania, United States|GSK Investigational Site, Lansdale, Pennsylvania, United States|GSK Investigational Site, Newport, Pennsylvania, United States|GSK Investigational Site, Penndel, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Sellersville, Pennsylvania, United States|GSK Investigational Site, Pawtucket, Rhode Island, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Myrtle Beach, South Carolina, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, Bristol, Tennessee, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bellaire, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Georgetown, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Huntsville, Texas, United States|GSK Investigational Site, Kingwood, Texas, United States|GSK Investigational Site, Plano, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Schertz, Texas, United States|GSK Investigational Site, Suite 101, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Layton, Utah, United States|GSK Investigational Site, Manassas, Virginia, United States|GSK Investigational Site, Federal Way, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Wenatchee, Washington, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Adrogue, Buenos Aires, Argentina|GSK Investigational Site, Bahia Blanca, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, Pergamino, Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Godoy Cruz, Mendoza, Argentina|GSK Investigational Site, San Rafael, Mendoza, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Berazategui, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Argentina|GSK Investigational Site, La Plata, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Bonheiden, Belgium|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Roeselare, Belgium|GSK Investigational Site, Byala, Bulgaria|GSK Investigational Site, Gabrovo, Bulgaria|GSK Investigational Site, Montana, Bulgaria|GSK Investigational Site, Sevlievo, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Stara Zagora, Bulgaria|GSK Investigational Site, Kelowna, British Columbia, Canada|GSK Investigational Site, Surrey, British Columbia, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Victoria, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, St. John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Truro, Nova Scotia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Burlington, Ontario, Canada|GSK Investigational Site, Cambridge, Ontario, Canada|GSK Investigational Site, Cornwall, Ontario, Canada|GSK Investigational Site, Corunna, Ontario, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Sarnia, Ontario, Canada|GSK Investigational Site, Smiths Falls, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Brossard, Quebec, Canada|GSK Investigational Site, Chicoutimi, Quebec, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Laval, Quebec, Canada|GSK Investigational Site, Levis, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, Canada|GSK Investigational Site, St-Lambert, Quebec, Canada|GSK Investigational Site, Trois-Rivieres, Quebec, Canada|GSK Investigational Site, Beroun, Czechia|GSK Investigational Site, Krnov, Czechia|GSK Investigational Site, Olomouc, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Praha 1, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Pribram 1, Czechia|GSK Investigational Site, Uherske Hradiste, Czechia|GSK Investigational Site, Usti nad Labem, Czechia|GSK Investigational Site, Zlin, Czechia|GSK Investigational Site, Copenhagen, Denmark|GSK Investigational Site, Esbjerg, Denmark|GSK Investigational Site, Frederikssund, Denmark|GSK Investigational Site, Hellerup, Denmark|GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Holbæk, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, København NV, Denmark|GSK Investigational Site, København S, Denmark|GSK Investigational Site, Roskilde, Denmark|GSK Investigational Site, Amiens Cedex 1, France|GSK Investigational Site, Broglie, France|GSK Investigational Site, Corbeil-Essonnes, France|GSK Investigational Site, La Rochelle Cedex 1, France|GSK Investigational Site, Nantes cedex 2, France|GSK Investigational Site, Narbonne, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pau Cedex, France|GSK Investigational Site, Pierre-Bénite, France|GSK Investigational Site, Strasbourg cedex, France|GSK Investigational Site, Vandœuvre-lès-Nancy, France|GSK Investigational Site, Deggingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Gueglingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Karlsruhe, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ludwigsburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Dachau, Bayern, Germany|GSK Investigational Site, Haag, Bayern, Germany|GSK Investigational Site, Kuenzing, Bayern, Germany|GSK Investigational Site, Rednitzhembach, Bayern, Germany|GSK Investigational Site, Wallerfing, Bayern, Germany|GSK Investigational Site, Elsterwerda, Brandenburg, Germany|GSK Investigational Site, Falkensee, Brandenburg, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Floersheim, Hessen, Germany|GSK Investigational Site, Gelnhausen, Hessen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Stuhr, Niedersachsen, Germany|GSK Investigational Site, Wardenburg, Niedersachsen, Germany|GSK Investigational Site, Bad Oeynhausen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Kleve, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Witten, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bad Kreuznach, Rheinland-Pfalz, Germany|GSK Investigational Site, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Sankt Ingbert, Saarland, Germany|GSK Investigational Site, Hohenmoelsen, Sachsen-Anhalt, Germany|GSK Investigational Site, Jerichow, Sachsen-Anhalt, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Delitzsch, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzg, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Oschatz, Sachsen, Germany|GSK Investigational Site, Pirna, Sachsen, Germany|GSK Investigational Site, Riesa, Sachsen, Germany|GSK Investigational Site, Schkeuditz, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Dortmund, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Mannheim, Germany|GSK Investigational Site, Muenchen, Germany|GSK Investigational Site, Alexandroupolis, Greece|GSK Investigational Site, Athens,, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Haidari, Athens, Greece|GSK Investigational Site, Heraklion, Crete, Greece|GSK Investigational Site, Ioannina, Greece|GSK Investigational Site, Lamia, Greece|GSK Investigational Site, Nikaia Piraeus, Greece|GSK Investigational Site, Pireas, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Baja, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Eger, Hungary|GSK Investigational Site, Gödöllő, Hungary|GSK Investigational Site, Hatvan, Hungary|GSK Investigational Site, Komarom, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Sátoraljaújhely, Hungary|GSK Investigational Site, Chieti, Abruzzo, Italy|GSK Investigational Site, Catanzaro, Calabria, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Parma, Emilia-Romagna, Italy|GSK Investigational Site, Ravenna, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Arenzano (GE), Liguria, Italy|GSK Investigational Site, Bergamo, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Vigevano (PV), Lombardia, Italy|GSK Investigational Site, Ancona, Marche, Italy|GSK Investigational Site, Ascoli Piceno, Marche, Italy|GSK Investigational Site, Bari, Puglia, Italy|GSK Investigational Site, San Giovanni Rotondo (FG), Puglia, Italy|GSK Investigational Site, Olbia (OT), Sardegna, Italy|GSK Investigational Site, Siena, Toscana, Italy|GSK Investigational Site, S.Andrea Delle Fratte - S. Sisto (PG), Umbria, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Gyeonggido, Korea, Republic of|GSK Investigational Site, Kangwondo, Korea, Republic of|GSK Investigational Site, Pusan, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Aguascalientes, Ags, Aguascalientes, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Tlaquepaque, Jalisco, Mexico|GSK Investigational Site, Monterrey NL, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Queretaro, Querétaro, Mexico|GSK Investigational Site, Mazatlán, Sinaloa, Mexico|GSK Investigational Site, Mazatlán, Sinaloa, Mexico|GSK Investigational Site, Mérida, Yucatán, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Eindhoven, Netherlands|GSK Investigational Site, Gouda, Netherlands|GSK Investigational Site, Hardenberg, Netherlands|GSK Investigational Site, Heerlen, Netherlands|GSK Investigational Site, Hoogeveen, Netherlands|GSK Investigational Site, Meppel, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Sneek, Netherlands|GSK Investigational Site, Hoenefoss, Norway|GSK Investigational Site, Kolbjørnsvik, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Stavanger, Norway|GSK Investigational Site, Trujillo, La Libertad, Peru|GSK Investigational Site, Callao, Lima, Peru|GSK Investigational Site, San Martin de Porres, Lima, Peru|GSK Investigational Site, Arequipa, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Piura, Peru|GSK Investigational Site, Cebu City, Philippines|GSK Investigational Site, Iloilo City, Philippines|GSK Investigational Site, Laoag City, Philippines|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Gniewkowo, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Sopot, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wierzchoslawice, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Arkhangelsk, Russian Federation|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Nizhny Novgorod, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, Rostov-on-Don, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, Saint Petersburg, Russian Federation|GSK Investigational Site, Samara, Russian Federation|GSK Investigational Site, Saratov, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Bloemfontein, Free State, South Africa|GSK Investigational Site, Tongaat, KwaZulu- Natal, South Africa|GSK Investigational Site, Bloemfontein, South Africa|GSK Investigational Site, Cape Town, South Africa|GSK Investigational Site, Houghton, South Africa|GSK Investigational Site, Kuilsrivier, South Africa|GSK Investigational Site, Paarl, South Africa|GSK Investigational Site, Pinelands, South Africa|GSK Investigational Site, Umhlanga, South Africa|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Almeria, Spain|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Badalona / Barcelona, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Boadilla Del Monte (Madrid), Spain|GSK Investigational Site, Canet De Mar - Barcelona, Spain|GSK Investigational Site, Cangas Del Narcea/Asturias, Spain|GSK Investigational Site, Centelles (Barcelona), Spain|GSK Investigational Site, Córdoba, Spain|GSK Investigational Site, Elche, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, La Coruña, Spain|GSK Investigational Site, León, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Malaga, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Pontevedra, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Sagunto/Valencia, Spain|GSK Investigational Site, San Juan (Alicante), Spain|GSK Investigational Site, Sanlucar De Barrameda - Cádiz, Spain|GSK Investigational Site, Santa Coloma De Gramanet (Barcelona), Spain|GSK Investigational Site, Santiago De Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Tarrasa, Barcelona, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Vigo-Pontevedra, Spain|GSK Investigational Site, Borås, Sweden|GSK Investigational Site, Eksjö, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Helsingborg, Sweden|GSK Investigational Site, Härnösand, Sweden|GSK Investigational Site, Karlskrona, Sweden|GSK Investigational Site, Kristianstad, Sweden|GSK Investigational Site, Linköping, Sweden|GSK Investigational Site, Ljungby, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Rättvik, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Umeå, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Örebro, Sweden|GSK Investigational Site, Changhua, Taiwan|GSK Investigational Site, Hualien, Taiwan|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand|GSK Investigational Site, Pathumthani, Thailand|GSK Investigational Site, Songkla, Thailand|GSK Investigational Site, Chernivtsi, Ukraine|GSK Investigational Site, Dnipropetrovsk, Ukraine|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kherson, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Mykolaiv, Ukraine|GSK Investigational Site, Odesa, Ukraine|GSK Investigational Site, Poltava, Ukraine|GSK Investigational Site, Uzhgorod, Ukraine|GSK Investigational Site, Vinnytsia, Ukraine|GSK Investigational Site, Zaporizhzhya, Ukraine|GSK Investigational Site, Soham, Cambridgeshire, United Kingdom|GSK Investigational Site, Chesterfield, Derbyshire, United Kingdom|GSK Investigational Site, Romford, Essex, United Kingdom|GSK Investigational Site, Northwood, Middlesex, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Trowbridge, Wiltshire, United Kingdom|GSK Investigational Site, Aberdeen, United Kingdom|GSK Investigational Site, Axbridge, Somerset, United Kingdom|GSK Investigational Site, Ayr, United Kingdom|GSK Investigational Site, Blackpool, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Dumfries, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Fife, United Kingdom|GSK Investigational Site, Fife, United Kingdom|GSK Investigational Site, Gloucester, United Kingdom|GSK Investigational Site, Lancaster, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Newport, United Kingdom|GSK Investigational Site, Oxford, United Kingdom|GSK Investigational Site, Rotherham, United Kingdom|GSK Investigational Site, Sidcup, Kent, United Kingdom|GSK Investigational Site, Trowbridge, United Kingdom|GSK Investigational Site, Wigan, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02465515/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02465515/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02465515
255,NCT03745937,A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo,MedImmune LLC,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03745937/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03745937/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03745937
256,NCT02024750,Tailored Diabetes Self-Management Resources,Completed,Has Results,"Diabetes Mellitus, Type 1",Behavioral: Tailored Resources,"University of Wisconsin, Madison|Medical College of Wisconsin",8 Years to 16 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Wisconsin - Madison, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02024750/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02024750/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02024750
257,NCT03107208,Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes,Completed,Has Results,Diabetic Ketoacidosis|Type 1 Diabetes Mellitus,Drug: Glargine|Device: Continuous Glucose Monitor (Abbott FreeStyle Libre Pro),"University of Colorado, Denver","6 Years to 18 Years   (Child, Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03107208/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03107208
258,NCT03960424,Diabetes Management Program for Hispanic/Latino,Recruiting,No Results Available,Type 2 Diabetes Mellitus|Type 2 Diabetes,Other: Comprehensive Outpatient Management|Behavioral: Diabetes Telemonitoring,Northwell Health|Patient-Centered Outcomes Research Institute,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Feinstein Institute of Medical Research, Manhasset, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/Prot_SAP_004.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03960424/ICF_005.pdf",https://ClinicalTrials.gov/show/NCT03960424
259,NCT04733690,METABOLIC CHARACTERISTICS OF A NOVEL COMMON BEAN PRODUCT,Not yet recruiting,No Results Available,Type 2 Diabetes,Dietary Supplement: Common bean product,Jomo Kenyatta University of Agriculture and Technology|KU Leuven|Legumes Centre of Excellence for Food and Nutrition Security|VLIR-UOS,"18 Years to 69 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,Kenya,"""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04733690/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04733690
260,NCT03416127,Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Propolis|Drug: Metformin|Drug: Placebo,University of Guadalajara,30 Years to 60 Years   (Adult),Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03416127/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03416127/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03416127
261,NCT02548585,"A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo,MedImmune LLC,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Berlin, Germany|Research Site, Erfurt, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Neu-Ulm, Germany|Research Site, Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02548585/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02548585/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02548585
262,NCT04765358,Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring,"Active, not recruiting",No Results Available,Type 1 Diabetes|Type 2 Diabetes,Other: Virtual Clinic,Jaeb Center for Health Research,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Jaeb Center for Health Research, Tampa, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04765358/Prot_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04765358/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT04765358
263,NCT02597101,Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus|Insulin Resistance,Drug: Metformin|Drug: saxagliptin|Drug: AZD9668|Drug: placebo,"Nick Giannoukakis, PhD|National Institutes of Health (NIH)|University of Pittsburgh|University of South Florida|AstraZeneca|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","21 Years to 75 Years   (Adult, Older Adult)",Phase 2,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allegheny Health Network, Pittsburgh, Pennsylvania, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02597101/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02597101
264,NCT02759055,Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard),Completed,Has Results,Pre-diabetes,Other: Clinical Decision Support,HealthPartners Institute|Essentia Health,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Essentia Health, Duluth, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02759055/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02759055
265,NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Canagliflozin|Drug: Placebo (canagliflozin)|Drug: Placebo (semaglutide),Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Hallandale Beach, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Spring Hill, Florida, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lake Charles, Louisiana, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Trenton, New Jersey, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Splendora, Texas, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Herndon, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Rosario, Argentina|Novo Nordisk Investigational Site, Salta, Argentina|Novo Nordisk Investigational Site, Porto Alegre, Brazil|Novo Nordisk Investigational Site, Rio de Janeiro, Brazil|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Pointe Claire, Quebec, Canada|Novo Nordisk Investigational Site, Pointe-Claire, Quebec, Canada|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Mallow, Ireland|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Lebanon - Beirut, Lebanon|Novo Nordisk Investigational Site, Mansourieh, Lebanon|Novo Nordisk Investigational Site, Zgharta, Lebanon|Novo Nordisk Investigational Site, Alor Gajah, Malaysia|Novo Nordisk Investigational Site, Ipoh, Malaysia|Novo Nordisk Investigational Site, Melaka, Malaysia|Novo Nordisk Investigational Site, Penang, Malaysia|Novo Nordisk Investigational Site, Sandakan, Malaysia|Novo Nordisk Investigational Site, Seremban, Malaysia|Novo Nordisk Investigational Site, Cuernavaca, Morelos, Mexico|Novo Nordisk Investigational Site, Mexico City, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Eksjö, Sweden|Novo Nordisk Investigational Site, Kristianstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Haxey, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Torquay, United Kingdom|Novo Nordisk Investigational Site, Wellingborough, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03136484/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03136484/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03136484
266,NCT02691247,Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study),Completed,Has Results,Diabetes Mellitus,Biological: CLBS03 Low Dose|Biological: CLBS03 High Dose|Biological: Placebo,"Caladrius Biosciences, Inc.|Sanford Health|California Institute for Regenerative Medicine (CIRM)",8 Years to 17 Years   (Child),Phase 2,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Diabetes Research Institute, Miami, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Kansas City, Kansas City, Missouri, United States|Sanford Research, Fargo, North Dakota, United States|Oregon Health Science University, Portland, Oregon, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02691247/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02691247/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02691247
267,NCT03377127,Impact of Pharmacy Clinic on Diabetes Management,Completed,Has Results,"Diabetes Mellitus, Type 2",Behavioral: Pharmacy Managed Diabetes Clinic (PMDC)|Other: Standard of Care (SOC),William Beaumont Hospitals,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beaumont Geriatric Assessment Center, Berkley, Michigan, United States|Beaumont Outpatient Clinic, Royal Oak, Michigan, United States|Beaumont Internal Medicine Center, Southfield, Michigan, United States|Norton, Klein, Hug, Sabin and Maddens Internal Medicine & Primary Care Practice, Troy, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03377127/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03377127/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03377127
268,NCT02863328,Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: empagliflozin,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baton Rouge, Louisiana, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Krapinske Toplice, Croatia|Novo Nordisk Investigational Site, Pula, Croatia|Novo Nordisk Investigational Site, Virovitica, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Cegléd, Hungary|Novo Nordisk Investigational Site, Nyíregyhaza, Hungary|Novo Nordisk Investigational Site, Salgótarján, Hungary|Novo Nordisk Investigational Site, Szekszárd, Hungary|Novo Nordisk Investigational Site, Bologna, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Pulawy, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Centelles (Barcelona), Spain|Novo Nordisk Investigational Site, Hospitalet de Llobregat, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02863328/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02863328/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02863328
269,NCT03191396,Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Liraglutide,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Burgas, Bulgaria|Novo Nordisk Investigational Site, Dupnitsa, Bulgaria|Novo Nordisk Investigational Site, Lukovit, Bulgaria|Novo Nordisk Investigational Site, Madan, Bulgaria|Novo Nordisk Investigational Site, Petrich, Bulgaria|Novo Nordisk Investigational Site, Ruse, Bulgaria|Novo Nordisk Investigational Site, Sliven, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Vratsa, Bulgaria|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Jyväskylä, Finland|Novo Nordisk Investigational Site, Kuusamo, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Rauma, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Varkaus, Finland|Novo Nordisk Investigational Site, Béziers, France|Novo Nordisk Investigational Site, Dambach-la-ville, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Nantes, France|Novo Nordisk Investigational Site, Obernai, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, PERPIGNAN cedex, France|Novo Nordisk Investigational Site, Schiltigheim, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Vandoeuvre Les Nancy, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Siófok, Hungary|Novo Nordisk Investigational Site, Szolnok, Hungary|Novo Nordisk Investigational Site, Tatabánya, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Como, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Celje, Slovenia|Novo Nordisk Investigational Site, Jesenice, Slovenia|Novo Nordisk Investigational Site, Koper, Slovenia|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Alcorcón, Spain|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain|Novo Nordisk Investigational Site, Kristianstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Ängelholm, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Blackpool, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Crewe, United Kingdom|Novo Nordisk Investigational Site, Faringdon, United Kingdom|Novo Nordisk Investigational Site, Hinckley, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Northwood, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Nuneaton, United Kingdom|Novo Nordisk Investigational Site, Rhyl, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom|Novo Nordisk Investigational Site, Sidcup, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, St Helens, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03191396/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT03191396/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03191396
270,NCT03377699,"Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Insulin degludec|Drug: Insulin Aspart|Drug: Insulin detemir,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, Salta, Argentina|Novo Nordisk Investigational Site, Blacktown, New South Wales, Australia|Novo Nordisk Investigational Site, Campbelltown, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Ipswich, Queensland, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, Australia|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Goiânia, Goias, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Ribeirao Preto, Brazil|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, St John's, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Cambridge, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, PQ, Quebec, Canada|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, København ø, Denmark|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Nea Efkarpia - Thessaloniki, Greece|Novo Nordisk Investigational Site, Dublin 2, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Petach Tikva, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Sant'Andrea Delle Fratte (PG), Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Ekaterinburg, Russian Federation|Novo Nordisk Investigational Site, Kirov, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Bath, United Kingdom|Novo Nordisk Investigational Site, Bradford, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, High Wycombe, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Oxford, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03377699/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03377699/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03377699
271,NCT02692716,A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,"50 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Monroe, Louisiana, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Canton, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Moncks Corner, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Knoxville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Hurst, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Annaba, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Setif, Algeria|Novo Nordisk Investigational Site, Tizi Ouzou, Algeria|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Mogi das Cruzes, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São José dos Campos, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Esbjerg, Denmark|Novo Nordisk Investigational Site, Hellerup, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Bochum, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Elsterwerda, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Oldenburg, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderbad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Thiruvananthapuram, Kerala, India|Novo Nordisk Investigational Site, Goa, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Pune, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Ipoh, Perak, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Malaysia|Novo Nordisk Investigational Site, Kota Samarahan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Melaka, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Seremban, Malaysia|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Merida, Yucatan, Mexico|Novo Nordisk Investigational Site, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Almere, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Middleburg, Mpumalanga, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Alcala de Henares, Spain|Novo Nordisk Investigational Site, Badalona, Spain|Novo Nordisk Investigational Site, Fuenlabrada - Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Pontevedra, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Kaohsiung City, Taiwan|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Tainan city, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Klong Luang, Pathumthani, Thailand|Novo Nordisk Investigational Site, Nakhon Ratchasima, Thailand|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Aydin, Turkey|Novo Nordisk Investigational Site, Denizli, Turkey|Novo Nordisk Investigational Site, Gaziantep, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Rize, Turkey|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Exeter, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02692716/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02692716/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02692716
272,NCT03243383,Readmission Prevention Pilot Trial in Diabetes Patients,Completed,No Results Available,Diabetes Mellitus,Other: DiaTOHC Program,Temple University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Temple University Hospital, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03243383/Prot_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03243383/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03243383
273,NCT02863419,Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Hallandale Beach, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, West Palm Beach, Florida, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Lebanon, New Hampshire, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Dublin, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Summerville, South Carolina, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, North Richland Hills, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Newport News, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Slavonski Brod, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Praha 5, Czechia|Novo Nordisk Investigational Site, Bochum, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Villingen-Schwenningen, Germany|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Kalocsa, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szigetvár, Hungary|Novo Nordisk Investigational Site, Szolnok, Hungary|Novo Nordisk Investigational Site, Székesfehérvár, Hungary|Novo Nordisk Investigational Site, Tatabánya, Hungary|Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bydgoszcz, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gniewkowo, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Toa Baja, Puerto Rico|Novo Nordisk Investigational Site, Bardejov, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Vrutky, Slovakia|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Ajman, United Arab Emirates|Novo Nordisk Investigational Site, Al Mafraq, United Arab Emirates|Novo Nordisk Investigational Site, Dubai, United Arab Emirates|Novo Nordisk Investigational Site, Rahba City, United Arab Emirates|Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02863419/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02863419/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02863419
274,NCT02827708,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Bermuda Dunes, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Danbury, Connecticut, United States|Novo Nordisk Investigational Site, Norwalk, Connecticut, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Cooper City, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Lebanon, New Hampshire, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, New Hyde Park, New York, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Delaware, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Aalborg, Denmark|Novo Nordisk Investigational Site, Gentofte, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, København S, Denmark|Novo Nordisk Investigational Site, Køge, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Kerava, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Ähtäri, Finland|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Belgorod, Russian Federation|Novo Nordisk Investigational Site, Chelyabinsk, Russian Federation|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Volgograd, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Skövde, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden|Novo Nordisk Investigational Site, Vindeln, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Bexhill-on-Sea, United Kingdom|Novo Nordisk Investigational Site, Doncaster, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Milton Keynes, United Kingdom|Novo Nordisk Investigational Site, Rothwell, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Wellingborough, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02827708/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02827708/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02827708
275,NCT03377946,Effect of Probiotics on Pre-diabetes and Diabetes in China,Unknown status,No Results Available,Type 2 Diabetes Mellitus,Biological: probiotics|Biological: placebo,Chinese PLA General Hospital,18 Years to 60 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"health management center,Southwest hospital, Chongqing, Chongqing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03377946/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03377946/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03377946
276,NCT02607865,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: sitagliptin|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Carmichael, California, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Plantation, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Spring Hill, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Trenton, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, High Point, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Gaffney, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Summerville, South Carolina, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Jackson, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Angers, France|Novo Nordisk Investigational Site, Chalons-en-Champagne Cedex, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, LA ROCHE-sur-YON cedex 9, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Limoges, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, Nanterre, France|Novo Nordisk Investigational Site, Nantes Cedex 01, France|Novo Nordisk Investigational Site, Nantes, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, PERPIGNAN cedex, France|Novo Nordisk Investigational Site, Périgueux, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Elsterwerda, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Leipzig, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Gurgaon, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Bhubaneshwar, Orissa, India|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Ra'anana, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Gunma, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Iruma-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Toluca, Estado De México, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Pitesti, Arges, Romania|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Craiova, Dolj, Romania|Novo Nordisk Investigational Site, Baia Mare, Maramures, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Iasi, Romania|Novo Nordisk Investigational Site, Iasi, Romania|Novo Nordisk Investigational Site, Satu Mare, Romania|Novo Nordisk Investigational Site, Timisoara, Romania|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Krugersdorp, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, South Africa|Novo Nordisk Investigational Site, Pretoria, South Africa|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, İstanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Samsun, Turkey|Novo Nordisk Investigational Site, Cherkasy, Ukraine|Novo Nordisk Investigational Site, Ivano-Frankivsk, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Mykolaiv, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Zaporizhia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Crewe, United Kingdom|Novo Nordisk Investigational Site, Doncaster, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Preston, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom|Novo Nordisk Investigational Site, Sidcup, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom|Novo Nordisk Investigational Site, Taunton, United Kingdom|Novo Nordisk Investigational Site, Torquay, United Kingdom|Novo Nordisk Investigational Site, Wellingborough, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02607865/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02607865/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02607865
277,NCT02648204,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: Dulaglutide,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Carlsbad, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Huntington Park, California, United States|Novo Nordisk Investigational Site, Lincoln, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Norwalk, Connecticut, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Edgewater, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Port Orange, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Adairsville, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Addison, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Newton, Kansas, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Covington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Owensboro, Kentucky, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Methuen, Massachusetts, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, United States|Novo Nordisk Investigational Site, Missoula, Montana, United States|Novo Nordisk Investigational Site, Trenton, New Jersey, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Winston-Salem, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Moncks Corner, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Riverton, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Blagoevgrad, Bulgaria|Novo Nordisk Investigational Site, Burgas, Bulgaria|Novo Nordisk Investigational Site, Montana, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Krapinske Toplice, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Virovitica, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Jyväskylä, Finland|Novo Nordisk Investigational Site, Kerava, Finland|Novo Nordisk Investigational Site, Kuusamo, Finland|Novo Nordisk Investigational Site, Raisio, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Chalkida, Evia, Greece|Novo Nordisk Investigational Site, Ioannina, Greece|Novo Nordisk Investigational Site, Piraeus, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Guntur, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Visakhapatnam, Andhra Pradesh, India|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Goa, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Mohali, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Gorey, Ireland|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Panevezys, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Aveiro, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Tomar, Portugal|Novo Nordisk Investigational Site, Viana do Castelo, Portugal|Novo Nordisk Investigational Site, Vila Nova de Gaia, Portugal|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Buzau, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Piestany, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Alicante, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Segovia, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Northwood, United Kingdom|Novo Nordisk Investigational Site, Romford, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02648204/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02648204/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02648204
278,NCT01855399,Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes,Completed,Has Results,Diabetes,Behavioral: Peer Coaching|Behavioral: Decision Aid,VA Office of Research and Development,"18 Years to 99 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01855399/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01855399/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01855399
279,NCT02906930,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, North Hollywood, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Jose, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, Doral, Florida, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Spring Hill, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Blackfoot, Idaho, United States|Novo Nordisk Investigational Site, Nampa, Idaho, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Elkhorn, Nebraska, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Willoughby Hills, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Salem, Virginia, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Broumov, Czechia|Novo Nordisk Investigational Site, Chrudim, Czechia|Novo Nordisk Investigational Site, Mlada Boleslav, Czechia|Novo Nordisk Investigational Site, Olomouc, Czechia|Novo Nordisk Investigational Site, Prague 1, Czechia|Novo Nordisk Investigational Site, Como, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Pisa, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Targoviste, Dambovita, Romania|Novo Nordisk Investigational Site, Targoviste, Dambovita, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02906930/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02906930/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02906930
280,NCT03015220,Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Dulaglutide,Novo Nordisk A/S,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Adachi-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Annaka-shi, Gunma, Japan|Novo Nordisk Investigational Site, Arakawa-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chiba-shi, Chiba, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Gunma, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Iruma-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kawaguchi-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kurashiki-shi, Okayama, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Mitaka-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shinagawa-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Toshima-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03015220/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03015220/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03015220
281,NCT03268005,"Research Study Comparing a New Medicine ""Fast-acting Insulin Aspart"" to Another Already Available Medicine ""NovoRapid""/""NovoLog"" in People With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Faster-acting insulin aspart|Drug: Insulin aspart|Drug: Insulin degludec|Drug: Metformin,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Norco, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Boynton Beach, Florida, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Alpharetta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Valparaiso, Indiana, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Beaumont, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Pearland, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Bennington, Vermont, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Seattle, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Green Bay, Wisconsin, United States|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Kozloduy, Bulgaria|Novo Nordisk Investigational Site, Razgrad, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Newmarket, Ontario, Canada|Novo Nordisk Investigational Site, Thunder Bay, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Trutnov, Czechia|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Schweinfurt, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Ioannina, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Cittadella (PD), Italy|Novo Nordisk Investigational Site, Milano (MI), Italy|Novo Nordisk Investigational Site, Olbia, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Bucheon, Korea, Republic of|Novo Nordisk Investigational Site, Daegu, Korea, Republic of|Novo Nordisk Investigational Site, Seongnam-si, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Wonju, Korea, Republic of|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Skorzewo, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Baia Mare, Maramures, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Arkhangelsk, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Zajecar, Serbia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Kysucke Nove Mesto, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Lucenec, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Alcobendas, Spain|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Girona, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain|Novo Nordisk Investigational Site, Sabadell, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03268005/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03268005/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03268005
282,NCT02762578,Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/insulin aspart|Drug: biphasic insulin aspart,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Chongqing, Chongqing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Nanning, Guangxi, China|Novo Nordisk Investigational Site, Nanning, Guangxi, China|Novo Nordisk Investigational Site, Cangzhou, Hubei, China|Novo Nordisk Investigational Site, Baotou, Inner Mongolia, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Siping, Jilin, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Chengdu, Sichuan, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Tianjin, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02762578/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02762578/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02762578
283,NCT03917576,Heart Rate During Exercise in Type 2 Diabetes,Completed,No Results Available,Type2 Diabetes Mellitus|Hyperglycemia|Heart Rate|Exercise Training,Other: Behavioral|Other: Exercise training intervention,Universidad de Los Lagos|Universidad de La Frontera,18 Years to 60 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Cristian ALvarez, Osorno, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03917576/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03917576
284,NCT03018028,"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo|Drug: Liraglutide,Novo Nordisk A/S,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Akita-shi, Akita, Japan|Novo Nordisk Investigational Site, Arakawa-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Gunma, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Minato-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Naka-shi, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03018028/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03018028/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03018028
285,NCT02825251,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Newark, Delaware, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Arlington Heights, Illinois, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Arlon, Belgium|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Sint-Niklaas, Belgium|Novo Nordisk Investigational Site, Wilrijk, Belgium|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Caen, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Rostock, Germany|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Hoofddorp, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Leiden, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Venlo, Netherlands|Novo Nordisk Investigational Site, Cheboksary, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Ljubljana, Slovenia|Novo Nordisk Investigational Site, Novo mesto, Slovenia|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Guildford, United Kingdom|Novo Nordisk Investigational Site, Harrogate, North Yorkshire, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, St Helens, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02825251/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02825251/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02825251
286,NCT03172494,"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/liraglutide|Drug: Insulin degludec|Drug: Liraglutide,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Huai'an, Jiangsu, China|Novo Nordisk Investigational Site, Huai'an, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Dalian, Liaoning, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Pudong New District, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Fuzhou, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03172494/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03172494/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03172494
287,NCT04997512,Freestyle Libre and Hospital Admissions in Type 2 Diabetes,Not yet recruiting,No Results Available,Type 2 Diabetes,Device: Freestyle libre|Other: Nurse led structured intervention - hypoglycaemia education and diabetes treatment modification modification,University of Leeds|Abbott Diabetes Care,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Diabetes centre, St James hospital, Leeds, West Yorkshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04997512/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04997512/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04997512
288,NCT02849080,Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: sitagliptin,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Boynton Beach, Florida, United States|Novo Nordisk Investigational Site, Lake Worth, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, Port Orange, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Blackfoot, Idaho, United States|Novo Nordisk Investigational Site, Evanston, Illinois, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Corrientes, Argentina|Novo Nordisk Investigational Site, Rosario, Argentina|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Boussu, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Alexandria, Egypt|Novo Nordisk Investigational Site, Cairo, Egypt|Novo Nordisk Investigational Site, Cairo, Egypt|Novo Nordisk Investigational Site, Ansan, Korea, Republic of|Novo Nordisk Investigational Site, Gangwon-do, Korea, Republic of|Novo Nordisk Investigational Site, Pusan, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Suwon, Korea, Republic of|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Trondheim, Norway|Novo Nordisk Investigational Site, Bern, Switzerland|Novo Nordisk Investigational Site, Einsiedeln, Switzerland|Novo Nordisk Investigational Site, Genève 14, Switzerland|Novo Nordisk Investigational Site, Luzern 16, Switzerland|Novo Nordisk Investigational Site, Olten, Switzerland|Novo Nordisk Investigational Site, St. Gallen, Switzerland|Novo Nordisk Investigational Site, St. Gallen, Switzerland|Novo Nordisk Investigational Site, Winterthur, Switzerland|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Rize, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02849080/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02849080/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02849080
289,NCT02505334,A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide,Novo Nordisk A/S,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Annaka-shi, Gunma, Japan|Novo Nordisk Investigational Site, Chitose, Hokkaido, Japan|Novo Nordisk Investigational Site, Chuo-ku Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chuo-ku,, Japan|Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Higashiosaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ichikawa-shi, Chiba, Japan|Novo Nordisk Investigational Site, Iruma-shi, Saitama, Japan|Novo Nordisk Investigational Site, Izumisano-shi, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miyazaki-shi, Japan|Novo Nordisk Investigational Site, Naka-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Neyagawa-shi, Osaka, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Oyama-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Saga-shi,Saga, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sappro-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Shizuoka-shi, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Takatsuki-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Yokohama, Kanagawa, Japan|Novo Nordisk Investigational Site, Yokohama-shi Kanagawa, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02505334/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02505334/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02505334
290,NCT03078478,A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec|Drug: Insulin glargine,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Downey, California, United States|Novo Nordisk Investigational Site, Duarte, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Moreno Valley, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, Pomona, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, Roseville, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Stanford, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, West Hills, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Englewood, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Brandon, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Cooper City, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami Springs, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Port Charlotte, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Marietta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Blackfoot, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Mishawaka, Indiana, United States|Novo Nordisk Investigational Site, Valparaiso, Indiana, United States|Novo Nordisk Investigational Site, Council Bluffs, Iowa, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Bloomfield Hills, Michigan, United States|Novo Nordisk Investigational Site, Richfield, Minnesota, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, Kalispell, Montana, United States|Novo Nordisk Investigational Site, Elkhorn, Nebraska, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, East Brunswick, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Northport, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Morehead City, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Gaffney, South Carolina, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Mount Pleasant, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, West Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Dakota Dunes, South Dakota, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Knoxville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Humble, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Bennington, Vermont, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, United States|Novo Nordisk Investigational Site, Midlothian, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, West Allis, Wisconsin, United States|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Mirabel, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Esbjerg, Denmark|Novo Nordisk Investigational Site, Hellerup, Denmark|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, Odense, Denmark|Novo Nordisk Investigational Site, Pärnu, Estonia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Viljandi, Estonia|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Elsterwerda, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Nikaia, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szombathely, Hungary|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Hoenefoss, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Skedsmokorset, Norway|Novo Nordisk Investigational Site, Trondheim, Norway|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bytom, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Manati, Puerto Rico|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Buzau, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03078478/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03078478/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03078478
291,NCT02670915,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,Novo Nordisk A/S,1 Year to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Boise, Idaho, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Neptune, New Jersey, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, Mineola, New York, United States|Novo Nordisk Investigational Site, Raleigh, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Tulsa, Oklahoma, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Sioux Falls, South Dakota, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Opava, Czechia|Novo Nordisk Investigational Site, Ostrava - Poruba, Czechia|Novo Nordisk Investigational Site, Pardubice, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Usti nad Labem, Czechia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Tartu, Estonia|Novo Nordisk Investigational Site, Espoo, Finland|Novo Nordisk Investigational Site, OYS, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Bochum, Germany|Novo Nordisk Investigational Site, Freiburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Oldenburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Zerifin, Israel|Novo Nordisk Investigational Site, Ancona, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Amagasaki-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Chuo-shi, Yamanashi, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Hiroshima-shi, Hiroshima, Japan|Novo Nordisk Investigational Site, Iruma-gun, Saitama, Japan|Novo Nordisk Investigational Site, Kitakyushu,Fukuoka, Japan|Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kochi-shi, Kochi, Japan|Novo Nordisk Investigational Site, Kofu, Yamanashi, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kure-shi, Hiroshima, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Maebashi-shi, Gunma, Japan|Novo Nordisk Investigational Site, Matsumoto-shi, Nagano,, Japan|Novo Nordisk Investigational Site, Matsuyama-shi, Ehime, Japan|Novo Nordisk Investigational Site, Musashino-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Okayama Kita-ku, Okayama, Japan|Novo Nordisk Investigational Site, Okayama-shi, Okayama, Japan|Novo Nordisk Investigational Site, Okayama-shi, Okayama, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Ota-shi, Gunma, Japan|Novo Nordisk Investigational Site, Otsu-shi, Shiga, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Suzaka-shi ,Nagano, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tsu-shi, Mie, Japan|Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Yokosuka-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, San Juan, Puerto Rico|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Rostov-on-Don, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Samara, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ufa, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, İzmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Samsun, Turkey|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Ivano-Frankivsk, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kiev, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02670915/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02670915/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02670915
292,NCT02500706,Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: Faster-acting insulin aspart|Drug: insulin aspart|Drug: insulin degludec,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Fullerton, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Newport Beach, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Hamilton, New Jersey, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Bend, Oregon, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Beaumont, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, Federal Way, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Tacoma, Washington, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Dimitrovgrad, Bulgaria|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Ruse, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Schweinfurt, Germany|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Visakhapatnam, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Chandigarh, India|Novo Nordisk Investigational Site, New Dehli, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Pune, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Ancona, Italy|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Sesto San Giovanni (MI), Italy|Novo Nordisk Investigational Site, Amagasaki-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Izumisano-shi, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kobe-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Matsumoto-shi, Nagano, Japan|Novo Nordisk Investigational Site, Mito-shi, Ibaraki, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Oita-shi, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02500706/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02500706/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02500706
293,NCT04545567,Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Device: RocketAP|Device: USS Virginia,University of Virginia,"12 Years to 25 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04545567/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04545567/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04545567
294,NCT03421379,A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Drug: Glucagon Nasal Powder|Drug: Glucagon Hydrochloride Solution,Eli Lilly and Company,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03421379/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03421379/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03421379
295,NCT02299050,Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy,Completed,Has Results,Type 2 Diabetes,Drug: Cycloset,The University of Texas Health Science Center at San Antonio|VeroScience,"30 Years to 69 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Science Center, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02299050/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02299050
296,NCT03021187,Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Anniston, Alabama, United States|Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Mesa, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Hialeah, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Paducah, Kentucky, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Summerville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Murray, Utah, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Moncton, New Brunswick, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Besançon cedex, France|Novo Nordisk Investigational Site, Bourgoin-jallieu, France|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, LA ROCHE-sur-YON cedex 9, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Le Creusot, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Ioannina, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Piraeus, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, India|Novo Nordisk Investigational Site, Amagasaki-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Ebina-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Iruma-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Naka-shi, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Shizuoka-shi, Shizuoka, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Ube-shi, Yamaguchi, Japan|Novo Nordisk Investigational Site, Durango, Mexico|Novo Nordisk Investigational Site, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Pulawy, Poland|Novo Nordisk Investigational Site, Manati, Puerto Rico|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03021187/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03021187/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03021187
297,NCT03442595,MedStar Diabetes Pathway Chart Reviews,Completed,Has Results,Type2 Diabetes Mellitus,Other: Intensive diabetes education and medication management,Medstar Health Research Institute,"21 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,United States,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03442595/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03442595/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03442595
298,NCT02801942,Immune Profile in Subjects With New Onset Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Procedure: Inguinal lymph node fine needle aspirate biopsy|Procedure: Inguinal lymph node core biopsy|Procedure: Peripheral blood collection|Other: Pre- and post-biopsy questionnaire,GlaxoSmithKline,18 Years to 40 Years   (Adult),Not Applicable,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02801942/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02801942
299,NCT02501161,A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Muscle Shoals, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Bermuda Dunes, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Boynton Beach, Florida, United States|Novo Nordisk Investigational Site, Lake Worth, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Blackfoot, Idaho, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Metairie, Louisiana, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Midlothian, Virginia, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Brazil|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Prague 1, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Dunaujvaros, Hungary|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Pecs, Hungary|Novo Nordisk Investigational Site, Secunderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Visakhapatnam, Andhra Pradesh, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Zerifin, Israel|Novo Nordisk Investigational Site, Bologna, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Cittadella (PD), Italy|Novo Nordisk Investigational Site, Negrar (VR), Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Cuernavaca, Morelos, Mexico|Novo Nordisk Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Durango, Mexico|Novo Nordisk Investigational Site, Bodø, Norway|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Hoenefoss, Norway|Novo Nordisk Investigational Site, Kløfta, Norway|Novo Nordisk Investigational Site, Lierskogen, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Tananger, Norway|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Stavropol, Russian Federation|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Sabinov, Slovakia|Novo Nordisk Investigational Site, Trebisov, Slovakia|Novo Nordisk Investigational Site, Trencin, Slovakia|Novo Nordisk Investigational Site, Trnava, Slovakia|Novo Nordisk Investigational Site, Cosmo City, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Umkomaas, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Brits, North West, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Alberton, South Africa|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Bursa, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Rize, Turkey|Novo Nordisk Investigational Site, Samsun, Turkey|Novo Nordisk Investigational Site, Angus, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Dudley, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Fife, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom|Novo Nordisk Investigational Site, Torquay, United Kingdom|Novo Nordisk Investigational Site, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02501161/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02501161/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02501161
300,NCT02730377,Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: alpha-glucosidase inhibitors|Drug: DPP-4 inhibitors|Drug: meglitinides|Drug: SGLT-2 inhibitors|Drug: sulphonylurea|Drug: thiazolidinediones,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Haleyville, Alabama, United States|Novo Nordisk Investigational Site, Tuscumbia, Alabama, United States|Novo Nordisk Investigational Site, Fountain Hills, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tempe, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Harrisburg, Arkansas, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, North Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Alhambra, California, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Carlsbad, California, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Elk Grove, California, United States|Novo Nordisk Investigational Site, Encinitas, California, United States|Novo Nordisk Investigational Site, Huntington Beach, California, United States|Novo Nordisk Investigational Site, La Mirada, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Montclair, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Rancho Cucamonga, California, United States|Novo Nordisk Investigational Site, Riverside, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Westminster, California, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Centennial, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Monument, Colorado, United States|Novo Nordisk Investigational Site, Chiefland, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocala, Florida, United States|Novo Nordisk Investigational Site, Ocoee, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Ormond Beach, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Palm Harbor, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Seminole, Florida, United States|Novo Nordisk Investigational Site, Bainbridge, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Perry, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Woodstock, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Aurora, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Wauconda, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, Newton, Kansas, United States|Novo Nordisk Investigational Site, Park City, Kansas, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Shreveport, Louisiana, United States|Novo Nordisk Investigational Site, Sunset, Louisiana, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Troy, Michigan, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, United States|Novo Nordisk Investigational Site, Port Gibson, Mississippi, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Missoula, Montana, United States|Novo Nordisk Investigational Site, Fremont, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Albuquerque, New Mexico, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, North Massapequa, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheboro, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Elizabeth City, North Carolina, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Mooresville, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Edmond, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Oklahoma City, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, Fleetwood, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Lansdale, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, Levittown, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Smithfield, Pennsylvania, United States|Novo Nordisk Investigational Site, Uniontown, Pennsylvania, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Columbia, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Indian Land, South Carolina, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Simpsonville, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Athens, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Carrollton, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Corpus Christi, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Georgetown, Texas, United States|Novo Nordisk Investigational Site, Gonzales, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Irving, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, Killeen, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Missouri City, Texas, United States|Novo Nordisk Investigational Site, New Braunfels, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Splendora, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Gloucester Courthouse, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Bellevue, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Truro, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Strathroy, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Bogota, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mysore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Noida, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hubli, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Tukums, Latvia|Novo Nordisk Investigational Site, Achrafieh, Lebanon|Novo Nordisk Investigational Site, Beirut, Lebanon|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Jbeil, Lebanon|Novo Nordisk Investigational Site, Toa Baja, Puerto Rico|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Adapazari, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02730377/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02730377/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02730377
301,NCT01923181,"Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: semaglutide|Drug: oral placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Chula Vista, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Santa Ana, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Plantation, Florida, United States|Novo Nordisk Investigational Site, South Miami, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Conyers, Georgia, United States|Novo Nordisk Investigational Site, Addison, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Wichita, Kansas, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Raleigh, North Carolina, United States|Novo Nordisk Investigational Site, Salisbury, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Jersey Shore, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Moncks Corner, South Carolina, United States|Novo Nordisk Investigational Site, Humboldt, Tennessee, United States|Novo Nordisk Investigational Site, Spring Hill, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Newport News, Virginia, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Bathurst, New Brunswick, Canada|Novo Nordisk Investigational Site, Moncton, New Brunswick, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, Stayner, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Pointe-Claire, Quebec, Canada|Novo Nordisk Investigational Site, Aalborg, Denmark|Novo Nordisk Investigational Site, Esbjerg, Denmark|Novo Nordisk Investigational Site, Hellerup, Denmark|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Elsterwerda, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Speyer, Germany|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Herzliya, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Rishon Le Zion, Israel|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Ipoh, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Malaysia|Novo Nordisk Investigational Site, Penang, Malaysia|Novo Nordisk Investigational Site, Seri Manjung, Malaysia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Sabadell, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Linköping, Sweden|Novo Nordisk Investigational Site, Oskarshamn, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Bexhill-on-Sea, United Kingdom|Novo Nordisk Investigational Site, Chesterfield, Derbyshire, United Kingdom|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Crewe, United Kingdom|Novo Nordisk Investigational Site, Hinckley, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT01923181/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT01923181/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01923181
302,NCT03445065,A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus,Completed,Has Results,Diabetes Mellitus,Device: Eversense XL CGM System|Device: Usual SMBG or FGM device used by participants,Hoffmann-La Roche|Roche Diabetes Care France SAS,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"CHU Amiens Picardie, Amiens, France|CHU Caen Normandie, Caen, France|CHU Grenoble Alpes, La Tronche, France|Hopital Hotel Dieu - Creusot, Le Creusot, France|CHRU de Lille, Lille, France|APHM - Hopital Sainte-Marguerite, Marseille, France|CHU de Montpellier, Montpellier, France|Hopital Caremeau-CHU Nimes, Nimes, France|Paris Lariboisière, Paris, France|APHP Groupe Hospitalier Cochin (Paris), Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU de Poitiers, Poitiers, France|CHU Reims, Reims Cedex, France|CHU Rouen, Rouen, France|CHU de Nantes, St Herblain, France|CHRU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|CHU de Nancy, Vandoeuvre Les Nancy, France|Groupe hospitalier Les Portes du Sud, Venissieux, France|Institut de diabétologie et Nutrition du Centre, Vernouillet, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03445065/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03445065/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03445065
303,NCT02670928,Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.,Completed,Has Results,Type 2 Diabetes Mellitus (T2DM),Behavioral: Lifestyle intervention,Novartis Pharmaceuticals|Novartis,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02670928/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02670928/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02670928
304,NCT04201496,SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus,Completed,No Results Available,Type 1 Diabetes,Combination Product: Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Combination Product: Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks|Device: No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks|Device: No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks,"Ananda Basu, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Tandem Diabetes Care, Inc.|DexCom, Inc.|University of Virginia","18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Virginia, Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04201496/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04201496/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04201496
305,NCT02415556,Memory Aid by Intranasal Insulin in Diabetes (MemAID),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Regular Human Insulin|Drug: Placebo,Beth Israel Deaconess Medical Center|Novo Nordisk A/S|Medtronic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"50 Years to 85 Years   (Adult, Older Adult)",Phase 2,Other|Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States|Vera Novak, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02415556/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02415556/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02415556
306,NCT03061214,Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT),Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Semaglutide 0.5 mg|Drug: Semaglutide 1.0 mg|Drug: Sitagliptin placebo|Drug: Sitagliptin|Drug: Semaglutide placebo 0.5 mg|Drug: Semaglutide placebo 1.0 mg,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Aparecida de Goiania, Goias, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Zhuhai, Guangdong, China|Novo Nordisk Investigational Site, Guiyang, Guizhou, China|Novo Nordisk Investigational Site, Qiqihar, Heilongjiang, China|Novo Nordisk Investigational Site, Chenzhou, Hunan, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Suzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Yanji, Jilin, China|Novo Nordisk Investigational Site, Shenyang, Liaoning, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Qingdao, Shandong, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Taiyuan, Shanxi, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Changsha, China|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Daejeon, Korea, Republic of|Novo Nordisk Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Suwon, Korea, Republic of|Novo Nordisk Investigational Site, Wonju, Korea, Republic of|Novo Nordisk Investigational Site, Boksburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan city, Taiwan|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03061214/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03061214/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03061214
307,NCT04585776,A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: LY900014|Drug: Insulin Degludec,Eli Lilly and Company,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atlanta Diabetes Associates, Atlanta, Georgia, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04585776/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04585776/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04585776
308,NCT02911948,A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/liraglutide|Drug: Insulin degludec,Novo Nordisk A/S,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Chigasaki-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Chitose, Hokkaido, Japan|Novo Nordisk Investigational Site, Chiyoda-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Fujisawa-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Fukui-shi, Fukui, Japan|Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Fukushima, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Kawagoe-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kawaguchi-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Mitaka-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nagano, Japan|Novo Nordisk Investigational Site, Nakagami, Okinawa, Japan|Novo Nordisk Investigational Site, Neyagawa-shi, Osaka, Japan|Novo Nordisk Investigational Site, Niigata-shi, Niigata, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Ota-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Saitama-shi, Saitama, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tomigusuku-shi, Okinawa, Japan|Novo Nordisk Investigational Site, Tomigusuku-shi, Okinawa, Japan|Novo Nordisk Investigational Site, Yamaguchi-shi, Yamaguchi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02911948/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02911948/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02911948
309,NCT03143816,Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Technosphere insulin,"University of Colorado, Denver|Atlanta Diabetes Associates|University of Southern California|Rainier Clinical Research Center|Mannkind Corporation","18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03143816/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03143816/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03143816
310,NCT02443155,A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 1",Drug: NNC0114-0006|Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,18 Years to 45 Years   (Adult),Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Mesquite, Texas, United States|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Brussel, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Kingston, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, PQ, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Esbjerg, Denmark|Novo Nordisk Investigational Site, Hellerup, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Stavanger, Norway|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Amadora, Portugal|Novo Nordisk Investigational Site, Braga, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Viana do Castelo, Portugal|Novo Nordisk Investigational Site, Arkhangelsk, Russian Federation|Novo Nordisk Investigational Site, Chelyabinsk, Russian Federation|Novo Nordisk Investigational Site, Dzerzhinskiy, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Syktyvkar, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Girona, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Sabadell, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Karlstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Blackburn, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Newcastle upon Tyne, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02443155/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02443155/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02443155
311,NCT00658021,Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Placebo|Drug: Exenatide,"AstraZeneca|Quintiles, Inc.",10 Years to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Montclair, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Dalton, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Dearborn, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Jamaica, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Fortaleza, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Santo André, Brazil|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Pune, India|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, San Juan del Rio, Mexico|Research Site, Tamaupilas, Mexico|Research Site, Tampico, Mexico|Research Site, Quezon City, Philippines|Research Site, Moscow, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Moloto, South Africa|Research Site, Paarl, South Africa|Research Site, Pretoria, South Africa|Research Site, Verulam, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT00658021/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT00658021/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00658021
312,NCT02773368,A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: insulin degludec/liraglutide|Drug: insulin glargine,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Mission Viejo, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Boynton Beach, Florida, United States|Novo Nordisk Investigational Site, Chiefland, Florida, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Moncton, New Brunswick, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Smiths Falls, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Rovaniemi, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Komarom, Hungary|Novo Nordisk Investigational Site, Salgótarján, Hungary|Novo Nordisk Investigational Site, Szekszárd, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Hyderbad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Bhopal, Madhya Pradesh, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Varanasi, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petesburg, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Lucenec, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Presov, Slovakia|Novo Nordisk Investigational Site, Trnava, Slovakia|Novo Nordisk Investigational Site, Celje, Slovenia|Novo Nordisk Investigational Site, Koper, Slovenia|Novo Nordisk Investigational Site, Kranj, Slovenia|Novo Nordisk Investigational Site, Murska Sobota, Slovenia|Novo Nordisk Investigational Site, Trbovlje, Slovenia|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Antequera, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Boadilla del Monte, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Villamartin, Spain|Novo Nordisk Investigational Site, Baden, Switzerland|Novo Nordisk Investigational Site, Genève 14, Switzerland|Novo Nordisk Investigational Site, Luzern 16, Switzerland|Novo Nordisk Investigational Site, Olten, Switzerland|Novo Nordisk Investigational Site, Schaffhausen, Switzerland|Novo Nordisk Investigational Site, Winterthur, Switzerland|Novo Nordisk Investigational Site, Zollikerberg, Switzerland|Novo Nordisk Investigational Site, Zürich, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02773368/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02773368/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02773368
313,NCT02419612,"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",Completed,Has Results,Diabetes,Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Glimepiride|Other: Placebo,AstraZeneca,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, Huntington Park, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Tarzana, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Edina, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Greer, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Cheb, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Krnov, Czechia|Research Site, Kromeriz, Czechia|Research Site, Nachod, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Dresden, Germany|Research Site, Leipzig, Germany|Research Site, Ajka, Hungary|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Cuautla, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guanajuato, Mexico|Research Site, Monterrey, Mexico|Research Site, Veracruz, Mexico|Research Site, Białystok, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Opole, Poland|Research Site, Oswiecim, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Galati, Romania|Research Site, Oradea, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Ploiesti, Romania|Research Site, Satu-Mare, Romania|Research Site, Targu, Romania|Research Site, Timisoara, Romania|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Rättvik, Sweden|Research Site, Dundee, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02419612/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02419612/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02419612
314,NCT02750930,"Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects",Terminated,Has Results,"Diabetes Mellitus, Type 2",Drug: Albiglutide|Device: Auto-injector,GlaxoSmithKline,"Child, Adult, Older Adult",Phase 4,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Lomita, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Tustin, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Littleton, Colorado, United States|GSK Investigational Site, Bradenton, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Hallandale Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Columbia, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Schertz, Texas, United States|GSK Investigational Site, Shavano Prk, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02750930/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02750930/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02750930
315,NCT03607799,A Culturally-tailored Personalized Nutrition Intervention in South Asian Women at Risk of Gestational Diabetes,Recruiting,No Results Available,"Diabetes, Gestational",Behavioral: Dietary Intervention|Behavioral: Control,McMaster University|Hamilton Health Sciences Corporation|Population Health Research Institute,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Farah Khan, Hamilton, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03607799/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03607799/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03607799
316,NCT02814123,Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes,Completed,No Results Available,"Diabetes Mellitus, Type 1",Other: 24-hour inpatient intervention,McGill University|Juvenile Diabetes Research Foundation,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"McGill University Health Centre, Montréal, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02814123/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02814123/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02814123
317,NCT03074630,Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2),Completed,Has Results,"Diabetes Mellitus, Type 2|Hypercholesterolemia",Drug: Dapagliflozin|Drug: Rosuvastatin,"Amsterdam UMC, location VUmc|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","18 Years to 75 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Academic Medical Center, Amsterdam, North Holland, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03074630/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03074630
318,NCT02683746,Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Lyophilized albiglutide DCC pen injector|Drug: Lyophilized albiglutide DCC pen injector matching placebo|Drug: Albiglutide liquid auto-injector|Drug: Albiglutide liquid auto-injector matching placebo,GlaxoSmithKline,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Chandler, Arizona, United States|GSK Investigational Site, Glendale, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Canyon Country, California, United States|GSK Investigational Site, Chula Vista, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Lomita, California, United States|GSK Investigational Site, Oceanside, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Spring Valley, California, United States|GSK Investigational Site, Tustin, California, United States|GSK Investigational Site, Van Nuys, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Littleton, Colorado, United States|GSK Investigational Site, Bradenton, Florida, United States|GSK Investigational Site, Brooksville, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Fleming Island, Florida, United States|GSK Investigational Site, Hallandale Beach, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Snellville, Georgia, United States|GSK Investigational Site, Meridian, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Elgin, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Lake Charles, Louisiana, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Troy, Michigan, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, New Hyde Park, New York, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Shelby, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Maumee, Ohio, United States|GSK Investigational Site, Norwood, Ohio, United States|GSK Investigational Site, Perrysburg, Ohio, United States|GSK Investigational Site, Altoona, Pennsylvania, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Katy, Texas, United States|GSK Investigational Site, Pharr, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Schertz, Texas, United States|GSK Investigational Site, Spring, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Federal Way, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02683746/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02683746/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02683746
319,NCT02793154,An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects,Terminated,Has Results,"Diabetes Mellitus, Type 2",Drug: Exenatide|Drug: Albiglutide,GlaxoSmithKline|Wake Forrest Baptist Health,18 Years to 60 Years   (Adult),Phase 4,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02793154/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02793154/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02793154
320,NCT02229227,Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Albiglutide|Drug: Insulin Glargine and Insulin Lispro,GlaxoSmithKline|PPD,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Searcy, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Tustin, California, United States|GSK Investigational Site, West Hills, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Brooksville, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Hialeah, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Pembroke Pines, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Paducah, Kentucky, United States|GSK Investigational Site, Lake Charles, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Staten Island, New York, United States|GSK Investigational Site, Shelby, North Carolina, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Kettering, Ohio, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Pharr, Texas, United States|GSK Investigational Site, Round Rock, Texas, United States|GSK Investigational Site, Sugar Land, Texas, United States|GSK Investigational Site, Hampton, Virginia, United States|GSK Investigational Site, Renton, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Fortaleza - CE, Ceará, Brazil|GSK Investigational Site, Fortaleza, Ceará, Brazil|GSK Investigational Site, Goiânia, Goiás, Brazil|GSK Investigational Site, Uberlandia, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Campinas, São Paulo, Brazil|GSK Investigational Site, Marília, São Paulo, Brazil|GSK Investigational Site, Pará, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Penticton, British Columbia, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Oakville, Ontario, Canada|GSK Investigational Site, Thornhill, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Saint Laurent, Quebec, Canada|GSK Investigational Site, Corbeil-Essonnes, France|GSK Investigational Site, Nantes Cedex 1, France|GSK Investigational Site, Valenciennes, France|GSK Investigational Site, Vandoeuvre les Nancy, France|GSK Investigational Site, Venissieux, France|GSK Investigational Site, Bad Mergentheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Sulzbach-Rosenberg, Bayern, Germany|GSK Investigational Site, Asslar, Hessen, Germany|GSK Investigational Site, Schwerin, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany|GSK Investigational Site, Rhaunen, Rheinland-Pfalz, Germany|GSK Investigational Site, Saarlouis, Saarland, Germany|GSK Investigational Site, Sankt Ingbert, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Pirna, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Baja, Hungary|GSK Investigational Site, Balatonfured, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budaörs, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Pecs, Hungary|GSK Investigational Site, Zalaegerszeg, Hungary|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Gyeonggido, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Pachuca, Hidalgo, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Monterrey NL, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Aguascalientes, Mexico|GSK Investigational Site, Chihuahua, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Durango, Mexico|GSK Investigational Site, Guadalajara, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Veracruz, Mexico|GSK Investigational Site, Davao City, Philippines|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Marikina City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Kamieniec Zabkowicki, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Oswiecim, Poland|GSK Investigational Site, Pulawy, Poland|GSK Investigational Site, Radom, Poland|GSK Investigational Site, Ruda Slaska, Poland|GSK Investigational Site, Zamosc, Poland|GSK Investigational Site, Bloemfontein, Free State, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Johannesburg, Gauteng, South Africa|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Johannesburg, South Africa|GSK Investigational Site, Krugersdorp, South Africa|GSK Investigational Site, Worcester, South Africa|GSK Investigational Site, Alcala de Henares, Spain|GSK Investigational Site, Alzira/Valencia, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barakaldo (Vizcaya), Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Ferrol. La Coruña, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, La Coruña, Spain|GSK Investigational Site, León, Spain|GSK Investigational Site, Lleida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda, Spain|GSK Investigational Site, Malaga, Spain|GSK Investigational Site, Merida, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Welwyn Garden City, Hertfordshire, United Kingdom|GSK Investigational Site, Bath, Somerset, United Kingdom|GSK Investigational Site, Hull, United Kingdom|GSK Investigational Site, Lancashire, United Kingdom|GSK Investigational Site, Sidcup, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02229227/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02229227/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02229227
321,NCT04150107,A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Drug: ORMD-0801 Treatment A|Drug: ORMD-0801 Treatment B|Other: Placebo,"Oramed, Ltd.|Integrium","18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Orange County Research Center, Tustin, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04150107/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04150107/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04150107
322,NCT01541215,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes",Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo|Drug: metformin,Novo Nordisk A/S,10 Years to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Corona, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Moreno Valley, California, United States|Novo Nordisk Investigational Site, Palo Alto, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, New Haven, Connecticut, United States|Novo Nordisk Investigational Site, Wilmington, Delaware, United States|Novo Nordisk Investigational Site, Washington, District of Columbia, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Tallahassee, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Columbus, Georgia, United States|Novo Nordisk Investigational Site, Bloomington, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Silver Spring, Maryland, United States|Novo Nordisk Investigational Site, Worcester, Massachusetts, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Grand Rapids, Michigan, United States|Novo Nordisk Investigational Site, Saint Paul, Minnesota, United States|Novo Nordisk Investigational Site, Columbia, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Hackensack, New Jersey, United States|Novo Nordisk Investigational Site, West Orange, New Jersey, United States|Novo Nordisk Investigational Site, Buffalo, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Sleepy Hollow, New York, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Rapid City, South Dakota, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Edinburg, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Charlottesville, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Charleston, West Virginia, United States|Novo Nordisk Investigational Site, Ipswich, Queensland, Australia|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wels, Austria|Novo Nordisk Investigational Site, Brussel, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Westmount, Quebec, Canada|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Herlev, Denmark|Novo Nordisk Investigational Site, Næstved, Denmark|Novo Nordisk Investigational Site, Alexandria, Egypt|Novo Nordisk Investigational Site, Cairo, Egypt|Novo Nordisk Investigational Site, Cairo, Egypt|Novo Nordisk Investigational Site, Mansoura, Egypt|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, MONTPELLIER cedex 05, France|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Mayen, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Goudi/ Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Miskolc, Hungary|Novo Nordisk Investigational Site, Szombathely, Hungary|Novo Nordisk Investigational Site, Guntur, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Hyderbad, Telengana, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, India|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Petah Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Hazmieh, Lebanon|Novo Nordisk Investigational Site, Lebanon - Beirut, Lebanon|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Tampico, Tamaulipas, Mexico|Novo Nordisk Investigational Site, Puebla, Mexico|Novo Nordisk Investigational Site, Fès, Morocco|Novo Nordisk Investigational Site, Rabat, Morocco|Novo Nordisk Investigational Site, Den Bosch, Netherlands|Novo Nordisk Investigational Site, Grafton, New Zealand|Novo Nordisk Investigational Site, Skopje, North Macedonia|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Katowice, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Braga, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Constanta, Romania|Novo Nordisk Investigational Site, Chelyabinsk, Russian Federation|Novo Nordisk Investigational Site, Izhevsk, Russian Federation|Novo Nordisk Investigational Site, Krasnoyarsk, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Leganés, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Vigo, Spain|Novo Nordisk Investigational Site, Vitoria, Spain|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Huddinge, Sweden|Novo Nordisk Investigational Site, Uppsala, Sweden|Novo Nordisk Investigational Site, Tainan city, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Kocaeli, Turkey|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01541215/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01541215/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01541215
323,NCT04255381,Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID),Completed,Has Results,Type1 Diabetes,Device: Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP),Yale University|Harvard University,"2 Years to 18 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale University, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04255381/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04255381
324,NCT03311724,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Tirzepatide|Drug: Placebo,Eli Lilly and Company,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Valley Research, Fresno, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Solaris Clinical Research, Meridian, Idaho, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Aventiv Research, Columbus, Ohio, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03311724/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03311724/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03311724
325,NCT01991795,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Ticagrelor 60 mg|Drug: Ticagrelor placebo,AstraZeneca,"50 Years to 130 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Research Site, Alexander City, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Fairhope, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Cottonwood, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Fremont, California, United States|Research Site, Fresno, California, United States|Research Site, Irvine, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Hills, California, United States|Research Site, Newport Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Stockton, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Greenwich, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Cooper City, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Merritt Island, Florida, United States|Research Site, Miami Gardens, Florida, United States|Research Site, Miami Shores, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, North Miami Beach, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Cloud, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Nampa, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Crystal Lake, Illinois, United States|Research Site, Elmhurst, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Moline, Illinois, United States|Research Site, North Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Bossier City, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Crowley, Louisiana, United States|Research Site, Minden, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bowie, Maryland, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, North Attleboro, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Mount Clemens, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Joplin, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lee's Summit, Missouri, United States|Research Site, North Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Helena, Montana, United States|Research Site, Hastings, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, East Brunswick, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Binghamton, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Hawthorne, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Utica, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Clayton, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Butler, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Harleysville, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Port Matilda, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenwood, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Varnville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Channelview, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Huntsville, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Pharr, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Shavano Park, Texas, United States|Research Site, Bountiful, Utah, United States|Research Site, Draper, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Arlington, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Port Orchard, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Kenosha, Wisconsin, United States|Research Site, Waukesha, Wisconsin, United States|Research Site, Buenos aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad Autonomade Buenos Aires, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ranelagh, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Venado Tuerto, Argentina|Research Site, Villa Maria, Argentina|Research Site, Adelaide, Australia|Research Site, Ashford, Australia|Research Site, Coffs Harbour, Australia|Research Site, Fitzroy, Australia|Research Site, Fullarton, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Merewether, Australia|Research Site, Milton, Australia|Research Site, Murdoch, Australia|Research Site, Braunau, Austria|Research Site, Eisenstadt, Austria|Research Site, Feldkirch, Austria|Research Site, Innsbruck, Austria|Research Site, Saint Stefan/Stainz, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Bouge, Belgium|Research Site, Bruges, Belgium|Research Site, De Pinte, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Mechelen, Belgium|Research Site, Mol, Belgium|Research Site, Overpelt, Belgium|Research Site, Roeselare, Belgium|Research Site, Yvoir, Belgium|Research Site, Zottegem, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasilia, Brazil|Research Site, Brasillia, Brazil|Research Site, Brasillia, Brazil|Research Site, Brasília, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Cariacica, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Goiânia, Brazil|Research Site, Marilia, Brazil|Research Site, Maringa, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S.J.Rio Preto, Brazil|Research Site, Sao Jose dos Campos, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Tatui, Brazil|Research Site, Uberlândia, Brazil|Research Site, Vitoria, Brazil|Research Site, Vitória, Brazil|Research Site, Votuporanga, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Burgas, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Red Deer, Alberta, Canada|Research Site, Spruce Grove, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Jarvis, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Lambert, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Chicoutimi, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Los Angeles, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Cangzhou, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Yinchuan, China|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogotá, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Cali, Colombia|Research Site, Cali, Colombia|Research Site, Cartagena, Colombia|Research Site, Floridablanca, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellin, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceska Lipa, Czechia|Research Site, Chomutov, Czechia|Research Site, Frydek-Mistek, Czechia|Research Site, Jablonec nad Nisou, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kolin, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Louny, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Zabreh, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Ostrava, Czechia|Research Site, Pelhrimov, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 9, Czechia|Research Site, Praha, Czechia|Research Site, Praha, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Slany, Czechia|Research Site, Trebic, Czechia|Research Site, Turnov, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aarhus N, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hjørring, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kolding, Denmark|Research Site, Købehhavn Ø, Denmark|Research Site, København NV, Denmark|Research Site, Næstved, Denmark|Research Site, Odense C, Denmark|Research Site, Roslev, Denmark|Research Site, Svendborg, Denmark|Research Site, Viborg, Denmark|Research Site, Værløse, Denmark|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Jyväskylä, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Avignon Cedex, France|Research Site, Bayonne, France|Research Site, Bobigny, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, La Rochelle Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Lyon, France|Research Site, Montauban, France|Research Site, NICE Cedex 01, France|Research Site, Nimes, France|Research Site, PARIS Cedex 15, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Toulouse Cedex, France|Research Site, TOURCOING cedex, France|Research Site, TOURS Cedex 9, France|Research Site, Altdorf, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Markkleeberg, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf Am Inn, Germany|Research Site, München, Germany|Research Site, Neuwied, Germany|Research Site, Nürnberg, Germany|Research Site, Papenburg, Germany|Research Site, Schwerin, Germany|Research Site, Wangen, Germany|Research Site, Wermsdorf, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Kisvárda, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pásztó, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Naharia, Israel|Research Site, Petach Tikva, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Pavia, Italy|Research Site, Rivoli, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Udine, Italy|Research Site, Viterbo, Italy|Research Site, Adachi-ku, Japan|Research Site, Beppu-shi, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Edogawa-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Fussa-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kawanishi-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Otaru-shi, Japan|Research Site, Sanyoonoda-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Shimajiri-gun, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takayama-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Toyota-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Urasoe-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Changwon-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Iksan-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, Culiacán, Mexico|Research Site, D.F, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, México, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Pachuca, Mexico|Research Site, Querétaro, Mexico|Research Site, Tijuana, Mexico|Research Site, Xalapa, Mexico|Research Site, Zapopan, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Blaricum, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Goes, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Stadskanaal, Netherlands|Research Site, Tiel, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bergen, Norway|Research Site, Bodø, Norway|Research Site, Bodø, Norway|Research Site, Kongsvinger, Norway|Research Site, Lillehammer, Norway|Research Site, Oslo, Norway|Research Site, Oslo, Norway|Research Site, Oslo, Norway|Research Site, Sandefjord, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Svelvik, Norway|Research Site, Tromsø, Norway|Research Site, Trondheim, Norway|Research Site, Ålesund, Norway|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Callao, Peru|Research Site, Chiclayo, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Miraflores, Peru|Research Site, Cebu City, Philippines|Research Site, Cebu, Philippines|Research Site, Davao City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Biała Rawska, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Bielsko-Biała, Poland|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chojnice, Poland|Research Site, Chorzów, Poland|Research Site, Chrzanow, Poland|Research Site, Chrzanów, Poland|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Koszalin, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kędzierzyn Koźle, Poland|Research Site, Legnica, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Mikołów, Poland|Research Site, Myszków, Poland|Research Site, Nakło nad Notecią, Poland|Research Site, Nowogard, Poland|Research Site, Nysa, Poland|Research Site, Opole, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Oświęcim, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Puławy, Poland|Research Site, Płock, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Siedlce, Poland|Research Site, Sobótka, Poland|Research Site, Sokółka, Poland|Research Site, Staszów, Poland|Research Site, Szczecin, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Tychy, Poland|Research Site, Ustroń, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Włocławek, Poland|Research Site, Zabrze, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Zielona Góra, Poland|Research Site, Łódź, Poland|Research Site, Żnin, Poland|Research Site, Canovanas, Puerto Rico|Research Site, Cidra, Puerto Rico|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Suceava, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Khanty-Mansiysk, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Khobar, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Benoni, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Greenbury, Phoenix, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Soweto, South Africa|Research Site, Stanger, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, A Coruña, Spain|Research Site, Alcalá de Henares, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Cáceres, Spain|Research Site, El Palmar, Spain|Research Site, Ferrol (A Coruña), Spain|Research Site, Girona, Spain|Research Site, Granada, Spain|Research Site, Hospitalet de Llobregat, Spain|Research Site, Huelva, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Móstoles, Spain|Research Site, Pontevedra, Spain|Research Site, Sabadell, Spain|Research Site, San Juan de Alicante, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Santander, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Son Ferriol, Spain|Research Site, Valdemoro, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Lessebo, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Malmö, Sweden|Research Site, Rättvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Changhua City, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, Pingtung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Muang, Thailand|Research Site, Naimuang, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Antalya, Turkey|Research Site, Aydin, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Mersin, Turkey|Research Site, Belo Horizonte, Ukraine|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Rivne, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Antrim, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Durham, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Faringdon, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrogate, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, London, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Newcastle-Upon-Tyne, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Paisley, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Rothwell, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, York, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01991795/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01991795/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01991795
326,NCT03433677,A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes,Completed,Has Results,Diabetes Type 1,Drug: LY900014|Drug: Insulin lispro,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Valley Research, Fresno, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03433677/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03433677/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03433677
327,NCT04789473,OneinSeven Gestational Diabetes Genetic and Socioeconomic Risk Study,Recruiting,No Results Available,Gestational Diabetes|Pregnancy Complications|Pregnancy Related|Genetic Predisposition|Risk Reduction,Genetic: Polygenic Risk Score Generation,Prenome,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Illumina Accelerator, Foster City, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04789473/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04789473
328,NCT03014479,Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: Trelagliptin|Drug: Daily DPP-4 inhibitor,Takeda,"20 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Takeda Selected Site 17, Nagoya, Aichi, Japan|Takeda Selected Site 18, Nagoya, Aichi, Japan|Takeda Selected Site 25, Kanra, Gunma, Japan|Takeda Selected Site 9, Kobe, Hyogo, Japan|Takeda Selected Site 27, Koga, Ibaraki, Japan|Takeda Selected Site 14, Kawasaki, Kanagawa, Japan|Takeda Selected Site 11, Sagamihara, Kanagawa, Japan|Takeda Selected Site 10, Yamato, Kanagawa, Japan|Takeda Selected Site 4, Sendai, Miyagi, Japan|Takeda Selected Site 5, Sendai, Miyagi, Japan|Takeda Selected Site 3, Kashihara, Nara, Japan|Takeda Selected Site 15, Kashiwara, Osaka, Japan|Takeda Selected Site 1, Suita, Osaka, Japan|Takeda Selected Site 24, Okegawa, Saitama, Japan|Takeda Selected Site 26, Oyama, Tochigi, Japan|Takeda Selected Site 23, Adachi-ku, Tokyo, Japan|Takeda Selected Site 6, Chuo-ku, Tokyo, Japan|Takeda Selected Site 7, Chuo-ku, Tokyo, Japan|Takeda Selected Site 22, Edogawa-ku, Tokyo, Japan|Takeda Selected Site 19, Musashino, Tokyo, Japan|Takeda Selected Site 21, Ota-ku, Tokyo, Japan|Takeda Selected Site 12, Shibuya-ku, Tokyo, Japan|Takeda Selected Site 13, Shinagawa-ku, Tokyo, Japan|Takeda Selected Site 20, Shinagawa-ku, Tokyo, Japan|Takeda Selected Site 2, Shinjuku-ku, Tokyo, Japan|Takeda Selected Site 8, Shinjuku-ku, Tokyo, Japan|Takeda Selected Site 16, Osaka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03014479/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03014479/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03014479
329,NCT02906917,A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/insulin aspart|Drug: Insulin glargine|Drug: Insulin aspart,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Danbury, Connecticut, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Chesterfield, Missouri, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Franklin, Ohio, United States|Novo Nordisk Investigational Site, Bartlett, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Knoxville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Chesapeake, Virginia, United States|Novo Nordisk Investigational Site, Midlothian, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Sidi Bel Abbes, Algeria|Novo Nordisk Investigational Site, Broumov, Czechia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Prague 4, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Trutnov, Czechia|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Surat, Gujarat, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Aurangabad, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Arkhangelsk, Russian Federation|Novo Nordisk Investigational Site, Cheboksary, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Syktyvkar, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02906917/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02906917/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02906917
330,NCT03987919,A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Tirzepatide|Drug: Semaglutide,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cahaba Research, Birmingham, Alabama, United States|Syed Research Consultants Llc, Sheffield, Alabama, United States|National Research Institute - Huntington Park, Huntington Park, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute - Huntington Park, Panorama City, California, United States|Artemis Institute for Clinical Research, Riverside, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Institute for Clinical Research, San Marcos, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|CMR of Greater New Haven, Hamden, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|East Coast Institute for Research at The Jones Center, Lake City, Florida, United States|South Florida Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|South Broward Research, Pembroke Pines, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Sky Clinical Research Network, Union City, Georgia, United States|Elite Clinical Trials, Blackfoot, Idaho, United States|University of Iowa Hospital & Clinic, Iowa City, Iowa, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|NECCR PrimaCare Research, Fall River, Massachusetts, United States|ActivMed Practices and Research, Methuen, Massachusetts, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Clinvest Research LLC, Springfield, Missouri, United States|Premier Research, Trenton, New Jersey, United States|Albany Medical College, Division of Community Endocrinology, Albany, New York, United States|PharmQuest, Greensboro, North Carolina, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aventiv Research Inc, Columbus, Ohio, United States|Intend Research, LLC, Norman, Oklahoma, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Detweiler Family Medicine & Associates, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh, Pennsylvania, United States|Holston Medical Group, Bristol, Tennessee, United States|Dallas Diabetes Research Center, Dallas, Texas, United States|Biopharma Informatic, Inc., Houston, Texas, United States|Consano Clinical Research, LLC, Shavano Park, Texas, United States|Carl R. Meisner Medical Clinic, PLLC, Sugar Land, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Burke Internal Medicine and Research, Burke, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States|The Vancouver Clinic, Vancouver, Washington, United States|CEDIC, Caba, Ar-b, Argentina|CIPREC, Ciudad Autonoma de Buenos Aire, Ar-b, Argentina|Investigaciones Medicas Imoba Srl, Buenos Aires, Ar-c, Argentina|CEMEDIAB, C.a.b.a., Ar-c, Argentina|Sanatorio Norte, Santiago del Estero, Ar-g, Argentina|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Centro Médico Viamonte, Caba, Buenos Aires, Argentina|Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada, Caba, Buenos Aires, Argentina|Mautalen Salud e Investigacion-Centro de Osteopatías Médicas, Ciudad Autonoma De Buenos Air, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|Instituto de Investigaciones Clínicas Mar del Plata, Mar del Plata, Provincia De Buenos Aires, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Paratus Clinical Research Western Sydney, Blacktown, Au-nsw, Australia|Campbelltown Medical & Dental Centre, Campbelltown, Au-nsw, Australia|Paratus Clinical Research Central Coast, Kanwal, Au-nsw, Australia|Holdsworth House Medical Practice, Sydney, New South Wales, Australia|GenesisCare - Bundaberg, Bundaberg, Queensland, Australia|Royal Brisbane and Womens Hospital, Herston, Queensland, Australia|Core Research Group, Milton, Queensland, Australia|AusTrials, Taringa, Queensland, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|GenesisCare - Wexford Medical Centre WA, Joondalup, Western Australia, Australia|GenesisCare - Wexford Medical Centre WA, Murdoch, Western Australia, Australia|Adelaide Medical Solutions, Woodville South, Australia|CEDOES, Vitória, Br-es, Brazil|ISPEM - Instituto São José dos Campos em Pesquisas Médicas, São José dos Campos, Br-sp, Brazil|CPQuali Pesquisa Clínica, São Paulo, Br-sp, Brazil|CEPIC - Centro Paulista de Investigação Clínica, São Paulo, Br-sp, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Rio Grande Do Sul, Brazil|CPCLIN, São Paulo, SP, Brazil|Dr. Consulta Clínica Médica LTDA, São Paulo, Brazil|Milestone Research Inc., London, Ca-on, Canada|Bluewater Clinical Research Group Inc., Sarnia, Ca-on, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ca-on, Canada|Manna Research, Lévis, Ca-qc, Canada|Manna Research - Burlington North, Burlington, Ontario, Canada|Manna Research - Burlington North, Nepean, Ontario, Canada|Manna Research - Burlington North, Stoney Creek, Ontario, Canada|Manna Research - Burlington North, Toronto, Ontario, Canada|Meir Medical Center, Kfar Saba, HaMerkaz, Israel|Clalit Health Services - Shuali Clinic, Raanana, HaMerkaz, Israel|Sheba Medical Center, Ramat Gan, HaMerkaz, Israel|Diabetes Medical Center, Tel Aviv, Il-ta, Israel|Hadassah Medical Center, Jerusalem, Yerushalayim, Israel|Clalit Health Services - Sakhnin Community Clinic, Sakhnin, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv Jaffa, Israel|Rambam Health Care Campus, Haifa, Ḥeifā, Israel|Linn Medical Center, Haifa, Ḥeifā, Israel|Centro Especializado en Diabetes Obesidad y Enfermedades, Mexico, D.f., Mexico|Diseno y Planeacion en Investigacion Medica, Guadalajara, Jalisco, Mexico|Instituto Jalisciense de Investigacion en Diabetes y Obesida, Guadalajara, Jalisco, Mexico|Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente, Guadalajara, Mx-jal, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Unidad Médica para la Salud Integral, San Nicolás de los Garza, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, Ciudad Madero, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Paola Mansilla-Letelier, MD, Guaynabo, Puerto Rico|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, San Juan, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, Puerto Rico|Oldfield Surgery, Bath, Avon, United Kingdom|Staploe Medical Centre, Ely, Gb-cam, United Kingdom|Fowey River Practice, Fowey, Gb-con, United Kingdom|Oak Tree Surgery, Liskeard, Gb-con, United Kingdom|Rame Medical Ltd, Torpoint, Gb-con, United Kingdom|Royal Primary Care Chesterfield North west, Chesterfield, Gb-dby, United Kingdom|Knowle House Surgery, Plymouth, Gb-dev, United Kingdom|Queen Alexandra Hospital, Portsmouth, Gb-ham, United Kingdom|Lister Hospital, Stevenage, Gb-hrt, United Kingdom|Oakenhurst Medical Practice, Blackburn, Gb-lan, United Kingdom|Rowden Surgery, cHIPPENHAM, Gb-wil, United Kingdom|Leicester General Hospital, Leicester, Leicestershire, United Kingdom|University Hospital Coventry & Warwickshire, Coventry, Warwickshire, United Kingdom|Wickersley Health Centre - Clifton Medical Centre, Rotherham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03987919/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03987919/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03987919
331,NCT04665999,Glycemic Profiles And Insulin Delivery Across The Menstrual Cycle In Women With Type 1 Diabetes,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: Continuous Glucose Monitor,"University of Virginia|DexCom, Inc.",18 Years to 40 Years   (Adult),,Other|Industry,Observational,Observational Model: Other|Time Perspective: Prospective,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04665999/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04665999/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04665999
332,NCT01554618,Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes,Completed,Has Results,Children and Adolescent With Type 2 Diabetes,Drug: Exenatide Once Weekly|Drug: Placebo,AstraZeneca,10 Years to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Los Angeles, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Jackson, Mississippi, United States|Research Site, Buffalo, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Pleven, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Szeged, Hungary|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Ramat Gan, Israel|Research Site, Kuwait City, Kuwait|Research Site, Aguascalientes, Mexico|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Veracruz, Mexico|Research Site, Chernivts?, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Odesa, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01554618/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01554618/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT01554618
333,NCT04980014,A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: NesinaAct® Tablet,Takeda,"19 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Busan, Korea, Republic of|Chuncheon, Korea, Republic of|Daejeon, Korea, Republic of|Gangneung-si, Korea, Republic of|Goyang-si, Korea, Republic of|Jeonju, Korea, Republic of|Seongam, Korea, Republic of|Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04980014/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04980014/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04980014
334,NCT03315780,A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03315780/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03315780/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03315780
335,NCT02623998,Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita),Completed,Has Results,Type 2 Diabetes Mellitus,Drug: insulin glargine|Drug: sitagliptin/metformin|Behavioral: lifestyle therapy,Population Health Research Institute|Merck Sharp & Dohme LLC,"30 Years to 80 Years   (Adult, Older Adult)",Phase 3,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Calgary, Calgary, Alberta, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|St. Joseph's Hospital, London, Ontario, Canada|LMC, Markham, Ontario, Canada|Univeristy of Montreal, Montreal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02623998/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02623998/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02623998
336,NCT02927639,MyDiaText Text Messaging Intervention for Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Other: MyDiaText,Children's Hospital of Philadelphia|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"12 Years to 18 Years   (Child, Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02927639/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02927639/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02927639
337,NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,Completed,Has Results,Type 2 Diabetes,Drug: Tirzepatide|Drug: Placebo,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Valley Endocrine, Fresno, Fresno, California, United States|Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Manhattan Medical Research, New York, New York, United States|Intend Research, Norman, Oklahoma, United States|Milan Kvapil s.r.o., Pribram, Středočeský Kraj, Czechia|Diacentrum Brandys n.L. s.r.o., Brandys Nad Labem-Stara Bolesl, Czechia|Diabetologicka ordinace pro dospele, Krnov, Czechia|Diahelp s.r.o., Interni a diabetologicka ambulance, Pardubice, Czechia|Lekarna Dr. Max, Praha 1, Czechia|Milan Kvapil s.r.o., Praha 4, Czechia|RESTRIAL s.r.o., Praha 8, Czechia|Praxis Dr. Jörg Lüdemann, Falkensee, Brandenburg, Germany|Arztpraxis Dr. Cornelia Marck, Pohlheim, Hessen, Germany|InnoDiab Forschung GmbH, Essen, Nordrhein-Westfalen, Germany|Institut für Diabetesforschung Münster GmbH, Münster, Nordrhein-Westfalen, Germany|Praxis Dr. Kempe - Dr. Stemler, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany|Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach, Saarland, Germany|SMO.MD GmbH, Magdeburg, Sachsen-Anhalt, Germany|RED-Institut GmbH, Oldenburg in Holstein, Schleswig Holstein, Germany|Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen, Hamburg, Germany|Gemeinschaftspraxis für innere Medizin und Diabetologie, Hamburg, Germany|Kashiwa hospital, Kashiwa, Chiba, Japan|Manda Hospital, Sapporo, Hokkaido, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|The Institute for Adult Diseases, Asahi Life Foundation, Chuou-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Jinnouchi Hospital, Kumamoto, Japan|Centrum Medyczne AMED, Warszawa, Mazowieckie, Poland|NZOZ ZDROWIE Osteo-Medic, Bialystok, Podlaskie, Poland|Centrum Badan Klinicznych, PI House, Gdansk, Pomorskie, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|Centro de Endocrinologia y Nutricion del Turabo, Caguas, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ambulancia vnútorného lekárstva Hnúša (Diabetes care), Hnusta, Slovakia|Sin Azucar, Malacky, Slovakia|Dia-Clarus.s.r.o., Prievidza, Slovakia|JAL, Trnava, Slovakia|Medivasa, s.r.o., Zilina, Slovakia|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital de la Ribera, Alcira, Valencia, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Infanta Luisa, Sevilla, Spain|Hospital Universitari i Politecnic La Fe-ENDO, València, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04039503/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04039503/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04039503
338,NCT03338010,A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes,Drug: LY2963016|Drug: Lantus®,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Lanzhou University, Lanzhou, Gansu, China|Shantou University Medical College No.2 Affiliated Hospital, Shantou, Guang Dong Province, China|Guangdong Province People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|Tongji Hosp Tongji Med Col Huazhong Univ of Sci & Tech, Wu Han, Hubei, China|Wuhan Central Hospital, Wuhan, Hubei, China|The First People Hospital of Yueyang, Yueyang, Hunan, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The Affliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Nanjing First Hospital, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, China|Xuzhou central Hospital, Xuzhou, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|No.2 Hospital Affiliated to Jilin University, Changchun City, Jilin, China|Siping central people's hospital, Siping, Jilin, China|Dalian Med. Univ. No 2 Affiliate Hospital, Dalian, Liao Ning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The First Affiliated Hospital with Nanjing Medical Universit, Nanjing, Nanjing, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|1st affiliated Hospital of Shanxi Medical University, Tai Yuan, Shan XI, China|Jinan Central Hospital, Jinan, Shandong, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Peking Union Medical College Hospital, Beijing, China|Chongqing General Hospital, Chongqing, China|Shanghai Putuo District Center Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03338010/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03338010/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03338010
339,NCT03675165,Can You Reduce Diabetes Symptomatology by Becoming Your 'Best Possible Self': The Role of Stress and Resilience,Completed,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Best Possible Self,Liverpool John Moores University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Liverpool John Moores University, Liverpool, Merseyside, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03675165/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03675165/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03675165
340,NCT01528254,VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo of vildagliptin|Drug: vildagliptin|Drug: Metformin,Novartis Pharmaceuticals|Novartis,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, San Isidro, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Brookvale, New South Wales, Australia|Novartis Investigative Site, Woy Woy, New South Wales, Australia|Novartis Investigative Site, Morayfield, Queensland, Australia|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Belem, PA, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Mogi das Cruzes, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Gabrovo, Bulgaria|Novartis Investigative Site, Kazanlak, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Razgrad, Bulgaria|Novartis Investigative Site, Ruse, Bulgaria|Novartis Investigative Site, Smolian, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Cartagena, Bolivar, Colombia|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Baranquilla, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Pisek, Czech Republic, Czechia|Novartis Investigative Site, Prague 5, Czech Republic, Czechia|Novartis Investigative Site, Brandys Nad Labem, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Santo Domingo, Republica Dominicana, Dominican Republic|Novartis Investigative Site, Santo Domingo, Dominican Republic|Novartis Investigative Site, Saku, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Lahti, Suomi, Finland|Novartis Investigative Site, Kerava, Finland|Novartis Investigative Site, Kouvola, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Hainstadt, Hainburg, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen am Neckar, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Gelnhausen, Germany|Novartis Investigative Site, Kamp-Lintfort, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Saint Ingbert - Oberwuerzbach, Germany|Novartis Investigative Site, Wangen, Germany|Novartis Investigative Site, Clinica, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, HongKong, Hong Kong|Novartis Investigative Site, Zalaegerszeg, Zala, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Csongrad, Hungary|Novartis Investigative Site, Eger, Hungary|Novartis Investigative Site, Kalocsa, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Kochi, Kerala, India|Novartis Investigative Site, Indore, Madhya Pradesh, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Chennai, Tamilnadu, India|Novartis Investigative Site, Chandigarh, India|Novartis Investigative Site, Heifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Sefad, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Tel Giborim, Holon, Israel|Novartis Investigative Site, Montichiari, BS, Italy|Novartis Investigative Site, Campobasso, CB, Italy|Novartis Investigative Site, Arenzano, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Casorate Primo, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Incheon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Uijeongbu-Si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Daejeon, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Jelgava, LV, Latvia|Novartis Investigative Site, Liepaja, LV, Latvia|Novartis Investigative Site, Ogre, LV, Latvia|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Talsi, LV, Latvia|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Vilnius, LT, Lithuania|Novartis Investigative Site, Jonava, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Kota Bahru, Kelantan, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Ciudad De Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico D.F, Distrito Federal, Mexico|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Cuautla, Morelos, Mexico|Novartis Investigative Site, Cuernavaca, Morelos, Mexico|Novartis Investigative Site, Aguascalientes, Mexico|Novartis Investigative Site, Distrito Federal, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Querétaro, Mexico|Novartis Investigative Site, Enebakk, Norway|Novartis Investigative Site, Fetsund, Norway|Novartis Investigative Site, Honefoss, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Spikkestad, Norway|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Trujillo, La Libertad, Peru|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, Chorrillos, Lima, Peru|Novartis Investigative Site, Magdalena, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Martin de Porres, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Marikina, Metro Manila, Philippines|Novartis Investigative Site, Quezon City, Metro Manila, Philippines|Novartis Investigative Site, Marikina City, Philippines|Novartis Investigative Site, Pasay City, Philippines|Novartis Investigative Site, Pasig City, Philippines|Novartis Investigative Site, San Juan City, Philippines|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Zabrze, Poland|Novartis Investigative Site, Oradea, Bihor, Romania|Novartis Investigative Site, Oradea, Jud. Bihor, Romania|Novartis Investigative Site, Ploiesti, Jud. Prahova, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Penza, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St.- Petersburg, Russian Federation|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Lucenec, Slovak Republic, Slovakia|Novartis Investigative Site, Namestovo, Slovak Republic, Slovakia|Novartis Investigative Site, Roznava, Slovak Republic, Slovakia|Novartis Investigative Site, Sala, Slovak Republic, Slovakia|Novartis Investigative Site, Trebisov, Slovak Republic, Slovakia|Novartis Investigative Site, Zilina, Slovak Republic, Slovakia|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Nové Zámky, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Sabinov, Slovakia|Novartis Investigative Site, Sered, Slovakia|Novartis Investigative Site, Sturovo, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Novartis Investigative Site, Alberton, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Gauteng, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Sant Adria Del Besos, Barcelona, Spain|Novartis Investigative Site, Santa Coloma De Gramanet, Barcelona, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Hsintien, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Denizli, Turkey|Novartis Investigative Site, Diskapi / Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kahramanmaras, Turkey","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01528254/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01528254/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01528254
341,NCT04090580,Impact on Glycemic Variability After Treatment With Dapagliflozin on Type 2 Diabetes Patients,Recruiting,No Results Available,Type 2 Diabetes,Diagnostic Test: Continuous glucose monitoring,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|AztraZeneca,"18 Years to 77 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Ciudad de mexico, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04090580/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04090580
342,NCT03338023,A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes,Drug: LY2963016|Drug: Lantus®|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Peoples Hospital, Beijing, Beijing, China|Shantou University Medical College No.2 Affiliated Hospital, Shantou, Guang Dong Province, China|Guangdong Province People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|Wu Han Tongji Hospital, Wu Han, Hu Bei, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|Nanjing First Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|No.2 Hospital Affiliated to Jilin University, Changchun City, Jilin, China|Dalian Med. Univ. No 2 Affiliate Hospital, Dalian, Liao Ning, China|The First Affiliated Hospital with Nanjing Medical Universit, Nanjing, Nanjing, China|Shanghai Tenth People's Hospital, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|Peking Union Medical College Hospital, Beijing, China|Shanghai Putuo District Center Hospital, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03338023/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03338023/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03338023
343,NCT02750410,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,"20 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adachi-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiyoda, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chuo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chuo-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chuou-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fuchu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ichikawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Isahaya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kamakura, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kashihara, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maebashi-City, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mito, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Naka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nishinomiya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ooita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sasebo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shimotsuke, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toda, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokohama, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02750410/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02750410/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02750410
344,NCT02862730,Four Way Crossover Closed Loop With Exercise Detection,Completed,Has Results,Type 1 Diabetes,Device: Artificial Pancreas Controller in Dual Hormone Mode|Device: Subject's insulin pump|Device: Artificial Pancreas Controller in Single Hormone Mode|Device: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode,Oregon Health and Science University,21 Years to 45 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02862730/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02862730
345,NCT02660827,Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Device: Insulin Pump,Medtronic Diabetes,2 Years to 13 Years   (Child),Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AMCR Institute, Escondido, California, United States|Stanford Hospital and Clinics, Palo Alto, California, United States|SoCal Diabetes, Torrance, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of South Florida - USF Health, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Indiana University, Indianapolis, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Sheba Medical Center, Tel Aviv, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02660827/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02660827/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02660827
346,NCT03175120,A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD),Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: Insulin degludec/liraglutide|Drug: Insulin degludec,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Hefei, Anhui, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, ChongQing, Chongqing, China|Novo Nordisk Investigational Site, Fuzhou, Fujian, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, China|Novo Nordisk Investigational Site, Hengshui, Hebei, China|Novo Nordisk Investigational Site, Shijiazhuang, Hebei, China|Novo Nordisk Investigational Site, Tangshan, Hebei, China|Novo Nordisk Investigational Site, Harbin, Heilongjiang, China|Novo Nordisk Investigational Site, Yueyang, Hunan, China|Novo Nordisk Investigational Site, Huhehaote, Inner Mongolia, China|Novo Nordisk Investigational Site, Huhhot, Inner Mongolia, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Nanchang, Jiangxi, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Changchun, Jilin, China|Novo Nordisk Investigational Site, Siping, Jilin, China|Novo Nordisk Investigational Site, Dalian, Liaoning, China|Novo Nordisk Investigational Site, Yinchuan, Ningxia, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Taiyuan, Shanxi, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, China|Novo Nordisk Investigational Site, Kunming, Yunnan, China|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03175120/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03175120/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03175120
347,NCT04276207,A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,18 Years to 64 Years   (Adult),Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04276207/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04276207/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04276207
348,NCT02733991,Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes,Device: MiniMed™640G and Suspend before low|Device: MiniMed™640G,Medtronic Diabetes,"24 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU de Besançon, Besançon, France|CHU Grenoble, Grenoble, France|APHM - La Conception, Marseille, France|CHU Montpellier - Hôpital Lapeyronie, Montpellier, France|Ospedale Papa Giovanni XXIII, Bergamo, Italy|Ospedale S. Raffaele, Milan, Italy|Ospedale S. Gionanni di Dio, Olbia, Italy|Groene Hart Ziekenhuis, Gouda, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Isala, Zwolle, Netherlands|Harrogate District Hospital, Harrogate, N. Yorkshire, United Kingdom|King's College London, London, United Kingdom|Manchester Diabetes Center, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02733991/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02733991/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02733991
349,NCT02963766,A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,10 Years to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Advanced Research Center, Anaheim, California, United States|Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Center of Excellence in Diabetes & Endocrinology, Sacramento, California, United States|Rady Childrens Hospital - San Diego, San Diego, California, United States|JC Cabaccan, San Jose, California, United States|Touro University, Vallejo, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Florida Center for Endocrinology & Metabolism, Orlando, Florida, United States|St. Luke's Regional Medical Center, Boise, Idaho, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|ECU Pediatric Specialty Care, Greenville, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Seattle Children's Hospital Research Foundation, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|CAMC Institute, Charleston, West Virginia, United States|Centro de Pesquisas em Diabetes, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto da Criança com Diabetes, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Estadual de Diabetes e Endocrinologia, Rio de Janeiro, RJ, Brazil|Hospital PUC-CAMPINAS, Campinas, Sao Paulo, Brazil|CPCLIN, São Paulo, SP, Brazil|Hospital da Clinicas da Faculdade de Medicina da USP, São Paulo, SP, Brazil|Hospital das Clinicas da FMRP, Ribeirão Preto, São Paulo, Brazil|UNIFESP - Escola Paulista de Medicina, São Paulo, Brazil|Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France|Hopital Robert Debre, Paris, France|Praxis Dr. med. Landers, Mayen, Rheinland-Pfalz, Germany|Zentrum für klinische Studien, Sankt Ingbert, Saarland, Germany|RED-Institut GmbH, Oldenburg in Holstein, Schleswig Holstein, Germany|Heim Pal Gyermekkorhaz, Budapest, Hungary|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Dr Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karmnataka, India|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Post Graduate Institute of Medical Education & Research, Chandigarh, Punjab, India|Banaras Hindu University - BHU, Varanasi, Uttar Pradesh, India|Park Clinic, Kolkata, West Bengal, India|Apollo Gleneagles Hospitals Kolkata, Kolkata, West Bengal, India|Health Pharma Professional Research, S.A. de C.V., Mexico City, Federal District, Mexico|Centro de Inv. Medica de Occidente, SC, Zapopan, Jalisco, Mexico|Centro Medico San Francisco, Monterrey, Nuevo Leon, Mexico|Cli-nica Hospital Cemain, Tampico, Tamaulipas, Mexico|Hospital Angeles Puebla, Puebla, Mexico|Arke Estudios Clinicos S.A. de C.V., Veracruz, Mexico|Centro de Diabetes y Endocrinologia Pediatrica de PR, Bayamon, Puerto Rico|King Saud University Hospital, Riyadh, Saudi Arabia|King Salman bin Abdulaziz Hospital - Diabetic Center, Riyadh, Saudi Arabia|Ankara University Medicine Hospital, Ankara, Mamak, Turkey|Sami Ulus Education & Research Hospital, Ankara, Turkey|Duzce University Medical Faculty, Duzce, Turkey|Ondokuz Mayis University Medical Faculty, Samsun, Turkey|Alder Hey Children's Hospital, Liverpool, Lancashire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02963766/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02963766/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02963766
350,NCT02756832,An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2,Completed,Has Results,Diabetes Mellitus,Drug: Alogliptin Benzoate,Takeda,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"First City Clinical Hospital named after E.E. Vlosevich, Arkhangelsk, Russian Federation|City polyclinic #11, Barnaul, Russian Federation|Belgorod Regional Clinical hospital named after Saint I Belgorod Regional Clinical Hospital of St. Joasaph, Belgorod, Russian Federation|LLC Medical center Lotos, Chelyabinsk, Russian Federation|Istochnik clinic, Chelyabinsk, Russian Federation|Regional clinical hospital #3, Chelyabinsk, Russian Federation|Medical center Health Academy, Chita, Russian Federation|Chita State Medical Academy, Chita, Russian Federation|Ural State Medical Academy, Ekaterinburg, Russian Federation|City polyclinic #11, Kazan, Russian Federation|Ciry polyclinic #10, Kazan, Russian Federation|Kemerovo Regional Clinical Hospital named after S.V. Belyaev, Kemerovo, Russian Federation|Medical Center Clinic of Hormonal Health, Khabarovsk, Russian Federation|Regional Clinical hospital named after S.I. Sergeev, Khabarovsk, Russian Federation|Road Clinical Hospital at Khabarovsk Station - 1, Khabarovsk, Russian Federation|Northern Clinical Emergency Hospital, Kirov, Russian Federation|Kirov Clinical Hospital #7 named after V.I. Yurlova, Kirov, Russian Federation|Kostroma City hospital, Kostroma, Russian Federation|Kursk Regional Clinical Hospital, Kursk, Russian Federation|Lobnya Central City Hospital, Lobnya, Russian Federation|City polyclinic #166, Moscow, Russian Federation|Endocrinology Research Center, Moscow, Russian Federation|City polyclinic #22, Moscow, Russian Federation|City polyclinic #52, Moscow, Russian Federation|The Scientific Center of Cardiovascular Surgery named after A.N. Bakulev, Moscow, Russian Federation|CJSC Medsi, Moscow, Russian Federation|Diagnostical Center #5, Moscow, Russian Federation|Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Clinical Diagnostical Center, Nizhniy Novgorod, Russian Federation|City polyclinic #3, Nizhniy Novgorod, Russian Federation|Medical Center Healthy family LLC, Novosibirsk, Russian Federation|Republican Hospital named after V.A.Baranov, Petrozavodsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|City Clinical hospital #11, Ryazan, Russian Federation|City policlinic #117, Saint-Petersburg, Russian Federation|City polyclinic #109, Saint-Petersburg, Russian Federation|Saint-Petersburg Territorial Diabetological Center, Saint-Petersburg, Russian Federation|City policlinic #86, Saint-Petersburg, Russian Federation|Consultative and diagnostic polyclinic 1 of Primorsky district, Saint-Petersburg, Russian Federation|Samara Regional Clinical Diagnostical polyclinic #14, Samara, Russian Federation|LLC Center Diabet, Samara, Russian Federation|City policlinic #9, Samara, Russian Federation|City polyclinic #22, Saratov, Russian Federation|City policlinic #3, Tomsk, Russian Federation|LLC Medical center Ideale, Tomsk, Russian Federation|City policlinic #3, Tomsk, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|City polyclinic #43, Ufa, Russian Federation|Regional Clinical Hospital, Vladimir, Russian Federation|Regional Clinical Hospital #1, Volgograd, Russian Federation|Volgograd State Medical University, Volgograd, Russian Federation|LLC Zdorovye, Diabetes Center, Vologda, Russian Federation|Voronezh Regional Clinical Diagnostical center, Voronezh, Russian Federation","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02756832/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02756832/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02756832
351,NCT03406377,Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: OPK-88003|Drug: Placebo,"OPKO Health, Inc.","18 Years to 80 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","National Research Institute - Huntington Park, Huntington Park, California, United States|National Research Institute - Wilshire, Los Angeles, California, United States|Clinical Pharmacology of Miami, LLC, Hialeah, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03406377/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03406377/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03406377
352,NCT03736785,A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY3209590|Drug: Insulin Degludec,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Research Associates, Inc., Birmingham, Alabama, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|AMCR Institute INC, Escondido, California, United States|Valley Endocrine, Fresno, Fresno, California, United States|Marin Endocrine Associates, Greenbrae, California, United States|National Research Institute, Huntington Park, California, United States|First Valley Medical Group, Lancaster, California, United States|National Research Institute, Los Angeles, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Metabolic Research Institute Inc., West Palm Beach, Florida, United States|East West Medical Institute, Honolulu, Hawaii, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Iderc, P.L.C., West Des Moines, Iowa, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Metrolina Internal Medicine, P.A., Charlotte, North Carolina, United States|Intend Research, Norman, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians - Jacob Murphy Lane, Uniontown, Pennsylvania, United States|Internal Medicine Associates of Anderson, Anderson, South Carolina, United States|The Research Center of the Upstate, Mauldin, South Carolina, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Rainier Clinical Research Center, Renton, Washington, United States|Confluence Health Clinical Research Department, Wenatchee, Washington, United States|Hospital Universitario UANL, Monterrey, Nuevo León, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, Puerto Rico|Centro de Endocrinologia del Este, Yabucoa, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03736785/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03736785/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03736785
353,NCT03952143,A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Centro Médico Viamonte, Buenos Aires, Ar-c, Argentina|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Beijing Pinggu District Hospital, Beijing, Cn-11, China|Tianjin Medical University General Hospital, Tianjin, Cn-12, China|Cangzhou People's Hospital, Cangzhou, Cn-13, China|The First Hospital of Qinhuangdao, Qinhuangdao Shi, Cn-13, China|Inner Mongolia People's Hospital, Hohhot, Cn-15, China|Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Cn-21, China|Shengjing Hospital of China Medical University, Shenyang, Cn-21, China|Shanghai Putuo District Center Hospital, Shanghai, Cn-31, China|Shanghai 6th people's hospital, Shanghai, Cn-31, China|The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Cn-32, China|Zhongda Hospital Southeast University, Nanjing, Cn-32, China|Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing, Cn-32, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Cn-32, China|The Third Hospital of Nanchang, Nanchang, Cn-36, China|The Central Hospital of Wuhan, Wuhan, Cn-42, China|The First People's Hospital of Yueyang, Yueyang, Cn-43, China|Chongqing General Hospital, Chongqing, Cn-50, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Xingtai People's Hospital, Xingtai, Hebei, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China|The First Hospital of Qiqihar, Qiqihar, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, Henan, China|Wuhan Pu'ai Hospital, Wuhan, Hubei, China|Yichang Central People's Hospital, Yichang, Hubei, China|Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|The First Hospital of Nanjing, Nanjing, Jiangsu, China|China-Japan Union Hospital, CJUH., Changchun, Jilin, China|Siping Central People's Hospital, Siping, Jilin, China|Qinghai University Affiliated Hospital, Xining, Qinghai, China|Jinan Central Hospital, Jinan, Shandong, China|The First Affiliated Hospital of Xi'an Medical University, XI 'an, Shanxi, China|Beijing Peking Union Medical College Hospital, Beijing, China|Pingxiang People's Hospital, Pingxiang, China|Unidad de patologia Clinica, Guadalajara, Jalisco, Mexico|Centro de Inv. Medica de Occidente, SC, Zapopan, Jalisco, Mexico|Unidad Médica para la Salud Integral, San Nicolás de los Garza, Mx-nle, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03952143/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03952143/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03952143
354,NCT02211261,"A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus",Completed,Has Results,Type 2 Diabetes Mellitus,Biological: PF-06293620|Biological: Placebo,Pfizer,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|Profil Institute for Clinical Research, Incorporated, Chula Vista, California, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Qps Mra, Llc, South Miami, Florida, United States|Qps-Mra Llc, South Miami, Florida, United States|High Point Clinical Trials Center, LLC, High Point, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02211261/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02211261/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02211261
355,NCT03449433,A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Aspart,Eli Lilly and Company,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03449433/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03449433/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03449433
356,NCT03407118,A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03407118/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03407118/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03407118
357,NCT03882970,A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Insulin Degludec,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arkansas Clinical Research, Little Rock, Arkansas, United States|Valley Research, Fresno, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|East Coast Clinical Research, Jacksonville, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Bayside Clinical Research, LLC, New Port Richey, Florida, United States|East Coast Institute For Research, Macon, Georgia, United States|Sky Clinical Research Network, Union City, Georgia, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Humphreys Diabetes Center, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Springfield Diabetes & Endocrine Center, Springfield, Illinois, United States|Crescent City Clinical Research, Metairie, Louisiana, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Aventiv Research, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Office of Dr. Osvaldo Brusco, Corpus Christi, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Mautalen Salud e Investigación - Servicio de Endocrinología, Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|AXISMED SRL - Bioclinica Research Network, Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|CENUDIAB, Ciudad Autonoma de Buenos Aire, Argentina|Landesklinikum Korneuburg-Stockerau, Standort Stockerau, Stockerau, Niederösterreich, Austria|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|KA Rudolfstiftung, Wien, Austria|Iatriko Palaiou Falirou, Medical Center, Palaio Faliro, Athens, Greece|Laiko General Hospital of Athens, Ampelokipoi, Attica, Greece|Gen Hospital of Athens G Gennimatas, Athens, Attiki, Greece|General Hospital of Thessaloniki Papageorgiou, N. Efkarpia, Thessaloniki, Greece|Thermi Clinic, Thermi, Thessaloniki, Greece|Athens Euroclinic, Athens, Greece|University General Hospital of Larissa, Larissa, Greece|AHEPA Hospital, Thessaloniki, Greece|Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Greece|Euromedica - General Clinic of Thessaloniki, Thessaloniki, Greece|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hajdu-Bihar, Hungary|Szent Margit Rendelointezet, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|XIII.ker Onkormanyzat Egeszsegugyi Szolgalat, Budapest, Hungary|Strazsahegy Medicina Bt., Budapest, Hungary|TRANTOR 99 Bt., Budapest, Hungary|Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Azienda ospedaliero-universitaria Mater Domini, Germaneto, Catanzaro, Italy|Policlinico Univ. Agostino Gemelli, Roma, Lazio, Italy|Centro Cardiologico Monzino, IRCCS, Milano, MI, Italy|Azienda Ospedaliera Policlinico Consorziale, Bari, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Ospedale Santa Maria Goretti, Latina, Italy|Bucheon St. Mary's Hospital, Bucheon,, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggido, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|Korea University Ansan Hospital, Ansan-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Kyunghee University Hospital at Gangdong, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ambulatorium Barbara Bazela, Elblag, Warminsko-Mazurki, Poland|NZOZ ZDROWIE Osteo-Medic, Bialystok, Poland|Poradnia Diabetologiczna SN ZOZ Lege Artis, Bialystok, Poland|NZOZ Diab-Endo-Met, Krakow, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A., Lodz, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek, Ruda Slaska, Poland|Latin Clinical Trial Center, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|San Miguel Medical, Trujillo Alto, Puerto Rico|S. C. Grandmed S.R.L., Str., Oradea, Bihor, Romania|Spitalul Judetean de Urgenta Satu Mare, Satu-Mare, Jud Satu-Mare, Romania|SC Diamed Obesity SRL, Galati, Judetul Galati, Romania|CMI DNBM Dr. Pop Lavinia, Baia Mare, Maramures, Romania|Cosamext SRL, Targu Mures, Mures, Romania|Societatea Civila Medicala ""Dr. Paveliu"", Bucuresti, Sect.5, Romania|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|Cabinetul Medical Nicodiab SRL, Bucharest, Romania|SC Nutrilife SRL, Bucuresti, Romania|Consultmed SRL, Iasi, Romania|Hospital Infanta Luisa, Sevilla, Andalucía, Spain|Hospital Universitario Marques De Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Instituto de Ciencias médicas, Alicante, Spain|Hospital Clinico Universitario San Cecilio, Granada, Spain|Clinica Juaneda, Palma de Mallorca, Spain|Clinica Nuevas Tecnologias en Diabetes y Endocrinologia, Seville, Spain|Policlinica Galileo, Teruel, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taiwan|Kuang Tien General Hospital, Taichung County, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Dnipro City Clinical Hospital #9, Dnipro, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Kyiv, Ukraine|Communal Institution ""Poltava Reg.Cl.H. n.a.M.V.Sklifosovskogo"", Poltava, Ukraine|Vinnytsia Regional Clinical Highly Specialized Endocrinology Center, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03882970/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03882970/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03882970
358,NCT03465878,A Study of LY900014 in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,"6 Years to 64 Years   (Child, Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","LMC Endocrinology Centres Ltd., Toronto, Ontario, Canada|Kinderkrankenhaus auf der Bult, Hannover, Niedersachsen, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03465878/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03465878/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03465878
359,NCT03861039,A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Oral antihyperglycemic medication (OAM),Eli Lilly and Company,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Akaicho Clinic, Chiba-shi, Chiba, Japan|Kashiwa hospital, Kashiwa, Chiba, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Manda Hospital, Sapporo, Hokkaido, Japan|Miyanomori Hospital, Sapporo, Hokkaido, Japan|Ikeda Hospital, Amagasaki, Hyogo, Japan|Nakamoto Naika Clinic, Mito, Ibaraki, Japan|Naka Memorial Clinic, Naka, Ibaraki, Japan|Ohishi Naika Clinic, Tsuchiura, Ibaraki, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Tsuruma Kaneshiro Diabetes Clinic, Yamato, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|H.E.C. Science Clinic, Yokohama, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Otsu City Hospital, Otsu, Shiga, Japan|Wakakusa Clinic, Shimotsuke, Tochigi, Japan|Seiwa Clinic, Adachi-ku, Tokyo, Japan|HDC Atlas Clinic, Chiyoda, Tokyo, Japan|Asahi Life Foundation Adult Disease Research Center, Chuo-ku, Tokyo, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo Clinical Trial Centre Fukuwa Clinic, Chuo-ku, Tokyo, Japan|Kanno Naika, Mitaka, Tokyo, Japan|Shinjuku Research Park Clinic, Shinjuku-Ku, Tokyo, Japan|Futata Tetsuhiro Clinic, Fukuoka, Japan|Morinaga Ueno Clinic, Kumamoto, Japan|Jinnouchi Hospital, Kumamoto, Japan|Abe Diabetes Clinic, Oita, Japan|Saiseikai Noe Hospital, Osaka, Japan|Kitada Clinic, Osaka, Japan|Kansai Denryoku Hospital, Osaka, Japan|Shizuoka City Shizuoka Hospital, Shizuoka, Japan|Suruga Clinic, Shizuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03861039/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03861039/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03861039
360,NCT02416193,Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D),Terminated,Has Results,Diabetes|Executive Dysfunction,Drug: Cholecalciferol,Loyola University|University of Chicago,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Loyola University Medical Center, Maywood, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02416193/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02416193/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02416193
361,NCT03985293,A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: PF-06882961,Pfizer,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Holy Trinity Medical Clinic, Harbor City, California, United States|Innovative Clinical Research, Inc., Harbor City, California, United States|Long Beach Clinical Trials Services, Inc., Long Beach, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Empire Clinical Research, Pomona, California, United States|Rancho Cucamonga Clinical Research, Rancho Cucamonga, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Incorporated, Tustin, California, United States|San Fernando Valley Health Institute, LLC, Van Nuys, California, United States|Diablo Clinical Research Incorporated, Walnut Creek, California, United States|Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|NewPhase Clinical Trials, Corp., Miami Beach, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Sunshine Research Center, Inc, Opa-locka, Florida, United States|Andres Patron D.O. P.A., Pembroke Pines, Florida, United States|Ellipsis Group, Alpharetta, Georgia, United States|East Coast Institute for Research, LLC, Macon, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Viable Research Management LLC, Henderson, Nevada, United States|Premier Research, Trenton, New Jersey, United States|PharmQuest, Greensboro, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Velocity Clinical Research, Cincinnati, Ohio, United States|Conrad Clinical Research, Edmond, Oklahoma, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Palmetto Primary Care Physicians (physicals only), Summerville, South Carolina, United States|Dallas Diabetes Research Center, Dallas, Texas, United States|Endocrine Associates, Houston, Texas, United States|PrimeCare Medical Group, Houston, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Northeast Clinical Research of San Antonio, Live Oak, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|MHAT Dobrich AD, Dobrich, Bulgaria|Medical Center ASKLEPII OOD, Dupnitsa, Bulgaria|UMHAT Pulmed, Plovdiv, Bulgaria|Fourth MHAT - Sofia EAD, Sofia, Bulgaria|MHAT ""Doverie"" AD, Sofia, Bulgaria|MC ""New rehabilitation center"" EOOD, Stara Zagora, Bulgaria|GA Research Associates Ltd., Moncton, New Brunswick, Canada|Aggarwal and Associates Limited, Brampton, Ontario, Canada|Manna Research (Toronto), Toronto, Ontario, Canada|Manna Research (Quebec), Levis, Quebec, Canada|Manna Research (Mirabel), Mirabel, Quebec, Canada|Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada|Diex Recherche Victoriaville Inc., Victoriaville, Quebec, Canada|Diex Recherche Quebec Inc., Quebec, Canada|Centre de Recherche Saint-Louis, Quebec, Canada|Alpha Recherche Clinique, Quebec, Canada|Belinus Orvosi es Szamitastechnikai Bt, Debrecen, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|CRU Hungary Kft., Miskolc, Hungary|Borbanya Praxis Egeszsegugyi KFT, Nyiregyhaza, Hungary|Clinfan Kft., Szekszard, Hungary|Yonsei University-Wonju Severance Christian Hospital, Wonju-si, Gangwon-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of|Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik, Bialystok, Poland|Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne DIAB-ENDO-MET Sp. z o. o., Krakow, Poland|Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer, Lodz, Poland|MEDICOME Sp. z o.o., Oswiecim, Poland|KO-MED CENTRA KLINICZNE Sp. z o.o. Ośrodek Badań Klinicznych w Puławach, Puławy, Poland|Centralny Szpital Kliniczny MSWiA, Warszawa, Poland|Metabol KLINIK s.r.o., Bratislava, Slovakia|Medispektrum, s.r.o, Bratislava, Slovakia|HUMAN-CARE, s.r.o., Kosice, Slovakia|SchronerMED s.r.o., Moldava nad Bodvou, Slovakia|Funkystuff, s.r.o., Nove Zamky, Slovakia|DIAB s.r.o., Roznava, Slovakia|MUDr. Jana Rociakova, s.r.o., Zilina, Slovakia|Far Eastern Memorial Hospital, New Taipei City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03985293/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03985293/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03985293
362,NCT03830281,A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Ultra-Rapid Lispro|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Research, Fresno, California, United States|Marin Endocrine Associates, Greenbrae, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|First Valley Medical Group, Lancaster, California, United States|Center of Excellence in Diabetes & Endocrinology, Sacramento, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States|Metabolic Research Institute Inc., West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Northwestern Feinberg School of Medicine, Chicago, Illinois, United States|Prairie Education and Research Cooperative, Springfield, Illinois, United States|Iderc, P.L.C., West Des Moines, Iowa, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Physicians East, Greenville, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Texas Diabetes and Endocrinology-Austin South, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Texas Diabetes and Endocrinology, P.A., Round Rock, Texas, United States|Private: Dr. Larry Stonesifer, Federal Way, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Tacoma Center for Arthritis Research, PS, Tacoma, Washington, United States|The AIM Centre, Merewether, New South Wales, Australia|GP Plus Marion, Oaklands Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Universitätsklinikum Graz, Graz, Steiermark, Austria|VIVIT Institut am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|KA Rudolfstiftung, Vienna, Austria|LMC Endocrinology Centres Ltd., Barrie, Ontario, Canada|LMC Endocrinology Centres Ltd., Concord, Ontario, Canada|LMC Endocrinology Centres, Oakville, Ontario, Canada|LMC Endocrinology Centres Ltd., Toronto, Ontario, Canada|IRCM, Montreal, Quebec, Canada|LMC Endocrinology Centres Ltd., Ville St-Laurent, Quebec, Canada|CHU Toulouse Hopital de Rangueil, Toulouse, Cedex 9, France|Clinique Hotel Dieu, Le Creusot, France|Centre hospitalier universitaire Lapeyronie, Montpellier Cedex 5, France|Hopital Cochin, Paris CEDEX 14, France|Hôpital de HautePierre, Strasbourg, France|Groupe hospitalier mutualiste Les Portes du sud, Venissieux, France|Arztpraxis Dr. Cornelia Marck, Pohlheim, Hessen, Germany|Institut für Diabetesforschung Münster GmbH, Münster, Nordrhein-Westfalen, Germany|Praxis Dr. Kempe - Dr. Stemler, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany|Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach, Saarland, Germany|RED-Institut GmbH, Oldenburg, Schleswig-Holstein, Germany|Diabetespraxis Prenzlauer Allee, Berlin, Germany|Diabetologische Schwerpunktpraxis B. Scholz/Dr. B. Paschen, Hamburg, Germany|Gemeinschaftspraxis für innere Medizin und Diabetologie, Hamburg, Germany|Budai Irgalmasrendi Korhaz, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|UNO Medical Trials Kft., Budapest, Hungary|TRANTOR 99 Bt., Budapest, Hungary|Soroka Medical Center - Pediatric Outpatient Clinic, Beer-Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Schneider Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Ramat Gan, Israel|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Ospedale San Giovanni di Dio, Olbia, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Dip.to Med. Sperimentale -Polic.Umberto I -Univ. La Sapienza, Roma, Italy|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Centro de Endocrinologia Alcantara Gonzalez, Lomas Verdes, Puerto Rico|Corporació Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Cataluña, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03830281/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03830281/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03830281
363,NCT00135226,ASCEND: A Study of Cardiovascular Events iN Diabetes,"Active, not recruiting",Has Results,Diabetes Mellitus,Drug: Aspirin|Drug: Omega-3 Ethyl Esters|Drug: Placebo Aspirin|Drug: Placebo Omega-3 Ethyl Esters,University of Oxford|British Heart Foundation|Bayer|Medical Research Council|Solvay Pharmaceuticals|Abbott|Mylan,"40 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Clinical Trial Service Unit, NDPH, University of Oxford, Oxford, United Kingdom","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/Prot_ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT00135226/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00135226
364,NCT03495102,A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dulaglutide,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Synexus- Chandler, Chandler, Arizona, United States|Synexus/Central Arizona Medical Associates, PC, Mesa, Arizona, United States|Central Phoenix Med Clinic LLC, Phoenix, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Valley Research, Fresno, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|National Research Institute, Panorama City, California, United States|Sierra Clinical Research, Roseville, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Care Access Research, Santa Clarita, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Urban Family Practice Associates, PC, Marietta, Georgia, United States|In-Quest Medical Research, LLC- Peachtree Corners, Peachtree Corners, Georgia, United States|Pacific Diabetes & Endocrine Center, Honolulu, Hawaii, United States|East West Medical Institute, Honolulu, Hawaii, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Saltzer Medical Group. P.A., Nampa, Idaho, United States|Prairie Education and Research Cooperative, Springfield, Illinois, United States|Synexus/Clinical Research Advantage, Evansville, Indiana, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Iderc, P.L.C., West Des Moines, Iowa, United States|InterMed, PA, Portland, Maine, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|Aa Mrc Llc, Flint, Michigan, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Montana Health Research, Billings, Montana, United States|Glacier View Research Institute, Kalispell, Montana, United States|Premier Research, Trenton, New Jersey, United States|Manhattan Medical Research, New York, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Metrolina Internal Medicine, P.A., Charlotte, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|IPS Research Company, Oklahoma City, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Summit Research Network Inc, Portland, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Sudir Bansal M.D. Inc., Warwick, Rhode Island, United States|PMG Research of Charleston, LLC, Moncks Corner, South Carolina, United States|Chattanooga Research and Medicine (CHARM), Chattanooga, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Southern Endocrinology and Associates PA, Mesquite, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|ClinPoint Trials, LLC, Waxahachie, Texas, United States|Progressive Clinical Research, Bountiful, Utah, United States|Advanced Research Institute, Ogden, Utah, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|Capital Clincial Research Center, Olympia, Washington, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Prevea Clinic, Inc, Green Bay, Wisconsin, United States|Centro Medico CICEMO, Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|Centro de Investigaciones Metabólicas (CINME), Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|AXISMED SRL - Bioclinica Research Network, Buenos Aires, Argentina|CENUDIAB, Ciudad Autonoma de Buenos Aire, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|Cemediab - Centro Médico Diabetológico Dr. Alejandro Chertkoff, Ciudad Autonoma de Buenos Aire, Argentina|Mautalen Salud e Investigación - Servicio de Endocrinología, Ciudad Autonoma De Buenos Air, Argentina|Instituto Medico Strusberg, Cordoba, Argentina|Centro Medico Privado San Vicente Diabetes, Cordoba, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Landesklinikum Korneuburg-Stockerau, Standort Stockerau, Stockerau, Niederösterreich, Austria|Universitätsklinikum Graz, Graz, Steiermark, Austria|Ordination Dr. Evelyn Fließer-Görzer, Saint Stefan Ob Stainz, Steiermark, Austria|VIVIT Institut am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|KA Rudolfstiftung, Wien, Austria|Zentrum für klinische Studien Dr. Ursula Hanusch GmbH, Wien, Austria|Bailey Clinic, Red Deer, Alberta, Canada|Aggarwal and Associates Ltd, Brampton, Ontario, Canada|T. Nemtean Medicine Professional Corporation, Mississauga, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Stayner Medical Clinic, Stayner, Ontario, Canada|Dr. Anil K. Gupta Medicine Professional Corporation, Toronto, Ontario, Canada|Iatriko Palaiou Falirou, Medical Center, Palaio Faliro, Athens, Greece|Laiko General Hospital of Athens, Ampelokipoi, Attica, Greece|Gen Hospital of Athens G Gennimatas, Athens, Attiki, Greece|G.Papanikolaou General Hospital, Exohi, Thessaloniki, Greece|Thermi Clinic, Thermi, Thessaloniki, Greece|Athens Euroclinic, Athens, Greece|University General Hospital of Larissa, Larissa, Greece|AHEPA Hospital, Thessaloniki, Greece|Ippokrateio General Hospital of Thessaloniki, Thessaloniki, Greece|Euromedica - General Clinic of Thessaloniki, Thessaloniki, Greece|Studium Egeszseghaz Kft., Kalocsa, Bacs-Kiskun, Hungary|Kenezy Gyula Korhaz es Rendelointezet, Debrecen, Hajdu-Bihar, Hungary|Grof Esterhazy Korhaz es Rendelointezeti Szakrendelo, Papa, Veszprem, Hungary|Szent Margit Rendelointezet, Budapest, Hungary|ClinDiab Kft., Budapest, Hungary|Strazsahegy Medicina Bt., Budapest, Hungary|TRANTOR 99 Bt., Budapest, Hungary|Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Maccabi Diabetes Clinic, Grand Canyon, North District, Haifa, Haifa, Israel|Linn Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Clalit Health Services - Shuali Clinic, Raanana, Israel|ZIV Medical Center, Safed, Israel|Sakhnin Community Clinic, Clalit Health Services, Sakhnin, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv Jaffa, Israel|Diabetes Medical Center (DMC), Tel Aviv, Israel|Azienda Ospedaliera Universitaria Careggi, Firenze, Florence, Italy|Istituto Clinico Humanitas, Rozzano, Milano, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, SI, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Policlinico Mater Domini, Catanzaro, Italy|Fondazione Universitaria degli Studi G D'Annunzio, Chieti, Italy|Ospedale Santa Maria Goretti, Latina, Italy|Policlinico Giaccone, Palermo, Italy|Ospedale Civile Maggiore Borgo Trento, Verona, Italy|Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|NZOZ ZDROWIE Osteo-Medic, Bialystok, Poland|Poradnia Diabetologiczna SN ZOZ Lege Artis, Bialystok, Poland|NS ZOZ Osrodek Diabetologiczny "" Popula"", Bialystok, Poland|Centrum Badan Klinicznych, PI House, Gdansk, Poland|NZOZ Salvia s.c., Katowice, Poland|NZOZ Diab-Endo-Met, Krakow, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A., Lodz, Poland|Gabinety Terpa, Lublin, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|Centrum Medyczne OMEDICA, Poznan, Poland|Praktyka Lekarska, Poznan, Poland|Nzoz Neuro - Kard, Poznan, Poland|NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek, Ruda Slaska, Poland|Centralny Szpital Kliniczny MSW, Warszawa, Poland|Regionalna Poradnia Diabetologiczna, Wroclaw, Poland|Research and Cardiovascular Corp., Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Office: Dr. Luis Rivera Colon, San Juan, Puerto Rico|S. C. Grandmed S.R.L., Str., Oradea, Bihor, Romania|SC Gama Diamed SRL, Mangalia, Constanta, Romania|Spitalul Judetean de Urgenta Satu Mare, Satu-Mare, Jud Satu-Mare, Romania|CMI DNBM Dr. Pop Lavinia, Baia Mare, Maramures, Romania|Cosamext SRL, Targu Mures, Mures, Romania|SC Diabmed Dr Popescu Alexandrina SRL, Ploiesti, Prahova, Romania|SC Dianutrilife Medica SRL, Ploiesti, Prahova, Romania|Centrul Medical Dr. Negrisanu, Timisoara, Timis, Romania|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|Cabinetul Medical Nicodiab SRL, Bucharest, Romania|Easydiet SRL, Bucuresti, Romania|SC Nutrilife SRL, Bucuresti, Romania|SC Medcon SRL, Buzau, Romania|Centrul Medical Unirea SRL, Cluj Napoca, Romania|Cabinet Medical Urodiamed S.R.L., Craiova, Romania|Milena Sante SRL, Galati, Romania|SC Olimpia Med SRL, Iasi, Romania|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|Arkhangelsk the first city clinical hospital, Arkhangelsk, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|City Hospital of Saint Martyr Elizabeth, Saint Petersburg, Russian Federation|SPb GUZ ""Diagnostic Center #85"", Saint Petersburg, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Human care s.r.o., Kosice, Slovak Republic, Slovakia|MediVet s.r.o., Malacky, Slovak Republic, Slovakia|Areteus s.r.o., Trebisov, Slovak Republic, Slovakia|Diacrin s.r.o., Bratislava, Slovakia|Noemis, s.r.o., Nove Mesto nad Vahom, Slovakia|FUNKYSTUFF s.r.o., Nove Zamky, Slovakia|MUDr. Jan Culak, s.r.o., Prievidza, Slovakia|DIA-MED CENTRUM s.r.o., Puchov, Slovakia|Tatratrial s.r.o., Roznava, Slovakia|Hospital Infanta Luisa, Sevilla, Andalucía, Spain|Corporació Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital Universitario Marques De Valdecilla, Santander, Cantabria, Spain|Clinica Juaneda, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Instituto de Ciencias medicas, Alicante, Spain|Clinica San Pedro, Almeria, Spain|Centre Medico Teknon, Barcelona, Spain|Hospital Clinico Universitario San Cecilio, Granada, Spain|Virgen de Las Nieves, Granada, Spain|Centro Especialidades San Jose Obrero (Barbarela), Malaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Clinica Nuevas Tecnologias en Diabetes y Endocrinologia, Seville, Spain|Policlinica Galileo, Teruel, Spain|Chung Shan Medical University Hospital, Taichung City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03495102/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03495102/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03495102
365,NCT03922750,A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin icodec|Drug: Insulin glargine U100,Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Broumov, Czechia|Novo Nordisk Investigational Site, Holešov, Czechia|Novo Nordisk Investigational Site, Hranice, Czechia|Novo Nordisk Investigational Site, Trutnov, Czechia|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Roma, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03922750/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03922750/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03922750
366,NCT04552470,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Placebo|Drug: PF-06882961,Pfizer,"20 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04552470/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04552470/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04552470
367,NCT03740919,A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec,Eli Lilly and Company,1 Year to 17 Years   (Child),Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Children's Hospital Los Angeles - Dept of Endocrinology, Los Angeles, California, United States|Stanford University School of Medicine - Division of Pediatric Endocrinology & Diabetes, Palo Alto, California, United States|Center of Excellence in Diabetes & Endocrinology, Sacramento, California, United States|Rady Childrens Hospital - San Diego, San Diego, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Florida Hospital, Orlando, Florida, United States|Tallahassee Memorial HealthCare, Tallahassee, Florida, United States|University of South Florida Diabetes & Endocrinology Center, Tampa, Florida, United States|VanMeter Pediatric Endocrinology, P.C., Atlanta, Georgia, United States|St. Luke's Children's Endocrinology, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Indiana University- Riley Children's Hospital, Indianapolis, Indiana, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Barry Reiner Clinic, Baltimore, Maryland, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|UBMD Pediatrics, Buffalo, New York, United States|Suny Health Science Center at Syracuse, Syracuse, New York, United States|Endocrinology Services NorthWest, Bend, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States|Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, United States|Diabetes and Glandular Disease Research Associates PA, San Antonio, Texas, United States|MultiCare Institute for Research & Innovation, Tacoma, Washington, United States|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinik Innsbruck, Innsbruck, Tyrol, Austria|Hospital das Clinicas da FMRP, Ribeirao Preto, SP, Brazil|CPCLIN, São Paulo, SP, Brazil|CPQuali Pesquisa Clínica, São Paulo, Brazil|Children's hospital of Nanjing, Nanjing, Jiangsu, China|Wuxi Children's Hospital, Wuxi, Jiangsu, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Nangang District, China|Children's Hospital Capital Institute of Pediatrics, Beijing, China|Children's hospital of Fudan University, Shanghai, China|Zhengzhou Children's Hospital, Zhengzhou, China|Fakultni Nemocnice v Motole, Praha 5, Motole, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Pediatricke odd. Nemocnice Jihlava, Jihlava, Czechia|Medica Iberia, Opava, Czechia|FN Ostrava, Ostrava-Poruba, Czechia|Pardubicka krajska nemocnice, Pardubice, Czechia|Herlev and Gentofte Hospital, Herlev, Denmark|CHRU Lille - Hôpital Jeanne de Flandre, Lille, France|CHU Hopital d'enfants de la Timone, Marseille CEDEX 05, France|Hopital Robert Debre, Paris, France|Hôpital Universitaire Necker enfants malades, Paris, France|InnoDiab Forschung Gmbh, Essen, Nordrhein-Westfalen, Germany|Diabetologische Schwerpunktpraxis Dr. Ziegler, Münster, North Rhine-Westphalia, Germany|Medizinisches Versorgungszentrum am Universitätsklinikum Leipzig GmbH, Leipzig, Sachsen, Germany|RED-Institut GmbH, Oldenburg in Holstein, Schleswig Holstein, Germany|Shamir Medical Center (Asaf Harofe)-Pediatric Endocrinology Unit, Beer Yaakov, Israel|Soroka Medical Center - Pediatric Outpatient Clinic, Beer-Sheva, Israel|Rambam Medical Center - Department of Pediatrics A, Ruth Rappaport Children's Hospital, Haifa, Israel|Schneider Children's Medical Center, Petah Tikva, Israel|Shiba Medical Center, Ramat-gan, Israel|Azienda Ospedaliera Umberto I, Ancona, Italy|Azienda Ospedaliero Universitaria Meyer, Firenze, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Ospedale Bambino Gesu, Roma, Italy|Ospedale Civile Maggiore Borgo Trento, Verona, Italy|Saitama Children's Medical Center, Saitama-shi, Saitama, Japan|Nihon University Hospital, Chiyoda-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Hiroshima Prefectural Hospital, Hiroshima, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Osaka City University Hospital, Osaka, Japan|Unidad de Investigacion Clinica Cardiometabolica de Occidente, Guadalajara, Jalisco, Mexico|Centro de Inv. Medica de Occidente, SC, Zapopan, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, N.l., Mexico|Cli-nica Hospital Cemain, Tampico, Tamaulipas, Mexico|Hospital Angeles Puebla, Puebla, Mexico|Gdanski Uniwersytet Medyczny, Gdansk, Poland|Uniwersytecki Szpital Kliniczny, Lodz, Poland|Instytut Diabetologii Sp. z o.o, Warsaw, Poland|Pediatric Endocrine Research Associates, Rio Piedras, Puerto Rico|San Jorge Children and Women's Hospital- Shipping Location, San Juan, Puerto Rico|Research Institute for Pediatric Endocrinology, Moscow, Russian Federation|Morozovsky Children's City Clinical Hospital, Moscow, Russian Federation|Samarskiy Regional Children's Clinical Hospital, Samara, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|Smolensk Regional Children's Clinical Hospital, Smolensk, Russian Federation|St.Petersburg Children's City Polyclinic #44, St.Petersburg, Russian Federation|Siberian State Medical University of Roszdrav, Tomsk, Russian Federation|Tver Children's Clinical Hospital, Tver, Russian Federation|Voronezh State Medical University, Voronezh, Russian Federation|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Virgen del Camino, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario HM Monteprincipe, Boadilla del Monte, Spain|Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain|CHUS - Hospital Clinico Universitario, La Coruña, Spain|Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE), Sevilla, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Ivano-Frankivsk regional clinical children hospital, Ivano-Frankivsk, Ukraine|Institute of the Health Care of Children & Adolescents, Kharkiv, Ukraine|V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine, Kyiv, Ukraine|Odesa regional children's clinical hospital, Odesa, Ukraine|Vinnytsia Regional Clinical Highly Specialized Endocrinology Center, Vinnytsia, Ukraine|Zaporizhzhia regional clinical children hospital, Zaporizhzhia, Ukraine|Stepping Hill Hospital, Stockport, Cheshire, United Kingdom|Norfolk and Norwich Hospital, Norwich, Norfolk, United Kingdom|King's Mill Hospital, Sutton In Ashfield, Nottinghamshire, United Kingdom|Worthing Hospital, Worthing, West Sessex, United Kingdom|St Richards Hospital, Chichester, West Sussex, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom|St. George's University Hospitals NHS Foundation Trust, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03740919/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03740919/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03740919
368,NCT02734667,Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Device: CGM at diagnosis of T1D,"Korey Hood|University of Colorado, Denver|Stanford University",2 Years to 17 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02734667/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02734667/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02734667
369,NCT03005288,"Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: BYM338 10 mg/kg|Other: Placebo,Novartis Pharmaceuticals|Novartis,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Miami Lakes, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Berlin, New Jersey, United States|Novartis Investigative Site, Eatontown, New Jersey, United States|Novartis Investigative Site, Merthyr Tydfil, Mid Glamorgan, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT03005288/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT03005288/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03005288
370,NCT03131687,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: tirzepatide|Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Internal Medicine Center LLC, Mobile, Alabama, United States|Anaheim Clinical Trails, Anaheim, California, United States|Valley Research, Fresno, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|Valley Clinical Trails, Inc, Northridge, California, United States|Artemis Institute For Clinical Research, San Diego, California, United States|Artemis Institute For Clinical Research, San Marcos, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators INC, Tustin, California, United States|Chase Medical Research, Waterbury, Connecticut, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Suncoast Research Group, LCC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Palm Harbor Medical Associate, Palm Harbor, Florida, United States|Solaris Clinical Research, Meridian, Idaho, United States|Iderc P.L.C., West Des Moines, Iowa, United States|Cotton O'Neil Diabetes and Endocrine, Topeka, Kansas, United States|ActivMed Practices & Research, Methuen, Massachusetts, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Premier Research, Trenton, New Jersey, United States|Manhattan Medical Research, New York, New York, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aventiv Research, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|PMG Research Of Charleston LLC, Moncks Corner, South Carolina, United States|New Phase Research & Development, Knoxville, Tennessee, United States|PMG Research Of Knoxville, Knoxville, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Chrysalis Clinical Research, Saint George, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Gdańsk, Poland|""For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician."", Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Katowice, Poland|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Szczecin, Poland|Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária LTDA, Łódź, Poland|Manati Center for Clinical Research, Manati, Puerto Rico|Clinical Research Puerto Rico. Inc, San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Košice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malacky, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Púchov, Slovakia|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Trenčín, Slovakia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Trenčín, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03131687/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03131687/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03131687
371,NCT03954834,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Placebo,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|National Research Institute, Panorama City, California, United States|Southern California Dermatology, Santa Ana, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Encore Medical Research, LLC, Hollywood, Florida, United States|Axcess Medical Research, Loxahatchee Groves, Florida, United States|South Florida Wellness & Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Sky Clinical Research Network, Atlanta, Georgia, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Capital Clinical Research Center, Olympia, Washington, United States|Rockwood Clinic Research Center, Spokane, Washington, United States|Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad, Gujarat, India|Bangalore Medical College and Research Institute, Bangalore, Karnataka, India|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|BSES Municipal General Hsptl, Mumbai, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Vijay Vallabh Hospital, Virar, Maharashtra, India|Lifepoint Multispecialty Hsptl, Wakad, Pune, India|Ramdevrao Hospital, Hyderabad, Telangana, India|Gandhi Hospital, Telangana, India|Minamiakatsuka Clinic, Mito, Ibaraki, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Tsuruma Kaneshiro Diabetes Clinic, Yamato, Kanagawa, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Meiwa Hospital, Chiyodaku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Sato Naika Clinic, Ota-ku, Tokyo, Japan|Hospital Universitario UANL, Monterrey, Nuevo León, Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Madero, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03954834/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03954834/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03954834
372,NCT03951805,A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin icodec|Drug: Insulin Glargine,Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Pohlheim, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Radom, Poland|Novo Nordisk Investigational Site, Tomaszow Mazowiecki, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Banska Bystrica, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Rimavska Sobota, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Velky Meder, Slovakia|Novo Nordisk Investigational Site, Baracaldo, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, La Roca del Vallés, Spain|Novo Nordisk Investigational Site, Vic (Barcelona), Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03951805/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03951805/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03951805
373,NCT03166124,A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03166124/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03166124/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03166124
374,NCT03214367,A Study of LY900014 in Participants With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Internal Medicine Center LLC, Mobile, Alabama, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|AMCR Institute INC, Escondido, California, United States|Valley Endocrine, Fresno, Fresno, California, United States|Marin Endocrine Associates, Greenbrae, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|The Center For Diabetes & Endocrine Care, Fort Lauderdale, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States|Metabolic Research Institute Inc., West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|East Coast Institute For Research, Macon, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Northwest Clinical Trials, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Prairie Education and Research Cooperative, Springfield, Illinois, United States|Iderc, P.L.C., West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|MassResearch, Waltham, Massachusetts, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Manhattan Medical Research, New York, New York, United States|Physicians East, Greenville, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Your Diabetes Endocrine Nutrition Group PC, Mentor, Ohio, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Partners in Nephrology & Endocrinology, Pittsburgh, Pennsylvania, United States|Sudir Bansal M.D. Inc., Warwick, Rhode Island, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Texas Diabetes and Endocrinology, P.A., Round Rock, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Progressive Clinical Research, Bountiful, Utah, United States|Private: Dr. Larry Stonesifer, Federal Way, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mar del Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Box Hill, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Geelong, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Merewether, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Oaklands Park, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bad Mergentheim, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Falkensee, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hessen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mayen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Saterland, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ampelókipoi, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Lárisa, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Thessaloníki, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Thessaloníki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloníki, Greece|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Thérmi, Greece|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indore, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Secunderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Visakhapatnam, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ravenna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kamakura, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Miyazaki, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Naka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sasebo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Shinjuku, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ōita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ōsaka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ōsaka, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zapopan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Takapuna, Auckland, New Zealand|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Auckland, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christchurch, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdańsk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kraków, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ruda Śląska, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warszawa, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wrocław, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Łódź, Poland|Dr Altagracia Aurora Alcantara Gonzalez, Bayamon, Puerto Rico|Advanced Clinical Research, LLC, Bayamon, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, Puerto Rico|Centro de Endocrinologia del Este, Yabucoa, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bacău, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Braşov, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucuresti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ploieşti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ploieşti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Satu Mare, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Timişoara, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Târgu-Mureş, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangel'sk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kursk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Košice, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malacky, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nové Mesto nad Váhom, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rožňava, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcira, Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Málaga, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teruel, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Göteborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linköping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chang-hua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yongkang, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03214367/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03214367/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03214367
375,NCT03730662,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Tirzepatide|Drug: Insulin Glargine,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Advanced Research Center, Anaheim, California, United States|Valley Clinical Trials, Inc., Covina, California, United States|Marin Endocrine Associates, Greenbrae, California, United States|National Research Institute, Huntington Park, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|First Valley Medical Group, Lancaster, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Monterey Endocrine & Diabetes Institute, Inc., Monterey, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Desert Medical Group Inc, Palm Springs, California, United States|Havana Research Institute, Pasadena, California, United States|Western University of Health Sciences, Pomona, California, United States|LCGK Research, San Carlos, California, United States|Olive View Medical Center, Sylmar, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Touro University, Vallejo, California, United States|Coastal Metabolic Research Centre, Ventura, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|Advanced Pharma Research, Cutler Bay, Florida, United States|South Florida Wellness & Clinical Research Institute, Margate, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Clinical Neuroscience Solutions Inc, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Primary Care Specialists, LLC, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Solaris Clinical Research, Meridian, Idaho, United States|Saltzer Medical Group. P.A., Nampa, Idaho, United States|Northwestern Feinberg School of Medicine, Chicago, Illinois, United States|NorthShore University HealthSystem, Skokie, Illinois, United States|University of Iowa Hospital & Clinic, Iowa City, Iowa, United States|Iowa Diabetes Research, West Des Moines, Iowa, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|Robley Rex VAMC, Louisville, Kentucky, United States|NECCR PrimaCare Research, LLC, Fall River, Massachusetts, United States|AA Medical Research Center, Flint, Michigan, United States|Troy Internal Medicine, PC, Troy, Michigan, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Montana Medical Research, Inc, Missoula, Montana, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|PharmQuest, Greensboro, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Rapid Medical Research Inc, Cleveland, Ohio, United States|Ohio State Univ College Of Medicine, Columbus, Ohio, United States|Aventiv Research, Columbus, Ohio, United States|Intend Research, Norman, Oklahoma, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Capital Area Research, Camp Hill, Pennsylvania, United States|Detweiler Family Medicine, Lansdale, Pennsylvania, United States|Capital Area Research, Newport, Pennsylvania, United States|Parkside Family Medical, Philadelphia, Pennsylvania, United States|Preferred Primary Care Physicians- Bower Hill, Pittsburgh, Pennsylvania, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|The Research Center of the Upstate, Mauldin, South Carolina, United States|Holston Medical Group Clinical Research, Kingsport, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|PCP for Life, Houston, Texas, United States|BFHC Research, San Antonio, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Alpine Research Organization, Farmington, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Private: Dr. Larry Stonesifer, Federal Way, Washington, United States|Capital Clinical Research Center, Olympia, Washington, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Centro de Investigaciones Metabólicas (CINME), Caba, Buenos Aires, Argentina|Mautalen Salud e Investigación - Servicio de Endocrinología, Caba, Buenos Aires, Argentina|Investigaciones Medicas IMOBA S.R.L., Caba, Buenos Aires, Argentina|CEDIC-Centro de Investigaciones Clinicas, Caba, Buenos Aires, Argentina|CEMEDIC, Caba, Buenos Aires, Argentina|Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Ciudad Autonoma de, Buenos Aires, Argentina|CIPADI, Godoy Cruz, Mendoza, Argentina|AXISMED SRL - Bioclinica Research Network, Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Buenos Aire, Argentina|Instituto Centenario, Ciudad Autonoma de Buenos Aire, Argentina|Cemediab - Centro Médico Diabetológico Dr. Alejandro Chertkoff, Ciudad Autonoma de Buenos Aire, Argentina|Centro Diabetologico Dr Waitman, Cordoba, Argentina|Centro Medico Privado San Vicente Diabetes, Cordoba, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Paratus Clinical Blacktown Clinic, Blacktown, New South Wales, Australia|Campbelltown Medical & Dental Centre, Campbelltown, New South Wales, Australia|Paratus Clinical Kanwal Clinic, Kanwal, New South Wales, Australia|The AIM Centre, Merewether, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|CORE Research Group Pty Ltd, Brisbane, Queensland, Australia|Morayfield Medical and Dental Centre, Morayfield, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Victoria Point Medical and Dental Centre, Victoria Point, Queensland, Australia|GP Plus Marion, Oaklands Park, South Australia, Australia|Eastern Clinical Research Unit, Box Hill, Victoria, Australia|Forest Hill Medical and Dental Centre, Forest Hill, Victoria, Australia|Barwon Health - The Geelong Hospital, Geelong, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Instituto de Ensino e Pesquisa Clinica do Ceara, Fortaleza, Ceara, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|Cedoes Centro Diagnostico Pequisa Osteoporose E Santo Ltd, Vitoria, ES, Brazil|Centro de Diabetes Curitiba, Curitiba, Parana, Brazil|CCBR Brasil Centro de Analises e Pesquisas Clínicas LTDA, Rio de Janeiro, RJ, Brazil|CPQuali Pesquisa Clínica Ltda., São Paulo, SP, Brazil|Cpclin Centro de Pesquisas Clinicas, São Paulo, SP, Brazil|Centro de Pesq. em Diabetes e Doencas Endocrino Metabol., Fortaleza, Brazil|Dr. Consulta Clínica Médica LTDA, São Paulo, Brazil|LMC Manna Research, Calgary, Alberta, Canada|C-Health Diabetes and Endocrinology Clinic Calgary, Calgary, Alberta, Canada|Synergy Medical Research, Sherwood Park, Alberta, Canada|LMC Endocrinology Centres Ltd., Barrie, Ontario, Canada|LMC Endocrinology Centers Brampton, Brampton, Ontario, Canada|Aggarwal and Associates Ltd, Brampton, Ontario, Canada|LMC Endocrinology Centres Ltd., Concord, Ontario, Canada|Milestone Research Inc., London, Ontario, Canada|LMC Endocrinology Centres Ltd., Nepean, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Canadian Centre for Research on Diabetes, Smiths Falls, Ontario, Canada|Manna Research, Inc., Stoney Creek, Ontario, Canada|Medicor Research Inc, Sudbury, Ontario, Canada|LMC Endocrinology Centres Ltd., Toronto, Ontario, Canada|Sameh Fikry Medicine Professional Corporation, Waterloo, Ontario, Canada|Q & T Research Outaouais, Gatineau, Quebec, Canada|Centre De Recherche Clinique De Laval, Laval, Quebec, Canada|Manna Research (Quebec), Levis, Quebec, Canada|LMC Endocrinology Centres Ltd., Ville St-Laurent, Quebec, Canada|Iatriko Palaiou Falirou, Medical Center, Palaio Faliro, Athens, Greece|Thermi Clinic, Thermi, Thessaloniki, Greece|University General Hospital of Larissa, Larissa, Greece|AHEPA Hospital, Thessaloniki, Greece|Euromedica - General Clinic of Thessaloniki, Thessaloniki, Greece|Ha'Emek Medical Center, Afula, Israel|Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Sakhnin Community Clinic, Clalit Health Services, Sakhnin, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv Jaffa, Israel|Instituto Jalisciense de Investigacion en Diabetes y Obesida, Guadalajara, Jalisco, Mexico|Diseno y Planeacion en Investigacion Medica S.C., Guadalajara, Jalisco, Mexico|St. Lucas Clinical Research Center, Merida, Mexico State, Mexico|Unidad Medica para la Salud Integral (UMSI), Monterrey, Nuevo León, Mexico|Centro de Estudios de Investigacion Metabolicos y Cardiovasc, Tampico, Tamaulipas, Mexico|Investigacion en Salud y Metabolismo S.C, Chihuahua, Mexico|Centralny Szpital Kliniczny MSWiA Klinika Dermatologiczna, Warszawa, Mazowieckie, Poland|Poradnia Diabetologiczna SN ZOZ Lege Artis, Bialystok, Poland|NZOZ Diab-Endo-Met, Krakow, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A., Lodz, Poland|NZOZ CenterMed Lublin, Lublin, Poland|Gabinety Terpa, Lublin, Poland|NZOZ Przychodnia Specjalistyczna MEDICA, Lublin, Poland|Praktyka Lekarska, Poznan, Poland|Nzoz Neuro - Kard, Poznan, Poland|NZOZ Przychodnia Specjalistyczna Henryk RudzkiAndrzej Wittek, Ruda Slaska, Poland|Woj. Zesp. Spec. Opieki Zdrowotnej, Wroclaw, Poland|Emanuelli Research & Development Center, LLC, Arecibo, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico|Research and Cardiovascular Corp., Ponce, Puerto Rico|University Of Puerto Rico, Rio Pedras, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|Consultorio Medico, San Juan, Puerto Rico|SC Gama Diamed SRL, Mangalia, Constanta, Romania|Spitalul Judetean de Urgenta Satu Mare, Satu-Mare, Jud Satu-Mare, Romania|CMI DNBM Dr. Pop Lavinia, Baia Mare, Maramures, Romania|Cosamext SRL, Targu Mures, Mures, Romania|Centrul Medical Dr. Negrisanu, Timisoara, Timis, Romania|Centrul Medical de Diagnostic si Tratament Ambulatoriu Neomed SRL, Brasov, Romania|Cabinetul Medical Nicodiab SRL, Bucharest, Romania|SC Nutrilife SRL, Bucuresti, Romania|Milena Sante SRL, Galati, Romania|Arkhangelsk the first city clinical hospital, Arkhangelsk, Russian Federation|FSBI Endocrinological Research Center of the MOH of the ROF, Moscow, Russian Federation|Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|Ryazan Regional Clinincal Cardiology Dispensary, Ryazan, Russian Federation|City Hospital of Saint Martyr Elizabeth, Saint Petersburg, Russian Federation|Medical Military Academy, Saint Petersburg, Russian Federation|SPb GUZ ""Diagnostic Center #85"", Saint Petersburg, Russian Federation|City Consultative and Diagnostic Center, Saint-Petersburg, Russian Federation|Regional Clinical Hospital, Saratov, Russian Federation|Research & Practice Ltd, Yaroslavl, Russian Federation|Human care s.r.o., Kosice, Slovak Republic, Slovakia|MediVet s.r.o., Malacky, Slovak Republic, Slovakia|Areteus s.r.o., Trebisov, Slovak Republic, Slovakia|DIA-MED CENTRUM s.r.o., Puchov, Slovakia|Tatratrial s.r.o., Roznava, Slovakia|MEDI-DIA s.r.o., Sabinov, Slovakia|Hospital Universitario Marques De Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Quiron Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital de la Ribera, Alcira, Valencia, Spain|Instituto de Ciencias medicas, Alicante, Spain|Centro Periférico de Especialidades Bola Azul, Almeria, Spain|Hospital Quironsalud Barcelona- END, Barcelona, Spain|Hospital Clinico Universitario San Cecilio, Granada, Spain|Complexo Hospitalario Universitario A Coruña, CHUAC, La Coruña, Spain|Centro Especialidades San Jose Obrero (Barbarela), Malaga, Spain|Clinica Juaneda, Palma de Mallorca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Clinica Nuevas Tecnologias en Diabetes y Endocrinologia, Seville, Spain|Cardinal Tien Hospital, Sindian City, Taipei County, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taiwan|Kuang Tien General Hospital, Taichung County, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03730662/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03730662/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03730662
376,NCT02481596,FAMS Mobile Health Intervention for Diabetes Self-care Support,Completed,Has Results,"Diabetes Mellitus, Type 2",Behavioral: REACH + FAMS|Behavioral: REACH|Behavioral: Helpline & A1c results,Vanderbilt University Medical Center,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Federally Qualified Health Centers & Vanderbilt Primary Care Clinics, Nashville, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02481596/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT02481596/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02481596
377,NCT03751657,A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin icodec|Drug: Placebo (insulin 287)|Drug: Metformin|Drug: Dipeptidyl peptidase-4 inhibitors|Drug: Insulin glargine|Drug: Placebo (insulin glargine),Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Pardubice, Czechia|Novo Nordisk Investigational Site, Praha 1, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Praha 5, Czechia|Novo Nordisk Investigational Site, Praha 8, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Rakovník, Czechia|Novo Nordisk Investigational Site, Slaný, Czechia|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Wierzchoslawice, Poland|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Moldava nad Bodvou, Slovakia|Novo Nordisk Investigational Site, Sahy, Slovakia|Novo Nordisk Investigational Site, Trencin, Slovakia|Novo Nordisk Investigational Site, Koper, Slovenia|Novo Nordisk Investigational Site, Ljubljana, Slovenia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03751657/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03751657/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03751657
378,NCT03687827,A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Insulin degludec|Drug: Insulin glargine,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, Van Nuys, California, United States|Novo Nordisk Investigational Site, Hamden, Connecticut, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Cooper City, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Pembroke Pines, Florida, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Kalispell, Montana, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Toledo, Ohio, United States|Novo Nordisk Investigational Site, Pelzer, South Carolina, United States|Novo Nordisk Investigational Site, Dakota Dunes, South Dakota, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Kerrville, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Oakville, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bytca, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Malacky, Slovakia|Novo Nordisk Investigational Site, Nove Mesto nad Vahom, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Trebisov, Slovakia|Novo Nordisk Investigational Site, Trnava, Slovakia|Novo Nordisk Investigational Site, Zilina, Slovakia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03687827/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03687827/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03687827
379,NCT03056456,A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: LY900014|Drug: Insulin Lispro (Humalog),Eli Lilly and Company,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Neuss, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03056456/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03056456/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03056456
380,NCT03214380,A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro|Drug: Insulin Glargine|Drug: Insulin Degludec|Drug: Metformin|Drug: SGLT2 inhibitor,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Valley Research, Fresno, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|First Valley Medical Group, Lancaster, California, United States|National Research Institute, Los Angeles, California, United States|Care Access Research, Santa Clarita, California, United States|Encompass Clinical Research, Spring Valley, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|The Center For Diabetes & Endocrine Care, Fort Lauderdale, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States|East West Medical Institute, Honolulu, Hawaii, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Northwest Clinical Trials, Boise, Idaho, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Prairie Education and Research Cooperative, Springfield, Illinois, United States|Iderc, P.L.C., West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cotton O'Neil Diabetes and Endocrinology Center, Kansas City, Kansas, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Manhattan Medical Research, New York, New York, United States|Aventiv Research, Columbus, Ohio, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|Partners in Nephrology & Endocrinology, Pittsburgh, Pennsylvania, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|Texas Diabetes and Endocrinology-Austin South, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|Progressive Clinical Research, Bountiful, Utah, United States|Private: Dr. Larry Stonesifer, Federal Way, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Caba, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Mar del Plata, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Keswick, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Oaklands Park, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fremantle, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Krnov, Czechia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Pardubice, Czechia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Praha, Czechia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Praha, Czechia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Praha, Czechia|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bad Mergentheim, Baden-Württemberg, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Falkensee, Brandenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pohlheim, Hessen, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Münster, Nordrhein-Westfalen, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Mayen, Rheinland-Pfalz, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Saint Ingbert-Oberwürzbach, Saarland, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Magdeburg, Sachsen-Anhalt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Schleswig-Holstein, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagykanizsa, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ahmedabad, Gujarat, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ahmedabad, Gujarat, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ahmedabad, Gujarat, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Bangalore, Karnataka, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, Karnataka, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Pune, Maharashtra, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, Maharashtra, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, Maharshtra, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, Rajasthan, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Chennai, Tamil Nadu, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Hyderabad, Telangana, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabad, Telangana, India|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Palmero, Italy|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Sesto San Giovanni, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hyōgo, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|""For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."", Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyazaki, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Naka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sasebo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sendai, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamato, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ōita, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ōsaka, Japan|For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ōsaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucheon, Gyeonggi-do, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ansan-si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daegu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daejeon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gangwon-do, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gangwon-do, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jalisco, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zapopan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zapopan, Mexico|Centro de Endocrinologia y Nutricion del Turabo, Caguas, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico|Research and Cardiovascular Corp., Ponce, Puerto Rico|GCM Medical Group PSC, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arkhangel'sk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kursk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Košice, Slovak Republic, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malacky, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nove Mesto nad Vahom, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Púchov, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rožňava, Slovakia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lleida, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Málaga, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yongkang, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03214380/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03214380/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03214380
381,NCT02688218,Exercise Detection Study,Completed,Has Results,Type 1 Diabetes,Behavioral: Aerobic Exercise|Behavioral: Resistance Exercise,Oregon Health and Science University,21 Years to 45 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02688218/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02688218
382,NCT01135394,Pharmacogenomics of Thiazolidinediones,Completed,Has Results,Type 2 Diabetes,Drug: Pioglitazone,"University of Maryland, Baltimore|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",35 Years to 64 Years   (Adult),Not Applicable,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Maryland School of Medicine, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01135394/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01135394
383,NCT03231709,Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Trelagliptin|Drug: Alogliptin,Takeda,"20 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OCROM Clinic, Suita, Osaka, Japan|ToCROM Clinic, Shinjuku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03231709/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03231709/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03231709
384,NCT03259789,Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,Completed,Has Results,Type2 Diabetes Mellitus,"Drug: Bexagliflozin tablets, 20 mg|Drug: Bexagliflozin tablets, placebo",Theracos,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Clinical Research Site 1232, Birmingham, Alabama, United States|Clinical Research Site 1378, Birmingham, Alabama, United States|Clinical Research Site 1269, Foley, Alabama, United States|Clinical Research Site 1363, Little Rock, Arkansas, United States|Clinical Research Site 1381, Anaheim, California, United States|Clinical Research Site 1375, North Hollywood, California, United States|Clinical Research Site 1365, Norwalk, California, United States|Clinical Research Site 1382, Norwalk, Connecticut, United States|Clinical Research Site 1372, Hollywood, Florida, United States|Clinical Research Site 1362, Palm Springs, Florida, United States|Clinical Research Site 1373, Pembroke Pines, Florida, United States|Clinical Research Site 1376, Nampa, Idaho, United States|Clinical Research Site 1366, Chicago, Illinois, United States|Clinical Research Site 1294, New Orleans, Louisiana, United States|Clinical Research Site 1374, Saint Louis, Missouri, United States|Clinical Research Site 1370, Las Vegas, Nevada, United States|Clinical Research Site 1009, Berlin, New Jersey, United States|Clinical Research Site 1037, Trenton, New Jersey, United States|Clinical Research Site 1286, Albuquerque, New Mexico, United States|Clinical Research Site 1275, Bronx, New York, United States|Clinical Research Site 1368, New York, New York, United States|Clinical Research Site 1019, Portland, Oregon, United States|Clinical Research Site 1379, Gonzales, Texas, United States|Clinical Research Site 1369, Houston, Texas, United States|Clinical Research Site 1371, San Antonio, Texas, United States|Clinical Research Site 1360, San Antonio, Texas, United States|Clinical Research Site 6048, Nagoya, Aichi, Japan|Clinical Research Site 6050, Sapporo, Hokkaido, Japan|Clinical Research Site 6041, Koga, Ibaraki, Japan|Clinical Research Site 6029, Atsugi, Kanagawa, Japan|Clinical Research Site 6051, Kamakura, Kanagawa, Japan|Clinical Research Site 6020, Yokohama, Kanagawa, Japan|Clinical Research Site 6055, Tokyo, Meguro, Japan|Clinical Research Site 6046, Higashiosaka, Osaka, Japan|Clinical Research Site 6033, Kashiwara, Osaka, Japan|Clinical Research Site 6013, Toyonaka, Osaka, Japan|Clinical Research Site 6052, Kawaguchi, Saitama, Japan|Clinical Research Site 6053, Shimotsuke, Tochigi, Japan|Clinical Research Site 6040, Fukuoka, Japan|Clinical Research Site 6043, Kyoto, Japan|Clinical Research Site 6015, Osaka, Japan|Clinical Research Site 6045, Tokyo, Japan|Clinical Research Site 6047, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03259789/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03259789/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03259789
385,NCT03689374,"A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Insulin aspart|Drug: Insulin glargine U100,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Banja Luka, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Sarajevo, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Tuzla, Bosnia and Herzegovina|Novo Nordisk Investigational Site, Burgas, Bulgaria|Novo Nordisk Investigational Site, Byala, Bulgaria|Novo Nordisk Investigational Site, Dimitrovgrad, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Ruse, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Karlovac, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Pula, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Beroun, Czechia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Kladno - Krocehlavy, Czechia|Novo Nordisk Investigational Site, Mlada Boleslav, Czechia|Novo Nordisk Investigational Site, Nachod, Czechia|Novo Nordisk Investigational Site, Olomouc, Czechia|Novo Nordisk Investigational Site, Plzeň, Czechia|Novo Nordisk Investigational Site, Prostejov, Czechia|Novo Nordisk Investigational Site, Pärnu, Estonia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Tallinn, Estonia|Novo Nordisk Investigational Site, Viljandi, Estonia|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Bad Mergentheim, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Eisenach, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Esslingen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Jerichow, Germany|Novo Nordisk Investigational Site, Kiel Kronshagen, Germany|Novo Nordisk Investigational Site, Leipzig, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Pohlheim, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Schwabenheim, Germany|Novo Nordisk Investigational Site, Schweinfurt, Germany|Novo Nordisk Investigational Site, Stuhr, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Villingen-Schwenningen, Germany|Novo Nordisk Investigational Site, Alexandroupolis, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Piraeus, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Gyula, Hungary|Novo Nordisk Investigational Site, Nagykanizsa, Hungary|Novo Nordisk Investigational Site, Pécs, Hungary|Novo Nordisk Investigational Site, Salgótarján, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Bhubaneswar, Orissa, India|Novo Nordisk Investigational Site, Chandigarh, Punjab, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Mohali, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Madurai, Tamil Nadu, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Hyderbad, Telengana, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Jelgava, Latvia|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Sigulda, Latvia|Novo Nordisk Investigational Site, Talsi, Latvia|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Kaunas, Lithuania|Novo Nordisk Investigational Site, Panevezys, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Vilnius, Lithuania|Novo Nordisk Investigational Site, Skopje, North Macedonia|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gorzow Wielkopolski, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Pulawy, Poland|Novo Nordisk Investigational Site, Ruda Slaska, Poland|Novo Nordisk Investigational Site, Siedlce, Poland|Novo Nordisk Investigational Site, Skorzewo, Poland|Novo Nordisk Investigational Site, Warsaw, Poland|Novo Nordisk Investigational Site, Wierzchoslawice, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Zabrze, Poland|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Braga, Portugal|Novo Nordisk Investigational Site, Coimbra, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Loures, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Setubal, Portugal|Novo Nordisk Investigational Site, Cluj Napoca, Cluj, Romania|Novo Nordisk Investigational Site, Targoviste, Dambovita, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Zajecar, Serbia|Novo Nordisk Investigational Site, Bardejov, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Dolny Kubin, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Lubochna, Slovakia|Novo Nordisk Investigational Site, Martin, Slovakia|Novo Nordisk Investigational Site, Presov, Slovakia|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Sabinov, Slovakia|Novo Nordisk Investigational Site, Brezice, Slovenia|Novo Nordisk Investigational Site, Jesenice, Slovenia|Novo Nordisk Investigational Site, Koper, Slovenia|Novo Nordisk Investigational Site, Murska Sobota, Slovenia|Novo Nordisk Investigational Site, Nova Gorica, Slovenia|Novo Nordisk Investigational Site, Nova Gorica, Slovenia|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Cosmo City, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Umkomaas, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Almeria, Spain|Novo Nordisk Investigational Site, Antequera, Spain|Novo Nordisk Investigational Site, Córdoba, Spain|Novo Nordisk Investigational Site, Fuenlabrada - Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Segovia, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Denizli, Turkey|Novo Nordisk Investigational Site, Erzurum, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Trabzon, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03689374/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03689374/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03689374
386,NCT03684642,Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Efpeglenatide|Drug: Dulaglutide|Drug: Background therapy Metformin,Sanofi|Hanmi Pharmaceutical Company Limited,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400038, Birmingham, Alabama, United States|Investigational Site Number 8400035, Chandler, Arizona, United States|Investigational Site Number 8400005, Glendale, Arizona, United States|Investigational Site Number 8400054, Peoria, Arizona, United States|Investigational Site Number 8400057, Huntington Park, California, United States|Investigational Site Number 8400009, Los Angeles, California, United States|Investigational Site Number 8400007, San Diego, California, United States|Investigational Site Number 8400045, Spring Valley, California, United States|Investigational Site Number 8400040, Tustin, California, United States|Investigational Site Number 8400026, Van Nuys, California, United States|Investigational Site Number 8400050, Waterbury, Connecticut, United States|Investigational Site Number 8400055, Orlando, Florida, United States|Investigational Site Number 8400041, Pembroke Pines, Florida, United States|Investigational Site Number 8400025, Lawrenceville, Georgia, United States|Investigational Site Number 8400060, Meridian, Idaho, United States|Investigational Site Number 8400059, Skokie, Illinois, United States|Investigational Site Number 8400044, Lexington, Kentucky, United States|Investigational Site Number 8400061, Boston, Massachusetts, United States|Investigational Site Number 8400001, Bridgeton, New Jersey, United States|Investigational Site Number 8400039, New Windsor, New York, United States|Investigational Site Number 8400028, Burlington, North Carolina, United States|Investigational Site Number 8400036, Morehead City, North Carolina, United States|Investigational Site Number 8400013, Maumee, Ohio, United States|Investigational Site Number 8400014, Goose Creek, South Carolina, United States|Investigational Site Number 8400030, Dallas, Texas, United States|Investigational Site Number 8400020, San Antonio, Texas, United States|Investigational Site Number 8400043, San Antonio, Texas, United States|Investigational Site Number 8400053, San Antonio, Texas, United States|Investigational Site Number 8400037, Layton, Utah, United States|Investigational Site Number 8400049, Manassas, Virginia, United States|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480003, Debrecen, Hungary|Investigational Site Number 3480001, Gyula, Hungary|Investigational Site Number 3480005, Hatvan, Hungary|Investigational Site Number 3480002, Nyíregyháza, Hungary|Investigational Site Number 6160008, Gdansk, Poland|Investigational Site Number 6160004, Gdynia, Poland|Investigational Site Number 6160010, Katowice, Poland|Investigational Site Number 6160009, Poznan, Poland|Investigational Site Number 6160003, Warszawa, Poland|Investigational Site Number 6160001, Wroclaw, Poland|Investigational Site Number 8040003, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040002, Kyiv, Ukraine|Investigational Site Number 8040004, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03684642/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03684642/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03684642
387,NCT02489942,Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Jardiance,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Multiple Locations, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02489942/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02489942/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02489942
388,NCT02973321,A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: SAR425899|Drug: Placebo|Drug: Liraglutide|Drug: Metformin,Sanofi,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8400028, Sheffield, Alabama, United States|Investigational Site Number 8400002, Huntington Park, California, United States|Investigational Site Number 8400024, Los Angeles, California, United States|Investigational Site Number 8400001, Los Angeles, California, United States|Investigational Site Number 8400012, Port Hueneme, California, United States|Investigational Site Number 8400027, Denver, Colorado, United States|Investigational Site Number 8400025, Miami, Florida, United States|Investigational Site Number 8400007, Palm Harbor, Florida, United States|Investigational Site Number 8400013, Chicago, Illinois, United States|Investigational Site Number 8400016, Wichita, Kansas, United States|Investigational Site Number 8400023, Wichita, Kansas, United States|Investigational Site Number 8400018, New Orleans, Louisiana, United States|Investigational Site Number 8400019, Rockville, Maryland, United States|Investigational Site Number 8400014, Flint, Michigan, United States|Investigational Site Number 8400003, Troy, Michigan, United States|Investigational Site Number 8400020, Linden, New Jersey, United States|Investigational Site Number 8400022, New York, New York, United States|Investigational Site Number 8400005, Fargo, North Dakota, United States|Investigational Site Number 8400004, Austin, Texas, United States|Investigational Site Number 8400006, Dallas, Texas, United States|Investigational Site Number 8400021, Houston, Texas, United States|Investigational Site Number 8400026, San Antonio, Texas, United States|Investigational Site Number 8400017, Sugar Land, Texas, United States|Investigational Site Number 1240008, Quebec, Canada|Investigational Site Number 1240005, Sainte-Foy, Canada|Investigational Site Number 1240002, Sherbrooke, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030003, Ceske Budejovice, Czechia|Investigational Site Number 2030001, Krnov, Czechia|Investigational Site Number 2030004, Praha 10 - Uhrineves, Czechia|Investigational Site Number 2030002, Praha 9 - Klanovice, Czechia|Investigational Site Number 2760003, Berlin, Germany|Investigational Site Number 2760001, Dresden, Germany|Investigational Site Number 2760006, Hohenmölsen, Germany|Investigational Site Number 3480001, Balatonfüred, Hungary|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480006, Budapest, Hungary|Investigational Site Number 3480007, Budapest, Hungary|Investigational Site Number 4840004, Actopan, Mexico|Investigational Site Number 4840001, Guadalajara, Mexico|Investigational Site Number 4840003, Guadalajara, Mexico|Investigational Site Number 4840002, Monterrey, Mexico|Investigational Site Number 4840006, San Juan Del Rio, Mexico|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430002, St-Petersburg, Russian Federation|Investigational Site Number 6430001, St-Petersburg, Russian Federation|Investigational Site Number 6430004, St. Petersburg, Russian Federation|Investigational Site Number 6430005, Voronezh, Russian Federation|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240007, Ferrol, Spain|Investigational Site Number 7240001, La Coruña, Spain|Investigational Site Number 7240006, Las Palmas De Gran Canaria, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240003, Málaga, Spain|Investigational Site Number 7240004, Málaga, Spain|Investigational Site Number 7240008, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02973321/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02973321/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02973321
389,NCT03018938,A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin Analog Mid Mixture|Drug: Basal Insulin Analog,Eli Lilly and Company,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Huaxin Hospital, Beijing, Beijing, China|Peking University Peoples Hospital, Beijing, Beijing, China|China Meitan General Hospital, Chaoyang, Beijing, China|Beijing Yanhua hospital, Fangshan, Beijing, China|The 2nd Hospital of Lanzhou University, Lanzhou, Gansu, China|Shenzhen City People Hospital, Shenzhen, Guangdong, China|The 1st Hospital with Guangdong Pharmaceutical University, Yuexiu, Guangdong, China|The 1st Affiliated Hospital of Henan Science and technology, Luoyang, Henan, China|People's Hospital of Henan Province, Zhengzhou, Henan, China|Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China|Changzhou No.2 People's Hospital, Changzhou, Jiangsu, China|Nanjing TCM hospital, Nanjing, Jiangsu, China|Jiang Su Province Official Hospital, Nanjing, Jiangsu, China|Nanjing Jiangbei Hospital, Nanjing, Jiangsu, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, China|Taizhou City People Hospital, Taizhou, Jiangsu, China|The second People's hospital of Wuxi, Wuxi, Jiangsu, China|Xuzhou central Hospital, Xuzhou, Jiangsu, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|Taian City Central Hospital, Taian, Shandong, China|Shanghai Pudong New Area Gongli Hospital, Shanghai, Shanghai, China|Shanghai Pudong New District Zhoupu Hospital, Shanghai, Shanghai, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, Shunqing, China|The Third Affiliated Hospital of Chengdu University of TCM, Chengdu, Sichuan, China|Southwest Medical University Affiliated Hospital, Luzhou, Sichuan, China|Tianjin First Central Hospital, Nankai, Tianjin, China|Beijing LuHe Hospital Capital Medical University, Beijing, Tongzhou, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo First Hospital, Ningbo, Zhejiang, China|Peking University International Hospital, Beijing, China|Beijing Hai Dian Hospital, Beijing, China|Shanghai Yangpu District Central Hospital, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03018938/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03018938/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03018938
390,NCT03260868,Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy),Terminated,Has Results,Type 1 Diabetes Mellitus,"Drug: Insulin glargine, 300 units per milliliter (U/mL)|Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)",Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400002, West Des Moines, Iowa, United States|Investigational Site Number 8400004, Houston, Texas, United States|Investigational Site Number 8400003, Bridgeport, West Virginia, United States|Investigational Site Number 1240001, Barrie, Canada|Investigational Site Number 1240003, Oakville, Canada|Investigational Site Number 1240002, Thornhill, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03260868/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03260868/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03260868
391,NCT03770728,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Efpeglenatide SAR439977|Drug: Placebo|Drug: Background therapy: Metformin alone or in combination with SU,Sanofi|Hanmi Pharmaceutical Company Limited,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8400038, Birmingham, Alabama, United States|Investigational Site Number 8400035, Chandler, Arizona, United States|Investigational Site Number 8400005, Glendale, Arizona, United States|Investigational Site Number 8400042, Mesa, Arizona, United States|Investigational Site Number 8400051, Phoenix, Arizona, United States|Investigational Site Number 8400056, Tucson, Arizona, United States|Investigational Site Number 8400057, Huntington Park, California, United States|Investigational Site Number 8400009, Los Angeles, California, United States|Investigational Site Number 8400045, Spring Valley, California, United States|Investigational Site Number 8400040, Tustin, California, United States|Investigational Site Number 8400047, Colorado Springs, Colorado, United States|Investigational Site Number 8400046, Coral Gables, Florida, United States|Investigational Site Number 8400041, Pembroke Pines, Florida, United States|Investigational Site Number 8400025, Lawrenceville, Georgia, United States|Investigational Site Number 8400044, Lexington, Kentucky, United States|Investigational Site Number 8400001, Bridgeton, New Jersey, United States|Investigational Site Number 8400039, New Windsor, New York, United States|Investigational Site Number 8400036, Morehead City, North Carolina, United States|Investigational Site Number 8400013, Maumee, Ohio, United States|Investigational Site Number 8400048, Oklahoma City, Oklahoma, United States|Investigational Site Number 8400030, Dallas, Texas, United States|Investigational Site Number 8400043, San Antonio, Texas, United States|Investigational Site Number 8400037, Layton, Utah, United States|Investigational Site Number 1560005, Baotou, China|Investigational Site Number 1560042, Beijing, China|Investigational Site Number 1560053, Hangzhou, China|Investigational Site Number 1560051, Hefei, China|Investigational Site Number 1560011, Hunan, China|Investigational Site Number 1560025, Meihekou, China|Investigational Site Number 1560055, Nanchang, China|Investigational Site Number 1560024, Nanjing, China|Investigational Site Number 1560020, Pingxiang, China|Investigational Site Number 1560031, Shandong, China|Investigational Site Number 1560030, Shandong, China|Investigational Site Number 1560012, Shanghai, China|Investigational Site Number 1560013, Shanghai, China|Investigational Site Number 1560004, Shanghai, China|Investigational Site Number 1560022, Shanghai, China|Investigational Site Number 1560041, Tianjin, China|Investigational Site Number 1560010, Wenzhou, China|Investigational Site Number 1560052, Wuhu, China|Investigational Site Number 1560034, Wuxi, China|Investigational Site Number 1560026, Xuzhou, China|Investigational Site Number 1560044, Yichun, China|Investigational Site Number 1560003, Zhengzhou, China|Investigational Site Number 1580006, Kaohsiung, Taiwan|Investigational Site Number 1580003, Taichung, Taiwan|Investigational Site Number 1580002, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03770728/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03770728/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03770728
392,NCT03353350,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: efpeglenatide (SAR439977)|Drug: placebo,Hanmi Pharmaceutical Company Limited|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8400004, Birmingham, Alabama, United States|Investigational Site Number 8400005, Glendale, Arizona, United States|Investigational Site Number 8400003, Canoga Park, California, United States|Investigational Site Number 8400007, Chula Vista, California, United States|Investigational Site Number 8400011, La Mesa, California, United States|Investigational Site Number 8400009, Los Angeles, California, United States|Investigational Site Number 8400029, Pomona, California, United States|Investigational Site Number 8400024, Tarzana, California, United States|Investigational Site Number 8400026, Van Nuys, California, United States|Investigational Site Number 8400010, DeLand, Florida, United States|Investigational Site Number 8400006, Hialeah, Florida, United States|Investigational Site Number 8400032, West Palm Beach, Florida, United States|Investigational Site Number 8400025, Lawrenceville, Georgia, United States|Investigational Site Number 8400034, Chicago, Illinois, United States|Investigational Site Number 8400033, Kansas City, Missouri, United States|Investigational Site Number 8400018, Lincoln, Nebraska, United States|Investigational Site Number 8400062, Las Vegas, Nevada, United States|Investigational Site Number 8400021, Las Vegas, Nevada, United States|Investigational Site Number 8400001, Bridgeton, New Jersey, United States|Investigational Site Number 8400028, Burlington, North Carolina, United States|Investigational Site Number 8400031, Wilmington, North Carolina, United States|Investigational Site Number 8400013, Maumee, Ohio, United States|Investigational Site Number 8400008, Hatboro, Pennsylvania, United States|Investigational Site Number 8400017, Carrollton, Texas, United States|Investigational Site Number 8400030, Dallas, Texas, United States|Investigational Site Number 8400015, Houston, Texas, United States|Investigational Site Number 8400019, Plano, Texas, United States|Investigational Site Number 8400020, San Antonio, Texas, United States|Investigational Site Number 8400016, San Antonio, Texas, United States|Investigational Site Number 8400027, San Antonio, Texas, United States|Investigational Site Number 8400023, Schertz, Texas, United States|Investigational Site Number 8400002, Holladay, Utah, United States|Investigational Site Number 2760005, Berlin, Germany|Investigational Site Number 2760003, Frankfurt Am Main, Germany|Investigational Site Number 2760001, Leipzig, Germany|Investigational Site Number 6160005, Gdansk, Poland|Investigational Site Number 6160004, Gdynia, Poland|Investigational Site Number 6160007, Katowice, Poland|Investigational Site Number 6160002, Krakow, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160003, Warszawa, Poland|Investigational Site Number 6160001, Wroclaw, Poland|Investigational Site Number 8040003, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040002, Kyiv, Ukraine|Investigational Site Number 8040004, Vinnitsa, Ukraine|Investigational Site Number 8260005, Birmingham, United Kingdom|Investigational Site Number 8260004, Cardiff, United Kingdom|Investigational Site Number 8260007, Chorley, United Kingdom|Investigational Site Number 8260008, Glasgow, United Kingdom|Investigational Site Number 8260001, Hexham, United Kingdom|Investigational Site Number 8260003, Liverpool, United Kingdom|Investigational Site Number 8260006, Manchester, United Kingdom|Investigational Site Number 8260002, Reading, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03353350/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03353350/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03353350
393,NCT03555565,"Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets ""Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age""",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin and Metformin hydrochloride,Takeda,"Child, Adult, Older Adult",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Takeda Selected Site, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03555565/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03555565/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03555565
394,NCT03115112,Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Sitagliptin|Drug: Placebo for sitagliptin|Drug: Placebo for bexagliflozin,Theracos,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Site 1357, Lincoln, California, United States|Clinical Research Site 1358, Long Beach, California, United States|Clinical Research Site 1361, San Dimas, California, United States|Clinical Research Site 1031, Port Orange, Florida, United States|Clinical Research Site 1271, Chicago, Illinois, United States|Clinical Research Site 1359, Topeka, Kansas, United States|Clinical Research Site 1009, Berlin, New Jersey, United States|Clinical Research Site 1037, Trenton, New Jersey, United States|Clinical Research Site 1008, Munroe Falls, Ohio, United States|Clinical Research Site 1360, San Antonio, Texas, United States|Clinical Research Site 3119, Hodonín, Czechia|Clinical Research Site 3123, Mladá Boleslav, Czechia|Clinical Research Site 3120, Olomouc, Czechia|Clinical Research Site 3112, Praha, Czechia|Clinical Research Site 3122, Prostějov, Czechia|Clinical Research Site 9102, Balatonfüred, Hungary|Clinical Research Site 9101, Balatongyörök, Hungary|Clinical Research Site 9106, Budapest, Hungary|Clinical Research Site 9107, Szeged, Hungary|Clinical Research Site 9105, Zalaegerszeg, Hungary|Clinical Research Site 9103, Zamardi, Hungary|Clinical Research Site 6031, Chiba, Japan|Clinical Research Site 6037, Chiba, Japan|Clinical Research Site 6042, Chiba, Japan|Clinical Research Site 6040, Fukuoka, Japan|Clinical Research Site 6035, Fukuoka, Japan|Clinical Research Site 6034, Ibaraki, Japan|Clinical Research Site 6039, Ibaraki, Japan|Clinical Research Site 6041, Ibaraki, Japan|Clinical Research Site 6032, Ibaraki, Japan|Clinical Research Site 6036, Shizuoka, Japan|Clinical Research Site 6038, Tochigi, Japan|Clinical Research Site 6033, Ōsaka, Japan|Clinical Research Site 7137, Gdańsk, Poland|Clinical Research Site 7144, Kraków, Poland|Clinical Research Site 7142, Kraków, Poland|Clinical Research Site 7139, Kraków, Poland|Clinical Research Site 7141, Kraków, Poland|Clinical Research Site 7120, Lublin, Poland|Clinical Research Site 7138, Lublin, Poland|Clinical Research Site 7131, Olsztyn, Poland|Clinical Research Site 7143, Poznań, Poland|Clinical Research Site 7140, Poznań, Poland|Clinical Research Site 7136, Poznań, Poland|Clinical Research Site 7107, Puławy, Poland|Clinical Research Site 7128, Toruń, Poland|Clinical Research Site 9002, Alicante, Spain|Clinical Research Site 9016, Almería, Spain|Clinical Research Site 9005, Alzira, Spain|Clinical Research Site 9017, Barcelona, Spain|Clinical Research Site 9013, Barcelona, Spain|Clinical Research Site 9012, Madrid, Spain|Clinical Research Site 9011, Sevilla, Spain|Clinical Research Site 9014, Sevilla, Spain|Clinical Research Site 9015, Sevilla, Spain|Clinical Research Site 9018, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03115112/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03115112/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03115112
395,NCT03217175,Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise,Terminated,Has Results,Type 1 Diabetes Mellitus,Device: Bihormonal Bionic Pancreas|Device: Insulin Only Bionic Pancreas|Drug: Glucagon|Drug: Placebo,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"MGH Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03217175/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03217175
396,NCT02836873,Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo,Theracos,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Fresno, California, United States|Research Site, La Palma, California, United States|Research Site, Lincoln, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Dimas, California, United States|Research Site, Monument, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Paducah, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Rockport, Maine, United States|Research Site, Nashua, New Hampshire, United States|Research Site, Bronx, New York, United States|Research Site, Stow, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Dijon, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pierre Benite, France|Research Site, Poitiers, France|Research Site, Venissieux, France|Research Site, Atsugi-shi, Kanagawa, Japan|Research Site, Kamakura-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Kawaguchi-shi, Saitama, Japan|Research site, Sayama-shi, SAitama, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Toshima-ku, Toyko, Japan|Research Site, Alcala de Henares, Spain|Research Site, Alicante, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Malaga, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02836873/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02836873/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02836873
397,NCT02460978,Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin|Other: Placebo for dapagliflozin,AstraZeneca|Bristol-Myers Squibb,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Mateo, California, United States|Research Site, San Ramon, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Golden, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Des Moines, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Flushing, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bennington, Vermont, United States|Research Site, Federal Way, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Brussels (Uccle), Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Falkensee, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Oldenburg, Germany|Research Site, Pohlheim, Germany|Research Site, Saarlouis, Germany|Research Site, Sulzbach-Rosenberg, Germany|Research Site, Wangen, Germany|Research Site, Aki-gun, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Chitose-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Ibusuki-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kashiwara-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Miura-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Obihiro-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Ushiku-shi, Japan|Research Site, Uwajima-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Hoogeveen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Gdańsk, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Wroclaw, Poland|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Linkoping, Sweden|Research Site, Uddevalla, Sweden|Research Site, Olten, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zollikerberg, Switzerland|Research Site, Manchester, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Oldham, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Wakefield, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02460978/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02460978/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02460978
398,NCT03713684,Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s),Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Efpeglenatide SAR439977|Drug: Placebo|Drug: Background therapy,Sanofi|Hanmi Pharmaceutical Company Limited,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8400038, Birmingham, Alabama, United States|Investigational Site Number 8400035, Chandler, Arizona, United States|Investigational Site Number 8400005, Glendale, Arizona, United States|Investigational Site Number 8400057, Huntington Park, California, United States|Investigational Site Number 8400058, La Jolla, California, United States|Investigational Site Number 8400009, Los Angeles, California, United States|Investigational Site Number 8400045, Spring Valley, California, United States|Investigational Site Number 8400040, Tustin, California, United States|Investigational Site Number 8400026, Van Nuys, California, United States|Investigational Site Number 8400055, Orlando, Florida, United States|Investigational Site Number 8400041, Pembroke Pines, Florida, United States|Investigational Site Number 8400025, Lawrenceville, Georgia, United States|Investigational Site Number 8400052, West Des Moines, Iowa, United States|Investigational Site Number 8400044, Lexington, Kentucky, United States|Investigational Site Number 8400001, Bridgeton, New Jersey, United States|Investigational Site Number 8400039, New Windsor, New York, United States|Investigational Site Number 8400036, Morehead City, North Carolina, United States|Investigational Site Number 8400013, Maumee, Ohio, United States|Investigational Site Number 8400030, Dallas, Texas, United States|Investigational Site Number 8400063, Dallas, Texas, United States|Investigational Site Number 8400043, San Antonio, Texas, United States|Investigational Site Number 8400037, Layton, Utah, United States|Investigational Site Number 1560005, Baotou, China|Investigational Site Number 1560017, Beijing, China|Investigational Site Number 1560006, Changsha, China|Investigational Site Number 1560001, Chengdu, China|Investigational Site Number 1560004, Shanghai, China|Investigational Site Number 1560036, Shanghai, China|Investigational Site Number 1560012, Shanghai, China|Investigational Site Number 1560013, Shanghai, China|Investigational Site Number 1560003, Zhengzhou, China|Investigational Site Number 4100009, Busan, Korea, Republic of|Investigational Site Number 4100001, Daejeon, Korea, Republic of|Investigational Site Number 4100016, Gwangju, Korea, Republic of|Investigational Site Number 4100010, Gwangju, Korea, Republic of|Investigational Site Number 4100013, Gyeonggi-do, Korea, Republic of|Investigational Site Number 4100015, Incheon, Korea, Republic of|Investigational Site Number 4100014, Jeonju, Korea, Republic of|Investigational Site Number 4100007, Seongnam-Si, Korea, Republic of|Investigational Site Number 4100008, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100005, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100011, Seoul, Korea, Republic of|Investigational Site Number 4100006, Seoul, Korea, Republic of|Investigational Site Number 4100012, Suwon, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03713684/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03713684/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03713684
399,NCT02715258,Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo,Theracos,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Canoga Park, California, United States|Research Site, Chino, California, United States|Research Site, Huntington Park, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Trenton, New Jersey, United States|Research Site, Calabash, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Munroe Falls, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, DeSoto, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Newmarket, Ontario, Canada|Research Site 2, Toronto, Ontario, Canada|Research Site 1, Toronto, Ontario, Canada|Research Site, Pointe-Claire, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02715258/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02715258/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02715258
400,NCT03989232,A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Semaglutide|Drug: Placebo (semaglutide),Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Mesa, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, West Hills, California, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Coral Gables, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Adairsville, Georgia, United States|Novo Nordisk Investigational Site, Alpharetta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Meridian, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Lake Charles, Louisiana, United States|Novo Nordisk Investigational Site, Sterling Heights, Michigan, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Trenton, New Jersey, United States|Novo Nordisk Investigational Site, New Windsor, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Salisbury, North Carolina, United States|Novo Nordisk Investigational Site, Statesville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, Mason, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Gaffney, South Carolina, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Humble, Texas, United States|Novo Nordisk Investigational Site, Hurst, Texas, United States|Novo Nordisk Investigational Site, Katy, Texas, United States|Novo Nordisk Investigational Site, Plano, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Walla Walla, Washington, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Kozloduy, Bulgaria|Novo Nordisk Investigational Site, Montana, Bulgaria|Novo Nordisk Investigational Site, Petrich, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Stara Zagora, Bulgaria|Novo Nordisk Investigational Site, Yambol, Bulgaria|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Etobicoke, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Stoney Creek, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Ceske Budejovice, Czechia|Novo Nordisk Investigational Site, Praha 10, Czechia|Novo Nordisk Investigational Site, Praha 5, Czechia|Novo Nordisk Investigational Site, Vlasim, Czechia|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Debrecen, Hungary|Novo Nordisk Investigational Site, Kaposvár, Hungary|Novo Nordisk Investigational Site, Komarom, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szekszárd, Hungary|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gorzow Wielkopolski, Poland|Novo Nordisk Investigational Site, Katowice, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Wroclaw, Poland|Novo Nordisk Investigational Site, Manati, Puerto Rico|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Hnusta, Slovakia|Novo Nordisk Investigational Site, Kezmarok, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Krupina, Slovakia|Novo Nordisk Investigational Site, Levice, Slovakia|Novo Nordisk Investigational Site, Nove Zamky, Slovakia|Novo Nordisk Investigational Site, Pezinok, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Povazska Bystrica, Slovakia|Novo Nordisk Investigational Site, Puchov, Slovakia|Novo Nordisk Investigational Site, Dnipro, Ukraine|Novo Nordisk Investigational Site, Mykolaiv, Ukraine|Novo Nordisk Investigational Site, Ternopil, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03989232/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03989232/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT03989232
401,NCT03616171,A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Behavioral: SLEEP-Extend intervention|Other: Control,Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),18 Years to 25 Years   (Adult),Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Georgia State University, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03616171/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03616171/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03616171
402,NCT03386344,Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,"55 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8409009, Escondido, California, United States|Investigational Site Number 8409010, Greenbrae, California, United States|Investigational Site Number 8409005, Walnut Creek, California, United States|Investigational Site Number 8409012, Columbus, Georgia, United States|Investigational Site Number 8409011, Evansville, Indiana, United States|Investigational Site Number 8409014, Wichita, Kansas, United States|Investigational Site Number 8409015, Albuquerque, New Mexico, United States|Investigational Site Number 8409002, Chapel Hill, North Carolina, United States|Investigational Site Number 8409001, Wilmington, North Carolina, United States|Investigational Site Number 8409008, Dayton, Ohio, United States|Investigational Site Number 8409004, Chattanooga, Tennessee, United States|Investigational Site Number 8409013, Austin, Texas, United States|Investigational Site Number 8409003, Dallas, Texas, United States|Investigational Site Number 8409007, Katy, Texas, United States|Investigational Site Number 0369003, Fremantle, Australia|Investigational Site Number 0369002, Merewether, Australia|Investigational Site Number 0369004, Parkville, Australia|Investigational Site Number 1249003, Brampton, Canada|Investigational Site Number 1249008, Etobicoke, Canada|Investigational Site Number 1249005, Pointe-Claire, Canada|Investigational Site Number 1249006, Thornhill, Canada|Investigational Site Number 1249004, Thornhill, Canada|Investigational Site Number 1249007, Vancouver, Canada|Investigational Site Number 1249002, Victoriaville, Canada|Investigational Site Number 4109006, Daejeon, Korea, Republic of|Investigational Site Number 4109005, Guri-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4109003, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4109004, Seoul, Korea, Republic of|Investigational Site Number 4109001, Seoul, Korea, Republic of|Investigational Site Number 4849006, Aguascalientes, Aguascalientes, Mexico|Investigational Site Number 4849001, Aguascalientes, Mexico|Investigational Site Number 4849003, Cuernavaca, Mexico|Investigational Site Number 4849002, Guadalajara Jalisco, Mexico|Investigational Site Number 4849004, Monterrey, Mexico|Investigational Site Number 4849005, Xalapa, Mexico|Investigational Site Number 5549004, Auckland, New Zealand|Investigational Site Number 5549003, Christchurch, New Zealand|Investigational Site Number 5549001, Rotorua, New Zealand|Investigational Site Number 5549002, Wellington, New Zealand|Investigational Site Number 6439007, Kemerovo, Russian Federation|Investigational Site Number 6439005, Novosibirsk, Russian Federation|Investigational Site Number 6439002, Saint-Petersburg, Russian Federation|Investigational Site Number 6439003, Saint-Petersburg, Russian Federation|Investigational Site Number 6439001, St. Petersburg, Russian Federation|Investigational Site Number 6439006, Yaroslavl, Russian Federation|Investigational Site Number 1589005, Changhua, Taiwan|Investigational Site Number 1589008, New Taipei City, Taiwan|Investigational Site Number 1589006, Taichung, Taiwan|Investigational Site Number 1589007, Taichung, Taiwan|Investigational Site Number 1589001, Tainan, Taiwan|Investigational Site Number 1589002, Tainan, Taiwan|Investigational Site Number 1589004, Taipei, Taiwan|Investigational Site Number 1589003, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03386344/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03386344/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03386344
403,NCT02737891,Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Tesofensine/Metoprolol|Drug: Placebo,Saniona|Profil Institut für Stoffwechselforschung GmbH,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02737891/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02737891/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02737891
404,NCT03267576,An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Canagliflozin 300 mg|Drug: Sitagliptin 100 mg|Drug: Metformin,"Janssen Research & Development, LLC",19 Years to 54 Years   (Adult),Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Consultorio Privado, Guadalajara, Mexico|Investigación Clínica Especializada, Guadalajara, Mexico|Consultorio Privado en Unidad de Patología Clínica, Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03267576/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT03267576/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03267576
405,NCT04216875,Best Practice Study of Diabetes Type 2 Management in Primary Care in Switzerland,Completed,No Results Available,"Diabetes Mellitus, Type 2|Primary Care",Procedure: Best Practice Diabetes Management in Primary Care,"QualiCCare|Swiss Society of Endocrinology and Diabetology|Roche Diabetes Care, Switzerland|Sanofi|Concordia Versicherungen AG|Novo Nordisk A/S|Galenica","Child, Adult, Older Adult",,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Hausarztmedizin KSSG, Saint Gallen, SG, Switzerland","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Study protocol and statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04216875/Prot_SAP_ICF_000.pdf|""Informed Consent Form: Informed Consent Form document (translated)"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04216875/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04216875
406,NCT01964963,Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin,Takeda,"Child, Adult, Older Adult",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT01964963/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT01964963/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT01964963
407,NCT02926950,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin (SAR439954)|Drug: Placebo|Drug: Metformin,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 8402003, Birmingham, Alabama, United States|Investigational Site Number 8402017, Birmingham, Alabama, United States|Investigational Site Number 8402052, Phoenix, Arizona, United States|Investigational Site Number 8402056, Canoga Park, California, United States|Investigational Site Number 8402020, Escondido, California, United States|Investigational Site Number 8402028, Gold River, California, United States|Investigational Site Number 8402067, Greenbrae, California, United States|Investigational Site Number 8402025, Huntington Park, California, United States|Investigational Site Number 8402051, La Mirada, California, United States|Investigational Site Number 8402042, Lemon Grove, California, United States|Investigational Site Number 8402011, Lincoln, California, United States|Investigational Site Number 8402014, Long Beach, California, United States|Investigational Site Number 8402066, Long Beach, California, United States|Investigational Site Number 8402029, Los Angeles, California, United States|Investigational Site Number 8402041, Los Angeles, California, United States|Investigational Site Number 8402001, Los Angeles, California, United States|Investigational Site Number 8402043, San Diego, California, United States|Investigational Site Number 8402031, San Ramon, California, United States|Investigational Site Number 8402047, Tarzana, California, United States|Investigational Site Number 8402009, Boynton Beach, Florida, United States|Investigational Site Number 8402016, Daytona Beach, Florida, United States|Investigational Site Number 8402006, Hialeah, Florida, United States|Investigational Site Number 8402035, Hialeah, Florida, United States|Investigational Site Number 8402044, Hialeah, Florida, United States|Investigational Site Number 8402045, Jacksonville, Florida, United States|Investigational Site Number 8402060, Miami Beach, Florida, United States|Investigational Site Number 8402026, Miami, Florida, United States|Investigational Site Number 8402036, Miami, Florida, United States|Investigational Site Number 8402064, Miami, Florida, United States|Investigational Site Number 8402007, Miami, Florida, United States|Investigational Site Number 8402061, Miami, Florida, United States|Investigational Site Number 8402033, Opa-locka, Florida, United States|Investigational Site Number 8402039, Orlando, Florida, United States|Investigational Site Number 8402063, West Palm Beach, Florida, United States|Investigational Site Number 8402038, Winter Haven, Florida, United States|Investigational Site Number 8402008, Macon, Georgia, United States|Investigational Site Number 8402054, Chicago, Illinois, United States|Investigational Site Number 8402069, Newton, Iowa, United States|Investigational Site Number 8402022, West Des Moines, Iowa, United States|Investigational Site Number 8402059, Lexington, Kentucky, United States|Investigational Site Number 8402068, Baton Rouge, Louisiana, United States|Investigational Site Number 8402012, Metairie, Louisiana, United States|Investigational Site Number 8402037, New Orleans, Louisiana, United States|Investigational Site Number 8402053, New Orleans, Louisiana, United States|Investigational Site Number 8402021, Rockville, Maryland, United States|Investigational Site Number 8402062, Omaha, Nebraska, United States|Investigational Site Number 8402005, Las Vegas, Nevada, United States|Investigational Site Number 8402018, Greensboro, North Carolina, United States|Investigational Site Number 8402002, Morehead City, North Carolina, United States|Investigational Site Number 8402019, Oklahoma City, Oklahoma, United States|Investigational Site Number 8402015, Eugene, Oregon, United States|Investigational Site Number 8402058, Lansdale, Pennsylvania, United States|Investigational Site Number 8402030, Dallas, Texas, United States|Investigational Site Number 8402050, DeSoto, Texas, United States|Investigational Site Number 8402010, Fort Worth, Texas, United States|Investigational Site Number 8402040, Houston, Texas, United States|Investigational Site Number 8402065, Houston, Texas, United States|Investigational Site Number 8402057, Houston, Texas, United States|Investigational Site Number 8402049, Magnolia, Texas, United States|Investigational Site Number 8402046, Odessa, Texas, United States|Investigational Site Number 8402013, San Antonio, Texas, United States|Investigational Site Number 8402004, San Antonio, Texas, United States|Investigational Site Number 8402023, Schertz, Texas, United States|Investigational Site Number 8402027, Clinton, Utah, United States|Investigational Site Number 8402032, Salt Lake City, Utah, United States|Investigational Site Number 8402024, Virginia Beach, Virginia, United States|Investigational Site Number 8402034, Seattle, Washington, United States|Investigational Site Number 1242014, Barrie, Canada|Investigational Site Number 1242004, Brampton, Canada|Investigational Site Number 1242005, Brampton, Canada|Investigational Site Number 1242001, Concord, Canada|Investigational Site Number 1242007, Etobicoke, Canada|Investigational Site Number 1242010, Levis, Canada|Investigational Site Number 1242012, Newmarket, Canada|Investigational Site Number 1242013, Oakville, Canada|Investigational Site Number 1242006, Pointe Claire, Canada|Investigational Site Number 1242008, Sherbrooke, Canada|Investigational Site Number 1242015, Toronto, Canada|Investigational Site Number 1242002, Toronto, Canada|Investigational Site Number 1242003, Toronto, Canada|Investigational Site Number 1242011, Vancouver, Canada|Investigational Site Number 3482002, Budapest, Hungary|Investigational Site Number 3482003, Budapest, Hungary|Investigational Site Number 3482006, Budapest, Hungary|Investigational Site Number 3482004, Debrecen, Hungary|Investigational Site Number 3482001, Esztergom, Hungary|Investigational Site Number 3482007, Nyiregyhaza, Hungary|Investigational Site Number 7032001, Bratislava, Slovakia|Investigational Site Number 7032005, Bratislava, Slovakia|Investigational Site Number 7032003, Malacky, Slovakia|Investigational Site Number 7032002, Nitra, Slovakia|Investigational Site Number 7032004, Sturovo, Slovakia|Investigational Site Number 7032006, Trencin, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02926950/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02926950/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02926950
408,NCT03332771,Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin (SAR439954)|Drug: Glimepiride|Drug: Metformin|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8407040, Birmingham, Alabama, United States|Investigational Site Number 8407048, Birmingham, Alabama, United States|Investigational Site Number 8407035, Little Rock, Arkansas, United States|Investigational Site Number 8407051, Anaheim, California, United States|Investigational Site Number 8407065, Canoga Park, California, United States|Investigational Site Number 8407078, Carmichael, California, United States|Investigational Site Number 8407089, Downey, California, United States|Investigational Site Number 8407011, Gold River, California, United States|Investigational Site Number 8407044, Greenbrae, California, United States|Investigational Site Number 8407006, Huntington Park, California, United States|Investigational Site Number 8407037, Lemon Grove, California, United States|Investigational Site Number 8407100, Lomita, California, United States|Investigational Site Number 8407033, Long Beach, California, United States|Investigational Site Number 8407019, Los Angeles, California, United States|Investigational Site Number 8407098, Northridge, California, United States|Investigational Site Number 8407094, Norwalk, California, United States|Investigational Site Number 8407106, Pomona, California, United States|Investigational Site Number 8407096, Rancho Cucamonga, California, United States|Investigational Site Number 8407036, Sacramento, California, United States|Investigational Site Number 8407084, Tarzana, California, United States|Investigational Site Number 8407034, Upland, California, United States|Investigational Site Number 8407032, Van Nuys, California, United States|Investigational Site Number 8407004, Walnut Creek, California, United States|Investigational Site Number 8407117, Wildomar, California, United States|Investigational Site Number 8407045, Colorado Springs, Colorado, United States|Investigational Site Number 8407074, Bradenton, Florida, United States|Investigational Site Number 8407027, Clearwater, Florida, United States|Investigational Site Number 8407103, Cooper City, Florida, United States|Investigational Site Number 8407021, Coral Gables, Florida, United States|Investigational Site Number 8407062, Lake Worth, Florida, United States|Investigational Site Number 8407121, Ocoee, Florida, United States|Investigational Site Number 8407024, Orlando, Florida, United States|Investigational Site Number 8407038, Palmetto Bay, Florida, United States|Investigational Site Number 8407093, Pembroke Pines, Florida, United States|Investigational Site Number 8407107, Spring Hill, Florida, United States|Investigational Site Number 8407091, Tampa, Florida, United States|Investigational Site Number 8407113, Tampa, Florida, United States|Investigational Site Number 8407092, West Palm Beach, Florida, United States|Investigational Site Number 8407115, Winter Haven, Florida, United States|Investigational Site Number 8407017, Chicago, Illinois, United States|Investigational Site Number 8407018, Elgin, Illinois, United States|Investigational Site Number 8407046, Gurnee, Illinois, United States|Investigational Site Number 8407119, Springfield, Illinois, United States|Investigational Site Number 8407075, Waterloo, Iowa, United States|Investigational Site Number 8407120, West Des Moines, Iowa, United States|Investigational Site Number 8407095, Topeka, Kansas, United States|Investigational Site Number 8407083, Wichita, Kansas, United States|Investigational Site Number 8407043, Lexington, Kentucky, United States|Investigational Site Number 8407087, Lexington, Kentucky, United States|Investigational Site Number 8407060, Lake Charles, Louisiana, United States|Investigational Site Number 8407058, New Orleans, Louisiana, United States|Investigational Site Number 8407009, New Orleans, Louisiana, United States|Investigational Site Number 8407079, Zachary, Louisiana, United States|Investigational Site Number 8407085, Baltimore, Maryland, United States|Investigational Site Number 8407001, Rockville, Maryland, United States|Investigational Site Number 8407069, Troy, Michigan, United States|Investigational Site Number 8407110, Olive Branch, Mississippi, United States|Investigational Site Number 8407054, Bridgeton, Missouri, United States|Investigational Site Number 8407049, Norfolk, Nebraska, United States|Investigational Site Number 8407039, Omaha, Nebraska, United States|Investigational Site Number 8407061, Papillion, Nebraska, United States|Investigational Site Number 8407108, Las Vegas, Nevada, United States|Investigational Site Number 8407050, Albuquerque, New Mexico, United States|Investigational Site Number 8407116, New York, New York, United States|Investigational Site Number 8407086, New York, New York, United States|Investigational Site Number 8407122, New York, New York, United States|Investigational Site Number 8407123, West Seneca, New York, United States|Investigational Site Number 8407020, Greensboro, North Carolina, United States|Investigational Site Number 8407114, Lenoir, North Carolina, United States|Investigational Site Number 8407015, Morehead City, North Carolina, United States|Investigational Site Number 8407030, Salisbury, North Carolina, United States|Investigational Site Number 8407041, Wilmington, North Carolina, United States|Investigational Site Number 8407101, Winston-Salem, North Carolina, United States|Investigational Site Number 8407099, Cincinnati, Ohio, United States|Investigational Site Number 8407081, Lyndhurst, Ohio, United States|Investigational Site Number 8407057, Norman, Oklahoma, United States|Investigational Site Number 8407073, Oklahoma City, Oklahoma, United States|Investigational Site Number 8407068, Eugene, Oregon, United States|Investigational Site Number 8407104, Beaver, Pennsylvania, United States|Investigational Site Number 8407025, Hatboro, Pennsylvania, United States|Investigational Site Number 8407053, Lansdale, Pennsylvania, United States|Investigational Site Number 8407016, Charleston, South Carolina, United States|Investigational Site Number 8407071, Greer, South Carolina, United States|Investigational Site Number 8407022, Mount Pleasant, South Carolina, United States|Investigational Site Number 8407031, Mount Pleasant, South Carolina, United States|Investigational Site Number 8407014, Jefferson City, Tennessee, United States|Investigational Site Number 8407002, Knoxville, Tennessee, United States|Investigational Site Number 8407056, Memphis, Tennessee, United States|Investigational Site Number 8407026, Austin, Texas, United States|Investigational Site Number 8407029, Beaumont, Texas, United States|Investigational Site Number 8407070, Carrollton, Texas, United States|Investigational Site Number 8407102, Corpus Christi, Texas, United States|Investigational Site Number 8407023, Dallas, Texas, United States|Investigational Site Number 8407111, Dallas, Texas, United States|Investigational Site Number 8407013, Fort Worth, Texas, United States|Investigational Site Number 8407080, Houston, Texas, United States|Investigational Site Number 8407088, Houston, Texas, United States|Investigational Site Number 8407090, Katy, Texas, United States|Investigational Site Number 8407042, Lampasas, Texas, United States|Investigational Site Number 8407067, Lufkin, Texas, United States|Investigational Site Number 8407118, Lufkin, Texas, United States|Investigational Site Number 8407059, McAllen, Texas, United States|Investigational Site Number 8407012, Mesquite, Texas, United States|Investigational Site Number 8407007, Plano, Texas, United States|Investigational Site Number 8407005, San Antonio, Texas, United States|Investigational Site Number 8407064, San Antonio, Texas, United States|Investigational Site Number 8407010, Schertz, Texas, United States|Investigational Site Number 8407076, Splendora, Texas, United States|Investigational Site Number 8407063, Clinton, Utah, United States|Investigational Site Number 8407055, Holladay, Utah, United States|Investigational Site Number 8407097, Ogden, Utah, United States|Investigational Site Number 8407072, Salt Lake City, Utah, United States|Investigational Site Number 8407124, Manassas, Virginia, United States|Investigational Site Number 8407105, Richmond, Virginia, United States|Investigational Site Number 8407028, Renton, Washington, United States|Investigational Site Number 1007002, Gabrovo, Bulgaria|Investigational Site Number 1007008, Plovdiv, Bulgaria|Investigational Site Number 1007003, Plovdiv, Bulgaria|Investigational Site Number 1007001, Ruse, Bulgaria|Investigational Site Number 1007004, Smolyan, Bulgaria|Investigational Site Number 1007009, Sofia, Bulgaria|Investigational Site Number 1007005, Stara Zagora, Bulgaria|Investigational Site Number 1007006, Stara Zagora, Bulgaria|Investigational Site Number 1007007, Varna, Bulgaria|Investigational Site Number 3487005, Balatonfured, Hungary|Investigational Site Number 3487001, Budapest, Hungary|Investigational Site Number 3487010, Budapest, Hungary|Investigational Site Number 3487006, Debrecen, Hungary|Investigational Site Number 3487008, Debrecen, Hungary|Investigational Site Number 3487002, Kecskemet, Hungary|Investigational Site Number 3487007, Nyiregyhaza, Hungary|Investigational Site Number 3487004, Nyíregyháza, Hungary|Investigational Site Number 7037004, Bardejov, Slovakia|Investigational Site Number 7037008, Bratislava, Slovakia|Investigational Site Number 7037007, Bratislava, Slovakia|Investigational Site Number 7037005, Kosice, Slovakia|Investigational Site Number 7037002, Levice, Slovakia|Investigational Site Number 7037010, Nitra, Slovakia|Investigational Site Number 7037009, Roznava, Slovakia|Investigational Site Number 7037001, Sabinov, Slovakia|Investigational Site Number 7037003, Trnava, Slovakia|Investigational Site Number 7037006, Vrutky, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03332771/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03332771/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03332771
409,NCT02589639,Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,"20 Years to 74 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nakayama Clinic, Aichi, Japan|Kashiwa City Hospital, Chiba, Kashiwa, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka, Japan|Seiwakai Medical Corporation Nagata Hospital, Fukuoka, Yanagawa, Japan|Kunisaki Makoto Clinic, Fukuoka, Japan|Saiseikai Maebashi Hospital, Gunma, Maebashi, Japan|Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama, Japan|Jiyugaoka Yokoyama Naika Clinic, Hokkaido, Obihiro, Japan|Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan|Souen Diabetes Clinic, Hokkaido, Sapporo, Japan|Kotani Diabetes Clinic, Hyogo, Kobe, Japan|Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya, Japan|Noritake Clinic, Ibaraki, Ushiku, Japan|Yokoi Medical Clinic, Kagawa, I.M., Kagawa, Japan|Izuro Imamura Hospital, Kagoshima, Kagoshima, Japan|Wakamatsu Memorial Hospital, Kagoshima, Satsumasendai, Japan|Fukumoto clinic, Kagoshima, Japan|STOP DM SUZUKI DIABETES CLINIC, Kanagawa, I.M., Kanagawa, Atsugi, Japan|Takai Naika Clinic, Kanagawa, Kamakura, Japan|Kokan Clinic, Kanagawa, Kawasaki, Japan|Yoshimasa Diabetes & Endocrine Clinic, Kyoto, Kyoto, Japan|Medical Corporation KEISEIKAI Kajiyama clinic, Kyoto, kyoto, Japan|Saka General Clinic, Miyagi, Tagajo, Japan|North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan|Asama Nanroku Komoro Medical center, Nagano, Komoro, Japan|Abe Clinic, Oita, Oita, Japan|Tsuyama Chuo Hospital, Okayama, Tsuyama, Japan|Medical Corporation Kyojinkai Clinic Komatsu, Osaka, Neyagawa, Japan|Minamiosaka Hospital, Osaka, Osaka, Japan|OCROM Clinic, Osaka, Suita, Japan|AMC Nishi-umeda Clinic, Osaka, Japan|Shiraiwa Medical Clinic, Osaka, Japan|Ageo Central General Hospital, Saitama, Ageo, Japan|Medical Corporation Kaishinkai Masunaga Clinic, Saitama, Fujimi, Japan|Medical Corporation Fusa Shimizu Clinic Fusa, Saitama, Saitama, Japan|Seiwa Clinic, Tokyo, Adachi-ku, Japan|Juntendo University Hospital, Tokyo, Bunkyo-ku, Japan|Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku, Japan|HDC Atlas Clinic, Tokyo, Chiyoda-ku, Japan|Fukuwa Clinic, Tokyo, Chuo-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan|Tokyo Center Clinic, Tokyo, Chuo-ku, Japan|Shin Clinic, Tokyo, Ota-ku, Japan|Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku, Japan|Sumida Chuou Hospital, Tokyo, Sumida-ku, Japan|Sagae City Hospital, Yamagata, Sagae, Japan|Clinic Sugiyama, Yamagata, Yamagata, Japan|Yamanashi Prefectural Central Hospital, Yamanashi, Kofu, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02589639/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02589639/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02589639
410,NCT02769481,Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Placebo for Bexagliflozin|Drug: Glimepiride|Drug: Placebo for Glimepiride,Theracos,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Huntington Park, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Carlos, California, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Calabash, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Magnolia, Texas, United States|Research Site, Aschaffenburg, Germany|Research Site, Essen, Germany|Research Site 2, Essen, Germany|Research Site 2, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Magdeburg, Germany|Research Site, Wangen, Germany|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Kraków, Poland|Research Site 2, Kraków, Poland|Research Site 2, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznań, Poland|Research Site, Puławy, Poland|Research Site, Staszów, Poland|Research Site, Swarzędz, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Zamość, Poland|Research Site, Łódź, Poland|Research Site, Świdnik, Poland|Research Site, Alicante, Spain|Research Site 2, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site 2, Madrid, Spain|Research Site 3, Madrid, Spain|Research Site, Madrid, Spain|Research Site 2, Malaga, Spain|Research Site, Malaga, Spain|Research Site 2, Oviedo, Spain|Research Site, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02769481/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02769481/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02769481
411,NCT02390050,A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Bexagliflozin tablets|Drug: Bexagliflozin tablets, placebo",Theracos,"20 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phoenix Medical Research Institute LLC, Peoria, Arizona, United States|Advanced Arizona Clinical Research, Tucson, Arizona, United States|Hope Clinical Research, LLC, Canoga Park, California, United States|Catalina Research Institute, Chino, California, United States|National Research Institute, Huntington Park, California, United States|Long Beach Clinical Trials, Long Beach, California, United States|Synergy San Diego, National City, California, United States|Northern California Research, Sacramento, California, United States|Artemis Institute for Clinical Research, LLC, San Diego, California, United States|Infosphere Clinical Research, Inc, West Hills, California, United States|M&O Clinical Research LLC, Fort Lauderdale, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Compass Research North, Leesburg, Florida, United States|Sweet Hope Research Specialty, Inc, Miami Lakes, Florida, United States|Sunshine Research Center, Opa-locka, Florida, United States|Compass Research LLC, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|PICR Clinic, Atlanta, Georgia, United States|Sundance Clinical Research, Saint Louis, Missouri, United States|Premier Research Ltd, Trenton, New Jersey, United States|Regional Clinical Research, Inc, Endwell, New York, United States|Calabash Medical Center, Calabash, North Carolina, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|CTI Research, Cincinnati, Ohio, United States|Summit Research Group, LLC, Stow, Ohio, United States|Columbia Research Group, Inc., Portland, Oregon, United States|Detweiler Family Medicine and Associate, P.C., Lansdale, Pennsylvania, United States|North Myrtle Beach Family Practice, Myrtle Beach, South Carolina, United States|Global Medical Research, DeSoto, Texas, United States|Rockwood Medical Clinic, Fort Worth, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Medical Corporation Hitomi-kai Motomachi Takatsuka Naika Clinic, Yokohama Naka-ku, Kanagawa, Japan|Medical Corporation Hayashi katagihara Clinic, Nishikyo-ku, Kyoto, Japan|Medical Corporation KEISEIKAI Kajiyama clinic, Ukyou-ku, Kyoto, Japan|Ikeoka Medical Corp. Ikeoka Clinic, Joto-ku, Osaka, Japan|Miyauchi Medical Center, Takatsuki-shi, Osaka, Japan|Medical Corporation Senrichuo Ekimae Clinic, Toyonaka-shi, Osaka, Japan|Medical Corporation Segawa Hospital, Hikigun Ogawamachi, Saitama, Japan|Medical Corporation Yukeikai Asano Clinic, Kawagoe-shi, Saitama, Japan|Medical Corporation Ishii Internal Medicine Clinic, Kawaguchi, Saitama, Japan|Medical Corporation Fusanokai Shimizu Clinic Fusa, Saitama-shi, Saitama, Japan|Medical Corp. SEIKOUKAI New Medical Research System Clinic, Hachioji-shi, Tokyo, Japan|Medical Corporation Jototowakai Shinkoiwa ekimae sogo Clinic, Katsushika-ku, Tokyo, Japan|Medical Corporation IHL Pedi Shiodome Medical Clinic, Minato-ku, Tokyo, Japan|Medical Corporation IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Kenkokan Suzuki Clinic, Ota-ku, Tokyo, Japan|Medical Corporation Souyu-kai Hirahata Clinic, Shibuya-ku, Tokyo, Japan|Medical Corporation Yuhokai Miho-Clinic, Shinagawa-ku, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02390050/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02390050/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02390050
412,NCT01483560,REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Metformin|Drug: Placebo,"University of Glasgow|NHS Greater Glasgow and Clyde|Juvenile Diabetes Research Foundation|Imperial College London|University of Wisconsin, Madison|University of Dundee|Merck Serono S.A., Geneva|Itamar-Medical, Israel|University of Western Ontario, Canada|University of Melbourne|Steno Diabetes Center Copenhagen|Maastricht University Medical Center","40 Years and older   (Adult, Older Adult)",Phase 3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Royal Melbourne Hospital, Melbourne, Australia|St Vincent's Hospital, Melbourne, Australia|Royal Prince Albert Hospital, Sydney, Australia|St Joseph's Health Care, London, Ontario, Canada|Ottawa Hospital Riverside Campus, Ottawa, Canada|Steno Diabetes Centre, Gentofte, Denmark|Maastricht University Medical Centre, Maastricht, Netherlands|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Ayr Hospital, Ayr, United Kingdom|University Hospitals Bristol, Bristol, United Kingdom|Diabetes Support Unit, Ninewells Hospital and Medical School, Dundee, United Kingdom|University Hospital North Durham, Durham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|Edinburgh Western Infirmary, Edinburgh, United Kingdom|Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|Stobhill Hospital, Diabetes Clinic, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Michael White Diabetes Centre, Hull Royal Infirmary, Hull, United Kingdom|Clinical Sciences Centre, University Hospital, Liverpool, United Kingdom|Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust, London, United Kingdom|Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary, Manchester, United Kingdom|Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital, Newcastle, United Kingdom|Diabetes Clinical Research Centre, Plymouth, Plymouth, United Kingdom|Salford Royal NHS Foundation Trust, Salford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT01483560/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT01483560/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01483560
413,NCT03434119,Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Insulin glargine/Lixisenatide|Drug: Insulin glargine (HOE901)|Drug: Background therapy,Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400072, Montgomery, Alabama, United States|Investigational Site Number 8400077, Little Rock, Arkansas, United States|Investigational Site Number 8400095, Little Rock, Arkansas, United States|Investigational Site Number 8400013, Little Rock, Arkansas, United States|Investigational Site Number 8400076, Anaheim, California, United States|Investigational Site Number 8400052, Anaheim, California, United States|Investigational Site Number 8400069, Anaheim, California, United States|Investigational Site Number 8400060, Burbank, California, United States|Investigational Site Number 8400049, Cerritos, California, United States|Investigational Site Number 8400078, Chula Vista, California, United States|Investigational Site Number 8400047, Escondido, California, United States|Investigational Site Number 8400066, Fountain Valley, California, United States|Investigational Site Number 8400050, Greenbrae, California, United States|Investigational Site Number 8400092, Huntington Park, California, United States|Investigational Site Number 8400015, Los Angeles, California, United States|Investigational Site Number 8400011, Los Angeles, California, United States|Investigational Site Number 8400301, Los Angeles, California, United States|Investigational Site Number 8400302, Los Angeles, California, United States|Investigational Site Number 8400303, Los Angeles, California, United States|Investigational Site Number 8400304, Los Angeles, California, United States|Investigational Site Number 8400006, Los Gatos, California, United States|Investigational Site Number 8400048, Oakland, California, United States|Investigational Site Number 8400053, Orange, California, United States|Investigational Site Number 8400084, Pomona, California, United States|Investigational Site Number 8400081, Pomona, California, United States|Investigational Site Number 8400042, Rancho Cucamonga, California, United States|Investigational Site Number 8400063, San Carlos, California, United States|Investigational Site Number 8400091, San Diego, California, United States|Investigational Site Number 8400086, San Jose, California, United States|Investigational Site Number 8400074, Santa Ana, California, United States|Investigational Site Number 8400037, Temecula, California, United States|Investigational Site Number 8400087, Vallejo, California, United States|Investigational Site Number 8400024, Van Nuys, California, United States|Investigational Site Number 8400007, Ventura, California, United States|Investigational Site Number 8400054, Englewood, Colorado, United States|Investigational Site Number 8400023, Hamden, Connecticut, United States|Investigational Site Number 8400041, Gainesville, Florida, United States|Investigational Site Number 8400075, Jacksonville, Florida, United States|Investigational Site Number 8400016, Miami Lakes, Florida, United States|Investigational Site Number 8400036, Miami, Florida, United States|Investigational Site Number 8400017, Miami, Florida, United States|Investigational Site Number 8400014, Ocoee, Florida, United States|Investigational Site Number 8400028, Port Charlotte, Florida, United States|Investigational Site Number 8400097, Saint Petersburg, Florida, United States|Investigational Site Number 8400035, Saint Petersburg, Florida, United States|Investigational Site Number 8400094, Tampa, Florida, United States|Investigational Site Number 8400025, Atlanta, Georgia, United States|Investigational Site Number 8400051, Atlanta, Georgia, United States|Investigational Site Number 8400093, Atlanta, Georgia, United States|Investigational Site Number 8400005, Savannah, Georgia, United States|Investigational Site Number 8400038, Chicago, Illinois, United States|Investigational Site Number 8400088, Chicago, Illinois, United States|Investigational Site Number 8400031, Des Plaines, Illinois, United States|Investigational Site Number 8400064, Evanston, Illinois, United States|Investigational Site Number 8400057, Gurnee, Illinois, United States|Investigational Site Number 8400030, Gretna, Louisiana, United States|Investigational Site Number 8400009, New Orleans, Louisiana, United States|Investigational Site Number 8400065, Baltimore, Maryland, United States|Investigational Site Number 8400061, Rockville, Maryland, United States|Investigational Site Number 8400079, Chelsea, Michigan, United States|Investigational Site Number 8400001, Flint, Michigan, United States|Investigational Site Number 8400012, Flint, Michigan, United States|Investigational Site Number 8400090, Las Vegas, Nevada, United States|Investigational Site Number 8400082, Las Vegas, Nevada, United States|Investigational Site Number 8400018, Linden, New Jersey, United States|Investigational Site Number 8400003, Bronx, New York, United States|Investigational Site Number 8400062, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400043, Columbia, South Carolina, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400040, Fort Worth, Texas, United States|Investigational Site Number 8400045, Houston, Texas, United States|Investigational Site Number 8400002, Humble, Texas, United States|Investigational Site Number 8400039, Kerrville, Texas, United States|Investigational Site Number 8400096, Lufkin, Texas, United States|Investigational Site Number 8400027, San Antonio, Texas, United States|Investigational Site Number 8400083, San Antonio, Texas, United States|Investigational Site Number 8400008, Splendora, Texas, United States|Investigational Site Number 8400055, Spring, Texas, United States|Investigational Site Number 8400070, Sugar Land, Texas, United States|Investigational Site Number 8400085, Sugar Land, Texas, United States|Investigational Site Number 8400059, Webster, Texas, United States|Investigational Site Number 8400044, Manassas, Virginia, United States|Investigational Site Number 8400068, Norfolk, Virginia, United States|Investigational Site Number 8400033, Richmond, Virginia, United States|Investigational Site Number 8400029, Richland, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03434119/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03434119/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03434119
414,NCT02926937,Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin (SAR439954)|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 8401049, Tucson, Arizona, United States|Investigational Site Number 8401026, Tucson, Arizona, United States|Investigational Site Number 8401028, Anaheim, California, United States|Investigational Site Number 8401057, Canoga Park, California, United States|Investigational Site Number 8401058, Garden Grove, California, United States|Investigational Site Number 8401029, Hawaiian Gardens, California, United States|Investigational Site Number 8401017, Huntington Park, California, United States|Investigational Site Number 8401056, Long Beach, California, United States|Investigational Site Number 8401013, Long Beach, California, United States|Investigational Site Number 8401063, Los Angeles, California, United States|Investigational Site Number 8401011, Los Angeles, California, United States|Investigational Site Number 8401022, Montclair, California, United States|Investigational Site Number 8401039, Norwalk, California, United States|Investigational Site Number 8401035, San Dimas, California, United States|Investigational Site Number 8401025, Tustin, California, United States|Investigational Site Number 8401015, Van Nuys, California, United States|Investigational Site Number 8401031, Denver, Colorado, United States|Investigational Site Number 8401060, Northglenn, Colorado, United States|Investigational Site Number 8401024, Bradenton, Florida, United States|Investigational Site Number 8401040, Clearwater, Florida, United States|Investigational Site Number 8401014, Daytona Beach, Florida, United States|Investigational Site Number 8401007, Hialeah, Florida, United States|Investigational Site Number 8401046, Homestead, Florida, United States|Investigational Site Number 8401018, Miami, Florida, United States|Investigational Site Number 8401008, Miami, Florida, United States|Investigational Site Number 8401053, Orlando, Florida, United States|Investigational Site Number 8401062, Palm Harbor, Florida, United States|Investigational Site Number 8401061, West Palm Beach, Florida, United States|Investigational Site Number 8401033, Atlanta, Georgia, United States|Investigational Site Number 8401044, Chicago, Illinois, United States|Investigational Site Number 8401052, Newton, Iowa, United States|Investigational Site Number 8401016, West Des Moines, Iowa, United States|Investigational Site Number 8401034, Wichita, Kansas, United States|Investigational Site Number 8401038, Lake Charles, Louisiana, United States|Investigational Site Number 8401042, Fayetteville, North Carolina, United States|Investigational Site Number 8401012, Greensboro, North Carolina, United States|Investigational Site Number 8401048, Akron, Ohio, United States|Investigational Site Number 8401003, Marion, Ohio, United States|Investigational Site Number 8401020, Corvallis, Oregon, United States|Investigational Site Number 8401006, Eugene, Oregon, United States|Investigational Site Number 8401041, Levittown, Pennsylvania, United States|Investigational Site Number 8401051, Anderson, South Carolina, United States|Investigational Site Number 8401002, Greer, South Carolina, United States|Investigational Site Number 8401005, Fort Worth, Texas, United States|Investigational Site Number 8401019, Houston, Texas, United States|Investigational Site Number 8401050, Houston, Texas, United States|Investigational Site Number 8401037, Katy, Texas, United States|Investigational Site Number 8401043, McAllen, Texas, United States|Investigational Site Number 8401059, North Richland Hills, Texas, United States|Investigational Site Number 8401004, San Antonio, Texas, United States|Investigational Site Number 8401054, San Antonio, Texas, United States|Investigational Site Number 8401001, San Antonio, Texas, United States|Investigational Site Number 8401055, Schertz, Texas, United States|Investigational Site Number 8401023, Sugar Land, Texas, United States|Investigational Site Number 8401032, Chesapeake, Virginia, United States|Investigational Site Number 8401010, Suffolk, Virginia, United States|Investigational Site Number 1241002, Sherbrooke, Canada|Investigational Site Number 1241005, Toronto, Canada|Investigational Site Number 1241001, Toronto, Canada|Investigational Site Number 1241006, Vancouver, Canada|Investigational Site Number 4841006, Aguascalientes, Mexico|Investigational Site Number 4841010, Aguascalientes, Mexico|Investigational Site Number 4841003, Cd. México, México, Mexico|Investigational Site Number 4841004, Chihuahua, Mexico|Investigational Site Number 4841001, Culiacan, Mexico|Investigational Site Number 4841005, Durango, Durango, Mexico|Investigational Site Number 4841009, Guadalajara, Mexico|Investigational Site Number 4841007, Mexico, Mexico|Investigational Site Number 4841002, Monterrey, Nuevo León, Mexico|Investigational Site Number 4841008, Monterrey, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02926937/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02926937/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02926937
415,NCT02000817,"Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients",Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: Otelixizumab|Biological: Placebo,GlaxoSmithKline|Parexel,"16 Years to 27 Years   (Child, Adult)",Phase 1|Phase 2,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02000817/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02000817/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02000817
416,NCT02973100,A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy,Completed,Has Results,Type 2 Diabetes,Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Parexel Early Phase Unit at Glendale, Glendale, California, United States|Marin Endocrine Associates, Greenbrae, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Encompass Clinical Research, Spring Valley Lake, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Infosphere, Van Nuys, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Axes Medical Research, LLC, Cooper City, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|Suncoast Research Group, LLC, Miami Lakes, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|In-Quest Medical Research, LLC - Norcross, Norcross, Georgia, United States|East West Medical Institute, Honolulu, Hawaii, United States|Elite Cilnical Trials LLLP, Blackfoot, Idaho, United States|Solaris Clinical Research, Meridian, Idaho, United States|HSHS Medical Group Diabetes Research, Springfield, Illinois, United States|American Health Network, Indianapolis, Indiana, United States|Iderc, P.L.C., Des Moines, Iowa, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|StudyMetrix Research, LLC, Saint Peters, Missouri, United States|Manhattan Medical Research, New York Mills, New York, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Aventiv Research, Columbus, Ohio, United States|The Corvallis Clinic P.C., Corvallis, Oregon, United States|Heritage Valley Medical Group, Inc., Beaver, Pennsylvania, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Consano Clinical Research, San Antonio, Texas, United States|Clinpoint Trial, LLC, Waxahachie, Texas, United States|Chrysalis Clinical Research, Saint George, Utah, United States|Rainier Clinical Research Center, Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brandýs Nad Labem-Stará Boleslav, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krnov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 1, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 4 - Krc, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 4, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 8, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chihuahua, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cuernavaca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampico, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ruda Slaska, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin, Poland|Marginal Doctor's Center, Manati, Puerto Rico|American Telemedicine Center, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alba Iulia, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baia Mare, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Satu-Mare, Romania","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02973100/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02973100/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02973100
417,NCT02666430,Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Mylan's insulin glargine|Drug: Lantus®,Mylan Inc.|Mylan GmbH|Viatris Inc.,"18 Years to 66 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mylan Investigator Site, Fresno, California, United States|Mylan Investigator Site, Greenbrae, California, United States|Mylan Investigator Site, La Jolla, California, United States|Mylan Investigator Site, Northridge, California, United States|Mylan Investigator Site, Tustin, California, United States|Mylan Investigator Site, Fort Lauderdale, Florida, United States|Mylan Investigator Site, New Port Richey, Florida, United States|Mylan Investigator Site, Palm Harbor, Florida, United States|Mylan Investigator Site, West Palm Beach, Florida, United States|Mylan Investigator Site, Atlanta, Georgia, United States|Mylan Investigator Site, Columbus, Georgia, United States|Mylan Investigator Site, Idaho Falls, Idaho, United States|Mylan Investigator Site, Crystal Lake, Illinois, United States|Mylan Investigator Site, Springfield, Illinois, United States|Mylan Investigator Site, Des Moines, Iowa, United States|Mylan Investigator Site, Overland Park, Kansas, United States|Mylan Investigator Site, Lexington, Kentucky, United States|Mylan Investigator Site, Billings, Montana, United States|Mylan Investigator Site, Omaha, Nebraska, United States|Mylan Investigator Site, Albany, New York, United States|Mylan Investigator Site, Staten Island, New York, United States|Mylan Investigator Site, Syracuse, New York, United States|Mylan Investigator Site, Asheville, North Carolina, United States|Mylan Investigator Site, Burlington, North Carolina, United States|Mylan Investigator Site, Greenville, North Carolina, United States|Mylan Investigator Site, Morehead City, North Carolina, United States|Mylan Investigator Site, Wilmington, North Carolina, United States|Mylan Investigator Site, Cincinnati, Ohio, United States|Mylan Investigator Site, Mentor, Ohio, United States|Mylan Investigator Site, Chattanooga, Tennessee, United States|Mylan Investigator Site, Austin, Texas, United States|Mylan Investigator Site, Dallas, Texas, United States|Mylan Investigator Site, San Antonio, Texas, United States|Mylan Investigator Site, Ogden, Utah, United States|Mylan Investigator Site, Salt Lake City, Utah, United States|Mylan Investigator Site, Chesapeake, Virginia, United States|Mylan Investigator Site, Renton, Washington, United States|Mylan Investigator Site, Tacoma, Washington, United States|Mylan Investigator Site, Vancouver, Washington, United States|Mylan Investigator Site, Red Deer, Alberta, Canada|Mylan Investigator Site., Vancouver, British Columbia, Canada|Mylan Investigator Site, Winnipeg, Manitoba, Canada|Mylan Investigator Site, Laval, Quebec, Canada|Mylan Investigator Site, Montreal, Quebec, Canada|Mylan Investigator Site, Brno Bohunice, Czechia|Mylan Investigator Site, Ceske Budejovice, Czechia|Mylan Investigator Site, Olomouc, Czechia|Mylan Investigator Site, Pardubice, Czechia|Mylan Investigator Site, Praha 10, Czechia|Mylan Investigator Site, Praha, Czechia|Mylan Investigator Site, Parnu, Estonia|Mylan Investigator Site, Tallinn, Estonia|Mylan Investigator Site, Tartu, Estonia|Mylan Investigator Site, Aschaffenburg, Bayern, Germany|Mylan Investigator Site, Munster, Nordrhein Westfalen, Germany|Mylan Investigator Site, Hohenmolsen, Sachsen Anhalt, Germany|Mylan Investigator Site, Hamburg, Germany|Mylan Investigator Site, Hamburg, Germany|Mylan Investigator Site, Budapest, Hungary|Mylan Investigator Site, Budapest, Hungary|Mylan Investigator Site, Eger, Hungary|Mylan Investigator Site, Letavertes, Hungary|Mylan Investigator Site, Miskolc, Hungary|Mylan Investigator Site, Szeged, Hungary|Mylan Investigator Site, Limbazi, Latvia|Mylan Investigator Site, Ogre, Latvia|Mylan Investigator Site, Riga, Latvia|Mylan Investigator Site, Riga, Latvia|Mylan Investigator Site, Sigulda, Latvia|Mylan Investigator Site, Talsi, Latvia|Mylan Investigator Site, Bratislava, Slovakia|Mylan Investigator Site, Bratislava, Slovakia|Mylan Investigator Site, Dolny Kubin, Slovakia|Mylan Investigator Site, Levice, Slovakia|Mylan Investigator Site, Lubochna, Slovakia|Mylan Investigator Site, Nove Zamky, Slovakia|Mylan Investigator Site, Prievidza, Slovakia|Mylan Investigator Site, Rimavska Sobota, Slovakia|Mylan Investigator Site, Sturovo, Slovakia|Mylan Investigator Site, Trebisov, Slovakia|Mylan Investigator Site, Zilina, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02666430/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02666430/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02666430
418,NCT03285594,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Insulin glargine (HOE901)|Drug: Placebo|Drug: Oral Antidiabetes Drugs (OADs),Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 8406028, Mesa, Arizona, United States|Investigational Site Number 8406013, Phoenix, Arizona, United States|Investigational Site Number 8406020, Phoenix, Arizona, United States|Investigational Site Number 8406006, Huntington Park, California, United States|Investigational Site Number 8406053, Lincoln, California, United States|Investigational Site Number 8406040, Los Angeles, California, United States|Investigational Site Number 8406043, Coral Gables, Florida, United States|Investigational Site Number 8406008, DeLand, Florida, United States|Investigational Site Number 8406030, Maitland, Florida, United States|Investigational Site Number 8406003, New Port Richey, Florida, United States|Investigational Site Number 8406029, North Miami Beach, Florida, United States|Investigational Site Number 8406052, Ocoee, Florida, United States|Investigational Site Number 8406001, Port Charlotte, Florida, United States|Investigational Site Number 8406022, Saint Petersburg, Florida, United States|Investigational Site Number 8406025, Tampa, Florida, United States|Investigational Site Number 8406002, West Palm Beach, Florida, United States|Investigational Site Number 8406054, Chicago, Illinois, United States|Investigational Site Number 8406027, Chicago, Illinois, United States|Investigational Site Number 8406042, Evansville, Indiana, United States|Investigational Site Number 8406044, New Orleans, Louisiana, United States|Investigational Site Number 8406051, New Orleans, Louisiana, United States|Investigational Site Number 8406024, Rockville, Maryland, United States|Investigational Site Number 8406016, Detroit, Michigan, United States|Investigational Site Number 8406011, Saint Louis, Missouri, United States|Investigational Site Number 8406010, Papillion, Nebraska, United States|Investigational Site Number 8406018, New York, New York, United States|Investigational Site Number 8406034, Asheville, North Carolina, United States|Investigational Site Number 8406046, Chapel Hill, North Carolina, United States|Investigational Site Number 8406026, Charlotte, North Carolina, United States|Investigational Site Number 8406038, Greenville, North Carolina, United States|Investigational Site Number 8406036, Hickory, North Carolina, United States|Investigational Site Number 8406015, Wilmington, North Carolina, United States|Investigational Site Number 8406019, Winston-Salem, North Carolina, United States|Investigational Site Number 8406031, Beachwood, Ohio, United States|Investigational Site Number 8406023, Columbus, Ohio, United States|Investigational Site Number 8406005, Dublin, Ohio, United States|Investigational Site Number 8406004, Mentor, Ohio, United States|Investigational Site Number 8406033, Oklahoma City, Oklahoma, United States|Investigational Site Number 8406032, Moncks Corner, South Carolina, United States|Investigational Site Number 8406009, Chattanooga, Tennessee, United States|Investigational Site Number 8406045, Seymour, Tennessee, United States|Investigational Site Number 8406047, Dallas, Texas, United States|Investigational Site Number 8406017, Dallas, Texas, United States|Investigational Site Number 8406048, Houston, Texas, United States|Investigational Site Number 8406037, Houston, Texas, United States|Investigational Site Number 8406039, McAllen, Texas, United States|Investigational Site Number 8406050, San Antonio, Texas, United States|Investigational Site Number 8406021, Shavano Park, Texas, United States|Investigational Site Number 8406035, Salt Lake City, Utah, United States|Investigational Site Number 8406014, West Jordan, Utah, United States|Investigational Site Number 1006009, Gabrovo, Bulgaria|Investigational Site Number 1006003, Plovdiv, Bulgaria|Investigational Site Number 1006004, Ruse, Bulgaria|Investigational Site Number 1006001, Ruse, Bulgaria|Investigational Site Number 1006006, Smolyan, Bulgaria|Investigational Site Number 1006002, Sofia, Bulgaria|Investigational Site Number 1006010, Sofia, Bulgaria|Investigational Site Number 1006005, Stara Zagora, Bulgaria|Investigational Site Number 1006007, Varna, Bulgaria|Investigational Site Number 1246003, Brampton, Canada|Investigational Site Number 1246005, Burlington, Canada|Investigational Site Number 1246004, Etobicoke, Canada|Investigational Site Number 1246002, Toronto, Canada|Investigational Site Number 1246001, Vancouver, Canada|Investigational Site Number 2036003, Holesov, Czechia|Investigational Site Number 2036002, Krnov, Czechia|Investigational Site Number 2036001, Olomouc, Czechia|Investigational Site Number 2036005, Ostrava, Czechia|Investigational Site Number 2036006, Praha 10 - Uhrineves, Czechia|Investigational Site Number 2036007, Praha 4, Czechia|Investigational Site Number 2036008, Praha 4, Czechia|Investigational Site Number 2506008, Besançon Cedex, France|Investigational Site Number 2506003, Corbeil-Essonnes, France|Investigational Site Number 2506005, Dijon, France|Investigational Site Number 2506012, Mulhouse, France|Investigational Site Number 2506004, Nantes, France|Investigational Site Number 2506007, Narbonne, France|Investigational Site Number 2506006, Paris, France|Investigational Site Number 2506010, Pierre-Benite, France|Investigational Site Number 2506009, Poitiers, France|Investigational Site Number 2506011, Saint-Mande, France|Investigational Site Number 2506002, Vénissieux, France|Investigational Site Number 3486007, Budapest, Hungary|Investigational Site Number 3486002, Budapest, Hungary|Investigational Site Number 3486006, Hatvan, Hungary|Investigational Site Number 3486009, Kecskemet, Hungary|Investigational Site Number 3486003, Komarom, Hungary|Investigational Site Number 3486005, Nyíregyháza, Hungary|Investigational Site Number 3486001, Pécs, Hungary|Investigational Site Number 3486008, Zalaegerszeg, Hungary|Investigational Site Number 7036004, Bardejov, Slovakia|Investigational Site Number 7036008, Bratislava, Slovakia|Investigational Site Number 7036001, Bratislava, Slovakia|Investigational Site Number 7036010, Kosice, Slovakia|Investigational Site Number 7036003, Kosice, Slovakia|Investigational Site Number 7036007, Levice, Slovakia|Investigational Site Number 7036009, Levice, Slovakia|Investigational Site Number 7036011, Lucenec, Slovakia|Investigational Site Number 7036006, Nitra, Slovakia|Investigational Site Number 7036005, Sabinov, Slovakia|Investigational Site Number 8266002, Darlington, United Kingdom|Investigational Site Number 8266006, Doncaster, United Kingdom|Investigational Site Number 8266008, Dundee, United Kingdom|Investigational Site Number 8266001, Leicester, United Kingdom|Investigational Site Number 8266004, London, United Kingdom|Investigational Site Number 8266003, Salford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03285594/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03285594/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03285594
419,NCT03066830,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin (SAR439954)|Drug: Placebo|Drug: Metformin|Drug: Sulfonylurea,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 8403003, Litchfield Park, Arizona, United States|Investigational Site Number 8403018, Peoria, Arizona, United States|Investigational Site Number 8403009, Greenbrae, California, United States|Investigational Site Number 8403012, Huntington Park, California, United States|Investigational Site Number 8403019, Los Angeles, California, United States|Investigational Site Number 8403034, Montclair, California, United States|Investigational Site Number 8403016, Spring Valley, California, United States|Investigational Site Number 8403014, Tustin, California, United States|Investigational Site Number 8403001, Northglenn, Colorado, United States|Investigational Site Number 8403029, Bradenton, Florida, United States|Investigational Site Number 8403004, New Port Richey, Florida, United States|Investigational Site Number 8403020, North Miami Beach, Florida, United States|Investigational Site Number 8403026, Ocoee, Florida, United States|Investigational Site Number 8403032, Orlando, Florida, United States|Investigational Site Number 8403008, Palm Harbor, Florida, United States|Investigational Site Number 8403006, Pembroke Pines, Florida, United States|Investigational Site Number 8403013, Port Charlotte, Florida, United States|Investigational Site Number 8403007, Nampa, Idaho, United States|Investigational Site Number 8403011, Flint, Michigan, United States|Investigational Site Number 8403025, Richfield, Minnesota, United States|Investigational Site Number 8403021, Henderson, Nevada, United States|Investigational Site Number 8403028, Greensboro, North Carolina, United States|Investigational Site Number 8403015, Shelby, North Carolina, United States|Investigational Site Number 8403033, Hatboro, Pennsylvania, United States|Investigational Site Number 8403030, Kingsport, Tennessee, United States|Investigational Site Number 8403002, Dallas, Texas, United States|Investigational Site Number 8403022, Houston, Texas, United States|Investigational Site Number 8403005, Burke, Virginia, United States|Investigational Site Number 1003003, Plovdiv, Bulgaria|Investigational Site Number 1003002, Ruse, Bulgaria|Investigational Site Number 1003004, Sofia, Bulgaria|Investigational Site Number 2333003, Parnu, Estonia|Investigational Site Number 3483001, Balatonfüred, Hungary|Investigational Site Number 3483007, Budapest, Hungary|Investigational Site Number 3483008, Budapest, Hungary|Investigational Site Number 3483010, Budapest, Hungary|Investigational Site Number 3483004, Budapest, Hungary|Investigational Site Number 3483006, Budapest, Hungary|Investigational Site Number 3483011, Gyula, Hungary|Investigational Site Number 3483009, Hatvan, Hungary|Investigational Site Number 3483005, Kecskemet, Hungary|Investigational Site Number 3483003, Pécs, Hungary|Investigational Site Number 3483012, Zalaegerszeg, Hungary|Investigational Site Number 4103001, Goyang-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4103011, Guri-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4103003, Seongnam-Si, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4103007, Seoul, Korea, Republic of|Investigational Site Number 4103006, Seoul, Korea, Republic of|Investigational Site Number 4103010, Seoul, Korea, Republic of|Investigational Site Number 4103005, Seoul, Korea, Republic of|Investigational Site Number 4103009, Wonju-Si, Gangwon-Do, Korea, Republic of|Investigational Site Number 6163005, Gdansk, Poland|Investigational Site Number 6163006, Gdynia, Poland|Investigational Site Number 6163003, Katowice, Poland|Investigational Site Number 6163002, Poznan, Poland|Investigational Site Number 6163001, Warszawa, Poland|Investigational Site Number 6163004, Wroclaw, Poland|Investigational Site Number 6423004, Bucuresti, Romania|Investigational Site Number 6423002, Iasi, Romania|Investigational Site Number 7033006, Bratislava, Slovakia|Investigational Site Number 7033001, Bratislava, Slovakia|Investigational Site Number 7033002, Bratislava, Slovakia|Investigational Site Number 7033004, Malacky, Slovakia|Investigational Site Number 7033003, Sturovo, Slovakia|Investigational Site Number 7033007, Trencin, Slovakia|Investigational Site Number 8043001, Kyiv, Ukraine|Investigational Site Number 8043003, Kyiv, Ukraine|Investigational Site Number 8043002, Kyiv, Ukraine|Investigational Site Number 8263012, Birmingham, United Kingdom|Investigational Site Number 8263009, Cardiff, United Kingdom|Investigational Site Number 8263007, Glasgow, United Kingdom|Investigational Site Number 8263008, Hexham, United Kingdom|Investigational Site Number 8263003, Inverness, United Kingdom|Investigational Site Number 8263014, Liverpool, United Kingdom|Investigational Site Number 8263011, Manchester, United Kingdom|Investigational Site Number 8263010, Reading, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03066830/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03066830/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03066830
420,NCT02688933,A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: HOE901-U300 (Insulin Glargine 300 U/ml)|Drug: Lantus (Insulin Glargine 100 U/ml)|Drug: Mandated back ground therapy,Sanofi,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 840-151, Little Rock, Arkansas, United States|Investigational Site Number 840-071, Concord, California, United States|Investigational Site Number 840-149, Escondido, California, United States|Investigational Site Number 840-004, Fresno, California, United States|Investigational Site Number 840-110, Greenbrae, California, United States|Investigational Site Number 840-124, La Jolla, California, United States|Investigational Site Number 840-030, La Mesa, California, United States|Investigational Site Number 840-044, Los Angeles, California, United States|Investigational Site Number 840-022, Los Angeles, California, United States|Investigational Site Number 840-129, Los Gatos, California, United States|Investigational Site Number 840-024, Northridge, California, United States|Investigational Site Number 840-069, Pomona, California, United States|Investigational Site Number 840-090, Pomona, California, United States|Investigational Site Number 840-132, Rolling Hills Estates, California, United States|Investigational Site Number 840-130, San Jose, California, United States|Investigational Site Number 840-055, San Ramon, California, United States|Investigational Site Number 840-028, Santa Barbara, California, United States|Investigational Site Number 840-063, Tarzana, California, United States|Investigational Site Number 840-138, Tustin, California, United States|Investigational Site Number 840-016, Ventura, California, United States|Investigational Site Number 840-039, Denver, Colorado, United States|Investigational Site Number 840-021, Denver, Colorado, United States|Investigational Site Number 840-070, Denver, Colorado, United States|Investigational Site Number 840-046, Englewood, Colorado, United States|Investigational Site Number 840-072, Coral Gables, Florida, United States|Investigational Site Number 840-133, Hialeah, Florida, United States|Investigational Site Number 840-137, Maitland, Florida, United States|Investigational Site Number 840-049, Miami, Florida, United States|Investigational Site Number 840-076, Miami, Florida, United States|Investigational Site Number 840-023, New Port Richey, Florida, United States|Investigational Site Number 840-053, Ocoee, Florida, United States|Investigational Site Number 840-112, Ormond Beach, Florida, United States|Investigational Site Number 840-018, Palm Harbor, Florida, United States|Investigational Site Number 840-047, Port Charlotte, Florida, United States|Investigational Site Number 840-114, Tampa, Florida, United States|Investigational Site Number 840-036, West Palm Beach, Florida, United States|Investigational Site Number 840-001, Atlanta, Georgia, United States|Investigational Site Number 840-064, Columbus, Georgia, United States|Investigational Site Number 840-012, Lawrenceville, Georgia, United States|Investigational Site Number 840-008, Roswell, Georgia, United States|Investigational Site Number 840-014, Stockbridge, Georgia, United States|Investigational Site Number 840-060, Idaho Falls, Idaho, United States|Investigational Site Number 840-125, Arlington Heights, Illinois, United States|Investigational Site Number 840-011, Chicago, Illinois, United States|Investigational Site Number 840-134, Crystal Lake, Illinois, United States|Investigational Site Number 840-002, West Des Moines, Iowa, United States|Investigational Site Number 840-073, Wichita, Kansas, United States|Investigational Site Number 840-062, Covington, Kentucky, United States|Investigational Site Number 840-042, Lexington, Kentucky, United States|Investigational Site Number 840-009, Metairie, Louisiana, United States|Investigational Site Number 840-032, New Orleans, Louisiana, United States|Investigational Site Number 840-054, Hyattsville, Maryland, United States|Investigational Site Number 840-006, Rockville, Maryland, United States|Investigational Site Number 840-157, Framingham, Massachusetts, United States|Investigational Site Number 840-122, Waltham, Massachusetts, United States|Investigational Site Number 840-037, Flint, Michigan, United States|Investigational Site Number 840-067, Billings, Montana, United States|Investigational Site Number 840-094, Lincoln, Nebraska, United States|Investigational Site Number 840-033, Omaha, Nebraska, United States|Investigational Site Number 840-142, Omaha, Nebraska, United States|Investigational Site Number 840-040, Henderson, Nevada, United States|Investigational Site Number 840-017, Las Vegas, Nevada, United States|Investigational Site Number 840-102, New York, New York, United States|Investigational Site Number 840-108, New York, New York, United States|Investigational Site Number 840-109, Staten Island, New York, United States|Investigational Site Number 840-045, Greenville, North Carolina, United States|Investigational Site Number 840-010, Morehead City, North Carolina, United States|Investigational Site Number 840-080, Morehead City, North Carolina, United States|Investigational Site Number 840-051, Fargo, North Dakota, United States|Investigational Site Number 840-123, Columbus, Ohio, United States|Investigational Site Number 840-104, Mentor, Ohio, United States|Investigational Site Number 840-079, Norman, Oklahoma, United States|Investigational Site Number 840-162, Bend, Oregon, United States|Investigational Site Number 840-096, Portland, Oregon, United States|Investigational Site Number 840-058, Chattanooga, Tennessee, United States|Investigational Site Number 840-003, Dallas, Texas, United States|Investigational Site Number 840-019, Dallas, Texas, United States|Investigational Site Number 840-075, Dallas, Texas, United States|Investigational Site Number 840-005, Dallas, Texas, United States|Investigational Site Number 840-013, Dallas, Texas, United States|Investigational Site Number 840-153, El Paso, Texas, United States|Investigational Site Number 840-026, Fort Worth, Texas, United States|Investigational Site Number 840-081, Houston, Texas, United States|Investigational Site Number 840-160, Houston, Texas, United States|Investigational Site Number 840-156, Houston, Texas, United States|Investigational Site Number 840-152, Houston, Texas, United States|Investigational Site Number 840-031, Houston, Texas, United States|Investigational Site Number 840-140, Lufkin, Texas, United States|Investigational Site Number 840-029, Mesquite, Texas, United States|Investigational Site Number 840-048, North Richland Hills, Texas, United States|Investigational Site Number 840-150, Pearland, Texas, United States|Investigational Site Number 840-083, Murray, Utah, United States|Investigational Site Number 840-101, Ogden, Utah, United States|Investigational Site Number 840-097, Salt Lake City, Utah, United States|Investigational Site Number 840-143, Bennington, Vermont, United States|Investigational Site Number 840-056, Burlington, Vermont, United States|Investigational Site Number 840-015, Renton, Washington, United States|Investigational Site Number 840-074, Spokane, Washington, United States|Investigational Site Number 840-139, Bridgeport, West Virginia, United States|Investigational Site Number 840-111, Manati, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02688933/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02688933/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02688933
421,NCT02414958,Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"AMCR Institute, Inc., Escondido, California, United States|Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|National Research Institute, Los Angeles, California, United States|Mills-Peninsula Health Services, San Mateo, California, United States|Metabolic Institute of America, Tarzana, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Baptist Diabetes Associates, PA, Miami, Florida, United States|Physicians Research Associates, LLC, Lawrenceville, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States|Midwest Endocrinology, Crystal Lake, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Diabetes anddocrine Associates, PC, Omaha, Nebraska, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Albany Medical Center / Albany Medical College, Albany, New York, United States|University Physicians Group Research Division, Staten Island, New York, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|The Carl and Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|Diabetes and Obesity Clinical Trials Center, Nashville, Tennessee, United States|North Texas Endocrine Center, Dallas, Texas, United States|Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States|Texas Diabetes and Endocrinology, Round Rock, Texas, United States|Bateman Horne Center, Salt Lake City, Utah, United States|Advanced Research Institute, South Ogden, Utah, United States|Larry D Stonesifer, MD Inc., PS, Federal Way, Washington, United States|Rainier Clinical Research Center, Inc, Renton, Washington, United States|The Polyclinic, Seattle, Washington, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Coffs Endocrine & Diabetes Services, Coffs Harbour, New South Wales, Australia|AIM Centre, Merewether, New South Wales, Australia|Royal Brisbane & Women's Hospital-Endocrinology, Herston, Queensland, Australia|VIVIT Instit.am LKH Feldkirch,Abt.f.Innere Med.u.Kardiologie, Feldkirch, Austria|LKH Steyr, Kardiologie, Steyr, Austria|KH Rudolfstiftung, 1. Med. Abt., Wien, Wien, Austria|Hospital Hietzing, Wien, Austria|Arlon - HOSP Sud Luxembourg - Vivalia, Arlon, Belgium|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|ULB Hopital Erasme, Bruxelles, Belgium|Edegem - UNIV UZ Antwerpen, Edegem, Belgium|UNIV UZ Gent, Gent, Belgium|La Louvière - UNIV CHU Tivoli, La Louvière, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Liège - HOSP CHR de la Citadelle, Liège, Belgium|Merksem - HOSP ZNA Jan Palfijn, Merksem, Belgium|LMC Endocrinology Centres (Calgary) Ltd., Calgary, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|CHUM - Pavillon R, Montreal, Migration Data, Canada|Capital District Health Auth., Halifax, Nova Scotia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|LMC Thornhill/Vaughan, Thornhill, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|General Univ.hosp.in Prague (VFN), Diabetes ambulance, Praha 2, Czechia|Diabetology and Internal Practice Dr. Vladimir Lelek, Slany, Czechia|Masaryk Hospital, Internal Department, Usti nad Labem, Czechia|Aalborg Sygehus Syd, Aalborg, Denmark|Aarhus Universitets Hospital, Aarhus C, Denmark|Steno Diabetes Center Copenhagen, Gentofte, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Køge Sygehus, Køge, Denmark|IteLasaretti, Kuopio, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|TYKS, Turku, Finland|HOP Côte de Nacre, Caen, France|HOP Saint-Louis, La Rochelle Cedex 1, France|HOP de Narbonne, diabéto endo, Narbonne, Narbonne, France|HOP Robert Debré, Reims, France|HOP de Brabois, Vandoeuvre-lès-Nancy, France|HOP les Portes du Sud, Diabéto, Vénissieux, Vénissieux, France|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Gemeinschaftspraxis, Asslar, Asslar, Germany|ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH, Berlin, Germany|InnoDiab Forschung GmbH, Essen, Germany|Praxis Dr. Kosch, Pirna, Pirna, Germany|Allgemeinmedizinische und Diabetologische Schwerpunktpraxis, Rehlingen-Siersburg, Germany|Praxis Dr. Hirschhäuser, Saarbrücken, Germany|Praxis Dr. Segner, St. Ingbert, Saint Ingbert/Oberwürzbach, Germany|Ambulanzzentrum Schweinfurt, Schweinfurt, Germany|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Bethesda Ziekenhuis Hoogeveen, Hoogeveen, Netherlands|Sint Franciscus Gasthuis, Rotterdam, Netherlands|Albert Schweitzer Ziekenhuis, Zwijndrecht, Zwijndrecht, Netherlands|Sykehuset Innlandet HF, Avd. Hamar, Hamar, Norway|Akershus Universitetssykehus HF, Lørenskog, Norway|Oslo Universitetssykehus HF, Aker Sykehus, Oslo, Norway|Helse Møre og Romsdal HF, Ålesund sjukehus, Ålesund, Norway|Med Univ Bialystok Clin Dep Endocrinol, Diabetol & Int Dis, Bialystok, Poland|NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny, Bialystok, Poland|Dobry Lekarz,Spec.Med.Clinics,Private Prac,Krakow, Krakow, Poland|NZOZ Specialized Ambulance ""MEDICA"", Lublin, Poland|Marcinkowski Poznan Univ of Med Sci, Clin Dept Diab, Poznan, Poznan, Poland|NZOZ Centrum Medyczne AESKULAP,Private Prac, Radom, Radom, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|NBR Polska, Warsaw, Poland|C.A.P. Sardenya, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Ladulaas Kliniska Studier, Borås, Sweden|Centralsjukhuset, Karlstad, Karlstad, Sweden|Läkarhuset, Vällingby, Vällingby, Sweden|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Milton Keynes Hospital, Buckinghamshire, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Wellcome Trust Clinical Research Facility, Edinburgh, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Royal London Hospital, London, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom|East Surrey Hospital, Surrey, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02414958/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02414958/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02414958
422,NCT03351478,Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sotagliflozin|Drug: Empagliflozin|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 8408035, Birmingham, Alabama, United States|Investigational Site Number 8408028, Sheffield, Alabama, United States|Investigational Site Number 8408047, Hawaiian Gardens, California, United States|Investigational Site Number 8408031, Spring Valley, California, United States|Investigational Site Number 8408067, Van Nuys, California, United States|Investigational Site Number 8408069, Northglenn, Colorado, United States|Investigational Site Number 8408009, Miami, Florida, United States|Investigational Site Number 8408049, Ocoee, Florida, United States|Investigational Site Number 8408005, Orlando, Florida, United States|Investigational Site Number 8408040, Orlando, Florida, United States|Investigational Site Number 8408019, Palmetto Bay, Florida, United States|Investigational Site Number 8408064, Port Charlotte, Florida, United States|Investigational Site Number 8408061, Columbus, Georgia, United States|Investigational Site Number 8408074, Macon, Georgia, United States|Investigational Site Number 8408079, Savannah, Georgia, United States|Investigational Site Number 8408059, Statesboro, Georgia, United States|Investigational Site Number 8408051, Blackfoot, Idaho, United States|Investigational Site Number 8408033, Elgin, Illinois, United States|Investigational Site Number 8408003, New Orleans, Louisiana, United States|Investigational Site Number 8408002, Rockville, Maryland, United States|Investigational Site Number 8408044, Fall River, Massachusetts, United States|Investigational Site Number 8408008, Flint, Michigan, United States|Investigational Site Number 8408027, West Seneca, New York, United States|Investigational Site Number 8408037, Fayetteville, North Carolina, United States|Investigational Site Number 8408053, Greensboro, North Carolina, United States|Investigational Site Number 8408012, Greensboro, North Carolina, United States|Investigational Site Number 8408013, Salisbury, North Carolina, United States|Investigational Site Number 8408045, Oklahoma City, Oklahoma, United States|Investigational Site Number 8408068, Warwick, Rhode Island, United States|Investigational Site Number 8408060, Fort Mill, South Carolina, United States|Investigational Site Number 8408018, Jefferson City, Tennessee, United States|Investigational Site Number 8408010, Knoxville, Tennessee, United States|Investigational Site Number 8408038, Knoxville, Tennessee, United States|Investigational Site Number 8408072, Brownsville, Texas, United States|Investigational Site Number 8408056, Dallas, Texas, United States|Investigational Site Number 8408082, Dallas, Texas, United States|Investigational Site Number 8408052, Dallas, Texas, United States|Investigational Site Number 8408001, Houston, Texas, United States|Investigational Site Number 8408032, Houston, Texas, United States|Investigational Site Number 8408016, Houston, Texas, United States|Investigational Site Number 8408017, Houston, Texas, United States|Investigational Site Number 8408036, Houston, Texas, United States|Investigational Site Number 8408022, Houston, Texas, United States|Investigational Site Number 8408029, Katy, Texas, United States|Investigational Site Number 8408054, McAllen, Texas, United States|Investigational Site Number 8408039, Mesquite, Texas, United States|Investigational Site Number 8408042, Plano, Texas, United States|Investigational Site Number 8408011, San Antonio, Texas, United States|Investigational Site Number 8408041, Schertz, Texas, United States|Investigational Site Number 8408007, Bountiful, Utah, United States|Investigational Site Number 8408026, Holladay, Utah, United States|Investigational Site Number 8408006, Burke, Virginia, United States|Investigational Site Number 8408004, Manassas, Virginia, United States|Investigational Site Number 1008011, Gabrovo, Bulgaria|Investigational Site Number 1008006, Plovdiv, Bulgaria|Investigational Site Number 1008001, Plovdiv, Bulgaria|Investigational Site Number 1008005, Ruse, Bulgaria|Investigational Site Number 1008007, Ruse, Bulgaria|Investigational Site Number 1008002, Smolyan, Bulgaria|Investigational Site Number 1008008, Sofia, Bulgaria|Investigational Site Number 1008012, Sofia, Bulgaria|Investigational Site Number 1008003, Stara Zagora, Bulgaria|Investigational Site Number 1008010, Stara Zagora, Bulgaria|Investigational Site Number 1008004, Varna, Bulgaria|Investigational Site Number 1248001, Brampton, Canada|Investigational Site Number 1248007, Burlington, Canada|Investigational Site Number 1248003, Newmarket, Canada|Investigational Site Number 1248010, Quebec, Canada|Investigational Site Number 1248009, Sherbrooke, Canada|Investigational Site Number 1248002, Thornhill, Canada|Investigational Site Number 1248004, Toronto, Canada|Investigational Site Number 1248011, Toronto, Canada|Investigational Site Number 1248005, Vancouver, Canada|Investigational Site Number 1248008, Victoriaville, Canada|Investigational Site Number 2038007, Brandys, Czechia|Investigational Site Number 2038003, Havirov, Czechia|Investigational Site Number 2038004, Krnov, Czechia|Investigational Site Number 2038011, Ostrava, Czechia|Investigational Site Number 2038006, Pardubice, Czechia|Investigational Site Number 2038010, Plzen, Czechia|Investigational Site Number 2038005, Prague, Czechia|Investigational Site Number 2038001, Praha 10 - Uhrineves, Czechia|Investigational Site Number 2038009, Praha 1, Czechia|Investigational Site Number 2038013, Praha 2, Czechia|Investigational Site Number 2038002, Praha 4, Czechia|Investigational Site Number 2038008, Praha 9, Czechia|Investigational Site Number 2508005, Corbeil-Essonnes, France|Investigational Site Number 2508006, La Roche Sur Yon, France|Investigational Site Number 2508007, La Tronche, France|Investigational Site Number 2508003, Mulhouse, France|Investigational Site Number 2508002, Nantes Cedex 1, France|Investigational Site Number 2508001, Paris, France|Investigational Site Number 2508004, Saint-Mandé, France|Investigational Site Number 3808010, Catania, Italy|Investigational Site Number 3808003, Catania, Italy|Investigational Site Number 3808002, Chieti, Italy|Investigational Site Number 3808004, Milano, Italy|Investigational Site Number 3808005, Milano, Italy|Investigational Site Number 3808009, Pavia, Italy|Investigational Site Number 3808008, Roma, Italy|Investigational Site Number 3808001, Roma, Italy|Investigational Site Number 3808007, Roma, Italy|Investigational Site Number 3808011, San Giovanni Rotondo, Italy|Investigational Site Number 3808006, Siena, Italy|Investigational Site Number 4288004, Kuldiga, Latvia|Investigational Site Number 4288008, Limbazi, Latvia|Investigational Site Number 4288003, Ogre, Latvia|Investigational Site Number 4288007, Riga, Latvia|Investigational Site Number 4288001, Riga, Latvia|Investigational Site Number 4288002, Riga, Latvia|Investigational Site Number 4288006, Sigulda, Latvia|Investigational Site Number 4288005, Talsi, Latvia|Investigational Site Number 4848002, Chihuahua, Mexico|Investigational Site Number 4848003, Cuernavaca, Mexico|Investigational Site Number 4848007, Durango, Durango, Mexico|Investigational Site Number 4848011, Mexico City, Mexico|Investigational Site Number 4848005, Monterrey, Mexico|Investigational Site Number 4848001, Monterrey, Mexico|Investigational Site Number 4848012, Monterrey, Mexico|Investigational Site Number 6438008, Chelyabinsk, Russian Federation|Investigational Site Number 6438006, Dzerzhinsky, Russian Federation|Investigational Site Number 6438009, Kemerovo, Russian Federation|Investigational Site Number 6438010, Novosibirsk, Russian Federation|Investigational Site Number 6438013, Saint-Petersburg, Russian Federation|Investigational Site Number 6438003, Saint-Petersburg, Russian Federation|Investigational Site Number 6438002, Saint-Petersburg, Russian Federation|Investigational Site Number 6438005, Saint-Petersburg, Russian Federation|Investigational Site Number 6438001, Saint-Petersburg, Russian Federation|Investigational Site Number 6438012, Saratov, Russian Federation|Investigational Site Number 6438014, St. Petersburg, Russian Federation|Investigational Site Number 6438015, Volgograd, Russian Federation|Investigational Site Number 6438007, Vsevolozhsk, Russian Federation|Investigational Site Number 6438011, Yaroslavl, Russian Federation|Investigational Site Number 7038005, Bardejov, Slovakia|Investigational Site Number 7038009, Bratislava, Slovakia|Investigational Site Number 7038001, Kosice, Slovakia|Investigational Site Number 7038006, Lucenec, Slovakia|Investigational Site Number 7038008, Nove Zamky, Slovakia|Investigational Site Number 7038004, Povazska Bystrica, Slovakia|Investigational Site Number 7038002, Roznava, Slovakia|Investigational Site Number 7038007, Sabinov, Slovakia|Investigational Site Number 7038003, Vrutky, Slovakia|Investigational Site Number 7248006, Barcelona, Spain|Investigational Site Number 7248002, Córdoba, Spain|Investigational Site Number 7248005, Malaga Malaga, Spain|Investigational Site Number 7248010, Santa Coloma De Gramenet, Spain|Investigational Site Number 7248009, Santiago De Compostela, Spain|Investigational Site Number 7248004, Sevilla, Spain|Investigational Site Number 7248008, Sevilla, Spain|Investigational Site Number 7248001, Sevilla, Spain|Investigational Site Number 7248003, Valencia Valencia, Spain|Investigational Site Number 7248007, Zaragoza, Spain|Investigational Site Number 8268008, Darlington, United Kingdom|Investigational Site Number 8268004, Dundee, United Kingdom|Investigational Site Number 8268006, Exeter, United Kingdom|Investigational Site Number 8268001, Hull, United Kingdom|Investigational Site Number 8268002, Huntingdon, United Kingdom|Investigational Site Number 8268007, Sheffield, United Kingdom|Investigational Site Number 8268003, Southampton, United Kingdom|Investigational Site Number 8268005, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03351478/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03351478/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03351478
423,NCT04328896,Telemedicine Monitoring of Nocturnal Incidents,Completed,No Results Available,"Diabetes Mellitus, Type 1|Hypoglycemia",Other: CGM-Tele-monitoring,University of Southern California,65 Years and older   (Older Adult),Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"USC Westside Center for Diabetes, Los Angeles, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04328896/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04328896
424,NCT02735044,Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus,Completed,Has Results,Type 1 Diabetes Mellitus,"Drug: Insulin glargine,300 U/mL|Drug: Insulin glargine (100 units /mL)|Drug: Background therapy",Sanofi,6 Years to 17 Years   (Child),Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400008, Tucson, Arizona, United States|Investigational Site Number 8400037, Atlanta, Georgia, United States|Investigational Site Number 8400032, Indianapolis, Indiana, United States|Investigational Site Number 8400015, Buffalo, New York, United States|Investigational Site Number 8400016, Chapel Hill, North Carolina, United States|Investigational Site Number 8400035, Morehead City, North Carolina, United States|Investigational Site Number 8400038, Oklahoma City, Oklahoma, United States|Investigational Site Number 8400030, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400010, Rapid City, South Dakota, United States|Investigational Site Number 8400005, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400029, Lufkin, Texas, United States|Investigational Site Number 8400034, Seattle, Washington, United States|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320004, Capital Federal, Argentina|Investigational Site Number 0320002, Capital Federal, Argentina|Investigational Site Number 0320006, Mendoza, Argentina|Investigational Site Number 0320005, Salta, Argentina|Investigational Site Number 0320007, San Miguel De Tucuman, Argentina|Investigational Site Number 0760005, Curitiba, Brazil|Investigational Site Number 0760006, Fortaleza, Brazil|Investigational Site Number 0760004, Fortaleza, Brazil|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 1000001, Plovdiv, Bulgaria|Investigational Site Number 1000005, Sofia, Bulgaria|Investigational Site Number 1000004, Varna, Bulgaria|Investigational Site Number 1240003, Halifax, Canada|Investigational Site Number 1240002, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240006, Sherbrooke, Canada|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520006, Santiago, Chile|Investigational Site Number 1520007, Temuco, Chile|Investigational Site Number 1520003, Viña Del Mar, Chile|Investigational Site Number 2030003, Hradec Kralove, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030001, Praha 5 - Motol, Czechia|Investigational Site Number 2080001, Herlev, Denmark|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500002, Toulouse, France|Investigational Site Number 2760002, Hannover, Germany|Investigational Site Number 2760001, Heidelberg, Germany|Investigational Site Number 2760004, Leipzig, Germany|Investigational Site Number 2760003, Münster, Germany|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480005, Gyula, Hungary|Investigational Site Number 3480002, Miskolc, Hungary|Investigational Site Number 3480006, Pécs, Hungary|Investigational Site Number 3480007, Székesfehérvár, Hungary|Investigational Site Number 3760003, Beer Sheva, Israel|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760006, Holon, Israel|Investigational Site Number 3760002, Petach Tikva, Israel|Investigational Site Number 3800001, Firenze, Italy|Investigational Site Number 3800005, Roma, Italy|Investigational Site Number 3800004, Torino, Italy|Investigational Site Number 3800006, Varese, Italy|Investigational Site Number 3800003, Verona, Italy|Investigational Site Number 3920006, Chiyoda-Ku, Japan|Investigational Site Number 3920002, Fukuoka-Shi, Japan|Investigational Site Number 3920003, Hiroshima-Shi, Japan|Investigational Site Number 3920007, Kobe-Shi, Japan|Investigational Site Number 3920005, Osaka-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 4280002, Daugavpils, Latvia|Investigational Site Number 4280001, Rīga, Latvia|Investigational Site Number 4840003, Durango, Mexico|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 4840004, México, Mexico|Investigational Site Number 4840002, Puebla, Mexico|Investigational Site Number 4840005, Veracruz, Mexico|Investigational Site Number 8070001, Skopje, North Macedonia|Investigational Site Number 6160005, Bielsko-Biala, Poland|Investigational Site Number 6160001, Gdansk, Poland|Investigational Site Number 6160006, Szczecin, Poland|Investigational Site Number 6160007, Warszawa, Poland|Investigational Site Number 6160004, Warszawa, Poland|Investigational Site Number 6160003, Warszawa, Poland|Investigational Site Number 6420005, Bucharest, Romania|Investigational Site Number 6420007, Constanta, Romania|Investigational Site Number 6420004, Craiova, Romania|Investigational Site Number 6420006, Sibiu, Romania|Investigational Site Number 6420003, Timisoara, Romania|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430004, Smolensk, Russian Federation|Investigational Site Number 6430002, St-Petersburg, Russian Federation|Investigational Site Number 6430003, Ufa, Russian Federation|Investigational Site Number 6880002, Belgrade, Serbia|Investigational Site Number 6880003, Belgrade, Serbia|Investigational Site Number 6880004, Nis, Serbia|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240003, Esplugues De Llobregat, Spain|Investigational Site Number 7240004, Sabadell, Spain|Investigational Site Number 7240006, Santa Cruz De Tenerife, Spain|Investigational Site Number 7240001, Vitoria, Spain|Investigational Site Number 7520002, Stockholm, Sweden|Investigational Site Number 8260005, Doncaster, United Kingdom|Investigational Site Number 8260001, Ipswich, United Kingdom|Investigational Site Number 8260004, Kettering, United Kingdom|Investigational Site Number 8260002, Salisbury, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02735044/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02735044/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02735044
425,NCT02738151,Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist,Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Insulin glargine, 300U/mL|Drug: Insulin degludec, 100 U/mL|Drug: Non-insulin anti-diabetic treatment",Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 840038, Sheffield, Alabama, United States|Investigational Site Number 840066, Phoenix, Arizona, United States|Investigational Site Number 840051, Anaheim, California, United States|Investigational Site Number 840081, Chino, California, United States|Investigational Site Number 840016, Huntington Park, California, United States|Investigational Site Number 840002, La Jolla, California, United States|Investigational Site Number 840091, Los Angeles, California, United States|Investigational Site Number 840058, Northridge, California, United States|Investigational Site Number 840021, Palm Springs, California, United States|Investigational Site Number 840087, Santa Ana, California, United States|Investigational Site Number 840030, Torrance, California, United States|Investigational Site Number 840065, Van Nuys, California, United States|Investigational Site Number 840075, Bradenton, Florida, United States|Investigational Site Number 840076, New Port Richey, Florida, United States|Investigational Site Number 840026, Ocoee, Florida, United States|Investigational Site Number 840052, Palm Harbor, Florida, United States|Investigational Site Number 840080, Palm Harbor, Florida, United States|Investigational Site Number 840018, Port Charlotte, Florida, United States|Investigational Site Number 840071, Lawrenceville, Georgia, United States|Investigational Site Number 840085, Roswell, Georgia, United States|Investigational Site Number 840072, Statesboro, Georgia, United States|Investigational Site Number 840039, Stockbridge, Georgia, United States|Investigational Site Number 840036, Arlington Heights, Illinois, United States|Investigational Site Number 840010, Chicago, Illinois, United States|Investigational Site Number 840005, Avon, Indiana, United States|Investigational Site Number 840063, Council Bluffs, Iowa, United States|Investigational Site Number 840098, Des Moines, Iowa, United States|Investigational Site Number 840101, Des Moines, Iowa, United States|Investigational Site Number 840096, West Des Moines, Iowa, United States|Investigational Site Number 840061, Paris, Kentucky, United States|Investigational Site Number 840011, Hyattsville, Maryland, United States|Investigational Site Number 840001, Rockville, Maryland, United States|Investigational Site Number 840041, Flint, Michigan, United States|Investigational Site Number 840057, Flint, Michigan, United States|Investigational Site Number 840033, Troy, Michigan, United States|Investigational Site Number 840084, Olive Branch, Mississippi, United States|Investigational Site Number 840048, Chesterfield, Missouri, United States|Investigational Site Number 840023, Las Vegas, Nevada, United States|Investigational Site Number 840045, Las Vegas, Nevada, United States|Investigational Site Number 840031, Linden, New Jersey, United States|Investigational Site Number 840060, Hickory, North Carolina, United States|Investigational Site Number 840064, Morganton, North Carolina, United States|Investigational Site Number 840043, Wilmington, North Carolina, United States|Investigational Site Number 840082, Winston-Salem, North Carolina, United States|Investigational Site Number 840025, Oklahoma City, Oklahoma, United States|Investigational Site Number 840022, Oklahoma City, Oklahoma, United States|Investigational Site Number 840029, Beaver, Pennsylvania, United States|Investigational Site Number 840056, Downingtown, Pennsylvania, United States|Investigational Site Number 840093, Anderson, South Carolina, United States|Investigational Site Number 840097, Greenville, South Carolina, United States|Investigational Site Number 840070, Greer, South Carolina, United States|Investigational Site Number 840044, North Myrtle Beach, South Carolina, United States|Investigational Site Number 840069, Simpsonville, South Carolina, United States|Investigational Site Number 840079, Bristol, Tennessee, United States|Investigational Site Number 840006, Chattanooga, Tennessee, United States|Investigational Site Number 840088, Knoxville, Tennessee, United States|Investigational Site Number 840077, New Tazewell, Tennessee, United States|Investigational Site Number 840007, Dallas, Texas, United States|Investigational Site Number 840086, Dallas, Texas, United States|Investigational Site Number 840027, Houston, Texas, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 840040, Houston, Texas, United States|Investigational Site Number 840046, Houston, Texas, United States|Investigational Site Number 840054, Hurst, Texas, United States|Investigational Site Number 840017, Mesquite, Texas, United States|Investigational Site Number 840008, Missouri City, Texas, United States|Investigational Site Number 840094, San Antonio, Texas, United States|Investigational Site Number 840009, Sugar Land, Texas, United States|Investigational Site Number 840053, Waco, Texas, United States|Investigational Site Number 840095, Ogden, Utah, United States|Investigational Site Number 840032, Salt Lake City, Utah, United States|Investigational Site Number 840024, Norfolk, Virginia, United States|Investigational Site Number 840020, Richmond, Virginia, United States|Investigational Site Number 840012, Renton, Washington, United States|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100002, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 191001, Rijeka, Croatia|Investigational Site Number 191002, Rijeka, Croatia|Investigational Site Number 191003, Zagreb, Croatia|Investigational Site Number 203009, Hlucin, Czechia|Investigational Site Number 203006, Jilove u Prahy, Czechia|Investigational Site Number 203005, Liberec, Czechia|Investigational Site Number 203001, Pardubice, Czechia|Investigational Site Number 203007, Praha 1, Czechia|Investigational Site Number 203008, Praha 2, Czechia|Investigational Site Number 203002, Praha 8, Czechia|Investigational Site Number 203004, Vsetin, Czechia|Investigational Site Number 208003, Aarhus, Denmark|Investigational Site Number 208002, Hillerød, Denmark|Investigational Site Number 208001, København NV., Denmark|Investigational Site Number 208004, Odense, Denmark|Investigational Site Number 250002, La Roche Sur Yon, France|Investigational Site Number 250003, La Rochelle Cedex 1, France|Investigational Site Number 250001, Nantes cedex 01, France|Investigational Site Number 250006, Nimes, France|Investigational Site Number 250005, POITIERS Cedex, France|Investigational Site Number 250007, Venissieux, France|Investigational Site Number 300005, Alexandroupolis, Greece|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300003, Athens, Greece|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348003, Gyöngyös, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376004, Haifa, Israel|Investigational Site Number 376008, Haifa, Israel|Investigational Site Number 376009, Kfar Saba, Israel|Investigational Site Number 376002, Petach tikva, Israel|Investigational Site Number 376006, Tel Aviv, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 376007, Tel-Aviv, Israel|Investigational Site Number 380007, Bari, Italy|Investigational Site Number 380009, Catanzaro, Italy|Investigational Site Number 380010, Chieti, Italy|Investigational Site Number 380014, Milano, Italy|Investigational Site Number 380002, Moncalieri, Italy|Investigational Site Number 380011, Napoli, Italy|Investigational Site Number 380008, Roma, Italy|Investigational Site Number 380015, Roma, Italy|Investigational Site Number 380016, Roma, Italy|Investigational Site Number 380013, Sesto San Giovanni, Italy|Investigational Site Number 380005, Torino, Italy|Investigational Site Number 380012, Verona, Italy|Investigational Site Number 642007, Brasov, Romania|Investigational Site Number 642008, Brasov, Romania|Investigational Site Number 642001, Bucharest, Romania|Investigational Site Number 642013, Bucharest, Romania|Investigational Site Number 642015, Bucuresti, Romania|Investigational Site Number 642003, Cluj-Napoca, Romania|Investigational Site Number 642009, Constanta, Romania|Investigational Site Number 642014, Iasi, Romania|Investigational Site Number 642005, Oradea, Romania|Investigational Site Number 642012, Oradea, Romania|Investigational Site Number 642010, Targu-Mures, Romania|Investigational Site Number 642004, Targu-Mures, Romania|Investigational Site Number 642006, Targu-Mures, Romania|Investigational Site Number 688001, Belgrade, Serbia|Investigational Site Number 688002, Nis, Serbia|Investigational Site Number 688003, Nis, Serbia|Investigational Site Number 703006, Kosice, Slovakia|Investigational Site Number 703002, Lubochna, Slovakia|Investigational Site Number 703001, Moldava nad Bodvou, Slovakia|Investigational Site Number 703003, Sabinov, Slovakia|Investigational Site Number 703005, Trebisov, Slovakia|Investigational Site Number 752102, Lund, Sweden|Investigational Site Number 752101, Skövde, Sweden|Investigational Site Number 756003, Olten, Switzerland|Investigational Site Number 756001, St. Gallen, Switzerland|Investigational Site Number 826001, Chertsey, United Kingdom|Investigational Site Number 826005, Gillingham, United Kingdom|Investigational Site Number 826008, Lincoln, United Kingdom|Investigational Site Number 826002, London, United Kingdom|Investigational Site Number 826009, Manchester, United Kingdom|Investigational Site Number 826006, Margate, United Kingdom|Investigational Site Number 826004, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02738151/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02738151/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02738151
426,NCT01650259,Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: OAD|Drug: Trazenta,Boehringer Ingelheim|Eli Lilly and Company,"Child, Adult, Older Adult",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"One Or Multiple Locations, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT01650259/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT01650259/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01650259
427,NCT02413398,A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10 mg|Drug: Matching Placebo for Dapagliflozin,AstraZeneca,"18 Years to 74 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Huntsville, Alabama, United States|Research Site, Burbank, California, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, Fullerton, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, Newport Beach, California, United States|Research Site, Salinas, California, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Brownsburg, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Flint, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Manassas, Virginia, United States|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Red Deer, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Cheb, Czechia|Research Site, Horovice, Czechia|Research Site, Krnov, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Praha 10, Czechia|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Chieti Scalo, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Pisa, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Bielsko-Biała, Poland|Research Site, Bydgoszcz, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Tczew, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, A Coruña, Spain|Research Site, Alicante, Spain|Research Site, Ferrol, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pozuelo de Alarcon, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02413398/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02413398/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02413398
428,NCT02660242,The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: G-Pen Mini™ (glucagon injection)|Other: Glucose Tabs|Other: Basal Insulin Reduction,Jaeb Center for Health Research|Xeris Pharmaceuticals,18 Years to 64 Years   (Adult),Phase 2,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Joslin Diabetes Center, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02660242/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02660242
429,NCT01927562,Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes,Completed,Has Results,Type II Diabetes,Device: Fractyl Duodenal Remodeling System,"Fractyl Laboratories, Inc.","28 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"INDISA, Santiago, Chile","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01927562/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01927562/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01927562
430,NCT03387683,"A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients",Completed,Has Results,Diabetes Mellitus Type 2,Drug: dapagliflozin|Drug: placebo,AstraZeneca,"40 Years to 75 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Turku, Finland|Research Site, Uppsala, Sweden","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03387683/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03387683/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03387683
431,NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Insulin glargine/lixisenatide fixed ratio combination|Drug: liraglutide|Drug: exenatide|Drug: exenatide extended-release|Drug: albiglutide|Drug: dulaglutide|Drug: Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400064, Birmingham, Alabama, United States|Investigational Site Number 8400073, Fountain Hills, Arizona, United States|Investigational Site Number 8400047, Phoenix, Arizona, United States|Investigational Site Number 8400103, Bakersfield, California, United States|Investigational Site Number 8400137, Fresno, California, United States|Investigational Site Number 8400043, Huntington Park, California, United States|Investigational Site Number 8400124, Lamont, California, United States|Investigational Site Number 8400027, Lancaster, California, United States|Investigational Site Number 8400098, Los Angeles, California, United States|Investigational Site Number 8400013, Los Angeles, California, United States|Investigational Site Number 8400042, Mission Hills, California, United States|Investigational Site Number 8400006, Northridge, California, United States|Investigational Site Number 8400021, Orange, California, United States|Investigational Site Number 8400126, Rialto, California, United States|Investigational Site Number 8400094, Santa Ana, California, United States|Investigational Site Number 8400009, Ventura, California, United States|Investigational Site Number 8400071, Denver, Colorado, United States|Investigational Site Number 8400036, Denver, Colorado, United States|Investigational Site Number 8400114, Jacksonville, Florida, United States|Investigational Site Number 8400133, Miami, Florida, United States|Investigational Site Number 8400058, Port Charlotte, Florida, United States|Investigational Site Number 8400084, Tampa, Florida, United States|Investigational Site Number 8400112, West Palm Beach, Florida, United States|Investigational Site Number 8400045, Lawrenceville, Georgia, United States|Investigational Site Number 8400096, Snellville, Georgia, United States|Investigational Site Number 8400023, Springfield, Illinois, United States|Investigational Site Number 8400049, Avon, Indiana, United States|Investigational Site Number 8400053, Avon, Indiana, United States|Investigational Site Number 8400085, Avon, Indiana, United States|Investigational Site Number 8400120, Avon, Indiana, United States|Investigational Site Number 8400041, Evansville, Indiana, United States|Investigational Site Number 8400038, Indianapolis, Indiana, United States|Investigational Site Number 8400130, Council Bluffs, Iowa, United States|Investigational Site Number 8400034, Lexington, Kentucky, United States|Investigational Site Number 8400091, Lexington, Kentucky, United States|Investigational Site Number 8400078, Marrero, Louisiana, United States|Investigational Site Number 8400032, Metairie, Louisiana, United States|Investigational Site Number 8400088, New Orleans, Louisiana, United States|Investigational Site Number 8400033, Baltimore, Maryland, United States|Investigational Site Number 8400051, Jefferson City, Missouri, United States|Investigational Site Number 8400083, Papillion, Nebraska, United States|Investigational Site Number 8400044, Henderson, Nevada, United States|Investigational Site Number 8400079, Albany, New York, United States|Investigational Site Number 8400061, New York, New York, United States|Investigational Site Number 8400123, North Massapequa, New York, United States|Investigational Site Number 8400095, Staten Island, New York, United States|Investigational Site Number 8400067, West Seneca, New York, United States|Investigational Site Number 8400111, Yonkers, New York, United States|Investigational Site Number 8400020, Morehead City, North Carolina, United States|Investigational Site Number 8400065, Wilmington, North Carolina, United States|Investigational Site Number 8400018, Fargo, North Dakota, United States|Investigational Site Number 8400019, Columbus, Ohio, United States|Investigational Site Number 8400056, Dayton, Ohio, United States|Investigational Site Number 8400125, Mentor, Ohio, United States|Investigational Site Number 8400099, Oklahoma City, Oklahoma, United States|Investigational Site Number 8400129, Scottdale, Pennsylvania, United States|Investigational Site Number 8400076, Smithfield, Pennsylvania, United States|Investigational Site Number 8400104, Warwick, Rhode Island, United States|Investigational Site Number 8400090, Columbia, South Carolina, United States|Investigational Site Number 8400139, Austin, Texas, United States|Investigational Site Number 8400001, Dallas, Texas, United States|Investigational Site Number 8400118, Edinburg, Texas, United States|Investigational Site Number 8400008, Houston, Texas, United States|Investigational Site Number 8400109, Houston, Texas, United States|Investigational Site Number 8400063, Houston, Texas, United States|Investigational Site Number 8400106, Houston, Texas, United States|Investigational Site Number 8400014, North Richland Hills, Texas, United States|Investigational Site Number 8400089, San Antonio, Texas, United States|Investigational Site Number 8400135, Schertz, Texas, United States|Investigational Site Number 8400075, Shavano Park, Texas, United States|Investigational Site Number 8400107, Sugar Land, Texas, United States|Investigational Site Number 8400054, Orem, Utah, United States|Investigational Site Number 8400025, Salt Lake City, Utah, United States|Investigational Site Number 8400092, Weber City, Virginia, United States|Investigational Site Number 1240003, Burlington, Canada|Investigational Site Number 1240006, Corunna, Canada|Investigational Site Number 1240002, Red Deer, Canada|Investigational Site Number 1240001, Vancouver, Canada|Investigational Site Number 2330002, Pärnu, Estonia|Investigational Site Number 2330003, Tallinn, Estonia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2330004, Viljandi, Estonia|Investigational Site Number 2760001, Dresden, Germany|Investigational Site Number 2760003, Oldenburg In Holstein, Germany|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760002, Haifa, Israel|Investigational Site Number 3760005, Jerusalem, Israel|Investigational Site Number 3760006, Jerusalem, Israel|Investigational Site Number 3760004, Tel Aviv, Israel|Investigational Site Number 3800008, Bergamo, Italy|Investigational Site Number 3800002, Bologna, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800006, Milano, Italy|Investigational Site Number 3800005, Napoli, Italy|Investigational Site Number 3800004, Roma, Italy|Investigational Site Number 3800003, Roma, Italy|Investigational Site Number 6420004, Bacau, Romania|Investigational Site Number 6420006, Brasov, Romania|Investigational Site Number 6420001, Bucuresti, Romania|Investigational Site Number 6420008, Buzau, Romania|Investigational Site Number 6420003, Cluj Napoca, Romania|Investigational Site Number 6420002, Oradea, Romania|Investigational Site Number 6420009, Targoviste, Romania|Investigational Site Number 6420005, Timisoara, Romania|Investigational Site Number 6420007, Târgu-Mureş, Romania|Investigational Site Number 7030006, Bratislava, Slovakia|Investigational Site Number 7030009, Lubochna, Slovakia|Investigational Site Number 7030002, Lucenec, Slovakia|Investigational Site Number 7030005, Malacky, Slovakia|Investigational Site Number 7030007, Presov, Slovakia|Investigational Site Number 7030001, Roznava, Slovakia|Investigational Site Number 7030008, Sabinov, Slovakia|Investigational Site Number 7030004, Trencin, Slovakia|Investigational Site Number 7030003, Zilina, Slovakia|Investigational Site Number 7240012, Alzira, Spain|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240002, Ferrol, Spain|Investigational Site Number 7240008, Málaga, Spain|Investigational Site Number 7240011, Pozuelo De Alarcón, Spain|Investigational Site Number 7240003, Quart De Poblet, Spain|Investigational Site Number 7240006, Sabadell, Spain|Investigational Site Number 7240007, Sevilla, Spain|Investigational Site Number 7240009, sEVILLA, Spain|Investigational Site Number 7240004, Sevilla, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02787551/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02787551/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02787551
432,NCT03586830,A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Obesity and Diabetes Mellitus, Type 2",Drug: JNJ-64565111 Dose Level 1|Drug: JNJ-64565111 Dose Level 2|Drug: JNJ-64565111 Dose Level 3|Drug: Placebo,"Janssen Research & Development, LLC","18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Central Research Associates, Inc., Birmingham, Alabama, United States|National Research Institute, Los Angeles, California, United States|Rancho Cucamonga Clinical Trials, Rancho Cucamonga, California, United States|Sierra Clinical Research, Roseville, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Premeir Clinical Research Institute, Miami, Florida, United States|International Research Associates, LLC, Miami, Florida, United States|CNS HealthCare, Orlando, Florida, United States|Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|M.D. Medical Research, Oxon Hill, Maryland, United States|AAMRC, Flint, Michigan, United States|Alas Science Clinical Research, Henderson, Nevada, United States|Prestige Clinical Research, Franklin, Ohio, United States|Albert J. Weisbrot and Associates, Mason, Ohio, United States|Clinical Research Institute of Southern Oregon, P.C., Medford, Oregon, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Heritage Valley Medical Group, Beaver, Pennsylvania, United States|Clinical Research Associates Inc, Nashville, Tennessee, United States|Dallas Diabetes & Endocrine Center at Medical City, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Spectrum Medical, Inc, Danville, Virginia, United States|Dominion Medical Associates, Inc., Richmond, Virginia, United States|National Clinical Research, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03586830/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03586830/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03586830
433,NCT02409329,Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Behavioral: REACH|Behavioral: Helpline and A1c results|Behavioral: REACH + FAMS,Vanderbilt University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care,"Federally Qualified Health Centers and Vanderbilt Primary Care Clinics, Nashville, Tennessee, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02409329/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT02409329/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02409329
434,NCT03152552,A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure,Terminated,Has Results,Diabetes Mellitus and Heart Failure,Drug: LIK066|Drug: Placebo|Drug: Empagliflozin,Novartis Pharmaceuticals|Novartis,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Carmichael, California, United States|Novartis Investigative Site, Concord, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Delray Beach, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Bogalusa, Louisiana, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Lennik, Brussels, Belgium|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, St-Jerome, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Krapinske toplice, Croatia|Novartis Investigative Site, Rijeka, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brandys nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Svitavy, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Karvina, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Prerov, Czechia|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Bad Oeynhausen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, San Donato Milanese, MI, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Rimini, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Wonju, Gangwon-Do, Korea, Republic of|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Loerenskog, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Paarl, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, London, GBR, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03152552/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03152552/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03152552
435,NCT04215328,Facilitated Release of Endogenous Enterokines,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Mixed-Meal|Dietary Supplement: Electrolyte Solution,University of Southern California|Halyard Health|Wallace H. Coulter Foundation,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,"Roybal Diabetes Management Clinic, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04215328/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04215328
436,NCT02984709,Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes,Completed,Has Results,Type1diabetes,Behavioral: Positive Psychology Intervention|Behavioral: Education,Vanderbilt University|Vanderbilt University Medical Center,13 Years to 17 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02984709/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02984709/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02984709
437,NCT05188625,Online Self-learning for Women With Gestational Diabetes Mellitus,Completed,No Results Available,Gestational Diabetes,Other: Telesupport - Telehealth,KK Women's and Children's Hospital,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"KK Women's and Children's Hospital, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT05188625/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT05188625/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05188625
438,NCT01897532,Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA),Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Placebo|Drug: Linagliptin,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Longwood Research, Huntsville, Alabama, United States|Scottsboro Quick Care Clinic, Scottsboro, Alabama, United States|Office of Dr. Terence T. Hart MD, Tuscumbia, Alabama, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Precision Trials, LLC, Phoenix, Arizona, United States|Harrisburg Family Medical Center, Harrisburg, Arkansas, United States|Cardiology and Medicine Clinic, Little Rock, Arkansas, United States|Little Rock Diagnostic Clinic, Little Rock, Arkansas, United States|Kaiser Permanente - San Diego, Bonita, Bonita, California, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Research, Fresno, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Clearview Medical Research, LLC, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Office of Dr. Richard S. Cherlin, Los Gatos, California, United States|Coastal Medical Research Group, Los Osos, California, United States|Novo Research, Incorporated, Modesto, California, United States|Providence Clinical Research, North Hollywood, California, United States|Northridge Clinical Research Inc., Northridge, California, United States|Carr Cardiology, Oceanside, California, United States|Center for Clinical Trials of Sacramento, Incorporated, Sacramento, California, United States|North America Research Institute, San Dimas, California, United States|Trinitas Research, Incorporated, San Jose, California, United States|Metabolic Institute of America, Tarzana, California, United States|Center for Clinical Trials of San Gabriel, West Covina, California, United States|Western Nephrology & Metabolic, Arvada, Colorado, United States|South Denver Nephrology, Denver, Colorado, United States|Colorado Center for Bone Research, P.C., Golden, Colorado, United States|Helix Biomedics LLC, Boynton Beach, Florida, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Nova Clinical Research, LLC, Bradenton, Florida, United States|PAB Clinical Research, Brandon, Florida, United States|Meridien Research, Brooksville, Florida, United States|Southeast Clinical Research, LLC, Chiefland, Florida, United States|BayCare Medical Group, Clearwater, Florida, United States|Cohen Medical Research Associates, LLC, Delray Beach, Florida, United States|Innovation Medical Research Center, Inc, Doral, Florida, United States|Integrative Research Associates, Fort Lauderdale, Florida, United States|Jellinger and Lerman, MD, PA dba The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|Direct Helpers Medical Center, Inc, Hialeah, Florida, United States|Universal Clinical Research, Hialeah, Florida, United States|Homestead Associates in Research, Homestead, Florida, United States|St. Vincent's Cardiology, Jacksonville, Florida, United States|Care Partners Clinical Research LLC, Jacksonville, Florida, United States|Altus Research, Inc., Lake Clarke Shores, Florida, United States|Meridien Research, Lakeland, Florida, United States|Precision Research Organization, Miami Lakes, Florida, United States|Clinical Research of Miami, Miami, Florida, United States|Prestige Clinical Research Center, Inc., Miami, Florida, United States|Jesscan Medical Research, Internal Medicine, Miami, Florida, United States|Clintex Research Group, Inc. Research, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Florida Medical Center & Research Inc, Miami, Florida, United States|A+ Research Incorporated, Miami, Florida, United States|Unlimited Medical Research, LLC, Miami, Florida, United States|Regenerate Clinical Trials, Miami, Florida, United States|Sanitas Research, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|Research Institute of South Florida Inc, Miami, Florida, United States|Tellus Clinical Research, Incorporated, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Kendall South Medical Center, Inc, Miami, Florida, United States|Coral Research Clinic Corp, Miami, Florida, United States|School of Clinical Research, North Miami Beach, Florida, United States|Harmony Clinical Research, Incorporated, North Miami Beach, Florida, United States|Magnolia Research Group, Ocala, Florida, United States|Family Medical Center, Orlando, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Infinity Clinical Research, LLC, Plantation, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Professional Health Care of Pinellas, Inc., Saint Petersburg, Florida, United States|Intercoastal Medical Group, Endocrinology, Sarasota, Florida, United States|Meridien Research, Tampa, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Laureate Clinical Research Group, LLC, Atlanta, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|Atlanta Heart Specialists, LLC, Cumming, Georgia, United States|McGarity, Jr., William C., Decatur, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States|Belleville Family Medical Associates, Ltd, Belleville, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States|Associates in Endocrinology, Incorporated, Elgin, Illinois, United States|Kidney Care Center, Nephrology, Joliet, Illinois, United States|American Health Network, Avon, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|American Health Network of Indiana, LLC, Greenfield, Indiana, United States|American Health Network of Indiana, LLC, Muncie, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|The Research Group of Lexington, LLC, Lexington, Kentucky, United States|Diabetes and Metabolism Associates APMC, Metairie, Louisiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Maryland Cardiovascular Specialists, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Delmarva Heart Research Foundation, Inc, Salisbury, Maryland, United States|Endeavor Medical Research, Alpena, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Aa Mrc Llc, Flint, Michigan, United States|McLaren Northern Michigan Hospital, Petoskey, Michigan, United States|Remedica LLC, Rochester, Michigan, United States|Tri-County Research, Inc, Sterling Heights, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|HealthEast St. Joseph's Hospital, Saint Paul, Minnesota, United States|Mississippi Medical Research, LLC, Carriere, Mississippi, United States|Truman Medical Centers, Inc., Kansas City, Missouri, United States|Kansas City Veterans Administration Medical Center, Kansas City, Missouri, United States|Glacier View Cardiology, PC, Kalispell, Montana, United States|Platte River Nephrology, North Platte, Nebraska, United States|Omaha Veterans Affairs Medical Center, Omaha, Nebraska, United States|Alas Science Clinical Research, Las Vegas, Nevada, United States|USMA Clin. Research/Union Square Med. Associates, Elizabeth, New Jersey, United States|Mount Sinai - PRIME, Linden, New Jersey, United States|New Mexico Clinical Research and Osteoporosis Center, Inc., Albuquerque, New Mexico, United States|Jacobi Medical Center, Bronx, New York, United States|Life Medi-Research and Management, Brooklyn, New York, United States|United Medical Associates, Johnson City, New York, United States|Saratoga Clinical Research, LLC, Saratoga Springs, New York, United States|Kernodle Clinic West, Burlington, North Carolina, United States|Main Street Physicians Care, Calabash, North Carolina, United States|Box Arthritis & Rheumatology of the Carolinas, Charlotte, North Carolina, United States|Clinical Research of Gastonia, Gastonia, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|PMG Research of Bristol, LLC, Hickory, North Carolina, United States|Novant Health Southern Piedmont Primary Care, Monroe, North Carolina, United States|Research Institute of the Carolinas, PLC, Mooresville, North Carolina, United States|Down East Medical Associates, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|Natalie A Doyle, M.D., P.A., Wilson, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Medical Frontiers, LLC, Carlisle, Ohio, United States|Dayton VA Medical Center, Dayton, Ohio, United States|Norton Community Care, Norton, Ohio, United States|Apex Medical Research, AMR, Incorporated, Springfield, Ohio, United States|ProMedica Health Education & Research Corp., Toledo, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|The Corvallis Clinic, PC, Corvallis, Oregon, United States|Blair Medical Associates, Altoona, Pennsylvania, United States|Clinical Research Associates of Central Pennsylvania, Altoona, Pennsylvania, United States|Central Bucks Cardiology, Doylestown, Pennsylvania, United States|Doylestown Health Cardiology, Doylestown, Pennsylvania, United States|Lycoming Internal Medicine, Inc, Jersey Shore, Pennsylvania, United States|Montgomery Medical Incorporated, Smithfield, Pennsylvania, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Spectrum Medical Research, LLC, Gaffney, South Carolina, United States|VitaLink Research, Greenville, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|Vita Link Research- Rock Hill, Rock Hill, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|State of Franklin Healthcare Associates, PLLC, Johnson City, Tennessee, United States|DCT- AACT, LLC dba Discovery Clinical Trials, Austin, Texas, United States|Rockwood Medical Clinic, Bedford, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|The Endocrine Center, Houston, Texas, United States|Texas Family Geriatrics Clinic, Houston, Texas, United States|Memorial Clinical Associates Research, Houston, Texas, United States|Break Through Medical Research, Irving, Texas, United States|Medical & Surgical Clinic, Irving, Texas, United States|West Memorial Family Practice, Katy, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Methodist Hospital Research Institute, Internal Medicine, Pearland, Texas, United States|Health Texas Research Institute, San Antonio, Texas, United States|Covenant Clinical Research, PA, San Antonio, Texas, United States|DM Clinical Research, San Antonio, Texas, United States|DCT-Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|Sealy Urgent Care Center and Medical Clinic, Sealy, Texas, United States|Pioneer Research Solutions, Inc., Sugar Land, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Ericksen Research & Development, LLC, Clinton, Utah, United States|Focus Clinical Research, Draper, Utah, United States|Advanced Research Institute, Ogden, Utah, United States|Paramount Medical Care, Ogden, Utah, United States|Burke Internal Medicine and Research, Burke, Virginia, United States|Nova Health Management & Research Group, PC, Herndon, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Dominion Medical Associates, Inc., Richmond, Virginia, United States|Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia, United States|Roanoke Heart Institute PLC, Roanoke, Virginia, United States|Salem Veterans Affairs Medical Center, Salem, Virginia, United States|Sound Medical Research, Port Orchard, Washington, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Instituto Médico Adrogué, Adrogue, Argentina|Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Argentina|Inst de Inv Clinicas-Bahia Blanca, Bahia Blanca, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Bahia Blanca, Argentina|Hospital Sirio-Libanés, Caba, Argentina|Centro de Investigaciones Metabólicas, Ciudad Autonoma Buenos Aires, Argentina|CIPREC, Ciudad Autonoma Buenos Aires, Argentina|Hospital Italiano, Ciudad Autonoma Buenos Aires, Argentina|Consultorios Asociados de Endocrinología e Invest Clínica, Ciudad Autonoma Buenos Aires, Argentina|CEDIC - Centro de Investigacion Clinica, Ciudad Autonoma Buenos Aires, Argentina|Instituto Cardiovascular de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|CCBR - Buenos Aires - AR, Ciudad Autonoma Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Bs As, Argentina|Centro Médico Colon, Cordoba, Argentina|CEMAIC - Centro Medico Especializado, Cordoba, Argentina|Inst. Privado de Inv. Clínicas de Córdoba, Cordoba, Argentina|Clínica Colombo, Cordoba, Argentina|Instituto DAMIC - Fundacion Rusculleda, Cordoba, Argentina|Hospital Cordoba, Cordoba, Argentina|IPAC - Clínica Privada Caraffa SRL, Cordoba, Argentina|Clinica Privada del Prado, Cordoba, Argentina|Centro Universitario de Investigacion Corrientes, Corrientes, Argentina|Sanatorio Allende S.A., Córdoba, Argentina|CIPADI, Godoy Cruz, Argentina|Centro Medico Dr. Javier Marino, Haedo, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|Unidad de Cardiologia Clinica, Mar del Plata, Argentina|Hospital Privado de Comunidad, Mar del Plata, Argentina|Hospital Central de Mendoza, Mendoza, Mendoza, Argentina|Hospital San Martin, Parana, Argentina|Sanatorio San Martin S.A., Venado Tuerto, Pellegrini 661, Argentina|CER Instituto Médico, Quilmes, Argentina|Instituto de Investigaciones Clínicas de Quilmes, Quilmes, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Rosario, Argentina|Instituto Medico Fundación Grupo Colaborativo Rosario, Rosario, Argentina|Sanatorio Británico, Rosario, Argentina|Sanatorio Norte, Rosario, Argentina|Instituto de Hematologia y Medicina Clinica Ruben Davoli, Rosario, Argentina|Sanatorio Delta, Rosario, Argentina|Centro Medico CIR, Rosario, Argentina|CEDyN, Rosario, Argentina|Instituto CAICI, Rosario, Argentina|Instituto Medico CENICLAR-C de Investigaciones Clinicas, Rosario, Argentina|Centro Cardiovascular Salta, Salta, Argentina|CORDIS S.A., Salta, Salta, Argentina|Prevencion Cardiovascular Salta, Salta, Salta, Argentina|CCBR Tucuman, San Miguel de Tucuman, Argentina|Investigaciones Clinicas Tucuman, San Miguel de Tucumán, Argentina|Instituto de Investigaciones Clinicas San Nicolas, San Nicolas, Argentina|Centro Medico Luquez, San Vicente, Argentina|Centro de Investigaciones Clínicas del Litoral, Santa Fe, Argentina|Hospital ""Dr. José Maria Cullen "", Santa Fé, Argentina|Clinica Privada Fusavim SRL, Villa Maria, Argentina|Instituto de Investigaciones Clínicas Zárate, Zarate, Argentina|Hospital Felício Rocho, Belo Horizonte, Brazil|Hospital Lifecenter, Belo Horizonte, Brazil|Hospital Vera Cruz, Belo Horizonte, Brazil|Hospital Universitário João de Barros Barreto, Belém, Brazil|Hospital Angelina Caron, Campina Grande do Sul, Brazil|HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas, Campinas, Brazil|CAEP - Centro Avançado de Estudos e Pesquisas Ltda.,Campinas, Campinas, Brazil|Hospital Universitário, Canoas, Brazil|Universidade de Caxias do Sul - IPCEM - Inst. de Pesq.clilni, Caxias do Sul, Brazil|Hospital de Caridade Santa Casa de Misericordia de Curitiba, Curitiba, Brazil|HC UFPR, Curitiba, Brazil|Cruz Vermelha Brasileira - Filial do Estado do Paraná, Curitiba, Brazil|Centro de Estudos em Diabetes e Hipertensão, Fortaleza, Brazil|Centro de Pesquisas em Diabetes e Doenças, Fortaleza, Brazil|ICE-HUWC - Instituto Cearense de Endocrinologia, Fortaleza, Brazil|Via Médica, Goiania, Brazil|Hospital Bruno Born, Lajeado, Brazil|ICM - Instituto do Coração de Marília, Marília, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Brazil|Instituto de Cardiologia Rio Grande do Sul, Porto Alegre, Brazil|Centro de Pesquisas Médicas Básica e Clínica Ltda, Recife, Brazil|CCBR - Rio de Janeiro - BR, Rio de Janeiro, Brazil|Centro de Pesquisa Clínica Santa Maria, Santa Maria, Brazil|CCBR Brasil - São Paulo, Santo Andre, Brazil|Instituto Domingo Braile, Sao Jose do Rio Preto, Brazil|Fundacao Faculdade Regional de Medicina, Sao Jose, Sao Jose do Rio Preto, Brazil|Centro de Pesquisa Clinica - CPCLIN, Sao Paulo, Brazil|FGM Clínica Paulista de Doenças Cardiovasculares LTDA, Sao Paulo, Brazil|Hospital Sao Paulo - UNIFESP, Sao Paulo, Brazil|Cpquali Pesquisa Clinica Ltda, São Paulo, Brazil|Hospital Alemao Oswaldo Cruz, São Paulo, Brazil|Hospital do Servidor Público Estadual, São Paulo, Brazil|Dr. Consulta, São Paulo, Brazil|Hospital das Clinicas da FMUSP, São Paulo, Brazil|Incor - Instituto do Coração - HCFMUSP, São Paulo, Brazil|IMC - Instituto de Moléstias Cardiovasculares Tatuí, Tatui, Brazil|ICT - Instituto do Coração do Triângulo, Uberlândia, Brazil|MHAT - Blagoevgrad, EOOD, Blagoevgrad, Bulgaria|MHAT ""Yuliya Vrevska"" EOOD, Byala, Byala, Bulgaria|MHAT ""Dr.Stambolski"", Cardiology&Intensiv Care Dept,Kazanlak, Kazanlak, Bulgaria|UMHAT ""Kaspela"", EOOD, Plovdiv, Plovdiv, Bulgaria|DCC 1 - Ruse, EOOD, Ruse, Bulgaria|Fifth MHAT - Sofia EAD, Sofia, Sofia, Bulgaria|MHAT Lyulin, Sofia, Bulgaria|MHAT 'Tokuda Hospital Sofia', EAD, Sofia, Bulgaria|USHATE Hospital 'Academy Ivan Penchev', Sofia, Sofia, Bulgaria|DCC ""Equita"" EOOD, Varna, Bulgaria|ALTA Clinical Research Inc., Edmonton, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Dr. Ronald Collette, Burnaby, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|LMC Clinical Research dba Manna Research Inc. Vancouver, Vancouver, British Columbia, Canada|Fraser Clinical Trials Inc., Victoria, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|CookMed Research, Victoria, British Columbia, Canada|Winnipeg Regional Health Authority, Winnipeg, Winnipeg, Manitoba, Canada|True North Clinical Research Halifax, Inc., Halifax, Nova Scotia, Canada|LMC Endocrinology Centres (Barrie) Ltd., Barrie, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|LMC Endocrinology Centres (Etobicoke) Ltd., Etobicoke, Ontario, Canada|LMC Endocrinology Centres (Markham) Ltd., Markham, Ontario, Canada|SKDS Research Incorporated, Newmarket, Ontario, Canada|Medicor Research, Sudbury, Ontario, Canada|Sudbury Cardiac Research, Sudbury, Ontario, Canada|Dr. R. Labonte Prof. Med. Corp, Sudbury, Ontario, Canada|ViaCar Recherche Clinique Inc, Brossard, Quebec, Canada|Hopital Charles - LeMoyne, Greenfield Park, Quebec, Canada|Centre De Recherche Clinique, Laval, Quebec, Canada|Recherche Invascor Inc., Longueuil, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|St Jerome Medical Research Inc., St-Jerome, Quebec, Canada|LMC Endocrinology Centres (Montreal), Ville Saint-Laurent, Quebec, Canada|Recherche Clinique Sigma Inc., Quebec, Canada|Clinique des maladies Lipidiques de Quebec, Quebec, Canada|Hospital Regional de Punta Arenas Dr. Lautaro Navarro Avaria, Punta Arenas, Chile|Hospital El Pino, Santiago, Chile|Sociedad Medica Cardiologica El Llano, Santiago, Chile|Hospital Militar de Santiago, Santiago, Chile|Hospital Sotero del Rio, Santiago, Chile|CeCim - Centro de Estudios Clinicos e Investigacion Medica, Santiago, Chile|Hospital Padre Alberto Hurtado, Santiago, Chile|Hospital Base Valdivia, Valdivia, Chile|Hospital Naval Almirante Nef, Viña del Mar, Chile|Beijing Jishuitan Hospital, Beijing, China|Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Zhejiang University School of Medicine SIR RUN RUN SHAW Hospital, Hangzhou, China|Center Hospital of Jinan, Jinan, China|People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China|Tongji Hospital, Tongji University, Shanghai, China|First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China|General Hospital of Ningxia Medical University, Yinchuan, China|CEQUIN, Armenia, Colombia|Corazon IPS S.A.S., Barranquilla, Colombia|Clínica de la Costa Ltda., Barranquilla, Colombia|IPS Centro Cientifico Asistencia, Barranquilla, Colombia|Centro de Atencion e Investigacion Medica S.A. - CAIMED, Bogota, Colombia|CAFESALUD Medicina Prepagada S.A., Bogota, Colombia|Solano y Terront Servicios Médicos Ltda., Bogota, Colombia|Dexa Diabetes Servicios Médicos Ltda, Bogotá, Colombia|Fundacion Reina Isabel, Cali, Colombia|IPS Centro Medico Julián Coronel S.A., Cali, Colombia|Fundación Centro de Investigaciones Biomédicas Riescard, Espinal, Colombia|Centro de Investigacion Clínica Avanzada, Medellin, Colombia|Fundacion Centro de Investigacion Clinica CIC, Medellin, Medellin, Colombia|Fundacion Centro de Obesidad y Metabolismo - COMETA, Pasto, Colombia|Healthy Medical CenterS.A.S, Zipaquirá, Zipaquirá, Colombia|General Hospital Karlovac, Karlovac, Croatia|Hospital for Medical Rehabilitation, Krapinske Toplice, Krapinske Toplice, Croatia|General Hospital Slavonski Brod, Slavonski Brod, Croatia|General Hospital Varazdin, Varazdin, Croatia|General Hosp. Zadar, Dept. of Internal Medicine-Pulmonology, Zadar, Croatia|Clinical Hospital Sveti Duh, Zagreb, Croatia|University hospital center Zagreb, Zagreb, Croatia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Revmatologie Bruntal, s.r.o., Bruntal, Czechia|Poliklinika Chocen, a.s., Chocen, Czechia|Aesculap Ambulance Sro, Dolni Brezany, Czechia|OKELI s.r.o., Hodonin, Czechia|Nemocnice Jindrichuv Hradec a.s., Jindrichuv Hradec, Czechia|Regional Hospital Liberec, Liberec, Czechia|InterKardioML s.r.o., Marianske Lazne, Czechia|Interna a diabetologicka ordinace s.r.o., Nachod, Czechia|PreventaMed, s.r.o., Olomouc, Czechia|Univ. Hospital Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice V Praze, Praha 2, Czechia|Thomayer Hospital, Praha 4 - Krc, Czechia|ResTrial s.r.o., Praha 8, Czechia|Hospital Slany, Internal Department, Slany, Czechia|Krajska zdravotni, a.s. - Nemocnice Teplice, o.z., Teplice, Czechia|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Zentrum für klinische Forschung Dr. med. Irma Schöll & Kollegen, Bad Homburg, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt am Main, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Frankfurt, Germany|Diabetologische Schwerpunktpraxis, Hohenmölsen, Hohenmölsen, Germany|EUGASTRO GmbH, Leipzig, Leipzig, Germany|Gemeinschaftspraxis Dr. Taeschner / Dr. Bonigut, Leipzig, Leipzig, Germany|Lausmed Kft. Outpatient Unit of Internal Medicine, Baja, Hungary|Dr. Kenessey Albert Kórház-Rendelõintézet, Balassagyarmat, Balassagyarmat, Hungary|DRC Gyogyszervizsgalo Kozpont Kft., Balatonfured, Balatonfured, Hungary|Clinexpert Kft., Budapest, Hungary|Obudai Egeszsegugyi Centrum, Budapest, Hungary|QUALICLINIC Kft, Budapest, Hungary|Semmelweis Egyetem, Budapest, Budapest, Hungary|Semmelweis Egyetem, Budapest, Budapest, Hungary|Semmelweis Egyetem, Budapest, Budapest, Hungary|University Debrecen Hospital, Debrecen, Hungary|Markhot Ferenc Hospital, Eger, Eger, Hungary|Csongrad Megyei Eu. Ellato Kozp. Hodmezovasarhely-Mako, Hodmezovasarhely, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Kaposvar, Kaposvar, Hungary|Selye Janos Hospital Komarom, Komarom, Hungary|Ermellek Egeszsegcentrum, Letavertes, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klin. Kozpont, Szeged, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Haemek Medical Center, Afula, Israel|Bnei Zion Medical Center, Haifa, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Herzliya Medical Center, Herzliya, Israel|Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Ein-Karem, Jerusalem, Israel|Meir Medical Center, Kfar-Saba, Israel|Galilee Medical Center, Nahariya, Israel|Ziv Medical Center, Safed, Israel|Sourasky Medical Center, Tel Aviv, Israel|Daishinkai Medical Corporation Ookuma Hospital, Aichi, Nagoya, Japan|Seikeikai New Tokyo Heart Clinic, Chiba, Matsudo, Japan|Saiseikai Matsuyama Hospital, Ehime, Matsuyama, Japan|Aso Co.,Ltd Iizuka Hospital, Fukuoka, Iizuka, Japan|Kitakyushubyoin Kitakyushu General Hospital, Fukuoka, Kitakyushu, Japan|The Veritas Hospital, Hyogo, Kawanishi, Japan|Ibaraki Seinan Medical Center Hospital, Ibaraki, Sashima-gun, Japan|Kokan Clinic, Kanagawa, Kawasaki, Japan|Nagano Red Cross Hospital, Nagano, Nagano, Japan|Josuikai Olive Takamatsu Medical Clinic, Takamatsu-shi, Japan|Hallym University Sacred Heart Hospital, Anyang-si, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National Univ. Hosp, Busan, Korea, Republic of|Myongji Hospital, Goyang-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hosp, Wonju, Korea, Republic of|Hospital Sultanah Bahiyah, Alor Setar, Malaysia|Hospital Tengku Ampuan Rahimah, Klang, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Monash University(Sunway Campus), Petaling Jaya, Malaysia|Hospital Pulau Pinang, Pulau Pinang, Malaysia|Universiti Putra Malaysia, Serdang, Malaysia|Hospital Seri Manjung, Seri Manjung, Malaysia|Hospital Taiping, Taiping, Malaysia|Klinik Kesihatan Tampin, Tampin, Malaysia|Investigación en Salud y Metabolismo S.C., Chihuahua, Mexico|Phylasis Clinicas Research S de RL de CV, Cuautitlan Izcalli, Mexico|Centro para el Desarrollo de la Medicina y de Asist Med Espe, Culiacan, Mexico|Centro de Investigacion Biomedica y Farmaceutica, S.C., Distrito Federal, Mexico|Servicios Medicos de la Pena SC, Guadalajara, Mexico|Medical Care & Research SA de CV, Merida, Mexico|Sociedad de Cirugia Vascular Plastica Reconstructiva, Merida, Mexico|Phytomedicamenta S.A. de C.V., Mexico, Mexico|Comite Mexicano Para la Prevencion de Osteoporosis AC, Mexico, Mexico|Centro de Atención e Investigación en Factores de Riesgo, Mexico, Mexico|Clinstile S.A. de C.V., Mexico, Mexico|Ultimate Medica SA de CV, Mexico, Mexico|Health Pharma Professional Research S.A. de C.V., Mexico, Mexico|Centro de Estudios Clinicos y Especialidades Medicas, S.C., Monterrey, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Global Trial Research Center S.A. de C.V., Monterrey, Mexico|Centro de Investigacion Clinica Chapultepec S. A. de C. V., Morelia, Mexico|Centro de Estudios Clínicos de Queretaro S.C., CECLIQ, Queretaro, Mexico|Centro de Investigacion Cardiovascular y Metabolica, Tijuana, Mexico|Centro de Investigación Médica de Ocidente, S.C., Zapopan, Mexico|Hospital Dr Angel Leano, Zapopan, Mexico|Rijnstate Hospital, Arnhem, Netherlands|Albert SchweitzerZiekenhuis, Dordrecht, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Bethesda Cardiology Group, Hoogeveen, Hoogeveen, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Rotterdam Research Institute, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|TweeSteden Ziekenhuis, Waalwijk, Netherlands|Gelre Ziekenhuis Zutphen, Zutphen, Netherlands|B_Serwis Popenda Sp.Jawna, Chorzow, Poland|Poradnia Kardiologiczna Jaroslaw Jurowiecki, Gdansk, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Indywidualna Specjalistyczna Praktyka Lekarska, Gdynia, Poland|MCBK Iwona Czajkowska Anna Podrazka- Szczepaniak S.C., Grodzisk Mazowiecki, Poland|Centrum Medyczne Pratia Katowice II, Katowice, Poland|Polimedica Centrum Bada?, Profilaktyki I Leczenia, Kielce, Poland|NZOZ Centrum Medyczne ProMiMed Sp. z o.o., Sp.k., Krakow, Krakow, Poland|Centrum Terapii Wspolczesnej J.M., Lodz, Poland|CCBR - Lodz - PL, Lodz, Lodz, Poland|Individual Specialized Practice, Lodz, Poland|Centrum Medyczne ""Luxmed"" Sp. z o.o., Lublin, Poland|KO-MED Centra Kliniczne Lublin II, Lublin, Poland|NZOZ Specialized Ambulance ""MEDICA"", Lublin, Poland|RCMed- Regionalne Centrum Medyczne, Nowy Duninow, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Prywatny Gabinet Lekarski Lech Lazuka, Parczew, Poland|Clin.Hosp.Med.Univ.Marcinkowski in Poznan, Poznan, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznan, Poland|KOMED Marek Konieczny, Pulawy, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Dr N Med Andrzej Wittek, Ruda Slaska, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|RCMed- Regionalne Centrum Medyczne, Sochaczew, Poland|NSZOZ Medicus, Sroda Wielkopolska, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|Lecznice Citomed Sp. z o.o., Torun, Poland|NZOZ Nasz Lekarz, Torun, Poland|NBR Polska, Warsaw, Poland|CCBR/Somed - Warszaw - PL, Warszaw, Poland|Regionalna Poradnia Diabetoloiczna Zytkiewicz-Jaruga, Wroclaw, Poland|KO-MED Centra Kliniczne Zamosc, Zamosc, Poland|Polimedica Centrum Bada?, Profilaktyki I Leczenia, Zgierz, Poland|Hospital de Braga-Escala Braga, Braga, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|APDP - Associação Protectora dos Diabéticos de Portugal, Lisboa, Portugal|CHLO, EPE - Hospital S. Francisco Xavier, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|Hospital CUF Porto, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia, V. N. Gaia, Portugal|SC Diana Barbonta SRL, Alba Iulia, Alba Iulia, Romania|Spitalul Universitar de Urgenta, Bucuresti, Bucuresti, Romania|I.N.D.N.B.M. ""Prof. Dr. N.C. Paulescu"" - Sediul Central, Bucuresti, Romania|I.N.D.N.B.M. ""Prof. Dr. N.C. Paulescu"" - Sediul Central, Bucuresti, Romania|CMI Dr. Stolea T. Violeta, Bucuresti, Romania|Clinica Medicala Data Plus SRL, Bucuresti, Romania|I.N.D.N.B.M. ""Prof. Dr. N.C. Paulescu"" - Sediul ""I.L. Caragiale"", Bucuresti, Romania|S.C Centrul Medical ""Sanatatea Ta"" S.R.L, Bucuresti, Romania|S.C. Policlinica CCBR SRL, Bucuresti, Bucuresti, Romania|Medcon SRL, Buzau, Romania|Spitalul Clinic Judetean de Urgenta ¿Sf. Apostol Andrei¿, Galati, Romania|Spitalul Clinic, Iasi, Iasi, Romania|Consultmed SRL, Iasi, Iasi, Romania|SC Diaconu-Sotropa Michaela, Cabinet de Diabet, Iasi, Romania|S.C Grandmed S.R.L, Oradea, Oradea, Romania|Pelican Impex SRL, Cabinet Nr. 15, Oradea, Romania|S.C Anamed S.R.L, Oradea, Romania|S.C. Diabmed Dr. Popescu Alexandrina S.R.L, Ploiesti, Romania|Gensan SRL, Sibiu, Romania|Centrul Medical Dr Negrisanu SRL, Timisoara, Romania|Mediab SRL, Tirgu Mures, Romania|SBEI HPE Altay State Medical University of MoH and SD, Barnaul, Russian Federation|Res.Inst.-Compl.Iss.Cardi.Dis., Kemerovo, Russian Federation|NSIH ""Departmental Hospital on Station Kemerovo of OJSC ""Russian Railways"", Kemerovo, Russian Federation|First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Russian Federation|Moscow 1st State Med.Univ.n.a.I.M.Sechenov, Moscow, Russian Federation|SBEI HPE ""Moscow State Medical and Dentistry University, Moscow, Russian Federation|Moscow State Medical Dentistry University, Moscow, Russian Federation|SBIH of Novosibirsk Region ""Clinical Emergency Hospital #2"", Novosibirsk, Russian Federation|Novosibirsk Regional Clinical Cardiological Dispansary, Novosibirsk, Russian Federation|FSBSI ""Scientific Research Institute"", Novosibirsk, Novosibirsk, Russian Federation|FSBSI ""Scientific and Research Institute of Physiology and Basic Medicine"", Novosibirsk, Russian Federation|BIH of OR ""City Hospital # 2"", Omsk, Omsk, Russian Federation|SBIH of Perm territory "" City Clinical Hospital # 2 n.a., Perm, Russian Federation|SBI of Ryazan region ""Regional Clinical Cardiological Dis., Ryazan, Russian Federation|FSBMEI HPE ""Military Medical Academy n.a. S.M. Kirov"", Saint-Petersburg, Russian Federation|1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., Saint-Petersburg, Russian Federation|Federal North-West Medical Research Centre, Saint-Petersburg, Russian Federation|SPb SBHI ""City Policlinic #74"", Saint-Petersburg, Russian Federation|SPb SBIH ""City Pokrovskaya Hospital"", Saint-Petersburg, Russian Federation|GUZ ""City Clinical Hospital #40, 197706 Saint-Petersburg, Sestroretsk, Russian Federation|Medical Research Institute LLC, St. Petersburg, St. Petersburg, Russian Federation|FSBI ""Research Institute for Cardiology"", Tomsk, Russian Federation|Cardiology Clinical Research, Alberton, South Africa|Iatros International, Bloemfontein, South Africa|Limaro Research, Bloemfontein, South Africa|Dr JM Engelbrecht Practice, Cape Town, South Africa|Dr Dawood, Mohamed and Pillay, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|Langeberg Clinical Trials, Cape Town, South Africa|Cape Town Medical Research Centre, Cape Town, South Africa|Ismail, SM, Cape Town, South Africa|Groote Schuur Hospital, Cape Town, South Africa|Latiff, GHVM, Durban, South Africa|Londisizwe Research Centre, Durban, Durban, South Africa|Diabetes Care Centre, Johannesburg, South Africa|Wits Clinical Research Chris Hani Baragwanath Hospital, Johannesburg, South Africa|WCR CMJAH Clinical Trial Site, Johannesburg, South Africa|DJW Navorsing, Krugersdorp, South Africa|Emmed Research, Pretoria, South Africa|University of Pretoria, Pretoria, South Africa|Syzygy Clinical Research Services, Pretoria, South Africa|Into Research, Pretoria, South Africa|Seeber, M, Pretoria, South Africa|Dr M Duki Research and Trial Site, Verulam, Verulam, South Africa|Clinical Projects Research, Worcester, South Africa|Hospital Virgen del Mar, Almeria, Spain|Hospital de la Ribera, Alzira, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Specialist, Barcelona, Spain|CAP Sarria, Barcelona, Spain|Hospital Quiron. I.C.U., Barcelona, Spain|EBA Centelles, Centelles, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Quironsalud Infanta Luisa, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital Virgen de las Montañas, Villamartin, Villamartin, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Far Eastern Memorial Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan|Chernivtsi Regional Endocrinology Dispensary, Chernivtsi, Ukraine|Regional CH Dept of Endocrinology SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, Ukraine|CI Ivano-Frankivsk Reg Cl Card Center, Ivano-Frankivsk, Ukraine|L.T. Malaya Institute of Therapy AMS of Ukraine, Kharkiv, Ukraine|CIPH Prof. O.I. Meshchaninov Kharkiv CCH of A&E, Kharkiv, Ukraine|CI of Healthcare Kharkiv CCH #8, Kharkiv, Kharkiv, Ukraine|KCCC of Endocr Dept of General Endocrine Pathology, Kyiv, Ukraine|City Clinical Hospital No. 1, Kiev, Kyiv, Ukraine|V.P. Komisarenko Inst. of Endocrinology and Metabolism, Kyiv, Ukraine|Kjiv City Oleksandrivska Clinical Hospital, Kyiv, Ukraine|LLC Treatment and Diagnostic Center Adonis Plus, Kyiv, Kyiv, Ukraine|SI National Scientific Centre of Radiation Medicine of NAMSU, Kyiv, Ukraine|P.L. Shupyk NMA of PGE Ch of D H for S-ts of NASU, Kyiv, Ukraine|SI V.P.Komisarenko Institute of Endocrinology and Metabolism, Kyiv, Ukraine|Lviv Regional Endocrinology Dispensary, Lviv, Ukraine|M.V. Sklifosovskyi Poltava RCH, Poltava, Poltava, Ukraine|CI Sumy City Clinical Hospital #1 Dept of Therapy Sumy SU, Sumy, Ukraine|CI of TRC Ternopil UH, Ternopli, Ukraine|Private Small Enterprise Medical Center Pulse, Vinnytsia, Ukraine|Vinnytsia RC Highly Special.Endocr.Center Dept of Therapy, Vinnytsia, Ukraine|M.I. Pyrogov VRCH, Vinnytsia, Vinnytsia, Ukraine|CCH #1 M.I. Pyrogov VNMU Ch of Propaedeutics of IM, Vinnytsia, Ukraine|CI Zapor CCH#10 SI ZMA PGE Ch of therapy clin pharmacol & endocrin, Zaporizhzhia, Ukraine|University Hospital Monklands, Airdrie, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bradford on Avon Health Centre, Bradford on Avon, United Kingdom|Ashgate Medical Practice, Chesterfield, United Kingdom|Dumfries and Galloway Royal Infirmary, Dumfries, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Barts and The London School of Medicine and Dentistry, London, United Kingdom|Morriston Hospital, Swansea, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01897532/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01897532/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01897532
439,NCT02784275,A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes,Completed,Has Results,Diabetes Mellitus Type 2 in Obese,Drug: Cyclo-Z|Drug: Placebo,"NovMetaPharma Co., Ltd.","18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Los Angeles, California, United States|Hialeah, Florida, United States|Houston, Texas, United States|Tomball, Texas, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02784275/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02784275/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02784275
440,NCT04198948,Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Omeprazole|Drug: Placebo oral tablet|Drug: Gliclazide,University of Sarajevo|General Hospital Prim. Dr. Abdulah Nakas|University of Dundee|Wellcome Trust,18 Years to 30 Years   (Adult),Phase 1,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"General Hospital Prim. Dr. Abdulah Nakas, Sarajevo, Bosnia and Herzegovina","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04198948/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04198948
441,NCT01864564,Early Gestational Diabetes Screening in the Gravid Obese Woman,Completed,Has Results,Gestational Diabetes|Obesity,Other: Early Screen,University of Alabama at Birmingham|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Ochsner Health System,18 Years to 50 Years   (Adult),Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Ochsner Health System, New Orleans, Louisiana, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01864564/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01864564/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01864564
442,NCT03985566,Effects of Fixed Meals With Special Formulated Rice on Blood Glucose Levels of Healthy Volunteers.,Completed,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Fibre Grain|Dietary Supplement: Jasmine white rice,"National University, Singapore|Alchemy Foodtech Pte Ltd","21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"National University of Singapore, Singapore, Singapore","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03985566/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03985566
443,NCT04927871,Hybridized Three Steps Intervention to Prevent Diabetes in Venezuela,Completed,No Results Available,"Obesity|Overweight|PreDiabetes|Diabetes Mellitus, Type 2|Risk Factor, Cardiovascular",Behavioral: Total Diet Replacement (TDR)|Behavioral: Medical Nutritional Therapy (MNT)|Behavioral: Diabetes Prevention Program 4 months|Behavioral: Diabetes Prevention Program,Foundation for Public Health and Epidemiological Research of Venezuela,"20 Years to 79 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maria M. Infante Garcia, Caracas, Chacao, Venezuela|FISPEVEN, Caracas, Chacao, Venezuela","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04927871/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04927871
444,NCT04470310,"Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination","Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus,Drug: Glimepiride|Drug: Alogliptin 25Mg Tab|Drug: Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet,Seoul National University Hospital,"19 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,South Korea,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04470310/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04470310
445,NCT03839641,Novel Approach to Assess Metabolic Flexibility in a Respiratory Chamber,Completed,Has Results,"Diabetes Mellitus, Type 2",Other: High fat meal|Other: Low fat meal,Pennington Biomedical Research Center,18 Years to 40 Years   (Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03839641/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03839641
446,NCT02513641,Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Device: Hypoxico Altitude Training Systems,Pennington Biomedical Research Center,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02513641/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02513641/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02513641
447,NCT01243424,CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: linagliptin|Drug: glimepiride|Drug: linagliptin placebo|Drug: glimepiride placebo,Boehringer Ingelheim|Eli Lilly and Company,"40 Years to 85 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","North Alabama Research Center, LLC, Athens, Alabama, United States|Alabama Internal Medicine, PC, Birmingham, Alabama, United States|Cahaba Research, Inc., Birmingham, Alabama, United States|Internal Medicine Center, LLC, Mobile, Alabama, United States|Diagnostic and Medical Clinic, Mobile, Alabama, United States|Extended Arm Physicians, Inc., Montgomery, Alabama, United States|Office of Dr. Terence T. Hart MD, Tuscumbia, Alabama, United States|Advanced Clinical Research, Pell City, Alaska, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Mesa, Arizona, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Mesa, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Quality of Life Medical & Research Center, Tucson, Arizona, United States|Northeast Arkansas Baptist Clinic, Jonesboro, Arkansas, United States|Medical Investigations, Inc, Little Rock, Arkansas, United States|Aureus Research, Inc, Little Rock, Arkansas, United States|Desert Oasis Healthcare, Bermuda Dunes, California, United States|Edinger Medical Group and Research Center, Fountain Valley, California, United States|Clinical Trials of St. Jude Heritage Med. Group, Fullerton, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Office of Dr. Richard S. Cherlin, Los Gatos, California, United States|Providence Clinical Research, North Hollywood, California, United States|Chaparral Medical Group, Inc, Pomona, California, United States|ARI Clinical Trials, Inc, Redondo Beach, California, United States|San Diego Sports Medicine and Family Health Center, San Diego, California, United States|West Coast Research, LLC, San Ramon, California, United States|University of California Los Angeles, Sylmar, California, United States|Metabolic Institute of America, Tarzana, California, United States|Matrix Research Institute, Tustin, California, United States|Orange County Research Center, Tustin, California, United States|Westlake Medical Research, Westlake Village, California, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Colorado Springs, Colorado, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Colorado Springs, Colorado, United States|East Coast Medical Associates, Boca Raton, Florida, United States|Todd Kazdan, DO Family Practice, Davie, Florida, United States|Century Clinical Research, Inc, Daytona Beach, Florida, United States|Doral Research Center, Doral, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Alan Graff, MD, PA, Fort Lauderdale, Florida, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Eastern Research, Hialeah, Florida, United States|Research in Miami Inc, Hialeah, Florida, United States|Jacksonville Impotence Treatment Center, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Care Partners Clinical Research LLC, Jacksonville, Florida, United States|Precision Clinical Research, LLC, Lauderdale Lakes, Florida, United States|Veritas Research Corporation, Miami, Florida, United States|APF Research, LLC, Miami, Florida, United States|Swiss Medical Research, Miami, Florida, United States|University of Miami, Miami, Florida, United States|South Miami Clinical Research, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Advanced Pharma CR, LLC, Miami, Florida, United States|AppleMed Research Group, LLC, Miami, Florida, United States|Kendall South Medical Center, Inc, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Advanced Research Institute, Inc, New Port Richey, Florida, United States|Sunshine Research Center, Opa-locka, Florida, United States|Diabetes and Endocrine Center of Orlando, Orlando, Florida, United States|Suncoast Clinical Research, Palm Harbor, Florida, United States|Misal Khan, MD FRCS, ED, PA, Panama City, Florida, United States|Iconic Clinical Trials, Pembroke Pines, Florida, United States|Gulf Region Clinical Research Institute, Pensacola, Florida, United States|St. John's Center for Clinical Research, Ponte Vedra Beach, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|PMI Health Research Group, Atlanta, Georgia, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Albert F. Johary MD, PC, Dunwoody, Georgia, United States|Georgia Clinical Research, LLC, Snellville, Georgia, United States|Hayden Lake Family Physicians, Hayden Lake, Idaho, United States|Boise Kidney and Hypertension Institute, Meridian, Idaho, United States|Suburban Clinical Research, Bolingbrook, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|John H. Stroger Jr. Hospital of Cook Country, Chicago, Illinois, United States|Apex Medical Research, Chicago, Illinois, United States|Pharmakon Inc, Evergreen Park, Illinois, United States|American Health Network, Avon, Indiana, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|Mapleton Medical Center, Indianapolis, Indiana, United States|American Health Network, LLC, Indianapolis, Indiana, United States|McKinley Research, LLC, Mishawaka, Indiana, United States|American Health Network of Indiana, LLC, Muncie, Indiana, United States|MCM Clinical Research, LLC, Florence, Kentucky, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Crescent City Clinical Research, Metairie, Louisiana, United States|Acadia Clinical Research, LLC, Bangor, Maine, United States|Office of Dr. Stephen R. Smith, MD, Baltimore, Maryland, United States|Endocrine and Metabolic Consultants, Rockville, Maryland, United States|Tristan Medical Enterprises, PC dba Regeneris, North Attleboro, Massachusetts, United States|ClinSite, LLC, Canton, Michigan, United States|Apex Medical Research, AMR Inc, Flint, Michigan, United States|Westside Family Medical Center, PC, Kalamazoo, Michigan, United States|Tri City Medical Centers, PC, Livonia, Michigan, United States|KMED Research, Saint Clair Shores, Michigan, United States|Tri-County Research, Inc, Sterling Heights, Michigan, United States|Medical Research Associates, Traverse City, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Park Nicollet Institute, Minneapolis, Minnesota, United States|The Center for Clinical Trials, Inc., Biloxi, Mississippi, United States|Mercy Health Research, Saint Louis, Missouri, United States|Quality Clinical Research, Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Henderson, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Palm Medical Research Center, Las Vegas, Nevada, United States|Atco Medical Associates, PC, Atco, New Jersey, United States|Summit Medical Group, Clifton, New Jersey, United States|USMA Clinical Research, Elizabeth, New Jersey, United States|Central Jersey Medical Research, Elizabeth, New Jersey, United States|Albany Medical Center / Albany Medical College, Albany, New York, United States|Endocrine Associates of Long Island, PC, Smithtown, New York, United States|Southgate Medical Group/ Southgate Medical Park, West Seneca, New York, United States|OnSite Clinical Solutions, LLC, Asheville, North Carolina, United States|Kernodle Clinic West, Burlington, North Carolina, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Internal Medicine Research, Charlotte, North Carolina, United States|Gaffney Health Services, Charlotte, North Carolina, United States|Durham Internal Medicine Associates, Durham, North Carolina, United States|Sentara Family Medicine, Elizabeth City, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Carolina Research Center, Inc, Shelby, North Carolina, United States|Piedmont Healthcare, Statesville, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Community Health Care of Manchester, Akron, Ohio, United States|Community Medical Associates, LLC, Austintown, Ohio, United States|Harrison Community Research Center, Cadiz, Ohio, United States|Medical Frontiers, LLC, Carlisle, Ohio, United States|Genoa Medical Center, Genoa, Ohio, United States|Office of Dr. Craig S. Thompson, MD, LLC, Marion, Ohio, United States|RAS Health Limited, Marion, Ohio, United States|Advanced Medical Research, LLC, Maumee, Ohio, United States|Pharmacotherapy Research Associates, Inc, Zanesville, Ohio, United States|Infinity Research Group, LLC, Oklahoma City, Oklahoma, United States|Castlerock Clinical Research Consultants, LLC, Tulsa, Oklahoma, United States|Oregon Medical Group, Eugene, Oregon, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Detweiler Family Medicine & Associates, PC, Lansdale, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Warminster Medical Associates, PC, Warminster, Pennsylvania, United States|New England Center for Clinical Research, Inc, Cranston, Rhode Island, United States|Hartwell Research Group, LLC, Anderson, South Carolina, United States|Paris View Family Practice, Greenville, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|South Carolina Nephrology and Hypertension Center, Inc, Orangeburg, South Carolina, United States|Carolina Diabetes & Kidney Center, Sumter, South Carolina, United States|PMG Research of Bristol, Bristol, Tennessee, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|University of Tennessee, Memphis, Tennessee, United States|Trinity Clinical Research, LLC, Tullahoma, Tennessee, United States|KRK Medical Research, Arlington, Texas, United States|Austin Center for Clinical Research, Austin, Texas, United States|Punzi Medical Center, Carrollton, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Baylor Endocrine Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Jacon Medical Research Associates, LLC, Houston, Texas, United States|JVC Family Medicine, Houston, Texas, United States|Clinical Trial Network, Houston, Texas, United States|Endocrine and Psychiastry Center, Houston, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|Naidu Clinic, Odessa, Texas, United States|The Methodist Hospital d/b/a HMRI CCAT at Pearland, Pearland, Texas, United States|Village Health Partners, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, LLC, Schertz, Texas, United States|Kenneth Otah and Associates, Sugar Land, Texas, United States|PHS Clinical Trials, Midvale, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Burke Internal Medicine and Research, Burke, Virginia, United States|Ettrick Health Center, Ettrick, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|Richmond Family Practice, Richmond, Virginia, United States|Larry D Stonesifer, MD Inc., PS, Federal Way, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Instituto de Investigaciones Clínicas de Bahía Blanca, Bahía Blanca, Argentina|CIPREC, Caba, Argentina|CENUDIAB, Caba, Argentina|Instituto Médico Especializado, Capital Federal, Argentina|Consultorios Asociados de Endocrinología e Invest Clínica, Capital Federal, Argentina|IPAC - Clínica Privada Caraffa SRL, Cordoba, Argentina|Instituto Cardiovascular de Corrientes Juana Francisca Cabra, Corrientes, Argentina|Ilaim-Ceom, Córdoba, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|CIPADI, Mendoza, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Argentina|Instituto de Hematología y Medicina Clínica Dr. Rubén Davoli, Rosario, Argentina|Hospital San Bernardo, Salta, Argentina|Investigaciones Clinicas Tucuman, San Miguel de Tucumán, Argentina|Instituto de Investigaciones Biomédicas, Santa Fe, Argentina|Centro de Investigaciones Clínicas del Litoral, Santa Fe, Argentina|Royal Brisbane & Women's Hospital-Endocrinology, Herston, Queensland, Australia|Logan Hospital, Meadowbrook, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Eastern Clinical Research Unit, East Ringwood, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Blankenberge - PRAC Vileyn, Geert, Blankenberge, Belgium|Bonheiden - HOSP Imelda, Bonheiden, Belgium|De Pinte - PRAC Hollanders, Geert, De Pinte, Belgium|Retie - PRAC De Vos, Axel, Dessel, Belgium|Deurne - PRAC Heyvaert, Frank, Deurne, Belgium|Deurne - PRAC Verelst, Joost, Deurne, Belgium|Genk - PRAC Vernijns, J., Genk, Belgium|Gozée - PRAC De Meulemeester, Marc, Gozée, Belgium|Hasselt - PRAC Vantroyen, Daniel, Hasselt, Belgium|Herent - PRAC Denolf, Bart, Herent, Belgium|Linkebeek - PRAC Maury, Olivier, Linkebeek, Belgium|Moorsel - PRAC Van Mulders, N., Moorsel, Belgium|Natoye - PRAC Balthazar, Y., Natoye, Belgium|Tremelo - PRAC Vermeersch, Lode, Tremelo, Belgium|Hospital Universitário João de Barros Barreto, Belém, Brazil|Universidade Federal do Paraná, Curitiba, Brazil|Hospital Geral de Goiânia Alberto Rassi, Goiânia, Brazil|Centro de Pesquisas Clínicas Ltda, Higienópolis, Brazil|Centro de Estudos em Diabetes e Hipertensão, Joaquim Távora, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Brazil|Instituto Estadual de Diabetes e Endocrinologia, Río de Janeiro, Brazil|Irmandade da Santa Casa de Misericórdia de São Paulo - IPEC - Instituto de Pesquisa Clínica, Santa Cecília, Brazil|Instituto de Molestias Cardiovasculares - IMC, São José do Rio Preto, Brazil|Hospital das Clinicas da FMUSP, São Paulo, Brazil|Hospital do Rim e Hipertensão - UNIFESP, Vila Clementino, Brazil|Univ.Multiprofile Hospital ""Dr. Georgy Stranski"" EAD, Pleven, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Zaritza Johanna"", Sofia, Bulgaria|Military Medical Academy, Clin. Endocrinology & Metab. Dis., Sofia, Bulgaria|MHAT Prof Stoyan Kirkovich AD, Stara Zagora, Bulgaria|IUCPQ (Laval University), Quebec, Migration Data, Canada|First Line Medical Services Ltd., St. John's, Newfoundland and Labrador, Canada|Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Cambridge Cardiac Care Inc., Cambridge, Ontario, Canada|Hamilton Medical Research Group, Hamilton, Ontario, Canada|SKDS Research Incorporated, Newmarket, Ontario, Canada|Wilderman Medical Clinic, Thornhill, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Albion Finch Medical Centre, Toronto, Ontario, Canada|Kings County Medical Centre, Montague, Prince Edward Island, Canada|Dynamik Research, Pointe Claire, Quebec, Canada|Consulta Privada Maria Loreto Aguirre Coveña, Providencia, Chile|Hospital de Servicios Médicos Godoy Ltda, Providencia, Chile|Centro Medico Antulawen, Temuco, Chile|Hospital Naval Almirante Nef, Viña del Mar, Chile|BioMelab, Barranquilla, Colombia|Centro Cientifico Asistencial Jose Luis Accini, Barranquilla, Colombia|Fundacion del Caribe de Investigacion Biomedica, Barranquilla, Colombia|Endocare Research Institute, Bogota, Colombia|Dexa Diabetes Servicios Médicos Ltda, Bogotá, Colombia|UNIENDO Unidad Integral de Endocrinologia, Bogotá, Colombia|Centro cardiovascular Aristides, Cartagena, Colombia|centro de Diagnostico Cardiologico para la Investigacion Bio, Cartagena, Colombia|Fundacion Cardiovascular de Colombia, El Bosque, Colombia|Fundación Oftalmologica de Santander, El Bosque, Colombia|Fundación Centro de Investigaciones Biomédicas Riescard, Tolima, Colombia|Internal & Diabetology Ambulance, Jablonec nad Nisou, Jablonec nad Nisou, Czechia|Diabetology & Internal Ambulance, Olomouc-Lazce, Czechia|Internal & Diabetology Ambulance Dr. Vrkoc, Ostrava, Ostrava, Czechia|Cardiology ambulance, Plzen, Plzen, Czechia|ResTrial s.r.o., Praha 8, Czechia|Diebetology internal Ambulance, Praha, Czechia|Internal & Diabetology Ambulance, Prostejov, Prostejov, Czechia|Hospital Strakonice, Internal Department, Strakonice, Czechia|Diabetesklinikka, Mehiläinen Töölö, Helsinki, Finland|Lääkärikeskus Ite, Joensuu, Finland|Lääkärikeskus Aava Kerava, Kerava, Finland|Kokkolan Lääkärikeskus, Kokkola, Finland|IteLasaretti, Kuopio, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|TYKS, Turku, Finland|CAB Hell M, MG, Behren Les Forbach, Behren Les Forbach, France|HOP Haut Levèque, Diabéto, Pessac, Bordeaux, France|CAB Lemarie B, MG, Bourg des Cptes, Bourg des Comptes, France|CAB Cadinot Dr D, Broglie, Broglie, France|CAB Breton Dr Nicolas, Béziers, France|CAB Ferrier R, MG, Cannes, Cannes, France|CAB Jordan E, MG, Carbonne, Carbonne, France|CAB Merlin P, MG Castets, Castets, France|CAB Fonteny R, MG, Chartres, Chartres, France|CAB Fournier P, MG, Chartres, Chartres, France|CAB Martocq G, MG, Cournonterral, Cournonterral, France|HOP, Fort de France, Fort de France, Fort De France, France|CAB Le Mouel S, MG, Hinx, Hinx, France|CAB Pholsena, MG, La Réunion, La Reunion, France|CAB Bismuth M, Labarthe sur Leze, France|CAB Zimmermann D, Louvigne De Bie, France|CAB Mainetti P, MG, Maintenon, Maintenon, France|CAB Barucq F, MG, Orthez, Orthez, France|CAB Mostephai M, Orthez, France|CAB Cassagnes JL, MG, Palau Del Vidre, Palau Del Vidre, France|CAB Mercey Y, MG, St Genies des Fontaines, Saint Genies Des Fontaines, France|Hop St Dié des Vosges, Diabéto, St Dié des Vosges, St Dié des Vosges Cedex, France|CAB Bonneau D, MG, Thouars, Thouars, France|CAB Morel H, MG, Tilly sur Seulles, Tilly sur Seulles, France|Unimed Ajara LLC, Private Practice, Batumi, Georgia|Central Hospital LTD 'Gormedi', Gori, Gori, Georgia|L&J Clinic, Kutaisi, Kutaisi, Georgia|EC Cardiology Clinic,Tbilisi, Tbilisi, Georgia|National Center for Diabetes Research Ltd., Tbilisi, Tbilisi, Georgia|National Institute of Endocrinology, Tbilisi, Tbilisi, Georgia|Zhordania Institute of Human Reproduction, Tbilisi, Tbilisi, Georgia|Medical Centre Medelite Ltd., Tbilisi, Tbilisi, Georgia|Chemotherapy & Immunotherapy Clinic 'Medulla', Tbilisi, Tbilisi, Georgia|JSC 'Curatio', Zugdidi, Georgia|Universitätsklinikum Aachen, AöR, Aachen, Germany|Studienzentrum Klausmann, Aschaffenburg, Germany|Gemeinschaftspraxis, Asslar, Asslar, Germany|Diabetes Schwerpunktpraxis, Bad Nauheim, Germany|Praxis Dr. Naumburger, Berlin, Berlin, Germany|emovis GmbH, Berlin, Germany|Praxis Dr. Rieker, Berlin, Berlin, Germany|IFG Institut für Gesundheitsförderung GmbH, Berlin, Germany|MVZ DaVita Dormagen GmbH, Dormagen- Hackenbroich, Germany|Praxis Dr. Busch, Dortmund, Dortmund, Germany|GWT-TUD GmbH, Dresden, Germany|Praxis Dr. Schlecht, Eisenach, Eisenach, Germany|ZKS Südbrandenburg GmbH, Elsterwerda, Germany|Praxis Dr. Huptas, Essen, Essen, Germany|Praxis Dr. Schmidt, Flörsheim, Flörsheim, Germany|Institut für Stoffwechselforschung, Frankfurt, Frankfurt, Germany|Praxis Dr. Groeneveld, Furth im Wald, Furth im Wald, Germany|Praxis Dr. Kohlhas, Gebhardshain, Gebhardshain, Germany|Praxis Dr. Samer, Haag, Haag, Germany|Klinische Forschung Management & Services GmbH, Hamburg, Germany|Diabetologische Schwerpunktpraxis, Hamburg, Germany|Praxis Dr. Burkhardt, Hamburg, Hamburg, Germany|Diabeteszentrum Alstertal, Hamburg, Hamburg, Germany|Praxis Dr. Herrmann, Hatten, Kirchhatten, Germany|Dünnwaldpraxis, Köln, Köln, Germany|Praxis Dr. Klein, Künzing, Künzing, Germany|Praxis Dr. Nischik, Leipzig, Leipzig, Germany|Praxis Dr. Kropp, Lübeck, Lübeck, Germany|PFÜTZNER Science & Health Institute GmbH, Mainz, Germany|Diabetologische Schwerpunktpraxis, Münster, Germany|Praxis Dr. Böckmann, Neumünster, Germany|Praxis Dr. Hilgenberg, Rehburg-Loccum, Germany|Praxis Dr. Naudts, Rodgau, Rodgau/Dudenhofen, Germany|Praxis Dr. Hirschhäuser, Saarbrücken, Germany|Praxis Dr. Segner, St. Ingberg, Saint Ingbert / Oberwürzbach, Germany|Praxis Dr. Herrmann, Schwabenheim, Germany|Praxis Dr. Dietlein, Stadtbergen, Germany|Praxis Dr. Sauter, Wangen, Germany|Schwerpunktpraxis Diabetologie, Zwenkau, Germany|General Hospital of Athens Evangelismos, Athens, Greece|General University Hospital ""Attikon"", Haidari, Athens, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|General Hospital ""Amalia Fleming"", Melissia, Athens, Greece|General Hospital of Nikaia, Nikaia, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|General Hopsital of Thessaloniki ""Ippokrateio"", Thessaloniki, Greece|Kliniki Thermi, Thessaloniki, Greece|Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Imre Magyar Hospital, Ajka, Ajka, Hungary|Lausmed Kft. Outpatient Unit of Internal Medicine, Baja, Hungary|Karolyi Sandor Hospital, Budapest, Budapest, Hungary|Bekes County Pandy Kalman Hospital, Gyula, Hungary|Erzsebet Hospital, Hodmezövasarhely, Hódmezövásárhely, Hungary|Dr. Samuel Diosszilagyi Hospital and Outpatient Clinic, Mako, Mako, Hungary|TaNa Med Kft., Mosonmagyarovar, Hungary|Grof Esterhazy Hospital and Outpatient Clinic, Papa, Hungary|Tolna County Balassa Janos Hospital, Szekszard, Hungary|Shree Krishna Hospital and Heart Care Centre, Ahmedabad, Ahmedabad, India|CIIGMA Institute of Medical Sciences Pvt Ltd, Aurangabad, India|MS Ramaiah Memorial Hospital,, Bangalore, Karnataka, India|Diabetes care and research centre, Bangalore, India|Manipal Hospital, Bangalore, India|Bangalore Diabetes Centre (BDC)- Medisys Clinical Research, Bangalore, India|Belgaum Diabetes Centre, Belgaum, Belgaum, India|Swamy Diabetes Centre, Chennai, India|Apollo Hospitals, Chennai, India|M V Hospital For Diabetes and Diabetes Research Centre, Chennai, India|Dr. Mohans Diabetes Speciality Centre, Chennai, India|Kovai Diabetes Speciality Centre & Hospital, Coimbatore, India|TOTALL Diabetes Hormone Institute, Indore, India|Diabetes Thyroid and Endocrine Centre, Jaipur, India|Diamed Clinical Research Services Pvt. Ltd., Jaipur, India|Grant Medical Foundation, Ruby Hall Clinic, Maharashtra, India|K.G.N. Diabetes and Endocrine Centre, Mumbai, Maharastra, India|Global Hospital- Superspeciality & Transplant Centre, Mumbai, India|RHIDEM, Mumbai, India|Sunil's Diabetes care and Research Centre, Nagpur, India|Jahingir Clinical Development Centre, Pune, India|Deshmukh Clinic, Pune, India|Diabetes Care Center, Thiruvananthapuram, India|Yalamanchi Hospitals & Research Centres Pvt Ltd., Vijayawada, India|The Red House Family Practice, Co. Cork, Ireland|Connolly Hospital Blanchardstown, Dublin, Ireland|The Palms GP Surgery, Gorey, Ireland|Fethard-on-Sea Medical Practice, Wexford, Ireland|Barzilai Medical Center, Ashkelon, Israel|Rambam Medical Center, Haifa, Israel|Edith Wolfson Medical Center, Diabetic Unit, Holon, Holon, Israel|Hadassah Medical Center, Ein-Karem, Jerusalem, Israel|Western Galilee Hospital, Nahariya, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Israel|Sourasky Medical Center, Tel-Aviv, Israel|Ospedale ""SS. Trinità"", Cagliari, Italy|Policlinico Universitario Mater Domini, Universita di Catanzaro, Catanzaro, Italy|Policlinico San Martino, Genova, Italy|Ospedale di Guastalla, Guastalla (RE), Italy|A.O.U.Policlinico G.Martino, Messina, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Ospedale S. Pertini, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|IRCCS Gruppo Multimedica, Sesto San Giovanni (MI), Italy|Daishinkai Medical Corporation Ookuma Hospital, Aichi, Nagoya, Japan|Chibanishi General Hospital, Chiba, Matsudo, Japan|New Tokyo Heart Clinic, Chiba, Matsudo, Japan|Kashinoki I.M. Clinic, Fukushima, I.M., Fukushima, Date, Japan|Japan Community Health care Organization Nihonmatsu Hospital, Fukushima, Nihonmatsu, Japan|Iwase General Hospital, Fukushima, Sukagawa, Japan|Iryohojinshadan Sasaki Clinic, Hyogo, Amagasaki, Japan|Takasagoseibu Hospital, Hyogo, Takasago, Japan|Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Yokohama, Japan|Jinnouchi Clinic Diabetes Care Center, Kumamoto, Kumamoto, Japan|Kumamoto Rosai Hospital, Kumamoto, Yatsushiro, Japan|Koga General Hospital, Miyazaki, Miyazaki, Japan|Saitama Medical Cooperative Association Hanyu General Hospital, Saitama, Hanyu, Japan|Nihon University Itabashi Hospital, Tokyo, Itabashi-ku, Japan|Korea University Ansan Hospital, Ansan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Health Insurance Service Ilsan Hospital, Goyang, Korea, Republic of|Dongguk University Ilsan Hospital, Goyang, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Pusan National Univ. Hosp, Pusan, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Wonju Severance Christian Hosp, Wonju, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of|Monash University, Johor Bahru, Johor, Malaysia|Hospital University Sains Malaysia, Kota Bharu, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Hospital Melaka, Melaka, Malaysia|Penang Medical College, Penang, Malaysia|Hospital Taiping, Taiping, Malaysia|Hospital General de Acapulco, Acapulco, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes, Aguascalientes, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Distrito Federal, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occident, Guadalajara, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico|Huisartspraktijk Emmers, 's-hertogenbosch, Netherlands|FlevoResearch, Almere, Netherlands|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Rode Kruis Ziekenhuis Beverwijk, Beverwijk, Netherlands|Andromed Breda, Breda, Netherlands|Noordwest Ziekenhuisgroep, location Den Helder, Den Helder, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Andromed Noord, Groningen, Netherlands|Vasculair Onderzoek Centrum, Hoorn, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Rotterdam Research Institute, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Andromed Oost, Velp, Netherlands|Andromed Leiden-Zoetermeer, Zoetermeer, Netherlands|Christchurch Hospital, Christchurch, New Zealand|RMC Medical Research Ltd, Dunedin, New Zealand|P3 Research, Wellington, Newtown Wellington NZ, New Zealand|P3 Research, Promed House, Tauranga, New Zealand|Bodø Legesenter AS, avd. for med. studier, Bodø, Norway|Medi 3 Innlandet AS, avd Elverum, Elverum, Norway|Vestre Viken HF, Bærum sykehus, Gjettum, Norway|M3 Helse AS, Hamar, Norway|Bylegene SA, Jessheim, Norway|Heiaklinikken, Lierskogen, Norway|Rådhuset Spesialistsenter, Oslo, Norway|Sandvika Spesialistsenter, Sandvika, Norway|Grålum Legesenter, Sarpsborg, Norway|Forusakutten - Kolibri Medical, Avd. Stavanger, Stavanger, Norway|Medi 3 AS, Ålesund, Norway|Instituto Delgado de Investigacion Medica, Arequipa, Peru|Clinica San Pedro, Huacho, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|Clinica Internacional, Lima, Peru|Centro de Investigaciones Médicas METABOLICARE SAC, Lima, Peru|Clinica San Gabriel, Lima, Peru|Centro De Especialidades Medicas Santa Maria S.A.C, Piura, Peru|Clinica San Judas Tadeo, San Miguel, Peru|Center for Diabetes Care, Iloilo, Philippines|Mary Mediatrix Medical Center, Lipa City, Batangas, Philippines|Philippine General Hospital, Manila, Philippines|University of Santo Tomas Hospital, Manila, Philippines|Manila Doctors Hospital, Manila, Philippines|Asian Hospital & Medical Center, Muntinlupa, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Quirino Memorial Medical Center, Quezon City, Philippines|Cardinal Santos Medical Center, San Juan, Philippines|Surigao Health Specialists, Surigao, Philippines|Hospital Fernando Fonseca, EPE, Amadora, Portugal|CHLO, EPE - Hospital de Santa Cruz, Carnaxide, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Centro Hospitalar da Cova da Beira Hospital Pêro da Covilhã, Covilhã, Portugal|Hospital Distrital Figueira da Foz, EPE, Figueira da Foz, Portugal|Hospital da Luz, Lisboa, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião, Santa Maria da Feira, Portugal|SC Diabol SRL, Brasov, Brasov, Romania|Nicodiab SRL, Bucharest, Bucharest, Romania|SC Medical Centre ""Sanatatea Ta"" SRL, Bucharest, Bucharest, Romania|Consultmed SRL, Iasi, Iasi, Romania|Emergency County Clinical Hospital, Sibiu, Sibiu, Romania|Private Practice Dr. Remus Gagiu, Tirgoviste, Romania|LLC Clinic of new technologies of medicine, Dzerzhinsky, Russian Federation|City Clinical Hospital No. 6 of MoH of Udmurt Republic, Izhevsk, Russian Federation|City Clinical Hospital No. 4, Moscow, Moscow, Russian Federation|City Clinical Hospital No. 13, Moscow, Moscow, Russian Federation|State Institution ""Central Clinical Hospital of RAS"", Moscow, Moscow, Russian Federation|City Clinical Hospital No. 61, Moscow, Moscow, Russian Federation|State Healthcare Institution, Regional hospital #2, Rostov-na-Donu, Russian Federation|Limited Liability Company ""CENTER DIABET"", Samara, Samara, Russian Federation|MMU City Outpatient Clinic no. 20, Saratov, Saratov, Russian Federation|Clinical Medical Center Zvezdara, Belgrade, Belgrade, Serbia|Clinical Centre Nis, Nis, Serbia|General Hospital Pancevo, Pancevo, Serbia|General Hospital Subotica, Internal Medicine, Subotica, Serbia|Clinical Hospital Center Zemun, Zemun, Serbia|DIASTYLE s.r.o., Diabetology Outpatient Department, Banska Bystrica, Slovakia|ENDIAMED s.r.o., Dolny Kubin, Dolny Kubin, Slovakia|CELL B s.r.o., Levice, Slovakia|DIA-KONTROL s.r.o., Levice, Slovakia|Funkystuff s.r.o., Nove Zamky, Nove Zamky, Slovakia|Diabetologicka ambulancia MUDr. Lucia Gajdosikova s.r.o., Povazska Bystrica, Slovakia|MEDIVASA s.r.o., Outpatient Clinic, Zilina, Zilina, Slovakia|Dr. P. Patel, Cape Town, South Africa|Dr. E. L. Janari, Cape Town, South Africa|Dr. Vawda, Durban, South Africa|Parklands Medical Centre, Durban, South Africa|Dr. Jurgens, Krugersdorp, South Africa|Dr. H. Makan, Lenasia, South Africa|Dr. D. R. Lakha, Johannesburg, Lenasia, South Africa|Greenacres Hospital, Port Elizabeth, South Africa|Dr. M. Seeber, Pretoria, South Africa|Vergelegen Medi-Clinic, Somerset West, South Africa|C.A.P. Sardenya, Barcelona, Spain|CAP Les Corts, Barcelona, Spain|CAP Casanova, Barcelona, Spain|CAP Burjassot 1, Burjassot, Spain|C.S. Natahoyo, Gijon, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|CAP Florida, L'Hospitalet de Llobregat, Spain|Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain|CAP La Roca, La Roca Del Vallés (Barcelona), Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|C.S. El Cristo, Oviedo, Spain|C.S. Colloto, Oviedo, Spain|C.S. Vallobin-La Florida, Oviedo, Spain|ABS Pineda de Mar, Pineda de Mar, Spain|Hospital de l'Esperit Sant, Santa Coloma De Gramanet, Spain|CAP Tàrrega, Tàrrega, Spain|CS Ingeniero Joaquin Benlloch, Valencia, Spain|Hospital Clínico de Valencia, Valencia, Spain|CTC Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Sjukhuset, Härnösand, Härnösand, Sweden|Avonova Hälsa AB, Järfälla, Sweden|Skånes universitetssjukhus, Malmö, Malmö, Sweden|Dalecarlia Clinical Research Center, Rättvik, Sweden|Södra Dalarnas vårdcentral, Hedemora, Rättvik, Sweden|Näsets Läkargrupp, Skanör, Sweden|Vårdcentralen Silentzvägen, Uddevalla, Sweden|S3 Clinical Research Centers, Vällingby, Sweden|Allgemeine Medizin, Basel, Switzerland|FMH endocrinologia diabetologia, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Dr. Pietro Gerber, Lugano, Switzerland|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|E-Da Hospital, Kaohsiung, Taiwan|Far Eastern Memorial Hospital, New Taipei City, Taiwan|Taichung Veterans General Hospital, Taichung,, Taiwan|China Medical University Hospital, Taichung, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shih-Kong Wu Ho-Shu Memorial Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Cardinal Tien Hospital, Taipei, Taiwan|Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|HOP Fattouma Bourguiba, Mint, Monastir, Monastir, Tunisia|HOP Hédi Chaker, Endo, Sfax, Sfax, Tunisia|HOP Farhat Hached, Mint, Sousse, Sousse, Tunisia|HOP Habib Thameur, Mint, Tunis, Tunis, Tunisia|Donetsk Regional Clinical Hosp, Therapy Department, Donetsk, Ukraine|Ivano-Frankivsk City Central Clinical Hospital, Ivano-Frankivsk, Ukraine|City Clinical Hospital No. 17, Kharkov, Kharkiv, Ukraine|City Clinical Hospital No. 27, Kharkiv, Kharkov, Ukraine|Clinic for Cardiology ""Sertse i sudyny"", Kiev, Kiev, Ukraine|City Clinical Hospital No. 1, Kiev, Kiev, Ukraine|Poliklinika #2, Kyiv, Kyiv, Ukraine|City Hospital No. 5, Lvov, Lvov, Ukraine|Odeska zaliznichna likarnya, Odessa, Odesa, Ukraine|Vinnitsia Regional Endocrinology Dispensary, Vinnitsa, Ukraine|Crouch Oak Family Practice, Addlestone, United Kingdom|Ash Vale Health Centre, Aldershot, Ash Vale, Aldershot, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Hathaway Medical Centre, Chippenham, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|St Mary's Surgery, Ely, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|James Paget University Hospital, Great Yarmouth, United Kingdom|Morriston Hospital, Swansea, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01243424/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01243424/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01243424
448,NCT03168295,PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin 10mg then Placebo Oral Tablet|Drug: Placebo Oral Tablet then Dapagliflozin 10mg,The University of Texas Health Science Center at San Antonio|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03168295/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03168295
449,NCT01707147,"A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Trajenta tablet,Boehringer Ingelheim|Eli Lilly and Company,"19 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,"Multiple Locations, Korea, Republic of","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01707147/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01707147/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01707147
450,NCT02949037,Enhancing mHealth Technology to Activate Chronic Care Patients,Completed,No Results Available,"Diabetes Mellitus, Type 2",Other: Mobile Health Care Environment (MHCE),Clemson University|Madigan Army Medical Center|U.S. Army Medical Research and Development Command,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,"Mike O'Callaghan Federal Medical Center, Nellis Air Force Base, Nevada, United States|Madigan Army Medicall Center, Tacoma, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02949037/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02949037
451,NCT02551874,"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",Completed,Has Results,Type 2 Diabetes Mellitus,"Drug: Saxagliptin, Onglyza|Drug: Dapagliflozin, Farxiga|Drug: Glargine insulin|Drug: Metformin",AstraZeneca,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Anaheim, California, United States|Research Site, Los Angeles, California, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Norcross, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Barto, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bountiful, Utah, United States|Research Site, Karlovy Vary, Czechia|Research Site, Olomouc, Czechia|Research Site, Koebenhavn, Denmark|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Lodz, Poland|Research Site, Nowy Duninow, Poland|Research Site, Sochaczew, Poland|Research Site, Craiova, Romania|Research Site, Ploiesti, Romania|Research Site, Timisoara, Romania|Research Site, Timișoara, Romania|Research Site, Lenasia, South Africa|Research Site, La Coruña, Spain|Research Site, Uddevalla, Sweden","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02551874/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02551874/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02551874
452,NCT02984644,Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin,Completed,Has Results,Type II; Diabetes,Drug: Dapagliflozin|Drug: Placebo,The University of Texas Health Science Center at San Antonio,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University of Texas Health Science Center, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02984644/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02984644
453,NCT02613897,"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Placebo,The University of Texas Health Science Center at San Antonio|AstraZeneca,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02613897/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02613897
454,NCT04193566,Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes,Completed,No Results Available,"Nephropathy|Hypoxia|Mitochondrial Alteration|Type 1 Diabetes|Autonomic Neuropathy, Diabetic",Drug: Forxiga,"Steno Diabetes Center Copenhagen|Glostrup University Hospital, Copenhagen|Novo Nordisk A/S","18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Steno Diabetes Center Copenhagen, Gentofte, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT04193566/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04193566
455,NCT01144338,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Exenatide Once Weekly|Drug: Placebo,AstraZeneca,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, Escondido, California, United States|Research Site, Fullerton, California, United States|Research Site, Greenbrae, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Redondo Beach, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Sylmar, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Victorville, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Thomaston, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Cape Coral, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Pocatello, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Hines, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Gary, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Covington, Kentucky, United States|Research Site, Evansville, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Randallstown, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Alpena, Michigan, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Hamilton, New Jersey, United States|Research Site, Lyons, New Jersey, United States|Research Site, Margate City, New Jersey, United States|Research Site, South Plainfield, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, North Massapequa, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Barberton, Ohio, United States|Research Site, Canal Fulton, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Mentor, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Penndel, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Murrells Inlet, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, McKenzie, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, CiudadAutonoma De Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Godoy Cruz, Argentina|Research Site, Jujuy, Argentina|Research Site, Mar Del Plata Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Salta, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Adelaide, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, East Gosford, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Fitzroy, Australia|Research Site, Garran, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Meadobank, Australia|Research Site, Milton, Australia|Research Site, Parkville, Australia|Research Site, Sydney, Australia|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Zams, Austria|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Merksem, Belgium|Research Site, Ronse, Belgium|Research Site, Aparecida de Goiânia, Brazil|Research Site, Belém, Brazil|Research Site, Brasilia, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Marília, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Recife, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Gulyantsi, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Delta, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Liverpool, Nova Scotia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sainte Foy, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Osorno, Chile|Research Site, Puerto Varas, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Chuangchun, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hong Kong, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Siping, China|Research Site, Suzhou, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Xian, China|Research Site, Yinchuan, China|Research Site, Barranquilla, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogotá D.C., Colombia|Research Site, Bogotá, Colombia|Research Site, Cali, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Olomouc-Lazce, Czechia|Research Site, Praha 10, Prague, Czechia|Research Site, Praha 4, Czechia|Research Site, Svitavy, Czechia|Research Site, Znojmo, Czechia|Research Site, Aachen, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Burghausen, Germany|Research Site, Burg, Germany|Research Site, Chemnitz, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Gießen, Germany|Research Site, Herne, Germany|Research Site, Hohenmölsen, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köthen, Germany|Research Site, Lichtenfels, Germany|Research Site, Mainz, Germany|Research Site, Mayen, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Obermichelbach, Germany|Research Site, Osnabrueck, Germany|Research Site, Riesa, Germany|Research Site, Rotenburg, Germany|Research Site, Stuttgart, Germany|Research Site, Würzburg, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrad, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyor, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jászberény, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pápa, Hungary|Research Site, Pécs, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szentes, Hungary|Research Site, Szentes, Hungary|Research Site, Szigetvár, Hungary|Research Site, Szikszo, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Sátoraljaújhely, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Givatayim, Israel|Research Site, Hadera, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Nahariya, Israel|Research Site, Nazareth, Israel|Research Site, Petah Tikva, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Tel-Aviv, Israel|Research Site, Firenze, Italy|Research Site, Foggia, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Sesto San Giovanni, Italy|Research Site, Terni, Italy|Research Site, Udine, Italy|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangjin-gu, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Jelgava, Latvia|Research Site, Kuldiga, Latvia|Research Site, Kuldiga, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Talsi, Latvia|Research Site, Tukums, Latvia|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kedainiai, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Panevezys, Lithuania|Research Site, Ukmerge, Lithuania|Research Site, Utena, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Alor Setar, Malaysia|Research Site, Batu Caves, Malaysia|Research Site, Kota Samarahan, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Sungai Buloh, Malaysia|Research Site, Taiping, Malaysia|Research Site, Aguascalientes, Mexico|Research Site, Cuautla, Mexico|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Puebla, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Meppel, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Nelson, New Zealand|Research Site, Newtown, New Zealand|Research Site, Palmerston North, New Zealand|Research Site, Takapuna, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Wellington, New Zealand|Research Site, Cebu, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Marikina, Philippines|Research Site, Pasig, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, Quezon, Philippines|Research Site, Quezon, Philippines|Research Site, San Juan, Philippines|Research Site, Elbląg, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Grudziadz, Poland|Research Site, Katowice, Poland|Research Site, Lublin, Poland|Research Site, Ostrołęka, Poland|Research Site, Poznań, Poland|Research Site, Płock, Poland|Research Site, Słupsk, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Satu-Mare, Romania|Research Site, Timisoara, Romania|Research Site, Timișoara, Romania|Research Site, Zalau, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Peterburg, Russian Federation|Research Site, St.Рetersburg, Russian Federation|Research Site, Thymen, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Presov, Slovakia|Research Site, Roznava, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Zilina, Slovakia|Research Site, Boksburg, South Africa|Research Site, Brits, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempton Park, South Africa|Research Site, Lenasia, South Africa|Research Site, Paarl, South Africa|Research Site, Parktown, South Africa|Research Site, Phoenix, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Potchefstroom, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Soweto, South Africa|Research Site, Umkomaas, South Africa|Research Site, A Coruña, Spain|Research Site, Alcalá de Henares, Spain|Research Site, Avila, Spain|Research Site, Ferrol, Spain|Research Site, Girona, Spain|Research Site, Granada, Spain|Research Site, Granada, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Manacor, Spain|Research Site, Málaga, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Palma deMallorca, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Tarragona, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan County, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chernivtsi, Ukraine|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetck, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Addlestone, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Irvine, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Ormskirk, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Redhill, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Suffolk, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Trowbridge, United Kingdom|Research Site, West Sussex, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT01144338/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT01144338/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01144338
456,NCT03235050,A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: MEDI0382 low dose|Drug: MEDI0382 mid dose|Drug: MEDI0382 high dose|Drug: Placebo|Drug: Liraglutide,AstraZeneca|MedImmune LLC,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Marietta, Georgia, United States|Research Site, Evansville, Indiana, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Elkridge, Maryland, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greer, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Arlington, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Botevgrad, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Red Deer, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Marc-des-Carrieres, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Plzen, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Gelnhausen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hof, Germany|Research Site, Löhne, Germany|Research Site, Lübeck, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Munster, Germany|Research Site, Oldenburg, Germany|Research Site, Pirna, Germany|Research Site, Rhaunen, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, México, Mexico|Research Site, Veracruz, Mexico|Research Site, Veracruz, Mexico|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Malacky, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Mesto nad Vahom, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Roznava, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03235050/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03235050/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03235050
457,NCT03444584,Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo|Drug: Dapaglifozin|Drug: Metformin,MedImmune LLC,"18 Years to 115 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Balatonfüred, Hungary|Research Site, Miskolc, Hungary|Research Site, Szeged, Hungary|Research Site, Manchester, United Kingdom|Research Site, Rotherham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03444584/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03444584/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03444584
458,NCT03244800,A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: MEDI0382|Drug: Placebo,MedImmune LLC,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Berlin, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Neu-Ulm, Germany|Research Site, Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03244800/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03244800/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03244800
459,NCT02197078,Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin,Completed,Has Results,"Diabetes Mellitus, Type 2",,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02197078/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02197078
460,NCT03334214,"Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes",Completed,Has Results,Hepatic Steatosis,Drug: IONIS DGAT2Rx|Drug: Placebo,"Ionis Pharmaceuticals, Inc.","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ionis Investigational Site, Halifax, Nova Scotia, Canada|Ionis Investigational Site, Chicoutimi, Quebec, Canada|Ionis Investigational Site, Budapest, Hungary|Ionis Investigational Site, Budapest, Hungary|Ionis Investigational Site, Budapest, Hungary|Ionis Investigational Site, Hatvan, Hungary|Ionis Investigational Site, Miskolc, Hungary|Ionis Investigational Site, Szekesfehervar, Hungary|Ionis Investigational Site, Bydgoszcz, Poland|Ionis Investigational Site, Bytom, Poland|Ionis Investigational Site, Chełm, Poland|Ionis Investigational Site, Katowice, Poland|Ionis Investigational Site, Kraków, Poland|Ionis Investigational Site, Kraków, Poland|Ionis Investigational Site, Mysłowice, Poland|Ionis Investigational Site, Wierzchosławice, Poland|Ionis Investigational Site, Wrocław, Poland|Ionis Investigational Site, Wrocław, Poland|Ionis Investigational Site, Wrocław, Poland|Ionis Investigational Site, Łódź, Poland|Ionis Investigational Site, Dundee, United Kingdom|Ionis Investigational Site, Nottingham, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03334214/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03334214
461,NCT02592421,SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2,Completed,Has Results,Type II Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo,The University of Texas Health Science Center at San Antonio|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02592421/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02592421
462,NCT02324842,Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Canagliflozin|Drug: Liraglutide,"The University of Texas Health Science Center at San Antonio|Janssen Scientific Affairs, LLC","18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02324842/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02324842
463,NCT03064841,"Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: No Treatment,Boehringer Ingelheim,"60 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,"Peking University Shougang Hospital, Beijing, China|Beijing Hospital, Beijing, China|Beijing Pinggu Hospital, Beijing, China|China Meitan General Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Chinese Traditional Medicine Hospital of Sichuna Provinc, Chengdu, China|West China Hospital, Chengdu, China|First Affiliated Hospital of Dalian Medical University, Dalian, China|Forth Clinical Hospital of Harbin Medical University, Harbin, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China|Nanjing First Hospital, Nanjing, China|Integrated Chinese and Western Medicine Hospital, Nanjing, China|Affiliated Hospital of Nantong University, Nantong, China|The affiliated hospital of medicalcollege qingdao university, Qingdao, China|Shengjing Hospital of China Medical University, Shenyang, China|Shenzhen People's Hospital, Shenzhen, China|The First Affiliated Hospital of Soochow University, Suzhou, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03064841/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03064841/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03064841
464,NCT02029846,Glycemia in Diabetic Elders Trial,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Standard Treatment|Drug: Incretin-Based Treatment,Johns Hopkins University,65 Years and older   (Older Adult),Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bay West Endocrinology Associates, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02029846/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02029846
465,NCT02681094,"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",Completed,Has Results,Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Placebo for Dapagliflozin|Drug: Saxagliptin|Drug: Placebo for Saxagliptin,AstraZeneca,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Saraland, Alabama, United States|Research Site, Fresno, California, United States|Research Site, Harbor City, California, United States|Research Site, Hawaiian Gardens, California, United States|Research Site, Lancaster, California, United States|Research Site, Los Angeles, California, United States|Research Site, Montclair, California, United States|Research Site, Pomona, California, United States|Research Site, Spring Valley, California, United States|Research Site, Vallejo, California, United States|Research Site, Denver, Colorado, United States|Research Site, Northglenn, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Cooper City, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Buford, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Zachary, Louisiana, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Florissant, Missouri, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, East Providence, Rhode Island, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Moncton, New Brunswick, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Mirabel, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Saint-Marc-des-Carrieres, Quebec, Canada|Research Site, Ceske Budejovice, Czechia|Research Site, Chrudim III, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 8, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Berlin, Germany|Research Site, Bünde, Germany|Research Site, Essen, Germany|Research Site, Giengen, Germany|Research Site, Grossheirath, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Karlsruhe, Germany|Research Site, Lichtenfels, Germany|Research Site, Meine, Germany|Research Site, Münster, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Stolberg, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Zapopan, Mexico|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladikavkaz, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02681094/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02681094/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02681094
466,NCT03211858,Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine,Completed,Has Results,Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus,Drug: Insulin aspart|Drug: NovoLog/NovoRapid|Drug: Insulin glargine (HOE901),Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 8400040, Little Rock, Arkansas, United States|Investigational Site Number 8400012, Concord, California, United States|Investigational Site Number 8400002, Escondido, California, United States|Investigational Site Number 8400030, Fresno, California, United States|Investigational Site Number 8400004, Greenbrae, California, United States|Investigational Site Number 8400014, La Jolla, California, United States|Investigational Site Number 8400043, Los Angeles, California, United States|Investigational Site Number 8400036, Pomona, California, United States|Investigational Site Number 8400011, Santa Barbara, California, United States|Investigational Site Number 8400013, Ventura, California, United States|Investigational Site Number 8400037, Aurora, Colorado, United States|Investigational Site Number 8400018, Englewood, Colorado, United States|Investigational Site Number 8400031, New Port Richey, Florida, United States|Investigational Site Number 8400027, Ocoee, Florida, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400022, Columbus, Georgia, United States|Investigational Site Number 8400032, Roswell, Georgia, United States|Investigational Site Number 8400038, Arlington Heights, Illinois, United States|Investigational Site Number 8400005, Des Moines, Iowa, United States|Investigational Site Number 8400041, Metairie, Louisiana, United States|Investigational Site Number 8400015, Rockville, Maryland, United States|Investigational Site Number 8400042, Waltham, Massachusetts, United States|Investigational Site Number 8400019, Flint, Michigan, United States|Investigational Site Number 8400003, Omaha, Nebraska, United States|Investigational Site Number 8400024, Henderson, Nevada, United States|Investigational Site Number 8400028, New York, New York, United States|Investigational Site Number 8400025, Morehead City, North Carolina, United States|Investigational Site Number 8400010, Wilmington, North Carolina, United States|Investigational Site Number 8400023, Fargo, North Dakota, United States|Investigational Site Number 8400029, Bend, Oregon, United States|Investigational Site Number 8400033, Chattanooga, Tennessee, United States|Investigational Site Number 8400044, Austin, Texas, United States|Investigational Site Number 8400009, Dallas, Texas, United States|Investigational Site Number 8400035, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400017, Houston, Texas, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400020, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400034, Salt Lake City, Utah, United States|Investigational Site Number 8400008, Renton, Washington, United States|Investigational Site Number 8400039, Bridgeport, West Virginia, United States|Investigational Site Number 2460006, Jyväskylä, Finland|Investigational Site Number 2460002, Kuopio, Finland|Investigational Site Number 2460004, Pori, Finland|Investigational Site Number 2460003, Seinäjoki, Finland|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760006, Essen, Germany|Investigational Site Number 2760004, Heidelberg, Germany|Investigational Site Number 2760005, Oldenburg In Holstein, Germany|Investigational Site Number 2760002, Pirna, Germany|Investigational Site Number 3480012, Balatonfüred, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Debrecen, Hungary|Investigational Site Number 3480003, Nagykanizsa, Hungary|Investigational Site Number 3480010, Nyíregyháza, Hungary|Investigational Site Number 3480009, Szentendre, Hungary|Investigational Site Number 3920009, Fukuyama-Shi, Japan|Investigational Site Number 3920008, Higashiosaka-Shi, Japan|Investigational Site Number 3920007, Kashiwara-Shi, Japan|Investigational Site Number 3920001, Koriyama-Shi, Japan|Investigational Site Number 3920005, Kumamoto-Shi, Japan|Investigational Site Number 3920003, Mito-Shi, Japan|Investigational Site Number 3920010, Osaka-Shi, Japan|Investigational Site Number 3920002, Sagamihara-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Ushiku-Shi, Japan|Investigational Site Number 6160004, Bialystok, Poland|Investigational Site Number 6160003, Krakow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160007, Lublin, Poland|Investigational Site Number 6160006, Nowy Sacz, Poland|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6430002, Samara, Russian Federation|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430001, St. Petersburg, Russian Federation|Investigational Site Number 6430004, Tomsk, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03211858/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03211858/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03211858
467,NCT02725593,Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years,Completed,Has Results,Type 2 Diabetes,Drug: Dapagliflozin|Drug: Dapagliflozin placebo,"AstraZeneca|Parexel|Q2 Solutions|PRA Health Sciences|Covance Laboratories, Inc","10 Years to 24 Years   (Child, Adult)",Phase 3,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Lampasas, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Budapest, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Ramat Gan, Israel|Research Site, Zerifin, Israel|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Merida, Mexico|Research Site, Monterrey, Mexico|Research Site, México, D.F., Mexico|Research Site, Zapopan, Mexico|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Kent, United Kingdom|Research Site, Leicester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02725593/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02725593/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02725593
468,NCT03596177,A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type II|Obesity",Drug: MEDI0382|Drug: Placebo,MedImmune LLC,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03596177/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03596177/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03596177
469,NCT02148250,PK/PD Study of U-500 Regular Insulin,Completed,Has Results,Type 2 Diabetes|Insulin Resistance|High Insulin Requirements,"Drug: U-500 insulin, 100 syringe units|Drug: U-500 insulin, 200 syringe units",University of Minnesota|Eli Lilly and Company,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02148250/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02148250
470,NCT02536248,Sitagliptin Therapy and Kinetics of Inflammatory Markers,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin|Drug: Placebo,Laval University|Merck Sharp & Dohme LLC,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Laval University, Quebec City, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02536248/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02536248/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02536248
471,NCT01986881,"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Ertugliflozin|Drug: Placebo|Drug: Glycemic Rescue,Merck Sharp & Dohme LLC|Pfizer,"40 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",United States,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT01986881/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT01986881/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01986881
472,NCT02512068,"A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Trelagliptin 25 mg|Drug: Placebo,Takeda,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Anjo, Aichi, Japan|Kasukabe, Aichi, Japan|Nagoya, Aichi, Japan|Toyohashi, Aichi, Japan|Yatomi, Aichi, Japan|Asahi, Chiba, Japan|Kisarazu, Chiba, Japan|Yotsukaido, Chiba, Japan|Imabari, Ehime, Japan|Matsuyama, Ehime, Japan|Niihama, Ehime, Japan|Chikushino, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kasuya-gun, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Munakata, Fukuoka, Japan|Tajimi, Gifu, Japan|Takasaki, Gunma, Japan|Fukuyama, Hiroshima, Japan|Chitose, Hokkaido, Japan|Himeji, Hyogo, Japan|Takarazuka, Hyogo, Japan|Mito, Ibaragi, Japan|Sakai, Ibaragi, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Sendai, Miyagi, Japan|Nakano, Nagano, Japan|Ueda, Nagano, Japan|Kasaoka, Okayama, Japan|Setouchi, Okayama, Japan|Fukaya, Saitama, Japan|Kumagaya, Saitama, Japan|Hamamatsu, Shizuoka, Japan|Yoshinogawa, Tokushima, Japan|Hachioji, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Kunitachi, Tokyo, Japan|Uozu, Toyama, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Akita, Japan|Kumamoto, Japan|Nagano, Japan|Niigata, Japan|Osaka, Japan|Yamagata, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02512068/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02512068/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02512068
473,NCT03832907,Dexcom G6 Observational Study,Completed,Has Results,Diabetes,Device: Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Diagnostic Test: POC BG - Point-of-Care Blood Glucose monitoring,Emory University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03832907/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03832907
474,NCT02516150,Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Ethanol|Drug: Glucagon,Massachusetts General Hospital,"21 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02516150/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02516150
475,NCT03424044,Three Way Crossover Closed Loop Study With Xeris Glucagon,Completed,Has Results,Type1diabetes,Device: Artificial Pancreas Controller in Dual Hormone Mode|Device: Artificial Pancreas Controller in Single Hormone Mode|Device: Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|Drug: XeriSol glucagon,Oregon Health and Science University|Xeris Pharmaceuticals,21 Years to 50 Years   (Adult),Phase 1,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03424044/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03424044
476,NCT03385265,Iterative Beta Testing of Videos for the DIPPer Academy,Completed,Has Results,Type1diabetes,Behavioral: DIPPer Academy|Other: Standard of Care,University of Kansas Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"3 Years to 65 Years   (Child, Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Kansas Medical Center, Kansas City, Kansas, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03385265/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03385265
477,NCT02969863,The Monitoring Study,Completed,Has Results,Type1diabetes,Device: Bihormonal Bionic Pancreas|Device: Insulin Only Bionic Pancreas|Other: Monitored for Hypoglycemia|Other: Not Monitored for Hypoglycemia,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MGH Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02969863/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02969863
478,NCT04876274,Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic,Completed,Has Results,Type 2 Diabetes,Behavioral: TMU-LOVE,Taipei Medical University|Taipei Medical University WanFang Hospital,"20 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"School of Pharmacy, Taipei Medical University, Taipei, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT04876274/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04876274
479,NCT01394952,Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND),Completed,Has Results,"Cardiovascular Disease|Diabetes Mellitus, Type 2",Drug: Dulaglutide|Drug: Placebo,Eli Lilly and Company,"50 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cork, Ireland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01394952/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01394952/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01394952
480,NCT02535715,A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED),Completed,Has Results,Type 1 Diabetes,Drug: ORMD-0801 capsules- 2x8mg|Drug: ORMD-0801 capsules- 3x8mg|Drug: ORMD-0801 capsules- 1x16mg,"The University of Texas Health Science Center at San Antonio|Oramed, Ltd.","18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02535715/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02535715
481,NCT02547935,"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",Completed,Has Results,"Type 2 Diabetes Mellitus, CKD and Albuminuria",Drug: Dapagliflozin 10 mg|Drug: Saxagliptin 2.5 mg|Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg,AstraZeneca,"18 Years to 130 Years   (Adult, Older Adult)",Phase 2|Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Peoria, Arizona, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, El Centro, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, North Hollywood, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, San Dimas, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Bangor, Maine, United States|Research Site, Kansas City, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bronx, New York, United States|Research Site, Springfield Gardens, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Brownsville, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Box Hill, Australia|Research Site, Campbelltown, Australia|Research Site, Geelong, Australia|Research Site, Herston, Australia|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Hachioji-shi, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Neyagawa-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Ansan-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Queretaro, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Kuilsrivier, South Africa|Research Site, Mamelodi East, South Africa|Research Site, Muckleneuk, South Africa|Research Site, Paarl, South Africa|Research Site, Pretoria, South Africa|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sabadell (Barcelona), Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Valencia, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Yong-Kang City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02547935/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02547935/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02547935
482,NCT03268941,"A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)",Completed,Has Results,"Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis",Drug: TAK-906 Maleate|Drug: Metaclopramide|Drug: TAK-906 Maleate Placebo,"Millennium Pharmaceuticals, Inc.|Takeda","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","9171 West Thunderbird Road, Peoria, Arizona, United States|850 North Kolb Road, Tucson, Arizona, United States|11219 Financial Centre Parkway, Little Rock, Arkansas, United States|13055 Southwest 42nd Street, Miami, Florida, United States|8200 Southwest 117th Avenue, Miami, Florida, United States|125 Clairemont Avenue, Decatur, Georgia, United States|616 South Washington Street, Bastrop, Louisiana, United States|6035 Shallowford Road, Chattanooga, Tennessee, United States|26 Stonecreek Circle, Jackson, Tennessee, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03268941/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03268941/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03268941
483,NCT02018627,Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon,Completed,Has Results,Type 1 Diabetes,Drug: Xeris glucagon|Drug: Lilly glucagon,"Steven J. Russell, MD, PhD|Massachusetts General Hospital","21 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02018627/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02018627
484,NCT02701257,"The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas",Terminated,Has Results,Diabetes Mellitus Type 1,Device: iPhone bionic pancreas|Device: iLet bionic pancreas|Drug: Xeris Xerisol glucagon|Drug: Lilly glucagon|Device: iLet infusion set|Device: Contact Detach infusion set,Massachusetts General Hospital|Boston University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MGH Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02701257/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02701257
485,NCT05115175,Acceptability of Self-Led Mindfulness-Based Intervention,Completed,No Results Available,"Diabetes Mellitus, Type 1",Behavioral: Mindfulness-Based Stress Reduction,"University of Nevada, Reno|AlterMed Research foundation","13 Years to 19 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Nevada, Reno, Reno, Nevada, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT05115175/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT05115175/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05115175
486,NCT02582814,The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Dapagliflozin 5 mg|Drug: Dapagliflozin 10mg,AstraZeneca,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Aizu Wakamatsu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Ise-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kunitachi-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Otsu-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjyuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Tama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02582814
487,NCT04694053,Fournier's Gangrene in Patient With Uncontrolled Type 2 Diabetes,Completed,No Results Available,Fournier Gangrene,Procedure: surgical debridement,University of Catania,"Child, Adult, Older Adult",,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,"University of Catania, Catania, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04694053/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04694053
488,NCT03643692,"Adaptive, Real-time, Intelligent System to Enhance Self-care of Chronic Disease",Completed,Has Results,"Diabetes Mellitus, Type 1",Device: ARISES,Imperial College London,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"Imperial College Clinical Research Facility, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03643692/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03643692
489,NCT03752567,New Patient Support Program in Type 2 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 2",Other: Follow up,Farmacia La Regina s.r.l.|Federfarma Campania|Federfarma Salerno|HTN - Health Telematic Network srl|BSI - Biochemical Systems International spa|Next Sight srl,"Child, Adult, Older Adult",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Farmacia La Regina dott. Rocco Vito, San Rufo, Salerno, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03752567/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03752567/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03752567
490,NCT04112069,The Insulin-Only Bionic Pancreas Bridging Study- Pediatric Transitional Study,Completed,Has Results,Type1 Diabetes Mellitus,Device: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|Other: Usual Care,Massachusetts General Hospital,6 Years to 17 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT04112069/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04112069
491,NCT04190693,IMCY-T1D-002: Long-term Follow-up Study of T1D Patients Previously Treated With IMCY-0098 or Placebo,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: IMCY-0098 or placebo,Imcyse SA,18 Years to 31 Years   (Adult),Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Hôpital Erasme, Brussels, Belgium|UZ Brussel, Brussels, Belgium|UZ Gent, Gent, Belgium|Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark|Hôpital Cochin, Paris, France|GWT-TUD GmbH, Dresden, Germany|Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), München, Germany|Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Lithuania|Klaipeda University Hospital, Klaipėda, Lithuania|University Hospital Santaros Klinikos, Vilnius, Lithuania|Clinical Trial Center, CTC, Göteborg, Sweden|ProbarE Stockholm, Stockholm, Sweden|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Cardiff University, Cardiff, United Kingdom|Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Guy's and St. Thomas NHS Trust, London, United Kingdom|St. Bartholomew's Hospital (Barts Health NHS Trust), London, United Kingdom|Newcastle University, Newcastle upon Tyne, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04190693/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04190693
492,NCT03554486,Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Fiasp|Drug: Novolog,Stanford University|Medtronic,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Stanford University, Palo Alto, California, United States|Stanford, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03554486/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03554486
493,NCT02471404,Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea,Completed,Has Results,Type 2 Diabetes Mellitus|Inadequate Glycaemic Control,Drug: Dapagliflozin|Drug: Saxagliptin|Drug: Glimepiride|Drug: Placebo for dapagliflozin|Drug: Placebo for saxagliptin|Drug: Placebo for glimepiride,AstraZeneca,"18 Years to 74 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Prelouc, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Neuenahr-Ahrweiler, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Bad Reichenhall, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Bünde, Germany|Research Site, Daaden, Germany|Research Site, Darmstadt, Germany|Research Site, Datteln, Germany|Research Site, Deggingen, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Erfurt, Germany|Research Site, Erlangen, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Freiburg, Germany|Research Site, Freudenstadt, Germany|Research Site, Gelnhausen, Germany|Research Site, Giengen, Germany|Research Site, Goch, Germany|Research Site, Grevesmühlen, Germany|Research Site, Grossheirath, Germany|Research Site, Göttingen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hameln, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildesheim, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Höhenkirchen, Germany|Research Site, Jerichow, Germany|Research Site, Kallstadt, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köln, Germany|Research Site, Köthen, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lichtenfels, Germany|Research Site, Lingen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Löhne, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Marl, Germany|Research Site, Meine, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf A. Inn, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Münster, Germany|Research Site, Neumünster, Germany|Research Site, Neuwied Am Rhein, Germany|Research Site, Oldenburg, Germany|Research Site, Papenburg, Germany|Research Site, Pirna, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Rehlingen Siersburg, Germany|Research Site, Reinfeld, Germany|Research Site, Remagen, Germany|Research Site, Rhaunen, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Saarlouis, Germany|Research Site, Schwabenheim, Germany|Research Site, Speyer, Germany|Research Site, Stadtbergen, Germany|Research Site, Stolberg, Germany|Research Site, Straubing, Germany|Research Site, Stuttgart, Germany|Research Site, Sulzbach, Germany|Research Site, Trier, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Wahlstedt, Germany|Research Site, Wangen, Germany|Research Site, Weinheim, Germany|Research Site, Westerkappeln, Germany|Research Site, Wetzlar, Germany|Research Site, Witten, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Hatvan, Hungary|Research Site, Kisvárda, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza-Szentetornya, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ács, Hungary|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chrzanow, Poland|Research Site, Gdańsk, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Legnica, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Poznan, Poland|Research Site, Sobótka, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Malacky, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Puchov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Vrutky, Slovakia","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02471404/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02471404/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02471404
494,NCT03840278,The Bihormonal iLet Bionic Pancreas Feasibility Study,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Bihormonal iLet Bionic Pancreas|Device: Insulin-only Bionic Pancreas|Drug: Dasiglucagon,"Massachusetts General Hospital|Beta Bionics, Inc.|Zealand Pharma","18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03840278/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03840278
495,NCT03477838,Pharmacist-driven CGM Use in the Uninsured Population,Completed,Has Results,Diabetes Mellitus,Device: FreeStyle LibrePro CGM,Virginia Commonwealth University,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03477838/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03477838
496,NCT04980040,A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin Benzoate,Takeda,"19 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Andong, Korea, Republic of|Anyang-si, Korea, Republic of|Bucheon-si, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gimhae, Korea, Republic of|Gongju, Korea, Republic of|Goyang-si, Korea, Republic of|Gwangju, Korea, Republic of|Gyeongju, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Namyangju-si, Korea, Republic of|Osan, Korea, Republic of|Seongnam-si, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suncheon, Korea, Republic of|Suwon- si, Korea, Republic of|Suwon-si, Korea, Republic of|Ulsan, Korea, Republic of|Wonju, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT04980040/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT04980040/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04980040
497,NCT03550378,A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated,Completed,Has Results,Type II Diabetes Mellitus|Renal Insufficiency,Drug: MEDI0382|Drug: Placebo,MedImmune LLC,"18 Years to 84 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Berlin, Germany|Research Site, Magdeburg, Germany|Research Site, Munster, Germany|Research Site, München, Germany|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Edinburgh, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03550378/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03550378/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03550378
498,NCT02679287,Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: CLC,"University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Roche Diagnostic Ltd.|TypeZero Technologies, LLC|Tandem Diabetes Care, Inc.|DexCom, Inc.","18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02679287/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02679287
499,NCT01180712,Study of Oral Anthocyanins on Insulin Resistance,Completed,No Results Available,Type 2 Diabetes,Dietary Supplement: Mirtoselect,University of Aberdeen,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Aberdeen Rowett Institute of Nutrition and Health, Aberdeen, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT01180712/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01180712
500,NCT02813421,Continue Glucose Monitoring Before Insulin Pump,Completed,Has Results,Type 1 Diabetes Mellitus,Device: CGM Informed,Children's Hospital Los Angeles,"2 Years to 24 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Children's Hospital Los Angeles, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02813421/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02813421
501,NCT02639637,Effect of DPP4 Inhibition on Vasoconstriction,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Sitagliptin|Drug: Placebo|Drug: Neuropeptide Y|Drug: Enalaprilat|Drug: Valsartan 160mg,Vanderbilt University|Vanderbilt University Medical Center,18 Years to 55 Years   (Adult),Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02639637/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02639637
502,NCT02531035,A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone,Completed,Has Results,Type 1 Diabetes Mellitus (T1DM)|High Level of Sugar (Glucose) in the Blood,Drug: Sotagliflozin|Drug: Placebo,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lexicon Investigational Site, Concord, California, United States|Lexicon Investigational Site, Escondido, California, United States|Lexicon Investigational Site, La Jolla, California, United States|Lexicon Investigational Site, San Marcos, California, United States|Lexicon Investigational Site, Ventura, California, United States|Lexicon Investigational Site, Walnut Creek, California, United States|Lexicon Investigational Site, Aurora, Colorado, United States|Lexicon Investigational Site, New Haven, Connecticut, United States|Lexicon Investigational Site, Orlando, Florida, United States|Lexicon Investigational Site, West Palm Beach, Florida, United States|Lexicon Investigational Site, Atlanta, Georgia, United States|Lexicon Investigational Site, Macon, Georgia, United States|Lexicon Investigational Site, Roswell, Georgia, United States|Lexicon Investigational Site, New Orleans, Louisiana, United States|Lexicon Investigational Site, Rockville, Maryland, United States|Lexicon Investigational Site, Boston, Massachusetts, United States|Lexicon Investigational Site, Bloomfield Hills, Michigan, United States|Lexicon Investigational Site, Omaha, Nebraska, United States|Lexicon Investigational Site, Las Vegas, Nevada, United States|Lexicon Investigational Site, Albany, New York, United States|Lexicon Investigational Site, Bronx, New York, United States|Lexicon Investigational Site, Asheville, North Carolina, United States|Lexicon Investigational Site, Chapel Hill, North Carolina, United States|Lexicon Investigational Site, Greenville, North Carolina, United States|Lexicon Investigational Site, Morehead City, North Carolina, United States|Lexicon Investigational Site, Grand Forks, North Dakota, United States|Lexicon Investigational Site, Bend, Oregon, United States|Lexicon Investigational Site, Sioux Falls, South Dakota, United States|Lexicon Investigational Site, Austin, Texas, United States|Lexicon Investigational Site, San Antonio, Texas, United States|Lexicon Investigational Site, Shavano Park, Texas, United States|Lexicon Investigational Site, Salt Lake City, Utah, United States|Lexicon Investigational Site, Seattle, Washington, United States|Lexicon Investigational Site, Córdoba, Cordoba, Argentina|Lexicon Investigational Site, Buenos Aires, Argentina|Lexicon Investigational Site, Buenos Aires, Argentina|Lexicon Investigational Site, Coffs Harbour, New South Wales, Australia|Lexicon Investigational Site, Merewether, New South Wales, Australia|Lexicon Investigational Site, St Leonards, New South Wales, Australia|Lexicon Investigational Site, Wollongong, New South Wales, Australia|Lexicon Investigational Site, Herston, Queensland, Australia|Lexicon Investigational Site, Keswick, South Australia, Australia|Lexicon Investigational Site, Box Hill, Victoria, Australia|Lexicon Investigational Site, Fitzroy, Victoria, Australia|Lexicon Investigational Site, Parkville, Victoria, Australia|Lexicon Investigational Site, Aalst, Belgium|Lexicon Investigational Site, Gent, Belgium|Lexicon Investigational Site, Sint-Niklaas, Belgium|Lexicon Investigational Site, Plovdiv, Bulgaria|Lexicon Investigational Site, Ruse, Bulgaria|Lexicon Investigational Site, Smolyan, Bulgaria|Lexicon Investigational Site, Sofia, Bulgaria|Lexicon Investigational Site, Sofia, Bulgaria|Lexicon Investigational Site, Varna, Bulgaria|Lexicon Investigational Site, Vancouver, British Columbia, Canada|Lexicon Investigational Site, Halifax, Nova Scotia, Canada|Lexicon Investigational Site, Barrie, Ontario, Canada|Lexicon Investigational Site, London, Ontario, Canada|Lexicon Investigational Site, Markham, Ontario, Canada|Lexicon Investigational Site, Oakville, Ontario, Canada|Lexicon Investigational Site, Thornhill, Ontario, Canada|Lexicon Investigational Site, Toronto, Ontario, Canada|Lexicon Investigational Site, Sherbrooke, Quebec, Canada|Lexicon Investigational Site, St. Laurent, Quebec, Canada|Lexicon Investigational Site, Atlantico, Colombia|Lexicon Investigational Site, Cundinamarca, Colombia|Lexicon Investigational Site, Cundinamarca, Colombia|Lexicon Investigational Site, Cundinamarca, Colombia|Lexicon Investigational Site, Krnov, Czechia|Lexicon Investigational Site, Olomouc, Czechia|Lexicon Investigational Site, Ostrava, Czechia|Lexicon Investigational Site, Praha 10, Czechia|Lexicon Investigational Site, Praha 4, Czechia|Lexicon Investigational Site, Praha 5, Czechia|Lexicon Investigational Site, Corbeil-Essonnes, France|Lexicon Investigational Site, Pierre-Bénite, France|Lexicon Investigational Site, Mainz, Palatinate, Germany|Lexicon Investigational Site, Sulzbach, Rosenberg Bavaria, Germany|Lexicon Investigational Site, Münster, Westphalia, Germany|Lexicon Investigational Site, Aschaffenburg, Germany|Lexicon Investigational Site, Asslar, Germany|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Budapest, Hungary|Lexicon Investigational Site, Eger, Hungary|Lexicon Investigational Site, Esztergom, Hungary|Lexicon Investigational Site, Gyor, Hungary|Lexicon Investigational Site, Sátoraljaújhely, Hungary|Lexicon Investigational Site, Holon, Israel|Lexicon Investigational Site, Petach-Tikvah, Israel|Lexicon Investigational Site, Petah Tikva, Israel|Lexicon Investigational Site, Rehovot, Israel|Lexicon Investigational Site, Tel Hashomer, Israel|Lexicon Investigational Site, Bologna, Italy|Lexicon Investigational Site, Catania, Italy|Lexicon Investigational Site, Catania, Italy|Lexicon Investigational Site, Latina, Italy|Lexicon Investigational Site, Milan, Italy|Lexicon Investigational Site, Rome, Italy|Lexicon Investigational Site, Epsom, Auckland, New Zealand|Lexicon Investigational Site, Takapuna, Auckland, New Zealand|Lexicon Investigational Site, Christchurch, Canterbury, New Zealand|Lexicon Investigational Site, Dunedin, Otago, New Zealand|Lexicon Investigational Site, Newtown, Wellington, New Zealand|Lexicon Investigational Site, Christchurch, New Zealand|Lexicon Investigational Site, Otahuhu, New Zealand|Lexicon Investigational Site, Gdynia, Poland|Lexicon Investigational Site, Katowice, Poland|Lexicon Investigational Site, Katowice, Poland|Lexicon Investigational Site, Lublin, Poland|Lexicon Investigational Site, Warsaw, Poland|Lexicon Investigational Site, Warsaw, Poland|Lexicon Investigational Site, Warszawa, Poland|Lexicon Investigational Site, Bardejov, Slovakia|Lexicon Investigational Site, Bratislava, Slovakia|Lexicon Investigational Site, Bratislava, Slovakia|Lexicon Investigational Site, Levice, Slovakia|Lexicon Investigational Site, Goodwood, Cape Town, South Africa|Lexicon Investigational Site, Middelburg, Mpumalanga, South Africa|Lexicon Investigational Site, Bloemfontein, South Africa|Lexicon Investigational Site, Cape Town, South Africa|Lexicon Investigational Site, Cape Town, South Africa|Lexicon Investigational Site, Johannesburg, South Africa|Lexicon Investigational Site, Port Elizabeth, South Africa|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Barcelona, Spain|Lexicon Investigational Site, Malaga, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Sevilla, Spain|Lexicon Investigational Site, Dundee, Scotland, United Kingdom|Lexicon Investigational Site, Blackburn, United Kingdom|Lexicon Investigational Site, Guildford, United Kingdom|Lexicon Investigational Site, Leicester, United Kingdom|Lexicon Investigational Site, Northampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02531035/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02531035/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02531035
503,NCT02835495,Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study,Completed,Has Results,Pre-diabetes|Obesity,Behavioral: HELP Vets Intervention|Behavioral: Individual Education Program,Wake Forest University Health Sciences|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|US Department of Veterans Affairs,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"W.G. ""Bill"" Hefner VA Medical Center, Salisbury, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02835495/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02835495/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02835495
504,NCT04104711,Home-Based Intervention to the Diabetics,Completed,No Results Available,"Diabetes Mellitus, Type 2|Home Visit","Other: Home visits, health education","Dilay AÇIL,PhD|Dokuz Eylul University","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,İzmir.,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04104711/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04104711
505,NCT02120794,Threshold Suspend in Pediatrics at Home,Completed,Has Results,Type 1 Diabetes,Device: 530G Insulin pump,Medtronic Diabetes,2 Years to 15 Years   (Child),Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Sutter Institute for Medical Research Excellence in Diabetes and Endocrinology, Sacramento, California, United States|Madison Clinic for Pediatric Diabetes at UCSF, San Francisco, California, United States|Stanford University, Stanford, California, United States|SoCal Diabetes, Torrance, California, United States|University of Colorado Health Science Center, Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Nemours Children's Health System, Jacksonville, Florida, United States|Park Nicollet Clinic - International Diabetes Center, Minneapolis, Minnesota, United States|University of Minnesota Pediatric Endocrinology Clinic, Minneapolis, Minnesota, United States|Children's Hospital and Clinics of Minnesota, Saint Paul, Minnesota, United States|The Pediatric and Endocrine Diabetes Specialists, Las Vegas, Nevada, United States|Stony Brook Children's Hospital, East Setauket, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Children Hospital/Baylor College of Medicine, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02120794/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02120794/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02120794
506,NCT02206152,A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes|Hypoglycemia Unawareness,Drug: N-acetyl cysteine|Drug: Placebo,University of Minnesota,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","University of Minnesota Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02206152/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02206152/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02206152
507,NCT01874392,"Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp",Completed,Has Results,Type 1 Diabetes Mellitus,Drug: Investigational inhaled insulin (Technosphere)|Device: Artificial Pancreas (AP) device (APS©),Sansum Diabetes Research Institute|Juvenile Diabetes Research Foundation,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sansum Diabetes Research Institute, Santa Barbara, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT01874392/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01874392
508,NCT02509065,The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Bionic Pancreas|Other: Usual Care,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masscahusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02509065/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02509065
509,NCT03252964,Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics,Completed,Has Results,Type2 Diabetes,Device: Continuous Glucose Monitor (CGM)|Device: Activity Tracker|Behavioral: Coaching,"Savvysherpa, Inc.",65 Years and older   (Older Adult),Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Rogelio Machuca, MD Family Medicine, PLLC, Las Vegas, Nevada, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03252964/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03252964/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03252964
510,NCT03819634,Longevity of Multi-Slitted Catheter With Lantern Technology,Completed,Has Results,Insulin Dependent Diabetes Mellitus 1,Device: Inset II with Lantern Technology,Stanford University|ConvaTec Inc.,"22 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03819634/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03819634
511,NCT05115188,DIAgnosing GDM usiNg Oral Sugar InStead,Not yet recruiting,No Results Available,"Diabetes, Gestational",Dietary Supplement: Dex4/ dextrose|Dietary Supplement: Glucose beverage,Sunnybrook Health Sciences Centre,"Child, Adult, Older Adult",Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Toronto , Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT05115188/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT05115188/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05115188
512,NCT05267990,Coronary Artery Calcium-guided Primary Prevention of Major Coronary Heart Disease in Asymptomatic Diabetes,Enrolling by invitation,No Results Available,Type2 Diabetes|Coronary Heart Disease,Diagnostic Test: Multi-Detector Computed Tomography,"JuFeng, Hsiao|Lotung Poh-Ai Hospital","40 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Lo-Tung Poh-Ai Hospital, YiLan, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT05267990/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT05267990/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05267990
513,NCT03013985,Glargine U300 Hospital Trial,Completed,Has Results,Type 2 Diabetes,Drug: Glargine U300|Drug: Glargine U100|Drug: Glulisine Insulin,Emory University,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03013985/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03013985/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03013985
514,NCT01989754,A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2|Albuminuria","Drug: Placebo|Drug: Canagliflozin, 100 mg|Drug: Canagliflozin, 300 mg","Janssen Research & Development, LLC|The George Institute for Global Health, Australia","30 Years and older   (Adult, Older Adult)",Phase 4,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Little Rock, Arkansas, United States|Carmichael, California, United States|Concord, California, United States|Pismo Beach, California, United States|Roseville, California, United States|Thousand Oaks, California, United States|Denver, Colorado, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Opa-locka, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Tampa, Florida, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Valparaiso, Indiana, United States|Topeka, Kansas, United States|Louisville, Kentucky, United States|Mandeville, Louisiana, United States|Metairie, Louisiana, United States|Elkridge, Maryland, United States|Flint, Michigan, United States|Picayune, Mississippi, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Washington, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Cornelius, North Carolina, United States|Hickory, North Carolina, United States|Mooresville, North Carolina, United States|Canal Fulton, Ohio, United States|Franklin, Ohio, United States|Mason, Ohio, United States|Oklahoma City, Oklahoma, United States|Beaver, Pennsylvania, United States|Levittown, Pennsylvania, United States|Norristown, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Tipton, Pennsylvania, United States|Greer, South Carolina, United States|Jefferson City, Tennessee, United States|Austin, Texas, United States|Pearland, Texas, United States|Bountiful, Utah, United States|Draper, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Falls Church, Virginia, United States|Norfolk, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Milwaukee, Wisconsin, United States|Wauwatosa, Wisconsin, United States|Buenos Aires, Argentina|Ciudad Autonoma De Buenos Aires, Argentina|Ciudad De Buenos Aires, Argentina|Cordoba, Argentina|Mar Del Plata, Argentina|Moron, Argentina|Rosario, Argentina|Zarate, Buenos Aires, Argentina|Box Hill, Australia|Cairns, Australia|Daw Park, Australia|Freemantle, Australia|Liverpool, Australia|Melbourne, Australia|Newcastle, Australia|Sherwood, Australia|Sydney, Australia|Tasmania, Australia|Woden, Australia|Woolloongabba, Australia|Bonheiden, Belgium|Brugge, Belgium|Edegem, Belgium|Gent, Belgium|La Louvière, Belgium|Leuven, Belgium|Liege, Belgium|Liÿge, Belgium|Merksem, Belgium|Ransart, Belgium|Roeselare, Belgium|Tessenderlo, Belgium|Belem, Brazil|Belo Horizonte, Brazil|Campinas, Brazil|Caxias Do Sul, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Mogi Das Cruzes, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Coquitlam, British Columbia, Canada|Winnipeg, Manitoba, Canada|Halifax, Nova Scotia, Canada|Guelph, Ontario, Canada|Mississauga, Ontario, Canada|Oshawa, Ontario, Canada|Sarnia, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Lévis, Quebec, Canada|Quebec City, Quebec, Canada|Saint Marc Des Carriéres, Quebec, Canada|Sherbrooke, Quebec, Canada|Westmont, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Baotou, China|Beijing, China|Hangzhou, China|Jinan, China|Shenyang, China|Wuxi, China|Beroun, Czechia|Ostrava, Czechia|Plzen, Czechia|Praha 10, Czechia|Praha 1, Czechia|Praha 4, Czechia|Praha 8, Czechia|Znojmo, Czechia|Amiens, France|Bois Guillaume, France|Bordeaux, France|Dijon, France|Grenoble, France|La Rochelle Cedex 1, France|Le Creusot, France|Narbonne Cedex, France|Paris, France|Poitiers, France|Aschaffenburg, Germany|Aßlar, Germany|Bad Oeynhausen, Germany|Dortmund, Germany|Dresden, Germany|Freiburg, Germany|Hannover, Germany|Kassel, Germany|Mainz, Germany|Neuwied, Germany|Saarbrücken, Germany|Villingen-Schwenningen, Germany|Balatonfured, Hungary|Budapest, Hungary|Dunaújváros, Hungary|Eger, Hungary|Kecskemét, Hungary|Nagykanizsa, Hungary|Pecs, Hungary|Szekesfehervar, Hungary|Szikszó, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|*Osenza*, Italy|Arenzano, Italy|Bologna, Italy|Catanzaro, Italy|Chieri (Torino), Italy|Firenze, Italy|Messina, Italy|Milano, Italy|Napoli, Italy|Ravenna, Italy|Roma N/A, Italy|Roma, Italy|Sesto San Giovanni (Milano), Italy|Verona, Italy|Ansan, Korea, Republic of|Bucheon, Korea, Republic of|Busan, Korea, Republic of|Changwon, Korea, Republic of|Cheongju, Korea, Republic of|Daegu, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Iksan, Korea, Republic of|Incheon, Korea, Republic of|Jeonju, Korea, Republic of|Seongnam-Si, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Ulsan, Korea, Republic of|Wonju-Si, Korea, Republic of|Batu Caves, Malaysia|Georgetown, Malaysia|Ipoh, Malaysia|Kelantan, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Aguascalientes, Mexico|Celaya, Mexico|Cuernavaca, Mexico|Culiacan, Mexico|Guadalajara, Mexico|Mexico, Mexico|Pachuca De Soto, Mexico|Queretaro, Mexico|San Luis Potosi, Mexico|Tampico, Mexico|Almelo, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hardenberg, Netherlands|Hoogeveen, Netherlands|Hoogezand, Netherlands|Kloosterhaar, Netherlands|Leiden, Netherlands|Meppel, Netherlands|Poortvliet, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Velp, Netherlands|Waalwijk, Netherlands|Wamel, Netherlands|Zoetermeer, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Newtown, New Zealand|Palmerston North, New Zealand|Rotorua, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Bialystok, Poland|Bydgoszcz, Poland|Chrzanow, Poland|Gdansk, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Krakow, Poland|Lublin, Poland|Oswiecim, Poland|Torun, Poland|Tychy, Poland|Warszawa, Poland|Wroclaw, Poland|Ponce Pr, Puerto Rico|Trujillo Alto, Puerto Rico|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Kemerovo, Russian Federation|Nizhny Novgorod, Russian Federation|Penza, Russian Federation|Rostov-On-Don, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St-Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tyumen, Russian Federation|Vsevolzhsk, Russian Federation|Yaroslavl, Russian Federation|A Coruna, Spain|Alcalá De Henares, Spain|Alicante, Spain|Almeria, Spain|Alzira, Spain|Barcelona, Spain|Ciudad Real, Spain|Cordoba, Spain|Ferrol, Spain|Figueres, Spain|Galdakao, Spain|Madrid, Spain|Malaga, Spain|Móstoles, Spain|Palma De Mallorca, Spain|Sabadell, Spain|San Sebastian De Los Reyes, Spain|Sant Joan D'Alacant, Spain|Santa Cruz De Tenerife, Spain|Santiago De Compostela, Spain|Segovia, Spain|Sevilla N/A, Spain|Sevilla, Spain|Valencia, Spain|Viladecans, Spain|Borås, Sweden|Goteborg, Sweden|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Lund, Sweden|Malmo, Sweden|Stockholm, Sweden|Uddevalla, Sweden|Uppsala, Sweden|Vallingby, Sweden|Västra Frölunda, Sweden|Kaohsiung County, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Tiachung, Taiwan|Xindian, Taiwan|Cherkasy, Ukraine|Chernivtsy, Ukraine|Dnipropetrovsk, Ukraine|Ivan-Frankivsk, Ukraine|Ivano-Frankovsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Vinnytsya, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhya, Ukraine|Addlestone, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bristol, United Kingdom|Bury St Edmunds, United Kingdom|Chesterfield, United Kingdom|Derby, United Kingdom|Doncaster, United Kingdom|Ipswich, United Kingdom|Leicester, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Salford, United Kingdom|Taunton, United Kingdom|Torquay, United Kingdom|Truro, United Kingdom|Wellingborough, United Kingdom|Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01989754/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01989754/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01989754
515,NCT02475070,Vildagliptin Versus Dapagliflozin on Glucagon,Completed,Has Results,Type 2 Diabetes,Drug: Vildagliptin|Drug: Dapagliflozin,Lund University,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Lund University, Lund, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02475070/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT02475070/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02475070
516,NCT03383627,Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease,Completed,Has Results,Diabetes|Kidney Diseases,Device: Continuous Glucose Monitoring,Northwell Health,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Northwell Health (Division Endocrinology and Nephrology), Great Neck, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03383627/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03383627/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03383627
517,NCT02256189,Sitagliptin and Glucagon Counterregulation,Completed,Has Results,Type 2 Diabetes,Drug: Sitagliptin|Drug: Placebo,Lund University|Merck Sharp & Dohme LLC,65 Years to 90 Years   (Older Adult),Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Skane University Hospital Malmö, Malmö, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02256189/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02256189/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02256189
518,NCT04234581,The Effect of Lysulin on Glycemic Control and Advanced Glycation,Terminated,No Results Available,Type 2 Diabetes,Dietary Supplement: Lysulin,Juraj Koska|Carl T. Hayden VA Medical Center,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Phoenix VA Healthcare System, Phoenix, Arizona, United States|Phoenix VA Medical Center, Phoenix, Arizona, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04234581/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04234581/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04234581
519,NCT03339453,A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: Nasal Glucagon|Drug: Intramuscular Glucagon,Eli Lilly and Company,18 Years to 64 Years   (Adult),Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03339453/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03339453/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03339453
520,NCT03618420,Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function,Completed,Has Results,"Diabetes Mellitus, Type 1|Nephropathy|Diabetic Nephropathies|Juvenile Diabetes|Diabetes Mellitus Complication|Autoimmune Diabetes|Type 1 Diabetes Mellitus",Drug: Aminohippurate Sodium Inj 20%|Drug: Iohexol Inj 300 mg/mL,"University of Colorado, Denver","12 Years to 21 Years   (Child, Adult)",Phase 1|Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Children's Hospital Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03618420/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03618420
521,NCT00038727,Diabetes Prevention Program Outcomes Study,"Active, not recruiting",Has Results,Diabetes Mellitus|Cancer|CVD,Behavioral: DPPOS Group Lifestyle|Drug: Metformin|Behavioral: DPPOS Boost Lifestyle|Behavioral: Intensive Lifestyle Group Session,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Aging (NIA)|National Institute on Minority Health and Health Disparities (NIMHD)|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Eye Institute (NEI)|National Center for Research Resources (NCRR)|Office of Research on Women's Health (ORWH)|Centers for Disease Control and Prevention|American Diabetes Association|Indian Health Service|General Clinical Research Program|US Department of Veterans Affairs","25 Years and older   (Adult, Older Adult)",Phase 3,NIH|U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"George Washington University, Rockville, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT00038727/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT00038727/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT00038727
522,NCT01904032,Sunshine 2 Study for Women With Diabetes,Completed,Has Results,Diabetes|Depression|Quality of Life,Drug: Vitamin D3|Drug: Vitamin D3 comparator,Loyola University|National Institutes of Health (NIH)|National Institute of Nursing Research (NINR),"21 Years and older   (Adult, Older Adult)",Phase 2,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Loyola University Medical Center, Maywood, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01904032/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01904032/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01904032
523,NCT03091920,"Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension",Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: IW-1973|Drug: Placebo,Cyclerion Therapeutics,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ProSciento, Inc., Chula Vista, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03091920/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03091920/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03091920
524,NCT03496298,Effect of Efpeglenatide on Cardiovascular Outcomes,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Efpeglenatide (SAR439977)|Drug: Placebo,Sanofi|Hanmi Pharmaceutical Company Limited,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8400032, Sheffield, Alabama, United States|Investigational Site Number 8400014, Gilbert, Arizona, United States|Investigational Site Number 8400012, Surprise, Arizona, United States|Investigational Site Number 8400046, Tucson, Arizona, United States|Investigational Site Number 8400022, Beverly Hills, California, United States|Investigational Site Number 8400065, Concord, California, United States|Investigational Site Number 8400060, Greenbrae, California, United States|Investigational Site Number 8400084, Long Beach, California, United States|Investigational Site Number 8400002, Los Gatos, California, United States|Investigational Site Number 8400085, Northridge, California, United States|Investigational Site Number 8400082, Pomona, California, United States|Investigational Site Number 8400025, Sacramento, California, United States|Investigational Site Number 8400064, Englewood, Colorado, United States|Investigational Site Number 8400019, Hamden, Connecticut, United States|Investigational Site Number 8400023, Waterbury, Connecticut, United States|Investigational Site Number 8400091, Hialeah, Florida, United States|Investigational Site Number 8400040, Hollywood, Florida, United States|Investigational Site Number 8400073, Hudson, Florida, United States|Investigational Site Number 8400011, Jacksonville, Florida, United States|Investigational Site Number 8400017, Jacksonville, Florida, United States|Investigational Site Number 8400042, Jacksonville, Florida, United States|Investigational Site Number 8400027, Miami, Florida, United States|Investigational Site Number 8400051, Miami, Florida, United States|Investigational Site Number 8400041, New Port Richey, Florida, United States|Investigational Site Number 8400059, Ormond Beach, Florida, United States|Investigational Site Number 8400006, Macon, Georgia, United States|Investigational Site Number 8400008, Roswell, Georgia, United States|Investigational Site Number 8400081, Idaho Falls, Idaho, United States|Investigational Site Number 8400095, Arlington Heights, Illinois, United States|Investigational Site Number 8400070, Chicago, Illinois, United States|Investigational Site Number 8400036, Crystal Lake, Illinois, United States|Investigational Site Number 8400030, New Albany, Indiana, United States|Investigational Site Number 8400074, Topeka, Kansas, United States|Investigational Site Number 8400077, Owensboro, Kentucky, United States|Investigational Site Number 8400043, Paris, Kentucky, United States|Investigational Site Number 8400034, Alexandria, Louisiana, United States|Investigational Site Number 8400079, Monroe, Louisiana, United States|Investigational Site Number 8400013, New Orleans, Louisiana, United States|Investigational Site Number 8400047, Oxon Hill, Maryland, United States|Investigational Site Number 8400001, Flint, Michigan, United States|Investigational Site Number 8400061, Flint, Michigan, United States|Investigational Site Number 8400010, Troy, Michigan, United States|Investigational Site Number 8400005, Troy, Michigan, United States|Investigational Site Number 8400024, Saint Paul, Minnesota, United States|Investigational Site Number 8400045, Saint Louis, Missouri, United States|Investigational Site Number 8400071, Billings, Montana, United States|Investigational Site Number 8400028, Great Falls, Montana, United States|Investigational Site Number 8400086, Kalispell, Montana, United States|Investigational Site Number 8400037, Las Vegas, Nevada, United States|Investigational Site Number 8400087, Raritan, New Jersey, United States|Investigational Site Number 8400018, Bronx, New York, United States|Investigational Site Number 8400056, Staten Island, New York, United States|Investigational Site Number 8400076, Greenville, North Carolina, United States|Investigational Site Number 8400007, Morehead City, North Carolina, United States|Investigational Site Number 8400093, Morehead City, North Carolina, United States|Investigational Site Number 8400094, Morganton, North Carolina, United States|Investigational Site Number 8400029, Fargo, North Dakota, United States|Investigational Site Number 8400031, Columbus, Ohio, United States|Investigational Site Number 8400078, Lorain, Ohio, United States|Investigational Site Number 8400072, Bend, Oregon, United States|Investigational Site Number 8400067, Beaver, Pennsylvania, United States|Investigational Site Number 8400096, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400021, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400015, Greer, South Carolina, United States|Investigational Site Number 8400063, Murrells Inlet, South Carolina, United States|Investigational Site Number 8400044, Rapid City, South Dakota, United States|Investigational Site Number 8400016, Memphis, Tennessee, United States|Investigational Site Number 8400009, Nashville, Tennessee, United States|Investigational Site Number 8400055, Corpus Christi, Texas, United States|Investigational Site Number 8400097, Dallas, Texas, United States|Investigational Site Number 8400088, El Paso, Texas, United States|Investigational Site Number 8400058, Fort Worth, Texas, United States|Investigational Site Number 8400069, Houston, Texas, United States|Investigational Site Number 8400089, Houston, Texas, United States|Investigational Site Number 8400092, Richmond, Texas, United States|Investigational Site Number 8400033, Waco, Texas, United States|Investigational Site Number 8400039, Salt Lake City, Utah, United States|Investigational Site Number 8400052, Norfolk, Virginia, United States|Investigational Site Number 8400049, Manitowoc, Wisconsin, United States|Investigational Site Number 0320009, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320013, Caba, Argentina|Investigational Site Number 0320010, Caba, Argentina|Investigational Site Number 0320005, Caba, Argentina|Investigational Site Number 0320008, Capital Federal, Argentina|Investigational Site Number 0320001, Capital Federal, Argentina|Investigational Site Number 0320004, Corrientes, Argentina|Investigational Site Number 0320012, Corrientes, Argentina|Investigational Site Number 0320011, Godoy Cruz, Argentina|Investigational Site Number 0320007, Mar Del Plata, Argentina|Investigational Site Number 0320006, Merlo, Argentina|Investigational Site Number 0320015, Rosario, Argentina|Investigational Site Number 0320017, Rosario, Argentina|Investigational Site Number 0320003, Salta, Argentina|Investigational Site Number 0320018, Salta, Argentina|Investigational Site Number 0320016, San Isidro, Argentina|Investigational Site Number 0320014, Santa Rosa, Argentina|Investigational Site Number 1000011, Blagoevgrad, Bulgaria|Investigational Site Number 1000014, Dimitrovgrad, Bulgaria|Investigational Site Number 1000017, Gabrovo, Bulgaria|Investigational Site Number 1000007, Kazanlak, Bulgaria|Investigational Site Number 1000013, Kyustendil, Bulgaria|Investigational Site Number 1000010, Lovech, Bulgaria|Investigational Site Number 1000008, Plovdiv, Bulgaria|Investigational Site Number 1000002, Plovdiv, Bulgaria|Investigational Site Number 1000012, Ruse, Bulgaria|Investigational Site Number 1000003, Sofia, Bulgaria|Investigational Site Number 1000001, Sofia, Bulgaria|Investigational Site Number 1000005, Sofia, Bulgaria|Investigational Site Number 1000006, Stara Zagora, Bulgaria|Investigational Site Number 1000009, Varna, Bulgaria|Investigational Site Number 1000016, Yambol, Bulgaria|Investigational Site Number 1240001, Barrie, Canada|Investigational Site Number 1240002, Brampton, Canada|Investigational Site Number 1240018, Burlington, Canada|Investigational Site Number 1240021, Burlington, Canada|Investigational Site Number 1240007, Calgary, Canada|Investigational Site Number 1240020, Calgary, Canada|Investigational Site Number 1240024, Chicoutimi, Canada|Investigational Site Number 1240004, Concord, Canada|Investigational Site Number 1240005, Etobicoke, Canada|Investigational Site Number 1240011, Levis, Canada|Investigational Site Number 1240025, London, Canada|Investigational Site Number 1240028, London, Canada|Investigational Site Number 1240029, Mirabel, Canada|Investigational Site Number 1240008, Montreal, Canada|Investigational Site Number 1240031, Montreal, Canada|Investigational Site Number 1240014, Montreal, Canada|Investigational Site Number 1240023, Montreal, Canada|Investigational Site Number 1240017, Montreal, Canada|Investigational Site Number 1240015, Oakville, Canada|Investigational Site Number 1240012, Oshawa, Canada|Investigational Site Number 1240030, Ottawa, Canada|Investigational Site Number 1240027, Peterborough, Canada|Investigational Site Number 1240016, Pointe-Claire, Canada|Investigational Site Number 1240010, Quebec, Canada|Investigational Site Number 1240019, Red Deer, Canada|Investigational Site Number 1240006, Sherbrooke, Canada|Investigational Site Number 1240022, Sudbury, Canada|Investigational Site Number 1240013, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1240009, Victoriaville, Canada|Investigational Site Number 1240026, Victoria, Canada|Investigational Site Number 1520012, Antofagasta, Chile|Investigational Site Number 1520008, Concepción, Chile|Investigational Site Number 1520013, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520011, Santiago, Chile|Investigational Site Number 1520010, Santiago, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520014, Santiago, Chile|Investigational Site Number 1520005, Santiago, Chile|Investigational Site Number 1520006, Temuco, Chile|Investigational Site Number 1520004, Viña Del Mar, Chile|Investigational Site Number 2080004, Aarhus N, Denmark|Investigational Site Number 2080005, Esbjerg, Denmark|Investigational Site Number 2080001, Hellerup, Denmark|Investigational Site Number 2080003, Hvidovre, Denmark|Investigational Site Number 2080002, København Nv, Denmark|Investigational Site Number 2330002, Pärnu, Estonia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2330003, Viljandi, Estonia|Investigational Site Number 2460002, Helsinki, Finland|Investigational Site Number 2460001, Jyväskylä, Finland|Investigational Site Number 2460003, Kuopio, Finland|Investigational Site Number 2460004, Oulu, Finland|Investigational Site Number 2760006, Berlin, Germany|Investigational Site Number 2760009, Berlin, Germany|Investigational Site Number 2760004, Essen, Germany|Investigational Site Number 2760008, Frankfurt Am Main, Germany|Investigational Site Number 2760005, Münster, Germany|Investigational Site Number 2760003, Oldenburg In Holstein, Germany|Investigational Site Number 2760002, Pirna, Germany|Investigational Site Number 2760007, Rotenburg An Der Fulda, Germany|Investigational Site Number 3480012, Balatonfüred, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480006, Budapest, Hungary|Investigational Site Number 3480002, Debrecen, Hungary|Investigational Site Number 3480009, Komárom, Hungary|Investigational Site Number 3480008, Mosonmagyaróvár, Hungary|Investigational Site Number 3480007, Székesfehérvár, Hungary|Investigational Site Number 3480004, Zalaegerszeg, Hungary|Investigational Site Number 3560001, Belgaum, India|Investigational Site Number 3560002, Gurgaon, India|Investigational Site Number 3560007, Kolkata, India|Investigational Site Number 3560006, Lucknow, India|Investigational Site Number 3560003, New Delhi, India|Investigational Site Number 3560009, New Delhi, India|Investigational Site Number 3560010, Pune, India|Investigational Site Number 3560005, Pune, India|Investigational Site Number 3560004, Vellore, India|Investigational Site Number 3800006, Catania, Italy|Investigational Site Number 3800003, Catanzaro, Italy|Investigational Site Number 3800005, Catanzaro, Italy|Investigational Site Number 3800002, Chieti, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Roma, Italy|Investigational Site Number 4100006, Guri-si, Gyeonggi-Do, Korea, Republic of|Investigational Site Number 4100007, Busan, Korea, Republic of|Investigational Site Number 4100005, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100009, Seoul, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100011, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100010, Seoul, Korea, Republic of|Investigational Site Number 4100008, Wonju, Korea, Republic of|Investigational Site Number 4280004, Daugavpils, Latvia|Investigational Site Number 4280002, Liepāja, Latvia|Investigational Site Number 4280001, Riga, Latvia|Investigational Site Number 4280003, Sigulda, Latvia|Investigational Site Number 4400001, Kaunas, Lithuania|Investigational Site Number 4400002, Kaunas, Lithuania|Investigational Site Number 4400003, Klaipeda, Lithuania|Investigational Site Number 4400004, Vilnius, Lithuania|Investigational Site Number 4840004, Actopan, Mexico|Investigational Site Number 4840007, Aguascalientes, Mexico|Investigational Site Number 4840009, Aguascalientes, Mexico|Investigational Site Number 4840013, Aguascalientes, Mexico|Investigational Site Number 4840014, Chihuahua, Mexico|Investigational Site Number 4840002, Cuernavaca, Mexico|Investigational Site Number 4840016, Durango, Mexico|Investigational Site Number 4840015, Durango, Mexico|Investigational Site Number 4840006, Guadalajara, Mexico|Investigational Site Number 4840003, Guadalajara, Mexico|Investigational Site Number 4840005, Guadalajara, Mexico|Investigational Site Number 4840011, Monterrey, Mexico|Investigational Site Number 4840010, Monterrey, Mexico|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 5780002, Hamar, Norway|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 5780003, Stavanger, Norway|Investigational Site Number 6040007, Lima, Peru|Investigational Site Number 6040004, Lima, Peru|Investigational Site Number 6040003, Lima, Peru|Investigational Site Number 6040006, Lima, Peru|Investigational Site Number 6040001, Lima, Peru|Investigational Site Number 6040005, Lima, Peru|Investigational Site Number 6040002, Piura, Peru|Investigational Site Number 6160017, Bialystok, Poland|Investigational Site Number 6160018, Bydgoszcz, Poland|Investigational Site Number 6160015, Bydgoszcz, Poland|Investigational Site Number 6160016, Gdansk, Poland|Investigational Site Number 6160012, Gdansk, Poland|Investigational Site Number 6160005, Katowice, Poland|Investigational Site Number 6160006, Plock, Poland|Investigational Site Number 6160011, Skierniewice, Poland|Investigational Site Number 6160013, Skorzewo, Poland|Investigational Site Number 6160010, Szczecin, Poland|Investigational Site Number 6160007, Torun, Poland|Investigational Site Number 6160009, Torun, Poland|Investigational Site Number 6160014, Tychy, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6160004, Wroclaw, Poland|Investigational Site Number 6420007, Bacau, Romania|Investigational Site Number 6420001, Brasov, Romania|Investigational Site Number 6420011, Brasov, Romania|Investigational Site Number 6420009, Bucuresti, Romania|Investigational Site Number 6420012, Oradea, Romania|Investigational Site Number 6420005, Oradea, Romania|Investigational Site Number 6420010, Oradea, Romania|Investigational Site Number 6420008, Ploiesti, Romania|Investigational Site Number 6420002, Târgu-Mureş, Romania|Investigational Site Number 6420003, Târgu-Mureş, Romania|Investigational Site Number 6430018, Kaliningrad, Russian Federation|Investigational Site Number 6430014, Kazan, Russian Federation|Investigational Site Number 6430001, Kemerovo, Russian Federation|Investigational Site Number 6430017, Krasnogorsk, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430015, Moscow, Russian Federation|Investigational Site Number 6430009, Novosibirsk, Russian Federation|Investigational Site Number 6430019, Novosibirsk, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430012, Saint-Petersburg, Russian Federation|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430020, Saratov, Russian Federation|Investigational Site Number 6430010, St-Petersburg, Russian Federation|Investigational Site Number 6430011, St-Petersburg, Russian Federation|Investigational Site Number 6430013, St. Petersburg, Russian Federation|Investigational Site Number 6430016, St. Petersburg, Russian Federation|Investigational Site Number 6880001, Belgrade, Serbia|Investigational Site Number 6880002, Belgrade, Serbia|Investigational Site Number 6880003, Belgrade, Serbia|Investigational Site Number 6880005, Belgrade, Serbia|Investigational Site Number 6880004, Kragujevac, Serbia|Investigational Site Number 6880006, Novi Sad, Serbia|Investigational Site Number 7030007, Bratislava, Slovakia|Investigational Site Number 7030001, Kosice, Slovakia|Investigational Site Number 7030004, Kosice, Slovakia|Investigational Site Number 7030003, Kralovsky Chlmec, Slovakia|Investigational Site Number 7030009, Moldava Nad Bodvou, Slovakia|Investigational Site Number 7030010, Pezinok, Slovakia|Investigational Site Number 7030006, Povazska Bystrica, Slovakia|Investigational Site Number 7030005, Presov, Slovakia|Investigational Site Number 7030008, Roznava, Slovakia|Investigational Site Number 7030011, Sturovo, Slovakia|Investigational Site Number 7030002, Trebisov, Slovakia|Investigational Site Number 7030012, Trencin, Slovakia|Investigational Site Number 7100007, Bloemfontein, South Africa|Investigational Site Number 7100005, Cape Town, South Africa|Investigational Site Number 7100006, Cape Town, South Africa|Investigational Site Number 7100003, Johannesburg, South Africa|Investigational Site Number 7100001, Johannesburg, South Africa|Investigational Site Number 7100002, Parow, South Africa|Investigational Site Number 7100004, Rivonia, South Africa|Investigational Site Number 7100008, Umhlanga Rocks Suburb, South Africa|Investigational Site Number 7240008, Alcorcón, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240009, Barcelona, Spain|Investigational Site Number 7240007, Granada, Spain|Investigational Site Number 7240010, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240006, Majadahonda, Spain|Investigational Site Number 7240011, Málaga, Spain|Investigational Site Number 7240005, Olot, Spain|Investigational Site Number 7240003, San Sebastián De Los Reyes, Spain|Investigational Site Number 7240013, Sevilla, Spain|Investigational Site Number 7240004, Valencia, Spain|Investigational Site Number 7240014, Valencia, Spain|Investigational Site Number 7520006, Goteborg, Sweden|Investigational Site Number 7520003, Helsingborg, Sweden|Investigational Site Number 7520004, Kristianstad, Sweden|Investigational Site Number 7520002, Malmö, Sweden|Investigational Site Number 7520005, Skövde, Sweden|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 7920005, Adana, Turkey|Investigational Site Number 7920010, Ankara, Turkey|Investigational Site Number 7920012, Antalya, Turkey|Investigational Site Number 7920015, Aydin, Turkey|Investigational Site Number 7920002, Bursa, Turkey|Investigational Site Number 7920013, Eskisehir, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Istanbul, Turkey|Investigational Site Number 7920011, Izmit, Turkey|Investigational Site Number 7920014, Kutahya, Turkey|Investigational Site Number 7920007, Samsun, Turkey|Investigational Site Number 7920009, Sivas, Turkey|Investigational Site Number 8040006, Dnipro, Ukraine|Investigational Site Number 8040009, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040001, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040003, Kharkiv, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040007, Kiev, Ukraine|Investigational Site Number 8040008, Kyiv, Ukraine|Investigational Site Number 8040004, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03496298/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT03496298/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03496298
525,NCT03216226,A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: dasiglucagon|Drug: GlucaGen,Zealand Pharma|SynteractHCR,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Compass Research, Orlando, Florida, United States|Advanced Clinical Research, Meridian, Idaho, United States|CRC - Clinical Research Center, Medizinische Universität Graz, Graz, Austria|LMC Manna Research, Barrie, Canada|LMC Calgary, Calgary, Canada|LMC Diabetes & Manna Research, Toronto, Canada|Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin, Hamburg, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03216226/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03216226/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03216226
526,NCT03378635,A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: Dasiglucagon|Drug: GlucaGen|Drug: Placebo,Zealand Pharma,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ProSciento, Chula Vista, California, United States|Clinical Research Center, Medizinische Universität Graz, Graz, Austria|LMC Diabetes & Manna Research, Toronto, Canada|Profil, Mainz, Germany|Profil, Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03378635/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03378635/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03378635
527,NCT02906579,"A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension",Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Matching Placebo|Drug: IW-1973,Cyclerion Therapeutics,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ICON Early Phase Unit, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02906579/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02906579/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02906579
528,NCT02692040,Study of the Gut Hormone Analogue G3215 in Adult Subjects,Completed,Has Results,Diabetes Mellitus|Obesity,Drug: G3215|Drug: Placebo,Imperial College London|Medical Research Council|Covance,18 Years to 60 Years   (Adult),Phase 1,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Covance Clinical Research Unit, Leeds, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02692040/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02692040
529,NCT02608905,Effect of Dapagliflozin on Inflammation and Endothelial Function,Terminated,Has Results,Type 2 Diabetes Mellitus,Drug: Dapagliflozin|Drug: Placebo,Baylor College of Medicine,"21 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Baylor College of Medicine, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02608905/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02608905
530,NCT02182830,24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension,Completed,Has Results,"Diabetes Mellitus, Type 2|Hypertension",Drug: Empagliflozin low dose|Drug: placebo|Drug: Empagliflozin high dose,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Birmingham, Alabama, United States|Longwood Research, Huntsville, Alabama, United States|Internal Medicine Center, LLC, Mobile, Alabama, United States|Mobile Medical and Diagnostic Center, Mobile, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Cardiology and Medicine Clinic, Little Rock, Arkansas, United States|Larry Watkins, M .D., Little Rock, Arkansas, United States|eStudySite, Chula Vista, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|MD Clinical Trials, Los Angeles, California, United States|Office of Dr. Alexander Ford, M.D., Los Angeles, California, United States|Diabetes Associates Medical Group, Orange, California, United States|Integrated Research Group, Inc., Riverside, California, United States|Clinical Trials Research, Sacramento, California, United States|Orange County Research Center, Tustin, California, United States|Lynn Institute of Denver, Denver, Colorado, United States|Pines Clinical Research Inc., Hollywood, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States|Care Partners Clinical Research LLC, Jacksonville, Florida, United States|Sunshine Research Center, Opa-locka, Florida, United States|Central Florida Internist, Orlando, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Alternative Solutions Medical Research and Prevention Center, Saint Petersburg, Florida, United States|International Clinical Research - US, LLC, Sanford, Florida, United States|Meridien Research, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta Center, Atlanta, Georgia, United States|Atlanta Clinical Research Centers, Atlanta, Georgia, United States|Albert F. Johary MD, PC, Dunwoody, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Marietta, Georgia, United States|WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Eagle's Landing Diabetes and Endocrinology, Stockbridge, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|John H. Stroger Jr. Hospital of Cook Country, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Investigators Research Group, LLC, Brownsburg, Indiana, United States|Centex Studies, Inc., Lake Charles, Louisiana, United States|Gulf Regional Research and Education Services, LLC, Metairie, Louisiana, United States|New Orleans Center for Clinical Research, New Orleans, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|American Institute of Research Studies, Baltimore, Maryland, United States|Phillips Medical Services, PLLC, Jackson, Mississippi, United States|Mercy Research, Washington, Missouri, United States|Quality Clinical Research Inc, Omaha, Nebraska, United States|Accent Clinical Trials, Las Vegas, Nevada, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Offic of Dr. Eric Cheng, Brooklyn, New York, United States|Healthwise Medical Associates, Brooklyn, New York, United States|Modern Medical, Brooklyn, New York, United States|Erie County Medical Center, Buffalo, New York, United States|Scott Research, Inc., Laurelton, New York, United States|Medex Healthcare Research, Inc., New York, New York, United States|Laurelton Heart Specialist, PC, Rosedale, New York, United States|Metrolina Internal Medicine, PA, Charlotte, North Carolina, United States|PhysiqueMed Clinical Trials, Greensboro, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Coastal Carolina Health Care, P.A., New Bern, North Carolina, United States|Hometown Urgent Care, Columbus, Ohio, United States|Dayton Clinical Research, Dayton, Ohio, United States|Today Clinical Research, Oklahoma City, Oklahoma City, Oklahoma, United States|Suburban Research Associates, Media, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Medical Research South, Charleston, South Carolina, United States|TLM Medical Services, LLC, Columbia, South Carolina, United States|Amistad Clinical Research Center, Columbia, South Carolina, United States|Greenville Pharmaceutical Rsch, Greenville, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|Berkley Family Practice, Moncks Corner, South Carolina, United States|Carolina Cardiology Clinical Research Institute, LLC, Rock Hill, South Carolina, United States|Community Research Partners, Inc, Varnville, South Carolina, United States|Memphis Veterans Affairs Medical Center, Memphis, Tennessee, United States|The Green Clinic PC, Memphis, Tennessee, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|University of Tennessee, Memphis, Tennessee, United States|Diagnostic Clinic of Houston, Houston, Texas, United States|Cullen Family Practice, PLLC, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Kelsey-Seybold Clinic, Houston, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Millennium Clinical Trials LLC, Arlington, Virginia, United States|York Clinical Research, LLC, Norfolk, Virginia, United States|Dominion Medical Associates, Inc., Richmond, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|Family Medical Clinic, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02182830/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT02182830/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02182830
531,NCT04518566,Empowering Patients With Chronic Disease Using Profiling and Targeted Feedbacks Delivered Through Wearable Device,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Behavioral: Nudges,"Singapore General Hospital|National University, Singapore|SingHealth Polyclinics|Duke-NUS Graduate Medical School","40 Years to 120 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Singapore General Hospital, Singapore, Singapore|Duke-NUS Medical School, Singapore, Singapore|National University of Singapore - Saw Swee Hock School of Public Health, Singapore, Singapore|National University of Singapore - School of Computing, Singapore, Singapore|SingHealth Polyclinic (Bedok), Singapore, Singapore|SingHealth Polyclinic (Punggol), Singapore, Singapore|SingHealth Polyclinic (Tampines), Singapore, Singapore","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT04518566/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT04518566
532,NCT01942694,Vitamin D and Type 2 Diabetes Study,"Active, not recruiting",Has Results,Prediabetes|Type 2 Diabetes,Dietary Supplement: Vitamin D (Cholecalciferol)|Other: Placebo,Tufts Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Office of Dietary Supplements (ODS)|American Diabetes Association,"30 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Southwest American Indian Center, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Orlando VA Medical Center, Orlando, Florida, United States|Florida Hospital Translational Research Institute, Orlando, Florida, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Tulane University Health Sciences, New Orleans, Louisiana, United States|Maine Medical Center, Scarborough, Maine, United States|MedStar Community Clinical Research Center, Hyattsville, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Health Partners Riverside Clinic, Minneapolis, Minnesota, United States|Omaha VA Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Beth Israel Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Kaiser Permanente Center for Health Research, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01942694/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01942694/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01942694
533,NCT02564926,Foxiga Korea Local Phase 4 Study,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dapagliflozin|Drug: Glimepiride,AstraZeneca,"19 Years to 75 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Ansan-si, Korea, Republic of|Research Site, Changwon-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02564926/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02564926/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02564926
534,NCT03152084,The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.,Terminated,Has Results,"Diabetes Mellitus, Type 2|Kidney Function Tests",Drug: Dapagliflozin,AstraZeneca,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Almelo, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Stockholm, Sweden|Research Site, Örebro, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03152084/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03152084/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03152084
535,NCT03600116,Collection of Breath and Sweat to Identify Indicators of Hypoglycemia,Completed,No Results Available,Type 1 Diabetes Mellitus,,Massachusetts General Hospital|Mitre Medical Corp.,"18 Years and older   (Adult, Older Adult)",,Other|Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,"Massachusetts General Hospital (MGH) Diabetes Research Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03600116/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03600116
536,NCT02502071,Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes|Diabetic Nephropathy|Diabetic Kidney Disease,Drug: sodium bicarbonate,"University of Colorado, Denver",18 Years to 45 Years   (Adult),Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02502071/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02502071
537,NCT03437044,Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI,Completed,Has Results,"Diabetes Mellitus, Type 2|Coronary Artery Disease",Drug: Ticagrelor|Drug: Clopidogrel,University of Florida|AstraZeneca,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03437044/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03437044/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03437044
538,NCT02309138,Comparison of Two Screening Strategies for Gestational Diabetes (GDM2),Completed,Has Results,Gestational Diabetes|Pregnancy|Glucose Intolerance,Diagnostic Test: Gestational diabetes screening with fasting 3 hour 100 gm|Diagnostic Test: Gestational diabetes screening with fasting 2 hour 75g,"Esa M Davis, MD MPH FAAFP|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Pittsburgh",18 Years to 45 Years   (Adult),Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","UPMC- Magee Womens Hospital, Pittsburgh, Pennsylvania, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02309138/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02309138/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02309138
539,NCT03305822,A Study of LY900014 in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Nordrhein-Westfalen, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03305822/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03305822/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03305822
540,NCT02539160,Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease,Completed,Has Results,Coronary Artery Disease|Diabetes Mellitus,Drug: ticagrelor,University of Florida,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02539160/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02539160/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02539160
541,NCT03368937,A Pilot Test of t:Slim X2 With Control-IQ Technology,Completed,Has Results,Type1 Diabetes Mellitus,Device: Tandem t:slim X2 with Control-IQ Technology,"University of Virginia|Tandem Diabetes Care, Inc.|DexCom, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,Other|Industry|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03368937/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03368937/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03368937
542,NCT03478969,Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Accu-Chek® Solo micropump system|Device: mylife™ OmniPod® Insulin Management System|Other: Multiple Daily Injections (MDI) therapy,Hoffmann-La Roche,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"VIVIT Institut am LKH Felkirch, Feldkirch, Austria|LKH Graz, Medizinische Universität Graz, Graz, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Salzburger Landeskliniken - Universitätsklinikum Salzburg (SALK), Salzburg, Austria|Diakonissen & Wehrle Privatklinik GmbH, Standort Andräviertel, Salzburg, Austria|Hietzing Hospital, Vienna, Austria|Diabetes Klinik Bad Mergentheim GmbH, Bad Mergentheim, Germany|InnoDiab Forschung GmbH, Essen, Germany|Gemeinschaftspraxis im Altstadt-Carree, Fulda, Germany|Gemeinschaftspraxis Drs Bieber Kraus Nolte Vortherms, Lage, Germany|Diabeteszentrum am CKQ, Quakenbrueck, Germany|Diabendo Praxiszentrum, Rostock, Germany|Regionalne Centrum Diabetologii - Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Jagiellonian University, Krakow, Poland|Central Clinical Hospital of the MSWiA in Warsaw, Warsaw, Poland|Bournemouth Diabetes and Endocrine Centre, Bournemouth, United Kingdom|Wolfson Diabetes & Endocrine Clinic, Cambridge, United Kingdom|Centre for Clinical Research and Innovation, Darlington, United Kingdom|King's College London, Diabetes Research Group, London, United Kingdom|Imperial College London, Diabetes, Endocrinology and Metabolism Division, London, United Kingdom|Manchester Royal Infirmary, University Hospital, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03478969/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT03478969/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03478969
543,NCT03091673,Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Glucagon,"Xeris Pharmaceuticals|The Emmes Company, LLC",2 Years to 17 Years   (Child),Phase 3,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Women & Children's Hospital of Buffalo, Buffalo, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03091673/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03091673
544,NCT03341299,A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus,Completed,Has Results,"Diabetes Mellitus, Type 1",Biological: LY900014|Biological: Insulin Lispro,Eli Lilly and Company,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03341299/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT03341299/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03341299
545,NCT03341312,A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM),Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: LY900014|Biological: Insulin Lispro,Eli Lilly and Company,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03341312/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03341312/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03341312
546,NCT02293837,Tocilizumab (TCZ) in New-onset Type 1 Diabetes,Completed,Has Results,Type 1 Diabetes Mellitus|New-onset Type 1 Diabetes Mellitus|T1DM|T1D,Drug: Tocilizumab (TCZ)|Drug: Placebo|Other: Standard of Care,"National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|PPD|Rho Federal Systems Division, Inc.",6 Years to 17 Years   (Child),Phase 2,NIH|Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale University School of Medicine: Diabetes Endocrinology Research Center, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami: Diabetes Research Institute, Miami, Florida, United States|University of South Florida: Diabetes Center, Tampa, Florida, United States|Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Harvard University, Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University, Naomi Berrie Diabetes Center, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Children's Hospital at Westmead: Kids Research Institute, Westmead, New South Wales, Australia|Lady Cilento Children's Hospital: Department of Endocrinology, South Brisbane, Queensland, Australia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02293837/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02293837/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02293837
547,NCT02916706,Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Teneligliptin 20mg|Drug: Placebo,Mitsubishi Tanabe Pharma Corporation,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational center, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02916706/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02916706/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02916706
548,NCT03362983,"Integrated, Multidisciplinary, Person-centered Care for Patients With Complex Comorbidities: Heart, Kidney and Diabetes",Completed,No Results Available,Diabetes Mellitus|Chronic Kidney Diseases|Cardiovascular Diseases|Chronic Disease|Multimorbidity,Other: CareHND,Danderyd Hospital|Karolinska Institutet|University of British Columbia,"Child, Adult, Older Adult",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HND centrum, Danderyd University Hospital, Stockholm, Stockholms LAN, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03362983/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03362983
549,NCT05301855,"Adherence and Beliefs About Medications, and Illness Perception Among Type 2 Diabetic Patients in Assiut Main Hospital",Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Adherence, Medication",,Assiut University,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,"Faculty of medicine, Assiut, Egypt","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT05301855/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT05301855
550,NCT02924064,Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Teneligliptin 20mg|Drug: Placebo|Drug: Metformin ≥ 1000 mg,Mitsubishi Tanabe Pharma Corporation,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational center, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02924064/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02924064/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02924064
551,NCT03844789,A Study of t:Slim X2 With Control-IQ Technology,Completed,No Results Available,Type 1 Diabetes Mellitus,Device: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Device: Control Group,"University of Virginia|Tandem Diabetes Care, Inc.|DexCom, Inc.|Jaeb Center for Health Research",6 Years to 13 Years   (Child),Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Stanford University, Stanford, California, United States|Barbara Davis Center, University of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|UVA Center for Diabetes Technology, Charlottesville, Virginia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03844789/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03844789/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03844789
552,NCT03242252,"Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control",Completed,Has Results,Type 2 Diabetes Mellitus|Chronic Kidney Disease Stage 3,Drug: Placebo|Drug: Sotagliflozin,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 8404018, Birmingham, Alabama, United States|Investigational Site Number 8404045, Guntersville, Alabama, United States|Investigational Site Number 8404004, Phoenix, Arizona, United States|Investigational Site Number 8404022, Phoenix, Arizona, United States|Investigational Site Number 8404007, Little Rock, Arkansas, United States|Investigational Site Number 8404023, Chula Vista, California, United States|Investigational Site Number 8404044, Gold River, California, United States|Investigational Site Number 8404011, Los Angeles, California, United States|Investigational Site Number 8404003, Norco, California, United States|Investigational Site Number 8404025, Northridge, California, United States|Investigational Site Number 8404038, San Dimas, California, United States|Investigational Site Number 8404019, Clearwater, Florida, United States|Investigational Site Number 8404001, DeLand, Florida, United States|Investigational Site Number 8404006, Ocoee, Florida, United States|Investigational Site Number 8404064, Orlando, Florida, United States|Investigational Site Number 8404043, Ormond Beach, Florida, United States|Investigational Site Number 8404013, Palmetto Bay, Florida, United States|Investigational Site Number 8404016, Savannah, Georgia, United States|Investigational Site Number 8404040, Wauconda, Illinois, United States|Investigational Site Number 8404036, Lake Charles, Louisiana, United States|Investigational Site Number 8404020, New Orleans, Louisiana, United States|Investigational Site Number 8404014, Norfolk, Nebraska, United States|Investigational Site Number 8404032, Papillion, Nebraska, United States|Investigational Site Number 8404048, Hackensack, New Jersey, United States|Investigational Site Number 8404009, Bronx, New York, United States|Investigational Site Number 8404074, New York, New York, United States|Investigational Site Number 8404051, Wilmington, North Carolina, United States|Investigational Site Number 8404028, Winston-Salem, North Carolina, United States|Investigational Site Number 8404029, Winston-Salem, North Carolina, United States|Investigational Site Number 8404026, Dayton, Ohio, United States|Investigational Site Number 8404052, Lansdale, Pennsylvania, United States|Investigational Site Number 8404031, Anderson, South Carolina, United States|Investigational Site Number 8404021, Mount Pleasant, South Carolina, United States|Investigational Site Number 8404056, Chattanooga, Tennessee, United States|Investigational Site Number 8404015, Austin, Texas, United States|Investigational Site Number 8404050, Austin, Texas, United States|Investigational Site Number 8404060, Austin, Texas, United States|Investigational Site Number 8404005, Beaumont, Texas, United States|Investigational Site Number 8404035, Dallas, Texas, United States|Investigational Site Number 8404039, Houston, Texas, United States|Investigational Site Number 8404055, Houston, Texas, United States|Investigational Site Number 8404012, Hurst, Texas, United States|Investigational Site Number 8404033, Lampasas, Texas, United States|Investigational Site Number 8404053, McAllen, Texas, United States|Investigational Site Number 8404057, Round Rock, Texas, United States|Investigational Site Number 8404059, San Antonio, Texas, United States|Investigational Site Number 8404010, San Antonio, Texas, United States|Investigational Site Number 8404008, Layton, Utah, United States|Investigational Site Number 8404042, Renton, Washington, United States|Investigational Site Number 8404041, Seattle, Washington, United States|Investigational Site Number 8404047, Kenosha, Wisconsin, United States|Investigational Site Number 0324001, Buenos Aires, Argentina|Investigational Site Number 0324002, Caba, Argentina|Investigational Site Number 0324005, Ciudad Autónoma Buenos Aires, Argentina|Investigational Site Number 0324008, Cordoba, Argentina|Investigational Site Number 0324006, Córdoba, Argentina|Investigational Site Number 0324009, La Plata, Argentina|Investigational Site Number 0324007, Mar Del Plata, Argentina|Investigational Site Number 0764007, Belo Horizonte, Brazil|Investigational Site Number 0764001, Belém, Brazil|Investigational Site Number 0764002, Curitiba, Brazil|Investigational Site Number 0764008, Curitiba, Brazil|Investigational Site Number 0764005, Rio De Janeiro, Brazil|Investigational Site Number 0764006, Sao Paulo, Brazil|Investigational Site Number 0764004, São Paulo, Brazil|Investigational Site Number 1244007, Brampton, Canada|Investigational Site Number 1244004, Burlington, Canada|Investigational Site Number 1244005, Etobicoke, Canada|Investigational Site Number 1244006, Laval, Canada|Investigational Site Number 1244009, Montreal, Canada|Investigational Site Number 1244010, Ottawa, Canada|Investigational Site Number 1244003, Thornhill, Canada|Investigational Site Number 1244002, Toronto, Canada|Investigational Site Number 1244008, Toronto, Canada|Investigational Site Number 1244001, Vancouver, Canada|Investigational Site Number 1704008, Barranquilla, Colombia|Investigational Site Number 1704007, Barranquilla, Colombia|Investigational Site Number 1704004, Bogota, Colombia|Investigational Site Number 1704009, Bogota, Colombia|Investigational Site Number 1704006, Ibague, Colombia|Investigational Site Number 1704001, Manizales, Colombia|Investigational Site Number 1704002, Medellin / Antioquia, Colombia|Investigational Site Number 1704005, Zipaquira, Colombia|Investigational Site Number 2764001, Frankfurt Am Main, Germany|Investigational Site Number 2764002, Hamburg, Germany|Investigational Site Number 2764003, Münster, Germany|Investigational Site Number 3484008, Baja, Hungary|Investigational Site Number 3484012, Baja, Hungary|Investigational Site Number 3484002, Balatonfured, Hungary|Investigational Site Number 3484007, Budapest, Hungary|Investigational Site Number 3484011, Debrecen, Hungary|Investigational Site Number 3484005, Debrecen, Hungary|Investigational Site Number 3484001, Gyula, Hungary|Investigational Site Number 3484010, Nyiregyhaza, Hungary|Investigational Site Number 3484013, Nyregyhza, Hungary|Investigational Site Number 3484004, Pécs, Hungary|Investigational Site Number 3764001, Ashkelon, Israel|Investigational Site Number 3764010, Be'Er-Sheva, Israel|Investigational Site Number 3764007, Haifa, Israel|Investigational Site Number 3764009, Kfar-Saba, Israel|Investigational Site Number 3764011, Kfar-Saba, Israel|Investigational Site Number 3764003, Nahariya, Israel|Investigational Site Number 3764004, Petach Tikva, Israel|Investigational Site Number 3764006, Ramat Gan, Israel|Investigational Site Number 3764005, Rehovot, Israel|Investigational Site Number 3764002, Tel Aviv, Israel|Investigational Site Number 3764008, Zefat, Israel|Investigational Site Number 3764013, Zerifin, Israel|Investigational Site Number 3804007, Catania, Italy|Investigational Site Number 3804005, Milano, Italy|Investigational Site Number 3804004, Milano, Italy|Investigational Site Number 3804008, Naples, Italy|Investigational Site Number 3804002, Napoli, Italy|Investigational Site Number 3804003, Roma, Italy|Investigational Site Number 3804006, Siena, Italy|Investigational Site Number 4844009, Chihuahua Chihuahua, Mexico|Investigational Site Number 4844008, Durango, Durango, Mexico|Investigational Site Number 4844001, Guadalajara, Mexico|Investigational Site Number 4844003, Guadalajara, Mexico|Investigational Site Number 4844006, Merida, Yucatan, Mexico|Investigational Site Number 4844005, Monterrey, Mexico|Investigational Site Number 4844004, Xalapa, Mexico|Investigational Site Number 6164002, Białystok, Poland|Investigational Site Number 6164006, Katowice, Poland|Investigational Site Number 6164010, Krakow, Poland|Investigational Site Number 6164009, Krakow, Poland|Investigational Site Number 6164004, Krakow, Poland|Investigational Site Number 6164008, Krakow, Poland|Investigational Site Number 6164011, Lodz, Poland|Investigational Site Number 6164005, Oswiecim, Poland|Investigational Site Number 6164003, Rzeszow, Poland|Investigational Site Number 6164012, Skierniewice, Poland|Investigational Site Number 6164007, Warszawa, Poland|Investigational Site Number 6424002, Bacau, Romania|Investigational Site Number 6424001, Bacau, Romania|Investigational Site Number 6424004, Bucuresti, Romania|Investigational Site Number 6424009, Bucuresti, Romania|Investigational Site Number 6424010, Bucuresti, Romania|Investigational Site Number 6424006, Hunedoara, Romania|Investigational Site Number 6424011, Oradea, Romania|Investigational Site Number 6424003, Targu-Mures, Romania|Investigational Site Number 6434003, Chelyabinsk, Russian Federation|Investigational Site Number 6434005, Kemerovo, Russian Federation|Investigational Site Number 6434002, Krasnodar, Russian Federation|Investigational Site Number 6434004, Novosibirsk, Russian Federation|Investigational Site Number 6434001, St. Petersburg, Russian Federation|Investigational Site Number 6434006, Yaroslavl, Russian Federation|Investigational Site Number 7104008, Cape Town, South Africa|Investigational Site Number 7104002, Cape Town, South Africa|Investigational Site Number 7104001, Johannesburg, South Africa|Investigational Site Number 7104010, Johannesburg, South Africa|Investigational Site Number 7104005, Johannesburg, South Africa|Investigational Site Number 7104006, Pretoria, South Africa|Investigational Site Number 7244011, Barcelona, Spain|Investigational Site Number 7244007, Granada, Spain|Investigational Site Number 7244003, Madrid, Spain|Investigational Site Number 7244006, Palma De Mallorca, Spain|Investigational Site Number 7244001, Sevilla, Spain|Investigational Site Number 7244002, Valencia, Spain|Investigational Site Number 7244009, Zaragoza, Spain|Investigational Site Number 8044004, Dnipropetrovsk, Ukraine|Investigational Site Number 8044007, Kharkiv, Ukraine|Investigational Site Number 8044010, Kharkiv, Ukraine|Investigational Site Number 8044008, Kiev, Ukraine|Investigational Site Number 8044003, Kiev, Ukraine|Investigational Site Number 8044009, Kyiv, Ukraine|Investigational Site Number 8044001, Kyiv, Ukraine|Investigational Site Number 8044006, Kyiv, Ukraine|Investigational Site Number 8044005, Lviv, Ukraine|Investigational Site Number 8044002, Zaporizhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03242252/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03242252/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03242252
553,NCT02236481,Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes,Terminated,No Results Available,"Diabetes Mellitus, Type 2|Arthritis, Rheumatoid",Drug: Anakinra|Drug: TNF alpha inhibitors,Prof. Roberto Giacomelli|University of L'Aquila,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"L'Aquila University, L'Aquila, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02236481/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT02236481/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02236481
554,NCT03242018,"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control",Completed,Has Results,Type 2 Diabetes Mellitus|Chronic Kidney Disease Stage 4,Drug: Placebo|Drug: Sotagliflozin,Lexicon Pharmaceuticals|Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigational Site Number 8405033, Guntersville, Alabama, United States|Investigational Site Number 8405005, Phoenix, Arizona, United States|Investigational Site Number 8405007, Little Rock, Arkansas, United States|Investigational Site Number 8405015, Chula Vista, California, United States|Investigational Site Number 8405032, La Jolla, California, United States|Investigational Site Number 8405003, Norco, California, United States|Investigational Site Number 8405013, Northridge, California, United States|Investigational Site Number 8405018, San Dimas, California, United States|Investigational Site Number 8405021, Clearwater, Florida, United States|Investigational Site Number 8405001, DeLand, Florida, United States|Investigational Site Number 8405043, Miami, Florida, United States|Investigational Site Number 8405006, Ocoee, Florida, United States|Investigational Site Number 8405025, Ormond Beach, Florida, United States|Investigational Site Number 8405039, Lawrenceville, Georgia, United States|Investigational Site Number 8405041, Arlington Heights, Illinois, United States|Investigational Site Number 8405030, Sellersburg, Indiana, United States|Investigational Site Number 8405019, Lake Charles, Louisiana, United States|Investigational Site Number 8405034, Flint, Michigan, United States|Investigational Site Number 8405012, Norfolk, Nebraska, United States|Investigational Site Number 8405035, Albany, New York, United States|Investigational Site Number 8405014, Bronx, New York, United States|Investigational Site Number 8405027, Laurelton, New York, United States|Investigational Site Number 8405037, New Bern, North Carolina, United States|Investigational Site Number 8405038, Winston-Salem, North Carolina, United States|Investigational Site Number 8405009, Dayton, Ohio, United States|Investigational Site Number 8405004, Beaumont, Texas, United States|Investigational Site Number 8405036, Dallas, Texas, United States|Investigational Site Number 8405020, Houston, Texas, United States|Investigational Site Number 8405026, Houston, Texas, United States|Investigational Site Number 8405047, Hurst, Texas, United States|Investigational Site Number 8405031, San Antonio, Texas, United States|Investigational Site Number 8405016, San Antonio, Texas, United States|Investigational Site Number 8405008, Layton, Utah, United States|Investigational Site Number 8405040, Winchester, Virginia, United States|Investigational Site Number 0325001, Buenos Aires, Argentina|Investigational Site Number 0325003, Launs Este, Argentina|Investigational Site Number 0325004, Mar Del Plata, Argentina|Investigational Site Number 0765003, Belém, Brazil|Investigational Site Number 0765001, Fortaleza, Brazil|Investigational Site Number 0765004, Rio De Janeiro, Brazil|Investigational Site Number 0765002, Sao Paulo, Brazil|Investigational Site Number 1705004, Barranquilla, Colombia|Investigational Site Number 1705005, Bogota, Colombia|Investigational Site Number 1705002, Manizales, Colombia|Investigational Site Number 1705001, Zipaquira, Colombia|Investigational Site Number 2765001, Frankfurt Am Main, Germany|Investigational Site Number 2765003, Hannover, Germany|Investigational Site Number 2765004, Münster, Germany|Investigational Site Number 3485005, Baja, Hungary|Investigational Site Number 3485007, Debrecen, Hungary|Investigational Site Number 3485004, Pécs, Hungary|Investigational Site Number 3765002, Ashkelon, Israel|Investigational Site Number 3765001, Haifa, Israel|Investigational Site Number 3765007, Kfar-Saba, Israel|Investigational Site Number 3765005, Ramat Gan, Israel|Investigational Site Number 3765004, Rehovot, Israel|Investigational Site Number 3765003, Tel Aviv, Israel|Investigational Site Number 3765006, Zefat, Israel|Investigational Site Number 3805003, Catania, Italy|Investigational Site Number 3805005, Milano, Italy|Investigational Site Number 3805006, Napoli, Italy|Investigational Site Number 3805002, Napoli, Italy|Investigational Site Number 3805001, Pavia, Italy|Investigational Site Number 3805004, Roma, Italy|Investigational Site Number 4845007, Guadalajara Jalisco, Mexico|Investigational Site Number 4845001, Guadalajara, Mexico|Investigational Site Number 4845004, Guadalajara, Mexico|Investigational Site Number 4845008, Merida, Yucatan, Mexico|Investigational Site Number 4845006, Monterrey, N.L, Mexico|Investigational Site Number 4845003, Morelia, Mexico|Investigational Site Number 4845002, Queretaro, Mexico|Investigational Site Number 4845005, Xalapa, Mexico|Investigational Site Number 6165003, Krakow, Poland|Investigational Site Number 6165002, Lodz, Poland|Investigational Site Number 6165004, Oswiecim, Poland|Investigational Site Number 6165005, Puławy, Poland|Investigational Site Number 6165001, Rzeszow, Poland|Investigational Site Number 6425005, Bacau, Romania|Investigational Site Number 6425002, Bucuresti, Romania|Investigational Site Number 6425003, Bucuresti, Romania|Investigational Site Number 6425007, Hunedoara, Romania|Investigational Site Number 6425004, Lasi, Romania|Investigational Site Number 6425001, Targu-Mures, Romania|Investigational Site Number 6435004, Chelyabinsk, Russian Federation|Investigational Site Number 6435005, Kemerovo, Russian Federation|Investigational Site Number 6435003, Krasnodar, Russian Federation|Investigational Site Number 6435006, Novosibirsk, Russian Federation|Investigational Site Number 6435001, Saint-Petersburg, Russian Federation|Investigational Site Number 7105003, Cape Town, South Africa|Investigational Site Number 7105004, Cape Town, South Africa|Investigational Site Number 7105001, Johannesburg, South Africa|Investigational Site Number 7105002, Pretoria, South Africa|Investigational Site Number 7245005, Barcelona, Spain|Investigational Site Number 7245007, Barcelona, Spain|Investigational Site Number 7245003, Ferrol, Spain|Investigational Site Number 7245009, Granada, Spain|Investigational Site Number 7245006, Madrid, Spain|Investigational Site Number 7245004, Málaga, Spain|Investigational Site Number 7245001, Sevilla, Spain|Investigational Site Number 7245002, Zaragoza, Spain|Investigational Site Number 8045004, Chernivtsi, Ukraine|Investigational Site Number 8045006, Kiev, Ukraine|Investigational Site Number 8045007, Kyiv, Ukraine|Investigational Site Number 8045003, Kyiv, Ukraine|Investigational Site Number 8045001, Kyiv, Ukraine|Investigational Site Number 8045002, Zaporizhzhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03242018/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03242018/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03242018
555,NCT05163964,"Chronotype, Chrononutrition and Glucose Tolerance Among Prediabetic Individuals: Research Protocol for Chrono-DM TM",Recruiting,No Results Available,"PreDiabetes|Diabetes Mellitus, Type 2",Behavioral: Lifestyle Intervention,Universiti Tunku Abdul Rahman|University of Malaya,"18 Years to 65 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Community Clinic Sungai Udang, Melaka Tengah, Melaka, Malaysia|Community Clinic Ayer Keroh, Melaka Tengah, Melaka, Malaysia|Community Clinic Ayer Molek, Melaka Tengah, Melaka, Malaysia|Community Clinic Bukit Rambai, Melaka Tengah, Melaka, Malaysia|Community Clinic Jalan Gereja, Melaka Tengah, Melaka, Malaysia|Community Clinic Klebang Besar, Melaka Tengah, Melaka, Malaysia|Community Clinic Seri Tanjung, Melaka Tengah, Melaka, Malaysia|Community Clinic Tengkera, Melaka Tengah, Melaka, Malaysia|Community Clinic Ujong Pasir, Melaka Tengah, Melaka, Malaysia|Community Clinic Peringgit, Melaka, Malaysia|Community Clinic Batu Berendam, Melaka, Malaysia","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT05163964/Prot_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05163964
556,NCT03338855,Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.,Completed,Has Results,"Diabetes Mellitus, Type 2|Skeletal Muscle Insulin Sensitivity",Drug: Dapagliflozin,AstraZeneca,"40 Years to 70 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Research Site, Maastricht, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03338855/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03338855/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03338855
557,NCT03443713,Evaluation of Physician-based Decision Support,Completed,Has Results,Type 1 Diabetes Mellitus|MDI|CGM|Exercise,Device: Dexcom G6 CGM,"Oregon Health and Science University|DexCom, Inc.",18 Years to 50 Years   (Adult),Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Oregon Health and Science University, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03443713/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03443713
558,NCT05440968,Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia,Recruiting,No Results Available,"Diabetes Mellitus, Type 2",Other: Point of Care - Glycated Hemoglobin (A1c)|Other: Oral Glucose Tolerance Test,Humberto Reynales MD MSc PhD|Centro de Atencion e Investigacion Medica,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"Maria Granados, Bogotá, Colombia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT05440968/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT05440968/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05440968
559,NCT04854187,The Effect of Personal Protective Aids on Hypertension and Diabetes in People Exposed to High Levels of Air Pollution,Recruiting,No Results Available,Pollution; Exposure|HTN|Diabetes Mellitus,Device: N95 Mask/Indoor air purifier: Including sham,Medstar Health Research Institute|Indian Institute of Technology Kanpur,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Sehat Charitable trust, Dalkhola, West Bengal, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04854187/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT04854187/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04854187
560,NCT02184455,Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment,Completed,Has Results,Diabetes Type I|Diabetes Type II,Biological: DermGEN,Dr. Paul F. Gratzer|Canadian Institutes of Health Research (CIHR)|Nova Scotia Health Authority|DeCell Technologies Inc.,"18 Years and older   (Adult, Older Adult)",Phase 1,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02184455/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02184455
561,NCT03760068,Mylan Insulin Aspart Study,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: MYL-1601D Product|Drug: FlexPen NovoLog®,Mylan Inc.|Mylan GmbH|Viatris Inc.,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Endocrinology Associates Montgomery, Montgomery, Alabama, United States|Phoenician Centers for Research, Phoenix, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|Medical Investigations Inc., Little Rock, Arkansas, United States|John Muir Physician Network, Concord, California, United States|Valley Research, Fresno, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|Diabetes/Lipid Management and Research Center, Huntington Beach, California, United States|Diabetes And Endocrine Associates, La Mesa, California, United States|Long Beach Center For Clinical Research, Long Beach, California, United States|Office of Richard S. Cherlin, M.D, Los Gatos, California, United States|The Rose Salter Medical Research Foundation, Newport Beach, California, United States|Providence Clinical Research, North Hollywood, California, United States|California Medical Research Associates Inc, Northridge, California, United States|Pacific Reserach Partners, Oakland, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Western Univ of Health Science, Pomona, California, United States|Mills-Peninsula Health Services Diabetes Research Institute, San Mateo, California, United States|NorCal Endocrinology and Internal Medicine, San Ramon, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|Coastal Biomedical Research, Inc., Santa Monica, California, United States|The Metabolic Institute Of America (Mioa Inc), Tarzana, California, United States|Diabetes Research Center, Tustin, California, United States|Dr.Ronald H. Chochinov MD,Office Of, Ventura, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Creekside Endocrine Associates, PC, Denver, Colorado, United States|New West Physicians, Golden, Colorado, United States|Paradigm Research, Wheat Ridge, Colorado, United States|Meridien Research, Bradenton, Florida, United States|Hi Tech and Global Research, LLC, Coral Gables, Florida, United States|Moonshine Research Center, Inc., Doral, Florida, United States|Northeast Research Institute, Fleming Island, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Care Research Center, Inc, Kendall, Florida, United States|Meridien Research, Lakeland, Florida, United States|Central Florida Endocrine & Diabetes Consultants, Maitland, Florida, United States|Meridien Research, Maitland, Florida, United States|Inpatient Research Clinic, Miami Lakes, Florida, United States|Pharmax Research Clinic, Inc., Miami, Florida, United States|Quality Professional Healthcare, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|Cordova Research Institute, Miami, Florida, United States|DL Research Solutions Inc, Miami, Florida, United States|Baptist Diabetes Associates, Pa, Miami, Florida, United States|Medi Clear Medical & Research Center, Inc, Miami, Florida, United States|Phoenix Medical Research LLC, Miami, Florida, United States|Dr. De Armas Research Center, LLC, Miami, Florida, United States|P & S Research, LLC, Miami, Florida, United States|Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare, Orlando, Florida, United States|Omega Research Maitland, LLC, Orlando, Florida, United States|Ribo Research, LLC dba Peninsula Research, Inc, Ormond Beach, Florida, United States|Suncoast Clinical Research Inc., Palm Harbor, Florida, United States|Hanson Clinical Research Center, Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Meridien Research, Saint Petersburg, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Meridien Research, Tampa, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|IACT Health, Columbus, Georgia, United States|Physicians Research Associates, LLC, Lawrenceville, Georgia, United States|The Jones Center for Diabetes and Endrocrine Wellness, Macon, Georgia, United States|In-Quest Medical Research, LLC, Peachtree Corners, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Rocky Mountain Diabetes And Osteoporosis Center, Idaho Falls, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|Northwest Endo Diabets Res.LLC, Arlington Heights, Illinois, United States|Midwest Endocrinology, Crystal Lake, Illinois, United States|NorthShore University Health System, Skokie, Illinois, United States|American Research, LLC, Jeffersonville, Indiana, United States|West Broadway Clinic, Council Bluffs, Iowa, United States|Iowa Diabetes and Endocrinology Research Center (IDERC), West Des Moines, Iowa, United States|Overland Park Surgical Specialties, LLC d/b/a College Park Family Care Center Physicians Group, Overland Park, Kansas, United States|Cotton O'Neil Clinical Research Ctr, Topeka, Kansas, United States|Veterans Affairs Medical Center, Lexington, Kentucky, United States|Kentucky Diabetes And Endocrinology Center, Lexington, Kentucky, United States|Crescent City Clinical Research Center, LLC, Metairie, Louisiana, United States|Model Clinical Research, Baltimore, Maryland, United States|Boston University School Of Medicine, Boston, Massachusetts, United States|MassResearch, Waltham, Massachusetts, United States|Elite Clinical Research, Flint, Michigan, United States|Professional Clinical Research, Traverse City, Michigan, United States|Diabetes & Endocrinology Specialists, Inc., Chesterfield, Missouri, United States|Jefferson City Medical Group (Jcmg) - Jcmg Medical Building, Jefferson City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Research, Springfield, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Glacier View Research Institute - Endocrinology, Kalispell, Montana, United States|Diabetes & Endocrine Associates, PC Research Center, Omaha, Nebraska, United States|Alegent Health Research Center, Omaha, Nebraska, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Northern Nevada Endocrinology, Reno, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|Albany Medical College, Albany, New York, United States|NY Scientific, Brooklyn, New York, United States|Northwell Health, Great Neck, New York, United States|Scott Research,Inc, Laurelton, New York, United States|Winthrop-University Hospital, Clinical Trials Center, Mineola, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|Endocrine Associates of West Village, New York, New York, United States|Manhattan Medical Research Practice, New York, New York, United States|Dr. Jonas Leibowitz MD, Office Of, Yonkers, New York, United States|Mountain Diabetes, Asheville, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Physician's East, PA, Greenville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Lucas Research, Inc., Morehead City, North Carolina, United States|Medication Management, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Diabetes & Endocrinology Associates of Stark County Inc, Canton, Ohio, United States|Sterling Research Group, Ltd, Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Intend Clinical Research, Norman, Oklahoma, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Endocrinology Service Northwest LLC - Bend; Advanced Specialty Care (ASC) - Bend Office, Bend, Oregon, United States|Care Access Research, Warwick, Warwick, Rhode Island, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Carolina Health Specialist, Myrtle Beach, South Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|WR Clinsearch, LLC, Chattanooga, Tennessee, United States|Omega Research Nashville, LLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Amarillo Medical Specialists, Amarillo, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|North Texas Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|UT Southwestern Medical Center Division of Endocrinology, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Academy of Diabetes Thyroid and Endocrine, El Paso, Texas, United States|Diabetes and Thyroid Center of Fort Worth, Fort Worth, Texas, United States|Victorium Clinical Research, Houston, Texas, United States|Juno Research, LLC, Houston, Texas, United States|Endocrine IPS, PLLC, Houston, Texas, United States|Clinova Clinical Trials, Houston, Texas, United States|Biopharma Informatic, LLC, Houston, Texas, United States|Dr.Amir Ali Hassan, MD Off of, Houston, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Clinical Trials of Texas, Inc, San Antonio, Texas, United States|Science Advancing Medicine (Sam) Clinical Research, San Antonio, Texas, United States|Victorium Clinical Research, San Antonio, Texas, United States|Northeast Clinical Research, LLC, Schertz, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|DM Clinical Research, Tomball, Texas, United States|Bay Area Metabolic Health, Webster, Texas, United States|Wasatch Clinical Research,LLC, Salt Lake City, Utah, United States|Dr.David Gorson Md, Office Of, Bennington, Vermont, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Dr. Larry D. Stonesifer,MD,Office Of, Federal Way, Washington, United States|Multicare Health System Research Institute, Spokane, Washington, United States|The Vancouver Clinic, Inc. PS, Vancouver, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03760068/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03760068/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03760068
562,NCT03531905,Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2|Cholesterolemia",Drug: Bempedoic acid + Ezetimibe FDC Oral Tablet|Drug: Ezetimibe 10 mg Oral Tablet|Drug: Placebo Oral Tablet|Drug: Placebo oral capsule,"Esperion Therapeutics, Inc.","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Trials Research, Lincoln, California, United States|FInlay Medical Research, Miami, Florida, United States|L-MARC Research Center, Louisville, Kentucky, United States|Hampton Roads Center for Clinical Research, Suffolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03531905/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03531905/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03531905
563,NCT03376789,Mylan Insulin Glargine Study,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: MYL-1501D product using manufacture process V|Drug: MYL-1501D product using manufacture process VI,Mylan Inc.|Mylan GmbH|Viatris Inc.,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mylan Investigator Site, Fresno, California, United States|Mylan Investigator Site, Greenbrae, California, United States|Mylan Investigator Site, Huntington Beach, California, United States|Mylan Investigator Site, La Mesa, California, United States|Mylan Investigator Site, Los Gatos, California, United States|Mylan Investigator Site, Mission Hills, California, United States|Mylan Investigator Site, Montclair, California, United States|Mylan Investigator Site, Northridge, California, United States|Mylan Investigator Site, Oakland, California, United States|Mylan Investigator Site, Santa Monica, California, United States|Mylan Investigator Site, Tarzana, California, United States|Mylan Investigator Site, Tustin, California, United States|Mylan Investigator Site, Walnut Creek, California, United States|Mylan Investigator Site, Denver, Colorado, United States|Mylan Investigator Site, Bradenton, Florida, United States|Mylan Investigator Site, Fort Lauderdale, Florida, United States|Mylan Investigator Site, Fort Myers, Florida, United States|Mylan Investigator Site, Hialeah, Florida, United States|Mylan Investigator Site, Maitland, Florida, United States|Mylan Investigator Site, Miami, Florida, United States|Mylan Investigator Site, Miami, Florida, United States|Mylan Investigator Site, Miami, Florida, United States|Mylan Investigator Site, New Port Richey, Florida, United States|Mylan Investigator Site, Palm Harbor, Florida, United States|Mylan Investigator Site, Saint Petersburg, Florida, United States|Mylan Investigator Site, Spring Hill, Florida, United States|Mylan Investigator Site, Tampa, Florida, United States|Mylan Investigator Site, West Palm Beach, Florida, United States|Mylan Investigator Site, Atlanta, Georgia, United States|Mylan Investigator Site, Columbus, Georgia, United States|Mylan Investigator Site, Lawrenceville, Georgia, United States|Mylan Investigator Site, Roswell, Georgia, United States|Mylan Investigator Site, Idaho Falls, Idaho, United States|Mylan Investigator Site, Meridian, Idaho, United States|Mylan Investigator Site, Springfield, Illinois, United States|Mylan Investigator Site, Council Bluffs, Iowa, United States|Mylan Investigator Site, Austin, Texas, United States|Mylan Investigator Site, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03376789/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03376789/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03376789
564,NCT03642717,Regulatory Request NIS in Korea,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: JARDIANCE DUO®,Boehringer Ingelheim,"19 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Case-Only|Time Perspective: Prospective,"Korea University Ansan Hospital, Ansan, Korea, Republic of|Hyewon Medical Foundation Sejong Hospital, Bucheon, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|Eulji University Hospital, Daejeon, Korea, Republic of|Myongji Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|SoonChunHyang University Seoul Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Hongik Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wonju, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03642717/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT03642717/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03642717
565,NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Dulaglutide|Drug: Placebo|Drug: SGLT2 inhibitor|Drug: Metformin,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical Group of Encino, Encino, California, United States|National Research Institute, Huntington Park, California, United States|National Research Institute, Los Angeles, California, United States|New Horizon Research Center, Miami, Florida, United States|Metabolic Research Institute Inc., West Palm Beach, Florida, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|JCMG Clinical Research, Jefferson City, Missouri, United States|Grand Street Medical PC, Brooklyn, New York, United States|Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Galenos Research, Dallas, Texas, United States|Endeavor Clinical Trials, San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Stefan Ob Stainz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Steyr, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brandys Nad Labem-Stara Bolesl, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holesov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krnov, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pardubice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 4, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Praha 8, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Münster, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Debrecen, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagykanizsa, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Holon, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zapopan, Mexico|Centro de Endocrinologia y Nutricion, Caguas, Puerto Rico|Manati Medical Center, Manati, Puerto Rico|Centro de Endocrinologia del Este, Yabucoa, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alicante, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malaga, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain","""Study Protocol: GBGE (a) Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02597049/Prot_000.pdf|""Study Protocol: GBGE (b) Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02597049/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02597049/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02597049
566,NCT02421055,Longitudinal Phenotyping of Bariatric Surgery Patients,Completed,Has Results,"Obesity|Diabetes Mellitus, Type 2",Procedure: Laparoscopic Roux-en-Y Gastric Bypass|Procedure: Laparoscopic Sleeve Gastrectomy,Imperial College London,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Imperial Weight Centre, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02421055/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02421055
567,NCT01629862,Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea,Completed,Has Results,"Sleep Apnea, Obstructive|Diabetes Mellitus",Device: Continuous positive airway pressure|Device: Sham continuous positive airway pressure,Sanjay R Patel|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|National Institutes of Health (NIH)|University of Pittsburgh,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Brigham & Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01629862/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01629862/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT01629862
568,NCT02589626,Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: empagliflozin 10mg|Drug: empagliflozin 25 mg|Drug: Placebo,Boehringer Ingelheim,"20 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Kunisaki Makoto Clinic, Fukuoka, Fukuoka, Japan|Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama, Japan|Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama, Japan|Nakakinen Clinic, Ibaraki, Naka, Japan|Kubota Clinic, Kanagawa, Kawasaki, Japan|Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic, Kanagawa, Yamato-shi, Japan|Yokohama Minoru Clinic, Kanagawa, Yokohama, Japan|Yokkaichi Diabetes Clinic, Mie, Yokkaichi, Japan|Shiraiwa Medical Clinic, Osaka, Kashiwara-shi, Japan|AMC Nishi-umeda Clinic, Osaka, Osaka-shi, Japan|OCROM Clinic, Osaka, Suita, Japan|Fukuwa Clinic, Tokyo, Chuo-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan|Minamino Heart Clinic, Tokyo, Hachioji, Japan|ToCROM Clinic, Tokyo, Shinjuku-ku, Japan|Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02589626/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02589626/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02589626
569,NCT02527265,Afrezza Safety and Pharmacokinetics Study in Pediatric Patients,Completed,Has Results,Type 1 Diabetes Mellitus,Biological: Afrezza,Mannkind Corporation,4 Years to 17 Years   (Child),Phase 2,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Los Angeles, Los Angeles, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University Hospital, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|USF Diabetes Center, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Van Meter Pediatric Endocrinology, P.C., Atlanta, Georgia, United States|Emory University Children's Center, Atlanta, Georgia, United States|Indiana University, Riley Hospital for Children, Indianapolis, Indiana, United States|Barry J. Reiner, MD, LLC, Baltimore, Maryland, United States|Diabetes, Obesity, Cardiovascular Clinical Specialists (DOCS), Las Vegas, Nevada, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02527265/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02527265/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02527265
570,NCT02580591,Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3),Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Empagliflozin|Drug: Placebo,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Healthscan Clinical Trials LLC, Montgomery, Alabama, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Research, Fresno, California, United States|Marin Endocrine Care and Research, Greenbrae, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|NorCal Endocrinology and Internal Medicine, San Ramon, California, United States|William Sansum Diabetes Center, Santa Barbara, California, United States|University of Colorado Denver, Aurora, Colorado, United States|International Research Associates, LLC, Hialeah, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Physicians Research Associates, LLC, Lawrenceville, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Eagle's Landing Diabetes and Endocrinology, Stockbridge, Georgia, United States|Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|MODEL Clinical Research, Baltimore, Maryland, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Desert Endocrinology Clinical Research Center, Henderson, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Endocrine-Diabetes Care and Resource Center, Rochester, New York, United States|Endocrine Associates of Long Island, PC, Smithtown, New York, United States|Diabetes Endocrinology Research Center of Western New York, Williamsville, New York, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|Holzer Clinic LLC, Gallipolis, Ohio, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Strand Physician Specialists dba Carolina Health Specialists, Myrtle Beach, South Carolina, United States|AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States|Holston Medical Group, Bristol, Tennessee, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Texas Diabetes & Endocrinology PA, Austin, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Endeavor Clinical Trials, PA, San Antonio, Texas, United States|Virginia Endocrinology Research, Chesapeake, Virginia, United States|Coffs Endocrine & Diabetes Services, Coffs Harbour, New South Wales, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|SA Endocrine Research P/L, Keswick, South Australia, Australia|Eastern Clinical Research Unit, East Ringwood, Victoria, Australia|Richmond Road and Diagnostic Treatment Centre, Calgary, Alberta, Canada|The Bailey Clinic, Red Deer, Alberta, Canada|Eastern Health (MUN), St. John's, Newfoundland and Labrador, Canada|Centre for Studies in Family Medicine, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Omnispec Recherche Clinique Inc., Mirabel, Quebec, Canada|Applied Medical Informatics Research INC., Westmount, Quebec, Canada|Clinique des maladies Lipidiques de Quebec, Quebec, Canada|University Hospital Brno, Brno, Czechia|Diahaza s.r.o.Intern.Med.Outpat.Clin.Dep.Diabetology,Holesov, Holesov, Czechia|AIDIN VK s.r.o.,Department Diabetology, Hranice, Hranice, Czechia|Univ. Hospital Kralovske Vinohrady, Prague, Czechia|DiaGolfova s.r.o., Department Diabetology, Prague, Prague, Czechia|Milan Kvapil s.r.o.,Diabetology ambulance,Prague, Prague, Czechia|ResTrial s.r.o.Diabetology Ambulance,Prague, Prague, Czechia|HUS, Lihavuustutkimusyksikkö Biomedicum Helsinki, Helsinki, Finland|Mehiläinen Jyväskylä, Jyväskylä, Finland|Satakunnan Diabetesasema, Pori, Pori, Finland|FinnMedi Oy, Tampere, Tampere, Finland|TYKS, Turku, Finland|HOP Jean Minjoz, Besancon, France|HOP Le Creusot, Le Creusot, France|HOP Paris Saint-Joseph, Paris, France|HOP Bichat, Paris, France|HOP de Poitiers, Poitiers, France|HOP Civil, Strasbourg, France|HOP Rangueil, Toulouse Cédex 04, France|Diabetes-Klinik Bad Mergentheim GmbH & Co. KG, Bad Mergentheim, Germany|Diabetologische Schwerpunktpraxis, Bosenheim, Bosenheim, Germany|Praxis Dr. Busch, Dortmund, Dortmund, Germany|GWT-TUD GmbH, Dresden, Germany|ZKS Südbrandenburg GmbH, Elsterwerda, Germany|InnoDiab Forschung GmbH, Essen, Germany|Praxis Dr. Kaiser, Frankfurt, Frankfurt, Germany|Institut für Diabetesforschung Münster GmbH, Münster, Germany|Diabetologische Schwerpunktpraxis, Münster, Germany|Praxis Dr. Behnke, Neuwied, Neuwied, Germany|Praxis Dr. Hilgenberg, Rehburg-Loccum, Germany|""Korgialeneio-Benakeio"" Hellenic Red Cross Hospital, Athens, Greece|General Hospital of Athens ""Laiko"", Athens, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|General Hospital of Nikaia, Nikaia, Greece|General Hopsital of Thessaloniki ""Ippokrateio"", Thessaloniki, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Clinexpert Kft., Budapest, Hungary|Synexus Magyarorszag Kft., Budapest, Hungary|University Debrecen Hospital, Debrecen, Hungary|CRU Hungary Ltd, Private Practice, Miskolc, Miskolc, Hungary|Clinfan SMO Ltd., Szekszard, Hungary|Csongrad Country Dr Bugyi Istvan Hosp., Szentes, Hungary|Zala Country Hospital, Diabetic Outpatient Clinic, Zalaegerszeg, Hungary|Mater Misericordiae University Hospital, Dublin, Ireland|Inrca-Irccs, Ancona, Italy|A.O. Spedali Civili di Brescia, Brescia, Italy|Osp. Campo di Marte, Lucca, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Policlinico Gemelli, Roma, Italy|Osp. S. Giovanni Calibita Fatebenefratelli, Roma, Italy|IRCCS Gruppo Multimedica, Sesto San Giovanni (MI), Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|Zemgales Center of diabetes, Jelgava, Jelgava, Latvia|A. Lucenko's Internist & Endocrinologist Doctor's Practice, Liepaja, Latvia|Dace Teterovska Doctor's Practice in Endocrinology,Ogre, Ogre, Latvia|P. Stradins Clinical University Hospital, Riga, Riga, Latvia|Riga Health Center, Private Practice, Riga, Latvia|Sigulda Hospital, Outpatient department, Sigulda, Latvia|VSV Centrs, Stalte Private Practice, Talsi, Talsi, Latvia|Clínica EndocrInol en Diabetes Obesidad y Tiroides (DOT), Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occident, Guadalajara, Mexico|Instituto Jaliscience de Inv. en Diabetes y Obesidad, S.C., Guadalajara, Mexico|Unidad de Patologia Clinica, Guadalajara, Mexico|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Ziekenhuisgroep Twente locatie Almelo, Almelo, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Gelre Ziekenhuizen Apeldoorn, Apeldoorn, Netherlands|EB Utrecht Research, Utrecht, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|South Pacific Clinical Trials, Auckland, New Zealand, New Zealand|Lipid and Diabetes Research Group, Christchurch, New Zealand|M3 Helse AS, Hamar, Norway|Oslo Universitetssykehus HF, Lipidklinikken, Oslo, Norway|Stavanger Helseforskning, Stavanger, Norway|Universitetssykehuset Nord-Norge, Tromsø, Tromsø, Norway|DiabSerwis S.C., Chorzow, Chorzow, Poland|Medical Centre Pratia Gdynia, Gdynia, Poland|Medical Centre Pratia Katowice I, Katowice, Poland|Medical Centre Pratia Krakow, Krakow, Poland|University Hospital in Krakow, Krakow, Poland|Independent Public Clin.Hosp.no1Lublin,Dep.Internal Diseases, Lublin, Poland|Witold Chodzko Institute Rural Medic,Dep.Diabetology,Lublin, Lublin, Poland|Reg.Spec.Hosp.Olsztyn,Clin,Endocrinology,Diabetics.&Int.Med., Olsztyn, Poland|Clinical Research Center Medicome, Oswiecim, Oswiecim, Poland|Omedica Medical Centre, Poznan, Poznan, Poland|Medical Centre Pratia Warszawa, Warsaw, Poland|NZOZ Med-Art.Specialist Clinics, Zory, Zory, Poland|Hospital de Braga-Escala Braga, Braga, Portugal|Centro Hospitalar da Cova da Beira Hospital Pêro da Covilhã, Covilhã, Portugal|APDP - Associação Protectora dos Diabéticos de Portugal, Lisboa, Portugal|H. Santo António - Centro Hospitalar do Porto, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|ULSAM, EPE - Hospital de Santa Luzia, Viana do Castelo, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Nicodiab SRL, Bucharest, Bucharest, Romania|Milit. Cent. Emerg. Univ. Hosp. Dr. Davila, Met. Dis. Dept., Bucharest, Romania|SC Medical Centre ""Sanatatea Ta"" SRL, Bucharest, Bucharest, Romania|SC Pelican Impex SRL, Cabinet Nr. 201, Diabetes Dept., Oradea, Bihor County, Romania|Centrul Medical Dr Negrisanu SRL, Timisoara, Romania|City Clinical Hospital no. 67, Moscow, Moscow, Russian Federation|CJSC""Polyclinic complex"",Dep.Endocrinology,St.Petersburg, St. Petersburg, Russian Federation|City Outpatient dep.no.107;clinc.pharmacology,st.petersburg, St. Petersburg, Russian Federation|Medical Academy named after I. Mechnikov, St. Petersburg, St. Petersburg, Russian Federation|City Hospital Saint Elizaveta, Dept. Endocrinology, St. Petersburg, Russian Federation|Policlinic No. 1 of Russian Academy of Sciences, St. Petersburg, St. Petersburg, Russian Federation|LCS Clinical Research Unit, Bryanston, South Africa|TREAD Research, Cape Town, South Africa|Dr Hilton Kaplan, Cape Town, South Africa|Dr. L. A.Distiller, Johannesburg, South Africa|VX Pharma (Pty) Ltd Pretoria, Pretoria, South Africa|Diabetes Care Centre, Pretoria, South Africa|Hospital A Coruña, A Coruña, Spain|CM Avances Médicos, Granada, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Endo-Diabesidad-Clínica Durán & Asociados, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain|CTC Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Karlskoga lasarett, Karlskoga, Sweden|Skånes universitetssjukhus, Lund, Lund, Sweden|S3 Clinical Research Centers, Vällingby, Sweden|Ängelholms Sjukhus, Ängelholm, Sweden|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Leicester General Hospital, Leicester, United Kingdom|Guy's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|Queen's Medical Centre, Nottingham, United Kingdom|George Eliot Hospital, Nuneaton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02580591/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02580591/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02580591
571,NCT01904383,PMS of Trazenta on the Long-term Use as Add-on Therapy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Trazenta,Boehringer Ingelheim|Eli Lilly and Company,"Child, Adult, Older Adult",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Multiple Locations, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01904383/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT01904383/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01904383
572,NCT02451137,"A ""Real World"" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)",Completed,Has Results,"Diabetes Mellitus, Type 2","Drug: Insulin glargine, 300 U/ml|Drug: Insulin glargine, 100 U/ml|Drug: Insulin detemir|Drug: Background Therapy",Sanofi,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 840731, Birmingham, Alabama, United States|Investigational Site Number 840305, Birmingham, Alabama, United States|Investigational Site Number 840811, Birmingham, Alabama, United States|Investigational Site Number 840218, Gulf Shores, Alabama, United States|Investigational Site Number 840739, Guntersville, Alabama, United States|Investigational Site Number 840367, Huntsville, Alabama, United States|Investigational Site Number 840130, Montgomery, Alabama, United States|Investigational Site Number 840729, Montgomery, Alabama, United States|Investigational Site Number 840281, Saraland, Alabama, United States|Investigational Site Number 840613, Sheffield, Alabama, United States|Investigational Site Number 840634, Sheffield, Alabama, United States|Investigational Site Number 840654, Sheffield, Alabama, United States|Investigational Site Number 840173, Phoenix, Arizona, United States|Investigational Site Number 840555, Phoenix, Arizona, United States|Investigational Site Number 840805, Sun City, Arizona, United States|Investigational Site Number 840725, Conway, Arkansas, United States|Investigational Site Number 840790, Jonesboro, Arkansas, United States|Investigational Site Number 840699, Little Rock, Arkansas, United States|Investigational Site Number 840528, Little Rock, Arkansas, United States|Investigational Site Number 840079, Searcy, Arkansas, United States|Investigational Site Number 840337, Bakersfield, California, United States|Investigational Site Number 840089, El Cajon, California, United States|Investigational Site Number 840024, Escondido, California, United States|Investigational Site Number 840020, Fresno, California, United States|Investigational Site Number 840470, Imperial, California, United States|Investigational Site Number 840155, Inglewood, California, United States|Investigational Site Number 840161, Inglewood, California, United States|Investigational Site Number 840194, Laguna Hills, California, United States|Investigational Site Number 840710, Laguna Hills, California, United States|Investigational Site Number 840204, Lancaster, California, United States|Investigational Site Number 840371, Los Angeles, California, United States|Investigational Site Number 840310, Los Angeles, California, United States|Investigational Site Number 840504, Los Angeles, California, United States|Investigational Site Number 840340, Los Angeles, California, United States|Investigational Site Number 840309, Los Gatos, California, United States|Investigational Site Number 840256, North Hollywood, California, United States|Investigational Site Number 840015, Northridge, California, United States|Investigational Site Number 840056, Norwalk, California, United States|Investigational Site Number 840090, Orange, California, United States|Investigational Site Number 840078, Palm Springs, California, United States|Investigational Site Number 840791, Palmdale, California, United States|Investigational Site Number 840216, Paramount, California, United States|Investigational Site Number 840413, Pomona, California, United States|Investigational Site Number 840244, Port Hueneme, California, United States|Investigational Site Number 840162, San Diego, California, United States|Investigational Site Number 840028, San Diego, California, United States|Investigational Site Number 840383, San Dimas, California, United States|Investigational Site Number 840627, San Jose, California, United States|Investigational Site Number 840120, San Ramon, California, United States|Investigational Site Number 840156, Santa Ana, California, United States|Investigational Site Number 840266, Sherman Oaks, California, United States|Investigational Site Number 840091, Sylmar, California, United States|Investigational Site Number 840208, Thousand Oaks, California, United States|Investigational Site Number 840115, Torrance, California, United States|Investigational Site Number 840792, Torrance, California, United States|Investigational Site Number 840612, Tulare, California, United States|Investigational Site Number 840467, Upland, California, United States|Investigational Site Number 840185, Vista, California, United States|Investigational Site Number 840472, Whittier, California, United States|Investigational Site Number 840411, Aurora, Colorado, United States|Investigational Site Number 840596, Denver, Colorado, United States|Investigational Site Number 840170, Denver, Colorado, United States|Investigational Site Number 840188, Englewood, Colorado, United States|Investigational Site Number 840329, Littleton, Colorado, United States|Investigational Site Number 840728, Littleton, Colorado, United States|Investigational Site Number 840687, Northglenn, Colorado, United States|Investigational Site Number 840643, Aventura, Florida, United States|Investigational Site Number 840652, Boca Raton, Florida, United States|Investigational Site Number 840449, Bradenton, Florida, United States|Investigational Site Number 840081, Cooper City, Florida, United States|Investigational Site Number 840027, Coral Gables, Florida, United States|Investigational Site Number 840446, Coral Gables, Florida, United States|Investigational Site Number 840407, Cutler Bay, Florida, United States|Investigational Site Number 840083, Doral, Florida, United States|Investigational Site Number 840141, Fleming Island, Florida, United States|Investigational Site Number 840035, Fort Lauderdale, Florida, United States|Investigational Site Number 840068, Fort Lauderdale, Florida, United States|Investigational Site Number 840145, Hialeah, Florida, United States|Investigational Site Number 840142, Jacksonville, Florida, United States|Investigational Site Number 840352, Jacksonville, Florida, United States|Investigational Site Number 840021, Jupiter, Florida, United States|Investigational Site Number 840639, Kissimmee, Florida, United States|Investigational Site Number 840640, Kissimmee, Florida, United States|Investigational Site Number 840777, Lake Clarke Shores, Florida, United States|Investigational Site Number 840362, Margate, Florida, United States|Investigational Site Number 840221, Miami Lakes, Florida, United States|Investigational Site Number 840303, Miami Lakes, Florida, United States|Investigational Site Number 840002, Miami, Florida, United States|Investigational Site Number 840012, Miami, Florida, United States|Investigational Site Number 840698, Miami, Florida, United States|Investigational Site Number 840102, Miami, Florida, United States|Investigational Site Number 840209, Miami, Florida, United States|Investigational Site Number 840014, Miami, Florida, United States|Investigational Site Number 840128, Miami, Florida, United States|Investigational Site Number 840143, Miami, Florida, United States|Investigational Site Number 840349, Miami, Florida, United States|Investigational Site Number 840758, Miami, Florida, United States|Investigational Site Number 840690, Miami, Florida, United States|Investigational Site Number 840415, Miami, Florida, United States|Investigational Site Number 840197, Miami, Florida, United States|Investigational Site Number 840414, Miami, Florida, United States|Investigational Site Number 840508, Ocala, Florida, United States|Investigational Site Number 840092, Ocoee, Florida, United States|Investigational Site Number 840118, Palm Harbor, Florida, United States|Investigational Site Number 840080, Panama City, Florida, United States|Investigational Site Number 840372, Plantation, Florida, United States|Investigational Site Number 840199, Port Charlotte, Florida, United States|Investigational Site Number 840538, Winter Haven, Florida, United States|Investigational Site Number 840261, Atlanta, Georgia, United States|Investigational Site Number 840232, Atlanta, Georgia, United States|Investigational Site Number 840129, Blue Ridge, Georgia, United States|Investigational Site Number 840820, Columbus, Georgia, United States|Investigational Site Number 840767, Decatur, Georgia, United States|Investigational Site Number 840812, Decatur, Georgia, United States|Investigational Site Number 840700, Dunwoody, Georgia, United States|Investigational Site Number 840648, East Point, Georgia, United States|Investigational Site Number 840110, Lawrenceville, Georgia, United States|Investigational Site Number 840444, Macon, Georgia, United States|Investigational Site Number 840003, Marietta, Georgia, United States|Investigational Site Number 840632, Sandersville, Georgia, United States|Investigational Site Number 840616, Savannah, Georgia, United States|Investigational Site Number 840591, Savannah, Georgia, United States|Investigational Site Number 840727, Smyrna, Georgia, United States|Investigational Site Number 840520, Snellville, Georgia, United States|Investigational Site Number 840163, Statesboro, Georgia, United States|Investigational Site Number 840297, Stockbridge, Georgia, United States|Investigational Site Number 840715, Thomson, Georgia, United States|Investigational Site Number 840400, Blackfoot, Idaho, United States|Investigational Site Number 840764, Boise, Idaho, United States|Investigational Site Number 840005, Chicago, Illinois, United States|Investigational Site Number 840399, Chicago, Illinois, United States|Investigational Site Number 840301, Elgin, Illinois, United States|Investigational Site Number 840402, Joliet, Illinois, United States|Investigational Site Number 840226, Morton, Illinois, United States|Investigational Site Number 840318, Peoria, Illinois, United States|Investigational Site Number 840125, Avon, Indiana, United States|Investigational Site Number 840344, Brownsburg, Indiana, United States|Investigational Site Number 840007, Evansville, Indiana, United States|Investigational Site Number 840164, Evansville, Indiana, United States|Investigational Site Number 840324, Evansville, Indiana, United States|Investigational Site Number 840022, Franklin, Indiana, United States|Investigational Site Number 840536, Greenfield, Indiana, United States|Investigational Site Number 840582, Indianapolis, Indiana, United States|Investigational Site Number 840694, Michigan City, Indiana, United States|Investigational Site Number 840052, Muncie, Indiana, United States|Investigational Site Number 840786, New Albany, Indiana, United States|Investigational Site Number 840686, Council Bluffs, Iowa, United States|Investigational Site Number 840175, Des Moines, Iowa, United States|Investigational Site Number 840466, West Des Moines, Iowa, United States|Investigational Site Number 840134, Topeka, Kansas, United States|Investigational Site Number 840801, Ashland, Kentucky, United States|Investigational Site Number 840754, Benton, Kentucky, United States|Investigational Site Number 840342, Covington, Kentucky, United States|Investigational Site Number 840713, Elizabethtown, Kentucky, United States|Investigational Site Number 840681, Hopkinsville, Kentucky, United States|Investigational Site Number 840578, Louisville, Kentucky, United States|Investigational Site Number 840478, Owensboro, Kentucky, United States|Investigational Site Number 840576, Owensboro, Kentucky, United States|Investigational Site Number 840819, Owensboro, Kentucky, United States|Investigational Site Number 840645, Paris, Kentucky, United States|Investigational Site Number 840741, Versailles, Kentucky, United States|Investigational Site Number 840592, Covington, Louisiana, United States|Investigational Site Number 840744, Covington, Louisiana, United States|Investigational Site Number 840532, Crowley, Louisiana, United States|Investigational Site Number 840760, Hammond, Louisiana, United States|Investigational Site Number 840463, Lake Charles, Louisiana, United States|Investigational Site Number 840675, Marrero, Louisiana, United States|Investigational Site Number 840133, Metairie, Louisiana, United States|Investigational Site Number 840622, Monroe, Louisiana, United States|Investigational Site Number 840147, Natchitoches, Louisiana, United States|Investigational Site Number 840609, New Orleans, Louisiana, United States|Investigational Site Number 840311, Shreveport, Louisiana, United States|Investigational Site Number 840619, Slidell, Louisiana, United States|Investigational Site Number 840673, Zachary, Louisiana, United States|Investigational Site Number 840387, Bangor, Maine, United States|Investigational Site Number 840689, Portland, Maine, United States|Investigational Site Number 840534, Baltimore, Maryland, United States|Investigational Site Number 840455, Catonsville, Maryland, United States|Investigational Site Number 840393, Rockville, Maryland, United States|Investigational Site Number 840423, Boston, Massachusetts, United States|Investigational Site Number 840117, Alpena, Michigan, United States|Investigational Site Number 840289, Detroit, Michigan, United States|Investigational Site Number 840053, Essexville, Michigan, United States|Investigational Site Number 840150, Flint, Michigan, United States|Investigational Site Number 840184, Flint, Michigan, United States|Investigational Site Number 840236, Kalamazoo, Michigan, United States|Investigational Site Number 840210, Southfield, Michigan, United States|Investigational Site Number 840258, Stevensville, Michigan, United States|Investigational Site Number 840158, Troy, Michigan, United States|Investigational Site Number 840524, Troy, Michigan, United States|Investigational Site Number 840033, Olive Branch, Mississippi, United States|Investigational Site Number 840302, Bridgeton, Missouri, United States|Investigational Site Number 840693, Chesterfield, Missouri, United States|Investigational Site Number 840041, Jefferson City, Missouri, United States|Investigational Site Number 840711, Saint Louis, Missouri, United States|Investigational Site Number 840753, Billings, Montana, United States|Investigational Site Number 840603, Butte, Montana, United States|Investigational Site Number 840264, Elkhorn, Nebraska, United States|Investigational Site Number 840742, Omaha, Nebraska, United States|Investigational Site Number 840294, Henderson, Nevada, United States|Investigational Site Number 840087, Henderson, Nevada, United States|Investigational Site Number 840664, Las Vegas, Nevada, United States|Investigational Site Number 840108, Las Vegas, Nevada, United States|Investigational Site Number 840412, Las Vegas, Nevada, United States|Investigational Site Number 840656, Las Vegas, Nevada, United States|Investigational Site Number 840638, Las Vegas, Nevada, United States|Investigational Site Number 840750, Las Vegas, Nevada, United States|Investigational Site Number 840815, Las Vegas, Nevada, United States|Investigational Site Number 840761, Reno, Nevada, United States|Investigational Site Number 840144, Nashua, New Hampshire, United States|Investigational Site Number 840799, Edison, New Jersey, United States|Investigational Site Number 840167, Linden, New Jersey, United States|Investigational Site Number 840060, Neptune, New Jersey, United States|Investigational Site Number 840679, Sicklerville, New Jersey, United States|Investigational Site Number 840559, Teaneck, New Jersey, United States|Investigational Site Number 840481, Albany, New York, United States|Investigational Site Number 840772, Amityville, New York, United States|Investigational Site Number 840746, Babylon, New York, United States|Investigational Site Number 840355, Brooklyn, New York, United States|Investigational Site Number 840136, Brooklyn, New York, United States|Investigational Site Number 840734, Forest Hills, New York, United States|Investigational Site Number 840659, Great Neck, New York, United States|Investigational Site Number 840644, Holbrook, New York, United States|Investigational Site Number 840159, Jamaica, New York, United States|Investigational Site Number 840148, Lake Success, New York, United States|Investigational Site Number 840253, Laurelton, New York, United States|Investigational Site Number 840789, Merrick, New York, United States|Investigational Site Number 840716, Nesconset, New York, United States|Investigational Site Number 840810, New Hyde Park, New York, United States|Investigational Site Number 840072, New Hyde Park, New York, United States|Investigational Site Number 840674, New Windsor, New York, United States|Investigational Site Number 840626, New York, New York, United States|Investigational Site Number 840586, New York, New York, United States|Investigational Site Number 840044, North Massapequa, New York, United States|Investigational Site Number 840587, Smithtown, New York, United States|Investigational Site Number 840577, Staten Island, New York, United States|Investigational Site Number 840773, Syosset, New York, United States|Investigational Site Number 840047, Yonkers, New York, United States|Investigational Site Number 840214, Asheville, North Carolina, United States|Investigational Site Number 840237, Burlington, North Carolina, United States|Investigational Site Number 840714, Burlington, North Carolina, United States|Investigational Site Number 840456, Charlotte, North Carolina, United States|Investigational Site Number 840312, Concord, North Carolina, United States|Investigational Site Number 840763, Greensboro, North Carolina, United States|Investigational Site Number 840611, Greensboro, North Carolina, United States|Investigational Site Number 840776, Greensboro, North Carolina, United States|Investigational Site Number 840361, Greenville, North Carolina, United States|Investigational Site Number 840705, High Point, North Carolina, United States|Investigational Site Number 840755, Lexington, North Carolina, United States|Investigational Site Number 840688, Mooresville, North Carolina, United States|Investigational Site Number 840747, Mooresville, North Carolina, United States|Investigational Site Number 840296, Morganton, North Carolina, United States|Investigational Site Number 840573, New Bern, North Carolina, United States|Investigational Site Number 840096, Salisbury, North Carolina, United States|Investigational Site Number 840697, Shelby, North Carolina, United States|Investigational Site Number 840636, Wilmington, North Carolina, United States|Investigational Site Number 840195, Wilson, North Carolina, United States|Investigational Site Number 840315, Winston-Salem, North Carolina, United States|Investigational Site Number 840545, Fargo, North Dakota, United States|Investigational Site Number 840077, Canal Fulton, Ohio, United States|Investigational Site Number 840738, Canton, Ohio, United States|Investigational Site Number 840064, Cincinnati, Ohio, United States|Investigational Site Number 840701, Cincinnati, Ohio, United States|Investigational Site Number 840779, Cleveland, Ohio, United States|Investigational Site Number 840380, Columbus, Ohio, United States|Investigational Site Number 840339, Columbus, Ohio, United States|Investigational Site Number 840063, Columbus, Ohio, United States|Investigational Site Number 840191, Columbus, Ohio, United States|Investigational Site Number 840752, Columbus, Ohio, United States|Investigational Site Number 840684, Elyria, Ohio, United States|Investigational Site Number 840663, Findlay, Ohio, United States|Investigational Site Number 840379, Franklin, Ohio, United States|Investigational Site Number 840126, Gallipolis, Ohio, United States|Investigational Site Number 840771, Kettering, Ohio, United States|Investigational Site Number 840257, Lancaster, Ohio, United States|Investigational Site Number 840584, Lyndhurst, Ohio, United States|Investigational Site Number 840165, Marion, Ohio, United States|Investigational Site Number 840800, Miamisburg, Ohio, United States|Investigational Site Number 840560, Tallmadge, Ohio, United States|Investigational Site Number 840515, Toledo, Ohio, United States|Investigational Site Number 840797, Vandalia, Ohio, United States|Investigational Site Number 840192, Wadsworth, Ohio, United States|Investigational Site Number 840389, Willoughby Hills, Ohio, United States|Investigational Site Number 840751, Wooster, Ohio, United States|Investigational Site Number 840262, Edmond, Oklahoma, United States|Investigational Site Number 840360, Midwest City, Oklahoma, United States|Investigational Site Number 840363, Oklahoma City, Oklahoma, United States|Investigational Site Number 840556, Oklahoma City, Oklahoma, United States|Investigational Site Number 840103, Bend, Oregon, United States|Investigational Site Number 840292, Altoona, Pennsylvania, United States|Investigational Site Number 840009, Beaver, Pennsylvania, United States|Investigational Site Number 840059, Downingtown, Pennsylvania, United States|Investigational Site Number 840181, Fleetwood, Pennsylvania, United States|Investigational Site Number 840743, Greensburg, Pennsylvania, United States|Investigational Site Number 840479, Huntingdon Valley, Pennsylvania, United States|Investigational Site Number 840712, Indiana, Pennsylvania, United States|Investigational Site Number 840523, Lansdale, Pennsylvania, United States|Investigational Site Number 840766, Levittown, Pennsylvania, United States|Investigational Site Number 840032, Penndel, Pennsylvania, United States|Investigational Site Number 840067, Philadelphia, Pennsylvania, United States|Investigational Site Number 840277, Philadelphia, Pennsylvania, United States|Investigational Site Number 840561, Philadelphia, Pennsylvania, United States|Investigational Site Number 840174, Philadelphia, Pennsylvania, United States|Investigational Site Number 840348, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840669, Pottstown, Pennsylvania, United States|Investigational Site Number 840748, Sayre, Pennsylvania, United States|Investigational Site Number 840187, Smithfield, Pennsylvania, United States|Investigational Site Number 840287, Uniontown, Pennsylvania, United States|Investigational Site Number 840341, Uniontown, Pennsylvania, United States|Investigational Site Number 840378, Providence, Rhode Island, United States|Investigational Site Number 840491, Anderson, South Carolina, United States|Investigational Site Number 840732, Greenville, South Carolina, United States|Investigational Site Number 840043, Greer, South Carolina, United States|Investigational Site Number 840109, Murrells Inlet, South Carolina, United States|Investigational Site Number 840327, North Myrtle Beach, South Carolina, United States|Investigational Site Number 840759, Simpsonville, South Carolina, United States|Investigational Site Number 840628, Summerville, South Carolina, United States|Investigational Site Number 840717, Bristol, Tennessee, United States|Investigational Site Number 840160, Chattanooga, Tennessee, United States|Investigational Site Number 840794, Franklin, Tennessee, United States|Investigational Site Number 840171, Jackson, Tennessee, United States|Investigational Site Number 840550, Jackson, Tennessee, United States|Investigational Site Number 840132, Kingsport, Tennessee, United States|Investigational Site Number 840140, Knoxville, Tennessee, United States|Investigational Site Number 840625, Memphis, Tennessee, United States|Investigational Site Number 840299, Nashville, Tennessee, United States|Investigational Site Number 840381, New Tazewell, Tennessee, United States|Investigational Site Number 840213, Amarillo, Texas, United States|Investigational Site Number 840157, Corpus Christi, Texas, United States|Investigational Site Number 840011, Dallas, Texas, United States|Investigational Site Number 840313, Dallas, Texas, United States|Investigational Site Number 840013, Dallas, Texas, United States|Investigational Site Number 840034, Dallas, Texas, United States|Investigational Site Number 840333, Dallas, Texas, United States|Investigational Site Number 840405, Dallas, Texas, United States|Investigational Site Number 840330, El Paso, Texas, United States|Investigational Site Number 840307, Fort Worth, Texas, United States|Investigational Site Number 840182, Houston, Texas, United States|Investigational Site Number 840366, Houston, Texas, United States|Investigational Site Number 840608, Houston, Texas, United States|Investigational Site Number 840323, Houston, Texas, United States|Investigational Site Number 840502, Houston, Texas, United States|Investigational Site Number 840513, Houston, Texas, United States|Investigational Site Number 840377, Houston, Texas, United States|Investigational Site Number 840306, Houston, Texas, United States|Investigational Site Number 840137, Houston, Texas, United States|Investigational Site Number 840521, Houston, Texas, United States|Investigational Site Number 840533, Houston, Texas, United States|Investigational Site Number 840211, Houston, Texas, United States|Investigational Site Number 840260, Humble, Texas, United States|Investigational Site Number 840403, Irving, Texas, United States|Investigational Site Number 840382, Lampasas, Texas, United States|Investigational Site Number 840680, Lubbock, Texas, United States|Investigational Site Number 840308, McAllen, Texas, United States|Investigational Site Number 840549, Mesquite, Texas, United States|Investigational Site Number 840351, Missouri City, Texas, United States|Investigational Site Number 840373, Palestine, Texas, United States|Investigational Site Number 840365, Pharr, Texas, United States|Investigational Site Number 840439, Plano, Texas, United States|Investigational Site Number 840707, Port Arthur, Texas, United States|Investigational Site Number 840692, Richmond, Texas, United States|Investigational Site Number 840431, San Antonio, Texas, United States|Investigational Site Number 840074, San Antonio, Texas, United States|Investigational Site Number 840691, San Antonio, Texas, United States|Investigational Site Number 840176, San Antonio, Texas, United States|Investigational Site Number 840135, San Antonio, Texas, United States|Investigational Site Number 840018, San Antonio, Texas, United States|Investigational Site Number 840434, San Antonio, Texas, United States|Investigational Site Number 840390, San Antonio, Texas, United States|Investigational Site Number 840207, Schertz, Texas, United States|Investigational Site Number 840615, Sealy, Texas, United States|Investigational Site Number 840097, Sugar Land, Texas, United States|Investigational Site Number 840460, Sugar Land, Texas, United States|Investigational Site Number 840514, Sugar Land, Texas, United States|Investigational Site Number 840530, Sugar Land, Texas, United States|Investigational Site Number 840008, Waco, Texas, United States|Investigational Site Number 840593, Waco, Texas, United States|Investigational Site Number 840809, Waxahachie, Texas, United States|Investigational Site Number 840651, Webster, Texas, United States|Investigational Site Number 840392, Clinton, Utah, United States|Investigational Site Number 840189, Saint George, Utah, United States|Investigational Site Number 840228, Salt Lake City, Utah, United States|Investigational Site Number 840765, West Jordan, Utah, United States|Investigational Site Number 840806, West Jordan, Utah, United States|Investigational Site Number 840580, Chatham, Virginia, United States|Investigational Site Number 840590, Chesapeake, Virginia, United States|Investigational Site Number 840788, Danville, Virginia, United States|Investigational Site Number 840706, Danville, Virginia, United States|Investigational Site Number 840736, Danville, Virginia, United States|Investigational Site Number 840575, Fredericksburg, Virginia, United States|Investigational Site Number 840662, Hampton, Virginia, United States|Investigational Site Number 840795, Lynchburg, Virginia, United States|Investigational Site Number 840605, Martinsville, Virginia, United States|Investigational Site Number 840620, Newport News, Virginia, United States|Investigational Site Number 840088, Norfolk, Virginia, United States|Investigational Site Number 840247, North Chesterfield, Virginia, United States|Investigational Site Number 840730, Pennington Gap, Virginia, United States|Investigational Site Number 840179, Richmond, Virginia, United States|Investigational Site Number 840076, Salem, Virginia, United States|Investigational Site Number 840354, Virginia Beach, Virginia, United States|Investigational Site Number 840704, Winchester, Virginia, United States|Investigational Site Number 840709, Everett, Washington, United States|Investigational Site Number 840238, Federal Way, Washington, United States|Investigational Site Number 840588, Vancouver, Washington, United States|Investigational Site Number 840084, Walla Walla, Washington, United States|Investigational Site Number 840658, Charleston, West Virginia, United States|Investigational Site Number 840595, Lewisburg, West Virginia, United States|Investigational Site Number 124002, Barrie, Canada|Investigational Site Number 124005, Brampton, Canada|Investigational Site Number 124001, Brampton, Canada|Investigational Site Number 124030, Burlington, Canada|Investigational Site Number 124017, Calgary, Canada|Investigational Site Number 124013, Concord, Canada|Investigational Site Number 124018, Etobicoke, Canada|Investigational Site Number 124014, Etobicoke, Canada|Investigational Site Number 124026, Guelph, Canada|Investigational Site Number 124008, Hamilton, Canada|Investigational Site Number 124027, Hamilton, Canada|Investigational Site Number 124010, London, Canada|Investigational Site Number 124015, Markham, Canada|Investigational Site Number 124020, Montreal, Canada|Investigational Site Number 124016, Newmarket, Canada|Investigational Site Number 124024, Oakville, Canada|Investigational Site Number 124029, Saint-Laurent, Canada|Investigational Site Number 124007, Surrey, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124025, Vancouver, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02451137/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02451137/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02451137
573,NCT02561078,An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Human regular U-500 insulin (CSII)|Drug: Human regular U-500 insulin (MDI),Eli Lilly and Company|Insulet Corporation,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Internal Medicine Center LLC, Mobile, Alabama, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Valley Endocrine, Fresno, Fresno, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|First Valley Medical Group, Lancaster, California, United States|Pacific Research Partners, LLC, Oakland, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|NorCal Endocrinology and Internal Medicine - Roseville, Roseville, California, United States|NorCal Endocrinology and Internal Medicine - Roseville, San Ramon, California, United States|Olive View Medical Center, Sylmar, California, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|East Coast Institute For Research, LLC, Jacksonville, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Metabolic Research Institute Inc., West Palm Beach, Florida, United States|East Coast Institute For Research, LLC, Macon, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|John H. Stroger Hospital of Cook County, Chicago, Illinois, United States|Midwest CRC, Crystal Lake, Illinois, United States|HSHS Medical Group Diabetes Research, Springfield, Illinois, United States|Iderc, P.L.C., Des Moines, Iowa, United States|Cotton O'Neil Diabetes and Endocrinology Center, Topeka, Kansas, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|The Arthritis & Diabetes Clinic Inc., Monroe, Louisiana, United States|Grunberger Diabetes Institute, Bloomfield Hills, Michigan, United States|Adult Endocrinology Consultants, P.C., Livonia, Michigan, United States|JCMG Clinical Research, Jefferson City, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Diabetes and Endocrinology Associates, Omaha, Nebraska, United States|Palm Research Center, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States|North Shore Diabetes and Endocrine Assoc, New Hyde Park, New York, United States|Mountain Diabetes and Endocrine Center, Asheville, North Carolina, United States|Physicians East, Greenville, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|University of Oklahoma Health Sciences Center-Tulsa, Oklahoma City, Oklahoma, United States|Portland Diabetes & Endocrine Center, Portland, Oregon, United States|Endocrine Metabolic Associates, P.C., Philadelphia, Pennsylvania, United States|Partners in Nephrology & Endocrinology, Pittsburgh, Pennsylvania, United States|Sudhir Bansal M.D. Inc., Warwick, Rhode Island, United States|AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States|University Diabetes and Endocrine Consultants, Chattanooga, Tennessee, United States|Vanderbilt Univeristy School of Medicine, Nashville, Tennessee, United States|Texas Diabetes and Endocrinology-Austin South, Austin, Texas, United States|Dallas Diabetes Endocrine Center, Dallas, Texas, United States|Texas Diabetes and Endocrinology, P.A., Round Rock, Texas, United States|Advanced Research Institute, South Ogden, Utah, United States|Dr. Larry Stonesifer, Federal Way, Washington, United States|Rainier Clinical Research Center, Renton, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Dr Altagracia Aurora Alcantara Gonzalez, Bayamon, Puerto Rico|Manati Center for Clinical Research Inc, Manati, Puerto Rico|Endocrine Lipid Diabetes Research Institute, Ponce, Puerto Rico|American Telemedicine Center, San Juan, Puerto Rico|Martha Gomez Cuellar M.D., San Juan, Puerto Rico","""Study Protocol: Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02561078/Prot_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02561078/SAP_004.pdf|""Study Protocol: Study Protocol (a)"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02561078/Prot_005.pdf",https://ClinicalTrials.gov/show/NCT02561078
574,NCT02240680,Linagliptin as Add on to Basal Insulin in the Elderly,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo|Drug: linagliptin,Boehringer Ingelheim|Eli Lilly and Company,"60 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Syed Research Consultants, LLC, Sheffield, Alabama, United States|Precision Research Institute, LLC, Chula Vista, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Internal Medicine of the Rockies, Colorado Springs, Colorado, United States|Cohen Medical Research Associates, LLC, Delray Beach, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Clinical Research of Hollywood, Hollywood, Florida, United States|East Coast Institute for Research LLC at NE FL Endo & Diabetes, Jacksonville, Florida, United States|Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Baptist Diabetes Associates, PA, Miami, Florida, United States|International Research Associates, Miami, Florida, United States|South Florida Research Solutions, LLC, Pembroke Pines, Florida, United States|Georgia Clinical Research, LLC, Snellville, Georgia, United States|Midwest Endocrinology, Crystal Lake, Illinois, United States|American Health Network, Avon, Indiana, United States|Accent Clinical Trials, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Manhattan Medical Research Practice PLLC, New York, New York, United States|Family Practice Center of Wadsworth, Inc., Wadsworth, Ohio, United States|Clinical Research Associates of Central Pennsylvania, Altoona, Pennsylvania, United States|Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Preferred Primary Care Phys, Uniontown, Pennsylvania, United States|TLM Medical Services, LLC, Columbia, South Carolina, United States|Advanced Research Associates, Hodges, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|Renaissance Clinical Research and Hypertension of Texas, Dallas, Texas, United States|Diabetes and Thyroid Center of Fort Worth, Fort Worth, Texas, United States|Houston Clinical Research Associates, Houston, Texas, United States|Science Advancing Medicine Clinical Research Center, San Antonio, Texas, United States|Office of Dr. Val R. Hansen, Bountiful, Utah, United States|Millennium Clinical Trials LLC, Arlington, Virginia, United States|York Clinical Research, LLC, Norfolk, Virginia, United States|Rowan Research, Inc., Spokane, Washington, United States|Family Medical Clinic, Milwaukee, Wisconsin, United States|AIM Centre, Merewether, New South Wales, Australia|Royal Brisbane & Women's Hospital-Endocrinology, Herston, Queensland, Australia|ECRU Maroondah, East Ringwood, Victoria, Australia|Ham - PRAC Mortelmans, Oostham, Belgium|CEQUIN, Armenia, Colombia|Dexa Diabetes Servicios Médicos Ltda, Bogotá, Colombia|CAFAM Caja de Compensación Familiar, Bogotá, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|Hospital Pablo Tobón Uribe, Medellín, Colombia|Aalborg Sygehus Syd, Aalborg, Denmark|Sydvestjyst Sygehus Esbjerg, Endokrinologisk afdeling, Esbjerg, Denmark|Frederiksberg Hospital, Endokrinologisk afd., Frederiksberg, Denmark|Gentofte University Hospital, Hellerup, Denmark|Kolding Sygehus, Kolding, Denmark|Bispebjerg Hospital, København NV, Denmark|Køge Sygehus, Køge, Denmark|Roskilde Sygehus, Roskilde, Denmark|Keravan terveyskeskus, Kerava, Finland|Terveystalo Oulu, Diapolis, Oulu, Finland|Lääkärikeskus Aava, Turku, Turku, Finland|TYKS, Turku, Finland|Gemeinschaftspraxis, Asslar, Asslar, Germany|ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH, Berlin, Germany|Diabetologische Schwerpunktpraxis, Bosenheim, Bosenheim, Germany|Dünnwaldpraxis, Köln, Koeln, Germany|Praxis Dr. Naudts, Rodgau, Rodgau, Germany|Praxis Dr. Braun, Unterschneidheim, Unterschneidheim, Germany|""Korgialeneio-Benakeio"" Hellenic Red Cross Hospital, Athens, Greece|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|General Hospital of Attiki ""KAT-EKA"", Kifisia, Greece|General Hospital of Nikaia, Nikaia, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Connolly Hospital Blanchardstown, Dublin, Ireland|Daishinkai Medical Corporation Ookuma Hospital, Aichi, Nagoya, Japan|Matsuyama Shimin Hospital, Ehime, Matsuyama, Japan|Iryohojin Kikuchi Naika Clinic, Gunma, Maebashi, Japan|Nakamura Digestive Organ Internal Medicine Clinic, Hokkaido, Bibai, Japan|Iida Medical Clinic, Hokkaido, Hakodate, Japan|Jiyugaoka Yamada Clinic, Hokkaido, Obihiro, Japan|Shinkotoni family Clinic, Hokkaido, Sapporo, Japan|Yoshida Memorial Hospital, Hokkaido, Sapporo, Japan|Teine Keijinkai Clinic, Hokkaido, Sapporo, Japan|Japan Community Health Care Organization Hokkaido Hospital, Hokkaido, Sapporo, Japan|Itabashi Diabetic medicine and Dermatology Clinic, Ibaraki, Koga, Japan|Nakakinen Clinic, Ibaraki, Naka, Japan|Takai Naika Clinic, Kanagawa, Kamakura, Japan|Kaneshiro DIAB Clinic, Kanagawa, I.M., Kanagawa, Sagamihara, Japan|Asahi Med. clinic, Kanagawa, I.M., Kanagawa, Yokohama, Japan|Ishikawa Med. Clinic, Kanagawa, I.M., Kanagawa, Yokohama, Japan|National Hospital Organization Yokohama Medical Center, Kanagawa, Yokohama, Japan|Okayama Saiseikai General Hospital Outpatient Center, Okayama, Okayama, Japan|AMC Nishi-umeda Clinic, Osaka, Osaka, Japan|Nissay Hospital Nippon Life Saiseikai Public Interest Incorporated Foundation, Osaka, Osaka, Japan|OCROM Clinic, Osaka, Suita, Japan|Saga Memorial Hospital, Saga, Saga, Japan|Asano Clinic, Saitama, Kawagoe, Japan|Hamamatsu Rosai Hospital, Shizuoka, Hamamatsu, Japan|Kuriyama Clinic, Tokyo, Adachi-ku, Japan|The Institute for Adult Deseases, Asahi Life Foundation, Tokyo, Chuo-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku, Japan|Tokyo Center Clinic, Tokyo, Chuo-ku, Japan|AGE Makita Medical Clinic, Tokyo, Chuo-ku, Japan|Kobayashi Internal Medicine Clinic, Tokyo, Koto-ku, Japan|Kunitachi Naika Clinic, Tokyo, Kunitachi, Japan|Japanese Red Cross Medical Center, Tokyo, Shibuya-ku, Japan|Investigación en Salud y Metabolismo S.C., Chihuahua, Mexico|Centro de At. e Inv.en Fact.de riesgo cardiovasc.Omega, S.C., Mexico, Mexico|CAIMED, Mexico, Mexico|Clinstile S.A. de C.V., México, Mexico|CEDOPEC-Ctro Esp en Diab, Obesidad y Prev de Enf Cardiovasc, México, Mexico|Asociación Mexicana para la Investigacion Clínica, A.C(AMIC), Pachuca, Mexico|South Pacific Clinical Trials, Auckland, New Zealand, New Zealand|Middlemore Clinical Trials, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Medicome Sp. z o.o., Oswiecim, Poland|Omedica Centrum Medyczne, Poznan, Poland|NBR Polska, Warszawa, Poland|Nicodiab SRL, Bucharest, Bucharest, Romania|Pelican Impex SRL, Cabinet Nr. 15, Oradea, Romania|Mediab SRL, Tirgu Mures, Romania|TREAD Research, Cape Town, South Africa|Tiervlei Trial Centre, Cape Town, South Africa|Paarl Research Centre, Cape Town, South Africa|Soweto Clinical Trials Centre, Johannesburg, South Africa|LCS Clinical Research Unit, Johannesburg, South Africa|Resego Health Services, Johannesburg, South Africa|Zinakekele Medical Centre, KwaMhlanga, South Africa|Mzansi Ethical Research Centre, Middleburg, South Africa|VX Pharma (Pty) Ltd Pretoria, Pretoria, South Africa|Hospital A Coruña, A Coruña, Spain|Instituto de Ciencias Médicas, Alicante, Spain|Hospital Quiron. I.C.U., Barcelona, Spain|C.A.P. Sardenya, Barcelona, Spain|CAP Les Corts, Barcelona, Spain|CAP Canet de Mar, Canet de Mar, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain|CAP El Remei, Vic, Spain|The Haven Surgery, Burnhope, United Kingdom|South Axholme Practice, Doncaster, United Kingdom|Fowey Clinical Research Company Ltd, Fowey, United Kingdom|Oak Tree Surgery, Liskeard, United Kingdom|St. Mary's Hospital, Vectasearch Clinic, Newport, Newport, United Kingdom|Mounts Bay Medical Ltd, Penzance, United Kingdom|Rame Medical, Penntorr Health, Torpoint, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02240680/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02240680/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02240680
575,NCT02221284,"Alogliptin Tablets Specified Drug-use Survey ""Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)""",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Alogliptin,Takeda,"Child, Adult, Older Adult",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Osaka, Japan|Tokyo, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02221284/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02221284/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02221284
576,NCT02022111,INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study,Completed,Has Results,Diabetes|Depression|Cardiovascular Risk Factor,Behavioral: Patient Education and Behavioral Activation|Behavioral: Supporting Self-Care (care coordinators)|Other: Psychiatrist and Diabetologist Reviews|Other: Decision-support Electronic Health Record System|Other: Standard of Care,"Emory University|National Institute of Mental Health (NIMH)|University of Washington|Madras Diabetes Research Foundation|All India Institute of Medical Sciences, New Delhi|Endocrine & Diabetes Centre|Diacon Hospital","35 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,"Diacon Hospital, Diabetes Care and Research Center, Bangalore, India|Madras Diabetes Research Foundation, Chennai, India|All India Institute of Medical Sciences, Delhi, India|Endocrine Diabetes Center, Visakhapatnam, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02022111/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02022111/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02022111
577,NCT04261738,Effects of HBO on Glucose in Patients With DM,Not yet recruiting,No Results Available,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Device: Hyperbaric Oxygen,"Legacy Health System|DexCom, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Portland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04261738/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04261738/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04261738
578,NCT02437084,"Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling",Completed,Has Results,Hyperlipidemia|Insulin Resistance|Type 2 Diabetes,Drug: Atorvastatin,Stanford University|Doris Duke Charitable Foundation,"30 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02437084/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02437084/Prot_SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02437084
579,NCT02690168,Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy,Completed,Has Results,Diabetes Complications|Hypoglycemia,Behavioral: Fasting,Pennington Biomedical Research Center,18 Years to 40 Years   (Adult),,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02690168/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02690168
580,NCT02897349,Linagliptin Add-on to Insulin Background Therapy,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: placebo|Drug: linagliptin|Drug: background therapy,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"China-Japan Friendship Hospital, Beijing, China|Beijing Tongren Hospital, Beijing, China|The General Hospital of Chinese People's Armed Police Forces, Beijing, China|First Hospital of Jilin University, Changchun, China|No.900 Hospital of PLA Joint Logistics Support Force, Fuzhou, China|Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China|General Hospital of Jinan Military Area, Jinan, China|Nanjing First Hospital, Nanjing, China|The affiliated hospital of medicalcollege qingdao university, Qingdao, China|Centre Hospital of Putuo District, Shanghai, Shanghai, China|Shanghai Tenth People's Hospital, Shanghai, China|Yangpu Hospital, Tongji University, Shanghai, China|Second Hospital Affiliated to Shantou Medical University, Shantou, China|Shengjing Hospital of China Medical University, Shengyang, China|Siping Central People's Hospital, Siping, China|The First Affiliated Hospital of Soochow University, Suzhou, China|Nankai University Affiliated Hospital, Tianjin, China|The 2nd Hospital of Tianjin Medical University, Tianjin, China|Tianjin Medical University General Hospital, Tianjin, China|Renmin Hospital of Wuhan University, Wuhan, China|First Affiliated Hospital of Xiamen University, Xiamen, China|the first people hospital of Yue Yang, Yueyang, China|Affiliated Hospital of Jiangsu University, Zhenjiang, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02897349/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02897349/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT02897349
581,NCT03455985,Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin,Completed,No Results Available,"Diabetes Mellitus, Type 2|Patient Discharge|Blood Glucose, Low|Blood Glucose, High",Other: Discharge Order Set (DOS)|Other: Enhanced Standard Care (ESC),Ohio State University,"25 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03455985/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03455985/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03455985
582,NCT03028220,Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data,Completed,Has Results,Type 1 Diabetes Mellitus With Hypoglycemia|Impaired Awareness of Hypoglycemia|Type1diabetes,Device: Dexcom G5 Continuous Glucose Monitor|Device: Abbott Freestyle Libre,Imperial College London,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,London,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03028220/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03028220
583,NCT03337828,Effect of Two Alcohol-free Beers With Different Carbohydrates Composition on Lipids and Glucose Metabolism,Unknown status,No Results Available,Glucose Metabolism Disorders (Including Diabetes Mellitus)|Overweight and Obesity,Other: Alcohol-free beer with regular composition|Other: Alcohol-free beer with modified composition,Instituto Aragones de Ciencias de la Salud|Aragon Institute of Health Sciences,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Fernando Civeira, Zaragoza, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03337828/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03337828
584,NCT05367024,Broccoli Effect on Glycated Haemoglobin (HbA1c),Enrolling by invitation,No Results Available,Pre-diabetes,Other: Broccoli soup|Other: Courgette soup,Quadram Institute Bioscience|Norfolk and Norwich University Hospitals NHS Foundation Trust,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Quadram Institute Bioscience, Norwich, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT05367024/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05367024
585,NCT04160988,"A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus",Completed,Has Results,Diabetic Retinopathy,,Acer Being Health Inc.|National Taiwan University Hospital,"20 Years and older   (Adult, Older Adult)",,Industry|Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,"National Taiwan University Hospital, Taipei, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04160988/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04160988
586,NCT03299010,10-year Risk Prediction Models of Complications and Mortality of DM in Hong Kong,Completed,No Results Available,Diabetes Mellitus|Cardiovascular Diseases|Mortality|Primary Health Care,,The University of Hong Kong,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Department of Family Medicine & Primary Care, University of Hong Kong, Hong Kong, Hong Kong, China|The University of Hong Kong, Hong Kong, Hong Kong","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03299010/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03299010
587,NCT01730534,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,Completed,Has Results,"Diabetes Mellitus, Non-Insulin-Dependent|High Risk for Cardiovascular Event",Drug: Dapagliflozin 10 mg|Drug: Placebo tablet,AstraZeneca|Bristol-Myers Squibb|The TIMI Study Group|Hadassah Medical Organization,"40 Years to 130 Years   (Adult, Older Adult)",Phase 3,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Alexander City, Alabama, United States|Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Bakersfield, California, United States|Research Site, Greenbrae, California, United States|Research Site, Huntington Park, California, United States|Research Site, La Mesa, California, United States|Research Site, Lomita, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, San Marino, California, United States|Research Site, San Ramon, California, United States|Research Site, Torrance, California, United States|Research Site, Ventura, California, United States|Research Site, Vista, California, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Bristol, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Seaford, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bradenton, Florida, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Spring Hill, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Trinity, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Calhoun, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Avon, Indiana, United States|Research Site, Bloomington, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Newburgh, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Beltsville, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Eagan, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lee's Summit, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Reno, Nevada, United States|Research Site, Edison, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Northport, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Southampton, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Westfield, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canal Fulton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Delaware, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Parma Hts., Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Kittanning, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Tyrone, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Midland, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bennington, Vermont, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Burien, Washington, United States|Research Site, Puyallup, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Lanus, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Adelaide - Oaklands Park, Australia|Research Site, Ashford, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Darlinghurst, Australia|Research Site, Fullarton, Australia|Research Site, Garran, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Milton, Australia|Research Site, Murdoch, Australia|Research Site, Wollongong, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Mechelen, Belgium|Research Site, Merksem, Belgium|Research Site, Roeselare, Belgium|Research Site, Tienen, Belgium|Research Site, Turnhout, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Jose dos Campos, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Calgary, Alberta, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Laval, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, ShiJiazhuang, China|Research Site, Tianjin, China|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Cheb, Czechia|Research Site, Chomutov, Czechia|Research Site, Chrudim III, Czechia|Research Site, Hodonin, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Kromeriz, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Ostrava - Dubina, Czechia|Research Site, Ostrava - Kuncice, Czechia|Research Site, Ostrava-Moravska, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 6, Czechia|Research Site, Praha, Czechia|Research Site, Prelouc, Czechia|Research Site, Rakovnik, Czechia|Research Site, Slany, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Angers cedex 9, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon Cedex, France|Research Site, Dijon, France|Research Site, La Rochelle, France|Research Site, Le Creusot, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Pessac, France|Research Site, Poitiers Cedex, France|Research Site, TOULOUSE Cedex 9, France|Research Site, Aschaffenburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Causeway Bay, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Tai Po, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Ballasagyarmat, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegléd, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Komárom, Hungary|Research Site, Mórahalom, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Polgár, Hungary|Research Site, Sopron, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Tát, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ács, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Bnei Barak, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Naharia, Israel|Research Site, Petach Tikva, Israel|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Negrar - VR, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Rozzano, Italy|Research Site, S Maria Capua Vetere, Italy|Research Site, Sessa Aurunca, Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsubara-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Jeonju-si, Jeollabuk-do, Korea, Republic of|Research Site, Jung-gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Acapulco, Mexico|Research Site, Culiacan, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Meridas, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Pachuca de Soto, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Tijuana, Mexico|Research Site, Veracruz, Mexico|Research Site, Xalapa, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sliedrecht, Netherlands|Research Site, Sneek, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Bacolod, Philippines|Research Site, Cebu City, Philippines|Research Site, Dasmarinas City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Makati City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Pasay City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Tanauan City, Philippines|Research Site, Biała Rawska, Poland|Research Site, Bydgoszcz, Poland|Research Site, ChrzanÓw, Poland|Research Site, Gdansk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Katowice, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Mrągowo, Poland|Research Site, Nakło nad Notecią, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Płock, Poland|Research Site, Ruda Śląska, Poland|Research Site, Skierniewice, Poland|Research Site, Sobótka, Poland|Research Site, Sokółka, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Węgrów, Poland|Research Site, Włocławek, Poland|Research Site, Zabrze, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Galati, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Ploiesti, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu Mures, Romania|Research Site, Târgu Mures, Romania|Research Site, Zalau, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Banská Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolný Kubín, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Košice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lučenec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Námestovo, Slovakia|Research Site, Piešťany, Slovakia|Research Site, Poprad, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavská Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Sala, Slovakia|Research Site, Trebišov, Slovakia|Research Site, Trenčín, Slovakia|Research Site, Vrutky, Slovakia|Research Site, Žilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Diepkloof, Soweto, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Goodwood, South Africa|Research Site, Houghton, South Africa|Research Site, Muckleneuk, South Africa|Research Site, Parktown West, South Africa|Research Site, Parktown, South Africa|Research Site, Phoenix, South Africa|Research Site, Somerset West, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, Almeria, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Sant Joan Despi, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Borås, Sweden|Research Site, Eksjö, Sweden|Research Site, Finspång, Sweden|Research Site, Gothenburg, Sweden|Research Site, Gothenburg, Sweden|Research Site, Järfälla, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Ostersund, Sweden|Research Site, Rättvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Vällingby, Sweden|Research Site, Changhua, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Muang, Thailand|Research Site, Nakhon Ratchasima, Thailand|Research Site, Pathumthani, Thailand|Research Site, Phisanulok, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchaburi, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, İzmir, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vynnitsa, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Addlestone, United Kingdom|Research Site, Aylesbury, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Canterbury, United Kingdom|Research Site, Corsham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Irvine, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Mortimer Reading, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Whitstable, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh City, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01730534/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01730534/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01730534
588,NCT02266576,A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians,Completed,Has Results,"Diabetes Mellitus, Type 2|Metabolic Syndrome|Insulin Resistance",Behavioral: Standard DPP|Behavioral: Enhanced DPP,Stanford University|San Jose State University|Patient-Centered Outcomes Research Institute,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Timpany Center of San Jose State University, San Jose, California, United States|Stanford University School of Medicine, Stanford, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02266576/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02266576/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02266576
589,NCT05249062,SHAPES: Supporting Multimorbid Older People,Recruiting,No Results Available,Heart Failure|Diabetes|Diabetes Mellitus,Device: SHAPES app,"Prof Michael Scott|Mid and East Antrim Agewell Partnership (MEAAP)|University of Nicosia|Vicomtech|TREE Technology S.A.|National University of Ireland, Maynooth|Gnomon Informatics S.A.|Edgeneering LDA|Fraunhofer-Institute of Toxicology and Experimental Medicine|University of Ulster|Northern Health and Social Care Trust","60 Years to 100 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Medicines Optimisation Innovation Centre, Antrim, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT05249062/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT05249062
590,NCT04127994,Glycemic Variability Comparing Two vs Six Meals in Type 2 Diabetes,Unknown status,No Results Available,Diabetes Mellitus Type 2|Overweight and Obesity|Meal Time,Other: Comparing 3 versus 6 meals in type 2 diabetes patients,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|L.N. Adrián Romero Villaseñor|L.N. Aurora Ramos Flores|L.N. Mariana Galindo Guzmán|Dr. Daniel Cuevas Ramos|Dr. Adrian Soto Mota|Dr. Francisco J. Gómez Pérez|Dr. Alfonso Gulias Herrero|Lucía Palacios Baez|Gerardo Saavedra Jiménez|Hector Donaldo Espinosa Salazar|Issa Lill Santiago Falfán|Cristina Aurora Tlapanco Beltrán|Horacio Correa Carranza|Alejandra Dominguez Sanchez,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Ciudad de mexico, Mexico","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04127994/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04127994/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04127994
591,NCT01030861,"Teplizumab for Prevention of Type 1 Diabetes In Relatives ""At-Risk""",Completed,Has Results,Autoantibody Positive|Non-diabetic Relatives at Risk for Type 1 Diabetes|High Risk|Impaired Glucose Tolerance,Drug: Teplizumab|Drug: Placebo infusion,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association,"8 Years to 45 Years   (Child, Adult)",Phase 2,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California in San Francisco, San Francisco, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes/ University of Colorado, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Forschergruppe Diabetes, Munich, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT01030861/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT01030861/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01030861
592,NCT03563456,Development of Structured Exercise Program for T2DM Management,Completed,No Results Available,Type 2 Diabetes Mellitus|High-Intensity Interval Training|Resistance Training|Oxidative Stress|Physical Fitness,Behavioral: structured combined exercise|Behavioral: cardiorespiratory exercise,Indonesia University,18 Years to 64 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Center for Sports and Exercise Studies, Indonesian Medical and Research Institute, Faculty of Medicine Universitas Indonesia, Jakarta, Jakarta Pusat, Indonesia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03563456/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03563456
593,NCT03827382,Bicycle Exercise and Lifestyle Intervention in Newly Diagnosed Diabetes,Recruiting,No Results Available,Life Style,Behavioral: Lifestyle Intervention,"University Hospital, Basel, Switzerland|Kantonsspital Olten|Kantonsspital Aarau|Luzerner Kantonsspital","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital Aarau, Aarau, Aargau, Switzerland|University Hospital Basel, Basel, Basel-Stadt, Switzerland|Cantonal Hospital Olten, Olten, Solothurn, Switzerland|Hopital du Jura, Delémont, Switzerland|Cantonal Hospital Lucerne, Lucerne, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03827382/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03827382
594,NCT01232946,Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake,Completed,Has Results,Type 2 Diabetes,Drug: liraglutide|Drug: insulin detemir|Drug: liraglutide plus insulin detemir,Indiana University|Novo Nordisk A/S,18 Years to 50 Years   (Adult),Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Indiana Clinical Research Center, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01232946/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01232946
595,NCT01884545,Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease,Completed,Has Results,"Coronary Heart Disease, Susceptibility to, 5|Prediabetic State",Behavioral: Health coaching|Genetic: Genetic risk counseling|Behavioral: Standard risk assessment,Duke University|David Grant U.S. Air Force Medical Center,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"David Grant Medical Center, Fairfield, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01884545/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01884545
596,NCT00786825,Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla,Completed,Has Results,Type 1 Diabetes,Drug: somatostatin,University of Minnesota,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Minnesota, Minneapolis, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT00786825/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT00786825/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00786825
597,NCT03404700,Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method,Completed,No Results Available,"Diabetes Mellitus, Type 2|Insulin Resistance",Behavioral: Egg breakfast|Behavioral: Egg breakfast with high saturated fat|Behavioral: Cereal breakfast|Behavioral: Cereal breakfast with high saturated fat,Texas Tech University|Pennington Biomedical Research Center|American Egg Board,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Texas Tech University - Department of Nutritional Sciences, Lubbock, Texas, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03404700/Prot_SAP_ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03404700
598,NCT02387164,Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies,Terminated,Has Results,"Diabetes Mellitus, Type 1|Prediabetic State",Drug: Alum-GAD|Drug: Vitamin D3,Lund University|Region Skane,"4 Years to 18 Years   (Child, Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Clinical Research Center, Pediatric Endocrinology, Jan Waldenströms gata 35, 60:11, Malmö, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02387164/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02387164/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02387164
599,NCT02747108,ForgIng New Paths to Prevent DIabeTes (FINDIT),Completed,Has Results,Prediabetes,Behavioral: Blood Test Group Intervention|Behavioral: Brochure Group Intervention,VA Office of Research and Development|VA Ann Arbor Healthcare System,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02747108/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02747108
600,NCT03403231,INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT),Completed,Has Results,Prediabetes,Behavioral: INVENT Secure Messaging Intervention,VA Office of Research and Development,"up to 75 Years   (Child, Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03403231/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03403231
601,NCT02215200,ATG-GCSF in New Onset Type 1 Diabetes,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Anti-Thymocyte Globulin (ATG)|Drug: Granulocyte colony stimulating factor (GCSF)|Drug: Placebo (for ATG)|Drug: Placebo (for GCSF),National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association|Sanofi|The Leona M. and Harry B. Helmsley Charitable Trust|Amgen,"12 Years to 45 Years   (Child, Adult)",Phase 2,NIH|Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Benaroya Research Institute, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02215200/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02215200/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02215200/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT02215200
602,NCT02350478,Effects of Linagliptin on Endothelial Function,Completed,Has Results,Type 2 Diabetes|Coronary Artery Disease,Drug: Linagliptin|Drug: Placebo,Medical University of Graz,"40 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University of Graz, Department for Internal Medicine, Graz, Austria","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02350478/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02350478
603,NCT03651622,ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development),Completed,Has Results,"Diabetes Mellitus, Type 1|Overweight and Obesity","Behavioral: Hypocaloric, low carbohydrate diet|Behavioral: Hypocaloric, moderate low fat diet|Behavioral: Mediterranean diet, no caloric restriction","University of North Carolina, Chapel Hill|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",19 Years to 30 Years   (Adult),Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03651622/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03651622/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03651622
604,NCT02917031,Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure,Completed,Has Results,Type 2 Diabetes Mellitus|Heart Failure,Drug: Saxagliptin|Drug: Sitagliptin|Drug: Placebo to match saxagliptin|Drug: Placebo to match sitagliptin,AstraZeneca,"18 Years to 130 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Chicoutimi, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Viña del Mar, Chile|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kisvárda, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Busan, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Hwaseong-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Brasov, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Rivne, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02917031/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02917031/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02917031
605,NCT02593032,Effects of Use of a Connected Pillbox On Medication Adherence,Completed,Has Results,Diabetes Mellitus|Hypertension|Hyperlipidemia,Device: Pre-filled trays,University of Pennsylvania|TowerView Health,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02593032/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02593032
606,NCT04742751,An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer,Recruiting,No Results Available,PreDiabetes|Adult Children,Drug: Metformin|Behavioral: Digital Intervention,St. Jude Children's Research Hospital|St. Baldrick's Foundation,18 Years to 44 Years   (Adult),Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT04742751/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04742751
607,NCT03495089,DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy),Completed,No Results Available,"Neuropathy, Diabetic|Diabetes Mellitus, Type 2",Diagnostic Test: dermal electrochemical conductance (DEC)|Diagnostic Test: Monofilament testing,Jordi Gol i Gurina Foundation|Hospital Mutua de Terrassa|Hospital Universitari Sant Joan de Reus,"40 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening,"Hospital Universitari Mútua Terrassa, Terrassa, Barcelona, Spain|Mútua Terrassa Primary Care, Terrassa, Barcelona, Spain|Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03495089/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03495089
608,NCT03557541,Sardine-enriched Diet for Prevention Type 2 Diabetes,Completed,No Results Available,"Diabetes Mellitus, Type 2|PreDiabetes|Diet Habit|Diabetes|Nutritional and Metabolic Disease",Dietary Supplement: Sardine|Dietary Supplement: Control,Institut d'Investigacions Biomèdiques August Pi i Sunyer,65 Years and older   (Older Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Diana A Diaz Rizzolo, Barcelona, Spain","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03557541/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03557541/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03557541
609,NCT03200535,Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs,Completed,Has Results,PreDiabetes|Obesity,Other: EHR gaps|Other: Bulk outreach|Other: Dietician call,Kaiser Permanente,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Kaiser Permanente Coloado, Denver, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03200535/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03200535
610,NCT03724981,A Study Comparing the Dulaglutide Pen and the Semaglutide Pen,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Dulaglutide Pen|Drug: Semaglutide Pen,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Valley Research, Fresno, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|Georgia Clinical Research, Snellville, Georgia, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|L-Marc Research Center, Louisville, Kentucky, United States|Evidera, Bethesda, Maryland, United States|Carolina Research Center, Inc., Shelby, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|BRCR Medical Center, Inc., Camp Hill, Pennsylvania, United States|Juno Research, Houston, Texas, United States|Juno Research, LLC, Houston, Texas, United States|PI-Coor Clinical Research, LLC, Annandale, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03724981/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03724981/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03724981
611,NCT02971202,"Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)",Completed,Has Results,"Type 1 Diabetes Mellitus|Maturity-Onset Diabetes of the Young, Type 2|MODY2|Insulin Resistance","Drug: Hyperinsulinemic, euglycemic clamp|Drug: 20% dextrose",Vanderbilt University|Vanderbilt University Medical Center,"13 Years to 51 Years   (Child, Adult)",Phase 1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02971202/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02971202/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02971202
612,NCT02065791,Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy,Completed,Has Results,"Diabetes Mellitus, Type 2|Diabetic Nephropathy",Drug: Canagliflozin|Drug: Placebo,"Janssen Research & Development, LLC|The George Institute for Global Health, Australia","30 Years and older   (Adult, Older Adult)",Phase 3,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Montgomery, Alabama, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Sherwood, Arkansas, United States|Bakersfield, California, United States|Chula Vista, California, United States|Covina, California, United States|Downey, California, United States|Fountain Valley, California, United States|Hawthorne, California, United States|Inglewood, California, United States|Laguna Hills, California, United States|Lakewood, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Lynwood, California, United States|Northridge, California, United States|Oakland, California, United States|Orange, California, United States|Pasadena, California, United States|Roseville, California, United States|Sacramento, California, United States|Salinas, California, United States|San Diego, California, United States|San Dimas, California, United States|Stanford, California, United States|Tustin, California, United States|Whittier, California, United States|Denver, Colorado, United States|Golden, Colorado, United States|Lakewood, Colorado, United States|Washington, Colorado, United States|Washington, District of Columbia, United States|Coral Springs, Florida, United States|Doral, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Miami Springs, Florida, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|Ocala, Florida, United States|Port Charlotte, Florida, United States|Saint Petersburg, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Columbus, Georgia, United States|Roswell, Georgia, United States|Snellville, Georgia, United States|Stockbridge, Georgia, United States|Chicago, Illinois, United States|Crystal Lake, Illinois, United States|Gurnee, Illinois, United States|Mount Prospect, Illinois, United States|Winfield, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Merrillville, Indiana, United States|Michigan City, Indiana, United States|Muncie, Indiana, United States|Council Bluffs, Iowa, United States|Louisville, Kentucky, United States|Paducah, Kentucky, United States|Kenner, Louisiana, United States|Rockport, Maine, United States|Scarborough, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Beltsville, Maryland, United States|Hyattsville, Maryland, United States|Silver Spring, Maryland, United States|Boston, Massachusetts, United States|Plymouth, Massachusetts, United States|Springfield, Massachusetts, United States|Worcester, Massachusetts, United States|Flint, Michigan, United States|Jackson, Mississippi, United States|Chesterfield, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Fremont, Nebraska, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Reno, Nebraska, United States|Las Vegas, Nevada, United States|Eatontown, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Binghamton, New York, United States|Buffalo, New York, United States|Great Neck, New York, United States|Lake Success, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Ridgewood, New York, United States|Riverhead, New York, United States|Smithtown, New York, United States|Springfield Gardens, New York, United States|Asheville, North Carolina, United States|Calabash, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|High Point, North Carolina, United States|Morehead City, North Carolina, United States|Morganton, North Carolina, United States|Raleigh, North Carolina, United States|Tabor City, North Carolina, United States|Whiteville, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Maumee, Ohio, United States|Roseburg, Oregon, United States|Beaver, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Anderson, South Carolina, United States|Columbia, South Carolina, United States|Lancaster, South Carolina, United States|Murrells Inlet, South Carolina, United States|Orangeburg, South Carolina, United States|Sumter, South Carolina, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Arlington, Texas, United States|Corpus Christi, Texas, United States|Corsicana, Texas, United States|Dallas, Texas, United States|Edinburg, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Mesquite, Texas, United States|San Antonio, Texas, United States|Schertz, Texas, United States|Sugar Land, Texas, United States|Temple, Texas, United States|Waco, Texas, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|Burlington, Vermont, United States|Bluefield, Virginia, United States|Mechanicsville, Virginia, United States|Norfolk, Virginia, United States|Suffolk, Virginia, United States|Spokane, Washington, United States|Huntington, West Virginia, United States|Milwaukee, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|Ciudad Autonoma Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|Córdoba, Argentina|Godoy Cruz, Argentina|Junin, Argentina|La Plata Lpl Lpl, Argentina|La Plata, Argentina|Mar del Plata, Argentina|Mendoza, Argentina|Moron, Argentina|Munro, Argentina|Parana, Argentina|Quilmes, Argentina|Ramos Mejia, Argentina|Rosario, Argentina|Salta, Argentina|San Luis, Argentina|San Martin, Argentina|San Migeul De Tucuman, Argentina|San Miguel de Tucuman, Argentina|San Nicolas, Argentina|Santa Fe, Argentina|Sarandi, Argentina|Tapiales, Argentina|Temperley, Argentina|Villa Maria, Argentina|Zarate, Buenos Aires, Argentina|Cairns, Australia|Concord, Australia|Darlinghurst, Australia|Elizabeth Vale, Australia|Fremantle, Australia|Gosford, Australia|Heidelberg, Australia|Keswick, Australia|Meadowbrook, Australia|Parkville, Australia|Reservoir, Australia|Richmond, Australia|St Albans, Australia|St Leonards, Australia|Sydney, Australia|Woolloongabba, Australia|Aparecida de Goiânia, Brazil|Belo Horizonte, Brazil|Belém, Brazil|Botucatu, Brazil|Brasilia, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Canoas, Brazil|Caxias do Sul, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Joinville, Brazil|Juiz de Fora, Brazil|Maringá, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Santo Andre, Brazil|Santo André, Brazil|Sao Jose Do Rio Preto, Brazil|Sao Paulo, Brazil|São José dos Campos, Brazil|São Paulo, Brazil|Tatuí, Brazil|Blagoevgrad, Bulgaria|Byala, Bulgaria|Gulyantsi, Bulgaria|Pazardzhik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Brampton, Ontario, Canada|London, Ontario, Canada|NewMarket, Ontario, Canada|Oshawa, Ontario, Canada|Smiths Falls, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Weston, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Québec, Quebec, Canada|Quebec, Canada|Québec, Canada|Toronto, Canada|Vancouver, Canada|Concepcion, Chile|Santiago, Chile|Temuco, Chile|Beijing, China|Changchun, China|Changde, China|Changsha, China|Chengdu, China|Chenzhou, China|Dalian, China|Foshan, China|Guangzhou, China|Huai'an, China|Nanchang, China|Nanjing, China|Shanghai, China|Shenyang, China|Wuhan, China|Wulumuqi, China|Xian, China|Barranquilla, Colombia|Bogota, Colombia|Bucaramanga, Colombia|Cali, Colombia|Floridablanca, Colombia|Manizales, Colombia|Medellin, Colombia|Pasto, Colombia|Pereira, Colombia|Ceske Budejovice, Czechia|Cesky Krumlov, Czechia|Chocen, Czechia|Havlickuv Brod, Czechia|Hradec Kralove-Vekose, Czechia|Hradec Nad Svitavou, Czechia|Jindrichuv Hradec, Czechia|Olomouc, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha, Czechia|Slany, Czechia|Trutnov, Czechia|Uherske Hradiste, Czechia|Usti Nad Labem, Czechia|Besancon Cedex, France|Brest cedex, France|Colmar N/a, France|Corbeil Essonnes Cedex, France|Créteil Cedex, France|Grenoble, France|Lyon cedex 03, France|Marseille Cedex 05, France|Metz cedex 03, France|Nantes Cedex 01, France|Paris Cedex 15, France|Paris Cedex 18, France|Paris, France|Pierre-Bénit, France|Poitiers, France|St Priest-en-Jarez, France|Strasbourg, France|Toulouse Cedex 9, France|Bad Kreuznach - Bosenheim, Germany|Dietzenbach, Germany|Dresden, Germany|Essen, Germany|Hamburg, Germany|Hannover, Germany|Köln, Germany|Muenster, Germany|Guatemala City, Guatemala|Guatemala, Guatemala|Baja, Hungary|Balatonfured, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Esztergom, Hungary|Godollo, Hungary|Gyula, Hungary|Hu-4012 Debrecen N/a, Hungary|Kaposvar, Hungary|Kecskemet N/a, Hungary|Komarom, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Szeged N/a, Hungary|Szigetvar, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Calicut, India|Chennai, India|Delhi, India|Hyderabad, India|Kozhikode, India|Lucknow, India|Ludhiyana, India|Mangalore, India|Mumbai, India|Mysore, India|Secunderabad, India|Trivandrum, India|Vijayawada, India|Vishakhapatnam, India|Ageo-shi, Japan|Chiyoda-ku, Japan|Fukuoka, Japan|Hamamatsu-shi, Japan|Hamura-shi, Japan|Ina-shi, Japan|Izumisano, Japan|Kamakura-shi, Japan|Kanazawa, Japan|Kawanishi-shi, Japan|Koriyama-shi, Japan|Kuki-shi, Japan|Kyoto, Japan|Matsuyama-shi, Japan|Midori-shi, Japan|Minato-ku, Japan|Nagoya-shi, Japan|Osaka-shi, Japan|Ota-shi, Japan|Saiki-shi, Japan|Sashima-gun, Japan|Shinjuku-ku, Japan|Toyama-shi, Japan|Uwajima-shi, Japan|Yamanashi, Japan|Yokohama-City, Japan|Yokohama-shi, Japan|Busan, Korea, Republic of|Daegu, Korea, Republic of|Incheon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Siauliai, Lithuania|Batu Caves, Malaysia|Ipoh, Malaysia|Johor, Malaysia|Kuala Lumpur N/a, Malaysia|Kuala Lumpur, Malaysia|Kuantan, Malaysia|Melaka, Malaysia|Perai, Malaysia|Petaling Jaya, Malaysia|Seremban, Malaysia|Seri Manjung, Malaysia|Sungai Petani, Kedah, Malaysia|Tampin, Malaysia|Temerloh, Malaysia|Aguascalientes, Mexico|Celaya, Mexico|Chihuahua, Mexico|Ciudad De Mexico, Mexico|Ciudad De Mexic, Mexico|Cuautitlan Izcalli, Mexico|Culiacan, Mexico|Culiacán, Mexico|Durango, Mexico|El Salto, Mexico|Guadalajara, Mexico|Leon, Mexico|Merida, Mexico|Mexico City, Mexico|Mexico, Mexico|Monterrey, Mexico|Morelia, Mexico|Orizaba, Mexico|Pachuca de Soto, Mexico|Pachuca, Mexico|Queretaro, Mexico|San Luis Potosi, Mexico|Tlalnepantla de Baz, Mexico|Veracruz, Mexico|Zapopan, Mexico|Auckland, New Zealand|Christchurch, New Zealand|Dunedin, New Zealand|Palmerston North, New Zealand|Rotorua, New Zealand|Takapuna Auckland, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Cagayan De Oro City, Philippines|Cebuu City, Philippines|Cebu, Philippines|Davao City, Philippines|Iloilo City, Philippines|Lipa City, Philippines|Marikina City, Philippines|Pasay City, Philippines|Pasig, Philippines|Quezon City, Philippines|San Fernando, Philippines|Tagbilaran City, Philippines|Taytay, Philippines|Bydgoszcz, Poland|Chorzow, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Parczew, Poland|Poznan, Poland|Radom, Poland|Rzeszow, Poland|Torun, Poland|Warswa, Poland|Wroclaw, Poland|Zgierz, Poland|Znin, Poland|Caguas, Puerto Rico|Ponce, Puerto Rico|San Juan, Puerto Rico|Brasov, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Deva, Romania|Iasi, Romania|Oradea, Romania|Ploiesti, Romania|Targu Mures, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Ivanovo, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Petrozavodsk, Russian Federation|Rostov-on-Don, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Sestroretsk, Saint-Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ufa, Russian Federation|Volgograd, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Nis, Serbia|Zajecar, Serbia|Bardejov, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Lubochna, Slovakia|Nitra, Slovakia|Prievidza, Slovakia|Puchov, Slovakia|Rimavska Sobota, Slovakia|Sturovo, Slovakia|Svidnik, Slovakia|Zilina, Slovakia|Cape Town, South Africa|Durban, South Africa|Isipingo Rail, South Africa|Johannesburg, South Africa|Krugersdorp, South Africa|Port Elizabeth, South Africa|Pretoria Gauteng, South Africa|Pretoria, South Africa|Soweto, South Africa|A Coruna, Spain|Almeria, Spain|Barcelona, Spain|Burela, Spain|Ciudad Real, Spain|Getafe, Spain|Girona, Spain|Granada, Spain|La Roca del Vallès, Spain|Madrid, Spain|Majadahonda, Spain|Málaga, Spain|Palma de Mallorca, Spain|Pozuelo de Alarcón, Spain|Sagunto, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Vic, Spain|Viladecans, Spain|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Chernivtsi, Ukraine|Dnipropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Ternopil, Ukraine|Vinnitsya, Ukraine|Vinnytsia, Ukraine|Zaporizhzhia, Ukraine|Ajman, United Arab Emirates|Dubai, United Arab Emirates|Sharjah, United Arab Emirates|Aberdeen, United Kingdom|Antrim, United Kingdom|Barry, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bolton, United Kingdom|Bournemouth, United Kingdom|Bradford, United Kingdom|Bristol, United Kingdom|Burbage, United Kingdom|Cardff, United Kingdom|Cardiff, United Kingdom|Carlshalton, United Kingdom|Carmarthen, United Kingdom|Chester, United Kingdom|Darlington, United Kingdom|Doncaster, United Kingdom|Durham, United Kingdom|Ely, United Kingdom|Hampstead, United Kingdom|Harlow, United Kingdom|Huntingdon, United Kingdom|Leamington Spa, United Kingdom|Liskeard, United Kingdom|London, United Kingdom|Middlesbrough, United Kingdom|Plymouth, United Kingdom|Rhyl, United Kingdom|Rugby, United Kingdom|Salford, United Kingdom|Stoke On Trent, United Kingdom|Swansea, United Kingdom|Torpoint, United Kingdom|Watford, United Kingdom|Welwyn Garden City, United Kingdom|Westcliff on Sea, United Kingdom|Wokingham, United Kingdom|Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02065791/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02065791/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02065791
613,NCT03286751,A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03286751/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03286751/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03286751
614,NCT03232983,A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants,Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: LY900014 (SC)|Drug: LY900014 (IV),Eli Lilly and Company,"21 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03232983/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03232983/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03232983
615,NCT03557658,Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment,Completed,Has Results,Type2 Diabetes Mellitus,Drug: Bexagliflozin,Theracos,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Site 1, Boston, Massachusetts, United States|Clinical Research Site 2, Saint Paul, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03557658/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03557658/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03557658
616,NCT03670641,Remission Through Early Monitored Insulin Therapy - Duration Month,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Glargine|Drug: Lispro|Device: Dexcom G6,Sandra Sobel|University of Pittsburgh,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UPMC Falk Diabetes Clinic, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03670641/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03670641/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03670641
617,NCT03608358,Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin,Terminated,No Results Available,Type 2 Diabetes Mellitus,Drug: Dapagliflozin 10 mg|Drug: Dapagliflozin 5 mg|Drug: Dapagliflozin 10 mg placebo to match|Drug: Dapagliflozin 5 mg placebo to match|Drug: Saxagliptin 5 mg|Drug: Metformin,AstraZeneca,"18 Years to 130 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03608358/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03608358/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03608358
618,NCT03544242,Nitrite Infusion in Islet Cell Transplantation,Terminated,Has Results,Diabetes,Other: Control|Drug: Pre-Isolation Infusion|Drug: Post-Isolation Infusion,University of Alabama at Birmingham,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03544242/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03544242
619,NCT02989649,Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice,Terminated,Has Results,"Diabetes Mellitus, Type 2",Drug: Alogliptin|Drug: Alogliptin FDC With Pioglitazone|Drug: Alogliptin FDC With Metformin,Takeda,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Beijing, Beijing, China|Wuhan, Hubei, China|Dalian, Liaoning, China|Shenyang, Liaoning, China|Jinan, Shandong, China|Qingdao, Shandong, China|Tai'an, Shandong, China|Taian, Shandong, China|Tianjin, Tianjin, China|Sai Ying Pun, Hong Kong|Sha Tin, Hong Kong","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02989649/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02989649/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02989649
620,NCT01234649,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Completed,Has Results,Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation,Drug: Metformin XR plus placebo|Drug: Metformin XR plus liraglutide,Woman's|Novo Nordisk A/S,18 Years to 45 Years   (Adult),Phase 3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Woman's Hospital, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT01234649/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT01234649/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01234649
621,NCT03197324,Bexagliflozin Drug/Drug Interaction Study With Digoxin,Completed,Has Results,Type2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Digoxin,Theracos,18 Years to 55 Years   (Adult),Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Covance CRU, Daytona Beach, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03197324/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03197324/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03197324
622,NCT03296800,"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects",Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Probenecid|Drug: Rifampin|Drug: Verapamil,Theracos,18 Years to 55 Years   (Adult),Phase 1,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Covance Clinical Research Unit, Daytona Beach, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03296800/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03296800/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03296800
623,NCT03167411,Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection,Completed,Has Results,Type2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Exenatide Injection,Theracos,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Site, Evansville, Indiana, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03167411/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03167411/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03167411
624,NCT01301521,Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics,Completed,No Results Available,Diabetes|Pre-Diabetes,Drug: water-soluble cinnamon extract (Cinnulin PF),Mike O'Callaghan Military Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Travis Air Force Base, Travis Air Force Base, California, United States|Eglin Air Foce Base, Eglin Air Force Base, Florida, United States|Offutt Air Force Base, Offutt Air Force Base, Nebraska, United States|Wilford Hall Ambulatory Surgical Center, Lackland Air Force Base, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT01301521/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT01301521/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01301521
625,NCT02956044,"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin",Completed,Has Results,Type2 Diabetes Mellitus,Drug: Bexagliflozin|Drug: Metformin|Drug: Glimepiride|Drug: Sitagliptin,Theracos,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Site, Evansville, Indiana, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02956044/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02956044/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02956044
626,NCT03283566,Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT,Completed,Has Results,Chronic Pancreatitis|Insulin Dependent Diabetes,Drug: Hydroxychloroquine|Drug: Placebo,The Cleveland Clinic|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)|Stanford University,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03283566/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03283566
627,NCT02820298,Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects,Completed,Has Results,Type 2 Diabetes Mellitus,Drug: Bexagliflozin,Theracos,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Denver Clinical Research Unit, Lakewood, Colorado, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02820298/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02820298/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02820298
628,NCT04413578,CGM - Reimagine Primary Care,Completed,No Results Available,"Diabetes Mellitus, Type 2",Device: Dexcom G6|Device: Contour NextOne,"Intermountain Health Care, Inc.","18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holladay Internal Medicine, Holladay, Utah, United States|Intermountain Cottonwood Family Practice, Murray, Utah, United States|Intermountain Senior Clinic, Murray, Utah, United States|Avenues Internal Medicine, Salt Lake City, Utah, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04413578/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04413578/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04413578
629,NCT03626623,Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care,Terminated,Has Results,"Diabetes|Diabetic Foot|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1",Device: Cytal Wound Matrix 1-Layer|Other: Standard of Care (SOC),Integra LifeSciences Corporation,"21 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Limb Preservation Platform, Inc., Fresno, California, United States|Louisiana State University Health Science Center (LSUHSC), New Orleans, Louisiana, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03626623/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03626623
630,NCT02656069,Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: G-Pen (glucagon injection)|Drug: Lilly Glucagon (glucagon injection [rDNA origin]),Xeris Pharmaceuticals,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|ProSciento, Inc., Chula Vista, California, United States|AMCR Institute, Escondido, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Rainier Research, Renton, Washington, United States|LMC Diabetes & Endocrinology, Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02656069/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02656069
631,NCT01795833,Diabetes Prevention Using SMS Technology,Completed,Has Results,Prediabetes,Other: Short text messages,"Imperial College London|Barts & The London NHS Trust|Mid and South Essex NHS Foundation Trust|Lister Hospital|Torbay Hospital|Queen Alexandra Hospital|East Surrey Hospital|Pennine Acute Hospitals NHS Trust|West Suffolk Hospital|Derriford Hospital|Exeter Hospital|Milton Keynes University Hospital NHS Foundation Trust|Royal Cornwall Hospitals Trust|Queen Margaret Hospital, Dunfermline|Harrogate & District NHS Foundation Trust|Royal Berkshire NHS Foundation Trust|Rotherham NHS Trust","18 Years to 74 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Imperial college Healthcare NHS Trust, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01795833/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT01795833
632,NCT03734445,"Effect of Vitamin C, D and Zinc Supplementation on the Immune and Inflammatory Process in Type 2 Diabetic Subjects",Unknown status,No Results Available,"Diabetes Mellitus, Type 2",Dietary Supplement: Vitamin Supplement|Other: Placebo,Universidad Autonoma del Estado de Mexico,25 Years to 55 Years   (Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Mexico,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03734445/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03734445/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT03734445
633,NCT03842683,CGM Precision and Glycaemic Variability,Completed,Has Results,Diabetes Type 1,Other: CGM,Peter Vestergaard|Aalborg University Hospital,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Retrospective,Denmark,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03842683/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03842683/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03842683
634,NCT02545049,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,Completed,Has Results,Diabetic Kidney Disease,Drug: Finerenone (BAY94-8862)|Drug: Placebo,Bayer,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Fort Payne, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Prescott, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Bakersfield, California, United States|Chula Vista, California, United States|Dublin, California, United States|El Centro, California, United States|Fresno, California, United States|Fresno, California, United States|La Mesa, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|Port Hueneme, California, United States|Poway, California, United States|Rancho Cucamonga, California, United States|Rialto, California, United States|Roseville, California, United States|San Diego, California, United States|Santa Rosa, California, United States|Torrance, California, United States|Vista, California, United States|New Haven, Connecticut, United States|Waterbury, Connecticut, United States|Fort Lauderdale, Florida, United States|Fort Lauderdale, Florida, United States|Fort Lauderdale, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami Gardens, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Lawrenceville, Georgia, United States|Macon, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Elgin, Illinois, United States|Morton, Illinois, United States|Springfield, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|West Des Moines, Iowa, United States|Hutchinson, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Metairie, Louisiana, United States|Monroe, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Flint, Michigan, United States|Flint, Michigan, United States|Kalamazoo, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Columbia, Missouri, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Brooklyn, New York, United States|New York, New York, United States|Rosedale, New York, United States|Smithtown, New York, United States|Staten Island, New York, United States|Asheboro, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Willoughby Hills, Ohio, United States|Beaver, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Hershey, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Murrells Inlet, South Carolina, United States|Myrtle Beach, South Carolina, United States|Orangeburg, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kingwood, Texas, United States|McAllen, Texas, United States|McKinney, Texas, United States|Missouri City, Texas, United States|Pearland, Texas, United States|Pflugerville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Sugar Land, Texas, United States|Tomball, Texas, United States|Waco, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Alexandria, Virginia, United States|Charlottesville, Virginia, United States|Manassas, Virginia, United States|Salem, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Caba, Buenos Aires, Argentina|Junín, Buenos Aires, Argentina|Lanús, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Sarandí, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Caba, Ciudad Auton. De Buenos Aires, Argentina|Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Córdoba, Argentina|Córdoba, Argentina|San Luis, Argentina|Garran, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|Kanwal, New South Wales, Australia|Liverpool, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Fitzroy, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Reservoir, Victoria, Australia|Richmond, Victoria, Australia|St. Albans, Victoria, Australia|Elizabeth Vale, Australia|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Saint Stefan, Steiermark, Austria|Zams, Tirol, Austria|Feldkirch, Vorarlberg, Austria|Innsbruck, Austria|Salzburg, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Ieper, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasilia, Distrito Federal, Brazil|Aparecida de Goiania, Goiás, Brazil|Goiania, Goiás, Brazil|Juiz de Fora, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Campina Grande do Sul, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|São Bernardo do Campo, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Blagoevgrad, Bulgaria|Botevgrad, Bulgaria|Dimitrovgrad, Bulgaria|Gorna Oryahovitsa, Bulgaria|Kazanlak, Bulgaria|Kozloduy, Bulgaria|Lukovit, Bulgaria|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Razgrad, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Yambol, Bulgaria|Edmonton, Alberta, Canada|Burnaby, British Columbia, Canada|Coquitlam, British Columbia, Canada|New Westminster, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|Newmarket, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Smith Falls, Ontario, Canada|Sudbury, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Greenfield Park, Quebec, Canada|Laval, Quebec, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Osorno, Los Lagos, Chile|Las Condes, Santiago, Chile|Providencia, Santiago, Chile|Providencia, Santiago, Chile|San Bernardo, Santiago, Chile|San Miguel, Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Xiamen, Fujian, China|Xiamen, Fujian, China|Lanzhou, Gansu, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhuhai, Guangdong, China|Nanning, Guangxi, China|Nanning, Guangxi, China|Haikou, Hainan, China|Haikou, Hainan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Changsha, Hunan, China|Hohhot, Inner Mongolia, China|Changzhou, Jiangsu, China|Huai'An, Jiangsu, China|Lianyungang, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Yancheng, Jiangsu, China|Nanchang, Jiangxi, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Urumqi, Xinjiang, China|Hangzhou, Zhejiang, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Medellin, Antioquia, Colombia|Medellín, Antioquia, Colombia|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Barranquilla, Atlántico, Colombia|Manizales, Caldas, Colombia|Zipaquirá, Cundinamarca, Colombia|Bogotá, Distrito Capital De Bogotá, Colombia|Bogotá, Distrito Capital De Bogotá, Colombia|Cundinamarca, Distrito Capital De Bogotá, Colombia|Pasto, Nariño, Colombia|Armenia, Quindío, Colombia|Pereira, Risaralda, Colombia|Cali, Valle Del Cauca, Colombia|Cali, Valle Del Cauca, Colombia|Barranquilla, Colombia|Bogota, Colombia|Floridablanca, Colombia|Medellín, Colombia|Beroun, Czechia|Brandys nad Labem, Czechia|Breclav, Czechia|Ceska Lipa, Czechia|Cesky Krumlov, Czechia|Cesky Krumlov, Czechia|Frydek-Mistek, Czechia|Hodonin, Czechia|Holesov, Czechia|Hranice, Czechia|Koprivnice, Czechia|Krnov, Czechia|Mlada Boleslav, Czechia|Olomouc, Czechia|Olomouc, Czechia|Ostrava, Czechia|Plzen, Czechia|Prague 6, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 4, Czechia|Praha 5, Czechia|Vlasim, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Esbjerg, Denmark|Gentofte, Denmark|Hellerup, Denmark|Herlev, Denmark|Hillerød, Denmark|Holbæk, Denmark|Holstebro, Denmark|Hvidovre, Denmark|Kolding, Denmark|København NV, Denmark|Odense C, Denmark|Svendborg, Denmark|Viborg, Denmark|Jyväskylä, Finland|Kajaani, Finland|Kerava, Finland|Klaukkala, Finland|Kuopio, Finland|Nurmijärvi, Finland|Oulu, Finland|Rauma, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Vantaa, Finland|Bois-guillaume, France|Boulogne Sur Mer, France|Brest, France|COLMAR Cedex, France|Dijon, France|Grenoble Cedex 9, France|Le Coudray, France|Le Creusot, France|Lyon Cedex, France|Mulhouse, France|NIMES cedex 9, France|Paris, France|Saint Herblain, France|Tourcoing, France|Vandoeuvre-les-nancy, France|Venissieux, France|Heidelberg, Baden-Württemberg, Germany|Ludwigsburg, Baden-Württemberg, Germany|Sinzheim, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Schweinfurt, Bayern, Germany|Würzburg, Bayern, Germany|Elsterwerda, Brandenburg, Germany|Bad Homburg, Hessen, Germany|Bad König, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Nettetal, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Athens, Greece|Athens, Greece|Chaidari, Greece|Larissa, Greece|Nea Ionia, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Sheung Wan, Hong Kong|Wong Tai Sin, Hong Kong|Baja, Hungary|Balatonfured, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Kistarcsa, Hungary|Nyiregyhaza, Hungary|Nyiregyhaza, Hungary|Papa, Hungary|Siofok, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szentes, Hungary|Szombathely, Hungary|Cork, Ireland|Dublin, Ireland|Galway, Ireland|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Nahariya, Israel|Nazareth, Israel|Ramat Gan, Israel|Rehovot, Israel|Sakhnin, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tiberias, Israel|Zefat, Israel|Zerifin, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza Brianza, Lombardia, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Catania, Sicilia, Italy|Messina, Sicilia, Italy|Pisa, Toscana, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyota, Aichi, Japan|Funabashi, Chiba, Japan|Ichikawa, Chiba, Japan|Matsuyama, Ehime, Japan|Matsuyama, Ehime, Japan|Chikushino, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Shirakawa, Fukushima, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Higashihiroshima, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Naka, Ibaraki, Japan|Ushiku, Ibaraki, Japan|Komatsu, Ishikawa, Japan|Sanuki, Kagawa, Japan|Takamatsu, Kagawa, Japan|Takamatsu, Kagawa, Japan|Atsugi, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Tamana, Kumamoto, Japan|Yatsushiro, Kumamoto, Japan|Sasebo, Nagasaki, Japan|Beppu, Oita, Japan|Yufu, Oita, Japan|Nakagami-gun, Okinawa, Japan|Shimajiri, Okinawa, Japan|Matsubara, Osaka, Japan|Suita, Osaka, Japan|Kawaguchi, Saitama, Japan|Sayama, Saitama, Japan|Otsu, Shiga, Japan|Iwata, Shizuoka, Japan|Oyama, Tochigi, Japan|Minato, Tokyo, Japan|Musashino, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Tacchikawa, Tokyo, Japan|Fukui, Japan|Fukui, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kumamoto, Japan|Kumamoto, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Wonju, Gang''weondo, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Utena, Lithuania|Vilnius, Lithuania|Johor Bahru, Malaysia|Kelantan, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Pahang, Malaysia|Perak, Malaysia|Perak, Malaysia|Pulau Pinang, Malaysia|Putrajaya, Malaysia|Selangor, Malaysia|Ciudad de México, Distrito Federal, Mexico|Ciudad de México, Distrito Federal, Mexico|Ciudad de México, Distrito Federal, Mexico|México D.F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Cuernavaca, Morelos, Mexico|Monterrey, Nuevo Leon, Mexico|Queretaro, Querétaro, Mexico|San Juan del Río, Querétaro, Mexico|Culiacán, Sinaloa, Mexico|Culiacán, Sinaloa, Mexico|Mazatlán, Sinaloa, Mexico|Puerto de Veracruz, Veracruz, Mexico|Xalapa, Veracruz, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Durango, Mexico|Alkmaar, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Breda, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Geleen, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Hamilton, New Zealand|Hawkes Bay, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Hamar, Norway|Hamar, Norway|Kløfta, Norway|Kongsvinger, Norway|Kristiansand, Norway|Levanger, Norway|Lierskogen, Norway|Oslo, Norway|Oslo, Norway|Skedsmokorset, Norway|Ålesund, Norway|Iloilo City, Philippines|Marikina City, Philippines|Pasig City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Chojnice, Poland|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Rzeszow, Poland|Skorzewo, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Zabrze, Poland|Covilha, Castelo Branco, Portugal|Loures, Lisboa, Portugal|Matosinhos, Porto, Portugal|Funchal, Região Autónoma Da Madeira, Portugal|Torres Novas, Santarém, Portugal|Setubal, Setúbal, Portugal|Almada, Portugal|Amadora, Portugal|Braga, Portugal|Faro, Portugal|Leiria, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Viana do Castelo, Portugal|Cidra, Puerto Rico|San Juan, Puerto Rico|San Juan, Puerto Rico|Alba-Iulia, Alba, Romania|Oradea, Bihor, Romania|Baia Mare, Maramures, Romania|Ploiesti, Prahova, Romania|Timisoara, Timis, Romania|Brasov, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Galati, Romania|Iasi, Romania|Oradea, Romania|Satu Mare, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Irkutsk, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Syktyvkar, Russian Federation|Voronezh, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Yekaterinburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Banska Bystrica, Slovakia|Bardejov, Slovakia|Nitra, Slovakia|Rimavska Sobota, Slovakia|Roznava, Slovakia|Zilina, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Benoni, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Lenasia South, Gauteng, South Africa|Newtown, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Soweto, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Isipingo Rail, Kwazulu-Natal, South Africa|Tongaat, Kwazulu-Natal, South Africa|Middelburg, Mpumalanga, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Ferrol, A Coruña, Spain|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Sant Joan Despi, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Burela, Lugo, Spain|Alcalá de Henares, Madrid, Spain|Getafe, Madrid, Spain|Sagunto, Valencia, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Granada, Spain|Jaén, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Göteborg, Sweden|Lund, Sweden|Lund, Sweden|Rättvik, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Uppsala, Sweden|Örebro, Sweden|Örebro, Sweden|St. Gallen, Sankt Gallen, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Olten, Solothurn, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Genève, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Khon Kaen, Thailand|Ankara, Turkey|Antalya, Turkey|Antalya, Turkey|Aydin, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Malatya, Turkey|Sivas, Turkey|Cherkasy, Ukraine|Chernivtsi, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Mykolayiv, Ukraine|Ternopil, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine|Zaporozhye, Ukraine|Llanelli, Carmarthenshire, United Kingdom|Liverpool, Merseyside, United Kingdom|Northampton, Northamptonshire, United Kingdom|Carshalton, Surrey, United Kingdom|Birmingham, West Midlands, United Kingdom|Chichester, West Sussex, United Kingdom|Bristol, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesborough, United Kingdom|Ha Noi, Vietnam|Ha Noi, Vietnam|Ho Chi Minh City, Vietnam|Ho Chi Minh City, Vietnam|Ho Chi Minh City, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02545049/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02545049/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02545049
635,NCT04508751,PED NEONAT 20-000599 Fetal Body Composition,Completed,No Results Available,IUGR|Gestational Diabetes|Pregnancy Related,"Other: 3T ""Free-Breathing"" Fetal Magnetic Resonance Imaging","University of California, Los Angeles","18 Years and older   (Adult, Older Adult)",Phase 1,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of California-Los Angeles, Los Angeles, California, United States|University of California- Los Angeles Santa Monica, Santa Monica, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT04508751/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04508751
636,NCT02833415,Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging,Completed,Has Results,"Obesity, Visceral",Drug: [U-13C3] glycerol|Drug: Empagliflozin|Drug: Placebo (for Empagliflozin),University of Texas Southwestern Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"30 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Texas Southwestern Medical Center, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02833415/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02833415
637,NCT02730962,Interventional Bioremediation of Microbiota in Metabolic Syndrome,Terminated,Has Results,Pre-Diabetes,Drug: Vancomycin|Other: Placebo|Drug: Neomycin|Drug: Clindamycin|Procedure: Fecal Microbiota Transplantation,University of Minnesota,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Minnesota Medical Center, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02730962/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02730962
638,NCT05240274,The POWERED Study: Prophylaxis With Metformin to Prevent PTDM,"Active, not recruiting",No Results Available,Post-transplant Diabetes Mellitus|New Onset Diabetes After Transplant|New Onset Diabetes After Transplantation|Kidney Transplant; Complications|Renal Transplantation|End Stage Renal Disease|Metformin,Drug: Metformin|Drug: Placebo,Barts & The London NHS Trust,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Royal London Hospital, Barts Health NHS Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT05240274/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05240274
639,NCT00679042,Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol,"Active, not recruiting",Has Results,Type 1 Diabetes Mellitus,Biological: Islets of Langerhans transplantation,CellTrans Inc.,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago Medical Center, Chicago, Illinois, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT00679042/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT00679042/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT00679042
640,NCT02964247,LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.,Completed,Has Results,"Diabetes|Diabetes Mellitus, Type 2",Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Montgomery, Alabama, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Sacramento, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Maitland, Florida, United States|Novo Nordisk Investigational Site, Miami Lakes, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Blackfoot, Idaho, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Kalamazoo, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Michigan, United States|Novo Nordisk Investigational Site, Billings, Montana, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Kinston, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Columbus, Ohio, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Moncks Corner, South Carolina, United States|Novo Nordisk Investigational Site, Mount Pleasant, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Edinburg, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Humble, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Schertz, Texas, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Hyderabad, Telengana, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Ponce, Puerto Rico|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Al Ain, United Arab Emirates|Novo Nordisk Investigational Site, Dubai, United Arab Emirates|Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates|Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02964247/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02964247/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02964247
641,NCT03764631,"Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration",Completed,Has Results,"Diabetes Mellitus, Type 2",Drug: Empagliflozin|Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors,Boehringer Ingelheim,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Abha International Private Hospital, Abha, Saudi Arabia|DAFA Special Polyclinic, Jeddah, Saudi Arabia|Ghassan Najeeb Pharaon Hospital, Jeddah, Saudi Arabia|International Medical Center, Jeddah, Saudi Arabia|Dr.Bakhsh Hospital, Jeddah, Saudi Arabia|Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia|Saudi German Hospital, Jeddah, Saudi Arabia|Al Abeer Medical Center, Jeddah, Saudi Arabia|Al-Abeer Medical Center, Jeddah, Saudi Arabia|Al Abeer Polyclinic, Jeddah, Saudi Arabia|Al Rahman Polyclinic, Makkah, Saudi Arabia|Shifa Hospital, Makkah, Saudi Arabia|Al-Noor Specialist Hospital, Makkah, Saudi Arabia|Al Zafer Hospital, Najran, Saudi Arabia|Obesity, Endocrine and Metabolism Center, Riyadh, Saudi Arabia|Riyadh Medical Center, Riyadh, Saudi Arabia|Alalam Medical Center, Riyadh, Saudi Arabia|Prince Fahad bin Sultan hospital, Tabuk, Saudi Arabia|Al Hada Armed Forces Hospital, Taif, Saudi Arabia|Al Amal Medical Group, Yanbu, Saudi Arabia|Alansari Specialist Hospital, Yanbu, Saudi Arabia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03764631/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03764631/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03764631
642,NCT03371355,"Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease",Completed,Has Results,"NAFLD|Diabetes Mellitus, Type 2|Hypertriglyceridemia|Fatty Liver, Nonalcoholic",Drug: Placebo|Drug: ISIS 703802 40 mg|Drug: ISIS 703802 80 mg|Drug: ISIS 703802 20 mg,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Sites, Chandler, Arizona, United States|Clinical Site, Fountain Hills, Arizona, United States|Clinical Site, Glendale, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Huntington Park, California, United States|Clinical Site, Los Angeles, California, United States|Clinical Site, Montclair, California, United States|Clinical Site, Panorama City, California, United States|Clinical Site, Poway, California, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jensen Beach, Florida, United States|Clinical Site, Jupiter, Florida, United States|Clinical Site, Miami, Florida, United States|Clinical Site, Port Saint Lucie, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Indianapolis, Indiana, United States|Clinical Site, Louisville, Kentucky, United States|Clinical Site, Edina, Minnesota, United States|Clinical Site, Bridgeton, New Jersey, United States|Clinical Site, Princeton, New Jersey, United States|Clinical Site, Greensboro, North Carolina, United States|Clinical Site, High Point, North Carolina, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Charleston, South Carolina, United States|Clinical Site, Austin, Texas, United States|Clinical Site, Carrollton, Texas, United States|Clinical Site, Dallas, Texas, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Hurst, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, Layton, Utah, United States|Clinical Site, Hamilton, Ontario, Canada|Clinical Site, Toronto, Ontario, Canada|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03371355/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03371355/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03371355
643,NCT04161131,Overcoming Barriers and Obstacles to Adopting Diabetes Devices,Completed,Has Results,Type 1 Diabetes,Behavioral: ONBOARD,Molly Tanenbaum|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Stanford University,18 Years to 50 Years   (Adult),Not Applicable,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04161131/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04161131/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04161131/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT04161131
644,NCT01736124,Computerized Cognitive Training for Diabetic Elderly Veterans,Completed,Has Results,"Diabetes Mellitus, Type 2",Other: computerized cognitive training|Other: control games,VA Office of Research and Development,"55 Years to 99 Years   (Adult, Older Adult)",Phase 4,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01736124/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01736124/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01736124
645,NCT01724060,Effects of Obesity Treatments on Food Preferences and Metabolism,Completed,Has Results,Obesity|Type 2 Diabetes Mellitus,,Imperial College London,"18 Years to 70 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,"Royal Surrey County Hospital, Guildford, United Kingdom|Imperial Weight Centre, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT01724060/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01724060
646,NCT02130687,Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure,Completed,Has Results,Type 2 Diabetes Mellitus|Hypertension,Drug: Placebo|Drug: Sitagliptin|Drug: Aprepitant|Other: Mixed Meal Test (MMT),Vanderbilt University|Vanderbilt University Medical Center,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University, Nashville, Tennessee, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02130687/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02130687
647,NCT03688711,Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM,Completed,Has Results,"Hypoglycemia|Diabetes Mellitus, Type 1",Drug: Dasiglucagon|Drug: Placebo,Zealand Pharma,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ProSciento, Inc., Chula Vista, California, United States|AMCR Institute, Escondido, California, United States|Rainier Clinical Research, Inc., Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03688711/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03688711/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03688711
648,NCT03490942,Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses,Terminated,Has Results,"Hypoglycemia Unawareness|Diabetes Mellitus, Type 1",Drug: Glucagon|Drug: Placebo,Xeris Pharmaceuticals|Integrated Medical Development,21 Years to 64 Years   (Adult),Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama, Birmingham, Birmingham, Alabama, United States|University of California, San Diego, San Diego, California, United States|Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03490942/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03490942/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03490942
649,NCT04058626,TEsting for Arterial Disease in Diabetes (TrEAD) Study,Completed,Has Results,Diabetic Foot|Peripheral Arterial Disease|Diabetic Foot Ulcer|Peripheral Vascular Diseases|Peripheral Artery Disease|Critical Limb Ischemia|Critical Lower Limb Ischemia,Diagnostic Test: Transcutaneous pressure of oxygen (TcPO2)|Diagnostic Test: Toe Brachial Pressure Index (TBPI)|Diagnostic Test: Podiatry Ankle Duplex scan (PAD-scan)|Diagnostic Test: Duplex Assist|Diagnostic Test: Ankle Brachial Pressure Index (ABPI),Imperial College Healthcare NHS Trust,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Prospective,"West Middlesex University Hospital, London, United Kingdom|Imperial College NHS Healthcare Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04058626/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04058626
650,NCT03478254,Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).,Completed,Has Results,Type 1 Diabetes Mellitus,Biological: Influenza vaccination|Biological: Pneumococcal vaccination|Biological: Hepatitis B Virus (HBV) vaccination,Jesús Moreno Fernández|Castilla-La Mancha Health Service|University of Castilla-La Mancha,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,"Obispo Rafael Torija, St., Ciudad Real, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03478254/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03478254/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03478254/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03478254
651,NCT03959423,Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System,"Active, not recruiting",Has Results,Type 1 Diabetes Mellitus,Device: AHCL insulin pump system,Medtronic Diabetes,"7 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arkansas Diabetes and Endocrinology Center, Little Rock, Arkansas, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|SoCal Diabetes, Torrance, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center - Adults, Aurora, Colorado, United States|Barbara Davis Center - Pediatric, Aurora, Colorado, United States|Yale Diabetes Research Program, New Haven, Connecticut, United States|University of South Florida, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Southeastern Endocrine, Roswell, Georgia, United States|Rocky Mountain Diabetes Center, Idaho Falls, Idaho, United States|International Diabetes Center, Minneapolis, Minnesota, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|Texas Endocrinology, Austin, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|Rainier Clinical Research, Renton, Washington, United States|Seattle Children's Hospital and Medical Center, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03959423/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03959423/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03959423
652,NCT03760640,A Study of LY900014 in a Medtronic Pump,Completed,Has Results,Type1 Diabetes Mellitus,Drug: LY900014|Drug: Insulin Lispro,Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Atlanta Diabetes Associates, Atlanta, Georgia, United States|International Diabetes Center, Saint Louis Park, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03760640/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03760640/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03760640
653,NCT02019264,A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors,Completed,Has Results,Cardiovascular Disease|High Cardiovascular Risk|Obesity|Overweight|Type 2 Diabetes,Drug: Lorcaserin hydrochloride|Drug: Placebo,Eisai Inc.|Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization,"40 Years and older   (Adult, Older Adult)",Phase 4,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Advanced Cardiovascular, LLC, Alexander City, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|UAB Medical Center, Birmingham, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Mobile Heart Specialists, PC, Mobile, Alabama, United States|Alaska Heart Institute, Anchorage, Alaska, United States|Connect Clinical Research Center, LCC, Chandler, Arizona, United States|Arrowhead Health Centers, Glendale, Arizona, United States|Phoenix Heart, PLLC, Glendale, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Preferred Research Partners, Little Rock, Arkansas, United States|Clinical Research Alliance, Alhambra, California, United States|Central Cardiology, Bakersfield, California, United States|Cardiovascular Research Foundation of Southern Cal, Beverly Hills, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|San Diego Costal Endocrinology Group AMC, Chula Vista, California, United States|John Muir Physician Network Clinical Research Cent, Concord, California, United States|Medical Group of Encino, Encino, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|California Heart Specialists, Huntington Beach, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Diabetes and Endocrine Associates, La Mesa, California, United States|La Mesa Cardiac Center, La Mesa, California, United States|Alliance Research Centers, Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Metabolic Clinic and Research Center, Los Angeles, California, United States|Beverly Hills Cardiology, Los Angeles, California, United States|VA Greater Los Angeles Health Care System, Los Angeles, California, United States|Clinical Interventions Research Institute, Mission Viejo, California, United States|Brigid Freyne MD Inc, Murrieta, California, United States|Valley Clinical Trials Inc, Northridge, California, United States|Carr Cardiology, Oceanside, California, United States|Northern California Clinical Research Center, Redding, California, United States|Sharp Rees-Stealy Medical Group, Inc., San Diego, California, United States|University of California San Diego, San Diego, California, United States|Ritchken and First MD's, San Diego, California, United States|West Coast Research LLC, San Ramon, California, United States|Coastal Multi-Specialty Research, Santa Ana, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Ronald Chochinov, MD, Ventura, California, United States|Ventura Cardiology Consultants, Ventura, California, United States|Infosphere Clinical Research, West Hills, California, United States|UCH-MHS Cardiac Research, Colorado Springs, Colorado, United States|Creekside Endocrine Associates PC, Denver, Colorado, United States|New West Physicians, PC, Golden, Colorado, United States|University of Colorado Health, Loveland, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Clinical Research Works, Bristol, Bristol, Connecticut, United States|Cardiology Associates of Fairfield County, Norwalk, Norwalk, Connecticut, United States|Cardiology Associates of Fairfield County, P.C., Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Cardiology Associates of Fairfield County, P.C., Trumbull, Connecticut, United States|Connecticut Heart and Vascular Center, Trumbull, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Red Clay Research, Newark, Delaware, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Aventura Heart Center, Aventura, Florida, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Meridien Research, Bradenton, Florida, United States|NOVA Southeastern University, Bradenton, Florida, United States|Bay Area Cardiology, Brandon, Florida, United States|Meridien Research, Brooksville, Brooksville, Florida, United States|Clearwater Cardiovascular and Interventional Cons., Clearwater, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Holy Cross Medical Group, Coral Springs, Florida, United States|Cardiology Research Associates, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Asclepius Medical Research, Doral, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Integrative Research Associates, Inc., Fort Lauderdale, Florida, United States|M & O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Primary Care Associates, Fort Myers, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|George E. Platt, M.D., Green Cove Springs, Florida, United States|Eastern Research, Inc., Hialeah, Florida, United States|Larry K. Levinson, D.O., P.A., Hollywood, Florida, United States|Research Physicians Network Alliance, Hollywood, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Florida- Jacksonville, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|Meridien Research, Lakeland, Florida, United States|Pharmax Research Clinic, Inc, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|United Clinical Research Corp., Miami, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|South Florida Research Group LLC, Miami, Florida, United States|South Florida Research Solutions, Miramar, Florida, United States|Southwest Florida Research, Naples, Florida, United States|Ocala Research Institute, Inc, Ocala, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Cardiology Partners Clinical Research Institute, Palm Beach Gardens, Florida, United States|Palm Beach Gardens Research Center, Palm Beach Gardens, Florida, United States|Research Physicians Network Alliance, Pembrok, Pembroke Pines, Florida, United States|South Florida Research Solutions, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|Clinical Research of Central Florida, Plant City, Florida, United States|Columbia Primary Care, LLC d/b/a Heart and Health Institute, Plantation, Florida, United States|St Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Brevard Cardiovascular Research Associates Inc, Rockledge, Florida, United States|Clearwater Cardiovascular and Interventional Cons., Safety Harbor, Florida, United States|Bayfront Health St. Petersburg, Research, Saint Petersburg, Florida, United States|Meridien Research - St. Petersburg, Saint Petersburg, Florida, United States|Professional Health Care of Pinellas, INC, Saint Petersburg, Florida, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Springfield Medical Center, Springfield, Florida, United States|Advanced Clinical Research Group, Stuart, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|Stedman Clinical Trials, Tampa, Florida, United States|Healthpoint Medical Group, Inc, Tampa, Florida, United States|Interventional Cardiac Consultants, Trinity, Florida, United States|Lovelace Scientific Research, Venice, Florida, United States|Indian River Medical Center-Cardiology, Vero Beach, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|Cleveland Clinic Foundation, West Palm Beach, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Atlanta Diabetes Associates, Endocrinology, Atlanta, Georgia, United States|Rockdale Medical-Research Associates, Conyers, Georgia, United States|Atlanta Heart Specialists, Cumming, Georgia, United States|Urban Family Practice Associates/Clinical Research Advantage, Marietta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Herman Clinical Research LLC, Suwanee, Georgia, United States|Atlanta Heart Specialists, Tucker, Georgia, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Consultants in Cardiovascular Medicine, Elmhurst, Illinois, United States|Clinical Investigation Specialists, Inc. in Gurnee, Gurnee, Illinois, United States|Advanced CardioVascular Consultants, SC, Rock Island, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of IN, LLC, Avon, Avon, Indiana, United States|Premier Healthcare, LLC, Bloomington, Indiana, United States|Deaconess Clinic, Inc., Evansville, Indiana, United States|American Health Network of IN, LLC, Franklin, Franklin, Indiana, United States|American Health Network of IN, LLC, Greenfield, Greenfield, Indiana, United States|American Health Network - Thomas Moretto, MD, Indianapolis, Indiana, United States|Medical Consultants PC, Muncie, Indiana, United States|American Health Network of IN, LLC, Muncie, Indiana, United States|Cardiology Associates of Northwest Indiana, P.C, Munster, Indiana, United States|The University of Iowa, College of Public Health, Iowa City, Iowa, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Norton Heart Specialists, Louisville, Kentucky, United States|Norton Heart Specialists, Louisville, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Central Maine Medical Center, Auburn, Maine, United States|Acadia Clinical Research, LLC, Bangor, Maine, United States|Eastern Maine Medical Center Northeast Cardiology Associates, Bangor, Maine, United States|Southern Maine Health Care/Maine Medical Center Research Ins, Biddeford, Maine, United States|InterMed, PA, Portland, Maine, United States|Medstar Cardiology Associates, Annapolis, Maryland, United States|Chesapeake Cardiovascular Associates, GBMC, Baltimore, Maryland, United States|Clinical Research, Inc, Baltimore, Maryland, United States|Medstar Union Memorial Heart Specialists, Baltimore, Maryland, United States|Medstar Union Memorial Hospital, Baltimore, Maryland, United States|Spectrum Clinical Research, Baltimore, Maryland, United States|Overlea Personal Physicians, Baltimore, Maryland, United States|Shahid Saeed MD, PC, Baltimore, Maryland, United States|Maryland Heart Associates, LLC, Glen Burnie, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Lutherville Personal Physicians, Lutherville, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Endocrine & Metabolic Consultants, Rockville, Maryland, United States|Lutherville Personal Physicians, Towson, Maryland, United States|Overlea Personal Physicians, Towson, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|MGH Weight Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New England Center for Clinical Research, IMCA, Fall River, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|ActivMed Practices, Methuen, Massachusetts, United States|Partners Community Physicians Organization, Natick, Massachusetts, United States|Partners Community Physicians Organization, Needham, Massachusetts, United States|Endeavor Medical Research PLC, Alpena, Michigan, United States|Cadillac Clinical Research, LLC, Cadillac, Michigan, United States|Westside Family Medical Center, PC, Kalamazoo, Michigan, United States|Cardiology Consultants of East Michigan, Lapeer, Michigan, United States|Marquette General Heart and Vascular Institute, Marquette, Michigan, United States|MidMichigan Medical Center, Midland, Michigan, United States|Nisus Research at McLaren Northern Michigan Hospital, Petoskey, Michigan, United States|Saint Joseph Mercy Oakland Hospital, Pontiac, Michigan, United States|Remedica LLC, Rochester, Michigan, United States|Michigan CardioVascular Institute, Saginaw, Michigan, United States|American Center for Clinical Trials, Southfield, Michigan, United States|Medical Research Associates, Inc., Traverse City, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Minneapolis Heart Institute Foundation, Baxter, Minnesota, United States|Essentia Institute of Rural Health, Duluth, Minnesota, United States|MNCOME Clinic, Eagan, Minnesota, United States|Radiant Research, Inc., Edina, Minnesota, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Coast Cardiovascular Consultants PLLC, Gulfport, Mississippi, United States|Cardiology Associates Research, LLC, Tupelo, Mississippi, United States|Diabetes & Endocrinology Specialists, Inc., Chesterfield, Missouri, United States|BodyAesthetic Research Center, Washington, Missouri, United States|Billings Clinic Research Center, Billings, Montana, United States|Montana Health Research Institute, Inc., Billings, Montana, United States|Glacier View Cardiology PC, Kalispell, Montana, United States|Internal Medical Associates of Grand Island, PC, Grand Island, Nebraska, United States|Clinical Research Advantage / Rita Chuang, M.D., Henderson, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Medicor Cardiology, PA, Bridgewater, New Jersey, United States|Advanced Heart Care, Bridgewater, New Jersey, United States|UmiMed Center LLC, East Brunswick, New Jersey, United States|Cardiovascular Associates of the Delaware Valley, Elmer, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Cardiovascular Associates of the Delaware Valley P, Haddon Heights, New Jersey, United States|NJ Heart, Linden, New Jersey, United States|Rutgers New Jersey Medical School, Mine Hill, New Jersey, United States|Cardiovascular Associates Delaware Valley Sewell, Sewell, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|New Mexico Heart Institute, PA, Albuquerque, New Mexico, United States|Albany College of Medicine, Division of Endocrinology, Albany, New York, United States|Capital Cardiology Associates, Albany, New York, United States|United Medical Associates, PC, Binghamton, New York, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Long Island Heart Associates, Mineola, New York, United States|North Shore Diabetes and Endocrine Associates, New Hyde Park, New York, United States|Weill Cornell Medical College, New York, New York, United States|DiGiovanna Institute for Medical Education, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|Rochester Clinical Research, Inc., Rochester, New York, United States|Northwell Health Physician Partners Cardiology, Southampton, New York, United States|Capital Cardiology Associates, Troy, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Kernodle Clinic, Burlington, North Carolina, United States|Clinical Trials of America Inc., Cary, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Clinical Trials of America Inc. Hickory, Hickory, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Clinical Trials of America, Inc., Lenoir, North Carolina, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Sanford Cardiology, Sanford, North Carolina, United States|Piedmont Healthcare, Statesville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Aultman Hospital, Canton, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Sentral Clinical Research, Cincinnati, Ohio, United States|Delaware Research Group, LLC, Delaware, Ohio, United States|Awasty Research Network, LLC, Marion, Ohio, United States|Community Health Care, Massillon, Ohio, United States|Apex Medical Research Inc., Springfield, Ohio, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Oklahoma Heart Institute, Tulsa, Oklahoma, United States|Vital Prospects Clinical Research Institute PC, Tulsa, Oklahoma, United States|Blair Medical Associates, Altoona, Pennsylvania, United States|Clinical Research Associates of Central PA, LLC, Altoona, Pennsylvania, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Geisinger Health Clinic, Danville, Pennsylvania, United States|Geisinger Health System, Danville, Pennsylvania, United States|Doylestown Health Cardiology a Division of Doylestown Health, Doylestown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Liberty Family Practice, Erie, Pennsylvania, United States|Endocrine Clinical Research LLC, Feasterville, Pennsylvania, United States|Joseph Lamantia, DO, Indiana, Pennsylvania, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Lycoming Internal Medicine, Inc., Jersey Shore, Pennsylvania, United States|Berkley Hills Clinicals, Johnstown, Pennsylvania, United States|Ilumina Clinical Associates, Johnstown, Johnstown, Pennsylvania, United States|Joseph Lamantia, DO, Johnstown, Pennsylvania, United States|Comprehensive Cardiology Consultants, Langhorne, Pennsylvania, United States|Detweiler Family Medicine and Associates PC, Lansdale, Pennsylvania, United States|Green & Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Capital Area Research LLC, Newport, Pennsylvania, United States|Endocrine Metabolic Associates, Philadelphia, Pennsylvania, United States|Pottstown Medical Specialists, Inc. (PMSI), Pottstown, Pennsylvania, United States|Geisinger Clinic, Scranton, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Radiant Research, Inc., Greer, South Carolina, United States|Mountain View Clinical Research, Greer, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|Brown Clinic, PLLP, Watertown, South Dakota, United States|PMG Research of Bristol, LLC, Bristol, Tennessee, United States|Chattanooga Research and Medicine (CHARM), Chattanooga, Tennessee, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Research Associates of Jackson, Jackson, Tennessee, United States|Kore Cardiovascular Research, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Wellmont CVA Heart Institute, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Wellmont CVA Heart Institute, Kingsport, Tennessee, United States|The Endocrine Clinic, Memphis, Tennessee, United States|Cardiology Wellness Center, Nashville, Tennessee, United States|Central Texas Clinical Research, LLC, Austin, Texas, United States|Texas Diabetes & Endocrinology, Austin, Texas, United States|Texas Health Physicians Group, Carrollton, Texas, United States|Adriana Pop-Moody MD Clinic, PA, Corpus Christi, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Texas Health Physicians Group, Dallas, Dallas, Texas, United States|Research Institute of Dallas, Dallas, Texas, United States|Odilon Alvarado, M.D., Fort Worth, Texas, United States|Texas Health Physicians Group Fort Worth, Fort Worth, Texas, United States|Tand R Clinic, PA, Fort Worth, Texas, United States|San Gabriel Clinical Research, LLC, Georgetown, Texas, United States|Angiocardiac Care of Texas PA, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|West Houston Area Clinical Trial Consultants, LLC, Houston, Texas, United States|Endocrine and Psychiatry Center, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|Texas Cardiology Associates of Houston, Kingwood, Texas, United States|Jalil Aziz Khan M.D., P.A., Lewisville, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Medical Clinic of North Texas, Plano, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|Texas Diabetes, Round Rock, Texas, United States|Physician PrimeCare Research Institute, PLLC, San Antonio, Texas, United States|Cardiology Clinic of San Antonio, San Antonio, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|Martin Diagnostic Clinic, Tomball, Texas, United States|Cardiovascular Associates of East Texas, Tyler, Texas, United States|Bay Area Total Health Medical Group, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Jean Brown Research, Salt Lake City, Utah, United States|Alexandria Clinical Research, LLC, Alexandria, Virginia, United States|Washington Center for Weight Management and Resear, Arlington, Virginia, United States|Burke Internal Medicine and Research, Burke, Virginia, United States|Cardiology Consultants of Danville, Inc., Danville, Virginia, United States|Danville Internal Medicine, Inc, Danville, Virginia, United States|Virginia Heart, Falls Church, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|INOVA Health Care Services, Manassas, Virginia, United States|Burke Internal Medicine and Research, Manassas, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Health Research of Hampton Roads - Norfolk, Inc., Norfolk, Virginia, United States|Clinical Research Associates of Tidewater, Norfolk, Virginia, United States|Clinical Research Partners, Richmond, Virginia, United States|Virginia Cardiovascular Specialists, Richmond, Virginia, United States|National Clinical Research-Richmond, Inc, Richmond, Virginia, United States|Selma Medical Associates, Winchester, Virginia, United States|Larry D. Stonesifer, MD, Inc PS, Federal Way, Washington, United States|Seattle Women's, Seattle, Washington, United States|Rowan Research Inc., Spokane, Washington, United States|MultiCare Research Institute, Tacoma, Washington, United States|Universal Research Group, Tacoma, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Prevea Clinic, Inc, Green Bay, Wisconsin, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Meriter hospital Inc., DBA: UnityPoint Health-Meriter Heart, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aspirus Research Institute, Wausau, Wisconsin, United States|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Gosford Hospital, Cardiology Clinical Trials, Gosford, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Illawarra Shoalhaven Local Health District, Clinical Trial and Research Unit, Wollongong, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Core Research Group, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Cardiology Research Department, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Endocrinology Department, Herston, Queensland, Australia|HeartCare Partners Clinical Research Unit, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Gold Coast Hospital, Cardiovascular Research Centre, Southport, Queensland, Australia|New Royal Adelaide Hospital, Cardiology Department, Adelaide, South Australia, Australia|Adelaide Medical Research, Ashford, South Australia, Australia|Lyell McEwin Hospital, Department of Cardiology, Elizabeth Vale, South Australia, Australia|Heart and Vascular Institute, Fullarton, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Geelong Cardiology Research Unit, Barwon Health, Geelong, Victoria, Australia|Austin Health - Heidelberg Repatriation Hospital, Department of Medicine, Boronia Centre, Heidelberg Heights, Victoria, Australia|Avenue Cardiovascular Centre, Saint Kilda East, Victoria, Australia|Joondalup Cardiovascular Trials Foundation Inc, Joondalup, Western Australia, Australia|Fiona Stanley Hospital, Cardiology Research Department,CDO11, Murdoch, Western Australia, Australia|South Australian Medical Research Inst, Centre for Clinical Research, Adelaide, Australia|The Partners Clinical Research Centre, Nassau, Bahamas|LMC Clinical Research Inc. (Calgary), Calgary, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Nova Scotia Health Authority /QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|LMC Diabetes & Endocrinology - Brampton, Brampton, Ontario, Canada|McMaster University, Brampton, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Aviva Clinical Trial Group In., Burlington, Ontario, Canada|Cambridge Cardiac Care Centre, Cambridge, Ontario, Canada|Joanne F. Liutkus Medicine Professional Corp., Cambridge, Ontario, Canada|Saul Vizel Professional Medicine Corporation, Vizel Cardiac Research, Cambridge, Ontario, Canada|LMC Diabetes & Endocrinology (Etobicoke), Etobicoke, Ontario, Canada|Wharton Medical Clinic Clinical Trials Group Inc., Hamilton, Ontario, Canada|Saint Josephs Health Care London, London, Ontario, Canada|LMC Diabetes & Endocrinoly, Markham, Ontario, Canada|New Market Cardiology Research Group, Newmarket, Ontario, Canada|Dr. Michael Heffernan, Oakville, Ontario, Canada|LMC Clinical Research Inc. (Oakville), Oakville, Ontario, Canada|Dr. Cha, Oshawa, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Dr. Dinkar Shukla Professional Medicine Corporation, Sudbury, Ontario, Canada|Dr Roger Labonte Professional Medicine Corp, Sudbury, Ontario, Canada|LMC Diabetes & Endocrinology (Thornhill), Thornhill, Ontario, Canada|JJ DIG Research Ltd., Toronto, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St Michael's Hospital Health Centre, Toronto, Ontario, Canada|ViaCar Recherche Clinique, Brossard, Quebec, Canada|Q&T Research Outaouais Inc., Gatineau, Quebec, Canada|ViaCar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|Manna Research Inc, Levis, Quebec, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada|Centre hospitalier régional de Lanaudière, Saint-Charles-Borromee, Quebec, Canada|Recherche Clinique London, Sherbrooke, Quebec, Canada|CardioVasc HR, Inc., St Jean sur Richelieu, Quebec, Canada|ViaCar Recherche Clinique Inc., St-Lambert, Quebec, Canada|LMC Clinical Research Inc. (Montreal), Ville Saint-Laurent, Quebec, Canada|Biomedica Research Group, Providencia, Santiago, Chile|Sociedad Medica Cardiologica El Llano, San Miguel, Santiago, Chile|Hospital Regional Concepcion, Concepcion, Chile|Cardiocob, Santiago, Chile|Servicios Medicos Godoy Ltda., Santiago, Chile|Ccbr Cecim, Santiago, Chile|Centro Investigacion Clinica del Sur, Temuco, Chile|CECMI Ltda., Temuco, Chile|ICLE, Guadalajara, Jalisco, Mexico|Private Medical Practice, Guadalajara, Jalisco, Mexico|IMED Clin Trials, Monterrey, Nuevo Leon, Mexico|Cardiolink ClinTrials S.C., Monterrey, Nuevo Leon, Mexico|Centro de Estudios Clinicos y Especialidades Medicas S.C., Monterrey, Nuevo Leon, Mexico|Hospital de Angeles Xalapa, Xalapa, Veracruz, Mexico|Fundacion Cardiovascular de Aguascalientes, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Mentrials S.A.de C.V., Distrito Federal, Mexico|North Shore Hospital-Cardiology Research, Milford, Auckland, New Zealand|Middlemore Hospital, Papatoetoe, Auckland, New Zealand|North Shore Hospital - Diabetes Clinic, Takapuna, Auckland, New Zealand|Christchurch Hospital, Lipids, Christchurch, Canterbury, New Zealand|Christchurch Hospital, Cardiology Research, Christchurch, Canterbury, New Zealand|Dunedin Hospital, Dunedin, Otago, New Zealand|Taranaki Base Hospital, New Plymouth, Taranaki, New Zealand|Hutt Hospital, Cardiology Dept, Lower Hutt, Wellington, New Zealand|Auckland City Hospital, Auckland, New Zealand|Hawkes Bay Regional Hospital, Hastings, New Zealand|Nelson Hospital, Cardiology Department, Nelson, New Zealand|Lakeland Clinical Trials, Rotorua, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Indywidualna Specjalistyczna Praktyka Lekarska, Bezrzecze, Poland|NZOZ ""Eskulap"", Biala Rawska, Poland|Podlaski Osrodek Kardiologii Janusz Korecki, Białystok, Poland|Centrum Medyczne KERmed, Bydgoszcz, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|Nzoz ""Mada-Med"", Chorzów, Poland|DIABET Centrum Medyczne s. c., Chrzanów, Poland|ISPL w Dziedzinie Kardiologii lek.med. Krzysztof Cymerman, Gdynia, Poland|NZOZ SCBK ProCordis, Gdynia, Poland|Gabinet Kardiologiczno-Internistyczny, Gdynia, Poland|Praktyka Lekarska dr n. med. Marek Bronisz, Inowroclaw, Poland|Piotr Mader Diabetic Clinic NZOZ PD-I, Kamieniec Ząbkowicki, Poland|NZOZ Eskulap SC, Koluszki, Poland|Ewa Mirek-Bryniarska Specjalistyczna Praktyka Lekarska, Kraków, Poland|LANDA' Specjalistyczne Gabinety Lekarskie, Kraków, Poland|Medyczne Centrum Diabetologiczno Endokrynologiczno, Kraków, Poland|Nzoz Cardiamed, Legnica, Poland|""CenterMed Lublin"" Sp. z o.o., Lublin, Poland|Indywidualna Praktyka Lekarska, Mrągowo, Poland|Zechowicz MEDEUSZ-PLUS, Olsztyn, Poland|Praktyka Lekarska Ewa Krzyzagorska, Poznań, Poland|NZOZ NEURO-KARD ""Ilkowski i Partnerzy"", Poznań, Poland|Specjalistyczna Przychodnia Lekarska MEDIKARD (SPL Medikard), Płock, Poland|Specjalistyczny Gabinet Lekarski, Tarnów, Poland|Lecznice Citomed Sp. z o.o., Toruń, Poland|Praktyka Lekarska Pawlowicz Lidia, Toruń, Poland|Centrum Medyczne AMED, Warszawa, Poland|Centrum Badawcze Wspolczesnej Terapii, Warszawa, Poland|SNZOZ Fundacji PROCLINICA, Warszawa, Poland|Centrum Zdrowia Wierzchoslawice, Wierzchosławice, Poland|Regionalna Poradnia Diabetologiczna, Wroclaw, Poland|Specjalistyczne Gabinety Lekarskie ""Medicor PLUS"", Włocławek, Poland|NZOZ ALL-MED Centrum Medyczne, Łódź, Poland|SP ZOZ w Lecznej, Łęczna, Poland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02019264/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02019264/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02019264
654,NCT03565666,The Insulin-Only Bionic Pancreas Bridging Study,Completed,Has Results,Type1 Diabetes Mellitus,Device: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|Drug: iLet Bionic Pancreas insulin-only configuration with Fiasp|Other: Usual care,Massachusetts General Hospital,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Nemours Children's Specialty Care, Jacksonville, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03565666/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03565666/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03565666
655,NCT03377244,Healthy Body Healthy Souls in the Marshallese Population,Completed,Has Results,Weight Loss|Pre Diabetes|Overweight and Obesity,Behavioral: HBHS|Behavioral: HBHS Policy|Behavioral: WORD DPP,University of Arkansas,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03377244/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03377244
656,NCT04035044,Study of the Analytical Performance of ALLEGRO™ Instrument,Completed,No Results Available,Diabetes,,Nova Biomedical|C-TRIC,"18 Years to 80 Years   (Adult, Older Adult)",,Industry|Other,Observational,Observational Model: Other|Time Perspective: Prospective,"C-TRIC, Derry, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04035044/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04035044
657,NCT03839511,Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study,Completed,Has Results,Diabetes,Procedure: Hyperinsulinemic-hypoglycemic clamp,Pennington Biomedical Research Center,18 Years to 40 Years   (Adult),,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03839511/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03839511
658,NCT03765164,"Glucose Control Using 1,5-AG Testing",Completed,Has Results,Diabetes,Diagnostic Test: GlycoMark 1-5-AG|Other: Clinical Performance and Value Vignettes,"Qure Healthcare, LLC|GlycoMark, Inc","Child, Adult, Older Adult",Not Applicable,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"QURE Healthcare, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03765164/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03765164
659,NCT04931030,Low Carbohydrate Diet in Diabetic Kidney Disease,Completed,No Results Available,Type 2 Diabetes Mellitus|Diabetic Kidney Disease|Obesity,Other: Dietary advice,Universiti Teknologi Mara|International Medical University,"40 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universiti Teknologi MARA, Petaling Jaya, Selangor, Malaysia","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04931030/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04931030
660,NCT02609633,Accu-Chek® CONNECT at School (CATS) Pediatric Study,Completed,Has Results,"Diabetes Mellitus, Type 1",Device: Accu-Chek® CONNECT DMS|Device: DMS,Hoffmann-La Roche,"7 Years to 18 Years   (Child, Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Pediatric Endocrinology of Phoenix, Phoenix, Arizona, United States|Center of Excellence in Diabetes and Endocrinology, Sacramento, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Nemours Childrens Hospital, Pensacola, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Pediatric Endocrine Associates, Atlanta, Georgia, United States|Rocky Mountain Diabetes & Osteoporosis Center, Idaho Falls, Idaho, United States|Advocate Center for Pediatric Research, Oak Lawn, Illinois, United States|Indiana University Riley, Carmel, Indiana, United States|Childrens Hospital and Clinics of Minnesota, Saint Paul, Minnesota, United States|Women and Children's Hospital of Buffalo, Buffalo, New York, United States|East Caroline University - Pediatric specialty Care, Greenville, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02609633/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02609633/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02609633
661,NCT04020822,Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices,Completed,Has Results,Type 1 Diabetes|Type 2 Diabetes,Device: Guardian Sensor (3),Medtronic Diabetes,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04020822/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04020822/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04020822
662,NCT03738865,G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes,Completed,Has Results,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Drug: G-Pen|Drug: Novo Glucagon,"Xeris Pharmaceuticals|Empiristat, Inc.","18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Diablo Clinical Research, Walnut Creek, California, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|PPD-Las Vegas Clinical Research Unit, Las Vegas, Nevada, United States|Rainier Research Center, Renton, Washington, United States|Medizinische Universität Graz-Center for Medical Research, Graz, Austria|LMC Diabetes & Endocrinology, Toronto, Ontario, Canada|AltaSciences, Montréal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03738865/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03738865/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03738865
663,NCT02971228,Feasibility Trial Testing the Bionic Pancreas With ZP4207,Completed,Has Results,"Diabetes Mellitus, Type 1",Drug: Insulin Lispro|Drug: ZP4207 (dasiglucagon)|Drug: Glucagon|Device: iPhone-based bionic pancreas|Device: iLet-based bionic pancreas,"Zealand Pharma|Massachusetts General Hospital|Beta Bionics, Inc.","18 Years and older   (Adult, Older Adult)",Phase 2,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MGH Diabetes Center, Boston, Massachusetts, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02971228/SAP_002.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02971228/Prot_003.pdf",https://ClinicalTrials.gov/show/NCT02971228
664,NCT03439072,G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes,Completed,Has Results,Insulin Hypoglycemia|Type 1 Diabetes Mellitus|Severe Hypoglycemia,Drug: G-Pen|Drug: Lilly Glucagon,Xeris Pharmaceuticals|SGS S.A.|Integrated Medical Development,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"ProSciento, Inc., Chula Vista, California, United States|Diablo Clinical Research, Inc., Walnut Creek, California, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|LMC ESD, Inc., Toronto, Ontario, Canada|Altasciences Algorithme Pharma, Montréal, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03439072/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03439072/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03439072
665,NCT02682056,Glucose Measurement Using Microneedle Patches,Completed,Has Results,Diabetes,Device: Microneedle patch|Device: Intravenous (IV) catheter|Device: Lancet,Emory University,"7 Years to 18 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory Children's Center, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02682056/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02682056
666,NCT02673203,Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects,Completed,Has Results,Diabetes,Device: Continuous Glucose Monitoring System (CGMS)|Behavioral: Food log,Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Yale New Haven Hospital, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02673203/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02673203
667,NCT01752842,Lipid Biomarkers for Diabetic Heart Disease,Completed,Has Results,Type II Diabetes Mellitus|Diabetes Complications,Drug: Fenofibrate|Drug: Placebo for fenofibrate,"Washington University School of Medicine|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|Leducq Foundation","30 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01752842
668,NCT03942471,Mindfulness for Adolescents With Type 1 Diabetes,Completed,No Results Available,Type 1 Diabetes Mellitus,Behavioral: Mindfulness Based Stress Reduction,Duquesne University,"12 Years to 19 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,United States,"""Informed Consent Form: Parental Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03942471/ICF_000.pdf|""Informed Consent Form: Consent Form Amended"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03942471/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03942471/Prot_002.pdf",https://ClinicalTrials.gov/show/NCT03942471
669,NCT00945659,Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control,Completed,Has Results,Type 1 Diabetes Mellitus,Device: Continuous Glucose Sensor|Other: Standard Care|Behavioral: CGS + Behavior Therapy,Nemours Children's Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),11 Years to 16 Years   (Child),Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Nemours Children's Clinic, Jacksonville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT00945659/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT00945659/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00945659
670,NCT04004273,"Diabetes, Exercise and Liver Fat (DELIVER)",Recruiting,No Results Available,Type 2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity|Insulin Resistance|Liver Diseases|Fatty Liver|Diabetes Mellitus|Glucose Metabolism Disorders|Glucose Intolerance|Metabolic Disease,Behavioral: Exercise,"James King|University Hospitals, Leicester|Nottingham University Hospitals NHS Trust|University of Nottingham|Loughborough University","30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals of Leicester Nhs Trust, Leicester, East Midlands, United Kingdom|NIHR Clinical Research Network, Leicester, East Midlands, United Kingdom|Sir Peter Mansfield Imaging Centre, Nottingham, East Midlands, United Kingdom|Nottingham University Hospitals Nhs Trust, Nottingham, East Midlands, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04004273/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04004273
671,NCT03109951,Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation,Completed,Has Results,Type 2 Diabetes Mellitus|Colonoscopy,Drug: Colonoscopy preparation using polyethylene glycol,Catholic Kwandong University,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"International St.Mary's Hospital, Incheon, Korea, Republic of","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03109951/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03109951/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03109951
672,NCT02653300,A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH),Completed,Has Results,Non-Alcoholic Steatohepatitis (NASH)|Type2 Diabetes Mellitus,Biological: Oral Insulin,"Oramed, Ltd.|Hadassah Medical Organization","18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah Medical Center, Jerusalem, Israel","""Study Protocol: Clinical Protocol ORA-D N01"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02653300/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02653300
673,NCT02662569,Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia,Completed,Has Results,"Diabetes, Hyperlipidemia, Mixed Dyslipidemia",Biological: Evolocumab|Drug: Atorvastatin|Other: Placebo,Amgen,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Monroe, Louisiana, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Brasília, Distrito Federal, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Woodstock, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, Beijing, Beijing, China|Research Site, Chongqing, Chongqing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Guiyang, Guizhou, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Hengyang, Hunan, China|Research Site, Zhuzhou, Hunan, China|Research Site, Baotou, Inner Mongolia, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Zhenjiang, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, ChangChun, Jilin, China|Research Site, Siping, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Wenzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Pasto, Nariño, Colombia|Research Site, Dijon, France|Research Site, Nantes Cedex 1, France|Research Site, Toulouse Cedex 9, France|Research Site, Bucheon-si, Wonmi-gu, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02662569/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02662569
674,NCT03702465,Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation,"Active, not recruiting",No Results Available,Pre Diabetes,Other: DNA-based dietary intervention|Other: DNA-based dietary intervention using an app|Other: Control arm,Imperial College London|DnaNudge Ltd,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Imperial Clinical Research Facility, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03702465/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03702465/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03702465
675,NCT00967798,Prevention of Cystic Fibrosis Diabetes,Terminated,Has Results,Cystic Fibrosis|Prediabetes,Drug: Sitagliptin,Emory University,"13 Years and older   (Child, Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Emory University and Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States|Nationwide Children's Hospital, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT00967798/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00967798
676,NCT03730480,User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS),Completed,Has Results,Diabetes Mellitus,Device: Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes,Ascensia Diabetes Care|Regulatory and Clinical Research Institute Inc,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"AMCR Institute, Escondido, California, United States|Ranier Clinical Research Center, Inc., Renton, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03730480/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03730480
677,NCT03542487,Blood Glucose Monitoring in Electronic Health Records,Completed,No Results Available,Diabetes Mellitus,Behavioral: Practice Orientation|Behavioral: Standard Reminder|Behavioral: Gift Card Reminder|Behavioral: Physician Reminders,"Inova Health Care Services|University of California, Berkeley|Abdul Latif Jameel Poverty Action Lab|General Services Administration (GSA)|Department of Health and Human Services","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Inova Heath System, Falls Church, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03542487/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03542487
678,NCT03132571,Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia,Terminated,Has Results,"Schizophrenia|Diabetes Mellitus, Type 2|Obesity",Drug: Naltrexone|Drug: Bupropion|Other: Placebo,Yale University,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Connecticut Mental Health Center, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03132571/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03132571
679,NCT03969719,A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus,Completed,Has Results,Non-alcoholic Steatohepatitis,Drug: Placebo|Drug: PF-06835919,Pfizer,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States|Clinical Research Consortium an AMR company, Tempe, Arizona, United States|Anaheim Clinical Trials LLC-Clinical Research, Anaheim, California, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|Hope Clinical Research, Canoga Park, California, United States|San Diego Imaging SDI, Chula Vista, California, United States|Sharp Coronado Hospital, Coronado, California, United States|Southern California Research Center, Coronado, California, United States|Holy Trinity Medical Clinic, Harbor City, California, United States|Innovative Clinical Research, Inc., Harbor City, California, United States|ICM Medical Group, Inglewood, California, United States|eStudySite, La Mesa, California, United States|Clinical Trials Research, Lincoln, California, United States|National Research Institute, Los Angeles, California, United States|Renaissance Imaging Medical Associates, Northridge, California, United States|Huntington Medical Research Institute, Pasadena, California, United States|Inland Empire Clinical Trials, LLC, Rialto, California, United States|Diagnostic Radiological Imaging Sacramento, Sacramento, California, United States|Precision Research Institute, San Diego, California, United States|Sharp and Children's MRI Center, LLC, San Diego, California, United States|Sharp & Children's MRI Center, LLC, San Diego, California, United States|West Coast Radiology, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Liberty Pacific Advanced Imaging, Tarzana, California, United States|Advanced Gastroenterology, Thousand Oaks, California, United States|University Clinical Investigators, Incorporated, Tustin, California, United States|Independant Imaging, Atlantis, Florida, United States|Twin Lakes Imaging, Daytona Beach, Florida, United States|Life Radiology, Doral, Florida, United States|MD Clinical LLC, Hallandale Beach, Florida, United States|Borland Groover, Jacksonville, Florida, United States|Multi-Specialty Research Associates, Inc., Lake City, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Health Care Family Rehab and Research Center, Miami, Florida, United States|Clinical Research of Miami, Miami, Florida, United States|Finlay Medical Research, Miami, Florida, United States|Suncoast Research Group, LLC, Miami, Florida, United States|Unique Imaging, Miami, Florida, United States|Y & L Advance Health Care, Inc D/B/A Elite Clinical Research, Miami, Florida, United States|Stand Up MRI of Miami, Miami, Florida, United States|Vital Imaging Center, Miami, Florida, United States|Vital Imaging, Miami, Florida, United States|Unique Imaging, Miami, Florida, United States|International Research Associates, Miami, Florida, United States|Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States|Rose Radiology, Palm Harbor, Florida, United States|Castillo & Torres MD PA, Palm Springs, Florida, United States|Ctmd Research Inc, Palm Springs, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Physicians Research Associates , LLC, Lawrenceville, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Alliance Multispecialty Research, LLC, Wichita, Kansas, United States|AA MRC, Flint, Michigan, United States|Nebraska Medicine, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Alliance for Multispecialty, LLC, Las Vegas, Nevada, United States|Desert Radiology, Las Vegas, Nevada, United States|Pueblo Imaging, Las Vegas, Nevada, United States|Northwell Imaging of Garden City, Garden City, New York, United States|Northwell Health - Center for Liver Diseases and Transplantation, Manhasset, New York, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Gastroenterology Associates of the Piedmont, PA, Winston-Salem, North Carolina, United States|PMG Research of Winston Salem, Winston-Salem, North Carolina, United States|CTI Clinical Research Center, Cincinnati, Ohio, United States|ProScan, Cincinnati, Ohio, United States|RAS Health, Marion, Ohio, United States|Dallas Diabetes and Endocrine Research Center, Dallas, Texas, United States|Southwest Diagnostics Imaging Center, Dallas, Texas, United States|PrimeCare Medical Group, Houston, Texas, United States|Endocrine IPS, PLLC, Houston, Texas, United States|The Endocrine Center, Houston, Texas, United States|Texas Center for Drug Development, Houston, Texas, United States|Houston Medical Imaging, Houston, Texas, United States|South Texas Radiology Imaging Centers, Live Oak, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|STRIC Northeast Imaging Center, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, LLC (NECRSA, LLC), Schertz, Texas, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|Virginia Endoscopy Group, Richmond, Virginia, United States|VCU Gateway Building Basement, Richmond, Virginia, United States|Salem VA Medical Center, Salem, Virginia, United States|Harborview Medical Center Investigational Drug Services, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|West Coast Medical Imaging, Victoria, British Columbia, Canada|Nova Scotia Health Authority QE II Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority QE II Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Aggarwal and Associates Limited, Brampton, Ontario, Canada|The Western Centre for Functional and Metabolic Mapping, London, Ontario, Canada|Oxford Medical Imaging, Mississauga, Ontario, Canada|Bluewater Clinical Research Group, Inc., Sarnia, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Resonance Magnetique du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Clinique de Medecine Urbaine du Quartier Latin, Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|MRI TTT Philips Radiation Oncology, Montreal, Quebec, Canada|Radiologie Varad, Montreal, Quebec, Canada|IRM Quebec, Quebec, Canada|Centre de Recherche Saint-Louis, Quebec, Canada|ALPHA Recherche Clinique Lebourgneuf, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03969719/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03969719/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03969719
680,NCT01354977,Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans,Completed,Has Results,Type 2 Diabetes Mellitus|Insulin Resistance,Drug: Resveratrol,Albert Einstein College of Medicine,"45 Years to 65 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albert Einstein College of Medicine, Bronx, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT01354977/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01354977
681,NCT03914183,Can mCPN Intervention Improve Injection Site Rotation,Completed,No Results Available,Injection Site Rotation|Diabete Mellitus,Device: mCPN Intervention|Device: Control,Pink Pearls Inc|Montméd,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shoppers Drug Mart 2335, Calgary, Alberta, Canada|Claresholm Pharamcy, Claresholm, Alberta, Canada|Rexall 7236, Edmonton, Alberta, Canada|Shoppers Drug Mart 2401, Okotoks, Alberta, Canada|Kipp Mallery Pharmacy, Kamloops, British Columbia, Canada|Our Own Health Centre, Winnipeg, Manitoba, Canada|Shoppers Drug Mart 535, Winnipeg, Manitoba, Canada|Kennegecasis Drugs, Rothesay, New Brunswick, Canada|Zak's Pharmacy, Milton, Ontario, Canada|Niagara Pharmacy, Niagara Falls, Ontario, Canada|Northgate Pharmacy, Sarnia, Ont, Canada|Murphy's Cornwall Pharmacy, Cornwall, PEI, Canada|Pharmacie Jacques Bourget PJC076, Laval, Quebec, Canada|Pharmacy Jean-Coutu Raffaele Delli Colli & Gino Consolante, Montreal, Quebec, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03914183/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03914183
682,NCT02522494,Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits,Completed,Has Results,Diabetes Mellitus,Behavioral: Pamphlet|Behavioral: Video,VA Office of Research and Development,"18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago, Illinois, United States|Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02522494/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02522494
683,NCT02739984,Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia,Completed,Has Results,Hypercholesterolemia|Mixed Dyslipidemia|Type 2 Diabetes,Biological: Evolocumab|Drug: Placebo to Evolocumab,Amgen,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Tuscumbia, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Roseville, California, United States|Research Site, San Ramon, California, United States|Research Site, Spring Valley, California, United States|Research Site, Tarzana, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, Lakewood, Colorado, United States|Research Site, Wilmington, Delaware, United States|Research Site, Boca Raton, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fleming Island, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Dunwoody, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Auburn, Maine, United States|Research Site, Scarborough, Maine, United States|Research Site, Salisbury, Maryland, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Shelby, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Suffolk, Virginia, United States|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chihuahua, Mexico|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Almeria, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02739984/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02739984
684,NCT02737722,Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus,Completed,Has Results,Diabetic Foot Infections,Drug: Bisphosphocin Nu-3|Drug: Placebo,Lakewood-Amedex Inc,"18 Years to 85 Years   (Adult, Older Adult)",Phase 1|Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Center for Clinical Research, Inc., San Francisco, California, United States|Journey Research, Inc., Oldsmar, Florida, United States|Clinical Research Solutions, Franklin, Tennessee, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02737722/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02737722/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02737722
685,NCT01684722,Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease,Completed,Has Results,Diabetes,Dietary Supplement: Vitamin D|Drug: Omega-3 fatty acids (fish oil)|Dietary Supplement: Vitamin D placebo|Dietary Supplement: Fish oil placebo,University of Washington|Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"50 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Brigham Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT01684722/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT01684722/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01684722
686,NCT02088203,Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.),Completed,No Results Available,Diabetes Prevention,Dietary Supplement: Dose 1|Dietary Supplement: Dose 2|Dietary Supplement: Dose 0|Dietary Supplement: Dose 3|Dietary Supplement: Dose 4|Dietary Supplement: Dose 5|Dietary Supplement: Dose 6,Pennington Biomedical Research Center|National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS),"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02088203/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02088203
687,NCT01032629,CANVAS - CANagliflozin cardioVascular Assessment Study,Completed,Has Results,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Risk Factors",Drug: Placebo|Drug: Canagliflozin (JNJ-28431754) 100 mg|Drug: Canagliflozin (JNJ-28431754) 300 mg,"Janssen Research & Development, LLC|The George Institute for Global Health, Australia","30 Years and older   (Adult, Older Adult)",Phase 3,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Mesa, Arizona, United States|Tucson, Arizona, United States|La Mesa, California, United States|Los Gatos, California, United States|Pismo Beach, California, United States|Stockton, California, United States|Walnut Creek, California, United States|Doral, Florida, United States|Fort Lauderdale, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Atlanta, Georgia, United States|Duluth, Georgia, United States|Boise, Idaho, United States|Eagle, Idaho, United States|Meridian, Idaho, United States|Peoria, Illinois, United States|Topeka, Kansas, United States|Crestview Hills, Kentucky, United States|Lexington, Kentucky, United States|Auburn, Maine, United States|Scarborough, Maine, United States|Oxon Hill, Maryland, United States|Royal Oak, Michigan, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Camden, New Jersey, United States|Bronx, New York, United States|Flushing, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Gallipolis, Ohio, United States|Mentor, Ohio, United States|Toledo, Ohio, United States|Beaver, Pennsylvania, United States|Norristown, Pennsylvania, United States|Sayre, Pennsylvania, United States|Greenville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Draper, Utah, United States|Salt Lake City, Utah, United States|Sandy, Utah, United States|West Jordan, Utah, United States|Danville, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Buenos Aires, Argentina|Capital Federal, Argentina|Ciudad Autonma Buenos Aires, Argentina|Ciudad Autonoma De Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|Godoy Cruz, Argentina|Mar Del Plata, Argentina|Rosario, Argentina|Santa Fe, Argentina|Auchenflower, Australia|Box Hill, Australia|Caboolture, Australia|Caringbah, Australia|Clayton, Australia|Daw Park, Australia|East Ringwood, Australia|Elizabeth Vale, Australia|Hornsby, Nsw 2077, Australia|Kippa Ring, Australia|Launceston, Australia|Liverpool, Australia|Melbourne, Australia|Milton, Australia|Parkville, Australia|Reservoir, Australia|Sherwood, Australia|Southport, Australia|St Leonards, Australia|West Heidelberg, Australia|Wollongong, Australia|Woolloongabba, Australia|Arlon, Belgium|Bonheiden, Belgium|Brussel, Belgium|Edegem, Belgium|Genk, Belgium|Leuven, Belgium|Calgary, Alberta, Canada|Coquitlam, British Columbia, Canada|Winnipeg, Manitoba, Canada|St. John'S, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Nemarket, Ontario, Canada|Sarnia, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Lévis, Quebec, Canada|Montreal, Quebec, Canada|Val-Belair, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Bogota, Colombia|Floridablanca, Colombia|Kralupy Nad Vltavou, Czechia|Moravsky Krumlov, Czechia|Olomouc 9, Czechia|Ostrava, Czechia|Pisek, Czechia|Prague 5, Czechia|Praha 11, Czechia|Praha 8, Czechia|Praha, Czechia|Znojmo N/A, Czechia|Pärnu, Estonia|Tallinn, Estonia|Tartu, Estonia|Viljandi, Estonia|Amiens, France|Nimes Cedex 9, France|Pessac, France|Berlin, Germany|Dortmund, Germany|Dresden, Germany|Hamburg, Germany|Künzing, Germany|Mainz, Germany|Münster, Germany|Pirna, Germany|Saarlouis, Germany|Speyer, Germany|Villingen-Schwenningen, Germany|Budapest, Hungary|Kecskemet, Hungary|Mosonmagyaróvár, Hungary|Zalaegerszeg, Hungary|Ahemadabad, India|Ahmedabad, India|Ambawadi, India|Bangalore, Karnataka, India|Bangalore, India|Belgaum, India|Calicut, India|Chennai, India|Cochin, India|Coimbatore, India|Ernakulam, India|Ghaziabad, India|Hyderabad, India|Indore, India|Jaipur, India|Karnal, India|Kerala, India|Kochi, India|Kolkata, India|Lucknow, India|Mangalore, India|Mumbai, India|Mysore, India|Nagpur, India|New Delhi, India|Patna, India|Pune, India|Rajkot, India|Trivandrum, Kerala, India|Vadodhara, India|Vijayawada, India|Visakhapatnam, India|Beer Sheba, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Luxembourg, Luxembourg|Georgetown, Malaysia|Johor Bahru, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur N/A, Malaysia|Petaling Jaya, Malaysia|Pulau Pinang, Malaysia|Subang Jaya, Malaysia|Aguascalientes, Mexico|Celaya, Mexico|Ciudad De Mexico, Mexico|Durango, Mexico|Guadalajara, Mexico|Monterrey, Mexico|Almelo, Netherlands|Almere, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Delft, Netherlands|Den Helder, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Groningen, Netherlands|Hoorn Nh, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Utrecht, Netherlands|Velp Gld, Netherlands|Zoetermeer, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Dunedin, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Alesund, Norway|Asker, Norway|Bekkestua, Norway|Elverum, Norway|Hamar, Norway|Lierskogen, Norway|Moss, Norway|Oslo, Norway|Skedsmokorset, Norway|Bialystok, Poland|Ciechocinek, Poland|Gniewkowo, Poland|Grudziadz, Poland|Katowice, Poland|Krakow, Poland|Lublin, Poland|Plock, Poland|Poznan, Poland|Rzeszow, Poland|Slawkow, Poland|Torun, Poland|Warszawa, Poland|Wroclaw, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Kursk, Russian Federation|Moscow N/A, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Penza, Russian Federation|Rostov-On-Don, Russian Federation|Russia, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|Tomsk, Russian Federation|Tula, Russian Federation|Tyumen, Russian Federation|Yaroslavl Nap, Russian Federation|Yaroslavl, Russian Federation|Alicante, Spain|Almeria, Spain|Barcelona, Spain|Figueres, Spain|Madrid, Spain|Málaga, Spain|Oviedo, Spain|Reus, Spain|Sabadell, Spain|San Juan De Alicante, Spain|Santiago De Compostela, Spain|Sevilla N/A, Spain|Valencia, Spain|Viladecans, Spain|Borås, Sweden|Göteborg, Sweden|Helsingborg, Sweden|Lund, Sweden|Malmö, Sweden|Oskarshamn N/A, Sweden|Piteå, Sweden|Stockholm, Sweden|Uddevalla, Sweden|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Odessa, Ukraine|Ternopol, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Zaporozhye, Ukraine|Belfast, United Kingdom|Blackburn, United Kingdom|Bolton, United Kingdom|Chorley, United Kingdom|Derby, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|Leicester, United Kingdom|Liverpool, United Kingdom|Londonderry, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Randalstown, United Kingdom|Salford, United Kingdom|York, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01032629/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01032629/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01032629
688,NCT05101330,Impact of Bilingual Prescription Medication Labels Among Elderly Singaporeans,Withdrawn,No Results Available,"Diabetes Mellitus, Type 2|Hypertension",Device: Bilingual prescription medication labels,Singapore General Hospital|Duke-NUS Graduate Medical School,"50 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research,"Singapore General Hospital, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT05101330/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT05101330/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05101330
689,NCT04378114,Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults,Completed,No Results Available,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,Device: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data.|Device: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data.|Drug: Acetominophen,Medtronic Diabetes,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,"AMCR Institue, Escondido, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center - Adults, Aurora, Colorado, United States|""Atlanta Diabetes Associates, Atlanta, Georgia, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04378114/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04378114/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04378114
690,NCT03368807,Assessment of Mealtime Bolus Insulin Behavior,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",Device: Continuous Glucose Monitoring|Drug: Insulin Lispro,Eli Lilly and Company,"21 Years to 65 Years   (Adult, Older Adult)",,Industry,Observational,Observational Model: Other|Time Perspective: Prospective,"AMCR Institute, Inc., Escondido, California, United States|Science 37 Inc, Los Angeles, California, United States|Coastal Metabolic Research Ctr, Ventura, California, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|Iowa Diabetes & Endocrinology Research Center, West Des Moines, Iowa, United States|Advanced Research Institute, Ogden, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03368807/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03368807/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03368807
691,NCT03966911,"Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics",Completed,Has Results,Type 1 Diabetes Mellitus|Type2 Diabetes Mellitus,Device: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter,Medtronic Diabetes,"2 Years to 80 Years   (Child, Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"AMCR Institue, Escondido, California, United States|Sansum Diabetes Research Institute, Santa Barbara, California, United States|SoCal Diabetes, Torrance, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Diablo Clinical Research, Walnut Creek, California, United States|Barbara Davis Center - Adults, Aurora, Colorado, United States|Barbara Davis Center for Childhood Diabetes (Pediatric), Aurora, Colorado, United States|University of South Florida, Tampa, Florida, United States|Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States|IDERC, Des Moines, Iowa, United States|Mayo Clinic (Rochester MN), Rochester, Minnesota, United States|AM Diabetes & Endocrinology Center, Bartlett, Tennessee, United States|Texas Diabetes and Endocrinology, Austin, Texas, United States|University of Virgina, Charlottesville, Virginia, United States|Rainer Clinical Research Center, Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03966911/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03966911/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03966911
692,NCT03427931,CGM Use in Islet Transplant Recipients,Completed,Has Results,Islet Transplantation|Type1 Diabetes Mellitus,Other: Continuous Glucose Monitor (CGM),"University of Virginia|DexCom, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03427931/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03427931/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03427931
693,NCT04361097,Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease,Completed,No Results Available,Chronic Kidney Disease Due to Hypertension|Chronic Kidney Disease Due to Type 2 Diabetes Mellitus,Biological: Faecal microbiota transplant|Biological: Placebo,Hospital Universitario Dr. Jose E. Gonzalez,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT04361097/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04361097
694,NCT03710083,A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China,Completed,Has Results,Diabetes Mellitus,Device: Guardian™ Sensor (3),Medtronic Diabetes,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Seventh Medical Center of PLA General Hospital, Beijing, China|Sir Run Run Shaw Hospital, Hangzhou, China|Shanghai Sixth People's Hospital, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03710083/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03710083/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03710083
695,NCT02665689,Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab,Terminated,Has Results,"Visual Acuity Reduced Transiently|Macular Edema, Cystoid",Drug: ranibizumab,"Prof. Dr. Antonia M. Joussen|Charite University, Berlin, Germany","18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Ophthalmology, Charite, Berlin, Berlin, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02665689/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02665689
696,NCT02540993,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,Completed,Has Results,Chronic Kidney Disease,Drug: Finerenone (BAY94-8862)|Drug: Placebo,Bayer,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Fort Payne, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Prescott, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Arvin, California, United States|Chula Vista, California, United States|Dublin, California, United States|El Centro, California, United States|Fresno, California, United States|Fresno, California, United States|La Mesa, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|Port Hueneme, California, United States|Poway, California, United States|Rancho Cucamonga, California, United States|Rialto, California, United States|Roseville, California, United States|San Diego, California, United States|San Francisco, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Waterbury, Connecticut, United States|Fleming Island, Florida, United States|Fort Lauderdale, Florida, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami Gardens, Florida, United States|Miami Lakes, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Duluth, Georgia, United States|Lilburn, Georgia, United States|Macon, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Elgin, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Hutchinson, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Metairie, Louisiana, United States|Monroe, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Takoma Park, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Flint, Michigan, United States|Flint, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Columbia, Missouri, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Saint Louis, Missouri, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Flushing, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Rosedale, New York, United States|Smithtown, New York, United States|Staten Island, New York, United States|Asheboro, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Beaver, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Hershey, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Greer, South Carolina, United States|Murrells Inlet, South Carolina, United States|Orangeburg, South Carolina, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kingwood, Texas, United States|McAllen, Texas, United States|McKinney, Texas, United States|Pearland, Texas, United States|Pflugerville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Sugar Land, Texas, United States|Waco, Texas, United States|Saint George, Utah, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Alexandria, Virginia, United States|Manassas, Virginia, United States|Salem, Virginia, United States|Virginia Beach, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Milwaukee, Wisconsin, United States|Junín, Buenos Aires, Argentina|Lanús, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Sarandí, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Caba, Ciudad Auton. De Buenos Aires, Argentina|Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Córdoba, Argentina|Córdoba, Argentina|San Luis, Argentina|Garran, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|Liverpool, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Wollongong, New South Wales, Australia|Adelaide, South Australia, Australia|Fitzroy, Victoria, Australia|Heidelberg, Victoria, Australia|Reservoir, Victoria, Australia|Richmond, Victoria, Australia|St. Albans, Victoria, Australia|Box Hill, Australia|Elizabeth Vale, Australia|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Saint Stefan, Steiermark, Austria|Feldkirch, Vorarlberg, Austria|Innsbruck, Austria|Salzburg, Austria|St. Pölten, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Ieper, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Feira de Santana, Bahia, Brazil|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasilia, Distrito Federal, Brazil|Aparecida de Goiania, Goiás, Brazil|Goiania, Goiás, Brazil|Juiz de Fora, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Campina Grande do Sul, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Santo Andre, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Blagoevgrad, Bulgaria|Botevgrad, Bulgaria|Dimitrovgrad, Bulgaria|Gorna Oryahovitsa, Bulgaria|Kazanlak, Bulgaria|Kozloduy, Bulgaria|Lukovit, Bulgaria|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Razgrad, Bulgaria|Sliven, Bulgaria|Smolyan, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Yambol, Bulgaria|Burnaby, British Columbia, Canada|Coquitlam, British Columbia, Canada|New Westminster, British Columbia, Canada|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|Newmarket, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Sarnia, Ontario, Canada|Smith Falls, Ontario, Canada|Sudbury, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Greenfield Park, Quebec, Canada|Laval, Quebec, Canada|Mirabel, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Osorno, Los Lagos, Chile|Las Condes, Santiago, Chile|Providencia, Santiago, Chile|Providencia, Santiago, Chile|Providencia, Santiago, Chile|San Bernardo, Santiago, Chile|San Miguel, Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Fuzhou, Fujian, China|Xiamen, Fujian, China|Xiamen, Fujian, China|Lanzhou, Gansu, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Zhuhai, Guangdong, China|Nanning, Guangxi, China|Nanning, Guangxi, China|Haikou, Hainan, China|Haikou, Hainan, China|Wuhan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Changsha, Hunan, China|Changsha, Hunan, China|Changzhou, Jiangsu, China|Huai'An, Jiangsu, China|Lianyungang, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Suzhou, Jiangsu, China|Wuxi, Jiangsu, China|Yancheng, Jiangsu, China|Nanchang, Jiangxi, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Shenyang, Liaoning, China|Yinchuan, Ningxia, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Qingdao, Shandong, China|Taiyuan, Shanxi, China|Chengdu, Sichuan, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Taizhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Tianjin, China|Tianjin, China|Medellín, Antioquia, Colombia|Medellín, Antioquia, Colombia|Medellín, Antioquia, Colombia|Barranquilla, Atlántico, Colombia|Barranquilla, Atlántico, Colombia|Manizales, Caldas, Colombia|Zipaquirá, Cundinamarca, Colombia|Bogotá, Distrito Capital De Bogotá, Colombia|Cundinamarca, Distrito Capital De Bogotá, Colombia|Armenia, Quindío, Colombia|Cali, Valle Del Cauca, Colombia|Cali, Valle Del Cauca, Colombia|Floridablanca, Colombia|Medellín, Colombia|Beroun, Czechia|Brandys nad Labem, Czechia|Breclav, Czechia|Ceska Lipa, Czechia|Cesky Krumlov, Czechia|Cesky Krumlov, Czechia|Frydek-Mistek, Czechia|Hodonin, Czechia|Holesov, Czechia|Hranice, Czechia|Koprivnice, Czechia|Krnov, Czechia|Mlada Boleslav, Czechia|Olomouc, Czechia|Olomouc, Czechia|Ostrava, Czechia|Plzen, Czechia|Prague 6, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 4, Czechia|Praha 5, Czechia|Vlasim, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Esbjerg, Denmark|Gentofte, Denmark|Hellerup, Denmark|Herlev, Denmark|Hillerød, Denmark|Holbæk, Denmark|Holstebro, Denmark|Hvidovre, Denmark|Kolding, Denmark|København NV, Denmark|Odense C, Denmark|Svendborg, Denmark|Viborg, Denmark|Jyväskylä, Finland|Kajaani, Finland|Kerava, Finland|Klaukkala, Finland|Kuopio, Finland|Nurmijärvi, Finland|Oulu, Finland|Rauma, Finland|Seinäjoki, Finland|Tampere, Finland|Turku, Finland|Vantaa, Finland|Bois-guillaume, France|Bordeaux, France|Boulogne Sur Mer, France|Brest, France|COLMAR Cedex, France|Dijon, France|La Rochelle, France|La Tronche, France|Le Coudray, France|Le Creusot, France|Lyon Cedex, France|Mulhouse, France|NIMES cedex 9, France|Paris, France|PESSAC cedex, France|Saint Herblain, France|Saint Priest En Jarez, France|Tourcoing, France|Vandoeuvre-les-nancy, France|Venissieux, France|Heidelberg, Baden-Württemberg, Germany|Ludwigsburg, Baden-Württemberg, Germany|Schweinfurt, Bayern, Germany|Würzburg, Bayern, Germany|Elsterwerda, Brandenburg, Germany|Bad König, Hessen, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Nettetal, Nordrhein-Westfalen, Germany|Witten, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Hoyerswerda, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Jena, Thüringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Athens, Greece|Athens, Greece|Chaidari, Greece|Larissa, Greece|Nea Ionia, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Shatin, Hong Kong|Sheung Wan, Hong Kong|Wong Tai Sin, Hong Kong|Baja, Hungary|Balatonfured, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Eger, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Nyiregyhaza, Hungary|Nyiregyhaza, Hungary|Papa, Hungary|Siofok, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szentes, Hungary|Szombathely, Hungary|Veszprem, Hungary|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Hadera, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Nahariya, Israel|Nazareth, Israel|Ramat Gan, Israel|Rehovot, Israel|Sakhnin, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Tiberias, Israel|Zefat, Israel|Zerifin, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Parma, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Genova, Liguria, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Bergamo, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza Brianza, Lombardia, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Cagliari, Sardegna, Italy|Sassari, Sardegna, Italy|Catania, Sicilia, Italy|Messina, Sicilia, Italy|Padova, Veneto, Italy|Verona, Veneto, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyota, Aichi, Japan|Funabashi, Chiba, Japan|Ichikawa, Chiba, Japan|Matsuyama, Ehime, Japan|Matsuyama, Ehime, Japan|Chikushino, Fukuoka, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Shirakawa, Fukushima, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Higashihiroshima, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Hakodate, Hokkaido, Japan|Obihiro, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Naka, Ibaraki, Japan|Ushiku, Ibaraki, Japan|Komatsu, Ishikawa, Japan|Sanuki, Kagawa, Japan|Takamatsu, Kagawa, Japan|Takamatsu, Kagawa, Japan|Atsugi, Kanagawa, Japan|Fujisawa, Kanagawa, Japan|Kamakura, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Tamana, Kumamoto, Japan|Yatsushiro, Kumamoto, Japan|Sasebo, Nagasaki, Japan|Beppu, Oita, Japan|Yufu, Oita, Japan|Nakagami-gun, Okinawa, Japan|Shimajiri, Okinawa, Japan|Suita, Osaka, Japan|Kawaguchi, Saitama, Japan|Sayama, Saitama, Japan|Otsu, Shiga, Japan|Iwata, Shizuoka, Japan|Oyama, Tochigi, Japan|Minato, Tokyo, Japan|Musashino, Tokyo, Japan|Shibuya-ku, Tokyo, Japan|Fukui, Japan|Fukui, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukuoka, Japan|Kagoshima, Japan|Kumamoto, Japan|Kumamoto, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Chuncheon, Gang''weondo, Korea, Republic of|Wonju, Gang''weondo, Korea, Republic of|Anyang-si, Gyeonggido, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Incheon Gwangyeogsi,, Incheon Gwang''yeogsi, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Seoul,, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Utena, Lithuania|Vilnius, Lithuania|Johor Bahru, Malaysia|Kelantan, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Pahang, Malaysia|Perak, Malaysia|Perak, Malaysia|Pulau Pinang, Malaysia|Putrajaya, Malaysia|Selangor, Malaysia|Ciudad de México, Distrito Federal, Mexico|México D.F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|México, D. F., Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Cuernavaca, Morelos, Mexico|Queretaro, Querétaro, Mexico|San Juan del Río, Querétaro, Mexico|Culiacán, Sinaloa, Mexico|Culiacán, Sinaloa, Mexico|Mazatlán, Sinaloa, Mexico|Puerto de Veracruz, Veracruz, Mexico|Xalapa, Veracruz, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Ciudad de México, Mexico|Alkmaar, Netherlands|Almere, Netherlands|Amersfoort, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Breda, Netherlands|Den Haag, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Geleen, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Nieuwegein, Netherlands|Zwijndrecht, Netherlands|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Hamilton, New Zealand|Hawkes Bay, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Wellington, New Zealand|Hamar, Norway|Hamar, Norway|Kløfta, Norway|Kristiansand, Norway|Levanger, Norway|Oslo, Norway|Oslo, Norway|Skedsmokorset, Norway|Trondheim, Norway|Ålesund, Norway|Iloilo City, Philippines|Marikina City, Philippines|Pasig City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Chojnice, Poland|Gdansk, Poland|Gdynia, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Olsztyn, Poland|Poznan, Poland|Rzeszow, Poland|Skorzewo, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Wroclaw, Poland|Zabrze, Poland|Covilha, Castelo Branco, Portugal|Loures, Lisboa, Portugal|Matosinhos, Porto, Portugal|Funchal, Região Autónoma Da Madeira, Portugal|Torres Novas, Santarém, Portugal|Setubal, Setúbal, Portugal|Almada, Portugal|Amadora, Portugal|Braga, Portugal|Faro, Portugal|Leiria, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Viana do Castelo, Portugal|Cidra, Puerto Rico|San Juan, Puerto Rico|Alba-Iulia, Alba, Romania|Baia Mare, Maramures, Romania|Ploiesti, Prahova, Romania|Timisoara, Timis, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Galati, Romania|Iasi, Romania|Oradea, Romania|Satu Mare, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Irkutsk, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kemerovo, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Omsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Ryazan, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Syktyvkar, Russian Federation|Voronezh, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Yaroslavl, Russian Federation|Yekaterinburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Bardejov, Slovakia|Nitra, Slovakia|Rimavska Sobota, Slovakia|Roznava, Slovakia|Zilina, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Lenasia South, Gauteng, South Africa|Newtown, Gauteng, South Africa|Petoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Soweto, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Isipingo Rail, Kwazulu-Natal, South Africa|Tongaat, Kwazulu-Natal, South Africa|Middelburg, Mpumalanga, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Pretoria, South Africa|Ferrol, A Coruña, Spain|Badalona, Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Manresa, Barcelona, Spain|Sant Joan Despi, Barcelona, Spain|Jerez de la Frontera, Cádiz, Spain|Burela, Lugo, Spain|Alcalá de Henares, Madrid, Spain|Boadilla del Monte, Madrid, Spain|Getafe, Madrid, Spain|Sagunto, Valencia, Spain|A Coruña, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Granada, Spain|Jaén, Spain|Madrid, Spain|Madrid, Spain|Málaga, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Göteborg, Sweden|Göteborg, Sweden|Lund, Sweden|Lund, Sweden|Rättvik, Sweden|Skövde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Uppsala, Sweden|Örebro, Sweden|Örebro, Sweden|Liestal, Basel-Landschaft, Switzerland|St. Gallen, Sankt Gallen, Switzerland|St. Gallen, Sankt Gallen, Switzerland|Olten, Solothurn, Switzerland|Frauenfeld, Thurgau, Switzerland|Lausanne, Vaud, Switzerland|Bern, Switzerland|Genève, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Chiangmai, Thailand|Khon Kaen, Thailand|Ankara, Turkey|Antalya, Turkey|Edirne, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Malatya, Turkey|Samsun, Turkey|Sivas, Turkey|Cherkasy, Ukraine|Chernivtsi, Ukraine|Dnipro, Ukraine|Dnipro, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Mykolayiv, Ukraine|Ternopil, Ukraine|Uzhgorod, Ukraine|Vinnytsia, Ukraine|Zaporizhzhya, Ukraine|Zaporizhzhya, Ukraine|Llanelli, Carmarthenshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Salford, Manchester, United Kingdom|Liverpool, Merseyside, United Kingdom|Northampton, Northamptonshire, United Kingdom|Carshalton, Surrey, United Kingdom|Newcastle Upon Tyne, Vale Of Glamorgan, The, United Kingdom|Chichester, West Sussex, United Kingdom|Bristol, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesborough, United Kingdom|Portsmouth, United Kingdom|Ha Noi, Vietnam|Ha Noi, Vietnam|Ho Chi Minh City, Vietnam|Ho Chi Minh City, Vietnam|Ho Chi Minh City, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02540993/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02540993/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02540993
697,NCT04166032,Validation Study for the Alertgy Non-invasive Continuous Glucose Monitor (ANICGM),Completed,Has Results,Type 2 Diabetes,Device: Alertgy non-invasive continuous glucose monitoring device (ANICGM),The Cleveland Clinic|Alertgy,"18 Years to 75 Years   (Adult, Older Adult)",,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT04166032/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04166032
698,NCT03334175,Walnuts to Achieve Lasting NUTrition to Prevent Diabetes,Completed,Has Results,PreDiabetes|Overweight and Obesity,Drug: Walnuts,"University of California, San Francisco","18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of California, San Francisco, San Francisco, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03334175/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03334175
699,NCT03936829,Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes,Recruiting,No Results Available,Lipodystrophy Acquired|Type1diabetes,Drug: Cyclophosphamide,Children's Hospital of Fudan University,"Child, Adult, Older Adult",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03936829/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03936829/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03936829/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03936829
700,NCT02337218,Electrical Stimulation for Improving Balance in Diabetes,Completed,Has Results,Diabetic Peripheral Neuropathy,Device: SENSUS Pain Management System,University of Texas Southwestern Medical Center,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UT Southwestern Medical Center at Dallas, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02337218/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02337218
701,NCT04143945,"A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",Completed,Has Results,"Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity",Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen),Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Groningen, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04143945/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04143945/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04143945
702,NCT02586155,Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD,Completed,Has Results,"Diabetes Mellitus, Type 2|Coronary Artery Disease",Drug: Apabetalone|Drug: Placebo|Drug: Atorvastatin|Drug: Rosuvastatin,Resverlogix Corp|PPD|ICON plc|Medidata Solutions,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Instituto de Investigaciones Clinicas Bahia Blanca, Bahía Blanca, Argentina|Bioclinica Buenos Aires, Buenos Aires, Argentina|Centro Privado de Enfermedades Cardiovasculares, Buenos Aires, Argentina|Consultorios Asociados Endocronología E Investigación Clínica Aplicada, Buenos Aires, Argentina|Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina|Sanatorio Guemes, Buenos Aires, Argentina|Clinica Coronel Suarez, Coronel Suárez, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|CEMAIC, Córdoba, Argentina|Centro Médico Colón, Córdoba, Argentina|Centro Médico Luquez, Córdoba, Argentina|Clínica Privada Del Prado Sociedad de Responsabilidad Limitada, Córdoba, Argentina|Fundación Clínica Colombo, Córdoba, Argentina|Hospital Cordoba, Córdoba, Argentina|Hospital San Roque, Córdoba, Argentina|Instituto Del Corazón, Córdoba, Argentina|Instituto Modelo de Cardiologia, Córdoba, Argentina|Instituto Médico DAMIC, Córdoba, Argentina|Ipac Caraffa, Córdoba, Argentina|Sanatorio Allende, Córdoba, Argentina|Centro Médico Libertad, Haedo, Argentina|CIMEL, Lanús, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Mar Del Plata, Argentina|Hospital Central, Mendoza, Argentina|DIM Clinica Privada, Ramos Mejia, Argentina|Instituto de Hematologia Y Medicina Clinica, Rosario, Argentina|Sanatorio Britanico de Rosario, Rosario, Argentina|Prevencion Cardio Vascular, Salta, Argentina|Grupo Medico Alem, San Isidro, Argentina|Bioclinica Tucumán, San Miguel De Tucumán, Argentina|Centro Modelo de Cardiologia, San Miguel De Tucumán, Argentina|Investigaciones Clinicas Tucuman, San Miguel De Tucumán, Argentina|Centro de Investigaciones Clínicas Del Litoral SRL, Santa Fe, Argentina|Sanatorio San Francisco, Santiago Del Estero, Argentina|Clínica FUSAVIM Privada, Villa María, Argentina|Instituto de Investigaciones Clínicas Zárate, Zárate, Argentina|Flinders Medical Centre, Bedford Park, Australia|ZNA Middelheim, Antwerpen, Belgium|Imelda VZW, Bonheiden, Belgium|AZ Turnhout, Turnhout, Belgium|Multiprofile Hospital For Active Treatment Dr Tota Venkova, Gabrovo, Bulgaria|Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD, Lovech, Bulgaria|Multiprofile Hospital For Active Treatment - Pazardzhik AD, Pazardzhik, Bulgaria|University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski EAD, Pleven, Bulgaria|Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda, Sofia, Bulgaria|City Clinic University Multiprofile Hospital for Active Treatment EOOD, Sofia, Bulgaria|Medical Center Kardiohelp EOOD, Sofia, Bulgaria|Second Multiprofile Hospital for Active Treatment Sofia, Sofia, Bulgaria|Synexus Affiliate - Diagnostic and Consulting Center Ascendent, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment and Emergency Medicine N. I. Pirogov EAD, Sofia, Bulgaria|Medical Center Orfey OOD, Stara Zagora, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria|General Hospital Karlovac, Karlovac, Croatia|Special Hospital for medicinal rehabilitation Krapinske Toplice, Krapinske Toplice, Croatia|Clinical Hospital Osijek, Osijek, Croatia|General Hospital Dr Josip Bencevic, Slavonski Brod, Croatia|General Hospital Virovitica, Virovitica, Croatia|Clinical Hospital Sveti duh, Zagreb, Croatia|DRK Kliniken Berlin Westend, Berlin, Germany|Medizinisches Versorgungszentrum am Küchwald GmbH, Chemnitz, Germany|Zentrum für Klinische Prüfung in der Facharztzentrum Dresden Neustadt Gbr, Dresden, Germany|Katholisches Krankenhaus St. Johann Nepomuk, Erfurt, Germany|Heidelberger Praxisklinik für Kardiologie, Heidelberg, Germany|Klinikum Hoyerswerda, Hoyerswerda, Germany|Studienzentrum Dr.Appel, Kassel, Germany|Asklepios Klinik Langen, Langen, Germany|Klinikum Leverkusen GmbH, Leverkusen, Germany|Bajai Szent Rókus Kórház, Baja, Hungary|Grof Tisza Istvan Korhaz Berettyoujfalu, Berettyóújfalu, Hungary|Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest, Hungary|Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet, Budapest, Hungary|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Magyar Honvédség Egészségügyi Központ, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Synexus (DRS) - Synexus Magyarország Kft. Budapest, Budapest, Hungary|Szent Margit Korhaz, Budapest, Hungary|Szent Rókus Kórház és Intézményei, Budapest, Hungary|Selye János Kórház, Komárom, Hungary|TaNaMed Kft., Mosonmagyaróvár, Hungary|Kanizsai Dorottya Kórház, Nagykanizsa, Hungary|Coromed-SMO Kft., Pécs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Tolna Megyei Balassa János Kórház, Szekszárd, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Székesfehérvár, Hungary|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Centre, Be'er Sheva, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Bnei Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Linn Medical Center Clalit Health Services, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kefar-Sava, Israel|Galilee Medical Center, Nahariya, Israel|Nazareth EMMS Hospital, Nazareth, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|ZIV Medical Center, Safed, Israel|Clalit Health Medical Center, Tel Aviv, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|Baruch Padeh Poriya Medical Center, Tiberias, Israel|Fundacion Cardiovascular de Aguascalientes AC, Aguascalientes, Mexico|Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico|Investigacion en Salud y Metabolismo S.C., Chihuahua, Mexico|Centro de Investigación Biomedica y Farmaceutica, Ciudad de México, Mexico|Clinica Integral del Paciente Diabetico y Obeso, Ciudad De México, Mexico|Fundación de Atención e Investigación Médica Lindavista S.C., Ciudad de México, Mexico|Centro Para el Desarrollo de la Medicina y de Asistencia Especializada SC, Culiacan, Mexico|Centro de Investigacion y Atencion de Diabetes, Endocrinologia y Nutricion, Durango, Mexico|Arechavaleta Granell Maria del Rosario, Guadalajara, Mexico|Centro de Investigacion Medica Biologica Y de Terapia Avanzada SC, Guadalajara, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente SC, Guadalajara, Mexico|Hospital Angeles Leon, León De Los Aldama, Mexico|Centro de Desarrollo Biomédico, Merida, Mexico|Sanatorio y Servicios Médicos Obregón S.A. de C.V., Mexico City, Mexico|Instituto Cardiovascular de Monclova, Monclova, Mexico|Hospital Universitario Dr. Jose Eleuterio González, Monterrey, Mexico|IMED Internal Medicine Clin Trials, Monterrey, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Mexico|Diabetes Total, S.A de C.V., Pachuca, Mexico|Investigacion Biomedica Aplicada de Hidalgo S.A. de C.V., Pachuca, Mexico|Cardioarritmias e Investigación S.C., San Luis Potosi, Mexico|Hospital Central Dr Ignacio Morones Prieto, San Luis Potosí, Mexico|INBIOMEDYC Toluca, Toluca, Mexico|Centro de Alta Especialidad Dr. Rafael Lucio, Veracruz, Mexico|Dr. Humberto Alvarez Lopez, Zapopan, Mexico|Meander Medisch Centrum, Amersfoort, Netherlands|OLVG locatie Oost, Amsterdam, Netherlands|VU Medisch Centrum, Amsterdam, Netherlands|Podlaski Osrodek Kardiologii Poradnia Prywatna, Bialystok, Poland|Malopolskie Centrum Sercowo-Naczyniowe, Chrzanow, Poland|Polsko-Amerykanskie Kliniki Serca, Dabrowa Gornicza, Poland|Gabinet Kardiologiczno-Internistyczny, Gdynia, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Uslug Medycznych Promont-Med., Kielce, Poland|Diamond Clinic, Kraków, Poland|Szpital Specjalistyczny im. Jozefa Dietla w Krakowie, Kraków, Poland|Zespol Przychodni Specjalistycznych DIAB-END-COR Sp. z o.o., Kraków, Poland|Prywatna Praktyka Lekarska MAZ-MEDICA Maciej R.Mazurkiewicz, Lodz, Poland|Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej Centralny Szpital Weteranow, Lódz, Poland|Polsko-Amerykanskie Kliniki Serca, Nysa, Poland|Pro Corde, Dom Medyczny, Opole, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Rodzinne Centrum Zdrowia, Otwock, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Specjalistyczna Przychodnia Lekarska ""MEDIKARD"", Plock, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne SBB, Tarnobrzeg, Poland|Centrum Medyczne doktorA, Warszawa, Poland|Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego, Warszawa, Poland|Niepubliczny Zaklad Opieki Zdrowotnej AURUM, Warszawa, Poland|Centrum Kardiologiczne Pro Corde Sp. z o.o. Niepubliczny Zaklad Opieki Zdrowotnej, Wroclaw, Poland|Wro Medica, Wroclaw, Poland|City Clinical Hospital #6, Chelyabinsk, Russian Federation|Ural State Medical University, Ekaterinburg, Russian Federation|Federal Budget Healthcare Institution Medici - sanitary unit of Ministry of internal affairs of Russ, Kemerovo, Russian Federation|Research Institute of Complex Cardiovascular Pathology, Kemerovo, Russian Federation|Krasnodar Regional Clinical Hospital #2, Krasnodar, Russian Federation|Moscow City State Budgetary Healthcare Institution City Clinical Hospital named after V.V. Veresayev, Moscow, Russian Federation|Russian Cardiology Research and Production Center, Moscow, Russian Federation|City Hospital 13, Nizhniy Novgorod, Russian Federation|State Budgetary Healthcare Institution of Novosibirsk Region City Clinical Hospital No. 19, Novosibirsk, Russian Federation|Republican Hospital n.a. V.A. Baranov, Petrozavodsk, Russian Federation|Municipal Budgetary Healthcare Institution City Emergency Hospital, Rostov-on-Don, Russian Federation|International Medical Center SOGAZ, Saint Petersburg, Russian Federation|North-West State Medical University n.a. I.I. Mechnikov, Saint Petersburg, Russian Federation|St Petersburg City Outpatient Clinic #109, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|State Healthcare Institution Regional Clinical Cardiologic Dispensary, Saratov, Russian Federation|City Hospital #4, Sochi, Russian Federation|Research Cardiology Institute of Tomsk Scientific Center of RAMS Siberian Branch, Tomsk, Russian Federation|State Budgetary Healthcare Institution of Vladimir Region City Hospital No. 4, Vladimir, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical Hospital Centar Zvezdara, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Hospital Centre Zemun, Belgrade, Serbia|Euromedik, Belgrade, Serbia|Institute of Cardiovascular Diseases Dedinje, Belgrade, Serbia|KBC Dr Dragisa Misovic Dedinje, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Institute Niska Banja, Niska Banja, Serbia|Clinical Center Nis, Nis, Serbia|Clinical Centre of Vojvodina, Novi Sad, Serbia|Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia|General Hospital Uzice, Uzice, Serbia|Health Center Zajecar, Zajecar, Serbia|ALIAN, s.r.o, Bardejov, Slovakia|CARDIOCONSULT, s.r.o., Bratislava, Slovakia|Univerzitna nemocnica Bratislava, Bratislava, Slovakia|Kardio-Onkologia, s.r.o., Dolny Kubin, Slovakia|CARDIO D&R, s.r.o. Kosice, Kosice, Slovakia|Zeleznicne zdravotnictvo Kosice, s.r.o., Kosice, Slovakia|KARDIOMED s.r.o., Lucenec, Slovakia|MEDI M&M s.r.o., Moldava nad Bodvou, Slovakia|Nemocnica s poliklinikou Nove Mesto nad Vahom n.o., Nove Mesto nad Vahom, Slovakia|Cardioinvest s. r. o., Nove Zamky, Slovakia|DIAB s.r.o., Roznava, Slovakia|MEDIVASA, s.r.o., Zilina, Slovakia|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Mackay Memorial Hospital-Taipei branch, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan City, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan|Cathay General Hospital, Taipei, Taiwan|Chi Mei Medical Center, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation Linkou Branch (Clinical Research Center), Taoyuan City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02586155/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02586155/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02586155
703,NCT04007107,"A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity",Completed,Has Results,"Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity",Drug: Semaglutide (administered by DV3396 pen)|Drug: Semaglutide (administered by PDS290 pen),Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Groningen, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04007107/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04007107/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04007107
704,NCT02765399,"The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis",Completed,Has Results,Type 2 Diabetes,Drug: Liraglutide|Drug: Placebo,Helsinki University Central Hospital|Göteborg University,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Helsinki University Central Hospital, Helsinki, Finland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02765399/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02765399
705,NCT02453711,Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: semaglutide|Drug: liraglutide|Drug: placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Anaheim, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Washington, District of Columbia, United States|Novo Nordisk Investigational Site, Crystal River, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Plantation, Florida, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Charleston, South Carolina, United States|Novo Nordisk Investigational Site, Greer, South Carolina, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Arlington, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, Merewether, New South Wales, Australia|Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Heidelberg Heights, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Liège, Belgium|Novo Nordisk Investigational Site, Mons, Belgium|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Surrey, British Columbia, Canada|Novo Nordisk Investigational Site, Moncton, New Brunswick, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Duisburg, Germany|Novo Nordisk Investigational Site, Leipzig, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Wangen, Germany|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar-Saba, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Liverpool, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Luton, United Kingdom|Novo Nordisk Investigational Site, Norwich, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02453711/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02453711/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02453711
706,NCT03417466,A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China,Completed,Has Results,Diabetes Mellitus,Device: Enlite 1 connected to iPro2 recorder,Medtronic Diabetes,"14 Years to 75 Years   (Child, Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PLA Army General Hospital, Beijing, China|Sir Run Run Shaw Hospital School of Medicine Zhejiang University, Hangzhou, China|Shanghai Sixth People's Hospital, Shanghai, China","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03417466/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03417466/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03417466
707,NCT02433678,An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin,Completed,Has Results,Type 2 Diabetes,Drug: dapagliflozin|Drug: Placebo,University at Buffalo|Kaleida Health,"20 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02433678/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02433678
708,NCT02338193,"Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women",Completed,Has Results,Diabetes Prevention in Women After GDM Who Are at High-risk,Drug: DAPA/MET XR|Drug: DAPA|Drug: MET XR,Woman's|AstraZeneca,18 Years to 45 Years   (Adult),Phase 3,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Woman's Hospital, Baton Rouge, Louisiana, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02338193
709,NCT03563313,The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas,Completed,Has Results,Type 1 Diabetes Mellitus,Device: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Device: Sensor-augmented pump (SAP),"University of Virginia|Jaeb Center for Health Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Tandem Diabetes Care, Inc.|DexCom, Inc.|Roche Diagnostics","14 Years and older   (Child, Adult, Older Adult)",Not Applicable,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sansum Diabetes Research Institute, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, University of Colorado, Aurora, Colorado, United States|Harvard University (Joslin Diabetes Center), Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Virginia Center for Diabetes Technology, Charlottesville, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03563313/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03563313/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT03563313/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03563313
710,NCT03861052,A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes,Completed,Has Results,Type 2 Diabetes,Drug: Tirzepatide|Drug: Dulaglutide,Eli Lilly and Company,"20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical corporation THY Tokuyama Clinic, Chiba Mihama-ku, Chiba, Japan|Akaicho Clinic, Chiba-shi, Chiba, Japan|National Hospital Organization Kure Medical Center, Kure, Hiroshima, Japan|Hasegawa Medical Clinic, Chitose, Hokkaido, Japan|Yuri Ono Clinic, Sapporo, Hokkaido, Japan|Watanabe Naika Clinic, Nishinomiya, Hyogo, Japan|Hayashi Clinic, Nishinomiya, Hyogo, Japan|Naka Memorial Clinic, Naka, Ibaraki, Japan|Hayashi Diabetes Internal Medicine Clinic, Chigasaki-sh, Kanagawa, Japan|Matoba Diabetes Clinic, Ebina, Kanagawa, Japan|Takai Naika Clinic, Kamakura, Kanagawa, Japan|Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan|H.E.C. Science Clinic, Yokohama, Kanagawa, Japan|Medical Corporation Heishinkai OCROM Clinic, Suita-shi, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Senrichuo Ekimae Clinic, Toyonaka, Osaka, Japan|Asano Clinic, Kawagoe, Saitama, Japan|Kawaguchi General Hospital, Kawaguchi, Saitama, Japan|Wakakusa Clinic, Shimotsuke, Tochigi, Japan|Seiwa Clinic, Adachi-ku, Tokyo, Japan|Meiwa Hospital, Chiyodaku, Tokyo, Japan|HDC Atlas Clinic, Chiyoda, Tokyo, Japan|Asahi Life Foundation Adult Disease Research Center, Chuo-ku, Tokyo, Japan|Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, Japan|Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku, Tokyo, Japan|Tokyo aSBo Clinic, Chuo-ku, Tokyo, Japan|Fukuwa Clinic, Chuo-ku, Tokyo, Japan|IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan|Sato Medical Clinic, Ootaku, Tokyo, Japan|Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan|Tomonaga Clinic, Shinjuku-ku, Tokyo, Japan|Shinjuku Research Park Clinic, Shinjuku, Tokyo, Japan|Shinei Clinic, Suginami, Tokyo, Japan|Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan|Futata Tetsuhiro Clinic, Fukuoka, Japan|JR Hiroshima Hospital, Hiroshima, Japan|Yoshimura Clinic, Kumamoto, Japan|Keiseikai Kajiyama Clinic, Kyoto, Japan|Abe Clinic, Oita, Japan|OKAYAMA Medical Center, Okayama, Japan|AMC Nishiumeda Clinic, Osaka, Japan|Kitada Clinic, Osaka, Japan|Nanko Clinic, Osaka, Japan|Suruga Clinic, Shizuoka, Japan|Yokohama Minoru Clinic, Yokohama, Japan","""Study Protocol: Clinical Study Protocol Amendment Version (a)"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03861052/Prot_000.pdf|""Study Protocol: Clinical Study Protocol Addendum Version (1)"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03861052/Prot_001.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Version 2"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03861052/SAP_002.pdf|""Statistical Analysis Plan: Statistical Analysis Plan Addendum Version 2"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03861052/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03861052
711,NCT03359590,Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients,Completed,Has Results,Pharmacological Action,Drug: Sitagliptin 100 mg|Drug: Placebo,Profil Institut für Stoffwechselforschung GmbH|Merck Sharp & Dohme LLC,18 Years to 64 Years   (Adult),Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03359590/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03359590
712,NCT03371108,Gan & Lee Insulin Glargine Target Type (2) Evaluating Research,Completed,Has Results,"Diabetes Mellitus, Type 2",Biological: Gan & Lee Insulin Glargine Injection|Biological: Lantus®,"Gan and Lee Pharmaceuticals, USA","18 Years to 75 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Simon Williamson Clinic, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Terence T. Hart, MD, Tuscumbia, Alabama, United States|Family Practice Specialists, Phoenix, Arizona, United States|Valley Research, Fresno, California, United States|The Rose Salter Medical Research Foundation, Newport Coast, California, United States|California Medical Research Association, Northridge, California, United States|Northern California Research Corp., Sacramento, California, United States|CMR of Greater New Haven, LLC, Hamden, Connecticut, United States|Chase Medical Research, LLC, Waterbury, Connecticut, United States|Meridien Research, Bradenton, Florida, United States|The Center for Diabetes and Endocrine Care, Fort Lauderdale, Florida, United States|Homestead Associates in Research, Homestead, Florida, United States|Biotech Pharmaceutical Group, LLC, Miami, Florida, United States|Genoma Research Group, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Peninsula Research, Ormond Beach, Florida, United States|Oviedo Medical Research, Oviedo, Florida, United States|Metabolic Research Institute, West Palm Beach, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|iResearch Atlanta, Decatur, Georgia, United States|Sestron Clinical Research, Marietta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Midwest CRC, Crystal Lake, Illinois, United States|Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States|Kentucky Diabetes Endocrinology Center, Lexington, Kentucky, United States|L-MARC Research Center, Louisville, Kentucky, United States|ActivMed Practices and Research - Methuen, Methuen, Massachusetts, United States|Palm Research Center, Inc., Las Vegas, Nevada, United States|Physicians East, PA, Greenville, North Carolina, United States|Lillestol Research LLC, Fargo, North Dakota, United States|Endocrinology Associates, Inc., Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|Mountain View Clinical Research, Greer, South Carolina, United States|University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States|ClinSearch - Clinical Research Specialists, Chattanooga, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Austin Regional Clinic, Austin, Texas, United States|Texas Diabetes & Endocrinology - Central Austin, Austin, Texas, United States|Texas Diabetes & Endocrinology - South Austin, Austin, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Texas Diabetes & Endocrinology - Round Rock, Round Rock, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, Schertz, Texas, United States|Radiant Research, Murray, Utah, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Stonesifer Clinical Research, Federal Way, Washington, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|Clinical Investigations Specialists-Wisconsin, Kenosha, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03371108/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03371108/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03371108/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03371108
713,NCT02003898,Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data,Completed,Has Results,Diabetes,Device: Medtronic MiniMed 530G Insulin Pump,Medtronic Diabetes,"16 Years and older   (Child, Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical Investigations, Inc., Little Rock, Arkansas, United States|AMCR Institute, Escondido, California, United States|Valley Research, Fresno, California, United States|Center of Excellence in Diabetes & Endocrinology, Sacramento, California, United States|So Cal Diabetes, Torrance, California, United States|Barbara Davis Center (1), Aurora, Colorado, United States|Barbara Davis Center (2), Aurora, Colorado, United States|East Coast Institute for Research, Jacksonville, Florida, United States|Endocrine Associates of Florida, P.A., Lake Mary, Florida, United States|TLC Diabetes Healthcare Consultants & Education Inc., Naples, Florida, United States|Pediatric Endocrine Associates, Tampa, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|East Alabama Endocrinology PC, Columbus, Georgia, United States|Endocrine Research Solutions, Roswell, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|Isaiah Pittman IV, MD, Terre Haute, Indiana, United States|Good Samaritan Hospital Physician Services, Vincennes, Indiana, United States|Iowa Diabetes and Endocrinology Center, Des Moines, Iowa, United States|Imperial Health, Lake Charles, Louisiana, United States|Eastern Shore Diabetes and Endocrinology Center, Salisbury, Maryland, United States|University of Michigan Diabetes Research Center, Ann Arbor, Michigan, United States|Grunberger Diabetes Institute, Bloomfield Hills, Michigan, United States|Spectrum Health System, Grand Rapids, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|The Diabetes Center, Ocean Springs, Mississippi, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Billings Clinic, Billings, Montana, United States|Glacier View Research Institute-Endocrinology, Kalispell, Montana, United States|Complete Endocrinology, Lincoln, Nebraska, United States|Diabetes, Endocrinology, Metabolism Specialties, Teaneck, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Rochester General Hospital, Rochester, New York, United States|Joslin Diabetes Center, Syracuse, New York, United States|University at Buffalo, The State University of New York, Williamsville, New York, United States|Physicians East, PA, Greenville, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|AM Diabetes and Endocrinology Center, Bartlett, Tennessee, United States|Endeavor Clinical Trials, San Antonio, Texas, United States|Consano Clinical Research, LLC, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio, LLC, Schertz, Texas, United States|Southwestern Vermont Health Care, Bennington, Vermont, United States|Tri-Cities Diabetes and Endocrinology Center, Richland, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02003898/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02003898/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02003898
714,NCT00929838,Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM,Completed,Has Results,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Adult-Onset|Diabetes Mellitus, Non-Insulin-Dependent|Diabetes Mellitus, Noninsulin Dependent|Diabetes Mellitus, Type II",Behavioral: Diabetes Knowledge/Information|Behavioral: Motivation/Behavioral Skills|Behavioral: Combined Intervention|Behavioral: Usual Care,Medical College of Wisconsin|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT00929838/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT00929838
715,NCT03911843,Omega-3 and Vitamin D Supplements in Childhood T1D,Completed,Has Results,Type 1 Diabetes Mellitus,Drug: omega-3 supplementation|Drug: Vitamin D supplementation,Azienda Ospedaliero Universitaria Maggiore della Carita|University of Eastern Piedmont,"1 Year to 18 Years   (Child, Adult)",Phase 2|Phase 3,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Carita,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03911843/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03911843
716,NCT03135015,Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans,Completed,Has Results,"Insulin Resistance, Diabetes",Other: Placebo capsules|Other: 2g capsules|Other: 4g capsules|Other: Water Control|Other: 2g tablets|Other: 4g tablets,"Housey Healthcare ULC|Glycemic Index Laboratories, Inc",18 Years to 60 Years   (Adult),Phase 1,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glycemic Index Laboratories, Inc., Toronto, Ontario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03135015/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03135015
717,NCT03693560,Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD,Completed,No Results Available,"Coronary Artery Disease|Diabetes Mellitus, Type 2",Drug: Vildagliptin 50 mg Oral Tablet|Drug: Metformin 1000 mg Oral Tablet|Drug: Glimepiride upto 4 mg Oral Tablet,Damanhour University|Tanta University,"25 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Pharmacy - Damanhour University., Damanhūr, Egypt","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03693560/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03693560
718,NCT03459638,Periodontitis as Signal for an Underlying Disease,Unknown status,No Results Available,Diabetes Mellitus|Periodontal Diseases|Cardiovascular Diseases|Obstructive Sleep Apnea Syndrome,"Other: Screening for DM, ASCVD, MetS and OSAS",Academic Centre for Dentistry in Amsterdam|Labonovum B.V.|Sunstar Suisse S.A.|Netherlands Enterprise Agency,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,"Academic Centre for Dentistry Amsterdam, Amsterdam, Noord-Holland, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03459638/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03459638
719,NCT04021602,Diabetes Prevention Program Feasibility Study of Breastfeeding,Completed,No Results Available,Pregnancy|Overweight and Obesity,Behavioral: Diabetes Prevention Program|Behavioral: Breastfeeding Education|Behavioral: Usual Care,"University of Kansas Medical Center|Ascension Via Christi Hospitals Wichita, Inc.|Kearny County Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kearny County Hospital, Lakin, Kansas, United States|Via Christi Maternal Fetal Medicine Clinic, Wichita, Kansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT04021602/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT04021602/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04021602
720,NCT01779141,Orchestra Pregnancy Observational Study in Poland,Completed,Has Results,Type 1 Diabetes Mellitus|Pregnancy,,Medtronic Diabetes|Medtronic Poland Spółka z ograniczoną odpowiedzialnością,18 Years to 45 Years   (Adult),,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Uniwersytecki Szpital Kliniczny w Białymstoku, Białystok, Poland|NZOZ Specjalistyczny Ośrodek Internistyczno-Diabetologiczny, Białystok, Poland|Szpital Wojewódzki w Bielsku Białej, Bielsko-Biala, Poland|Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Szpital Specjalistyczny w Jaśle, Jaslo, Poland|NZOZ WITAMED Outpatient Diabetes Clinic, Kielce, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 Uniwersytetu Medycznego w Lublinie, Lublin, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Poland|PSZOZ Wojewódzkie Centrum Medyczne w Opolu, Opole, Poland|Zakład Opieki Zdrowotnej Poznań-Jeżyce, Poznan, Poland|Clinic of Gynecology and Obstetrics of Marcinkowski Medical University, Poznań, Poland|Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej, Rzeszow, Poland|Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie im. Marii Skłodowskiej-Curie, Szczecin, Poland|Wojewódzki Szpital Zespolony im. L. Rydygiera, Torun, Poland|Szpital Kliniczny im. ks. Anny Mazowieckiej Warszawskiego Uniwersytetu Medycznego, Warszawa, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|Mazowiecki Szpital Wojewódzki Sp. z o.o., Warszawa, Poland|Wojewódzki Zespół Specjalistycznej Opieki Zdrowotnej, Wroclaw, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 im prof. Stanisława Szyszko, Zabrze, Poland|Zespół Wojewódzkich Przychodni Specjalistycznych w Katowicach, Zabrze, Poland|NZOZ MED-ART Poradnie Specjalistyczne Sp. z o.o., Zory, Poland|Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Łodzi, Łódź, Poland|Uniwersytet Medyczny w Łodzi, Klinika Diabetologii, Łódź, Poland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01779141/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01779141/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01779141
721,NCT01265537,A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf,Completed,Has Results,Acute Graft Rejection|Diabetes,Drug: Tacrolimus,"University of British Columbia|Astellas Pharma Canada, Inc.","19 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Paul's Hospital, Vancouver, British Columbia, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT01265537/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01265537
722,NCT01813305,CSTC1 for Diabetic Foot Ulcers Phase II Study,Completed,Has Results,Diabetic Foot Ulcer|Diabetes Mellitus|Wounds,Drug: CSTC1|Drug: CSTC1 Matched vehicle,Charsire Biotechnology Corp.|ASKLEP Inc.,"20 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01813305/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01813305
723,NCT03591458,Amitriptyline in Treating Hypoglycemia,Terminated,Has Results,Type1 Diabetes Mellitus|Hypoglycemia Unawareness,Drug: Amitriptyline|Drug: Placebo,University of Utah,21 Years to 60 Years   (Adult),Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03591458/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03591458/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03591458
724,NCT03674281,The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System,Completed,Has Results,Type 1 Diabetes Mellitus|Cognitive Change,Device: SAP|Device: CLC,"University of Virginia|Virginia Research Investment Fund|DexCom, Inc.|Tandem Diabetes Care, Inc.","6 Years and older   (Child, Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Virginia, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03674281/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03674281/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03674281
725,NCT02552355,Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin,Completed,Has Results,Physical Activity,Drug: Metformin|Drug: Placebo|Dietary Supplement: Carbohydrate Beverage|Dietary Supplement: Protein Beverage,Colorado State University,"55 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02552355/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02552355/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02552355
726,NCT03226457,SGLT2 Inhibition in Combination With Diuretics in Heart Failure,Completed,Has Results,Heart Failure|Type 2 Diabetes Mellitus,Drug: Empagliflozin 25mg|Drug: Placebo oral capsule|Drug: Frusemide,University of Dundee|British Heart Foundation,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Dundee, Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03226457/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03226457/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03226457
727,NCT04881890,Low-Carbohydrate Diabetes Prevention Program Among Veterans With Prediabetes,"Active, not recruiting",No Results Available,PreDiabetes,Behavioral: Low-Carbohydrate Diabetes Prevention Program,VA Ann Arbor Healthcare System,"18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Veteran Affairs, Ann Arbor, Michigan, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04881890/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04881890/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04881890
728,NCT02963922,Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin,Completed,Has Results,Metabolism and Nutrition Disorder|Obesity,Drug: Liraglutide 3.0 mg|Drug: Placebo,Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Plantation, Florida, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, North Dartmouth, Massachusetts, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Edmonton, Alberta, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Waterloo, Ontario, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Leipzig, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Bologna, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02963922/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02963922/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02963922
729,NCT01929018,Collaborative-care Rehabilitation After Dysvascular Amputation,Completed,Has Results,Diabetes Complications|Peripheral Arterial Disease,Behavioral: Exercise|Behavioral: Walking Program|Behavioral: Health Self-Management Support,"University of Colorado, Denver","50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01929018/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01929018/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01929018
730,NCT02682901,Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects,Completed,Has Results,Diabetic Autonomic Neuropathy,Drug: Cycloset|Drug: Placebo,Eastern Virginia Medical School,"30 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Eastern Virgnia Medical School, Strelitz Diabetes Center, Norfolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02682901/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02682901/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02682901
731,NCT03169530,Moderate Alcohol and Cardiovascular Health Trial,Terminated,Has Results,Cardiovascular Diseases|Diabetes,Other: Alcohol,Beth Israel Deaconess Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Harvard School of Public Health (HSPH)|Wake Forest University Health Sciences|Julius Center,"50 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Johns Hopkins ProHealth Clinical Research Center, Baltimore, Maryland, United States|Wake Forest Sticht Center on Aging, Winston-Salem, North Carolina, United States|Julius Clinical, Zeist, Netherlands|Center for Bioethics and Research, Ibadan, Nigeria","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03169530/Prot_SAP_004.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03169530/ICF_005.pdf",https://ClinicalTrials.gov/show/NCT03169530
732,NCT03878758,Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles,Completed,Has Results,Diabetes,Device: BD Nano™ PRO|Device: 33G Artsana Insupen Extr3me|Device: 34G Artsana Insupen Extr3me|Device: Simple Diagnostics Comfort EZ™,"Becton, Dickinson and Company","18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,"East West Medical Research Institute, Honolulu, Hawaii, United States|TKL Research Inc., Fair Lawn, New Jersey, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03878758/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03878758/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03878758
733,NCT03878745,Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle,Completed,Has Results,Diabetes,Device: Terumo Nanopass® 34G pen needle|Device: BD Nano™ PRO 32G pen needle,"Becton, Dickinson and Company","18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Mills-Peninsula Medical Center Dorothy L. and James E Frank Diabetes Research Institute, San Mateo, California, United States|East West Medical Research Institute, Honolulu, Hawaii, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03878745/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03878745/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03878745
734,NCT05141968,Vitamin D Supplementation and Glycemic Control Improvement Among Type 1 Diabetic Children,Completed,No Results Available,Type 1 Diabetes Mellitus|Vitamin D Deficiency,Dietary Supplement: vitamin D supplements (2000 IU/day),Al-Azhar University,4 Years to 14 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"Al-Rantisi pediatric hospital, Gaza City, Palestinian Territory, occupied","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT05141968/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT05141968/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT05141968/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT05141968
735,NCT03267264,Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle,Completed,Has Results,Diabetes,Device: BD Nano™ vs Nucleus|Device: NovoFine® vs Nucleus|Device: NovoTwist®/NovoFine® Plus vs Nucleus|Device: Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus,"Becton, Dickinson and Company","18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"East West Medical Research Institute, Honolulu, Hawaii, United States|PMG Research of Raleigh, Raleigh, North Carolina, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Corporation Lane Internal Medicine and Research Center, Virginia Beach, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03267264/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT03267264/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03267264
736,NCT05234281,Concentrated Cross-disciplinary Group Intervention for Common Health Complaints (Including Post COVID-19 Fatigue),Recruiting,No Results Available,"Mixed Anxiety Depression|Diabetes Mellitus, Type 2|Low Back Pain|Chronic Obstructive Pulmonary Disease|COVID-19",Other: Interdisciplincary concentrated group rehabilitation,Helse i Hardanger|Haukeland University Hospital,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Helse i Hardanger, Øystese, Norway","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT05234281/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05234281
737,NCT02572856,Continuous Glucose Monitoring During and After Surgery,Suspended,No Results Available,Diabetes,Device: Continuous Glucose Monitor (CGM),"University of Washington|DexCom, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Washington Medical Center, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02572856/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02572856/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02572856
738,NCT03323294,Bioenergetics and Metabolism in Pediatric Populations,"Active, not recruiting",No Results Available,Obesity|Type 2 Diabetes Mellitus|Insulin Resistance,,Arkansas Children's Hospital Research Institute|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)|University of Arkansas,5 Years to 17 Years   (Child),,Other|NIH,Observational,Observational Model: Other|Time Perspective: Prospective,"Arkansas Children's Hospital, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03323294/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03323294/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03323294
739,NCT02632747,Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study,Completed,Has Results,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Obesity",Drug: Empagliflozin|Drug: Placebo (matching empagliflozin)|Drug: ramipril,Boehringer Ingelheim|Eli Lilly and Company,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Toronto General Hospital, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02632747/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02632747/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02632747
740,NCT02299479,Adjusting Insulin Delivery to Activity,Completed,Has Results,Diabetes|Nocturnal Hypoglycemia,Device: Dexcom G4 Platinum CGM|Device: Activity monitor,Boston Children's Hospital,1 Year to 17 Years   (Child),Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Boston Children's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT02299479/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02299479
741,NCT02454153,Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy,Completed,Has Results,Sleep Apnea|Diabetes,Device: REMStar Positive Airway Pressure|Behavioral: LifeStyle Counseling,"Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)","21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02454153/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02454153
742,NCT04422145,"Hypoglycemia Requiring Emergency Services Intervention: Patient Characteristics, Outcome and Cardiovascular Risk Profile",Completed,No Results Available,Diabetes Mellitus|Hypoglycemia,Behavioral: Structured nurse led intervention programme|Other: Standard care,University of Leeds|Yorkshire Ambulance Service NHS Trust|LifeScan,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Diabetes centre, St James hospital, Leeds, West Yorkshire, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04422145/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04422145
743,NCT03178773,TExT-MED + FANS Full Trial,Completed,Has Results,Diabetes,Behavioral: TExT-MED|Behavioral: FANS,University of Southern California,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"LAC+USC Medicine Center Emergency Department, Los Angeles, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03178773/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03178773/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT03178773/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03178773
744,NCT03358121,Glucose-dependent Asprosin Dynamics,Completed,No Results Available,Diabetes Mellitus,Diagnostic Test: Clamp study,Heidelberg University,"18 Years to 75 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,"Medizinische Klinik, University Hospital, Heidelberg, Baden-Wuerttemberg, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03358121/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03358121/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03358121
745,NCT02802514,A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects,Terminated,Has Results,Diabetes Mellitus,Drug: Albiglutide 50mg|Drug: Albiglutide matching placebo|Drug: Exenatide 10microgram|Drug: Exenatide placebo (saline),GlaxoSmithKline|The General Hospital Corporation d/b/a Massachusetts General Hospital,18 Years to 50 Years   (Adult),Phase 4,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02802514/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02802514/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02802514
746,NCT03835312,Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM,Recruiting,No Results Available,"Diabetes Mellitus, Type 1|Immunologic Deficiency Syndromes",Procedure: Sequential transplantation,Children's Hospital of Fudan University,"up to 18 Years   (Child, Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03835312/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03835312/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03835312/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03835312
747,NCT03415880,Light Intensity Physical Activity Trial,Recruiting,No Results Available,Diabetes Mellitus|Physical Exercise|Light Intensity Physical Activity|Arterial Stiffness|Aortic Stiffness|Pulse Wave Velocity|Type2 Diabetes|Sedentary Lifestyle|Artery Disease|Physical Activity,Behavioral: Interactive workshops LiPAT intervention group|Device: Wrist-worn feedback physical activity monitor|Device: Smartphone application LiPAT|Behavioral: Telephone Coaching|Behavioral: Workshops control group LiPAT,Academisch Ziekenhuis Maastricht|European Foundation for the Study of Diabetes,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Maastricht University, Maastricht, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03415880/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03415880
748,NCT03135535,Micro-mobile Foot Compression and Diabetic Foot,Completed,Has Results,"Diabetes|PAD|Lower Extremity Edema|Neuropathy;Peripheral|Foot Ulcer, Diabetic|Lymphatic Diseases",Device: Avex Footbeat,Baylor College of Medicine|Avex LLC,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Baylor College of Medicine, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03135535/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03135535
749,NCT02274844,Improving Medication Adherence in the Alabama Black Belt,Completed,Has Results,Diabetes Mellitus|Medication Adherence,Behavioral: Living Well with Diabetes Program,Weill Medical College of Cornell University|Patient-Centered Outcomes Research Institute|University of Alabama at Birmingham,"19 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Univeristy of Alabama at Birmingham, Birmingham, Alabama, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02274844/Prot_SAP_003.pdf",https://ClinicalTrials.gov/show/NCT02274844
750,NCT03359629,Spectrophon LTD Glucometry Monitor Accuracy,Completed,Has Results,Glucose Metabolism Disorders|Diabetes Mellitus,Device: Spectrophon Glucometry Monitor|Device: YSI 2300 Stat Plus,Tirat Carmel Mental Health Center|Ariel University,"18 Years to 75 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Tirat Carmel Mental Health Center, Tirat Karmel, Haifa, Israel","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03359629/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03359629
751,NCT05031572,Energy -Sensing Metabolites in Caloric Restriction,Recruiting,No Results Available,Obesity|Insulin Sensitivity/Resistance|Diabetes Type 2,Other: dietary intervention,Institut Investigacio Sanitaria Pere Virgili,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Universitari Joan XXIII de Tarragona. IISPV, Tarragona, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT05031572/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT05031572/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05031572
752,NCT03040414,Fuzzy Logic Automated Insulin Regulation,Completed,Has Results,Type 1 Diabetes Mellitus,Device: MedtronicMinimed 670G 3.0 hybrid closed loop system|Device: Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.,"HealthPartners Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Medtronic|Jaeb Center for Health Research|Schneider Children's Medical Center, Israel|University of Ljubljana|Yale University|Joslin Diabetes Center|University of Florida|Stanford University|International Diabetes Center at Park Nicollet|Kinderkrankenhaus auf der Bult|University of Minnesota","14 Years to 30 Years   (Child, Adult)",Not Applicable,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|International Diabetes Center, Saint Louis Park, Minnesota, United States|Kinderkrankenhaus Auf Der Bult, Hannover, Germany|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|University of Ljubljana, Ljubljana, Slovenia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03040414/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03040414/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03040414/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03040414
753,NCT01574157,Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.,Completed,Has Results,Chronic Renal Insufficiency|Diabetes Mellitus,Drug: Sodium bicarbonate|Drug: Placebo,VA Office of Research and Development,"18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT01574157/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01574157
754,NCT05295706,Towards Understanding the Relationship Between Meals and Blood Biomarkers,Not yet recruiting,No Results Available,Type 2 Diabetes,Behavioral: Counterfactual Intervention,Texas A&M University|U.S. National Science Foundation,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research,"Center for Translational Research in Age and Longevity, College Station, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT05295706/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT05295706/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT05295706
755,NCT01763346,Beta Cell Restoration Through Fat Mitigation,Completed,Has Results,Prediabetes|Type 2 Diabetes|Obesity,Drug: Metformin|Device: gastric banding,University of Southern California|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Southern California, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01763346/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01763346/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01763346
756,NCT04502212,Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM,Completed,Has Results,Type 2 Diabetes,Device: Hepatic Ultrasound Insonification,General Electric Research|ProSciento,"21 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"ProSciento, Chula Vista, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04502212/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04502212/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04502212
757,NCT03077360,Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans,Completed,Has Results,"Diabetes Mellitus, Type 2|Pre-diabetes|Obesity",Behavioral: Lifestyle,"University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",30 Years to 50 Years   (Adult),Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03077360/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03077360/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03077360
758,NCT03597035,Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On,Terminated,Has Results,Type2 Diabetes|Hyperkalemia,Drug: Spironolactone,"University Hospitals Cleveland Medical Center|Relypsa, Inc.","45 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03597035/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03597035
759,NCT03481283,A Causative Role for Amylin in Diabetic Peripheral Neuropathy,Recruiting,No Results Available,Type2 Diabetes|Peripheral Neuropathy,,John Slevin|University of Kentucky,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,"UK Robert Straus Behavioral Science Laboratory, Lexington, Kentucky, United States|University of Kentucky - Kentucky Neuroscience Institute, Lexington, Kentucky, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03481283/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03481283
760,NCT03271879,Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients,Unknown status,No Results Available,Heart Failure|Diabetes Mellitus|Arrythmia,Drug: Empagliflozin at a dose of 10 mg/day,Rambam Health Care Campus|Boehringer Ingelheim,"18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Israel,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03271879/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03271879
761,NCT04599738,"Millet-based Muffins, Glycaemic Response, Insulinemic Response and Gastric Emptying",Completed,No Results Available,Healthy|Pre Diabetes,Other: Wheat muffin|Other: Finger millet grain muffin,Oxford Brookes University|Taibah University,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Oxford Brookes Centre for Nutrition and Health, Oxford, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04599738/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04599738/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04599738
762,NCT03192475,The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults,Completed,Has Results,Obesity|Cardiovascular Risk Factor|Eating Behavior|Diet Modification|Physical Activity|Quality of Life|Mobility Limitation,Behavioral: GLB plus phone contacts|Behavioral: GLB plus newsletter contacts,University of Pittsburgh,65 Years to 80 Years   (Older Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Pittsburgh,"""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03192475/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03192475/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03192475
763,NCT03552757,Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity,Completed,Has Results,Obesity|Overweight,Drug: Semaglutide 1.0 mg|Drug: Semaglutide 2.4 mg|Drug: Placebo I (Semaglutide)|Drug: Placebo II (Semaglutide),Novo Nordisk A/S,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Buena Park, California, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Mission Hills, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Tarzana, California, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Kissimmee, Florida, United States|Novo Nordisk Investigational Site, Saint Petersburg, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Alpharetta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Olive Branch, Mississippi, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Hickory, North Carolina, United States|Novo Nordisk Investigational Site, Salisbury, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Mount Pleasant, South Carolina, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Shavano Park, Texas, United States|Novo Nordisk Investigational Site, Saint George, Utah, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Chacabuco, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Mendoza, Argentina|Novo Nordisk Investigational Site, Santiago del Estero, Argentina|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Mount Pearl, Newfoundland and Labrador, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Stoney Creek, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Schweinfurt, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Haidari-Athens, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kochi, Kerala, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Secunderabad, India|Novo Nordisk Investigational Site, Chiba-shi, Chiba, Japan|Novo Nordisk Investigational Site, Chuo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Fukuoka-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Hokkaido, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Kashiwara-shi, Osaka, Japan|Novo Nordisk Investigational Site, Mitaka-shi, Tokyo, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, San Juan, Puerto Rico|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Brits, North West, South Africa|Novo Nordisk Investigational Site, Almeria, Spain|Novo Nordisk Investigational Site, Córdoba, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, San Cristóbal de La Laguna, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Dubai, United Arab Emirates|Novo Nordisk Investigational Site, Dubai, United Arab Emirates|Novo Nordisk Investigational Site, Dubai, United Arab Emirates|Novo Nordisk Investigational Site, Hatta, United Arab Emirates|Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Crewe, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Harrogate, North Yorkshire, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Watford, United Kingdom|Novo Nordisk Investigational Site, Wellingborough, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03552757/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03552757/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT03552757
764,NCT02608177,Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management,Completed,Has Results,Chronic Kidney Diseases|Type 2 Diabetes,Drug: Linagliptin|Drug: Glipizide,University of Washington|American Diabetes Association|Medtronic|Abbott,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Washington, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02608177/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02608177
765,NCT02512276,Tele-Pharmacy Intervention to Improve Treatment Adherence,Completed,Has Results,Hyperlipidemia|Diabetes|Hypertension,Behavioral: Telepharmacist intervention,Brigham and Women's Hospital|Harvard Vanguard Medical Associates,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Harvard Vanguard Medical Associates, Newton, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02512276/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02512276
766,NCT02642159,Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia),Completed,Has Results,Dyslipidemia,Drug: Alirocumab|Drug: Statins|Drug: Ezetimibe|Drug: Fenofibrate|Drug: Nicotinic acid|Drug: Omega-3 fatty acids|Drug: Antihyperglycemic Drug,Sanofi|Regeneron Pharmaceuticals,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 840-163, Little Rock, Arkansas, United States|Investigational Site Number 840-141, Fresno, California, United States|Investigational Site Number 840-152, Huntington Beach, California, United States|Investigational Site Number 840-115, La Jolla, California, United States|Investigational Site Number 840-118, Los Angeles, California, United States|Investigational Site Number 840-106, Northridge, California, United States|Investigational Site Number 840-176, Port Hueneme, California, United States|Investigational Site Number 840-122, Tarzana, California, United States|Investigational Site Number 840-156, Tustin, California, United States|Investigational Site Number 840-160, Van Nuys, California, United States|Investigational Site Number 840-107, Boca Raton, Florida, United States|Investigational Site Number 840-170, Boynton Beach, Florida, United States|Investigational Site Number 840-114, Bradenton, Florida, United States|Investigational Site Number 840-132, Ocoee, Florida, United States|Investigational Site Number 840-179, Oviedo, Florida, United States|Investigational Site Number 840-123, Tampa, Florida, United States|Investigational Site Number 840-137, Bainbridge, Georgia, United States|Investigational Site Number 840-128, Columbus, Georgia, United States|Investigational Site Number 840-169, Stockbridge, Georgia, United States|Investigational Site Number 840-167, Idaho Falls, Idaho, United States|Investigational Site Number 840-161, Chicago, Illinois, United States|Investigational Site Number 840-184, Crystal Lake, Illinois, United States|Investigational Site Number 840-174, Evanston, Illinois, United States|Investigational Site Number 840-138, Springfield, Illinois, United States|Investigational Site Number 840-108, Louisville, Kentucky, United States|Investigational Site Number 840-183, Paducah, Kentucky, United States|Investigational Site Number 840-190, Metairie, Louisiana, United States|Investigational Site Number 840-151, Rockville, Maryland, United States|Investigational Site Number 840-113, Jefferson City, Missouri, United States|Investigational Site Number 840-120, Saint Louis, Missouri, United States|Investigational Site Number 840-148, Omaha, Nebraska, United States|Investigational Site Number 840-101, Las Vegas, Nevada, United States|Investigational Site Number 840-140, Las Vegas, Nevada, United States|Investigational Site Number 840-178, Albany, New York, United States|Investigational Site Number 840-181, New York, New York, United States|Investigational Site Number 840-157, New York, New York, United States|Investigational Site Number 840-188, Greensboro, North Carolina, United States|Investigational Site Number 840-131, Morehead City, North Carolina, United States|Investigational Site Number 840-158, Morganton, North Carolina, United States|Investigational Site Number 840-129, Fargo, North Dakota, United States|Investigational Site Number 840-104, Columbus, Ohio, United States|Investigational Site Number 840-105, Marion, Ohio, United States|Investigational Site Number 840-175, Maumee, Ohio, United States|Investigational Site Number 840-136, Bend, Oregon, United States|Investigational Site Number 840-187, Murrells Inlet, South Carolina, United States|Investigational Site Number 840-111, Summerville, South Carolina, United States|Investigational Site Number 840-147, Chattanooga, Tennessee, United States|Investigational Site Number 840-159, Knoxville, Tennessee, United States|Investigational Site Number 840-153, Dallas, Texas, United States|Investigational Site Number 840-143, Houston, Texas, United States|Investigational Site Number 840-168, Houston, Texas, United States|Investigational Site Number 840-142, Round Rock, Texas, United States|Investigational Site Number 840-133, Tomball, Texas, United States|Investigational Site Number 840-185, Orem, Utah, United States|Investigational Site Number 840-150, Salt Lake City, Utah, United States|Investigational Site Number 840-126, Chesapeake, Virginia, United States|Investigational Site Number 840-171, Richmond, Virginia, United States|Investigational Site Number 036102, Herston, Australia|Investigational Site Number 036104, Merewether, Australia|Investigational Site Number 036101, St Leonards, Australia|Investigational Site Number 076103, Campinas, Brazil|Investigational Site Number 076104, Fortaleza, Brazil|Investigational Site Number 076101, Sao Paulo, Brazil|Investigational Site Number 076105, São paulo, Brazil|Investigational Site Number 076106, São Paulo, Brazil|Investigational Site Number 076102, SãO Paulo, Brazil|Investigational Site Number 246102, Oulu, Finland|Investigational Site Number 246101, Oulu, Finland|Investigational Site Number 246104, Tampere, Finland|Investigational Site Number 276112, Berlin, Germany|Investigational Site Number 276109, Berlin, Germany|Investigational Site Number 276104, Dippoldiswalde, Germany|Investigational Site Number 276101, Dresden, Germany|Investigational Site Number 276110, Essen, Germany|Investigational Site Number 276108, Essen, Germany|Investigational Site Number 276111, Goch, Germany|Investigational Site Number 276107, Karlsruhe, Germany|Investigational Site Number 276103, Künzing, Germany|Investigational Site Number 276102, Oldenburg in Holstein, Germany|Investigational Site Number 376101, Beer Sheva, Israel|Investigational Site Number 376103, Petach Tikva, Israel|Investigational Site Number 376104, Petach tikva, Israel|Investigational Site Number 376102, Rehovot, Israel|Investigational Site Number 376106, Tel-Aviv, Israel|Investigational Site Number 380104, Bergamo, Italy|Investigational Site Number 380107, Catanzaro, Italy|Investigational Site Number 380103, Napoli, Italy|Investigational Site Number 380108, Padova, Italy|Investigational Site Number 380106, Partinico, Italy|Investigational Site Number 380101, Pisa, Italy|Investigational Site Number 380105, Roma, Italy|Investigational Site Number 380102, Torino, Italy|Investigational Site Number 414101, Kuwait, Kuwait|Investigational Site Number 422101, Beirut, Lebanon|Investigational Site Number 422102, Hazmieh, Lebanon|Investigational Site Number 578101, Oslo, Norway|Investigational Site Number 578102, Oslo, Norway|Investigational Site Number 752102, Göteborg, Sweden|Investigational Site Number 752101, Stockholm, Sweden|Investigational Site Number 756101, Genève, Switzerland|Investigational Site Number 756102, Olten, Switzerland|Investigational Site Number 756103, Reinach, Switzerland|Investigational Site Number 792105, Adana, Turkey|Investigational Site Number 792106, Ankara, Turkey|Investigational Site Number 792102, Ankara, Turkey|Investigational Site Number 792108, Corum, Turkey|Investigational Site Number 792109, Hatay, Turkey|Investigational Site Number 792104, Izmir, Turkey|Investigational Site Number 792101, Izmir, Turkey|Investigational Site Number 792110, Izmir, Turkey|Investigational Site Number 792107, Kayseri, Turkey|Investigational Site Number 792103, Samsun, Turkey|Investigational Site Number 784101, Dubai, United Arab Emirates|Investigational Site Number 826104, Exeter, United Kingdom|Investigational Site Number 826106, Manchester, United Kingdom|Investigational Site Number 826105, Middlesborough, United Kingdom|Investigational Site Number 826103, Stevenage, United Kingdom|Investigational Site Number 826101, Torquay, United Kingdom|Investigational Site Number 826102, West Bromwich, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02642159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02642159/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02642159
767,NCT02738086,Physical Activity Behavior Change for Older Adults After Dysvascular Amputation,Completed,Has Results,"Amputation|Diabetes Mellitus, Type 2|Peripheral Artery Disease",Behavioral: Physical Activity Behavior Change (PABC),VA Office of Research and Development,"50 Years to 85 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02738086/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02738086/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02738086
768,NCT01858532,Study Of Diabetic Nephropathy With Atrasentan,Terminated,Has Results,Diabetic Nephropathy,Drug: Atrasentan|Drug: Placebo,AbbVie,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Ireland,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01858532/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01858532/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01858532
769,NCT02585778,Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin),Completed,Has Results,Hypercholesterolaemia,Drug: Alirocumab|Drug: Placebo|Drug: Lipid-Modifying Therapy (LMT)|Drug: Antihyperglycemic Drug,Sanofi|Regeneron Pharmaceuticals,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840020, Encino, California, United States|Investigational Site Number 840002, Fresno, California, United States|Investigational Site Number 840029, Oakland, California, United States|Investigational Site Number 840027, Loveland, Colorado, United States|Investigational Site Number 840026, Atlantis, Florida, United States|Investigational Site Number 840006, Bradenton, Florida, United States|Investigational Site Number 840023, Jacksonville, Florida, United States|Investigational Site Number 840028, Palm Harbor, Florida, United States|Investigational Site Number 840022, Ponte Vedra Beach, Florida, United States|Investigational Site Number 840021, Roswell, Georgia, United States|Investigational Site Number 840007, Springfield, Illinois, United States|Investigational Site Number 840011, Indianapolis, Indiana, United States|Investigational Site Number 840015, Valparaiso, Indiana, United States|Investigational Site Number 840010, Des Moines, Iowa, United States|Investigational Site Number 840005, Louisville, Kentucky, United States|Investigational Site Number 840018, Auburn, Maine, United States|Investigational Site Number 840013, Hyattsville, Maryland, United States|Investigational Site Number 840016, Rockville, Maryland, United States|Investigational Site Number 840004, Minneapolis, Minnesota, United States|Investigational Site Number 840012, Jamaica, New York, United States|Investigational Site Number 840014, Maumee, Ohio, United States|Investigational Site Number 840009, Greer, South Carolina, United States|Investigational Site Number 840024, Chattanooga, Tennessee, United States|Investigational Site Number 840001, Austin, Texas, United States|Investigational Site Number 840003, Dallas, Texas, United States|Investigational Site Number 840019, Dallas, Texas, United States|Investigational Site Number 840025, Houston, Texas, United States|Investigational Site Number 840017, Ogden, Utah, United States|Investigational Site Number 840008, Salt Lake City, Utah, United States|Investigational Site Number 040002, Innsbruck, Austria|Investigational Site Number 040005, Linz, Austria|Investigational Site Number 040003, Salzburg, Austria|Investigational Site Number 040004, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Edegem, Belgium|Investigational Site Number 056003, Haine-Saint-Paul, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250-008, Besancon, France|Investigational Site Number 250-005, Corbeil Essonnes, France|Investigational Site Number 250-004, La Rochelle Cedex 1, France|Investigational Site Number 250-003, Le Creusot, France|Investigational Site Number 250-009, Mulhouse, France|Investigational Site Number 250-002, Nantes cedex 01, France|Investigational Site Number 250-007, Paris, France|Investigational Site Number 250-006, Strasbourg Cedex 2, France|Investigational Site Number 250-001, TOULOUSE Cedex 9, France|Investigational Site Number 276015, Aschaffenburg, Germany|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276011, Dortmund, Germany|Investigational Site Number 276019, Dresden, Germany|Investigational Site Number 276014, Dresden, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276021, Hamburg, Germany|Investigational Site Number 276018, Hamburg, Germany|Investigational Site Number 276005, Heidelberg, Germany|Investigational Site Number 276013, Lüneburg, Germany|Investigational Site Number 276022, Magdeburg, Germany|Investigational Site Number 276008, Neumünster, Germany|Investigational Site Number 276017, Neuwied, Germany|Investigational Site Number 276004, Oldenburg, Germany|Investigational Site Number 276003, Pirna, Germany|Investigational Site Number 276006, Riesa, Germany|Investigational Site Number 276010, Saarlouis, Germany|Investigational Site Number 276016, Sulzbach-Rosenberg, Germany|Investigational Site Number 380004, Catania, Italy|Investigational Site Number 380003, Catanzaro, Italy|Investigational Site Number 380011, Como, Italy|Investigational Site Number 380006, Milano, Italy|Investigational Site Number 380007, Milano, Italy|Investigational Site Number 380005, Moncalieri, Italy|Investigational Site Number 380009, Napoli, Italy|Investigational Site Number 380008, Padova, Italy|Investigational Site Number 380002, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380010, Roma, Italy|Investigational Site Number 380012, Verona, Italy|Investigational Site Number 528002, Apeldoorn, Netherlands|Investigational Site Number 528005, Groningen, Netherlands|Investigational Site Number 528003, Hoogeveen, Netherlands|Investigational Site Number 528001, Rotterdam, Netherlands|Investigational Site Number 528004, Utrecht, Netherlands|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724006, Ferrol, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724011, Majadahonda, Spain|Investigational Site Number 724008, Málaga, Spain|Investigational Site Number 724014, Oviedo, Spain|Investigational Site Number 724009, Palma de Mallorca, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724010, Sant Joan Despí, Spain|Investigational Site Number 724012, Segovia, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 756001, Olten, Switzerland|Investigational Site Number 756003, St. Gallen, Switzerland|Investigational Site Number 826010, Airdrie, United Kingdom|Investigational Site Number 826011, Bath, United Kingdom|Investigational Site Number 826009, Bournemouth, United Kingdom|Investigational Site Number 826005, Bradford, United Kingdom|Investigational Site Number 826004, Bristol, United Kingdom|Investigational Site Number 826001, Burton On Trent, United Kingdom|Investigational Site Number 826015, Durham, United Kingdom|Investigational Site Number 826012, High Wycombe, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826006, Peterborough, United Kingdom|Investigational Site Number 826003, Southampton, United Kingdom|Investigational Site Number 826008, Truro, United Kingdom|Investigational Site Number 826002, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02585778
770,NCT03750695,Acute Exercise Effects in Obese Pregnancy,Completed,Has Results,Pregnancy Complications|Obesity|Pre-Eclampsia|Gestational Diabetes,Behavioral: Resistance exercise|Behavioral: Aerobic Exercise|Behavioral: Rest,Duke University,18 Years to 40 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03750695/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03750695
771,NCT02556918,Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery,Completed,Has Results,Hyperglycemia,Drug: Sitagliptin|Drug: Placebo|Drug: Regular Human Insulin|Drug: Insulin glargine|Drug: Supplemental insulin (Insulin lispro)|Drug: Supplemental insulin (Insulin aspart),Emory University,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Grady Health System, Atlanta, Georgia, United States|Emory Univeristy Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02556918/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02556918
772,NCT03304626,Budesonide for Liver Transplant Immune Suppression,Completed,Has Results,Acute Cellular Graft Rejection|New Onset Diabetes After Transplant,Drug: Budesonide 3Mg Capsule|Drug: Standard of Care Prednisone,University of Cincinnati|American College of Gastroenterology,"21 Years to 75 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati Medical Center, Cincinnati, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03304626/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03304626
773,NCT02118714,Atrasentan Spermatogenesis and Testicular Function,Completed,Has Results,Nephropathy|Diabetes,Drug: Atrasentan,AbbVie,"30 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Alliance Research Centers /ID# 125945, Laguna Hills, California, United States|Frank Clark Urology Center /ID# 147794, Santa Monica, California, United States|Research by Design, LLC /ID# 160784, Evergreen Park, Illinois, United States|Southern IL Univ School of Med /ID# 129010, Springfield, Illinois, United States|Crescent City Clinical Res Ctr /ID# 150989, Metairie, Louisiana, United States|Tulane Univ /ID# 130308, New Orleans, Louisiana, United States|Albany Medical College /ID# 131068, Albany, New York, United States|Urologic Consultants of Southeastern Pennsylvania /ID# 124277, Bala-Cynwyd, Pennsylvania, United States|Eastern Virginia Med School /ID# 153740, Norfolk, Virginia, United States|Charite Research Organisation GmbH /ID# 154264, Berlin, Germany|Ospedale S. Carlo Borromeo /ID# 151672, Milan, Italy|SCDU Nefrologia e dialisi-CMID /ID# 151673, Torino, Italy|Hospital Universitario Reina S /ID# 151692, Cordoba, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02118714/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02118714/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02118714
774,NCT05037591,Effect of Sea Grapes-antioxidants Extract in Obese Men : 4 Weeks Randomized-Double Blind Controlled Trial,Completed,No Results Available,Obesity|Aging|Diabetes,Drug: Sea grapes extract 1.68 g/70kg BW|Drug: Placebo,State Islamic University of Sunan Kalijaga Yogyakarta,19 Years to 60 Years   (Adult),Early Phase 1,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Fahrul Nurkolis, Manado, Sulawesi Utara, Indonesia","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT05037591/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT05037591
775,NCT04134650,Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes,Unknown status,No Results Available,Prediabetic State|Insulin Resistance,Combination Product: Linagliptin + metformin|Drug: Metformin,Universidad de Guanajuato|Hospital Regional de Alta Especialidad del Bajio,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanauato, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04134650/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04134650
776,NCT04189848,Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc,Completed,Has Results,"Healthy Volunteers|Diabetes Mellitus, Type 2|Overweight|Obesity",Drug: Semaglutide|Drug: Dulaglutide,Novo Nordisk A/S,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novo Nordisk Investigational Site, Groningen, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04189848/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04189848/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04189848
777,NCT04799925,Hyperuricemia and Diabetic Nephropathy,Not yet recruiting,No Results Available,Hyperuricemia|Diabetic Nephropathies,Drug: Febuxostat,Assiut University,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,Egypt,"""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT04799925/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04799925
778,NCT02057952,HealthyMe Online Weight Management Education/HealthyMe at Home,Completed,Has Results,Diabetes,Behavioral: Education and exercise,"Indiana University|Regenstrief Institute, Inc.|Wishard Health Services",40 Years to 64 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Indiana University School of Medicine, Indianapolis, Indiana, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02057952/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02057952/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02057952/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT02057952
779,NCT02287883,Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs,Completed,Has Results,Diabetes|Cardiovascular Disease,Other: Observational: Patient Activation and Engagement (PAE),"University of California, Berkeley|Dartmouth College|Advocate Health Care|HealthCare Partners Institute for Applied Research and Education","18 Years to 82 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"University of California, Berkeley, Berkeley, California, United States|HealthCare Partners Insitute for Applied Research and Education, Torrance, California, United States|Advocate Health Care, Chicago, Illinois, United States|Dartmouth Colelge, Hanover, New Hampshire, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02287883/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02287883/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02287883
780,NCT03656744,A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM),Completed,Has Results,"Fatty Liver, Nonalcoholic|NAFLD|Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Digestive System Diseases|Type 2 Diabetes Mellitus (T2DM)",Drug: HTD1801|Drug: Placebo,HighTide Biopharma Pty Ltd,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute for Liver Health, Chandler, Arizona, United States|Institute for Liver Health, Tucson, Arizona, United States|Adobe Clinical Research, Tucson, Arizona, United States|National Research Institute, Panorama City, California, United States|Excel Medical Clinical Trials, Boca Raton, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Compass Research, Orlando, Florida, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Cumberland Research Associates, Fayetteville, North Carolina, United States|Gastro One, Germantown, Tennessee, United States|Digestive Health Research, Hermitage, Tennessee, United States|Pinnacle Clinical Research, Austin, Texas, United States|Doctors Hospital at Renaissance, Edinburg, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Texas Digestive Disease Consultants, Southlake, Texas, United States|Harborview Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03656744/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03656744/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03656744
781,NCT01419535,Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults,Completed,Has Results,Endocrine Disease|Diabetes,Drug: Mifepristone|Drug: Placebo,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),"35 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01419535/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01419535/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01419535
782,NCT03463941,Peer Support Dyads in Churches,Completed,Has Results,Peer Support and Chronic Disease|Obesity|Type II Diabetes|Cardiovascular Disease|Cancer,Behavioral: Peer Support Dyad Intervention,Duke University|National Institute of Nursing Research (NINR),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Faithful Families Program, Raleigh, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03463941/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03463941
783,NCT03960333,Immunometabolism in Pediatric Obesity,"Active, not recruiting",No Results Available,Obesity|Type 2 Diabetes Mellitus|Insulin Resistance,,Arkansas Children's Hospital Research Institute|National Institutes of Health (NIH)|National Institute of General Medical Sciences (NIGMS)|University of Arkansas,5 Years to 17 Years   (Child),,Other|NIH,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,"Arkansas Children's Research Institute, Little Rock, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03960333/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03960333/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03960333
784,NCT03188263,Morning Light Treatment to Improve Glucose Metabolism,Completed,Has Results,PreDiabetes|Circadian Dysregulation,Other: Bright Light|Other: Dim Light,Northwestern University|Rush University,"35 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern Memorial Hospital, Chicago, Illinois, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03188263/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03188263
785,NCT03426345,Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02,Terminated,Has Results,Gastroparesis|Diabetes Mellitus,Drug: Placebo|Drug: Relamorelin,Allergan,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","North Alabama Research Center, LLC, Athens, Alabama, United States|Synexus Clinical Research US - Simon Williamson Clinic, Birmingham, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|GW Research Inc., Chula Vista, California, United States|Diagnamics Inc., Encinitas, California, United States|Fresno Clinical Research Center, Fresno, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Angel City Research Inc., Los Angeles, California, United States|Facey Medical Foundation, Mission Hills, California, United States|United Medical Doctors, Murrieta, California, United States|Stanford Hospital, Digestive Health Clinic, Palo Alto, California, United States|TriWest Research Associates, Poway, California, United States|Optimal Research California, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|New Hope Research Development, Whittier, California, United States|Synexus Clinical Research US, Inc. - Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Visionary Investigators Network, Aventura, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research LLC, Cooper City, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Sanchez Clinical Research, Inc., Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Synexus, Pinellas Park, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, LLC, Buford, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Synexus Clinical Research US, Inc., Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|American Research, LLC, Jeffersonville, Indiana, United States|Gastroenterology of Southern Indiana, New Albany, Indiana, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|Tri-State Gastroenterology, Crestview Hills, Kentucky, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Trialspark - Sood, Bowie, Maryland, United States|Capital Diabetes and Endocrine Associates, Camp Springs, Maryland, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Aa Mrc Llc, Flint, Michigan, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Heartland Clinical Research, Inc, Omaha, Nebraska, United States|USMA Clinical Research, LLC, Elizabeth, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|Winthrop-University Hospital, Mineola, New York, United States|Carolina Digestive Health Associates, PA, Davidson, North Carolina, United States|Kinston Medical Specialists, P.A., Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|The MetroHealth System MHS, Cleveland, Ohio, United States|Digestive Disease & Surgery Institute, Cleveland, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|CIC America Clinical Inquest Center Ltd., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Care Access Research, Warwick, Rhode Island, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Clinsearch, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Digestive & Liver Disease Center of San Antonio, PLLC, San Antonio, Texas, United States|Dwayne O. Williams MD, Sugar Land, Texas, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|Maffei Centro Medico-Investigacion Clinica Aplicada, C.a.b.a., Buenos Aires Province, Argentina|Hospital Sirio Libanes, Caba, Buenos Aires Province, Argentina|Centro de Investigaciones Medicas Mar del Plata SRL, Mar del Plata, Buenos Aires Province, Argentina|Instituto Privado de Investigaciones Clínicas de Córdoba, Córdoba, Cordoba, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de Hematologia y Medicina Clinica Dr. Ruben Davoli, Rosario, Santa Fe, Argentina|Clinica Mayo - Infectious DiseasesClínica Mayo de Urgencias, San Miguel de Tucuman, Tucuman, Argentina|CIPREC, Ciudad Autonoma de Buenos Aires, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegian, Córdoba, Argentina|Ordination, Sankt Stefan, Steiermark, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Privatklinik Wehrle-Diakonissen, Salzburg, Austria|Oö. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|AZ Sint Lucas Brugge, Brugge, Antwerpen, Belgium|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|Hospital Universitario Walter Cantidio, Fortaleza, Ceara, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|Hospital Universitario Joao de Barros Barreto, Belem, Para, Brazil|Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clinica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica em Campinas, Campinas, Sao Paulo, Brazil|CPQuali Pesquisa Clinica Ltda, Santa Cecília, Sao Paulo, Brazil|Instituto de Estudos E Persquisas Clinicas do Ceará - IEP/CE - Oncology, Fortaleza, Brazil|Instituto de Pesquisa ClÍnica e Medicina AvanCada Ltda, SÃo Paulo, Brazil|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Eastern Health, St. John's, Newfoundland and Labrador, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Vaughan, Ontario, Canada|CISSS de la Monteregie-Centre, Greenfield Park, Quebec, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal - CHUM, Montreal, Quebec, Canada|Central Alberta Research Centre, Red Deer, Canada|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundacion Bios, Barranquilla, Atlantico, Colombia|Asociación Colombiana de Diabetes, Bogotá, Cundinamarca, Colombia|Healthy Medical Center, Zipaquira, Cundinamarca, Colombia|Medplus Mp, Bogota, Distrito Capital De Bogotá, Colombia|Endocare Ltda., Bogota, Distrito Capital De Bogotá, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|Gastroenheden, Hvidovre hospital, Hvidovre, Copenhagen, Denmark|Endocrinology, Aalborg University Hospital, Aalborg, Denmark|Center for Clinical Metabolic Research, Hellerup, Denmark|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-SWÃƒÂ¼rttemberg, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Clinical Research Unit, Giessen, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|KRH Klinikum Siloah, Hannover, Germany|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|BKS Research Kft Synexus AS, Hatvan, Heves, Hungary|Hetenyi Geza Hospital, Szolnok, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Synexus Budapest DRS, Budapest, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|SYNEXUS Magyarorszag Kft Debrecen A.S., Debrecen, Hungary|Synexus Magyarország kft. Gyula DRS, Gyula, Hungary|Szegedi Tudomanyegyetem, Szeged, Hungary|Synexus Magyarorszag Kft, Zalaegerszeg, Hungary|Polana-D, Daugavpils, Latvia|Kraslava Hospital, Kraslava, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Medical and Nutritional Trials, Cuauhtemoc, Cdmx, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Distrito Federal, Mexico|Centro de Atención e Investigación en Factores de Riesgo Car, Mexico, Distrito Federal, Mexico|Clinicos Asociados BOCM SC, Portales, Distrito Federal, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, Guadalajara, Jalisco, Mexico|Consultorio Medico, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C., Guadalajara, Jalisco, Mexico|Centro de Desarrollo Biomedico S.C.P., Mérida, Yucatan, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|Sociedad de Metabolismo y Corazon, S.C., Veracruz, Mexico|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Novosibirsk Oblast, Russian Federation|GUZ Saratov City Clinical Hospital 9, Saratov, Saratov Region, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny Novgorod, Volga, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Russian Federation|Saratov City Clinical Hospital 12, Saratov, Russian Federation|FARMOVS, Bloemfontein, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clinical Research Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Silverton, Gauteng, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, Western Cape, South Africa|TREAD Research, Cape Town, South Africa|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Synexus Lancashire Dedicated Research Centre, Chorley, Lancashire, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Blackpool, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Synexus Merseyside Dedicated Research Centre, Liverpool, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|Wingate Institute of Neurogastroenterology and Barts Health Trust and the Royal London Hospital, London, United Kingdom|MAC Clinical Research, GAC House, Manchester, United Kingdom|Synexus Manchester Clinical Research Centre, Manchester, United Kingdom|Royal Victoria Infirmary: Clinical Research Facility, Newcastle upon Tyne, United Kingdom|Biomedical Research Centre, Nottingham, United Kingdom|Synexus Hexham Dedicated Research Centre, Stockton-on-Tees, United Kingdom|Synexus North Tees Clinical Research Centre, Stockton-on-Tees, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03426345/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03426345/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03426345
786,NCT03420781,A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03,Terminated,Has Results,Gastroparesis|Diabetes Mellitus,Drug: Placebo|Drug: Relamorelin,Allergan,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","North Alabama Research Center, LLC, Athens, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Del Sol Research Management, LLC, Chandler, Arizona, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|GW Research Inc, Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Diagnamics Inc., Encinitas, California, United States|VVCRD Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Angel City Research Inc., Los Angeles, California, United States|TriWest Research Associates, Poway, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Upland Clinical Research, Upland, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Synexus Clinical Research US, Inc. - Colorado Springs Family Practice, Colorado Springs, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|TrialSpark, Inc., Washington, District of Columbia, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|West Central Gastroenterology, Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research LLC, Cooper City, Florida, United States|Top Medical Research, Cutler Bay, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Panax Clinical Research, LLC., Miami Lakes, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|American Research Institute, Inc, Miami, Florida, United States|Synexus, Pinellas Park, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, LLC, Buford, Georgia, United States|Summit Clinical Research, LLC., Carnesville, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|Tri-State Gastroenterology, Crestview Hills, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, Bastrop, Louisiana, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Trialspark - Silverman, Bowie, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Frederick Gastroenterology Associates, PA an Elligo Health Research Site, Frederick, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Commonwealth Clinical Studies, PLLC., Brockton, Massachusetts, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Aa Mrc Llc, Flint, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|Minnesota Gastroenterology, P.A., Coon Rapids, Minnesota, United States|Montana Medical Research, Missoula, Montana, United States|Methodist Physicians Clinic Diabetes and Endocrine Specialists, Omaha, Nebraska, United States|Heartland Clinical Research, Inc, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology, Brick, New Jersey, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|Synexus Clinical Research US, Inc., Jamaica, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolina Digestive Health Associates, PA, Concord, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Vidant Multispeciality Clinic - Kinston, Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Dayton Gastroenterology, Inc., Beavercreek, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|CIC America Clinical Inquest Center Ltd., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Premier Clinical Research d.b.a. STAT Research, Franklin, Ohio, United States|Family Practice Center of Wadsworth, Inc. DBA New Venture Medical Research, Wadsworth, Ohio, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Clinsearch, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Avant Research Associates,LLC, Austin, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Synexus Clinical Research US, Inc., Dallas, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Southern Star Research Institute, LLC, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|Cardinal Internal Medicine Associates, PC, Woodbridge, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Maffei Centro Medico-Investigacion Clinica Aplicada, C.a.b.a., Buenos Aires Province, Argentina|Hospital Sirio Libanes, Caba, Buenos Aires Province, Argentina|Centro de Investigaciones Medicas Mar del Plata, Mar del Plata, Buenos Aires Province, Argentina|Instituto Privado de Investigaciones Clínicas de Córdoba, Córdoba, Cordoba, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto de Hematologia y Medicina Clinica Dr. Ruben Davoli, Rosario, Santa Fe, Argentina|Clinica Mayo de Urgencias Medicas Cruz Blanca SRL, San Miguel de Tucuman, Tucuman, Argentina|CIPREC, Ciudad Autonoma de Buenos Aires, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Nepean Hospital, Kingswood, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordination, Sankt Stefan ob Stainz, Styria, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch', Vorarlberg, Austria|Privatklinik Wehrle-Diakonissen, Salzburg, Austria|Landeskrankenhaus Steyr, Steyr, Austria|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|AZ Sint Lucas Brugge, Brugge, West-Vlaanderen, Belgium|Hospital Universitário Walter Cantídio, Fortaleza, Ceara, Brazil|Instituto de Estudos e Pesquisas Clinicas do Ceará IEP/CE - Oncology, Fortaleza, Ceará, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clinica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica de Campinas, Campinas, Sao Paulo, Brazil|CPQuali Pesquisa Clinica Ltda, Santa Cecília, São Paulo, Brazil|Hospital Universitário João de Barros Barreto, Belém, Brazil|IPEC-Instituto de Pesquisa Clinica, Sao Paulo, Brazil|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|Central Alberta Research Centre, Red Deer, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Toronto Digestive Disease Associates, Vaughan, Ontario, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S., Medellín, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundacion BIOS, Barranquilla, Atlantico, Colombia|Endocare Ltda., Bogotá, Cundinamarca, Colombia|Healthy Medical Center, Zipaquirá, Cundinamarca, Colombia|Medplus Medicina Prepagada, Bogota, Distrito Capital De Bogota, Colombia|Asociación Colombiana de Diabetes, Teusaquillo, Distrito Capital De Bogotá, Colombia|Fundacion Centro de Investigaciones Clinicas CARDIOMET, Pereira, Risaralda, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Gentofte Hospital, Hellerup, Copenhagen, Denmark|Gastroenheden, Hvidovre hospital, Hvidovre, Copenhagen, Denmark|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-Wuertemberg, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|KRH Klinikum Siloah, Hannover, Germany|First Department of Medicine, University of Szeged, Szeged, CsonfrÃ¡d, Hungary|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Hetenyi Geza Hospital, Tószeg, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Synexus Budapest DRS, Budapest, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation, Bakeri Medical Research Centre, Ahmedabad, Gujarat, India|Victoria Hospital, Bangalore, Karnataka, India|Life Care Hospital & Research Centre, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre, Mangalore, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|S.R. Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Diabetic Thyroid and Endocrine Centre, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India|M. V Hospital & Research Centre, Lucknow, Uttar Prandesh, India|Sir Ganga Ram Hospital, New Delhi, India|Bnai Zion Medical Center, Haifa, Israel|Endocrinology & Diabetes Center, Safed, Israel|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Diabetes Center, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kraslava Hospital, Kraslava, Kraslavas Nov., Latvia|Polana-D, Daugavpils, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Mentrials SA DE CV, Cuauhtemoc, Cdmx, Mexico|Clinicos Asociados BOCM SC, Mexico, Distrito Federal, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Distrito Federal, Mexico|Centro de Investigación y Atención de Diabetes - Endocrinología y Nutrición, Durango, Guillermina, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, S.C., Guadalajara, Jalisco, Mexico|Consultorio Medico, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C., Guadalajara, Jalisco, Mexico|Centro de Atención e Investigación en Factores de Riesgo Car, Mexico, Mexico DF, Mexico|Centro de Desarrollo Biomédico S.C.P, Mérida, Yucatán, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|Sociedad de Metabolismo y Corazon, S.C., Veracruz, Mexico|West Visayas State University Medical Center, IloIlo City, IloIlo, Philippines|St. Luke's Medical Center, Quezon City, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Manila Doctors Hospital, Ermita, Manila, Metropolitan Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metropolitan Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|NZOZ Vita Diabetica - Malgorzata Buraczyk, Bialystok, Podlaski, Poland|Endoskopia Sp. Z O.O., Sopot, Pomorskie, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Specjalistyczny Gabinet Neurologiczny Marta Banach, Krakow, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Novosibirskaya Oblast, Russian Federation|North-Western State Medical University named after I. I. Mechnikov, Saint-Petersburg, Sankt-Peterburg, Russian Federation|Nizhegorodsky Regional Clinical Hospital named after N. A. Semashko, Nizhny Novgorod, Volga, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|FSBI National medical endocrinology research centre, Moscow, Russian Federation|Moscow Regional Research Clinical Institute named by MF Vladimirski, Moscow, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|Rostov State Medical University, Rostov-on-Don, Russian Federation|GUZ Saratov City Clinical Hospital 9, Saratov, Russian Federation|Saratov City Clinical Hospital 12, Saratov, Russian Federation|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|FARMOVS, Bloemfontein, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clincal Reaserch Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Pretoria, Gauteng, South Africa|Synexus Helderberg Clinical Research Centre, Cape Town, Western Cape, South Africa|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine|Regional muniRegional municipal institution ""Chernivtsi's regional clinical hospital"", gastroenterological department, Higher state educational establishment of Ukraine ""Bukovinian state medical university"", department of internal medicine and infectious, Chernivtsi, Ukraine|Regional Public Organization ""Chernivtsi Regional Endocrinology Center"", Chernivtsi, Ukraine|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Ukraine|Municipal nonprofit entity of Kharkiv municipal council, Kharkiv, Ukraine|L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Limited Liability Company ""Medical and Diagnostic Center ""ADONIS Plus"", outpatient department, c. Kyiv, Kyiv, Ukraine|Kyiv clinical hospital on railway transport #2 of the ""Healthcare Centre"" branch of JSC ""Ukrainian Railway"", Kyiv, Ukraine|Medical Center Universal Clinic Oberig, Kyiv, Ukraine|Polyclinic of medical services and rehabilitation department of State Joint-Stock Holding Company Artem, day-patient unit, Kyiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Communal Institution ""Odesa Regional Clinical Hospital"", Out-patient department, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|Municipal nonprofit entity ""Vinnytsia's city clinical hospital #1"", c. Vinnytsia, Vinnytsia, Ukraine|6th City Clinical Hospital, c. Zaporizhzhia, Zaporizhzhia, Ukraine|Municipal Institution, City Hospital #7, Zaporizhzhia, Ukraine|Biomedical Research Centre, Nottingham, East Midland, United Kingdom|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Kaman Court, Blackpool, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|MAC Clinical Research, Liverpool, United Kingdom|MAC Clinical Research, GAC House, Stockton-on-Tees, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03420781/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03420781/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03420781
787,NCT03383146,A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04,Terminated,Has Results,Gastroparesis|Diabetes Mellitus,Drug: Placebo|Drug: Relamorelin,Allergan,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pinnacle Research Group, Anniston, Alabama, United States|North Alabama Research Center, LLC, Athens, Alabama, United States|Simon Williamson Clinic, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|G & L Research, LLC, Foley, Alabama, United States|Avant Research Associates, Huntsville, Alabama, United States|Alabama Medical Group, PC, Mobile, Alabama, United States|Phoenix Clinical LLC., Phoenix, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Synexus Clinical Research US, Inc., Tucson, Arizona, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Applied Research Center of Arkansas, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Unity Health - Searcy Medical Center, Searcy, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|GW Research Inc, Chula Vista, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|TriWest Research Associates, El Cajon, California, United States|Diagnamics Inc., Encinitas, California, United States|VVCRD Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Angel City Research Inc., Los Angeles, California, United States|Stanford Hospital, Palo Alto, California, United States|Optimal Research California, San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Upland Clinical Research, Upland, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|New Hope Research Development, Whittier, California, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Synexus, Colorado Springs, Colorado, United States|Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|ALL Medical Research, LLC, Cooper City, Florida, United States|Top Medical Research, Cutler Bay, Florida, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Vida Clinical Trials, Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|American Research Institute, Inc, Miami, Florida, United States|Gastroenterology Group of Naples, Naples, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Synexus, Pinellas Park, Florida, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|Gwinnett Research Institute, LLC, Buford, Georgia, United States|Summit Clinical Research, LLC., Carnesville, Georgia, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Clinical Research Consultants of Atlanta, Suwanee, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States|North Shore University Health System, Evanston, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|American Research, LLC, Jeffersonville, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|WestGlen Gastrointestinal Consultants, Shawnee Mission, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|Professional Research Network of Kansas, LLC, Wichita, Kansas, United States|Via Christi Clinic, PA, Wichita, Kansas, United States|St. Elizabeth Healthcare â€"" Clinical Research Institute, Erlanger, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|WK Physicians Network, Bossier City, Louisiana, United States|Avant Research Associates LLC, Crowley, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|Clinical Trials of SWLA, LLC, Lake Charles, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Clinical Trials of America, Inc., West Monroe, Louisiana, United States|Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Frederick Gastroenterology Associates, PA an Elligo Health Research Site, Frederick, Maryland, United States|Woodholme Gastroenterology Associates, P.A., Glen Burnie, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Meridian Clinical Research, LLC, Rockville, Maryland, United States|Clinical Research Institute of Michigan, Chesterfield, Michigan, United States|Vida Clinical Studies, Dearborn, Michigan, United States|Aa Mrc, Llc, Flint, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Gastroenterology Associates of Western Michigan, West Michigan Clinical Research Center, Wyoming, Michigan, United States|MNGI Digestive Health, Coon Rapids, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|Synexus Clinical Research US, Inc, Saint Louis, Missouri, United States|Montana Medical Research, Missoula, Montana, United States|Diabetes and Endocrine Associates, P.C., Omaha, Nebraska, United States|Heartland Clinical Research, Inc, Omaha, Nebraska, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Clinical Research of South Nevada - CROSN, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology LLC, Brick, New Jersey, United States|Synexus Clinical Research US, Inc., Bridgeton, New Jersey, United States|AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|CHEAR Center LLC, Bronx, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare-Charlotte, Charlotte, North Carolina, United States|Carolina Digestive Health Associates, PA, Concord, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|Vidant Multispeciality Clinic - Kinston, Kinston, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Synexus Clinical Research US, Inc., Akron, Ohio, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|Diabetes & Endocrinology Associates of Stark County, Inc., Canton, Ohio, United States|Synexus Clinical Research US - Cincinnati, Cincinnati, Ohio, United States|Synexus Clinical Research US, Inc, Cincinnati, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States|Aventiv Research, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|CIC America Clinical Inquest Center Ltd., Dayton, Ohio, United States|Hometown Urgent Care and Research, Dayton, Ohio, United States|Premier Clinical Research d.b.a. STAT Research, Franklin, Ohio, United States|Family Practice Center of Wadsworth, Inc., Wadsworth, Ohio, United States|Centennial Health-Synexus, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States|Frontier Clinical Research, LLC, Smithfield, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Synexus Clinical Research US, Inc, Anderson, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Carolina Medical Research, Clinton, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Synexus Clinical Research, Greer, South Carolina, United States|Health Concepts, Rapid City, South Dakota, United States|Clinsearch, Chattanooga, Tennessee, United States|Gastroenterology Centers of the Midsouth, Germantown, Tennessee, United States|East Tennessee Research Institute, Johnson City, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|ClinRx Research, LLC, Carrollton, Texas, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States|Biopharma Informatic Inc., Research Center, Houston, Texas, United States|Houston Endoscopy and Research Center, Inc., Houston, Texas, United States|Rodriguez Clinical Trials, Houston, Texas, United States|Amir Hassan, MD, PA, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Sagact Pllc., San Antonio, Texas, United States|Synexus Clinical Research US, Inc., San Antonio, Texas, United States|Synexus Clinical Research US, Inc., Layton, Utah, United States|Synexus Clinical Research US, Inc., Murray, Utah, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Blue Ridge Medical Research, Lynchburg, Virginia, United States|Manassas Clinical Research Centre, Manassas, Virginia, United States|VA Medical Center McGuire VAMC, Richmond, Virginia, United States|Washington Gastroenterology PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Consultorios Asociados de Endocrinologia e InvestigaciÃ³n Cl, Buenos Aires, Buenos Aires Province, Argentina|Hospital Sirio Libanes, Caba, Buenos Aires Province, Argentina|Centro de Investigaciones Medicas Mar del Plata SRL, Mar del Plata, Buenos Aires, Argentina|CIPREC, Buenos Aires, Ciudad Autonoma deBuenos Aires, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Santa Fe, Argentina|Instituto Medico Catamarca-I.ME.C, Rosario, Santa Fe, Argentina|Clinica Mayo de Urgencias Medicas Cruz Blanca SRL, San Miguel de Tucuman, Tucuman, Argentina|CIDIM - Centro Integral de Diagnóstico por Imágenes Marchegian, Cordoba, Argentina|Centro Universitario de Investigacion en Farmacologia Clinic, Corrientes, Argentina|Instituto Privado de Investigaciones Clinicas de Cordoba, Córdoba, Argentina|Nepean Hospital, Kingswood, New South Wales, Australia|Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Ordination, Osterreicher, Steiermark, Austria|VIVIT Institute, am LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Privatklinik wehlre-Diakonissen, Salzburg, Austria|Oö. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|Universitair Ziekenhuis Antwerpen, Gastro-Enterologie,, Edegem, Antwerp, Belgium|UZ Brussel, Jette, Brussel, Belgium|AZ Sint Lucas Brugge, Brugge, West-Vlaanderen, Belgium|Hospital Universitário Walter Cantídio, Fortaleza, CE, Brazil|Centro de Pesquisa Clinica do Brasil, Brasilia, Distrito Federal, Brazil|Hospital Universitário João de Barros Barreto - UFPA, Belem, PA, Brazil|Núcleo de Pesquisa Clínica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Catarinense de Endocrinologia e Diabetes (ICED), Joinville, Santa Catarina, Brazil|Scentryphar Pesquisa Clínica Ltda, Campinas, Sao Paulo, Brazil|Instituto de Pesquisa Clinica em Campinas, Campinas, Sao Paulo, Brazil|Instituto de Estudos e Pesquisas Clinicas do Ceara IEP/CE - Oncology, Fortaleza, Brazil|IPEC-Instituto de Pesquisa Clinica, Sao Paulo, Brazil|CPQuali Pesquisa Clinica Ltda, Sao Paulo, Brazil|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|University of Calgary, Calgary, Alberta, Canada|Central Alberta Research Centre, Red Deer, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Patient research centre, St. John's, Newfoundland and Labrador, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|Recherche GCP Research, Montreal, Quebec, Canada|Centro Cardiovascular Colombiano Clínica Santa María, Medellin, Antioquia, Colombia|Rodrigo Botero S.A.S., Medellín, Antioquia, Colombia|Centro Cardiovascular y de Diabetes, Barranquilla, Atlantico, Colombia|Fundación del Caribe para la InvestigacionBiomédica-Fundación BIOS, Barranquilla, Atlantico, Colombia|Asociación Colombiana de Diabetes, Bogotá, Cundinamarca, Colombia|Healthy Medical Center, Zipaquira, Cundinamarca, Colombia|Endocare Ltda., Bogotá, Distrito Capital De Bogotá, Colombia|Medplus Centro de Recuperacion Integral S.A.S., Bogotá, Distrito Capital, Colombia|Centro de Investigaciones Clínicas IPS CARDIOMET Pereira, Pereira, Risaralda, Colombia|IPS Centro Medico Julian Coronel S.A, Cali, Valle Del Cauca, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Valle Del Cauca, Colombia|Steno Diabetes Center Copenhagen, Hellerup, Copenhagen, Denmark|Gastroenheden, Hvidovre hospital, Hvidovre, København, Denmark|Klinische Forschung Karlsruhe GmbH, Karlsruhe, Baden-Wurttemberg, Germany|Studienzentrum Schwittay, Böhlen, Saxony, Germany|Klinische Forschung Dresden GmbH, Dresden, Saxony, Germany|Clinical Research Hamburg, Hamburg, Germany|Israelitisches Krankenhaus, Hamburg, Germany|KRH Klinikum Siloah, Hannover, Germany|Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger, Heves, Hungary|Hetenyi Geza Hospital, Szolnok, Jász-Nagykun-Szolnok, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Zala, Hungary|Strázsahegy Gyógyszertár Medicina, Budapest, Hungary|Szegedi TudomanyegyetemSzent-Gyorgyi Albert Klinikai Kozpont és Altalanos Orvostudomanyi Kar Belgyogyaszati Klinika, Szeged, Hungary|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology, Ahmedabad, Gujarat, India|Zydus Hospital, Ahmedabad, Gujarat, India|Lifecare Clinic and Research Centre - Internal Med/Diabetology, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Victoria Hospital Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|S R Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|M.V. Hospital for Diabetes & Diabetes Research Centre, Chennai, Tamil Nadu, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|Arthur Asirvatham Hospital, Madurai, Tamil Nadu, India|M V Hospital & Research Centre, Lucknow, Uttar Pradesh, India|Sir Ganga Ram Hospital (SGRH), Delhi, India|Vinaya Hospital & Research Centre, Mangalore, India|Bnei-Zion MC, Haifa, Israel|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Kraslava Hospital, Kraslava, Kraslavas Nov., Latvia|Polana-D, Daugavpils, Latvia|Pauls Stradins Clinical University Hospital, Endokrinologijas nodala, Riga, Latvia|Digestive Diseases Centre GASTRO, Riga, Latvia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Clinical Investigation Centre, Kuala Lumpur, Malaysia|Clinical Trial Unit, School of Medical Sciences, Health Campus, Hospital Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Mentrials Sa de Cv, Mexico DF, Distrito Federal, Mexico|Clinicos Asociados BOCM SC, Mexico, Distrito Federal, Mexico|Centro Especializado en Diabetes, Obesidad y Prevencion de E - Endocrinology, Mexico, Distrito Federal, Mexico|Centro de Atención e Investigación en Factores de Riesgo Car, Mexico, Distrito Federal, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occidente, Guadalajara, Jalisco, Mexico|Consultorio particular, Guadalajara, Jalisco, Mexico|Unidad de Investigación Clínica en Medicina S.C/, Guadalajara, Jalisco, Mexico|Centro de Desarrollo Biomédico S.C.P, Mérida, Yucatán, Mexico|Centro de Investigacion Cardiometabolica de Aguascalientes SA de CV, Aguascalientes, Mexico|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Dioderm Instituto de Investigacion, Durango, Mexico|CIADEN (Centro de Investigación y Atención de Diabetes, Endocrinología y Nutrición), Durango, Mexico|Sociedad de Metabolismo y Corazon S.C., Veracruz, Mexico|West Visayas State University Medical Center, IloIlo City, IloIlo, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Manila Doctors Hospital, Ermita, Manila, Metropolitan Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metropolitan Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Lesser Poland, Poland|CenterMed Krakow Ltd, Krakow, Malopolska, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Saint-Petersburg City Pokrovskaya Hospital, St-Petersburg, Leningrad Region, Russian Federation|GUZ Saratov City Clinical Hospital 9, Saratov, Saratov Region, Russian Federation|Scientific Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Rostov on Don, Rostov on Don, Russian Federation|National University Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|FARMOVS, Bloemfontein, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Synexus Stanza Clinical Research Centre, Pretoria, Gauteng, South Africa|Watermeyer Clinical Research Site, Pretoria, Val De Grace, South Africa|Synexus Helderberg Clinical Research Centre, Somerset West, South Africa|Hospital Universitario Principe de Asturias, Madrid, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Dnipropetrovs'ka Oblast', Ukraine|Municipal Institution, City Hospital #7, polyclinic department, c. Zaporizhzhia, Zaporizhzhia, Zaporizhzhia Region, Ukraine|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|Regional Municipal noncommercial Enterprise ""Chernivtsi Regional Endocrinology Center"", Polyclinic department, Higher State Educational Establishment of Ukraine ""Bukovinian State Medical University"", Department of Clinical Immunology, Allergology and Endo, Chernivtsi, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Municipal nonprofit entity of Kharkiv municipal council, Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Kyiv Railway Clinical Hospital No-2 of Branch of Healthcare Center of the PJSC Ukrainian Railway , Endocrynology Department, Kyiv, Ukraine|Polyclinic of medical services and rehabilitation department of State Joint-Stock Holding Company Artem, day-patient unit, Kyiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|Municipal Institution 6th City Clinical Hospital, Dept of Gastroenterology, Zaporizhzhia, Ukraine|Biomedical Research Centre, Nottingham, East Midland, United Kingdom|MAC Clinical Research Manchester, Manchester, Greater Manchester, United Kingdom|Royal Oldham Hospital, Oldham, Lancashire, United Kingdom|MAC Clinical Research, Liverpool, Merseyside, United Kingdom|MAC Research, Exchange House, Cannock, Staffordshire, United Kingdom|University Hospitals of North Midlands, Stoke on Trent, Staffordshire, United Kingdom|MAC Clinical Research, Monarch House, Leeds, West Yorkshire, United Kingdom|MAC Research, Barnsley, United Kingdom|MAC Clinical Research, Kaman Court, Blackpool, United Kingdom|Mid Essex Hospital Services NHS Trust Broomfield Hospital, Chelmsford, United Kingdom|MAC Clinical Research, GAC House, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03383146/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03383146/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03383146
788,NCT03285308,A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01,Terminated,Has Results,Gastroparesis|Diabetes Mellitus,Drug: Placebo|Drug: Relamorelin,Allergan,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialist of the South East, Dothan, Alabama, United States|Avant Research Associates, Huntsville, Alabama, United States|Synexus Clinical Research US, Inc., Fountain Hills, Arizona, United States|Central Arizona Medical Associates, Mesa, Arizona, United States|Phoenix Clinical LLC, Phoenix, Arizona, United States|Del Sol Research Management, LLC, Tucson, Arizona, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Arkansas Gastorenterology, North Little Rock, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States|Aurora Care Clinic, LLC, Costa Mesa, California, United States|Citrus Valley Gastroenterology Clinic, Covina, California, United States|VVCRD Research, Garden Grove, California, United States|University of California San Diego, La Jolla, California, United States|Om Research LLC, Lancaster, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|Medical Associates Research Group, Inc, San Diego, California, United States|Synexus Clinical Research, US, Santa Rosa, Santa Rosa, California, United States|Upland Clinical Research, Upland, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|Denver Esophageal and Stomach Center, Englewood, Colorado, United States|Connecticut Clinical Research Foundation, Bristol, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|TrialSpark, Inc., Washington, District of Columbia, United States|Innovative Research of West FL, Inc., Clearwater, Florida, United States|West Central Gastroenterology, Clearwater, Florida, United States|American Research Institute, Inc, Cutler Bay, Florida, United States|Top Medical Research, Cutler Bay, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Cfagi Llc, Maitland, Florida, United States|Savin Medical Group LLC, Miami Lakes, Florida, United States|APF Research LLC, Miami, Florida, United States|AMPM Research Clinic, Miami, Florida, United States|Advanced Medical Research Institute, Miami, Florida, United States|Florida Research Center, Inc., Miami, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Gulf Region Clinical Research Institute, Pensacola, Florida, United States|University of South Florida, Tampa, Florida, United States|West Central Gastroenterology, Tampa, Florida, United States|Summit Clinical Research, LLC, Carnesville, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Synexus Clinical Research US, Inc., Evansville, Indiana, United States|Indiana University Health University Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cotton-O'Neil Clinical Research Center - Digestive Health, Topeka, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Delta Research Partners, Bastrop, Louisiana, United States|Cronola LLC, Houma, Louisiana, United States|New Orleans Research Institute - Metropolitan Gastroenterology Associates, Metairie, Louisiana, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Frederick Gastroenterology Associates, PA an Elligo Health Research Site, Frederick, Maryland, United States|Boston VA Healthcare System, West Roxbury, Massachusetts, United States|Vida Clinical Studies, Dearborn, Michigan, United States|National Clinical, LLC, Hamtramck, Michigan, United States|Henry Ford Health System, Novi, Michigan, United States|Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States|MNGI Digestive Health, Coon Rapids, Minnesota, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|Montana Medical Research, Missoula, Montana, United States|Synexus Clinical Research, Henderson, Nevada, United States|Excel Clinical Research, Las Vegas, Nevada, United States|Clinical Research of South Nevada, Las Vegas, Nevada, United States|Advanced Biomedical Research of America, Las Vegas, Nevada, United States|Digestive Disease Specialists, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Garden State Endocrinology, Brick, New Jersey, United States|Synexus Clinical Research US, Inc., Bridgeton, New Jersey, United States|AGA Clinical Research Associates LLC, Egg Harbor Township, New Jersey, United States|CHEAR Center, LLC, Bronx, New York, United States|Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States|United Health Services Hospitals, Inc., Johnson City, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare-Charlotte, Charlotte, North Carolina, United States|Carolina Digestive Health Associates, Concord, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials, Greensboro, North Carolina, United States|PMG Research Salisbury, Salisbury, North Carolina, United States|The Center for Clinical Research, Winston-Salem, North Carolina, United States|Dayton Gastroenterology,Inc., Beavercreek, Ohio, United States|Endocrinology Research Associates, Inc., Columbus, Ohio, United States|Hometown Urgent Care and Research, Columbus, Ohio, United States|Premier Clinical Research d.b.a. STAT Research, Franklin, Ohio, United States|Family Practice Center of Wadsworth, Inc., Wadsworth, Ohio, United States|Digestive Disease Specialists Inc, Oklahoma City, Oklahoma, United States|Memorial Clinical Research, Oklahoma City, Oklahoma, United States|Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States|Family Medical Associates, Research Department, Levittown, Pennsylvania, United States|Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States|Montgomery Medical, Inc., Smithfield, Pennsylvania, United States|Synexus Clinical Research US, Inc., Anderson, South Carolina, United States|Carolina Medical Research, Clinton, South Carolina, United States|Gastroenterology Associates, PA, Greenville, South Carolina, United States|Synexus Clinical Research, Greer, South Carolina, United States|Quality Medical Research, Nashville, Tennessee, United States|Avant Research Associates,LLC, Austin, Texas, United States|Synexus Clinical Research US, Inc., Dallas, Texas, United States|Amir Ali Hassan, MD, PA, Houston, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Sagact Pllc, San Antonio, Texas, United States|Synexus Clinical Research US, Inc., Layton, Utah, United States|Synexus Clinical Research US, Inc., Murray, Utah, United States|Advanced Research Institute, Inc., Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Verity Research Inc., Fairfax, Virginia, United States|Cardinal Internal Medicine, Woodbridge, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Nepean Hospital, Kingswood, New South Wales, Australia|Royal Adelaide Hospital - Central Adelaide Local Health Network Incorporated, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|MHAT Yuliya Vrevska Byala, Byala, Ruse, Bulgaria|UMHAT - Kaspela- EOOD, Plovdiv, Bulgaria|Medical Center Asklepion - Humane Medicine Research EOOD, Sofia, Bulgaria|Alexandrovska University Hospital, Sofia, Bulgaria|CHU Nantes, Nantes Cedex 1, France|Hopital Charles Nicolle, Rouen Cedex, France|Kumudini Devi Diabetes Research Center; Ramdevrao Hospital, Hyderabad, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. Jivraj Mehta Smarak Health Foundation Bakeri Medical Research Centre - Gasterentrology, Ahmedabad, Gujarat, India|Victoria Hospital, Bangalore, Karnataka, India|Life Care Hospital & Research Centre, Bangalore, Karnataka, India|Diacon Hospital and research Center - Diabetology, Bengaluru, Karnataka, India|Rajalakshmi Hospital, Bengaluru, Karnataka, India|Vinaya Hospital & Research Centre, Mangalore, Karnataka, India|Bhatia Hospital, Mumbai, Maharashtra, India|B. J. Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India|Universal Hospital, Pune, Maharashtra, India|Noble Hospital Pvt. Ltd, Pune, Maharashtra, India|S R Kalla (SRK) Memorial Gastro & General Hospital, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|Diabetic Thyroid and Endocrine Centre, Jaipur, Rajasthan, India|Marudhar Hospital, Jaipur, Rajasthan, India|Eternal Hospital - Diabetology, Jaipur, Rajasthan, India|M.V. Hospital for Diabetes & Diabetes Research Centre, Chennai, Tamil Nadu, India|Kovai Diabetes Speciality Centre, Coimbatore, Tamil Nadu, India|M V Hospital & Research Centre, Lucknow, Uttar Pradesh, India|Arthur Asirvatham Hospital, Madurai, India|Sir Ganga Ram Hospital, New Delhi, India|Soroka University Medical Center, Beer Sheba, Israel|Bnai Zion Medical Center, Haifa, Israel|E. Wolfson Medical Center, Holon, Israel|Digestive Diseases Institute, Jerusalem, Israel|Gastroenterology Institute, Petach Tikva, Israel|Endocrinology & Diabetes Center, Safed, Israel|Gastroenterology Institute, Tel Aviv, Israel|Chonbuk National University Hospital, Jeonju, Jeollabuk-Do, Korea, Republic of|Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Nowon-gu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Universiti Sains Malaysia, Kubang Kerian, Malaysia|Hospital Taiping, Taiping, Malaysia|Manila Doctors Hospital, Ermita, Manila, Philippines|San Juan De Dios Educational Foundation, Inc., Pasay, Metro Manila, Philippines|Cardinal Santos Medical Center, San Juan City, Metro Manila, Philippines|Ospital ng Makati, Makati City, NCR, Philippines|Perpetual Succor Hospital, Cebu City, Philippines|West Visayas State University Medical Center, IloIlo City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Synexus Polska Sp.z o.o., Pomorskie, Gdansk, Poland|CenterMed Krakow Ltd, Krakow, Malopolska, Poland|Centrum Medyczne Pratia S.A. Warsaw, Poland, Warsaw, Mazowian, Poland|Endoskopia Sp. Z O.O., Sopot, Pomorskie, Poland|Synexus Polska Sp. z o.o.Oddzial w Poznaniu, Poznan, Poznañ, Poland|Wojewodzki Szpital Specjalistyczny w Olsztynie, Olsztyn, Warmia-Mazury, Poland|NZOZ Vita Diabetica - Malgorzata Buraczyk, Bialystok, Poland|Centrum Medyczne Lukamed, Chojnice, Poland|Synexus Polska sp.z.o.o oddzial Czestochowa, Czestochowa, Poland|Specjalistyczny Gabinet Neurologiczny Marta Banach, Kraków, Poland|Synexus Polska Sp. z o.o. Oddzial w Lodzi, Lodz, Poland|Sanitas Centrum Medyczne, Lublin, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Poland|DRS Wroclaw, Wroclaw, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|National University Hospital, Singapore, Singapore|Changi General Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Hospital Universitario Principe de Asturias, Madrid, Spain|Hospital Universitario De Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Communal Institution ""Odesa Regional Clinical Hospital"", Out-patient department, Odesa, Odesa Region, Ukraine|Limited Liability Company ""Medical Center ""Salutem"", Vinnitsa, Vinnyts'ka Oblast', Ukraine|Municipal Institution City Hospital No. 7, Zaporizhzhia, Zaporizhzhia Region, Ukraine|Regional municipal institution ""Chernivtsi's regional clinical hospital"", gastroenterological department, Higher state educational establishment of Ukraine ""Bukovinian state medical university"", department of internal medicine and infectious diseases, c.C, Chernivtsi, Ukraine|Regional Public Organization Chernivtsi Regional Endocrinology Center, Chernivtsi, Ukraine|State Institution Ukrainian State Research Institute of Medical and Social Problems of Disability of the Ministry of Health of Ukraine, Dnipro, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ukraine|Municipal nonprofit entity of Kharkiv municipal council, Kharkiv, Ukraine|L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine|Clinical Endocrinology of SI ""V.Danilevsky Institute for endocrine pathology problems National Academy of Medical sciences of Ukraine"", Kharkiv, Ukraine|Communal Institution Kherson City Clinical Hospital, Kherson, Ukraine|Kyiv municipal clinical endocrinological center, Kyiv, Ukraine|AS Medbud Clinic, Kyiv, Ukraine|AS PVNZ, Kyiv, Ukraine|Limited Liability Company ""Medical and Diagnostic Center ""ADONIS Plus"", outpatient department, c. Kyiv, Kyiv, Ukraine|Kyiv Railway hospital on the railway transport #2 of the branch ""health, Kyiv, Ukraine|Medical Center Universal Clinic Oberig, Kyiv, Ukraine|Polyclinic of medical services and rehabilitation department of State Joint-Stock Holding Company Artem, day-patient unit, Kyiv, Ukraine|Odessa Railway Clinical Hospital of Branch of HC JSC Ukrzaliznytsia, Odessa National Medical University, Odesa, Ukraine|Poltava Regional Clinical Hospital, Poltava, Ukraine|Ternopil University Hospital, Ternopil, Ukraine|Private Small-Scale Enterprise Medical Centre Pulse, Vinnytsia, Ukraine|Vinnytsia Regional Clinical highly specialized Endocrinology Centre, Vinnytsia, Ukraine|Municipal nonprofit entity ""Vinnytsia's city clinical hospital #1"", c. Vinnytsia, Vinnytsia, Ukraine|6th City Clinical Hospital, c. Zaporizhzhia, Zaporizhzhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03285308/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03285308/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03285308
789,NCT01369069,Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial,Completed,Has Results,Acute Ischemic Stroke|Diabetes|Hyperglycemia,Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL|Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL,University of Virginia|Neurological Emergencies Treatment Trials Network (NETT)|Medical University of South Carolina|National Institute of Neurological Disorders and Stroke (NINDS),"18 Years and older   (Adult, Older Adult)",Phase 3,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Arizona Medical Center - South Campus, Tucson, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Ronald Regan Medical Center, Los Angeles, California, United States|San Francisco General Hospital, San Francisco, California, United States|California Pacific Medical Center - Davies Campus, San Francisco, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Emory University Hospital - Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Lincoln Medical and Mental Health Center, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|SUNY Downstate University Hospital of Brooklyn, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Maimonides Medical Center, New York, New York, United States|Summa Akron City Hospital, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Wexner Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|UPMC - Mercy, Pittsburgh, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|St. Thomas Neuroscience Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dell Seton Medical Center at UT, Austin, Texas, United States|Seton Medical Center, Austin, Texas, United States|UT Southwestern-Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern-Zale Lipshy University Hospital, Dallas, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Memorial Herman Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Froedtert Memorial Hospital, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01369069/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01369069/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01369069
790,NCT02620787,Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis,Completed,Has Results,Diabetes|Wound Infection|Healthy Volunteers,Drug: Tedizolid|Procedure: Microdialysis Catheter Insertion,Hartford Hospital|Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Phase 1,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Hartford Hospital, Hartford, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02620787/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02620787
791,NCT02620774,Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections,Completed,Has Results,Diabetes|Wound Infection|Healthy Volunteers,Drug: Ceftolozane/tazobactam|Procedure: Microdialysis Catheter Insertion,Hartford Hospital|Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Phase 1,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Hartford Hospital, Hartford, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02620774/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02620774
792,NCT02363803,Lidocaine for Diabetic Peripheral Neuropathy,Completed,Has Results,Diabetes|Peripheral Neuropathy|Pain,Drug: lidocaine|Drug: Placebo,Washington University School of Medicine,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Washington University School of Medicine/Barnes Jewish Hospital, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02363803/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02363803
793,NCT03654651,Peanuts and Glycemic Control,Completed,Has Results,Type2 Diabetes|Cardiovascular Diseases,Drug: Peanut|Drug: High carbohydrate snack,Penn State University|The Peanut Institute,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Pennsylvania State University, University Park, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03654651/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03654651/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03654651
794,NCT01956773,Family Health History in Diverse Care Settings (FHH),Completed,Has Results,Diabetes|Heart Disease|Cancer,Other: MeTree,Duke University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"David Grant Medical Center, Fairfield, California, United States|Essentia Institute of Rural Health, Duluth, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT01956773/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01956773
795,NCT02587936,Improving Chronic Disease Management With Pieces,Completed,No Results Available,Chronic Kidney Disease|Diabetes|Hypertension|High BP|Type 2 Diabetes,Other: Collaborative Model of Primary care and Subspecialty care,"University of Texas Southwestern Medical Center|Parkland Center for Clinical Innovation|Parkland Health and Hospital System|Texas Health Resources|Connecticut Center for Primary Care|Dallas VA Research Corporation|G-Health Enterprises|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)","18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Other|Industry|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"ProHealth, Farmington, Connecticut, United States|Texas Health Resources, Arlington, Texas, United States|Veteran's Administration, Dallas, Texas, United States|Parkland Health and Hospital System, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02587936/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02587936
796,NCT02812238,Study to Evaluate the Effect of Nicotinamide Riboside on Immunity,Completed,Has Results,Atherosclerosis|Diabetes|Coronary Artery Disease,Dietary Supplement: Nicotinamide riboside (NR)|Drug: Placebo,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)",18 Years to 39 Years   (Adult),Not Applicable,NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02812238/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02812238
797,NCT02422446,Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects,Terminated,Has Results,Type 2 Diabetes|Coronary Artery Disease,Drug: Icosapent ethyl,Brigham and Women's Hospital,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02422446/Prot_SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02422446/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT02422446
798,NCT03698786,Exercise Effects on Appetite-regulating Hormones and Cardiovascular Risk Factors,Completed,No Results Available,"Risk Factor, Cardiovascular|Physical Activity|Pre-diabetes",Behavioral: Exercise,Kingston University,18 Years to 50 Years   (Adult),,Other,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,"Applied & Human Sciences Human Performance Lab, Kingston Upon Thames, Surrey, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03698786/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03698786/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03698786
799,NCT02821104,Complement and Cardiovascular Risk in Adolescents,Completed,Has Results,Cardiovascular Disease|Type 2 Diabetes,,Ohio State University|American Heart Association,"12 Years to 18 Years   (Child, Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02821104/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02821104/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02821104
800,NCT02566317,Stand & Move at Work,Completed,Has Results,Obesity|Hypertension|Diabetes,Device: Sit-Stand workstation|Behavioral: Move,Arizona State University|University of Minnesota,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Arizona State University, Tempe, Arizona, United States|University of Minnesota, Minneapolis, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02566317/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02566317
801,NCT03618628,Peak Plantar Pressures While Wearing a Carbon Fiber Off Loading Orthoses,Completed,Has Results,Diabetes Mellitus|Peripheral Neuropathy|Orthotic Device,Device: Carbon Fiber Off Loading Orthosis (CFO),Washington University School of Medicine,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Washington University, Saint Louis, Missouri, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03618628/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03618628
802,NCT04831606,Blue Light Photobiomodulation Therapy on Neuroischemic Patients,Recruiting,No Results Available,Diabetic Foot Ulcer,Procedure: debridement|Device: Offloading|Device: Advanced dressing|Device: Blue Light Photobiomodulation,Emoled|Ospedale San Donato|University of Pisa,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","San Donato Hospital, Arezzo, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT04831606/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04831606
803,NCT03561987,Biomarkers Derived From Adipose Tissue Useful for Diagnosis and Prognosis of Cardiovascular Risk (CVR) in Obese Patient,Unknown status,No Results Available,Metabolic Syndrome|Diabetes Mellitus|Inflammatory Response,Procedure: Bariatric surgery,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Mexico,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03561987/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03561987
804,NCT03179137,Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium,Unknown status,No Results Available,Coronary Artery Disease|Diabetes Mellitus|Mitochondrial Metabolism Disorders,Other: Standard therapy,"University of Split, School of Medicine","50 Years to 85 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,"School of Medicine, University of Split, Split, Croatia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03179137/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03179137
805,NCT02215408,MEDication Focused Outpatient Care for Underutilization of Secondary Prevention,Completed,No Results Available,Diabetes|Hyperlipidemia|Hypertension|Cardiovascular Disease,Behavioral: CVRS Intervention,Korey Kennelty|University of Iowa,"55 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Gainesville, Florida, United States|University of South Florida, Tampa, Florida, United States|Idaho State University, Pocatello, Idaho, United States|Midwestern University, Downers Grove, Illinois, United States|Genesis Health System, Davenport, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|Siouxland Medical Education Foundation, Sioux City, Iowa, United States|Northeast Iowa Medical Education Foundation, Waterloo, Iowa, United States|SUNY-University of Buffalo, Buffalo, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|Texas Tech University Health Science Center, Amarillo, Texas, United States|Memorial Hermann Hospital System, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States|Wheaton Franciscan Medical Group, Milwaukee, Wisconsin, United States|Milwaukee Health Services,Inc., Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02215408/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02215408
806,NCT02457897,Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations,Completed,Has Results,Insulin Resistance|Diabetes Mellitus|Abnormal Glucose Metabolism,Drug: Liothyronine,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),"12 Years to 65 Years   (Child, Adult, Older Adult)",Phase 2,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02457897/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02457897
807,NCT00736632,"Vitamin D, Insulin Resistance, and Cardiovascular Disease",Completed,Has Results,Vitamin D Deficiency|Insulin Resistance|Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension,Drug: Vitamin D3|Drug: Placebo,"Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)|American Diabetes Association","25 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington Universiy, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT00736632/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT00736632
808,NCT02017171,A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes,Completed,Has Results,Diabetic Nephropathies|Coronary Artery Disease,Drug: Allopurinol|Drug: Placebo,"Alessandro Doria|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation|Joslin Diabetes Center|University of Minnesota|University of Colorado, Denver|University of Michigan|University of Toronto|Feinberg School of Medicine, Northwestern University|Albert Einstein College of Medicine|Steno Diabetes Center Copenhagen|Washington University School of Medicine|University of Washington|Emory University|University of Calgary|University of Alberta|University of Texas Southwestern Medical Center|BCDiabetes.Ca","18 Years to 70 Years   (Adult, Older Adult)",Phase 3,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Barbara Davis Center / University of Colorado Denver, Aurora, Colorado, United States|Kaiser Permanente Colorado Institute of Health Research, Denver, Colorado, United States|Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|Brehm Center for Diabetes Research / University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Winthrop-University Hospital, Mineola, New York, United States|ICAHN School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Texas Southwestern, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Gunderson Health System, La Crosse, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|BC Diabetes, Vancouver, British Columbia, Canada|LMC Diabetes and Endocrinology, Toronto, Ontario, Canada|Mount Sinai Hospital / University of Toronto, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Steno Diabetes Center, Gentofte, Denmark","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02017171/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02017171/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02017171
809,NCT04766008,Metformin in Diabetic Patients Undergoing Coronary Angiography,Recruiting,No Results Available,Diabetes Mellitus|Coronary Artery Disease|Lactic Acidosis With Diabetes Mellitus|Contrast-induced Nephropathy|Metformin Associated Lactic Acidosis,Drug: Metformin,"Humanitas Hospital, Italy","18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Humanitas Research Hospital, Rozzano, Milan, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04766008/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04766008/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04766008
810,NCT03511521,Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia,Terminated,Has Results,"Hyperglycemia Steroid-induced|Insulin Resistance, Diabetes",Drug: NPH Insulin|Drug: glargine|Drug: Insulin Aspart,Northwestern University,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03511521/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03511521/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03511521
811,NCT02786134,Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR),Completed,Has Results,Coronary Heart Disease|Metabolic Syndrome|Diabetes Mellitus,Radiation: PET scan|Radiation: Echocardiogram,Brigham and Women's Hospital|Ottawa Heart Institute Research Corporation|University of Alabama at Birmingham,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02786134/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02786134
812,NCT03538015,Carvedilol in Treating Hypoglycemia Unawareness,Terminated,Has Results,Hypoglycemia Unawareness,Drug: Carvedilol 3.125 mg|Drug: Carvedilol 2.5 mg|Drug: Placebo capsule,"Owen Chan, PhD|University of Utah","18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03538015/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03538015/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03538015
813,NCT03879642,Reducing Hypoglycemia Fear in Parents of Young Children With Type 1 Diabetes,Completed,Has Results,Parents,Behavioral: REDCHiP,University of Kansas Medical Center|Children's Mercy Hospital Kansas City,1 Year to 6 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,United States,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03879642/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03879642
814,NCT03118739,Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria,Completed,Has Results,Hyperuricemia|Albuminuria|Type 2 Diabetes,Drug: Verinurad 9 mg+Febuxostat 80 mg|Drug: Placebo,AstraZeneca,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Canyon Country, California, United States|Research Site, Chula Vista, California, United States|Research Site, Corona, California, United States|Research Site, Escondido, California, United States|Research Site, Lakewood, California, United States|Research Site, Lincoln, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, North Hollywood, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Sacramento, California, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Pearland, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Webster, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT03118739/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03118739
815,NCT01552408,Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE),Completed,Has Results,Diabetic Macular Edema,Drug: 0.3 mg ranibizumab|Procedure: Targeted Pan Retinal Photocoagulation,"David M. Brown, M.D.|Genentech, Inc.|Greater Houston Retina Research","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retina Consultants of Houston, Houston, Texas, United States|Retina Consultants of Houston, Katy, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT01552408/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01552408
816,NCT01779375,RISE Pediatric Medication Study,Completed,Has Results,Prediabetes|Type 2 Diabetes,Drug: Metformin|Drug: Glargine,RISE Study Group|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"10 Years to 19 Years   (Child, Adult)",Phase 3,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Colorado, Denver, Colorado, United States|Yale School of Medicine Pediatric Obesity and Type 2 Diabetes Clinic, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01779375/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01779375/ICF_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01779375/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT01779375
817,NCT01794143,A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes,Completed,No Results Available,Type 2 Diabetes|Comparative Effectiveness of Glycemia-lowering Medications,Drug: Sulfonylurea (glimepiride)|Drug: DPP-4 inhibitor (sitagliptin)|Drug: GLP-1 receptor agonist (liraglutide)|Drug: Insulin (glargine),"GRADE Study Group|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Heart, Lung, and Blood Institute (NHLBI)|Becton, Dickinson and Company|Bristol-Myers Squibb|Merck Sharp & Dohme LLC|Novo Nordisk A/S|Roche Diagnostics|Sanofi|Centers for Disease Control and Prevention","30 Years and older   (Adult, Older Adult)",Phase 3,Other|NIH|Industry|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama-Birmingham, Birmingham, Alabama, United States|Southwestern American Indian Center, Phoenix, Arizona, United States|Veterans Medical Research Foundation, San Diego (San Diego VA), San Diego, California, United States|University of Colorado, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|South Florida VA Foundation (Miami VA), Miami, Florida, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Kaiser Permanente of Georgia, Duluth, Georgia, United States|Pacific Health Research and Education Institute (VA Pacific Islands), Honolulu, Hawaii, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|MedStar Health Research Institute, Hyattsville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|International Diabetes Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Albert Einstein College of Medicine, Bronx, New York, United States|State University of New York (SUNY)-Downstate Medical Center, Brooklyn, New York, United States|Columbia University Naomi Berrie Diabetes Center, New York, New York, United States|Mount Sinai St. Luke's Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of North Carolina Diabetes Care Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University School of Medicine, Cleveland, Ohio, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Endocrine Center, Dallas, Texas, United States|University of Texas-Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Seattle Institute for Biomedical and Clinical Research, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01794143/Prot_002.pdf|""Statistical Analysis Plan: GRADE Study"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01794143/SAP_001.pdf|""Statistical Analysis Plan: Manuscript - Long Term Differences in Metabolic Status (OP1)"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01794143/SAP_004.pdf|""Statistical Analysis Plan: Manuscript - Microvascular and Cardiovascular Outcomes (OP2)"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01794143/SAP_005.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01794143/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT01794143
818,NCT03490747,Evaluation of a Physical Activity Referral Scheme,Completed,No Results Available,"Cardiovascular Risk Factor|Diabetes Mellitus, Type 2|Anxiety|Depression|Musculoskeletal Injury|Cardiovascular Diseases|Cancer|Obesity|Metabolic Syndrome|Physical Activity",Behavioral: Physical activity referral scheme|Behavioral: Usual care exercise referral scheme,Paula Watson|University of Bath|University of Gloucestershire|University of Liverpool|Brock University|Radboud University Medical Center|Liverpool John Moores University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Liverpool John Moores University, Liverpool, Merseyside, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03490747/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03490747
819,NCT03480022,"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",Completed,Has Results,Pre Diabetes|Polycystic Ovary Syndrome|Obesity Android,Drug: Liraglutide Pen Injector [Saxenda]|Drug: Placebo Liraglutide Pen Injector,Woman's|Novo Nordisk A/S,18 Years to 45 Years   (Adult),Phase 3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Woman's Hospital, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03480022/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03480022/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03480022
820,NCT01052714,Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2,Completed,Has Results,Diabetes|Obesity|Weight Gain,Behavioral: Lifestyle Balance,VA Office of Research and Development,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, Sepulveda, CA, Sepulveda, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01052714/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT01052714/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01052714
821,NCT01594333,Cardiovascular Inflammation Reduction Trial,Completed,Has Results,Cardiovascular Disease,Drug: Methotrexate|Drug: Placebo,"Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","18 Years and older   (Adult, Older Adult)",Phase 3,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|Appalachian Research Associates, Fort Payne, Alabama, United States|Avant Research Associates, LLC, Guntersville, Alabama, United States|Saadat Ansari MD LLC, Huntsville, Alabama, United States|University of South Alabama: Division of Clinical Research, Mobile, Alabama, United States|Heart Vascular of Northern Arizona, Cottonwood, Arizona, United States|CardioVascular Associates of Mesa, Mesa, Arizona, United States|Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States|Scottsdale Medical Imaging, Scottsdale, Arizona, United States|The Heart Clinic, Scottsdale, Arizona, United States|Pima Heart, Tucson, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|Arkansas Cardiology, Little Rock, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|Oracle Clinical Research, Inc., Anaheim, California, United States|Medical Group of Culver City, Culver City, California, United States|Touro University California- Solano County Affiliated Clinics, Fairfield, California, United States|University Of California San Francisco, Fresno, California, United States|VACCHCS, Fresno, California, United States|UCSD Sulpizio Cardiovascular Center, La Jolla, California, United States|University Of California San Diego, La Jolla, California, United States|Desert Medical Care & Wellness, La Quinta, California, United States|Kumar Medical Corporation, Lancaster, California, United States|Loma Linda University Health, Loma Linda, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Cardiovascular Innovation and Research, Long Beach, California, United States|Los Alamitos Cardiovascular, Los Alamitos, California, United States|Faye Montegrande Md. Clinical Research, Los Angeles, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|Salman Khan A. Medical Corporation, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|West LA VA Medical Center, Los Angeles, California, United States|VA Northern California Health Care, Mather, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Orange County Heart Institute & Research, Orange, California, United States|University of CA Irvine Medical Center, Orange, California, United States|Diverse Research Solutions, Oxnard, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Central Coast Cardiology, Salinas, California, United States|Richard G. Friedman, MD, San Diego, California, United States|Ritchken and First MDs, San Diego, California, United States|Foundation for Cardiovascular Medicine, San Diego, California, United States|San Diego Cardiac Center, San Diego, California, United States|Veterans Affairs San Diego Healthcare System, San Diego, California, United States|UCSF at Zuckerberg SF General Hospital, San Francisco, California, United States|Coastal Heart Medical Group, Inc., Santa Ana, California, United States|Comprehensive Cardiovascular Care, Santa Maria, California, United States|Pacific Heart and Vascular Medical Group, Stockton, California, United States|Manoj D. Aswani M.D., Thousand Oaks, California, United States|Touro University California- Solano Public Health Affiliated Clinics, Vallejo, California, United States|Munni R. Selagamsetty, Md, Pc, Colorado Springs, Colorado, United States|Vijay - Aurora Denver Cardiology, Denver, Colorado, United States|Colorado Health Medical Group Heart Center of the Rockies, Fort Collins, Colorado, United States|Medical Center of the Rockies Research, Fort Collins, Colorado, United States|Unrein - Rocky Vista University Health Center, Parker, Colorado, United States|Connecticut Heart and Vascular Center, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Cardiology Physicians/Red Clay Research, Newark, Delaware, United States|Boisey Barnes MD, PC, Washington, District of Columbia, United States|GWU Medical Faculty Associatin, Inc., Washington, District of Columbia, United States|Pianko - Aventura Research Center, LLC, Aventura, Florida, United States|North Ridge Heart Associates, Boca Raton, Florida, United States|St. Francis Medical Institute, Clearwater, Florida, United States|Gonzalez MD & Aswad MD Health Ser, Coral Gables, Florida, United States|American Research Institute, Inc., Cutler Bay, Florida, United States|Daytona Heart Group, Daytona Beach, Florida, United States|Daytona Heart Group, DeLand, Florida, United States|Seidman Clinical Trials, Delray Beach, Florida, United States|Steven Cohen MD, Delray Beach, Florida, United States|Infinite Clinical Research, Doral, Florida, United States|International Research Partners, LLC, Doral, Florida, United States|Medical Research Institute at Doral, Inc., Doral, Florida, United States|Lake Internal Medicine Assocaties, Eustis, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|Primary Care Associates, Fort Myers, Florida, United States|Lee Physician Group, Fort Myers, Florida, United States|The Cardiac and Vascular Institute, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Qway Research, Hialeah, Florida, United States|State of the Art Research, Hialeah, Florida, United States|Healing Touch C&C Research, Hialeah, Florida, United States|Luzmed Clinical Research Institute, Hialeah, Florida, United States|Viviana Perez MD Research & Cosmetics, Hialeah, Florida, United States|Elite Cardiac Research Center LLC, Hialeah, Florida, United States|Nova Clinical Research Clinic, Hialeah, Florida, United States|Best Quality Research, Inc., Hialeah, Florida, United States|South Florida Research Solutions, LLC, Hollywood, Florida, United States|John Gutleber Medical Research Office, Homestead, Florida, United States|Cardiovascular Medical Associates of Palm Beach, Jupiter, Florida, United States|Hope Clinical Research, Kissimmee, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Lakes Research, LLC, Miami Lakes, Florida, United States|Veritas Research Corp., Miami Lakes, Florida, United States|Ocean Blue Medical Research Center, Miami Springs, Florida, United States|Medical Research Center of Florida, Miami, Florida, United States|LG Diagnostics, Inc., Miami, Florida, United States|St. Paul Medical Research Center, Inc., Miami, Florida, United States|Team Medical Research, Miami, Florida, United States|Paradise Clinical Research, LLC, Miami, Florida, United States|GAD Research Center, Miami, Florida, United States|Innovation Research Institute, Inc., Miami, Florida, United States|Sanitas Research, Miami, Florida, United States|Segui - Med Care Research, Miami, Florida, United States|South Florida Research Group, LLC, Miami, Florida, United States|Vista Health Research, LLC, Miami, Florida, United States|D De La Vega MD Research Group, Miami, Florida, United States|Southwest Florida Research, LLC, Naples, Florida, United States|Orlando Healthy Heart Institute, Orlando, Florida, United States|Palm Beach Gardens Research Center, LLC, Palm Beach Gardens, Florida, United States|Broward Research Center, Pembroke Pines, Florida, United States|Pioneer Clinical Research, Pembroke Pines, Florida, United States|Sandoval - Broward Research Center, Pembroke Pines, Florida, United States|Bay Area Heart Center: 49th Street, Saint Petersburg, Florida, United States|Bay Area Heart Center: 7th Avenue, Saint Petersburg, Florida, United States|Lenus Research & Medical Group, Sweetwater, Florida, United States|DBC Research, Tamarac, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Gupta - Premier Heart and Vascular Center, Wesley Chapel, Florida, United States|Athens Regional Medical Center, Athens, Georgia, United States|Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States|Laureate Medical Group at Northside, Atlanta, Georgia, United States|Synergy Therapeutic Partners, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Atlanta Heart Specialists, LLC, Cumming, Georgia, United States|Heart and Rhythm Specialists, Dalton, Georgia, United States|Albert F. Johary MD, PC, Dunwoody, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Atlanta Vanguard Medical Associates, Smyrna, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States|Cardiology Associates of Vidalia, P.C., Vidalia, Georgia, United States|VA Pacific Islands Health Care System, Honolulu, Hawaii, United States|St. Luke's Idaho Cardiology Associates, Boise, Idaho, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Northwest Heart Clinical Research, Arlington Heights, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Advocate Med Group-Heart & Vascular Of Illinois, Chicago, Illinois, United States|Illinois Heart & Lung Research Center, SC, Normal, Illinois, United States|Captain James A. Lovell Federal Health, North Chicago, Illinois, United States|Specialty Physicians of Illinois, LLC, Olympia Fields, Illinois, United States|Advanced CardioVascular Consultants, Rock Island, Illinois, United States|Cardiospecialists, LTD, Dyer, Indiana, United States|Martin - Martin Family Practice and Research, Evansville, Indiana, United States|Krannert Institute Of Cardiology, Indianapolis, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Indiana Heart Physicians, Indianapolis, Indiana, United States|Medical Consultants, PC, Muncie, Indiana, United States|Iowa Heart Center, West Des Moines, Iowa, United States|Stahl - Midwest Heart & Vascular Specialists, Overland Park, Kansas, United States|Professional Research Network of KS, Wichita, Kansas, United States|Robert J. Dole VAMC, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Robley Rex VAMC, Louisville, Kentucky, United States|Stoddard - University of Louisville, Louisville, Kentucky, United States|Bays - L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Dorothy H. Banish, MD, APMC Study Group, Covington, Louisiana, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|North Oaks Cardiology, Hammond, Louisiana, United States|American Clinical Research, LLC, Marrero, Louisiana, United States|Otis Barnum D.O.P.C., Natchitoches, Louisiana, United States|Tulane University Office of Health Research, New Orleans, Louisiana, United States|Veterans Affairs Medical Center Shreveport, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Paul A. Shapero, M.D., Bangor, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|InterMed, PA, Portland, Maine, United States|Maine Medical Partners Maine Health Cardiology, South Portland, Maine, United States|Maine Centers for Healthcare, Westbrook, Maine, United States|Sinai Center for Thrombosis Research, Baltimore, Maryland, United States|St. Mary's Medical Center, Charlotte Hall, Maryland, United States|Calvert Memorial Hospital, Clinton, Maryland, United States|Shah Associates, MD, LLC, Prince Frederick, Maryland, United States|Peninsula Cardiology Associates, Salisbury, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|MGH Cardiology, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Massachusetts General Hospital - Chelsea Health Care Center, Chelsea, Massachusetts, United States|Pentucket Medical Associates, Inc., Haverhill, Massachusetts, United States|VA Central Western Massachusetts Healthca, Leeds, Massachusetts, United States|South Shore Internal Medicine, Milton, Massachusetts, United States|Lahey Medical Center, Peabody, Massachusetts, United States|North Shore Cardiovascular Associates, Salem, Massachusetts, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Endeavor Medical Research, Alpena, Michigan, United States|John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States|Trace Research Group at Wayne State University, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Flint Clinical Research, Flint, Michigan, United States|Apex Medical Research MI, Inc., Flint, Michigan, United States|Garden City Hospital, Garden City, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|National Clinical LLC, Hamtramck, Michigan, United States|Academic Cardiology Associates PC, Rochester Hills, Michigan, United States|Beaumont Health Center, Royal Oak, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Mid-Michigan Heart & Vascular Center, Saginaw, Michigan, United States|Centra Care Heart & Vascular Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|United Heart and Vascular Clinic, Saint Paul, Minnesota, United States|Gulfside Clinical Research, LLC, Gulfport, Mississippi, United States|University of MS Medical Center, Jackson, Mississippi, United States|David M. Headley M.D. PA Planters Clinic, Port Gibson, Mississippi, United States|Stern Cardiovascular Foundation, Inc., Southaven, Mississippi, United States|Center for Advanced Medicine and Research LLC, Bridgeton, Missouri, United States|Clinical Research Center University of Missouri, Columbia, Missouri, United States|Quantum Research LLC, Festus, Missouri, United States|Midwest Cardiology Associates, Independence, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|VA Medical Center Kansas City, Kansas City, Missouri, United States|Lake Regional Cardiovascular Institute, Osage Beach, Missouri, United States|VA St. Louis Health Care System (VASTLHCS), Saint Louis, Missouri, United States|SLUCare Cardiology, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Clinical Investigators LLC, Saint Louis, Missouri, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Center for Advanced Medicine and Research, Saint Peters, Missouri, United States|CoxHealth: Wheeler Heart & Vascular Center, Springfield, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Great Falls Clinic Clinical Research Deptartment, Great Falls, Montana, United States|Cone - Montana Medical Research, Missoula, Montana, United States|Barrett Clinic, P.C., La Vista, Nebraska, United States|Heart Consultants, Omaha, Nebraska, United States|Alegent Creighton Health, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Internal Medicine Clinic, Las Vegas, Nevada, United States|Red Rock Clinical Research, LLC, Las Vegas, Nevada, United States|Sierra Nevada Health Care System, Reno, Nevada, United States|Renown Inst for Heart & Vasc Health, Reno, Nevada, United States|Lahey Cardiology, Nashua, New Hampshire, United States|Family Health at Mount Olive, Flanders, New Jersey, United States|Cardiocare, Hillsborough, New Jersey, United States|New Jersey Heart, Linden, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Cardiovascular Institute, New Brunswick, New Jersey, United States|Palisade Medical Center, North Bergen, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Mercer Bucks Cardiology, Robbinsville, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|Holy Name Medical Center, Inc., Teaneck, New Jersey, United States|Total Cardiology Care, LLC, Wayne, New Jersey, United States|Westwood Cardiology Associates, Westwood, New Jersey, United States|Presbyterian Heart Group, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Albany Stratton VA Medical Center, Albany, New York, United States|Novel Research of New York, LLC, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Brown - SUNY Downstate Medical Center, Brooklyn, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Bassett Healthcare Network, Cooperstown, New York, United States|NYU Hudson Valley Cardiology, Cortlandt Manor, New York, United States|NYHQ, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Long Island Heart Associates, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Queens Long Island Medical Group, New Hyde Park, New York, United States|Chinatown Cardiology, PC, New York, New York, United States|Weill Cornell Medical College and NY Presbyterian, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|DiGiovanna Institute for Medical Education and Research, North Massapequa, New York, United States|Champlain Valley Physician Hospital, Plattsburgh, New York, United States|Cardiology Associates of Schenectady, Schenectady, New York, United States|Clinical Study Center of Asheville, Asheville, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Gaffney Health Services, Charlotte, North Carolina, United States|Carolinas Research Center, Charlotte, North Carolina, United States|Eastern Carolina Cardiovascular, PA, Elizabeth City, North Carolina, United States|Eastern Cardiology, Greenville, North Carolina, United States|Northside Clinical Research, Lenoir, North Carolina, United States|Lake Shore Clinical Research, LLC., Mooresville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Cardiology Associates of Carolinas, PA, Morganton, North Carolina, United States|Eastern Nephrology Associates, PLLC, New Bern, North Carolina, United States|Boice Willis Clinic, Rocky Mount, North Carolina, United States|Sanford Cardiology, Sanford, North Carolina, United States|Natalie A. Doyle, MD, PA, Wilson, North Carolina, United States|Altru Health System Rehab Center, Grand Forks, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio, United States|Diabetes and Endocrinology Associates of Stark Cit, Canton, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Optimed Research, LTD, Columbus, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|Dayton Veteran Affairs Medical Center, Dayton, Ohio, United States|Colonnade Medical Group, Lancaster, Ohio, United States|Middletown Cardiovascular Associates, Middletown, Ohio, United States|Comprehensive Heart Care, Inc., Toledo, Ohio, United States|Mount Carmel Clinical Cardiovascular Care, Westerville, Ohio, United States|Premier Physicians, Westlake, Ohio, United States|Wooster Heart Group, Wooster, Ohio, United States|Unity Clinical Research, Lindsay, Oklahoma, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Thadani - VA Medical Center Oklahoma City, OK, Oklahoma City, Oklahoma, United States|Today Clinical Research, Oklahoma City, Oklahoma, United States|Cardiovascular Health Clinic, Oklahoma City, Oklahoma, United States|Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States|Samaritan Health Services, Corvallis, Oregon, United States|Southern Oregon Cardiology, LLC, Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Center for Clinical Res. Abington Health, Abington, Pennsylvania, United States|St. Luke's University Hospital, Bethlehem, Pennsylvania, United States|Renu-Ca Research Institute, Lower Bucks Hospital, Bristol, Pennsylvania, United States|Main Line Health Center, Broomall, Broomall, Pennsylvania, United States|Spirit Physician Services, Inc, Camp Hill, Pennsylvania, United States|The Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Central Bucks Cardiology, Doylestown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Heart Specialists of Lancaster County, Ephrata, Pennsylvania, United States|Saint Vincent Consultants in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Feasterville Family Healthcare Center, Feasterville, Pennsylvania, United States|Christiana Care Health System, Glen Mills, Pennsylvania, United States|Pinnacle Health Cardiovascular Institute, Harrisburg, Pennsylvania, United States|George Isajiw, MD, Lansdowne, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lehigh Valley Health Services, Sellersville, Pennsylvania, United States|Pish Medical Associates, Inc., Uniontown, Pennsylvania, United States|Lehigh Valley Family Practice, Whitehall, Pennsylvania, United States|Wilkes-Barre VA Medical Center, Wilkes-Barre, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Prtnr, Lincoln, Rhode Island, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ocean State Research Institute, Inc, Providence, Rhode Island, United States|South Carolina Heart Center, Columbia, South Carolina, United States|Amistad Research Center, LLC, Columbia, South Carolina, United States|Charlotte Hearts, Indian Land, South Carolina, United States|Miller - SC Internal Medicine Associates.: Irmo, Irmo, South Carolina, United States|Inlet Cardiopulmonary & Associates, Pawleys Island, South Carolina, United States|Fusion Clinical Research of Spartanburg, Spartanburg, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|New Phase Research & Development, Chattanooga, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|Kore Cardiovascular Research Institutue, Jackson, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|Ramanathan - VAMC Memphis, Memphis, Tennessee, United States|Clinical Research Center Meharry Medical College, Nashville, Tennessee, United States|Avant Research Associates LLC, Austin, Texas, United States|Texas Heart and Vascular Research, LLC, Austin, Texas, United States|Southeast TX Clinical Research Center, Beaumont, Texas, United States|Cornerstone Family Medicine, Big Spring, Texas, United States|IMD Medical Center, Carrollton, Texas, United States|Texas Health Physicians Group, Carrollton, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|North Texas Health Center, Dallas, Texas, United States|The Heart Center of Dallas, Dallas, Texas, United States|Global Medical Research, DeSoto, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T&R Clinic, P.A., Haltom City, Texas, United States|Michele P. Sartori, MD, Houston, Texas, United States|Grand Medical Care, Katy, Texas, United States|Team Research Of Central Texas, Killeen, Texas, United States|Houston Heart and Vascular Associates, Kingwood, Texas, United States|Grace Research, LLC, Marshall, Texas, United States|Valley Heart Consultants, McAllen, Texas, United States|Heart Center, Palo Pinto General Hospital, Mineral Wells, Texas, United States|Valley Central Research Inc, Mission, Texas, United States|North Hills Medical Research, Inc, North Richland Hills, Texas, United States|Grace Research, LLC, Palestine, Texas, United States|Avant Research Associates, LLC, Port Arthur, Texas, United States|Santoscoy - Health Texas Research Institute, San Antonio, Texas, United States|Element Research Group, San Antonio, Texas, United States|Schnitzler Cardiovascular Consultants, San Antonio, Texas, United States|San Antonio Endovascular & Heart Institute, San Antonio, Texas, United States|Acacia Medical Research Institute, Sugar Land, Texas, United States|Health Plus Clinical Research, Sugar Land, Texas, United States|Lone Star Heart and Vascular Center, Tomball, Texas, United States|Northwest Houston Clinical Research, Tomball, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Utah Cardiology, P.C., Layton, Utah, United States|Utah Diabetes Center, Salt Lake City, Utah, United States|VA Medical Center, White River Junction, White River Junction, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice Research, Hampton, Virginia, United States|Tidewater Physicians Multispecialty Group, Hampton, Virginia, United States|Virginia Cardiovascular Associates, Manassas, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Tucker Cardiology Associates, P.C., Mechanicsville, Virginia, United States|TPMG Clinical Research, Newport News, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Roanoke Heart Institute PLC, Roanoke, Virginia, United States|Cardinal Internal Medicine Associates, Woodbridge, Virginia, United States|Tidewater Physicians Multispecialty Group, Yorktown, Virginia, United States|Frandsen Family Medicine DBA Sound Medi, Port Orchard, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Northwest Medical Associates, P.S., Vancouver, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Dean Foundation, Madison, Wisconsin, United States|University Of Wisconsin, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Columbia St. Mary's, Milwaukee, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Medical Arts Health Research Group, North Vancouver, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Bramalea Medical Centre, Brampton, Ontario, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Philippe R Beaudry Medicine Professional Corporation, Burlington, Ontario, Canada|Vizel Cardiac Research, Cambridge, Ontario, Canada|Dr. Linda Sinnaeve's Office, Chatham, Ontario, Canada|Scisco Clinical Research, Cornwall, Ontario, Canada|Dr. Peter Spadafora Health Center, Guelph, Ontario, Canada|John Stimac, MD, Hamilton, Ontario, Canada|KMH Cardiology & Diagnostics: Hamilton, Hamilton, Ontario, Canada|Dr. William Liang, Hamilton, Ontario, Canada|Source Unique Clinic, Hawkesbury, Ontario, Canada|Dr. Ronald Fowlis, Kitchener, Ontario, Canada|University Hospital, London, Ontario, Canada|Malton Medical Research, Mississauga, Ontario, Canada|KMH Cardiology & Diagnostics: Mississauga, Mississauga, Ontario, Canada|Sewa Ram Singal Medicine Professional Corporation, Mississauga, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|Portage Medical Centre, Niagara Falls, Ontario, Canada|Humber River Regional Hospital, North York, Ontario, Canada|Bakbak Medicine Professional Corporation, Oshawa, Ontario, Canada|Dr. James Y. Cha, Oshawa, Ontario, Canada|University Of Ottawa Heart Institute, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Steeple Hill Medical Centre, Pickering, Ontario, Canada|Sarnia Institute Of Clinical Research, Sarnia, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Scarborough General Hospital Cardiology Research Associates, Scarborough, Ontario, Canada|Milliken Medical Centre, Scarborough, Ontario, Canada|Canadian Centre for Research on Diabetes, Smith Falls, Ontario, Canada|Lake Shore Cardiology, St. Catharines, Ontario, Canada|Sardar Medical Clinic, St. Thomas, Ontario, Canada|G.S. Cardiac Lab Medicine Professional Corp, Sudbury, Ontario, Canada|Dr. R. Labonte Professional Med Corp, Sudbury, Ontario, Canada|Dr. G. Garrioch, Independent Practice, Sudbury, Ontario, Canada|Dr. Laurence Gibbs Medicine Professional Corp., Thedford, Ontario, Canada|Tillsonburg Medical Centre, Tillsonburg, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Weston Road Medical Clinic, Toronto, Ontario, Canada|Dr. Nigel Jagan Medicine Professional Corporation, Whitby, Ontario, Canada|Dr. Nwadiaro Medicine Professional Corp, Windsor, Ontario, Canada|Viacar Recherche Clinique Inc., Brossard, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Q&T Research Chicoutimi, Chicoutimi, Quebec, Canada|Viacar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|CHUM Hotel-Dieu, Montreal, Quebec, Canada|Iucpq, Quebec City, Quebec, Canada|ALPHA Recherche Clinique, Québec, Quebec, Canada|CardioVasc HR, Saint-Jean-sur-Richelieu, Quebec, Canada|ViaCar Recherche Clinique Inc, Saint-Lambert, Quebec, Canada|Viacar Recherche Clinique, St. Lambert, Quebec, Canada|Hopital Pierre-Le Gardeur, Terrebonne, Quebec, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Instituto Sanacoop, Bayamón, Puerto Rico|San Juan Bautista School of Medicine, Caguas, Puerto Rico|Norma S. Severino-Pacheco, MD, Canovanas, Puerto Rico|Cardiometabolic Research Center, Ponce, Puerto Rico|Miguel Sosa-Padilla, MD, San Juan, Puerto Rico|Yolanda Sierra Quinones, MD, Toa Baja, Puerto Rico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01594333/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01594333
822,NCT03878277,Evaluation of Coffee Therapy for Improvement of Renal Oxygenation,Completed,Has Results,"Type1diabetes|Type1 Diabetes Mellitus|Diabetic Kidney Disease|Juvenile Diabetes|Diabetic Nephropathies|Diabetes Complications|Diabetes, Autoimmune",Drug: Starbucks® Cold brew - 325ml bottle,"University of Colorado, Denver|Johns Hopkins University","12 Years to 21 Years   (Child, Adult)",Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03878277/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03878277
823,NCT03804879,"Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy",Completed,Has Results,Diabetic Nephropathy,Drug: Nidufexor|Other: Placebo|Drug: Standard of Care (SoC),Novartis Pharmaceuticals|Novartis,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Miami Lakes, Florida, United States|Novartis Investigative Site, Albany, New York, United States|Novartis Investigative Site, Norman, Oklahoma, United States|Novartis Investigative Site, El Paso, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Essen, Nordrhine Westphalia, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03804879/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03804879/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03804879
824,NCT03092960,The HOMBRE Trial: Comparing Two Innovative Approaches to Reduce Chronic Disease Risk Among Latino Men,Completed,Has Results,Obesity|Metabolic Syndrome|Lifestyle Intervention|Pre Diabetes,Behavioral: Minimal intensity intervention|Behavioral: HOMBRE,Palo Alto Medical Foundation|Patient-Centered Outcomes Research Institute|University of Illinois at Chicago|RTI International|University of Pittsburgh|Arizona State University|Stanford University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Palo Alto Medical Foundation, Palo Alto, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT03092960/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03092960
825,NCT03771066,Bisphenol A and Muscle Insulin Sensitivity,Recruiting,No Results Available,Insulin Sensitivity|Glucose Metabolism Disorders|Microtia,Behavioral: bisphenol A|Behavioral: Placebo,California Polytechnic State University-San Luis Obispo|American Diabetes Association,18 Years to 50 Years   (Adult),Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","California Polytechnic State University, San Luis Obispo, California, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03771066/Prot_SAP_ICF_003.pdf",https://ClinicalTrials.gov/show/NCT03771066
826,NCT02068885,Framingham State Food Study,Completed,Has Results,Obesity|Diabetes|Cardiovascular Disease,Behavioral: Feeding study,Boston Children's Hospital|Framingham State University|Baylor College of Medicine|Nutrition Science Initiative|New Balance Foundation|Many Voices Foundation|Blue Cross Blue Shield,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Framingham State University, Framingham, Massachusetts, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02068885/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02068885/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02068885
827,NCT02023411,Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot,Completed,Has Results,Diabetic Neuropathic Arthropathy,Drug: Teriparatide|Other: Placebo,Postgraduate Institute of Medical Education and Research,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Deptt of Endocrinology, Chandigarh, India|PGIMER, Chandigarh, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02023411/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02023411
828,NCT01590433,Weight Loss With Exenatide Treatment,Completed,Has Results,Obesity,Drug: Exenatide|Drug: Placebo|Behavioral: Dietary counseling,Jody Dushay|AstraZeneca|Beth Israel Deaconess Medical Center,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01590433/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT01590433
829,NCT02597127,Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C),Completed,Has Results,Atherosclerotic Cardiovascular Disease|Familial Hypercholesterolemia|Diabetes,Drug: ALN-PCSSC|Drug: Normal Saline,The Medicines Company,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Midwest Institute For Clinical Research, Indianapolis, Indiana, United States|Mount Sinai Icahn School of Medicine, New York, New York, United States|Metabolic And Atherosclerosis Research Center, Cincinnati, Ohio, United States|Sterling Research Group, Cincinnati, Ohio, United States|Wellmont CVA Heart Institute, Greeneville, Tennessee, United States|Amarillo Heart Clinical Research Institute, Inc., Amarillo, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|St. Paul's Hospital, Vancouver, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Eastern Regional Health Authority, Patient Research Centre, St. Johns, Newfoundland and Labrador, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|ECOGENE-21 Clinical Trials Center, Chicoutimi, Quebec, Canada|Clinic Sante Cardio MC, Montreal, Quebec, Canada|Institut de Recherches Cliniques de Montreal, Montreal, Quebec, Canada|Université Laval Quebec, Quebec City, Quebec, Canada|Clinique des maladies lipidique Quebec, Quebec City, Quebec, Canada|Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada|Medical University Berlin, Berlin, Germany|Medical Center Essen, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|University Heart Center Hamburg, Hamburg, Germany|Medical University Hospital Heidelberg, Internal medicine III, Heidelberg, Germany|Technical University Munich, German Heart Center, Munich, Germany|Amsterdam Medical Center, Amsterdam, Netherlands|Haga Hospital, Den Haag, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Andromed Eindhoven, Eindhoven, Netherlands|Admiraal de Ruyter Hospital, Cardiology, Goes, Netherlands|Bethesda Diabetes Research Center, Hoogeveen, Netherlands|Medisch Centrum Gorecht, Hoogezand, Netherlands|VOC Hoorn, Hoorn, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Andromed Rotterdam, Rotterdam, Netherlands|Diakonessenhuis, Vascular Policlinic, Utrecht, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCurie Venlo, Cardiology, Venlo, Netherlands|Albert Schweitzer Hospital, Cardiology, Zwijndrecht, Netherlands|Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Edinburgh Royal Infirmary, Edinburgh, United Kingdom|The Royal Devon and Exeter NHS Trust, Exeter, United Kingdom|Fowey River Practice, Fowey, United Kingdom|Buckinghamshire NHS Trust, High Wycombe, United Kingdom|Oak Tree Surgery, Liskeard, United Kingdom|Royal Free Hospital, London, United Kingdom|Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom|The Alverton Practice, Penzance, United Kingdom|Knowle House Surgery, Plymouth, United Kingdom|Brannel Surgery, St. Austell, United Kingdom|Rame Medical Ltd (Rame Research), Torpoint, United Kingdom|Worcestershire Acute NHS Trust, Worcester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02597127/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02597127/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02597127
830,NCT03615755,"Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine",Completed,No Results Available,Hyperbaric Oxygen Therapy|Diabetic Foot Ulcer|Type II Diabetes Mellitus,Other: Hyperbaric Oxygen Therapy (HBOT),Hendry Irawan|Udayana University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Denpasar, Indonesia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03615755/Prot_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03615755/SAP_004.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03615755/ICF_005.pdf",https://ClinicalTrials.gov/show/NCT03615755
831,NCT01890226,A Mobile Personal Health Record for Behavioral Health Homes,Completed,Has Results,Hypertension|Hyperlipidemia|Diabetes,Behavioral: Mobile Personal Health Record App.,Emory University|National Institute of Mental Health (NIMH),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Viewpoint Health & Oakhurst Medical Center, Conyers, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT01890226/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT01890226/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01890226
832,NCT03366337,A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX,Completed,Has Results,IgA Nephropathy|CKD Associated With Type 1 Diabetes|Focal Segmental Glomerulosclerosis|Autosomal Dominant Polycystic Kidney,Drug: Bardoxolone methyl capsules,"Reata Pharmaceuticals, Inc.","18 Years to 65 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama Birmingham, Birmingham, Alabama, United States|Phoenician Centers for Research & Innovation (PCRI), Phoenix, Arizona, United States|University of California Los Angeles, Los Angeles, California, United States|Denver Nephrology, Denver, Colorado, United States|Gulfcoast Endocrine and Diabetes Center, Clearwater, Florida, United States|South Florida Research Institute, Lauderdale Lakes, Florida, United States|Coastal Nephrology Associates, Port Charlotte, Florida, United States|Kidney Care Augusta, Augusta, Georgia, United States|Boise Kidney & Hypertension, PLLC, Caldwell, Idaho, United States|Boise Kidney & Hypertension, PLLC, Meridian, Idaho, United States|Research By Design, Evergreen Park, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Tufts Medical Center - Division of Nephrology Tufts Medical Center, Boston, Massachusetts, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|Columbia University Medical Center - Nephrology, New York, New York, United States|Physician's East Endocrine Research, Greenville, North Carolina, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|The Warren Alpert School of Brown University, Providence, Rhode Island, United States|Nephrology Associates, Chattanooga, Tennessee, United States|Research Management, Inc., Austin, Texas, United States|Renal Disease Research Intitute, Dallas, Texas, United States|Renal Associates, PA, San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Mendez Center for Clinical Research LLC, Fairfax Station, Virginia, United States|Larry Stonesifer, M.D., Federal Way, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03366337/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT03366337/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03366337
833,NCT03821675,Electrical Stimulation to Accelerate Wound Healing,Completed,Has Results,Diabetes|Diabetic Foot Ulcer|Peripheral Neuropathy|Peripheral Arterial Disease,Device: Electrical Stimulation - Active|Device: Electrical Stimulation - Sham,"Baylor College of Medicine|Avazzia, Inc","18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Baylor College of Medicine, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03821675/Prot_005.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03821675/SAP_004.pdf",https://ClinicalTrials.gov/show/NCT03821675
834,NCT02360774,Mechanisms of Weight Loss With SGLT2 Inhibition,Completed,Has Results,Type 2 Diabetes|Overweight|Obesity,Drug: Canagliflozin|Drug: Placebo,"Beth Israel Deaconess Medical Center|Janssen Scientific Affairs, LLC","18 Years to 75 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02360774/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02360774/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02360774
835,NCT01775813,The Health Influences of Puberty (HIP) Study,Completed,Has Results,Obesity|Insulin Resistance|Gonadal Dysfunction|Type 2 Diabetes,Drug: Metformin|Drug: Placebo,"University of Colorado, Denver|American Diabetes Association|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Hospital Colorado",9 Years to 17 Years   (Child),Phase 4,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Children's Hospital Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01775813/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01775813
836,NCT02476409,Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders,Completed,Has Results,Congestive Heart Failure,Drug: tolvaptan|Other: Placebo,"University of North Carolina, Chapel Hill|Otsuka America Pharmaceutical","18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02476409/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02476409
837,NCT03889236,Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.,Completed,No Results Available,Diabetic Nephropathy Type 2|Albuminuria|Type2 Diabetes Mellitus|Glucose Metabolism Disorders|Microalbuminuria|Diabetic Nephropathies|Diabetic Complications Renal|Diabetes Mellitus|Kidney Diseases|South Asian,Other: Fasting mimicking diet Prolon|Dietary Supplement: Food supplement Endocalyx|Dietary Supplement: Placebo,Leiden University Medical Center|Dutch Kidney Foundation|Health Holland|Radboud University Medical Center,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Leiden Universitiy Medical Center (LUMC), Leiden, Noord Holland, Netherlands","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03889236/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03889236
838,NCT03369145,"High-fat Overfeeding, Hepatokines and Appetite Regulation",Completed,No Results Available,Insulin Resistance|Type2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity,Dietary Supplement: High-fat diet,Loughborough University|Nottingham Trent University|Nottingham University Hospitals NHS Trust,18 Years to 40 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"National Centre for Sport and Exercise Medicine, Loughborough University, Loughborough, Leicestershire, United Kingdom|Clifton Campus, Nottingham Trent University, Nottingham, Nottinghamshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03369145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03369145/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03369145/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03369145
839,NCT04078516,Methods of Early Detection and Grading Of Diabetic Peripheral Neuropathy (MEDON),Completed,No Results Available,"Neuropathy, Diabetic|Neuropathy, Painful",Diagnostic Test: Perception Threshold Tracking (PTT)|Diagnostic Test: Axon-flair mediated respons|Diagnostic Test: Heart rate variability|Diagnostic Test: Quantitative Sensory Testing (QST)|Diagnostic Test: Peripheral blood pressure and transcutaneous oxygen tension|Diagnostic Test: Magnetic Resonance Imaging (MRI)|Diagnostic Test: Questionnaires|Diagnostic Test: Corneal Confocal Microscopy /CCM),Aalborg University Hospital|Aalborg University,"18 Years to 70 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,"Aalborg University Hospital, Aalborg, North Denmark, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT04078516/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04078516
840,NCT04966754,Data Driven Behavior Intervention and Medical Outcome Evaluation of Patients' Comprehensive Monitoring,Not yet recruiting,No Results Available,Metabolic Syndrome|Metabolic Disturbance|Metabolic Complication|Infection|Obesity|Diabetes,,"Peking Union Medical College Hospital|Peking University|Guangdong Provincial People's Hospital|Guangzhou Huyun Hospital Management Co., Ltd","18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Beijing, China.","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04966754/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04966754
841,NCT01988246,Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery,Completed,Has Results,Diabetic Retinopathy,Drug: Aflibercept|Drug: Sham,Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01988246/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01988246/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01988246
842,NCT04074954,A (Prospective/Pilot) Study Evaluating the Effect of Cataract Surgery on the Daily Activity Levels of Elderly Patients,Unknown status,No Results Available,Cataract|Diabetes|Hypertension|Obesity|Vision Disability,Procedure: Cataract surgery,University of Pikeville,"60 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Bennett and Bloom Eye Centers, Louisville, Kentucky, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04074954/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04074954
843,NCT02378259,Randomized Clinical Trial; Medical vs Bariatric Surgery for Adolescents (13-16 y) With Severe Obesity,"Active, not recruiting",No Results Available,Obesity|Diabetes|Hypertension|Steatohepatitis|Inflammation,Procedure: Laparoscopic Roux-en-Y gastric bypass|Procedure: Intense conservative treatment,"Göteborg University|Sahlgrenska University Hospital, Sweden|Karolinska University Hospital|Lund University",13 Years to 16 Years   (Child),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sahlgrenska University hospital, Gothenburg, Sweden|Skåne University Hospital, Malmö, Sweden|Karolinska University hospital, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02378259/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT02378259
844,NCT05337644,Indocyanine Green Test for Evaluation of Perfusion of Staple Line of the Stomach During Laparoscopic Sleeve Gastrectomy,Completed,No Results Available,"Obesity, Morbid|Diabete Type 2|Cardiac Disease|Vascular Diseases",Drug: Indocyanine green solution,University of Foggia,"18 Years to 65 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,"University of Foggia, Foggia, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT05337644/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT05337644
845,NCT04612595,The Association Between sUCR and the Survival in Patients With DKD,Unknown status,No Results Available,Diabetic Kidney Disease,Other: serum urea nitrogen to creatinine ratio,Guangdong Provincial People's Hospital,"18 Years to 70 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04612595/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04612595
846,NCT03933956,Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN),Terminated,No Results Available,Diabetic Nephropathies,Drug: Empagliflozin 10 MG,Singapore General Hospital|Duke-NUS Graduate Medical School,"21 Years to 100 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Singapore General Hospital, Singapore, Singapore","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03933956/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03933956
847,NCT00955201,Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy,Completed,Has Results,Diabetic Neuropathy,Behavioral: Exercise,VA Office of Research and Development,"45 Years to 80 Years   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT00955201/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT00955201
848,NCT03219320,Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy,Completed,Has Results,Diabetic Peripheral Neuropathy,Drug: NYX-2925|Drug: Placebo,Aptinyx|Syneos Health,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Aptinyx Clinical Site, Phoenix, Arizona, United States|Aptinyx Clinical Site, Anaheim, California, United States|Aptinyx Clinical Site, Fresno, California, United States|Aptinyx Clinical Site, Norco, California, United States|Aptinyx Clinical Site, Santa Monica, California, United States|Aptinyx Clinical Site, Tustin, California, United States|Aptinyx Clinical Site, New London, Connecticut, United States|Aptinyx Clinical Site, Bradenton, Florida, United States|Aptinyx Clinical Site, Brandon, Florida, United States|Aptinyx Clinical Site, Fort Myers, Florida, United States|Aptinyx Clinical Site, Hallandale Beach, Florida, United States|Aptinyx Clinical Site, Jupiter, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Miami, Florida, United States|Aptinyx Clinical Site, Ocoee, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx Clinical Site, Orlando, Florida, United States|Aptinyx Clinical Site, Tampa, Florida, United States|Aptinyx Clinical Site, West Palm Beach, Florida, United States|Aptinyx Clinical Site, Columbus, Georgia, United States|Aptinyx Clinical Site, Decatur, Georgia, United States|Aptinyx Clinical Site, Meridian, Idaho, United States|Aptinyx Clinical Site, Flossmoor, Illinois, United States|Aptinyx Clinical Site, Hazelwood, Missouri, United States|Aptinyx Clinical Site, Berlin, New Jersey, United States|Aptinyx Clinical Site, Rochester, New York, United States|Aptinyx Clinical Site, Dayton, Ohio, United States|Aptinyx Clinical Site, Knoxville, Tennessee, United States|Aptinyx Clinical Site, Memphis, Tennessee, United States|Aptinyx Clinical Site, Tullahoma, Tennessee, United States|Aptinyx Clinical Site, Austin, Texas, United States|Aptinyx Clinical Site, Houston, Texas, United States|Aptinyx Clinical Site, Plano, Texas, United States|Aptinyx Clinical Site, Norfolk, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03219320/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03219320/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03219320
849,NCT02104739,Effects of Antidiabetic Medications on the Postprandial State in Prediabetes,Completed,Has Results,Prediabetes|Obesity,Drug: Exenatide|Drug: Saxagliptin|Drug: Exenatide extended-release (ER)|Other: Placebo,"The University of Texas Health Science Center, Houston|The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston","30 Years to 70 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02104739/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02104739
850,NCT02750501,Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study,Completed,Has Results,Cystic Fibrosis,Device: RELiZORB (immobilized lipase) cartridge|Other: Impact Peptide 1.5,"Alcresta Therapeutics, Inc.|Cystic Fibrosis Foundation","4 Years and older   (Child, Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Joe DiMaggio Children's Hospital / Memorial Healthcare System, Hollywood, Florida, United States|St. Luke's CF Center of Idaho, Boise, Idaho, United States|Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States|Maine Medical Center, Portland, Maine, United States|Helen DeVos Children's Hospital CF Care Center, Grand Rapids, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital / Saint Louis University, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02750501/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02750501/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02750501
851,NCT04864860,Effect of Sea Weed (Ecklonia Cava Extract) on Blood Glucose and Insulin Level on Pre-diabetic Patients,Recruiting,No Results Available,PreDiabetes,Dietary Supplement: brown seaweed (ecklonia cava),King Saud University|Dr. Khalid ALdybayan|Ms. Haneen Molla|Dr. Abdullah Alquwaihes,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","clinical Trial Unit, Riyadh, Saudi Arabia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT04864860/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT04864860/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04864860
852,NCT03316508,Copeptin- Relevance as a Perioperative Marker in Pediatric Cardiac Surgery,Completed,No Results Available,Congenital Heart Disease,,Claudia Herbst|Medical University of Vienna,up to 6 Years   (Child),,Other,Observational,Observational Model: Other|Time Perspective: Prospective,"Medical University of Vienna, Vienna, Austria","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03316508/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03316508/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03316508
853,NCT01982435,Safety and Efficacy of Ranibizumab for Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: Ranibizumab,"Justis Ehlers|Genentech, Inc.|The Cleveland Clinic","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States|Cole Eye Institute at Hillcrest Hospital, Mayfield Heights, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01982435/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01982435/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT01982435
854,NCT03161327,Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease,Completed,Has Results,Peripheral Artery Disease|Amputation|Smoking|Diabetes|Hypercholesterolemia|Hypertension,Device: ABI using QuantaFlo™,St. Louis University,"18 Years to 90 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Saint Louis University, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03161327/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03161327
855,NCT04459936,Urica Cor Intervention (URICORI) Trial,Withdrawn,No Results Available,"Gout|Cardiovascular Diseases|Dyslipidemias|Hypertension|Diabetes|Behavior, Smoking",Other: URICORI|Other: CONTROL,Torkell Ellingsen|Odense University Hospital|Frederiksberg University Hospital|Oak Foundation|The Danish Rheumatism Association|Region of Southern Denmark|University of Southern Denmark,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Odense University Hospital, Odense, Denmark","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04459936/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04459936
856,NCT04286529,"Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons",Terminated,Has Results,Pre-Diabetic,Drug: Calcitriol capsules|Drug: Oral Placebo,Mayo Clinic,20 Years to 45 Years   (Adult),Phase 1,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04286529/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04286529
857,NCT03502304,Concurrent Training and Prediabetes Control,Completed,No Results Available,Metabolic Disturbance,Behavioral: Endurance training plus resistant training,Universidad Santo Tomas|Universidad de Los Lagos|Healthcare Center Tomas Rojas|Universidad del Rosario,30 Years to 59 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,"Cristian Alvarez, Los Lagos, Osorno, Chile","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03502304/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03502304
858,NCT05238012,Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes,Not yet recruiting,No Results Available,"Metabolism Disorder, Lipid|Metabolism Disorder, Glucose",Drug: Xuezhikang Capsule|Drug: Atorvastatin Calcium Tablets,Heart Health Research Center|AstraZeneca,"40 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,China,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT05238012/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT05238012
859,NCT02678390,Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes,Completed,Has Results,Prediabetic State,Dietary Supplement: MCT|Dietary Supplement: MCT+ aerobic exercise|Dietary Supplement: Aerobic exercise|Dietary Supplement: Control day,Université de Sherbrooke,"60 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Research Centre on Aging - CSSS-IUGS - CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02678390/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02678390
860,NCT02631148,Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.,Terminated,Has Results,Obesity|Prediabetic State,Drug: Melatonin|Drug: Placebo,Brigham and Women's Hospital,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02631148/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02631148
861,NCT02308735,Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial,Terminated,Has Results,Infants of Diabetic Mothers,Other: N/A - No intervention,University of Oklahoma,"up to 45 Years   (Child, Adult)",,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,"Children's Hospital of Oklahoma, Oklahoma City, Oklahoma, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02308735/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02308735
862,NCT02168816,Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis,Terminated,Has Results,Osteomyelitis,Drug: Intravenous Antibacterial Agent|Drug: Oral Antibacterial Agent,Loyola University,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Loyola University Medical Center, Maywood, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02168816/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02168816
863,NCT01804049,Metformin and Muscle in Insulin-resistant Older Veterans,Completed,Has Results,Prediabetes,Drug: metformin|Drug: placebo,VA Office of Research and Development|Oregon Health and Science University,65 Years and older   (Older Adult),Phase 1|Phase 2,U.S. Fed|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","VA Portland Health Care System, Portland, OR, Portland, Oregon, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT01804049/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01804049
864,NCT03077893,Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy,Completed,Has Results,Diabetic Peripheral Neuropathy,Device: Active Provant Therapy System|Device: Inactive (sham) Provant Therapy System,"Regenesis Biomedical, Inc.","22 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Associated Foot & Ankle Specialists, LLC, Phoenix, Arizona, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03077893/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03077893
865,NCT02461225,Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain,Completed,Has Results,Diabetic Peripheral Neuropathy,Device: Erchonia® FX-635™|Device: Placebo Laser,Erchonia Corporation,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Arizona Institute of Footcare Physicians, Mesa, Arizona, United States|Midleton Foot Clinic, Midleton, Co. Cork, Ireland","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02461225/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02461225
866,NCT01856907,Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM,Completed,Has Results,Disorder of Glucose Regulation,Drug: Sitagliptin-Metformin|Drug: Metformin|Drug: Placebo pill,Woman's|Merck Sharp & Dohme LLC,18 Years to 42 Years   (Adult),Phase 4,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Woman's Hospital, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT01856907/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01856907
867,NCT03443635,Cooking for Health Optimization With Patients,Completed,Has Results,Cardiovascular Diseases|Cardiovascular Risk Factor|Nutrition Disorders|Diabetes|Hypertension|Cancer|Depression|Obesity|Physical Activity,Behavioral: Treatment,Tulane University,"7 Years to 115 Years   (Child, Adult, Older Adult)",Phase 1|Phase 2,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Goldring Center for Culinary Medicine at Tulane University School of Medicine, New Orleans, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03443635/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03443635
868,NCT04142710,Pragmatic Randomized Control Trial of Telehealth vs Standard Care in Follow-up of Patients With Chronic Conditions,Completed,No Results Available,Chronic Disease|Diabetes|Vascular Diseases|Chronic Lung Disease|Cancer|Psychiatric Disorder,Device: Telemedicine: tablet and possibly tools to perform measurements,University of Oslo|Oslo Economics|Norwegian Centre for Rural Medicine|Norsk Gallup Institutt AS,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Bodø municipality, Bodø, Norway|Eid municipality, Eidfjord, Norway|Ullensaker municipality, Jessheim, Norway|Kristiansand municipality, Kristiansand, Norway|Larvik municipality, Larvik, Norway|Gamle Oslo district, Oslo, Oslo, Norway|Grünerløkka district, Oslo, Oslo, Norway|Sagene ditrict, Oslo, Oslo, Norway|St.Hanshaugen district, Oslo, Oslo, Norway","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04142710/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04142710/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04142710
869,NCT01725815,The Health Access and Recovery Peer Program,Completed,Has Results,Hypertension|Arthritis|Coronary Artery Disease|Hepatitis|Diabetes|Asthma|Hyperlipidemia|HIV,Behavioral: HARP Intervention,Emory University|National Institute of Mental Health (NIMH),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Central Fulton Community Mental Health Center at Grady Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01725815/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01725815
870,NCT04037436,Functional Exercise and Nutrition Education Program for Older Adults,Completed,No Results Available,"Chronic Disease|Frail|Diabetes Mellitus|Cancer|Chronic Lung Disease|Cardiovascular Diseases|Congestive Heart Failure|Hypertension|Osteoporosis, Osteopenia|Arthritis|Stroke|Kidney Diseases",Other: Strength and Balance Training & Nutrition Education|Other: Usual Care,University of Waterloo|Canadian Institutes of Health Research (CIHR)|City of Lakes family Health Team|Schlegel Villages and Research Institute for Aging|YMCA|Kinnect to Wellness,"60 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Chaplin Family YMCA, Cambridge, Ontario, Canada|The Village of Arbour Trails, Guelph, Ontario, Canada|Village of Winston Park, Kitchener, Ontario, Canada|A.R. Kaufman Family YMCA, Kitchener, Ontario, Canada|Your Family Health Team, Sudbury, Ontario, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04037436/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04037436
871,NCT01864603,Sustainable East Africa Research in Community Health,Completed,Has Results,HIV|Tuberculosis|Hypertension|Diabetes|Maternal Child Health|Cost Effectiveness,Other: Universal ART in a streamlined care model|Other: Annual Community Health Campaigns|Other: Targeted PrEP and Targeted testing interventions|Other: Baseline community-based HIV and multi-disease testing,"University of California, San Francisco|Infectious Diseases Research Collaboration, Uganda|Makerere University|Kenya Medical Research Institute|Gilead Sciences|World Bank|National Institute of Allergy and Infectious Diseases (NIAID)|United States President's Emergency Plan for AIDS Relief|Bill and Melinda Gates Foundation","Child, Adult, Older Adult",Not Applicable,Other|Industry|NIH|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Nyanza Province Kenya, Nyanza Province, Kenya|Eastern Uganda, Mbale/Tororo Region, Uganda|Southwestern Uganda, Mbarara Region, Uganda","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01864603/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01864603/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01864603
872,NCT02579655,Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study,Completed,No Results Available,Coronary Disease|Stroke|Chronic Kidney Disease|Heart Failure|Diabetes Mellitus|Hypertension|Hypercholesterolemia,Behavioral: Copayment Elimination|Behavioral: Personalized Education,University of Calgary|Alberta Innovates Health Solutions,65 Years and older   (Older Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"University of Calgary, Calgary, Alberta, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02579655/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02579655
873,NCT01879228,Effect of Chronic Incretin-based Therapy in Cystic Fibrosis,Completed,Has Results,Cystic Fibrosis|Pancreatic Insufficiency,Drug: Sitagliptin|Drug: Placebo,University of Pennsylvania|Children's Hospital of Philadelphia,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT01879228/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT01879228/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT01879228
874,NCT03566810,Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt),Completed,Has Results,Healthy,Drug: Test GXR|Drug: Reference GXR,"Merck KGaA, Darmstadt, Germany",18 Years to 55 Years   (Adult),Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Xuanwu Hospital Capital Medical University, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03566810/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03566810/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03566810
875,NCT03393208,Glucophage Immediate Release (GIR) China Bioequivalence Study,Completed,Has Results,Healthy,Drug: Test GIR|Drug: Reference GIR,"Merck KGaA, Darmstadt, Germany",18 Years to 55 Years   (Adult),Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Xuanwu Hospital, Beijing, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03393208/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03393208/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03393208
876,NCT03048747,A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH,Completed,Has Results,Syndrome of Inappropriate Antidiuretic Hormone Secretion,Drug: Tolvaptan Oral Tablet,"Otsuka Pharmaceutical Co., Ltd.","20 Years to 85 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chubu Region, Japan|Chugoku Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan|Sikoku Region, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03048747/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT03048747/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03048747
877,NCT03455543,Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy,Completed,Has Results,Diabetic Neuropathy Peripheral,Device: Active Provant Therapy System|Device: Inactive (sham) Provant Therapy System,"Regenesis Biomedical, Inc.","22 Years to 80 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Physician's Research Group, Mesa, Arizona, United States|Valley Clinical Research, Northridge, California, United States|Northern California Research, Sacramento, California, United States|Diabetes Research Center, Tustin, California, United States|Mountain View Clinical Research, Denver, Colorado, United States|Lake Internal Medicine Associates, Eustis, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Spotlight Research Center, Miami, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|Heartland Research Associate, LLC, Wichita, Kansas, United States|Healthcare Research Network, Hazelwood, Missouri, United States|The Center for Pharmaceutical Research, LLC, Kansas City, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Great Lakes Medical Resarch, Westfield, New York, United States|Wake Family Medicine, PC, Cary, North Carolina, United States|Rainier Clinical Research, Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03455543/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT03455543/SAP_002.pdf",https://ClinicalTrials.gov/show/NCT03455543
878,NCT03398356,Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.,Completed,Has Results,PreDiabetes|Impaired Fasting Glucose (IFG)|Impaired Glucose Tolerance (IGT),Drug: Metformin,Wroclaw Medical University,"40 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science,"NZOZ Nowy Dwór, Wroclaw, Lower Silesia, Poland","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03398356/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03398356
879,NCT01837069,Risk Factor Control Before Orthopedic Surgery,Terminated,Has Results,Osteoarthritis|Cardiovascular Disease,Drug: Metoprolol|Drug: Lisinopril|Drug: Atorvastatin|Behavioral: Lifestyle counseling,NYU Langone Health,"21 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01837069/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01837069
880,NCT02040441,Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria,Completed,No Results Available,Diabetic Nephropathy|Diabetic Retinopathy,Drug: Spironolactone|Drug: Placebo|Drug: Standard care,Peter Rossing|Mosaiques Diagnostics GmbH|University Medical Center Groningen|University of Glasgow|Istituto Di Ricerche Farmacologiche Mario Negri|Univerzita Karlova v Praze|Geniko Nosokomeio Athinas Ippokrateio|Institut Klinické a Experimentální Mediciny Praze|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Klinikum St. Georg Leipzig|Cyril and Methodius University in Skopje|Hannover Clinical Trial Center|European Commission|Diabetes Vascular Research Foundation Hoogeveen|Universitair Ziekenhuis Gent|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden|Stichting VUMC|Diabetologen Hessen|Steno Diabetes Center Copenhagen,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Universitair Ziekenhuis, Gent, Belgium|Institut Klinické a Experimentální Mediciny, Prague, Czechia|Universita Karlova v Praze, Prague, Czechia|Steno Diabets Center Copenhagen, Gentofte, Denmark|Universitätsklinikum Carl Gustav Carus, Technischen Universität Dresden, Dresden, Germany|Diabetologen Hessen, Hessen, Germany|Klinikum St. Georg gGmbH, Leipzig, Germany|Geniko Nosikomeico Athinas Ippokrateio, Hospital Diabetes Center, Athens, Greece|Instituto de Ricerche Farmacologiche Mario Negri, Bergamo, Italy|Department of Nephrology, University of Skopje, Skopje, Macedonia, The Former Yugoslav Republic of|University Medical Center Groningen, Groningen, Netherlands|Diabetes Vascular Research Foundation, Hoogeveen, Netherlands|Stichting VUMC, Hoorn, Netherlands|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain|University of Glasgow, Glasgow, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02040441/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02040441/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT02040441
881,NCT02482610,Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat,Completed,Has Results,Prediabetes,Other: Glucose|Other: Glucose with Whole Fat Milk|Other: Glucose with Non-fat Milk,Ohio State University,18 Years to 50 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The Ohio State University, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02482610/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02482610
882,NCT02229487,The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers,Completed,Has Results,Prediabetes,Other: Oral glucose tolerance,Ramathibodi Hospital|Merck Sharp & Dohme LLC,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02229487/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02229487
883,NCT02456636,Rural Engagement in Primary Care for Optimizing Weight Reduction,Completed,Has Results,Obesity,"Behavioral: Fee-for-Service Model (FFS, In clinic individual visits)|Behavioral: Patient Centered Medical Home (PCMH, In clinic group visits)|Behavioral: Disease Management (DM, Phone group visits)",University of Kansas Medical Center|Patient-Centered Outcomes Research Institute,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kansas Medical Center, Kansas City, Kansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT02456636/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02456636
884,NCT01386645,Effect of Dietary Glycemic Index on Beta-cell Function,Completed,Has Results,Impaired Glucose Tolerance|Oxidative Stress|Prediabetes|Impaired Fasting Glucose,Other: low glycemic index (LGI) diet|Other: high glycemic index (HGI) diet plus placebo (PLAC)|Drug: high glycemic index diet plus N-acetylcysteine,Seattle Institute for Biomedical and Clinical Research|VA Puget Sound Health Care System,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","VA Puget Sound Health Care System, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01386645/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01386645
885,NCT02279524,A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH,Completed,Has Results,Fatty Liver|Non-Alcoholic Steatohepatitis|Liver Diseases|Liver Fibroses,Drug: Aramchol,"Galmed Research and Development, Ltd.|Sharp Clinical Services|Diamond Pharma Services Regulatory Affairs Consultancy|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|ClinIntel|Itamar-Medical, Israel|One Way Liver OWL|Medical University of Graz|Tel-Aviv Sourasky Medical Center|DSG EDC|TransPerfect|Clinical Reference Laboratory|Galmed Pharmaceuticals Ltd","18 Years to 75 Years   (Adult, Older Adult)",Phase 2,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Profil Institue for Clinical Research Inc., Chula Vista, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States|Inland Empoire Liver Foundation, Rialto, California, United States|University of California Department of Medicine Division of Gastroenterology, San Diego, California, United States|Orange County Research Center, Tustin, California, United States|Indiana University, Indianapolis, Indiana, United States|Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Research, Raleigh, North Carolina, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Gastroenterology Consultants of San Antonio, Live Oak, Texas, United States|Texas Liver Institute San Antonio, San Antonio, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Biomedica Research Group, Santiago, Chile|Centro de Investigacion Clinica CEIC, Santiago, Chile|Hospital Clinico Universidad de Chile, Santiago, Chile|Pontificia Universidad Catolica de Chile, Santiago, Chile|Centro de Investigaciones Clinicas Vina del Mar, Vina del Mar, Chile|Centre Hospitalier Universitaire (CHU) d'Angers, Angers, France|Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France|San Joseph Service Hepato Gastro Entrologie, Marseille, France|Hospital Saint Eloi, Montpellier, France|CHU Centre Hospiatalier Universitaire de Rennes, Paris, France|Hospital Pitie-Salpetriere, Paris, France|Hospital Saint-Antoine AP-HP, Paris, France|Hopital Paul Brousse, Villejuif, France|Unimed Adjara, Batumi, Georgia|Clinic Cortex, Tbilisi, Georgia|David Tatishvili Medical Center, Tbilisi, Georgia|LTD Diacor, Tbilisi, Georgia|Research Institute of Clinical Medicine, Tbilisi, Georgia|Medizinische Hochschule, Hannover, Germany|EUGASTRO GmbH, Leipzig, Germany|Universitat Leipzig Medizinische Fakultat, Leipzig, Germany|Humanity & Health Medical Centre, Central, Hong Kong|Carmel Medical Center, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Ein Karem Medical Cente, Jerusalem, Israel|Naharia Medical Center, Nahariya, Israel|The Holy family Medical Center, Nazareth, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Saurasky Medical Center, Tel-Aviv, Israel|Asaf Harofeh Medical Center, Zrifin, Israel|Spedali Civili di Brescia, Brescia, Italy|A.O. San Paolo, Milano, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|A.O. U. ""Federico II"" di Napoli, Napoli, Italy|Azienda Ospedaliera di Rilievo Nazionale ""A.Cardarelli"", Napoli, Italy|Azienda Ospidaliera Universitaria Seconda Universita di Napoli, Napoli, Italy|A.O.U. Maggiore della Carità, Novara, Italy|""Ospedale Cristo Re"" dell'Istituto Figlie di N.S. al Monte Calvario, Roma, Italy|Fondazione Policlinico di Tor Vergata, Roma, Italy|Ospedale San Camillo, Roma, Italy|Policlinico A. Gemelli, Roma, Italy|Policlinico Umberto I Di Roma, Roma, Italy|Policlinico Univestitario Campus Biomedico, Roma, Italy|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|Vilinius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Unidad de Hígado Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico|JM Research, Cuernavaca, Mexico|Consultorio Médico, Metepec, Mexico|Torre de Consultorios Clinica Londres, Mexico City, Mexico|Consultorio Medico, Mexico City, Mexico|Instituto de Ciencias Medicas y de la Nutricion Salvador Zubiran, Mexico City, Mexico|Torre de Consultorios Clinica Londres, Mexico Distrito Federal, Mexico|Accelerium Clinical Research, Monterrey, Mexico|Consultorio Medico del Dr. Mauricio Castillo Barradas, México Distrito Federal, Mexico|""Angeles Valle oriente"" Hospital, San Pedro Garza Garcia, Mexico|Clinical Institute Colentina, Bucharest, Romania|The National Institute for Infectious Diseases ""Prof. Dr. Matei Bals"", Clinical Department for Adults II, Bucharest, Romania|Cluj County Emergency Hospital, Cluj Napoca, Romania|TVM Medical, Cluj Napoca, Romania|County Hospital Mures-Gastroenterology Department, Targu Mures, Romania","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02279524/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02279524
886,NCT02819011,"OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO",Completed,Has Results,Accidental Falls|Fall Due to Loss of Equilibrium|High Risk of Falls Due to Mobility Limitation|Diabetes|Arthritis|Cancer|Peripheral Arterial Disease|Parkinson's Disease|End Stage Renal Failure on Dialysis,Device: MBB AFO|Other: Control,"Bijan Najafi, PhD|Orthotic Holdings, Inc.|Baylor College of Medicine",65 Years and older   (Older Adult),Phase 2,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Baylor College of Medicine, Houston, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02819011/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02819011/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02819011
887,NCT02950142,Evidence-based Laboratory Test Order Sets in Primary Care,Completed,No Results Available,Diabetes Mellitus|Hypertension|Cardiovascular Diseases|Fatigue|Anemia|Liver Diseases|Medication Monitoring|Gout|Chronic Kidney Diseases|Lung Embolism|Acute Coronary Syndrome|Diarrhea|Thyroid Diseases|Sexually Transmitted Diseases|Rheumatoid Arthritis|Obesity|General Check-up,Other: CPOE with order sets for lab testing|Other: CPOE without order sets for lab testing,Universitaire Ziekenhuizen Leuven|KU Leuven|University Ghent|Norwegian Institute of Public Health|Sciensano,"Child, Adult, Older Adult",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"Academic Centre for General Practice, Leuven, Belgium","""Study Protocol: Full protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02950142/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02950142/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02950142
888,NCT02552277,A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy,Completed,No Results Available,Diabetic Nephropathies|Peripheral Nervous System Diseases,Biological: PDA-002|Drug: Placebo,Celularity Incorporated,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Collaborative Neuroscience Network, LLC- Southland Neurologic Associates - Los Alamitos, Garden Grove, California, United States|SDS Clinial Trials, Inc, Orange, California, United States|Compass Research, LLC, Orlando, Florida, United States|Infinity Clinical Research, LLC, Sunrise, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Nerve And Muscle Center Of Texas, Houston, Texas, United States|Endeavor Clinical Trials PA, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02552277/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02552277
889,NCT04474496,Impact of COVID-19 on Marshallese Communities in the U.S.,Completed,Has Results,COVID-19,Other: Assessing the impact of COVID-19,University of Arkansas|Patient-Centered Outcomes Research Institute,"18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04474496/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04474496
890,NCT01862029,Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals,Completed,Has Results,Obesity,Drug: Roflumilast,"National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","30 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,NIH,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT01862029/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01862029
891,NCT02001051,Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism,Terminated,Has Results,Subclinical Hypercortisolism|Cushing Syndrome|Adrenal Neoplasm,Procedure: Adrenalectomy|Other: Observation,National Cancer Institute (NCI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Clinical Center Office of the Associates Director for Radiologic&Imaging Sciences|National Institutes of Health Clinical Center (CC),"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02001051/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02001051
892,NCT05441072,Validation of Bulbicam for DR- and AMD-patients,Not yet recruiting,No Results Available,Diabetic Retinopathy|Age-Related Macular Degeneration,Device: BulbiCam,Meddoc|Oslo University Hospital,"18 Years to 80 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Other|Time Perspective: Prospective,Norway,"""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT05441072/Prot_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT05441072
893,NCT05130385,High Resolution Optical Coherence Tomography,Not yet recruiting,No Results Available,Retinal Disease|Retinal Detachment|Retinal Vein Occlusion|Retinal Dystrophy|Retinal Artery Occlusion|Retinal Edema|Retinal Neovascularization|Uveitis|Diabetic Retinopathy|Diabetic Macular Edema|Macular Edema|Macular Degeneration|Macular Disease|Glaucoma|Optic Nerve Diseases|Hypertensive Retinopathy,Device: High-resolution optical coherence tomography (High-Res-OCT)|Device: Standard spectral domain OCT (SD-OCT),"University Hospital Inselspital, Berne","18 Years and older   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Department of Ophthalmology, Bern University Hospital, Bern, 3010 Bern, Switzerland, Bern 3010, Bern, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT05130385/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT05130385
894,NCT04018326,Loss to Follow-up in PDR Patients,Completed,No Results Available,Diabetic Retinopathy,,Assiut University,"40 Years to 70 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,Egypt,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04018326/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04018326
895,NCT04633642,Ultrasound Assisted Wound Debridement (UAW) Versus Standard Wound Treatment in Complicated Diabetic Foot Ulcers (DFU),Completed,Has Results,Diabetic Foot Ulcer,Procedure: Ultrasound group|Procedure: Surgical group,Universidad Complutense de Madrid|Francisco Javier Álvaro Afonso|David Sevillano Fernández|Yolanda García Álvarez|Irene Sanz Corbalan|Esther García Morales,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Fancisco Javier Álvaro Afonso, Madrid, Spain|José Luis Lázaro Martínez, Madrid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04633642/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04633642
896,NCT04619303,Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO,Completed,No Results Available,Diabetic Macular Edema|Diabetic Retinopathy,Drug: Dexamethasone intravitreal implant|Drug: Bevacizumab Injectable Product,"Lions Eye Institute, Perth, Western Australia|Lions Outback Vision|Allergan","18 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Broome Regional Aboriginal Medical Service, Broome, Western Australia, Australia|Derby Hospital, Derby, Western Australia, Australia|Fitzroy Crossing Hospital, Fitzroy Crossing, Western Australia, Australia|Halls Creek Health Service, Halls Creek, Western Australia, Australia|Bega Garnbirringu Health Service, Kalgoorlie, Western Australia, Australia|Nickol Bay Hospital, Karratha, Western Australia, Australia|Ord Valley Aboriginal Health Service, Kununurra, Western Australia, Australia|Laverton Hospital, Laverton, Western Australia, Australia|Derbarl Yerrigan Health Service Inc., Perth, Western Australia, Australia|Lions Eye Institute Nedlands, Perth, Western Australia, Australia|Lions Eye Institute Midland, Perth, Western Australia, Australia|Mawarnkarra Health Service, Roebourne, Western Australia, Australia|Wirraka Maya Health Service Aboriginal Corporation, South Hedland, Western Australia, Australia","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04619303/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04619303
897,NCT04577183,"A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1",Completed,Has Results,Diabetic Foot Ulcer|Pressure Ulcer|Venous Leg Ulcer|Trauma Injury|Skin Tear|Chronic Ulcer,Device: RD1 System,RedDress Ltd.,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sunnyview Nursing & Rehabilitation Center, Butler, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT04577183/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT04577183
898,NCT04336176,Evaluating Plantar Foot Pressure in a Novel Diabetic Offloading Device,Completed,No Results Available,Diabetic Foot Ulcer,Device: PulseFlow DF boot|Device: Usual standard of care|Device: Sham,University of Leeds|The Leeds Teaching Hospitals NHS Trust,"Child, Adult, Older Adult",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"The Leeds Teaching Hospitals NHS Trust., Leeds, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04336176/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04336176
899,NCT03905863,The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcer|Surgical Wound,Device: Natrox® Oxygen Wound Therapy,"Inotec AMD Limited|SerenaGroup, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New Hope Podiatry Clinic, Los Angeles, California, United States|San Marcus Research Clinic, Miami Lakes, Florida, United States|Global Health Research Center Inc, Miami Lakes, Florida, United States|MedCare Research, Miami, Florida, United States|Barry University Clinical Research, North Miami Beach, Florida, United States|Royal Research Corp, Pembroke Pines, Florida, United States|Doctors Research Network, South Miami, Florida, United States|Pharma Research Associates, Westchester, Florida, United States|Wahab Consulting and Research, Las Vegas, Nevada, United States|Cleveland Foot and Ankle Clinic, Cleveland, Ohio, United States|Tulsa Bone and Joint, Tulsa, Oklahoma, United States|The Foot and Ankle Wellness Center of Western Pennsylvania, Ford City, Pennsylvania, United States|Antria, Indiana, Pennsylvania, United States|ACMH Snyder Institute, Kittanning, Pennsylvania, United States|SerenaGroup Research Institute, Pittsburgh, Pennsylvania, United States|El Campo Memorial Hospital, El Campo, Texas, United States|Allure Health LLC, Friendswood, Texas, United States|Pinnacle Foot and Ankle Center, Houston, Texas, United States|Mercury Clinical Research, Webster, Texas, United States|Clinical Research Management Group, Coto Laurel, Puerto Rico","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03905863/Prot_SAP_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03905863
900,NCT03794752,Visual Enhancement Device in Low Vision Patients,Terminated,Has Results,"Macular Degeneration, Age-Related|Diabetic Retinopathy",Device: Head-Mounted Visual Enhancement Device,University of Texas Southwestern Medical Center,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,United States,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03794752/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03794752
901,NCT03742440,GrafixPL PRIME Evaluation Case Study,Completed,Has Results,Diabetic Foot Ulcer,Biological: GrafixPL PRIME,University of Texas Southwestern Medical Center|Osiris Therapeutics,"18 Years to 90 Years   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center at Dallas, Dallas, Texas, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03742440/Prot_ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03742440
902,NCT03662997,Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds,Completed,Has Results,Chronic Wound|Venous Leg Ulcer|Diabetic Foot Ulcer,Device: Bordered Five-Layer Foam Dressing|Device: Hydropolymer Foam Dressing|Device: Hydrocellular Multi-Layer Foam Dressing,Molnlycke Health Care AB,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Clinical Research, Inc., Castro Valley, California, United States|Center for Clinical Trials, Inc., San Francisco, California, United States|Vascular and Wound Care Center, Newark, New Jersey, United States|SerenaGroup Research Foundation, Pittsburgh, Pennsylvania, United States|SerenaGroup, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03662997/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03662997
903,NCT03615807,Less Infections for the Diabetic Foot,Completed,Has Results,Diabetic Foot,Procedure: Surgical debridement (if needed)|Diagnostic Test: Microbiological sampling|Procedure: Revascularisation (if needed).|Device: Off-loading|Behavioral: Patient's education and instructions|Procedure: Wound debridement|Drug: Antibiotic duration,"University Hospital, Geneva","18 Years to 120 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Geneva University Hospitals, Geneva, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03615807/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03615807
904,NCT03597815,Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study,"Active, not recruiting",No Results Available,Diabetic Macular Edema|Sleep Apnea|Non Proliferative Diabetic Retinopathy,Drug: Aflibercept 40 MG/ML [Eylea]|Diagnostic Test: OSA diagnostic test - overnight sleep study|Device: CPAP therapy for OSA positive patients,Uptown Eye Specialists,"18 Years to 110 Years   (Adult, Older Adult)",,Other,Observational,Observational Model: Case-Control|Time Perspective: Prospective,"Uptown Eye Speicialists, Brampton, Otario, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03597815/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03597815
905,NCT02823600,Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers,Completed,Has Results,"Kidney Failure, Chronic|Eye Diseases|Diabetic Retinopathy",Device: RetinaVue 100 camera,"University of North Carolina, Chapel Hill|Welch Allyn","18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,"UNC Ophthalmology, Chapel Hill, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02823600/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02823600
906,NCT02753400,Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy,Completed,Has Results,Proliferative Diabetic Retinopathy,Drug: emixustat hydrochloride|Other: Placebo,Kubota Vision Inc.,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Retina Institute of California, Arcadia, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02753400/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02753400
907,NCT03345901,PROMINENT-Eye Ancillary Study (Protocol AD),Terminated,Has Results,Diabetic Retinopathy|Diabetic Macular Edema,Drug: Pemafibrate|Drug: Placebo,"Jaeb Center for Health Research|Kowa Company, Ltd.","18 Years and older   (Adult, Older Adult)",Phase 3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|Retinal Diagnostic Center, Campbell, California, United States|Macula & Retina Institute, Glendale, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|South Coast Retina Center, Long Beach, California, United States|Northern California Retina Vitreous Associates, Mountain View, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Glenview, Illinois, United States|Illinois Retina Associates, S.C., Oak Park, Illinois, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Mid-America Retina Consultants, P.A., Overland Park, Kansas, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Retina Center, PA, Minneapolis, Minnesota, United States|The Retina Institute, Saint Louis, Missouri, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|MaculaCare, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Retina Research Center, Austin, Texas, United States|Robert E. Torti, MD, PA dba Retina Specialists, DeSoto, Texas, United States|Valley Retina Institute, DeSoto, Texas, United States|Retina Center of Texas, Grapevine, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Institute of Virginia, Richmond, Virginia, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|University Health Network - Toronto Western Hospital, Toronto, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03345901/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03345901
908,NCT03312595,Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU),Completed,Has Results,Diabetic Foot Ulcer,Device: Restrata TM Wound Matrix,"Acera Surgical, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Associated Foot & Ankle Specialists, Phoenix, Arizona, United States|Arizona Reginal Medical Research, Tucson, Arizona, United States|SAVAHCS, Tucson, Arizona, United States|Advanced Foot Care And Clinical Research Center, Fresno, California, United States|Richard C. Galperin, DPM, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03312595/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03312595
909,NCT03232333,MIRODERM H2H DFU Study,Completed,Has Results,Diabetic Foot Ulcer,Device: Biologic wound graft,Miromatrix Medical Inc.,"18 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,"ILD Research, Carlsbad, California, United States|Bond Clinic / Clinical Reseach of Central Florida, Winter Haven, Florida, United States|American Health Network, Avon, Indiana, United States|Kansas City Institute of Podiatry, Overland Park, Kansas, United States|St. Anthony's Wound Care Center, Saint Louis, Missouri, United States|A Step Ahead Foot Care, Mount Vernon, New York, United States|Gramercy Park Podiatry, New York, New York, United States|Foot Associates of New York, New York, New York, United States|Foot and Ankle Institute, Saint George, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT03232333/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03232333
910,NCT02783066,Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study,Completed,Has Results,Diabetic Foot Ulcer|Offloading,Device: Offloading boot: PulseFlow,Baylor College of Medicine|The Diabetic Boot Company,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Baylor College of Medicine, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02783066/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02783066
911,NCT02607280,DS-5565 Phase III Study for Renal Impairment in Japanese Subjects,Completed,Has Results,Diabetic Peripheral Neuropathic Pain|Post-herpetic Neuralgia,Drug: DS-5565,"Daiichi Sankyo Co., Ltd.|CMIC Co, Ltd. Japan|Daiichi Sankyo, Inc.","20 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shonan Kamakura General Hospital, Kamakura-shi, Kanagawa, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02607280/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02607280
912,NCT02510885,SD-OCT Angiography,Terminated,Has Results,Neovascular Age-related Macular Degeneration|Age-related Macular Degeneration|Diabetic Retinopathy|Retinal Vein Occlusion|Diabetic Macular Edema,Device: AngioVue SD-OCT,Duke University|Optovue,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Duke Eye Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT02510885/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02510885
913,NCT02501538,Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers,Completed,Has Results,"Foot Ulcer, Diabetic",Device: Transcutaneous O2 device,University of Texas Southwestern Medical Center,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center at Dallas, Dallas, Texas, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02501538/Prot_SAP_ICF_000.pdf",https://ClinicalTrials.gov/show/NCT02501538
914,NCT02463487,Negative Pressure Wound Therapy as a Drug Delivery System,Completed,Has Results,Diabetic Foot Ulcers,Device: Cardinal Pro +Simultaneous Irrigation (NPWTi)|Device: Cardinal Pro (NPWT) Therapy,University of Texas Southwestern Medical Center|Parkland Health and Hospital System,"21 Years to 89 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT Southwestern Medical Center at Dallas, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02463487/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02463487
915,NCT02318706,DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain,Completed,Has Results,Diabetic Peripheral Neuropathic Pain,Drug: DS-5565|Drug: placebo,"Daiichi Sankyo Co., Ltd.|CMIC Co, Ltd. Japan|Quintiles, Inc.|Quintiles Malaysia Sdn. Bhd.|Daiichi Sankyo, Inc.","20 Years and older   (Adult, Older Adult)",Phase 3,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Saiki Central Hospital, Oita, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02318706/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02318706
916,NCT02390245,Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study,Completed,Has Results,Glaucoma|Glaucoma Suspect|Diabetic Retinopathy|Ocular Hypertension|Cataract|Branch Retinal Vein Occlusion|Branch Retinal Arterial Occlusion|Central Retinal Vein Occlusion|Central Retinal Artery Occlusion|Epi-retinal Membrane|Macular Degeneration|Drusen|Loss of Vision,Other: Free Eye Screenings|Other: Enhanced Intervention|Other: Usual Care,"Wills Eye|Centers for Disease Control and Prevention|Westat|Public Health Management Corporation|Philadelphia Department of Public Health|The Health Federation of Philadelphia|Temple Physicians, Inc.","40 Years and older   (Adult, Older Adult)",Not Applicable,Other|U.S. Fed|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,"Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02390245/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02390245
917,NCT02294175,Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm,Completed,Has Results,Lower Extremity or Diabetic Foot Ulcers|Bacterial Infection,Device: Larval Debridement Therapy|Procedure: Bedside Sharp Debridement,North Florida Foundation for Research and Education|North Florida/South Georgia Veterans Health System|Biomonde,"21 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"North Florida Regional Medical Center, Gainesville, Florida, United States|North Florida / South Georgia Veterans Health System, Gainesville, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02294175/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02294175
918,NCT01898923,Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot,Drug: ON101 Cream|Other: Aquacel® Hydrofiber® dressing,"Oneness Biotech Co., Ltd.","20 Years to 80 Years   (Adult, Older Adult)",Phase 3,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Limb Preservation Platform, Inc., Fresno, California, United States|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University, Guanzhou, Guangdong, China|The First Affiliated Hospital, Sun Yat-sen University, Guanzhou, Guangdong, China|The First Affiliated Hospital of Henan Science & Technology University, Luoyang, Henan, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China|Shandong Provincial Hospital, Jinan, Shandong, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Shanghai TCM-Interated Hospital, Shanghai, Shanghai, China|Chang Gung Medical Hospital_Kaohsiung, Kaohsiung, Taiwan|Buddhist Tzu Chi Medical Hospital, New Taipei City, Taiwan|MacKay Memorial Hospital-Tamsui Branch, New Taipei City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Chi Mei Medical Center-Yongkang, Tainan City, Taiwan|MacKay Memorial Hospital-Taipei Branch, Taipei City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan|Chang Gung Medical Hospital_Linkou, Taoyuan City, Taiwan|China Medical University Hospital-Beigang Branch, Yunlin, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT01898923/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01898923
919,NCT01450943,VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic,Completed,Has Results,Diabetic Foot Ulcer,"Device: SECONDARY dressing gauze and tape|Procedure: debridement, irrigation|Device: Dermagraft|Device: Oasis",VA Office of Research and Development|VA Northern California Health Care System,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"VA Northern California Health Care System, Mather, CA, Sacramento, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT01450943/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01450943
920,NCT04757285,Copeptin and Psychological Stress of Medic During COVID-19 Pandemic,Completed,No Results Available,Psychological Stress|Hemostatic Disorder,,Alexandria University,24 Years to 37 Years   (Adult),,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Alexandria University Faculty of Medicine, Alexandria, Egypt","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT04757285
921,NCT03297294,Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN),Terminated,Has Results,Painful Diabetic Neuropathy,Drug: EMA401|Drug: Placebo,Novartis Pharmaceuticals|Novartis,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Broadmeadow, New South Wales, Australia|Novartis Investigative Site, Orange, New South Wales, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Heidelberg Heights, Victoria, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Klagenfurt, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pellenberg, Belgium|Novartis Investigative Site, Sofia, Sofia-Grad, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Ontario, CAN, Canada|Novartis Investigative Site, Thornhill, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Laval, Quebec, Canada|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Gentofte, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Boulogne Billancourt, France|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Halle (Saale), Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Debrecen, HUN, Hungary|Novartis Investigative Site, Esztergom, HUN, Hungary|Novartis Investigative Site, Szeged, HUN, Hungary|Novartis Investigative Site, Balatonfured, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Kistarcsa, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Krakow, POL, Poland|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Caldas da Rainha, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Matosinhos, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Viana do Castelo, Portugal|Novartis Investigative Site, Vila Nova de Gaia, Portugal|Novartis Investigative Site, Lucenec, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom|Novartis Investigative Site, Bath, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Middlesborough, United Kingdom|Novartis Investigative Site, Oldham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03297294/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03297294/SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03297294
922,NCT03228420,Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain,"Active, not recruiting",Has Results,Painful Diabetic Neuropathy,Device: Senza HF10 Therapy|Other: CMM,Nevro Corp,"22 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Coastal Orthopedics, Bradenton, Florida, United States|Georgia Pain Care, Stockbridge, Georgia, United States|Duke University Medical Center, Durham, North Carolina, United States|Advanced Pain Management, Greenfield, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03228420/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03228420/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03228420
923,NCT04339296,Connected Healthcare for Individuals Living at Home With Chronic Conditions,Completed,Has Results,Medication Adherence|Medication Compliance|Medication Nonadherence|Hypertension|Diabetes|Arthritis|Chronic Pain|Anxiety Depression|Asthma,Device: Spencer,"Alberta Health Services, Calgary|Centre for Aging and Brain Health Innovation|Catalyst Healthcare Ltd.","50 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"East Calgary Family Care Clinic, Calgary, Alberta, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04339296/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04339296/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04339296/ICF_003.pdf",https://ClinicalTrials.gov/show/NCT04339296
924,NCT04131582,Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes,Unknown status,No Results Available,Prediabetic State|Insulin Resistance,Combination Product: Linagliptin + metformin and Empagliflozin + metformin|Drug: Metformin,Universidad de Guanajuato|Hospital Regional de Alta Especialidad del Bajio,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04131582/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04131582
925,NCT03648307,Long Term Effect of Splenectomy on Metabolism,Completed,No Results Available,Trauma Splenic,Diagnostic Test: Blood sample,Imam Hossein General Hospital,"Child, Adult, Older Adult",,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,"Friarland, Dublin","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT03648307/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT03648307
926,NCT04507867,Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,Has Results,COVID19|Diabetes Mellitus|Hypertension|Obesity|Overweight|Oxygen Saturation|Mortality|Inflammation,Dietary Supplement: Nutritional support system (NSS)|Other: Conventional nutritional support designed by hospital nutritionists,Anahuac University,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ISSEMYM ""Arturo Montiel Rojas"" Medical Center, Toluca de Lerdo, Mexico State, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04507867/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04507867/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT04507867/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT04507867
927,NCT03004612,Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes,Completed,No Results Available,Prediabetic State|Insulin Resistance,Combination Product: Linagliptin + metformin|Drug: Metformin,Universidad de Guanajuato|Hospital Regional de Alta Especialidad del Bajio,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT03004612/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03004612
928,NCT04088461,Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine,Completed,No Results Available,Prediabetic State|Impaired Glucose Tolerance|Insulin Resistance,Drug: Linagliptin / Metformin Oral Tablet|Drug: Metformin,Universidad de Guanajuato|Hospital Regional de Alta Especialidad del Bajio,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Universidad de Guanajuato, León, Guanajuato, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04088461/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04088461
929,NCT01778556,Short-term Effects of Leptin in People With Lipodystrophy,Completed,Has Results,Lipodystrophy,Biological: Metreleptin,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),"14 Years to 70 Years   (Child, Adult, Older Adult)",Phase 2,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01778556/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT01778556
930,NCT02975297,Exenatide Once Weekly for Smoking Cessation,Completed,Has Results,Smoking Cessation,Drug: Exenatide|Drug: NRT|Behavioral: Counseling|Drug: Placebo,"The University of Texas Health Science Center, Houston","18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02975297/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02975297
931,NCT02059005,Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions,Completed,Has Results,Drug Use|Alcohol Use|Congestive Heart Failure|Pneumonia|Acute Myocardial Infarction|Diabetes Mellitus|Chronic Obstructive Pulmonary Disease|End-Stage Renal Disease,Behavioral: Specialized Community Disease Management|Behavioral: Treatment As Usual,Treatment Research Institute|Patient-Centered Outcomes Research Institute,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple University Hospital, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02059005/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02059005/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02059005/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT02059005
932,NCT04190849,European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD),Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease|Non-alcoholic Fatty Liver|Non-alcoholic Steatohepatitis,,Cambridge University Hospitals NHS Foundation Trust|The European Association for the Study of the Liver|Children's Liver Disease Foundation,"up to 18 Years   (Child, Adult)",,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,"Maastricht UMC, Maastricht, Netherlands|Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04190849/Prot_000.pdf",https://ClinicalTrials.gov/show/NCT04190849
933,NCT04175496,Glycemic and Insulinemic Responses of Low-Carbohydrate Snack Foods,Completed,No Results Available,Healthy,Other: Blueberry Cake|Other: Snacks with Cheese|Other: Spicy Crackers|Other: Glucose Solution First Repeat|Other: Glucose Solution Second Repeat,TC Erciyes University,19 Years to 30 Years   (Adult),Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Erciyes University Faculty of Health Sciences, Kayseri, Turkey","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04175496/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04175496
934,NCT04359771,Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema,Completed,Has Results,Diabetic Retinopathy|Macula Edema,Device: Yellow micro-pulse laser|Device: Diode micro-pulse laser,Cairo University,"20 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Cairo University, Cairo, Egypt","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04359771/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04359771/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04359771
935,NCT04154046,"Treatment of Impending Ulcers Associated With Hammer, Mallet and Claw Toe Deformities in the Diabetic Patient Setting",Completed,No Results Available,Diabetic Foot|Hammer Toe|Mallet Toe|Claw Toe,Procedure: Tenotomy(cutting) of flexor tendons is performed with needle,"Steno Diabetes Center Copenhagen|Bispebjerg Hospital|Hillerod Hospital, Denmark","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Steno Diabetes Center Copenhagen, Gentofte, Denmark|Hospitalerne i Nordsjælland Hillerød Hospital Ortopædkirurgisk afdeling, Hillerød, Denmark|Videncenter for Sårheling Bispebjerg Hospital, København NV, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04154046/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT04154046/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04154046
936,NCT04154020,"Treatment of Ulcers Associated With Hammer, Mallet and Claw Toe Deformities in the Diabetic Patient Setting",Completed,No Results Available,Diabetic Foot Ulcer|Hammer Toe|Mallet Toe|Claw Toe,Procedure: Flexor tenotomy,"Steno Diabetes Center Copenhagen|University Hospital Bispebjerg and Frederiksberg|Hillerod Hospital, Denmark","18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark|Hospitalerne i Nordsjælland Hillerød Hospital Ortopædkirurgisk afdeling, Hillerød, Denmark|Videncenter for Sårheling Bispebjerg Hospital, København NV, Denmark","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04154020/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04154020/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT04154020
937,NCT04085926,Sealed Therapeutic Shoe as Treatment of Diabetic Foot Ulcers,Recruiting,No Results Available,Diabetic Foot,Device: Sealed therapeutic shoe|Device: Total contact cast,Region Örebro County|Stiftelsen Promobila|Forte,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mölndahls sjukhus, Gothenburg, Sweden|Skånes Universitetssjukhus, Malmö, Malmö, Sweden|Örebro Universitetssjukhus, Örebro, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04085926/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04085926/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04085926
938,NCT03238963,"A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.",Completed,Has Results,Diabetic Retinopathy,Drug: BI 1467335|Drug: Placebo,Boehringer Ingelheim,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Trinity Research, Dothan, Alabama, United States|Retinal Research Institute, LLC, Phoenix, Arizona, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Florida Retina Institute, Orlando, Florida, United States|Northwestern Medical Group, Chicago, Illinois, United States|Raj K. Maturi, MD PC, Indianapolis, Indiana, United States|Cumberland Valley Retina Consultants, PC., Hagerstown, Maryland, United States|NJRetina, Teaneck, New Jersey, United States|New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States|Charlotte Eye Ear Nose and Throat Associates, PA, Charlotte, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Retina Research Institute of Texas, Abilene, Texas, United States|Retina Research Center, PLLC, Austin, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|LKH-Univ. Hospital Graz, Graz, Austria|Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|IRCCS Fondazione Bietti, Roma, Italy|Oslo Universitetssykehus HF, Ullevål sykehus, Oslo, Norway|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Espaço Médico de Coimbra, Coimbra, Portugal|CHULC, EPE - Hospital Sto. António Capuchos, Lisboa, Portugal|Hospital Dos de Maig, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Miguel Servet, Zaragoza, Spain|Bradford Royal Infirmary, Bradford, United Kingdom|Bristol Eye Hospital, Bristol, United Kingdom|Frimley Park Hospital, Frimley, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|Hospital of St Cross, Rugby, United Kingdom|Sunderland Eye Infirmary, Sunderland, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03238963/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03238963/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03238963
939,NCT02963441,A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy,Completed,Has Results,Diabetic Retinopathy,,"IDx LLC|The Emmes Company, LLC","22 Years and older   (Adult, Older Adult)",,Industry,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,United States.,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02963441/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02963441/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02963441
940,NCT03547635,AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcer,Other: AMNIOEXCEL Plus Amniotic Membrane|Device: A Marketed Comparator|Other: Standard of Care,Integra LifeSciences Corporation,"21 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California 1, Fresno, California, United States|California 3, Fresno, California, United States|California 2, Los Angeles, California, United States|Georgia 1, Gainesville, Georgia, United States|Illinois 1, Springfield, Illinois, United States|New Jersey 1, Toms River, New Jersey, United States|Texas 1, San Antonio, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03547635/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03547635/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03547635
941,NCT02863354,Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy,Completed,Has Results,Proliferative Diabetic Retinopathy,Drug: Aflibercept,"Charles C Wykoff, PhD, MD|Regeneron Pharmaceuticals|Greater Houston Retina Research","18 Years and older   (Adult, Older Adult)",Phase 2,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retina Consultants of Houston/The Medical Center, Houston, Texas, United States|Retina Consultants of Houston/Katy office, Katy, Texas, United States|Retina Consultants of Houston, Kingwood, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02863354/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02863354/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02863354
942,NCT02816710,Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy,Completed,Has Results,Proliferative Diabetic Retinopathy|Tractional Retinal Detachment,Drug: Conbercept,Ruijin Hospital,"18 Years and older   (Adult, Older Adult)",Phase 4,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital, Shanghai, Shanghai, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02816710/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT02816710/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02816710
943,NCT02718326,Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR),Completed,Has Results,Nonproliferative Diabetic Retinopathy,Drug: Intravitreal aflibercept injection [IAI]|Drug: Sham,Regeneron Pharmaceuticals,"18 Years and older   (Adult, Older Adult)",Phase 3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Arcadia, California, United States|Regeneron Study Site, Beverly Hills, California, United States|Regeneron Study Site, Encino, California, United States|Regeneron Study Site, Fullerton, California, United States|Regeneron Study Site, La Jolla, California, United States|Regeneron Study Site, Mountain View, California, United States|Regeneron Study Site, Oakland, California, United States|Regeneron Study Site, Oceanside, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Golden, Colorado, United States|Regeneron Study Site, New London, Connecticut, United States|Regeneron Study Site, Altamonte Springs, Florida, United States|Regeneron Study Site, Deerfield Beach, Florida, United States|Regeneron Study Site, Fort Myers, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Largo, Florida, United States|Regeneron Study Site, Melbourne, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Plantation, Florida, United States|Regeneron Study Site, Tallahassee, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Ssites, Marietta, Georgia, United States|Regeneron study Site, Tucker, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Oak Forest, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, New Albany, Indiana, United States|Regeneron Study Site, Lexington, Kentucky, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Siste, Baltimore, Maryland, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Hagerstown, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Henderson, Nevada, United States|Regeneron Study Site, Bloomfield, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Medford, Oregon, United States|Regeneron Study Site, Kingston, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Florence, South Carolina, United States|Regeneron Study Site, Ladson, South Carolina, United States|Regeneron Study Site, West Columbia, South Carolina, United States|Regeneron Study Site, Rapid City, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Germantown, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Abilene, Texas, United States|Regeneron Study Site 1, Austin, Texas, United States|Regeneron Study Site 2, Austin, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Harlingen, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, The Woodlands, Texas, United States|Regeneron Study Site, Willow Park, Texas, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Burlington, Vermont, United States|Regeneron Study Site, Fairfax, Virginia, United States|Regeneron Study Site, Spokane, Washington, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Marburg, Hesse, Germany|Regeneron Study Site, Münster, North Rhine-Westphalia, Germany|Regeneron Study Site, Leipzig, Saxony, Germany|Regeneron Study Site, Szeged, Csongrad, Hungary|Regeneron Study Site, Debrecen, Hajdu-Bihar, Hungary|Regeneron Study Site, Budapest, Pest, Hungary|Regeneron Study Site, Budapest, Pest, Hungary|Regeneron Study Site, Zalaegerszeg, Zala, Hungary|Regeneron Study Site, Asahikawa, Hokkaido, Japan|Regeneron Study Site, Amagasaki, Hyogo, Japan|Regeneron Study Site, Matsumoto, Nagano, Japan|Regeneron Study Site, Chiyoda, Tokyo, Japan|Regeneron Study Site, Kagoshima, Japan|Regeneron Study Site, Nagasaki, Japan|Regeneron Study Site, Arecibo, Puerto Rico|Regeneron Study Site, San Juan, Puerto Rico|Regeneron Study Site, Camberley, Surrey, United Kingdom|Regeneron Study Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02718326/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02718326/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02718326
944,NCT03230175,Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01),Completed,Has Results,Non-healing Wound|Non-healing Diabetic Foot Ulcer|Diabetic Foot Infection,Biological: TTAX01|Procedure: Surgical resection and debridement|Drug: Systemic antibiotics|Device: Off-loading,Tissue Tech Inc.,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Banner University Medical Center, Phoenix, Arizona, United States|UCLA Olive View, Sylmar, California, United States|University of Miami, Miami, Florida, United States|Village Podiatry Centers, Smyrna, Georgia, United States|Rosalind Franklin University, North Chicago, Illinois, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|St Luke's-Roosevelt Hospital Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Futuro Clinical Trials, LLC, McAllen, Texas, United States|Carilion Clinic, Roanoke, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03230175/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03230175/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03230175
945,NCT03182582,Efficacy of Laser Debridement on Pain and Bacterial Load in Chronic Wounds,Completed,Has Results,Wound Open|Chronic Venous Hypertension (Idiopathic) With Ulcer|Diabetic Foot Ulcer,Device: Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Procedure: Scalpel/Curette Debridement,Stanford University,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,California United States.,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03182582/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03182582/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03182582
946,NCT03010319,PriMatrix for the Management of Diabetic Foot Ulcers,Completed,Has Results,Diabetic Foot Ulcer,Device: PriMatrix Dermal Repair Scaffold|Device: Secondary Dressings|Device: Offloading device,Integra LifeSciences Corporation,"18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ILD Research Center, Carlsbad, California, United States|LA Foot & Ankle Clinic, Los Angeles, California, United States|Center for Clinical Research, Inc., San Francisco, California, United States|Central Valley Vein and Wound, Selma, California, United States|Georgetown University, Washington, District of Columbia, United States|Barry University Clinical Research, North Miami, Florida, United States|LA Podiatry Group, West Palm Beach, Florida, United States|Podiatry 1st, Belleville, Illinois, United States|The Mount Sinai Medical Center, New York, New York, United States|Wound Care of Tulsa, Tulsa, Oklahoma, United States|Martin Foot and Ankle, York, Pennsylvania, United States|Podiatric Medical Partners of Texas, P.A., Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|JPS Health Network, Fort Worth, Texas, United States|Futuro Clinical Trials, McAllen, Texas, United States|Element Research Group, San Antonio, Texas, United States|Foot and Ankle Institute, Saint George, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03010319/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03010319/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03010319
947,NCT02834663,Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy,Completed,Has Results,Nonproliferative Diabetic Retinopathy,Drug: Lucentis,Wonkwang University Hospital|Novartis Korea Ltd.,"40 Years and older   (Adult, Older Adult)",Phase 4,Other|Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,Korea,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02834663/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02834663/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02834663
948,NCT02681809,A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR,Terminated,Has Results,Diabetic Retinopathy|Posterior Vitreous Detachment|Disease Progression,Drug: ocriplasmin 0.0625mg|Drug: ocriplasmin 0.125mg|Drug: Sham injection,ThromboGenics|Oxurion,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Phoenix, Arizona, United States|Campbell, California, United States|Irvine, California, United States|Loma Linda, California, United States|Santa Ana, California, United States|Rapid City, South Dakota, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Brno, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Pardubice, Czechia|Praha 10, Czechia|Praha 4, Czechia|Zlin, Czechia|Paris, France|Munchen, Bayern, Germany|Darmstadt, Hessen, Germany|Leipzig, Sachsen, Germany|Debrecen, Hajdú-Bihar, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Szombathely, Hungary|Be'er Sheva', Israel|Petah Tiqva, Israel|Rehovot, Israel|Tel Aviv, Israel|Milan, Italy|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Valladolid, Spain|Frimley, Surrey, United Kingdom|London, United Kingdom|London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02681809/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT02681809/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02681809
949,NCT02634333,Anti-VEGF Treatment for Prevention of PDR/DME,"Active, not recruiting",Has Results,Diabetic Retinopathy|Diabetic Macular Edema,Procedure: Prompt Sham|Drug: Prompt aflibercept|Procedure: Deferred laser|Drug: Deferred aflibercept,Jaeb Center for Health Research|Regeneron Pharmaceuticals|Juvenile Diabetes Research Foundation|National Eye Institute (NEI)|National Institutes of Health (NIH),"18 Years and older   (Adult, Older Adult)",Phase 3,Other|Industry|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|University of Arizona Medical Center/Department of Ophthalmology, Tucson, Arizona, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|East Bay Retina Consultants, Inc., Oakland, California, United States|Southern California Desert Retina Consultants, MC, Palm Desert, California, United States|Shashi D Ganti, MD PC, Porterville, California, United States|Retina Consultants of Southern California, Redlands, California, United States|U.C. Davis Eye Center, Sacramento, California, United States|California Retina Consultants, Santa Barbara, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|New England Retina Associates, Hamden, Connecticut, United States|Retina Group of Florida, Fort Lauderdale, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent, Jacksonville, Florida, United States|Florida Retina Institute-Jacksonville, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|Springfield Clinic, LLP, Springfield, Illinois, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Mid Atlantic Retina Specialists, Hagerstown, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Mid-America Retina Consultants, P.A., Kansas City, Missouri, United States|Retinal and Ophthalmic Consultants, PC, Northfield, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|MaculaCare, New York, New York, United States|University of Rochester, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Retina, LLP, Eugene, Oregon, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Carolina Retina Center, Columbia, South Carolina, United States|Palmetto Retina Center, West Columbia, South Carolina, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Robert E. Torti, MD, PA dba Retina Specialists, DeSoto, Texas, United States|Retina Center of Texas, Grapevine, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Dept. of Ophthalmology, Richmond, Virginia, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|Nova Scotia District Health Authority, Halifax, Nova Scotia, Canada|Toronto Retina Institute (TRI), North York, Ontario, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02634333/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02634333/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02634333
950,NCT02626156,Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence,Completed,Has Results,Venous Hypertension Ulcers|Venous Stasis Ulcer|Venous Ulcer|Venous Insufficiency|Leg Ulcer|Foot Ulcer|Varicose Ulcer|Diabetic Foot,Device: Cooling gel pack|Device: Cooling cotton pack,Medical University of South Carolina,"50 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Medical University of South Carolina, Charleston, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02626156/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02626156/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT02626156
951,NCT02470806,Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT),Completed,Has Results,Venous Leg Ulcers|Diabetic Foot Ulcers,Device: PICO System|Device: tNPWT System,"Smith & Nephew, Inc.","18 Years and older   (Adult, Older Adult)",Not Applicable,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"ILD Consulting, Inc., Carlsbad, California, United States|Valley Foot & Ankle Specialty Providers, Fresno, California, United States|The Sun Healthcare & Surgery Group, Martinez, California, United States|Center for Clincial Research, San Francisco, California, United States|Olive View - UCLA Medical Center, Sylmar, California, United States|University of Miami, Miami, Florida, United States|NW University Feinberg School of Medicine, Chicago, Illinois, United States|Rosalind Franklin University of Med & Science, North Chicago, Illinois, United States|Ochsner Health System, New Orleans, Louisiana, United States|Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States|Advanced Foot & Ankle, Las Vegas, Nevada, United States|Center for Advanced Wound Care, Wyomissing, Pennsylvania, United States|Acclaim Bone & Joint, Fort Worth, Texas, United States|Futuro Clinical Trials, LLC, McAllen, Texas, United States|Carilion Clinic, Roanoke, Virginia, United States|The Mayer Institute, Hamilton, Ontario, Canada|Centre podiatrique et soins des plaies, Boucherville, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02470806/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02470806/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02470806
952,NCT02366468,Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema,Completed,Has Results,Diabetic Retinopathy,Drug: ranibizumab 0.5 mg,Novartis Pharmaceuticals|Novartis,"18 Years and older   (Adult, Older Adult)",Phase 4,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Novartis Investigative Site, Ahaus, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Freiburg I. Br, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hösbach, Germany|Novartis Investigative Site, Kempten, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02366468/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02366468/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02366468
953,NCT01831804,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863",Completed,Has Results,Wound Healing,Drug: GSK1278863|Drug: Placebo,GlaxoSmithKline,"18 Years to 90 Years   (Adult, Older Adult)",Phase 1,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"GSK Investigational Site, Castro Valley, California, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Pinellas Park, Florida, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Dallas, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01831804/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT01831804/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01831804
954,NCT00619983,"Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",Terminated,Has Results,Diabetic Neuropathic Pain|Chronic Low Back Pain,Drug: donepezil|Drug: duloxetine|Drug: donepezil 2.5 mg and duloxetine 30mg|Drug: placebo|Drug: gabapentin,Wake Forest University|National Institute of Neurological Disorders and Stroke (NINDS)|Wake Forest University Health Sciences,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT00619983/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT00619983/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT00619983
955,NCT03917784,Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes,Unknown status,No Results Available,PreDiabetes,Drug: Curcumin|Drug: Starch,Hospital General de México Dr. Eduardo Liceaga,18 Years to 60 Years   (Adult),Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital General de México Dr. Eduardo Liceaga, Mexico City, Cuauhtémoc, Mexico","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03917784/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03917784
956,NCT04516759,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,Completed,Has Results,Covid19,Drug: AZD1656|Other: Placebo,St George Street Capital,"18 Years and older   (Adult, Older Adult)",Phase 2,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Masarykova Univerzita - Fakultni Nemocnice U SV Anny V Brne (308), Brno, Czechia|Nemocnice Hořovice (309), Hořovice, Czechia|Oblastni Nemocnice Kolín (306), Kolín, Czechia|Klaudianova Nemonice (302), Mladá Boleslav, Czechia|Fakultni Nemocnice V Motole (303), Prague, Czechia|Thomayerova Nemonice (310), Prague, Czechia|Nemocnice Třebíč (305), Třebíč, Czechia|Colentina Clinical Hospital (204), Bucharest, Romania|Spitalul Clinic de Boli Infectioase Cluj-Napoca (203), Cluj-Napoca, Romania|Spitalul Clinic de Pneumoftiziologie ""Leon Daniello"" Cluj-Napoca (202), Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase Constanţa (207), Constanţa, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr Victor Babes Craiova (206), Craiova, Romania|Spitalul Judetean de Urgenta Deva (208), Deva, Romania|Spitalul Clinic de Boli Infectioase ""Sfanta Parascheva"" Iaşi (205), Iaşi, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr Victor Babes Timişoara (201), Timişoara, Romania|Barnsley Hospital NHS Foundation Trust (105), Barnsley, United Kingdom|Bolton NHS Foundation Trust (122), Bolton, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust (103), Bradford, United Kingdom|North Bristol NHS Trust (116), Bristol, United Kingdom|County Durham and Darlington NHS Foundation Trust (121), Darlington, United Kingdom|The Dudley Group NHS Foundation Trust (107), Dudley, United Kingdom|Medway NHS Foundation Trust (108), Gillingham, United Kingdom|Hull & East Yorkshire NHS Trust (102), Hull, United Kingdom|Barts Health NHS Trust (101 and 111), London, United Kingdom|Royal Free London NHS Foundation Trust (119), London, United Kingdom|St George's University Hospitals NHS Foundation Trust (114), London, United Kingdom|Penine Acute Hospitals NHS Trust (106), Salford, United Kingdom|Sheffield Hospitals NHS Foundation Trust (104), Sheffield, United Kingdom|Somerset NHS Foundation Trust (109), Taunton, United Kingdom|Walsall Healthcare NHS Trust (113), Walsall, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT04516759/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT04516759/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04516759
957,NCT03543644,Strategies To OPpose Sugars With Non-nutritive Sweeteners Or Water (STOP Sugars NOW) Trial,Completed,No Results Available,Healthy|Overweight and Obesity|Metabolic Syndrome|PreDiabetes|Diabetes|Overweight|Obesity|Dysglycemia|Cardiovascular Diseases|Cardiovascular Risk Factor|Hypertension,Other: Sugar-sweetened beverage (SSB)|Other: Non-nutritive sweetened beverages (NSB)|Other: Water,University of Toronto|Canadian Institutes of Health Research (CIHR),"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"St. Michael's Hospital, Toronto, Ontario, Canada","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form: Study Protocol, Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03543644/Prot_SAP_ICF_025.pdf|""Informed Consent Form: Genetic & Long Term Banking Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03543644/ICF_019.pdf|""Informed Consent Form: MRI Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03543644/ICF_023.pdf|""Informed Consent Form: Main Study Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03543644/ICF_024.pdf",https://ClinicalTrials.gov/show/NCT03543644
958,NCT03205150,Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients,Completed,Has Results,Obese Patients With Non-alcoholic Steatohepatitis (NASH),Drug: LIK066|Drug: Placebo,Novartis Pharmaceuticals|Novartis,"18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Live Oak, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Chia-Yi, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Bangkok, Thailand","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03205150/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03205150/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03205150
959,NCT03514420,Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL),Completed,Has Results,Familial Partial Lipodystrophy,Drug: AKCEA-ANGPTL3-LRx,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Site, Ann Arbor, Michigan, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT03514420/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03514420
960,NCT02755831,Targeted CPAP Therapy for Obstructive Sleep Apnea in Pregnancy,Completed,Has Results,Obstructive Sleep Apnea,Device: CPAP|Other: Pre-natal care,"United States Naval Medical Center, San Diego","18 Years and older   (Adult, Older Adult)",Not Applicable,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Naval Medical Center, San Diego, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02755831/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02755831
961,NCT03006471,Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension,Completed,Has Results,PreDiabetes|Prehypertension,Drug: Dapagliflozin|Drug: Placebo - Cap,University of Guadalajara,30 Years to 60 Years   (Adult),Phase 4,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03006471/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03006471/Prot_SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03006471
962,NCT04123093,Safety and Efficacy of the Noxsano Wound Care Bandage,Terminated,No Results Available,"Wound Heal|Peripheral Artery Disease|Ulcer, Leg|Ulcer Foot|Diabetic Foot Ulcer|Arterial Insufficiency",Device: Noxsano Bandage (Healthy Volunteers)|Device: Noxsano Bandage (Wound Care),"OhioHealth|Noxsano, Inc.","18 Years to 79 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"OhioHealth, Columbus, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04123093/Prot_SAP_000.pdf|""Informed Consent Form: Healthy Volunteer Consent"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04123093/ICF_001.pdf|""Informed Consent Form: Wound Care Patient Consent"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04123093/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT04123093
963,NCT02858076,Anti-VEGF vs. Prompt Vitrectomy for VH From PDR,Completed,Has Results,Proliferative Diabetic Retinopathy|Vitreous Hemorrhage,Drug: 2-mg Intravitreous Aflibercept Injection|Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation,Jaeb Center for Health Research|National Institutes of Health (NIH)|Regeneron Pharmaceuticals|National Eye Institute (NEI),"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Retinal Diagnostic Center, Campbell, California, United States|Macula & Retina Institute, Glendale, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|Shashi D Ganti, MD PC, Porterville, California, United States|Florida Retina Consultants, Lakeland, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Retina Associates of Sarasota, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Raj K. Maturi, MD, PC, Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Mayo Clinic Department of Ophthalmology, Rochester, Minnesota, United States|Mid-America Retina Consultants, P.A., Kansas City, Missouri, United States|The Retina Institute, Saint Louis, Missouri, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|MaculaCare, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Oregon Retina, LLP, Eugene, Oregon, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|Palmetto Retina Center, West Columbia, South Carolina, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Spokane Eye Clinic, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02858076/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02858076/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02858076/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT02858076
964,NCT03126786,Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: IVT aflibercept|Drug: Sham SC|Drug: SC CLS-TA,"Clearside Biomedical, Inc.","18 Years and older   (Adult, Older Adult)",Phase 2,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Retinal Consultants of Arizona and Retinal Research Institute, Phoenix, Arizona, United States|Retina Centers, PC, Tucson, Arizona, United States|California Retina Consultants, Bakersfield, California, United States|Retina Vitreous Medical Group Clinical Research, Beverly Hills, California, United States|Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View, California, United States|Retina Institute of California, Palm Desert, California, United States|Retina Consultants San Diego, Poway, California, United States|MedEye Associates, Miami, Florida, United States|Retina Specialty Institute, Pensacola, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Emory Eye Center, Augusta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Retina and Vitrous Associates of Kentucky, Lexington, Kentucky, United States|The Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, United States|Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States|Retina Associates of NJ, Teaneck, New Jersey, United States|Western Carolina Retinal Associates, Asheville, North Carolina, United States|Oregon Retina Institute, Medford, Oregon, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Retina Research Institute of Texas, Abilene, Texas, United States|Texas Retina Associates-Arlington, Arlington, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Texas Retina Associates, Dallas, Texas, United States|Valley Retina Institute, P.A., McAllen, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03126786/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03126786
965,NCT02949024,Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema,Completed,Has Results,Diabetic Macular Edema,Drug: IVT Aflibercept|Drug: SC CLS-TA,"Clearside Biomedical, Inc.","18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Retina Vitreous Associates Medical Group Inc, Mountain View, California, United States|Retina Consultants of Houston, PA, The Woodlands, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02949024/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02949024
966,NCT04115917,Evaluation of Discomfort Associated With Scleral Depression During Retina Examinations,Completed,No Results Available,Retina--Diseases|Retinal Detachment|Retinal Degeneration,Device: Schocket scleral depressor|Device: Cotton tipped applicator,New York City Health and Hospitals Corporation,"18 Years and older   (Adult, Older Adult)",Not Applicable,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Kings County Hospital, Brooklyn, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04115917/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04115917
967,NCT03724383,Atrial Fibrillation Lifestyle Project,Unknown status,No Results Available,Atrial Fibrillation Paroxysmal,Behavioral: Risk Factor Management Consult|Behavioral: Diet Classes|Behavioral: Stress Management Classes|Other: Exercise Classes|Other: Home based exercise program,Teddi Orenstein Lyall|Vancouver Coastal Health|Vancouver Coastal Health Research Institute|University of British Columbia,"19 Years to 75 Years   (Adult, Older Adult)",Not Applicable,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Richmond Hospital Cardiac Rehabilitation, Richmond, British Columbia, Canada|Richmond Health Services, Richmond, British Columbia, Canada|Garratt Wellness Centre, Richmond, British Columbia, Canada|Richmond Cardiology Clinic, Richmond, British Columbia, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Live Well Clinic, Vancouver, British Columbia, Canada|St. Paul's Healthy Heart Program, Vancouver, British Columbia, Canada","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03724383/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT03724383
968,NCT03998046,Coordinating Pragmatic Primary Care Population Management for Obesity,Completed,Has Results,Obesity|Cardiovascular Risk Factor,Behavioral: Outreach Support for Weight Loss Goal Setting and Self-Weighing|Behavioral: Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|Behavioral: Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support,Northwestern University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"18 Years and older   (Adult, Older Adult)",Not Applicable,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Northwestern Medicine, Chicago, Illinois, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03998046/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03998046/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03998046
969,NCT02804750,Study to Evaluate CORT125134 in Participants With Cushing's Syndrome,Completed,Has Results,Cushing's Syndrome,Drug: CORT125134,Corcept Therapeutics,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Laguna Hills, California, United States|Aurora, Colorado, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Covington, Kentucky, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Cleveland, Ohio, United States|Pittsburgh, Pennsylvania, United States|Richmond, Virginia, United States|Budapest, Hungary|Pecs, Hungary|Cuneo, Italy|Messina, Italy|Milano, Italy|Naples, Italy|Orbassano, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Leiden, Netherlands|Rotterdam, Netherlands|Salford, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02804750/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT02804750/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02804750
970,NCT02417935,A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP),Completed,Has Results,Diabetic Peripheral Neuropathic Pain,Drug: Duloxetine|Drug: Pregabalin|Drug: Placebo,Eli Lilly and Company|Shionogi,"20 Years to 79 Years   (Adult, Older Adult)",Phase 4,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cork, Ireland","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02417935/SAP_000.pdf|""Study Protocol: Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02417935/Prot_001.pdf|""Study Protocol: Protocol Amendment (a)"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02417935/Prot_002.pdf|""Study Protocol: Protocol Amendment (b)"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02417935/Prot_003.pdf|""Study Protocol: Protocol Amendment (c)"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02417935/Prot_004.pdf|""Study Protocol: Protocol Amendment (d)"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02417935/Prot_005.pdf",https://ClinicalTrials.gov/show/NCT02417935